Compounds > glimepiride
Page last updated: 2024-12-05

glimepiride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Glimepiride is a sulfonylurea oral hypoglycemic agent used to treat type 2 diabetes. It acts by stimulating the release of insulin from pancreatic beta cells. The compound is synthesized through a multi-step process involving the coupling of a sulfonylurea moiety with a substituted benzoic acid derivative. Glimepiride has been shown to effectively lower blood glucose levels and improve glycemic control in patients with type 2 diabetes. Its long duration of action, once-daily administration, and low risk of hypoglycemia make it a popular choice for treatment. Glimepiride is studied extensively due to its therapeutic efficacy, safety profile, and potential for further improvements in diabetes management.'

glimepiride: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3476
CHEMBL ID1481
CHEMBL ID149223
CHEBI ID5383
CHEBI ID92609
SCHEMBL ID16084
SCHEMBL ID16086
SCHEMBL ID14371714
SCHEMBL ID14965363
SCHEMBL ID8738802
MeSH IDM0161111

Synonyms (208)

Synonym
AC-476
1h-pyrrole-1-carboxamide, 2,5-dihydro-3-ethyl-4-methyl-n-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-
ccris 7083
glimepirida [spanish]
endial
hoe 490
glimepiridum [latin]
1h-pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-n-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-
glimepirid
brn 5365754
HMS3269A09
HMS3394L03
AB00513874-09
AB00513874-08
BRD-K42693031-001-01-8
BRD-K34776109-001-03-4
3-ethyl-4-methyl-n-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1h-pyrrole-1-carboxamide
glimepirida
1-((p-(2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea
amaryl
glimepiridum
gimepiride
1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1h-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea
CHEBI:5383 ,
glymepirid
solosa
glimer
hoe-490
roname
amarel
PRESTWICK3_000651
BSPBIO_000681
NCGC00016960-01
cas-93479-97-1
NCGC00181757-01
BPBIO1_000751
PRESTWICK2_000651
AB00513874
93479-97-1
C07669
glimepiride
glimepiride, >=98% (hplc), solid
smr000466368
MLS000759495
cpd000466368
DB00222
D00593
amaryl (tn)
glimepiride (jp17/usp/inn)
NCGC00161404-01
NCGC00161404-02
PRESTWICK1_000651
PRESTWICK0_000651
SPBIO_002602
OPREA1_382896
MLS001076674
MLS001401419
HMS2090K18
HMS2052L03
CHEMBL1481
nsc-759809
CHEMBL149223
FT-0668978
HMS1570C03
4-ethyl-3-methyl-n-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2h-pyrrole-1-carboxamide
NCGC00016960-03
A844609
n-(4-ethyl-3-methyl-5-oxo-2h-pyrrol-1-yl)-3-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]propanamide;glimepiride
HMS2097C03
unii-6ky687524k
glorion
hoe490
glemax
glimepiride [usan:usp:inn:ban]
6ky687524k ,
nsc 759809
nsc759809
pharmakon1600-01504915
tox21_110713
dtxcid3020675
dtxsid5040675 ,
G0395
glimepride
3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro
HMS2235L07
AKOS015969663
CCG-101156
NCGC00016960-04
NCGC00016960-05
NCGC00016960-02
BCP9000728
glista od
MLS003915622
smr001550123
FT-0626713
unii-24t6xir2mz
glimepiride, cis-
24t6xir2mz ,
AB07644
glimepiride [usan]
glimepiride [ema epar]
glimepiride [usp-rs]
glimepiride [orange book]
glimepiride [inn]
glimepiride [ep monograph]
glimepiride [mi]
glimepiride [usp monograph]
glimepiride [vandf]
duetact component glimepiride
glimepiride component of duetact
glimepiride [who-dd]
glimepiride [mart.]
glimepiride [jan]
glimepiride [usp impurity]
S1344
AKOS015894919
glimepiride impurity a [ep impurity]
1h-pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-n-(2-(4-(((((cis-4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-
1-((4-(2-(((3-ethyl-4-methyl-2-oxo-2,3-dihydro-1h-pyrrol-1-yl)carbonyl)amino)ethyl)phenyl)sulfonyl)-3-(cis-4-methylcyclohexyl)urea
glimepiride cis-isomer
cis-glimepiride
684286-46-2
3-ethyl-4-methyl-2-oxo-n-(2-{4-[({[(1r,4r)-4-methylcyclohexyl]carbamoyl}amino)sulfonyl]phenyl}ethyl)-2,5-dihydro-1h-pyrrole-1-carboxamide
HMS3372O07
gtpl6820
sugral
AB00513874-06
HY-B0104
CS-1844
MLS006011260
NC00406
SCHEMBL16084
SCHEMBL16086
NCGC00016960-07
tox21_110713_1
KS-5238
trans-3-ethyl-2,5-dihydro-4-methyl-n-[2-[4-[[[[(4-methyl cyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1h-pyrrole-1-carboxamide
trans-3-ethyl-2,5-dihydro-4-methyl-n-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1h-pyrrole-1-carboxamide
WIGIZIANZCJQQY-RUCARUNLSA-N
WIGIZIANZCJQQY-UHFFFAOYSA-N
n-[4-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)-ethyl]-benzenesulfonyl]-n'-4-methylcyclohexylurea
SCHEMBL14371714
SCHEMBL14965363
SCHEMBL8738802
Q-201158
glimperide
3-ethyl-2,5-dihydro-4-methyl-n-[2-[4-[[[[(trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1h-pyrrole-1-carboxamide
vitamine
boxamide
AB00513874_10
AB00513874_11
mfcd00878417
bdbm50237590
niddaryl
n'-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1h-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-n-(4-methylcyclohexyl)carbamimidic acid
3-ethyl-4-methyl-n-[2-(4-{[(4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1h-pyrrole-1-carboxamide
STL451059
STL453194
3-ethyl-4-methyl-n-{2-[4-({[(4-methylcyclohexyl)carbamoyl]amino}sulfonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1h-pyrrole-1-carboxamide
trans-1-(4-(2-(3-ethyl-4-me-2-oxo-2,5-dihydro-1h-pyrrole-1-carboxamido)ethyl)phenylsulfonyl)-3-(4-methylcyclohexyl)urea
SR-05000001508-3
sr-05000001508
3-ethyl-4-methyl-n-(4-(n-(((1r,4r)-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1h-pyrrole-1-carboxamide
CHEBI:92609
glimepiride, united states pharmacopeia (usp) reference standard
HMS3654F17
SR-05000001508-1
SR-05000001508-2
glimepiride, european pharmacopoeia (ep) reference standard
glimepiride for system suitability, european pharmacopoeia (ep) reference standard
glimepiride; 3-ethyl-2,5-dihydro-4-methyl-n-[2-[4-[[[[(trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl] 2-oxo-1h-pyrrole-1-carboxamide; amaryl; glimperide; hoe 490; trans-3-ethyl-2,5-dihydro-4-methyl-n-[2-[4-[[[[(4-methylcyclohexyl)ami
1-[[4-[2-[[(3-ethyl-4-methyl-2-oxo-2,3-dihydro-1h-pyrrol-1-yl)carbonyl]amino]ethyl]phenyl]sulphonyl]-3-(cis-4-methylcyclohexyl)urea (cis-glimepiride)
HMS3714C03
NCGC00371061-06
3-ethyl-4-methyl-n-(4-(n-((trans-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1h-pyrrole-1-carboxamide
glimepiride, british pharmacopoeia (bp) reference standard
SW196369-4
3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1h-pyrrole-1-carboxamide
3-ethyl-4-methyl-n-[2-(4-{[(cis-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1h-pyrrole-1-car
3-ethyl-4-methyl-n-[2-(4-{[(cis-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1h-pyrrole-1-carboxamide
BCP05331
Q425027
3-ethyl-4-methyl-n-(4-(n-((rel-(1r,4r)-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1h-pyrrole-1-carboxamide
nsc813217
nsc-813217
HMS3677K06
3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)
glimepiride,(s)
sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1h-pyrrole-1-carboxamide
HMS3413K06
Q27253874
glimepiride 100 microg/ml in acetonitrile
amaryl, glista od
glimepiride impurity a
;cis-3-ethyl-2,5-dihydro-4-methyl-n-[2-[4-[[[[(cis-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1h-pyrrole-1-carboxamide
A899888
NCGC00371061-02
261361-60-8
glimepiride for system suitability
BG164507
glimepiride- bio-x
CS-0165191
3-ethyl-4-methyl-n-(4-(n-(((1s,4s)-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1h-pyrrole-1-carboxamide? (glimepiride impurity pound(c)
DTXSID20861130
3-ethyl-2,5-dihydro-4-methyl-n-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1h-pyrrole-1-carboxamide
EN300-19873446
1h-pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-n-[2-[4-[[[[(trans- 4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-
Z1501475009

Research Excerpts

Overview

Glimepiride is a sulfonylurea known to have unique insulin mimetic and sensitizing effects. It is used as a first-line drug in the treatment of type 2 diabetes mellitus.

ExcerptReferenceRelevance
"Glimepiride is a sulfonylurea known to have unique insulin mimetic and sensitizing effects. "( Glimepiride treatment in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene.
He, X; Huang, Z; Li, Y; Liao, Z; Liu, J; Ng, K; Wan, X; Xu, L, 2018)		3.37
"Glimepiride is a third-generation sulfonylurea derivative and is used as a first-line drug in the treatment of type 2 diabetes mellitus."( Effect of glimepiride on the skeletal system of ovariectomized and non-ovariectomized rats.
Fronczek-Sokół, J; Pytlik, M, 2014)		1.53
"Glimepiride is a second-generation sulfonylurea excites pancreatic beta cells to discharge insulin."( Evaluation, efficacy and tolerability of GlucoNovax tablet in type 2 diabetic patients.
Ali, Z; Daniyal, M; Naveed, S; S I, I; Usmanghani, K, 2016)		1.16
"Glimepiride, which is a more appropriate sulfonylurea, was suggested as an alternative at order entry."( Implementation and Assessment of an Ambulatory Prescribing Guidance Tool to Improve Patient Safety in the Geriatric Population.
Bellone, JM; Ruhland, DJ; Wilkes, E, 2017)		1.18
"Glimepiride is a third generation oral antidiabetic sulphonylurea drug frequently prescribed to patients of type 2 diabetes. "( Design and evaluation of chitosan films for transdermal delivery of glimepiride.
Ammar, HO; El-Nahhas, SA; Elmotasem, H; Salama, HA, 2008)		2.02
"Glimepiride is a third-generation sulfonylurea agent and is widely used in the treatment of type 2 diabetes mellitus. "( Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway.
Cao, J; E, L; Gu, B; Liu, H; Ma, J; Ma, P; Wu, X, 2010)		3.25
"Glimepiride (Gmp) is a third generation antidiabetic sulphonylurea known to possess the antioxidant effect in streptozotocin (STZ) induced diabetes."( Inhibitory effect of glimepiride on nicotinamide-streptozotocin induced nuclear damages and sperm abnormality in diabetic Wistar rats.
Devi, K; Khanam, S; Rabbani, SI, 2009)		1.39
"Glimepiride is an oral sulfonylurea antihyperglycemic agent indicated for the treatment of type 2 diabetes mellitus. "( Bioequivalence and pharmacokinetic evaluation of two formulations of glimepiride 2 mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers.
Jia, JY; Li, S; Liu, GY; Liu, Y; Liu, YM; Weng, LP; Yu, C; Zhang, MQ; Zhu, JM, 2010)		2.04
"Glimepiride is an oral antidiabetic drug in the sulfonylurea class, which is widely used in treatment of Type 2 diabetes and it is currently available in more than 60 countries worldwide. "( A review of analytical techniques for determination of glimepiride: present and perspectives.
Bonfilio, R; de Araújo, MB; Salgado, HR, 2010)		2.05
"Glimepiride is a commonly used sulfonylurea hypoglycemic agent. "( Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population.
Cho, HJ; Huh, W; Huh, WS; Kim, HG; Kim, JW; Kim, YG; Ko, JW; Lee, SY; Oh, SY, 2011)		2.04
"Glimepiride is a second-generation sulfonylurea that stimulates pancreatic β cells to release insulin."( Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].
Basit, A; Fawwad, A; Riaz, M, 2012)		2.54
"Glimepiride appeared to be a more potent ADP-induced platelet aggregation inhibitor in vitro than gliclazide. "( Antiaggregatory activity of hypoglycaemic sulphonylureas.
Brzozowski, Z; Haber, P; Kaliszan, R; Petrusewicz, J; Siluk, D; Sut, G, 2002)		1.76
"Glimepiride is a once-daily SU that was introduced in 1995."( Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience.
Massi-Benedetti, M, 2003)		2.48
"Glimepiride is a popular choice of oral antidiabetic agent for patients with Type 2 diabetes since it increases both insulin secretion and insulin sensitivity and, unlike some other oral agents, is associated with weight neutrality or even weight loss."( Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.
Chi, EM; Lehr, KH; Shukla, UA, 2004)		2.49
"Glimepiride is a modern hypoglycaemic agent, which belongs to the group of sulfonylurea derivates. "( HPLC study of glimepiride under hydrolytic stress conditions.
Dohnal, J; Klimes, J; Kovaríková, P; Tisovská, L, 2004)		2.13
"Glimepiride is an oral sulfonylurea antihyperglycaemic agent. "( Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans.
Kang, W; Kwon, KI; Park, HC; Yun, HY, 2006)		2.02
"Glimepiride is an oral sulfonylurea drug; nicotinamide is an inhibitor of poly (ADP-ribose) synthetase and a precursor of NAD. "( The effects of nicotinamide and glimepiride on diabetes prevention in BB rats.
Chan, EK; Charles, MA; Cheta, D; Pan, J; Schranz, V, 1995)		2.02
"Glimepiride is a novel sulfonylurea drug for treatment of non-insulin-dependent diabetes mellitus with higher blood sugar lowering efficacy in diabetic patients than glibenclamide raising the question whether this characteristics is in line with different binding of glimepiride and glibenclamide to the beta-cell sulfonylurea receptor. "( Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics.
Hartz, D; Kramer, W; Müller, G; Okonomopulos, R; Pünter, J, 1994)		2.03
"Glimepiride is a novel sulfonylurea for the treatment of type II-diabetic patients exhibiting different receptor binding kinetics to beta-cell membranes with 8-9-fold higher koff rate and 2.5-3-fold higher kon rate compared to glibenclamide (see accompanying paper (Müller, G. "( Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride.
Girbig, F; Gutjahr, U; Hartz, D; Kowalewski, S; Kramer, W; Müller, G; Summ, HD, 1994)		2.03
"Glimepiride is a new generation sulphonylurea being prudently characterized in more than 2000 NIDDM patients. "( Clinical profile of the novel sulphonylurea glimepiride.
Draeger, E; Rosskamp, R; Wernicke-Panten, K, 1996)		2
"Glimepiride is a new sulphonylurea which is eliminated by the formation of a hydroxy-metabolite (hydroxy-gli) and a carboxymetabolite (carboxy-gli). "( Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration.
Badian, M; Korn, A; Lehr, KH; Malerczyk, V; Waldhäusl, W, 1996)		1.97
"Glimepiride is an effective and well-tolerated oral glucose-lowering agent. "( Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
Muchmore, DB; Rosenstock, J; Samols, E; Schneider, J, 1996)		3.18
"Glimepiride is a new sulfonylurea."( Cardiovascular effects of conventional sulfonylureas and glimepiride.
Geisen, K; Krause, E; Papp, JG; Végh, A, 1996)		1.26
"Glimepiride is a sulphonylurea agent that stimulates insulin release from pancreatic beta-cells and may act via extrapancreatic mechanisms. "( Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Balfour, JA; Langtry, HD, 1998)		3.19
"Glimepiride is a conveniently administered alternative to other sulphonylureas in patients with type 2 diabetes mellitus not well controlled by diet alone. "( Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Balfour, JA; Langtry, HD, 1998)		3.19
"Glimepiride is a sulfonylurea that is pharmacologically distinct from other sulfonylureas because of differences in receptor-binding properties and potentially selective effects on ATP-sensitive K+ channels. "( Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
Campbell, RK, 1998)		3.19
"Glimepiride appears to be a useful option for patients with type 2 diabetes not controlled by diet and exercise and who want to achieve tight glucose control. "( Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
Campbell, RK, 1998)		3.19
"Glimepiride is a new sulfonylurea for diabetes treatment which is supposed to impact less on extra-pancreatic ATP-dependent K+ channels than the conventional drug glibenclamide. "( Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.
Amann, FW; Boedeker, KH; Burger, W; Gruber, D; Harris, S; Kiowski, W; Klepzig, H; Kober, G; Luus, H; Matter, C; Schneider, H, 1999)		1.97
"Glimepiride is a new long-acting the third generation sulfonylurea given once daily. "( [Evaluation of efficacy, safety and tolerance of glimepiride (Amaryl) in patients with type 2 diabetes].
Drzewoski, J; Jasik, M; Karnafel, W; Kasperska-Czyzykowa, T; Lopatyński, J, 2000)		2
"Glimepiride (Glim) is a new sulfonylurea reported to affect nonpancreatic K(ATP) channels less than does Glib."( Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.
Baxter, GF; Lawrence, CL; Maddock, HL; Mocanu, MM; Standen, NB; Yellon, DM, 2001)		2.47
"Glimepiride is expected to be a new efficient agent for the treatment of Type 2 diabetes."( [Glimepiride (Amaryl): a review of its pharmacological and clinical profile].
Bando, K; Yamada, Y, 2001)		1.94
"Glimepiride (Hoe 490) is a new sulfonylurea. "( Special pharmacology of the new sulfonylurea glimepiride.
Geisen, K, 1988)		1.98

Effects

Glimepiride has the lowest ratio of insulin release to glucose decrease compared with other sulphonylureas. It has fewer and less severe effects on cardiovascular variables than glibenclamide (glyburide)

ExcerptReferenceRelevance
"Glimepiride sulfonamide has antidiabetic potential mainly through DPP-IV inhibition, but also through insulin stimulation and alpha-amylase inhibition."( Study on gluco-regulatory potential of glimepiride sulfonamide using in silico, in vitro and in vivo approaches.
Bhatia, M; Bhinchar, MK; Chauhan, DS; Chordia, N; Jatwa, R; Kumar, A; Manivannan, E; Parmar, HS; Raval, I, 2014)		1.39
"Glimepiride has no effect on superoxide anion production."( The role of ATP-sensitive potassium channel blockers in ischemia-reperfusion-induced renal injury versus their effects on cardiac ischemia reperfusion in rats.
Abo-Elmatty, DM; Ahmed, AA; Tawfik, MK, )		0.85
"Glimepiride has the lowest ratio of insulin release to glucose decrease compared with other sulphonylureas. "( Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B.
Andrassy, M; Balletshofer, B; Bierhaus, A; Chen, J; Elsenhans, S; Häring, HU; Heinle, H; Isermann, B; Kanitz, M; Nawroth, PP; Rudofsky, G; Schiekofer, S; Schleicher, E; Schneider, J, 2003)		3.2
"Glimepiride has fewer and less severe effects on cardiovascular variables than glibenclamide (glyburide)."( Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Balfour, JA; Langtry, HD, 1998)		2.46
"Glimepiride has already been used in more than 60 countries in the world."( [Glimepiride (Amaryl): a review of its pharmacological and clinical profile].
Bando, K; Yamada, Y, 2001)		1.94

Actions

ExcerptReferenceRelevance
"Glimepiride enhance the glucose transporter in rat osteoblasts at two different glucose concentrations."( [Effect of glimepiride on the glucose uptake of rat mandibular osteoblasts in hyperglycemia].
Gu, B; Liu, H; Ma, J; Ma, P; Tan, B, 2014)		2.23

Treatment

Glimepiride (10 microM) treatment for the first 10 min of reperfusion significantly reduced infarct size from 67.2 +/- 1.3% in controls to 35.8 +/- 4.5% (P < 0.01) Treatment was associated with altered synaptic membranes including the loss of specific glycosylphosphatidylinositol (GPI)-anchored proteins.

ExcerptReferenceRelevance
"Glimepiride treatment was associated with altered synaptic membranes including the loss of specific glycosylphosphatidylinositol (GPI)-anchored proteins including the cellular prion protein (PrP(C)) that acts as a receptor for Aβ42, increased synaptic gangliosides and altered cell signalling."( Glimepiride protects neurons against amyloid-β-induced synapse damage.
Bate, C; McHale-Owen, H; Nolan, W; Osborne, C; West, E; Williams, A, 2016)		2.6
"Glimepiride (10 microM) treatment for the first 10 min of reperfusion significantly reduced infarct size from 67.2 +/- 1.3% in controls to 35.8 +/- 4.5% (P < 0.01)."( Glimepiride treatment upon reperfusion limits infarct size via the phosphatidylinositol 3-kinase/Akt pathway in rabbit hearts.
Miyazaki, M; Nakaya, H; Nishida, H; Nomura, M; Sato, T, 2009)		2.52
"Glimepiride treatment significantly reduce both the amount of PrP82-146 that bound to neurones and PrP82-146 induced activation of cytoplasmic phospholipase A(2) (cPLA(2)) and the production of prostaglandin E(2) that is associated with neuronal injury in prion diseases."( Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines.
Bate, C; Diomede, L; Salmona, M; Tayebi, M; Williams, A, 2009)		2.52
"Glimepiride treatment more modestly decreased LDL particle number and increased LDL particle size."( Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes.
D'Agostino, R; Davidson, MH; Haffner, S; Mazzone, T; Perez, A; Sam, S, 2012)		1.1
"Glimepiride treatment as initial mono-therapy could effectively improve blood glucose control in type 2 diabetic patients, with a favorable safety profile. "( Efficacy and safety of glimepiride as initial treatment in Chinese patients with Type 2 diabetes mellitus.
Duan, WR; Gao, Y; Guo, XH; Han, P; Lv, XF; Yang, HZ; Zhang, XZ, 2013)		2.14
"In glimepiride-treated groups, the magnitude of attenuated lactate production was less in diabetes than that in nondiabetes at the second inflation, suggesting that diabetes mellitus per se plays a role in determining lactate production."( Impairment of myocardial protection in type 2 diabetic patients.
Chou, TF; Lee, TM, 2003)		0.83
"Glimepiride-treated patients also achieved a significantly greater improvement in FPG, with an adjusted mean (SE) treatment difference of -46.7 (16.7) mg/dL (P = 0.007)."( Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Atherton, T; Bugos, C; Dirnberger, G; Luis Bautista, J, 2003)		1.33
"The glimepiride + NPH insulin treatment resulted in a higher HbA(1c) level, as compared to the other regimens. "( Combined bedtime insulin--daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate--a randomised trial.
Adèr, HJ; DeVries, JH; Engbers, AM; Heine, RJ; Iperen Av, Av; Lumeij, JA; Snoek, FJ; Stehouwer, MH, )		0.69
"Glimepiride treatment produced significant reduction of atherosclerotic lesions (control, 57.5+/-7.1% versus glimepiride, 20.6+/-4.8%; P<0.01) with no significant change observed in levels of plasma lipids."( Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits.
Oshima, K; Shakuto, S; Tsuchiya, E, 2005)		2.49
"Glimepiride treatment was associated with an increased risk of hypoglycemia and pioglitazone with higher rate of peripheral edema."( Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Issa, M; Umpierrez, G; Vlajnic, A, 2006)		2.5
"Glimepiride pretreatment (0.001-0.01-0.1-5.0 mg/kg i.p., 30 min before coronary occlusion) significantly decreased the incidence of irreversible ventricular fibrillation and increased the survival rate during reperfusion (64%, 61%, 60%, and 67% vs."( Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats.
Baczkó, I; Bozdogan, O; El-Reyani, NE; Leprán, I; Papp, JG, 1999)		1.28
"Treatment with glimepiride did not improve insulin sensitivity in a patient with type A insulin resistance syndrome carrying Ile1143Phe heterozygous mutation in the INSR gene. "( Glimepiride treatment in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene.
He, X; Huang, Z; Li, Y; Liao, Z; Liu, J; Ng, K; Wan, X; Xu, L, 2018)		2.28
"Pre-treatment with glimepiride significantly reduced TNF, IL-1 and IL-6 secretion from RAW 264 and microglial cells incubated with LPS, Aβ42, αSN and PrP82-146."( Glimepiride reduces CD14 expression and cytokine secretion from macrophages.
Bate, C; Ingham, V; Williams, A, 2014)		2.16
"Treatment with glimepiride, a sulphonylurea approved for the treatment of diabetes mellitus, induced the release of PrP(C) from the surface of prion-infected neuronal cells. "( Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines.
Bate, C; Diomede, L; Salmona, M; Tayebi, M; Williams, A, 2009)		2.15
"Treatment with Glimepiride/Metformin significantly increased EDVI and %deltaMBF in diabetic patients from baseline, thus showing an improvement in coronary endothelial function."( [Effects of the combined treatment with Metformin/Glimepiride on endothelial function of patients with type 2 diabetes mellitus. A positron emission tomography (PET) evaluation study].
Alexánderson-Rosas, E; Alexánderson-Rosas, G; Calleja-Torres, R; de Jesús Martínez, A; González-Canudas, J; Iñarra-Talboy, F; Meave-González, A; Ochoa-López, JM; Sierra-Fernández, C, )		0.72
"Treatment with glimepiride and glibenclamide caused an increased accumulation of lipid droplets and triglycerides."( Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes.
Celner, J; Enzmann, H; Haas, B; Mayer, P; Pfeifer, A, 2011)		1.01
"Treatment with glimepiride also resulted in significant and stable weight loss relative to baseline, with the exception of patients with a body mass index of <25 kg/m(2)."( Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study.
Klingler, A; Lechleitner, M; Luger, A; Weitgasser, R, 2003)		1.05

Toxicity

Glimepiride also protected cortical and hippocampal neurones against the toxic effects of the prion-derived peptide PrP82-146. 39 (8%) patients had serious adverse events in the glimePiride group versus 24 (5%) in the canagliflozin 100 mg group and 26 (5% in the 300 mg group.

ExcerptReferenceRelevance
" neither toxic effects nor pathological changes were observed in the treated animals."( Subchronic and chronic toxicity of the new sulfonylurea glimepiride in dogs.
Brunk, R; Mayer, D; Schollmeier, U, 1993)		0.53
" In subchronic and chronic toxicity studies glimepiride was devoid of any significant toxic effects or pathological changes even at high dose levels."( Acute, subchronic and chronic toxicity of the new sulfonylurea glimepiride in rats.
Donaubauer, HH; Mayer, D, 1993)		0.79
" All of the patients provided an extensive medial history which included information on concomitant medications, underlying diseases, and ongoing adverse events."( An overview of the safety and tolerance of glimepiride.
Schneider, J, 1996)		0.56
" A recent multicenter trial of a new sulfonylurea, glimepiride, in combination with a single injection of 70/30 insulin before dinner has confirmed that this approach is safe and more consistently effective than insulin alone for obese patients beginning insulin in a setting resembling clinical practice."( Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine.
Riddle, MC, 1996)		0.55
" Glimepiride was well-tolerated and there were no drug-related adverse events."( Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.
Lange, C; Malerczyk, V; Metelko, Z; Mrzljak, V; Profozic, V; Rosenkranz, B, 1996)		1.49
" Safety was assessed by evaluating vital signs, laboratory values and the occurrence of adverse events."( [Evaluation of efficacy, safety and tolerance of glimepiride (Amaryl) in patients with type 2 diabetes].
Drzewoski, J; Jasik, M; Karnafel, W; Kasperska-Czyzykowa, T; Lopatyński, J, 2000)		0.56
"This study demonstrates that glimepiride is effective, safe and well tolerated in improving glycaemic control in patients with type 2 diabetes."( [Evaluation of efficacy, safety and tolerance of glimepiride (Amaryl) in patients with type 2 diabetes].
Drzewoski, J; Jasik, M; Karnafel, W; Kasperska-Czyzykowa, T; Lopatyński, J, 2000)		0.85
" The tolerability of glimepiride in this study population was determined by evaluating adverse events, hypoglycemic episodes, and physical examination as well as laboratory findings."( Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Atherton, T; Bugos, C; Dirnberger, G; Luis Bautista, J, 2003)		0.92
" Adverse events were carefully monitored during the study."( [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
González-Ortiz, M; Martínez-Abundis, E, )		0.44
" The frequency of adverse events was similar for all the groups."( [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
González-Ortiz, M; Martínez-Abundis, E, )		0.44
"The combined use of glimepiride plus metformin in a single presentation for 3 months showed to be efficacious and safe in patients with DM2 and secondary failure to glibenclamide."( [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
González-Ortiz, M; Martínez-Abundis, E, )		0.76
" These significant levels were achieved within 8 weeks and all patients tolerated the drug well with no reported case of serious adverse events including hypoglycaemia."( Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg pluspioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus.
Chopra, D; Kinagi, SB; Langade, DG; Meshram, DM; Morye, V; Naikwadi, AA, 2005)		0.57
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)		0.32
" 47%) and drug-related adverse experiences (AEs) (15 vs."( Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Fanurik, D; Hermansen, K; Khatami, H; Kipnes, M; Luo, E; Stein, P, 2007)		0.54
" The incidence of adverse events (AEs), serious AEs and adjudicated cardiovascular events was 74."( Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ahrén, B; Byiers, S; Dejager, S; Ferrannini, E; Fonseca, V; Matthews, D; Shao, Q; Zinman, B, 2009)		0.6
" Glimepiride also protected cortical and hippocampal neurones against the toxic effects of the prion-derived peptide PrP82-146."( Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines.
Bate, C; Diomede, L; Salmona, M; Tayebi, M; Williams, A, 2009)		2.71
" foenum-graecum seed when it was administered orally at high dose level (3 g/kg body weight), which is higher than effective antihyperglycemic dose, and closely observed for 24 hrs for any mortality and next 10 days for any delayed toxic effects on gross behavioral activities."( Antihyperglycemic effect of Trigonella foenum-graecum (fenugreek) seed extract in alloxan-induced diabetic rats and its use in diabetes mellitus: a brief qualitative phytochemical and acute toxicity test on the extract.
Ahmed, K; Alauddin, M; Mowla, A; Rahman, MA, 2009)		0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)		0.36
"1%) had five treatment-related adverse events, and 10 patients in group B (32."( A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes.
Hirayama, M; Hiroi, S; Kaku, K; Kawakami, K; Kuriyama, K; Matsuno, K; Sugiura, K, 2013)		0.61
" The reduction of prescribed sulfonylurea dose in DPP-4 patients following the safety alert coincided with a decrease of adverse event reports."( Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan.
Kimura, H; Masuda, S; Sato, D; Sato, Y, 2013)		0.39
" 39 (8%) patients had serious adverse events in the glimepiride group versus 24 (5%) in the canagliflozin 100 mg group and 26 (5%) in the 300 mg group."( Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Arias, P; Balis, DA; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Niskanen, L; Xie, J; Yoon, KH, 2013)		0.9
" The incidence rates of adverse events and adverse drug reactions, including hypoglycaemia, during the double-blind randomized period were similar in both groups."( Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki, T; Kondo, K, 2014)		0.66
" Rates of serious adverse events in the albiglutide group were similar to comparison groups."( HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F, 2014)		0.6
"The safe use of medications in pregnant females, their embryos and in offspring is important."( A toxicology study to evaluate the embryotoxicity of metformin compared with the hypoglycemic drugs, the anticancer drug, the anti-epileptic drug, the antibiotic, and the cyclo-oxygenase (COX)-2 inhibitor.
Chai, Z; Li, L; Liu, C; Shen, X; Wang, L; Zhang, X; Zhang, Z, 2015)		0.42
" The safety variables included were as follows: weight variation at the end of treatment; presentation of any type of adverse event; presentation of serious adverse events; patients who experienced any type of hypoglycaemia; patients who experienced severe hypoglycaemia; treatments suspended due to adverse effects; and deaths for any reason."( Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.
Almendro, N; Amate, JM; Bouza, C; Gonzalez-Canudas, J; Lopez-Cuadrado, T; Rivas-Ruiz, R; Saz-Parkinson, Z, 2015)		0.71
" Regarding safety variables, the main differences observed were in the greater number of cases with hypoglycaemia in the group treated with glimepiride, and the serious adverse events or treatment discontinuations due to these which occurred in slightly over 2% more cases in this group compared to the iDPP4 group."( Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.
Almendro, N; Amate, JM; Bouza, C; Gonzalez-Canudas, J; Lopez-Cuadrado, T; Rivas-Ruiz, R; Saz-Parkinson, Z, 2015)		0.91
"A greater effectiveness is seen in the glimepiride/metformin association, which should not be diminished by slight differences in adverse effects, with absence of severe hypoglycaemia in over 98% of patients under treatment."( Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.
Almendro, N; Amate, JM; Bouza, C; Gonzalez-Canudas, J; Lopez-Cuadrado, T; Rivas-Ruiz, R; Saz-Parkinson, Z, 2015)		0.98
"5 mg, compared with daily insulin glargine without forced titration, demonstrated greater HbA1c reduction and weight loss, with a higher incidence of gastrointestinal adverse events and a lower risk of hypoglycemia."( Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
Benroubi, M; Giorgino, F; Pechtner, V; Sun, JH; Zimmermann, AG, 2015)		0.62
" Safety was assessed based on adverse event (AE) reports."( Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
Alba, M; Cerdas, S; Chacon, Mdel P; Eliaschewitz, FG; Lavalle-González, FJ; Tong, C, 2016)		0.43
" Safety assessments comprised weight gain from baseline and the incidence of adverse events (AEs)."( Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
Chung, SC; Kim, IJ; Kim, SS; Kim, YI; Lee, KJ; Lee, SJ; Lee, YS; Park, JH, 2017)		0.68
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016)		0.43
"The incidence of renal-related adverse events (AEs) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active- and placebo-controlled trials (N = 5598) and in a 104-week study vs glimepiride (N = 1450) was low and similar in canagliflozin and non-canagliflozin groups."( Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Balis, D; Canovatchel, W; Desai, M; Rosenthal, N; Sun, D; Xie, J; Yavin, Y, 2017)		0.64
" The incidences of adverse events (AEs) were 29."( Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
Bi, Y; Engel, SS; Ji, L; Ji, Q; Jia, W; Lu, J; Mao, A; Mu, Y; Ran, X; Weng, J; Xu, W; Yang, W; Yao, B; Zeng, L; Zhao, B; Zhao, J; Zhou, Z; Zhu, D, 2017)		0.46
" Safety endpoints were adverse events including hypoglycaemia."( Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).
Ishida, H; Kitaoka, M; Ohsugi, M; Satoh, J; Seino, Y; Shihara, N; Terauchi, Y; Yabe, D; Yamada, Y, 2017)		0.71
" With the exception of hypoglycemia, the incidences of adverse events and discontinuations were similar between treatment groups."( A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Engel, SS; Gantz, I; Handelsman, Y; Iredale, C; Kaufman, KD; Lai, E; Lauring, B; O'Neill, EA; Suryawanshi, S; Wei, Z, 2017)		0.66
" The overall incidences of adverse events (AEs), serious AEs, drug-related AEs and discontinuations were generally similar between treatment groups."( A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
Ceesay, P; Engel, SS; Gantz, I; Kaufman, KD; Lai, E; Latham, M; Lee, SH; O'Neill, EA; Round, E; Suryawanshi, S, 2017)		0.64
" A Liver Safety Evaluation Committee consisting of hepatologists blinded to treatment assignments evaluated hepatic adverse events (AEs) and serious AEs (SAEs) for causal relationship to study drug."( Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
Marcinak, JF; Munsaka, MS; Ohira, T; Smith, N; Watkins, PB, 2018)		0.48
" The most common drug-related adverse events in both dulaglutide groups (≥5% of patients) included diarrhoea, nausea, increased lipase, decreased appetite, abdominal distension and vomiting."( Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.
Chen, YH; Cho, YM; Gu, L; Huang, CN; Li, P; Wang, F; Wang, WQ; Yang, J, 2018)		0.72
" The most frequent gastrointestinal drug-related adverse events with dulaglutide were diarrhea, abdominal distension, nausea and vomiting."( Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study.
Chen, LL; Du, LY; Li, QM; Li, YB; Liu, XM; Ma, JH; Shi, LX; Shi, YQ; Wang, F, 2020)		0.8
"Comparison of combined therapy consisting of either the G/M group or the G group indicated that both forms of therapy are relatively safe but that the former more effectively decreases blood glucose levels."( A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy.
Chun, SW; Hong, JH; Kim, SJ; Lee, JM; Lim, DM; Park, KS; Park, KY; Yu, HM, 2019)		0.75
"To assess the incidence of cardiovascular and hypoglycaemic adverse events associated with glimepiride compared with other second-generation sulphonylureas among patients with type 2 diabetes in a real-world clinical setting."( Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study.
Dell'Aniello, S; Douros, A; Suissa, S; Yu, OHY, 2020)		1.03
" Secondary endpoint was change in fasting plasma glucose (FPG), post prandial plasma glucose (PPG), body weight and any adverse reaction including no of hypoglycemic events, as well as a change in the percentage of subjects with A1C < 7."( Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.
Chakravarti, HN; Nag, A, 2021)		0.62
" The primary endpoint was time to first occurrence of three-point major adverse CV events (MACE: CV death, non-fatal myocardial infarction, or non-fatal stroke)."( Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
Andersen, KR; Espeland, MA; Johansen, OE; Kadowaki, T; Keller, A; Marx, N; Mattheus, M; McGuire, DK; Pratley, RE; Rosenstock, J; Seino, Y; Weber, M; Zinman, B, 2021)		0.83
" Adverse events increased with age, but were generally balanced between treatment groups."( Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
Andersen, KR; Espeland, MA; Johansen, OE; Kadowaki, T; Keller, A; Marx, N; Mattheus, M; McGuire, DK; Pratley, RE; Rosenstock, J; Seino, Y; Weber, M; Zinman, B, 2021)		0.83
" We compared the effects of three SU medications and initial SU doses on adverse glycemic and cardiovascular events among NH residents."( Comparative safety of sulfonylureas among U.S. nursing home residents.
Berry, SD; Hayes, KN; Munshi, MN; Riester, MR; Zullo, AR, 2023)		0.91

Pharmacokinetics

Gemigliptin and glimepiride did not alter the pharmacokinetic properties of each other when they were co-administered in healthy volunteers, and were generally tolerated. The mean elimination half-life of glimePiride was prolonged from 2 to 2.5 hours.

ExcerptReferenceRelevance
" Pharmacokinetic and pharmacodynamic effects of hydroxy-gli were assessed in humans."( Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration.
Badian, M; Korn, A; Lehr, KH; Malerczyk, V; Waldhäusl, W, 1996)		0.53
" Pharmacokinetic data on sulfonylureas are generally inconsistent in cirrhotic patients."( Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
Rosenkranz, B, 1996)		0.56
" Fifteen fasting patients received a single dose of 3 mg glimepiride and serial blood and urine samples were taken over 24 h for pharmacokinetic and efficacy analyses."( Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.
Lange, C; Malerczyk, V; Metelko, Z; Mrzljak, V; Profozic, V; Rosenkranz, B, 1996)		0.83
" Fluvoxamine moderately increased the plasma concentrations and slightly prolonged the elimination half-life of glimepiride."( Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Backman, JT; Kivistö, KT; Laitila, J; Neuvonen, M; Neuvonen, PJ; Niemi, M, 2001)		0.74
"We conducted CYP2C9 genotyping for 29 healthy volunteers who had participated in our previous pharmacokinetic studies on glyburide or glimepiride."( Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Cascorbi, I; Kivistö, KT; Kroemer, HK; Neuvonen, PJ; Niemi, M; Timm, R, 2002)		0.88
"To assess the pharmacokinetic characteristics of glimepiride and its metabolites in normal-weight and morbidly obese patients with type 2 diabetes to determine whether the pharmacokinetics of glimepiride are altered by obesity."( Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.
Chi, EM; Lehr, KH; Shukla, UA, 2004)		2.02
" The method was successfully applied to a kinetic study in order to assess the main pharmacokinetic parameters of glimepiride."( Improved liquid chromatographic tandem mass spectrometric determination and pharmacokinetic study of glimepiride in human plasma.
Koutsopoulou, M; Panderi, I; Pistos, C, 2005)		0.75
"To compare the pharmacokinetic and pharmacodynamic effects of glimepiride between once- and twice-daily dosing in type 2 diabetic patients."( Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing.
Kaku, K; Kanda, Y; Kawasaki, F; Kohara, K; Kotani, K; Matsuda, M; Matsuki, M; Shigetoh, M; Shimoda, M; Tawaramoto, K, 2007)		0.85
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008)		0.35
" The mean (SD) dose-normalized Cmax values of glimepiride 1 and 2 mg were 168."( Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in
Cho, JY; Jang, IJ; Kim, BH; Kim, J; Kim, JR; Kim, KP; Lim, KS; Shin, KH; Shin, SG; Yu, KS, 2009)		0.89
" Although there are reports in the literature regarding the pharmacokinetic (PK) characteristics of glimepiride, few data of PK parameters are available in a Chinese population; none are available regarding a recently developed generic formulation."( Bioequivalence and pharmacokinetic evaluation of two formulations of glimepiride 2 mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers.
Jia, JY; Li, S; Liu, GY; Liu, Y; Liu, YM; Weng, LP; Yu, C; Zhang, MQ; Zhu, JM, 2010)		0.81
" The current studies assessed the potential for pharmacokinetic (PK) interaction between dapagliflozin and pioglitazone, metformin, glimepiride or sitagliptin in healthy subjects following single-dose administration."( Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W, 2011)		0.78
" The developed method was applied for preclinical pharmacokinetic studies."( Novel liquid chromatographic method for simultaneous estimation of pioglitazone and glimepiride in rat plasma by solid phase extraction: application to preclinical pharmacokinetic studies.
Deshpande, PB; Karthik, A; Musmade, PB; Pandey, S; Pathak, SM; Talole, KB; Udupa, N, 2011)		0.59
"The purpose of this study was to develop a population pharmacokinetic (PPK) model of glimepiride and to investigate the influence of genetic polymorphisms in CYP2C9 on the PPK of glimepiride in healthy Korean subjects."( Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.
Cho, HY; Kim, MS; Lee, YB; Yoo, HD, 2011)		0.86
" The visual predictive check indicated that the pharmacokinetic profile of glimepiride was adequately described by the proposed PPK model."( Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.
Cho, HY; Kim, MS; Lee, YB; Yoo, HD, 2011)		0.87
"The goal of this study was to compare the pharmacokinetic properties of SR fixed-dose combinations of glimepiride/metformin 2/500 mg and the newly developed glimepiride/metformin 1/500 mg formulation to meet the regulatory requirements for marketing in Korea."( Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized
Cho, JY; Jang, IJ; Kim, SE; Shin, KH; Shin, SG; Yoon, SH; Yu, KS, 2011)		0.82
" Safety profiles were assessed for all 32 subjects who were administered the study drugs, and pharmacokinetic characteristics were evaluated in the 30 subjects who completed the study."( Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized
Cho, JY; Jang, IJ; Kim, SE; Shin, KH; Shin, SG; Yoon, SH; Yu, KS, 2011)		0.6
"Dose-proportional characteristics of glimepiride and comparable pharmacokinetic properties of metformin were observed between the SR fixed-dose combinations of glimepiride/metformin 1/500 mg and 2/500 mg."( Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized
Cho, JY; Jang, IJ; Kim, SE; Shin, KH; Shin, SG; Yoon, SH; Yu, KS, 2011)		0.88
" The pharmacokinetic parameters were calculated using non-compartmental analysis."( Pharmacokinetic modeling of glimepiride plasma concentration in healthy subjects.
Antonesi, IM; Ghiciuc, CM; Lupuşoru, CE; Potur, DM; Potur, R, )		0.43
" To compare the pharmacokinetic profiles of glimepiride/SR metformin (2 mg/500 mg) with the PK of immediate-release (IR) formulations, an open-label, randomized, 3-period, 3-sequence, 3-treatment, crossover study was conducted in 12 healthy subjects."( Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination.
Cho, JY; Jang, IJ; Kim, BH; Kim, KP; Lim, KS; Shin, HS; Shin, SG; Yu, KS, 2012)		0.92
" The complex pharmacokinetic and pharmacogenetic properties and the unfavourable short and long term risk profile of glibenclamide and glimepiride raise the question whether their use can be justified any longer."( CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.
Beil, W; Holstein, A; Kovacs, P, 2012)		0.58
" In normal and streptozotocin induced diabetic rats the combination of glimepiride with piperine increased all the pharmacokinetic parameters, such as Cmax, AUC0-n, AUCtotal, t1/2, and MRT, and decreased the clearance, Vd, markedly as compared with the control group."( Effect of piperine on the pharmacokinetics and pharmacodynamics of glimepiride in normal and streptozotocin-induced diabetic rats.
Rani, TS; Sujatha, S; Veeresham, C, 2012)		0.85
" For the colesevelam coadministration periods, 3,750 mg once daily was dosed throughout the pharmacokinetic sampling period."( The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil.
He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)		0.64
"The rapid, sensitive, and selective liquid chromatography-electrospray ionization-tandem mass spectrometry method (LC-ESI-MS/MS) for the simultaneous estimation and pharmacokinetic investigation of glimepiride and pioglitazone in human plasma has been developed and fully validated."( Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study.
Hu, JQ; Ni, XJ; Qiu, C; Shang, DW; Wang, ZZ; Wen, YG; Zhang, M, 2014)		0.88
"Gemigliptin and glimepiride did not alter the pharmacokinetic properties of each other when they were co-administered in healthy volunteers, and were generally tolerated."( Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Bae, KS; Bang, K; Choi, HY; Han, S; Kim, MJ; Kim, YH; Lee, SH; Lim, HS, 2014)		0.96
"The objective of the present work was to investigate the potential for pharmacokinetic drug-drug interactions between glimepiride (GMP) and piperazine dithioctate (PDT) in rats to support the development of an orally combined product of the two drugs."( Effect of Piperazine Dithioctate on the Oral Pharmacokinetics of Glimepiride in Rats.
Choi, K; Kim, EY; Lee, K; Oh, SJ; Yu, HE; Yu, K, 2015)		0.86
" In present investigation, pharmacodynamics and pharmacokinetic interactions with oral hypoglycemic drug, glimepiride (GLM) was studied in streptozotocin (STZ) induced diabetic rats."( Effects of Gymnema sylvestre extract on the pharmacokinetics and pharmacodynamics of glimepiride in streptozotocin induced diabetic rats.
Duraiswamy, B; Gupta, A; Jadhav, A; Janrao, S; Kamble, B; Khatal, L; Moothedath, I, 2016)		0.87
" This method was successfully applied to a pharmacokinetic study of coadministeration of BOS and GLP in rats."( Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study.
Chen, M; Chen, Q; Hu, G; Pan, P; Song, W; Wang, S; Xu, T; Zheng, Z, 2016)		0.7
" The method was successfully applied in pharmacokinetic studies followed by oral administration of GLM and ILA in rats."( Development of Solid-Phase Extraction and HPLC Method for Simultaneous Estimation of Ilaprazole and Glimepiride in Rat Plasma: Application to Pharmacokinetic Studies.
Bakal, RL; Chandewar, AV; Dewani, AP; Mohale, DS; Shelke, PG; Tripathi, AS, 2017)		0.67
" After that, pharmacokinetic studies were performed by sampling animal blood at different times, and biochemical parameters (pharmacodynamic), such as glucose and insulin, were also evaluated."( Pharmacokinetics and pharmacodynamics of glimepiride polymorphs.
de Araújo Paula, FB; de Araújo, MB; Doriguetto, AC; Freitas, JTJ; Ruela, ALM; Souto, BEM; Viana, ALM; Viana, OMMS, 2018)		0.75
" The study aimed to evaluate the bioequivalence and safety profiles of two different formulations of glimepiride 1 mg from two different manufactures in healthy Chinese subjects in the fasting and fed state in order to acquire adequate pharmacokinetic evidence for registration approval of the test formulation."( Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects.
Chen, S; Ju, G; Qiu, W; Xu, Y; Yan, K; Zheng, Z, 2020)		1
"This study is an open-label, two-period, two-sequence, randomized, two-way crossover pharmacokinetic study in healthy Chinese subjects in the fasting and fed state."( Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects.
Chen, S; Ju, G; Qiu, W; Xu, Y; Yan, K; Zheng, Z, 2020)		0.78
" In this study, we aimed to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between evogliptin and glimepiride."( Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects.
Jang, IJ; Kim, Y; Lee, S; Yoo, H; Yu, KS, 2020)		1
" Possible pharmacodynamic and pharmacokinetic interactions were observed for, following single-dose as well as multiple-dose treatment protocols in normal and alloxan-induced diabetes in albino Wistar rats and rabbits."( Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits.
Anilkumar, KV; Nagaraju, B, )		0.37
" In the present study, we aimed at evaluating the pharmacokinetic (PK) interactions between henagliflozin and glimepiride."( No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.
Chu, N; Ding, Y; He, Q; Huang, K; Que, L; Xiang, X, 2022)		1.14
" This study aims to investigate the possible influence of orally administered low- and high-dose glimepiride (GLM) on pharmacokinetic characteristics (PK) of benzbromarone (BNR) in rats."( Effects of different doses glimepiride intake on the pharmacokinetics of benzbromarone in rats.
Chen, Z; Gu, X; Lin, Y; Liu, J; Wang, Y; Weng, Q; Xiong, J; Xu, H; Yu, Y, 2023)		1.42

Compound-Compound Interactions

The risk for nocturnal hypoglycemia was lower with glimepiride in combination with morning and bedtime insulin glargine. Study compared the efficacy and safety of insulinglargine and NPH insulin, both in conjunction with a once-daily fixed dose of glimePiride.

ExcerptReferenceRelevance
"To investigate the efficacy and safety of glimepiride combined with either morning or bedtime insulin glargine or bedtime neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes."( Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Fritsche, A; Häring, HU; Schweitzer, MA, 2003)		2.03
"The risk for nocturnal hypoglycemia was lower with glimepiride in combination with morning and bedtime insulin glargine than with glimepiride in combination with bedtime NPH insulin in patients with type 2 diabetes."( Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Fritsche, A; Häring, HU; Schweitzer, MA, 2003)		2.01
" This study compared the efficacy and safety of insulin glargine and NPH insulin, both in combination with a once-daily fixed dose of glimepiride, in terms of glycemic control and incidence of hypoglycemia."( Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.
Aschner, P; Calvo, C; Eliaschewitz, FG; Jimenez, J; Ramirez, LA; Ruiz, M; Valbuena, H; Villena, J, 2006)		0.76
"Strategies for the addition of RSG in combination with GLIM were evaluated with data from two randomized, double-blind, placebo (PBO)-controlled studies."( Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
Chou, HS; Hamann, A; Matthaei, S; Rosenstock, J; Seidel, DK, 2008)		0.58
" Based on laboratory findings, we determined the clinical significance of potential CYP2C9-mediated drug-drug interactions in hospitalized patients receiving glibenclamide, glimepiride or glipizide, all of which are metabolized by CYP2C9, together with a CYP2C9 inhibitor."( Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.
Heikkilä, P; Huupponen, R; Laine, K; Tirkkonen, T, 2010)		0.75
"Almost 20% of patients were exposed to a potential drug-drug interaction with a CYP2C9 inhibitor during sulphonylurea treatment."( Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.
Heikkilä, P; Huupponen, R; Laine, K; Tirkkonen, T, 2010)		0.56
"To assess and compare the efficacy and safety of liraglutide with those of glimepiride, both in combination with metformin for the treatment of type 2 diabetes in Asian population from China, South Korea and India."( Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
Bech, OM; Bhattacharyya, A; Chen, L; Ji, Q; Kim, KW; Kumar, A; Liu, X; Ma, J; Tandon, N; Yang, W; Yoon, KH; Zychma, M, 2011)		0.85
"8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1)."( Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
Bech, OM; Bhattacharyya, A; Chen, L; Ji, Q; Kim, KW; Kumar, A; Liu, X; Ma, J; Tandon, N; Yang, W; Yoon, KH; Zychma, M, 2011)		0.95
" Sulfonylureas are commonly used in combination with other antidiabetic drugs to improve glycemic control."( Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Bae, KS; Bang, K; Choi, HY; Han, S; Kim, MJ; Kim, YH; Lee, SH; Lim, HS, 2014)		0.62
"In this study, we characterized the drug-drug interactions of losartan (LOS) and glimepiride (GLP) using recombinant cytochrome P450 (CYP) 2C9 enzymes (CYP2C9*1, CYP2C9*3, CYP2C9*13, and CYP2C9*16)."( Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.
Cai, J; Cai, JP; Chen, SZ; Dai, DP; Geng, PW; Hu, GX; Pan, PP; Shen, LB; Xu, SS, 2014)		0.9
" We aimed to compare mortality and cardiovascular risk among users of metformin in combination with pharmacologically different ISs."( Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015)		0.42
"Most ISs in combination with metformin were associated with similar mortality and cardiovascular risk."( Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015)		0.42
"We investigated the possibilities of drug-drug interactions between luseogliflozin, a sodium-glucose co-transporter-2 inhibitor, and oral antidiabetic drugs (OADs) in healthy Japanese males."( Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M, 2015)		0.42
" We aimed to systematically screen for drugs that interact with the five most commonly used secretagogues-glipizide, glyburide, glimepiride, repaglinide, and nateglinide-to cause serious hypoglycemia."( Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017)		0.66
" We first predicted the drug-drug interaction potential based on the pharmacokinetics of each secretagogue-precipitant pair."( Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017)		0.46
"We predicted 34 pharmacokinetic drug-drug interactions with the secretagogues, nine moderate and 25 weak."( Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017)		0.46
"The self-controlled case series design has the potential to be widely applicable to screening for drug-drug interactions that lead to adverse outcomes identifiable in healthcare databases."( Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017)		0.46

Bioavailability

Study was designed to investigate the potency of niosomes, for glimepiride (GLM) encapsulation, aiming at enhancing its oral bioavailability and hypoglycemic efficacy. The relative bioavailability of glimePiride-TDDS was 20.

ExcerptReferenceRelevance
"4-fold those for males, while Vss and oral bioavailability were nearly equal."( Sex difference in pharmacokinetics of the novel sulfonylurea antidiabetic glimepiride in rats.
Tabata, S; Yamazaki, H, 1993)		0.52
" 100% absolute bioavailability and the absence of a food interaction guarantee highly reproducible pharmacokinetics."( Clinical profile of the novel sulphonylurea glimepiride.
Draeger, E; Rosskamp, R; Wernicke-Panten, K, 1996)		0.56
" The absolute bioavailability of the tablet formulation was 107% (AUDC(glimepiride)), 109% (AUDC(M1)) and 97% (urinary recovery)."( Absolute bioavailability of glimepiride (Amaryl) after oral administration.
Badian, M; Korn, A; Lehr, KH; Malerczyk, V; Waldhäusl, W, 1994)		0.82
" The proposed method enables the unambiguous identification and quantitation of glimepiride for pharmacokinetic, bioavailability or bioequivalence studies."( Determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry.
Al Tamimi, JI; Idrees, J; Salem, II, 2004)		0.89
"To study the pharmaceutical characterization, the pharmacokinetics and relative bioavailability of glimepiride gel-matrix controlled-release patch in rats."( [Preparation and evaluation in vivo and in vitro of glimepiride gel-matrix controlled-release patch].
Chen, Y; Ma, Z; Xu, DH; Xu, SB; Zhang, Y; Zhao, JJ, 2004)		0.79
" Another HPLC method after pre-column derivatization was developed to determine the glimepiride serum concentration and then employed to study the pharmacokinetics and relative bioavailability of glimepiride after a single dose of oral or patch administration in rats."( [Preparation and evaluation in vivo and in vitro of glimepiride gel-matrix controlled-release patch].
Chen, Y; Ma, Z; Xu, DH; Xu, SB; Zhang, Y; Zhao, JJ, 2004)		0.8
" The relative bioavailability of glimepiride-TDDS was 20."( [Preparation and evaluation in vivo and in vitro of glimepiride gel-matrix controlled-release patch].
Chen, Y; Ma, Z; Xu, DH; Xu, SB; Zhang, Y; Zhao, JJ, 2004)		0.86
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007)		0.34
"To compare the bioavailability of two glimepiride 4-mg tablet formulation in 26 healthy volunteers of both sexes."( [Comparison study of two glimepiride formulations bioavailability in healthy volunteers of both sexes after a single dose administration].
Astigarraga, RE; Borges, NC; Haddad, AL; Mazucheli, JA; Moreno, RA; Taveira, Ydel A, 2007)		0.91
" However, its oral therapy is encountered with bioavailability problems due to its poor solubility leading to irreproducible clinical response, in addition to adverse effects like dizziness and gastric disturbances."( Design and evaluation of chitosan films for transdermal delivery of glimepiride.
Ammar, HO; El-Nahhas, SA; Elmotasem, H; Salama, HA, 2008)		0.58
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)		0.36
"This study compared the bioavailability and tolerability of a fixed-dose combination (FDC) tablet of glimepiride/metformin 2/500 mg and glimepiride 2-mg + metformin 500-mg tablets administered separately in healthy Korean subjects."( Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers.
Cho, JY; Chung, JY; Gu, N; Jang, IJ; Kim, BH; Kim, JR; Rhim, H; Shin, HS; Shin, SG; Yoon, SH; Yu, KS, 2010)		0.81
" Furthermore, the oral bioavailability was evaluated for the three formulations in fasted beagle dogs."( Strategies to improve dissolution and oral absorption of glimepiride tablets: solid dispersion versus micronization techniques.
Han, J; Han, X; He, Z; Ning, X; Sun, J; Wu, Y; Yan, Z, 2011)		0.61
"This study demonstrates for the first time that fixed-dose glimepiride and SR metformin 2 mg/500 mg shows a PK profile similar to that of glimepiride, but with a delayed time to maximum concentration and slightly decreased bioavailability for metformin compared with the IR fixed-dose combination, in healthy volunteers."( Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination.
Cho, JY; Jang, IJ; Kim, BH; Kim, KP; Lim, KS; Shin, HS; Shin, SG; Yu, KS, 2012)		0.9
" The results revealed that a combination of glimepiride with piperine led to the enhancement of the bioavailability of glimepiride by inhibiting the CYP2C9 enzyme, which suggested that piperine might be beneficial as an adjuvant to glimepiride in a proper dose, in diabetic patients."( Effect of piperine on the pharmacokinetics and pharmacodynamics of glimepiride in normal and streptozotocin-induced diabetic rats.
Rani, TS; Sujatha, S; Veeresham, C, 2012)		0.88
"Low aqueous solubility is often a limiting aspect to the bioavailability of poorly soluble, but highly permeable drugs (class II compounds according to the Biopharmaceutics Classification System - BCS) administered in single drug products or as fixed dose combinations."( New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin.
Dressman, JB; Klein, S; Taupitz, T, 2013)		0.6
" The in vivo studies demonstrated that a marked enhancement of bioavailability of nanocrystal-loaded capsules was superior compared to the marketed formulation and microcrystal-loaded capsules, which may reduce the risk of side effect by allowing a reduction in either the dose or its frequency of administration."( Development and characterization of glimepiride nanocrystal formulation and evaluation of its pharmacokinetic in rats.
Chen, Z; Du, B; Liu, Z; Pang, L; Shen, G; Wang, D, 2013)		0.66
"001) increase in the bioavailability of GLIM in the presence of SIL in DN after the 1(st) dose of administration of the drug as compared to GLIM treated rat, whereas at the end of 6(th) week of drug administration, there were significant (p<0."( Evaluation of drug interaction of glimepiride with phosphodiesterase inhibitors type V in diabetic nephropathy.
Chandewar, AV; Mazumder, PM; Tripathi, AS, 2014)		0.68
"The purpose of this study was to improve the solubility and bioavailability of glimepiride (GLMP) by utilizing hydrotropy technique."( A simple and effective method to improve bioavailability of glimepiride by utilizing hydrotropy technique.
Chen, M; Cui, X; Li, H; Li, X; Ma, L; Shen, S; Yang, W, 2015)		0.89
" The present study concludes that bioavailability of SIL increases when co-administered chronically with GLIM in the management of DN animals, and the mechanism is supported by molecular modeling studies."( Does glimepiride alter the pharmacokinetics of sildenafil citrate in diabetic nephropathy animals: investigating mechanism of interaction by molecular modeling studies.
Chandewar, A; Mazumder, PM; Timiri, AK; Tripathi, AS, 2015)		0.93
" ME could be an effective oral drug delivery system to improve bioavailability of GM."( Improved oral bioavailability of poorly water-soluble glimepiride by utilizing microemulsion technique.
Cui, Y; Gao, J; Li, H; Li, X; Pan, T; Shen, S; Yang, W, 2016)		0.68
"This study was designed to investigate the potency of niosomes, for glimepiride (GLM) encapsulation, aiming at enhancing its oral bioavailability and hypoglycemic efficacy."( Enhanced oral bioavailability and sustained delivery of glimepiride via niosomal encapsulation: in-vitro characterization and in-vivo evaluation.
AbouSamra, MM; ElShebiney, SA; Mohsen, AM, 2017)		0.94
"Improve GLMP bioavailability and pharmacokinetics in type II diabetic patients."( Clinical pharmacokinetic study for the effect of glimepiride matrix tablets developed by quality by design concept.
Abd-Allah, FI; Ahmed, TA; Hosny, KM; Suhail, MAA, 2018)		0.74
" In vivo oral bioavailability was assessed using rabbits as a model."( Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
Amin, F; Khan, S; Mahmood, HM; Rahim, H; Sadiq, A; Shahat, AA; Ullah, R, 2019)		0.79
"The optimized batch fabricated by ultrasonication-assisted precipitation can be useful in boosting oral bioavailability, which may be accredited to enhanced solubility and dissolution rate of Glm, ultimately resulting in its faster rate of absorption due to nanonization."( Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
Amin, F; Khan, S; Mahmood, HM; Rahim, H; Sadiq, A; Shahat, AA; Ullah, R, 2019)		0.79
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
" Among NS and SNEDDS, NS was found more efficacious than that of the SNEDDS possibly due to higher enhancement of oral bioavailability in case of NS."( Expanding arsenal against diabetes mellitus through nanoformulations loaded with glimepiride and simvastatin: A comparative study.
Chellappan, DK; Dua, K; Dureja, H; Gulati, M; Gupta, G; Gupta, PK; Gupta, S; Jha, NK; Jha, SK; Khursheed, R; Kumar, B; Pandey, NK; Prasher, P; Sharma, A; Singh, SK; Vishwas, S, 2022)		0.95

Dosage Studied

There were no significant differences between self-monitored blood glucose measured at each time-point. The developed methods were successfully applied for the determination of glimepiride and pioglitazone hydrochloride in pure powder and dosage form.

ExcerptRelevanceReference
" Eighty rats were studied for all treatment periods with 40 receiving a daily oral gavage dosage of glimepiride and 40 receiving a daily oral gavage dosage of vehicle solution."( Glimepiride-induced prevention of diabetes and autoimmune events in the BB rat: revised.
Chan, EK; Charles, MA; Cheta, DM; Kunakorn, T; Lim, J, 1995)		1.95
"To assess the efficacy, safety, and dose-response relationship of glimepiride in patients with NIDDM."( A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.
Goldberg, RB; Holvey, SM; Schneider, J, 1996)		0.83
"05), indicating a dose-response relationship."( A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.
Goldberg, RB; Holvey, SM; Schneider, J, 1996)		0.6
" The long-term follow-up (457 patients) confirmed that glimepiride (1-8 mg) once daily provides equivalent metabolic control to a higher dosage (2."( Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.
Draeger, KE; Lomp, HJ; Rosskamp, R; Schüler, E; Wernicke-Panten, K, 1996)		0.77
" A dosage of 70/30 insulin before supper was titrated, seeking fasting capillary blood glucose (FBG) 120 mg/dl (6."( Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
Riddle, MC; Schneider, J, 1998)		0.53
" Its convenient once daily dosing may enhance compliance for diabetic patients who often also require medications for other co-morbid conditions, such as hypertension, hyperlipidaemia and cardiac disease."( Clinical review of glimepiride.
McCall, AL, 2001)		0.64
"Patients aged 35-70 years with poorly controlled diabetes [fasting plasma glucose (FPG) > or =1,40 g/l and < 3 g/l at baseline] were treated with glimepiride for 6 months, with dosage titrated from 1-6 mg daily, depending on the monthly FPG measurement."( Predictors of response to glimepiride in patients with type 2 diabetes mellitus.
Altman, JJ; Charpentier, G; Derobert, E; Etienne, S; Fleury, F; Grimaldi, A; Halimi, S; Oriol, V; Vaur, L, 2001)		0.81
"This study aimed to confirm the efficacy of glimepiride given once daily in the treatment of Thai type 2 diabetic patients and to find out the optimum dosage for Thai patients."( Glimepiride in type 2 diabetes mellitus Thai patients.
Benjasuratawong, Y; Chandraprasert, S; Deerochanawong, C; Himathongkam, T; Nitiyanant, W; Sarinnapakorn, V; Suthijumroon, A; Suwanwalaikorn, S; Vichayanrat, A; Vongterapak, S, 2001)		2.01
"With single doses, there was a clear dose-response relationship for the reduction in AUC, with a statistically significant difference only between placebo (mean 1981, 95% confidence intervals (CI) 1883-2078) and 2 mg glimepiride (mean 1763, 95% CI 1665-1861)."( The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose.
Lindblad, U; Lindwall, K; Melander, A; Ranstam, J; Sjöstrand, A, 2001)		0.73
" The patients started at a baseline dosage of 1 mg which was then it was gradually adjusted according to the blood sugar level."( Amaryl (glimepiride) in patients with type 2 diabetes mellitus.
Botushanov, NP; Husianitis, HK; Iliev, DA; Simeonov, SB, 2002)		0.75
" Given that the dosage is titrated to achieve optimal fasting glucose levels, no special dose consideration is required for the use of glimepiride in the treatment of obese patients with type 2 diabetes."( Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.
Chi, EM; Lehr, KH; Shukla, UA, 2004)		1.97
" Insulin dosage was titrated to target FBG ( Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka, HU; Kliebe-Frisch, C; Plewe, G; Riddle, MC; Schweitzer, MA; Yki-Järvinen, H, 2005)		0.33
"Ninety-five patients with type 2 diabetes for at least 6 months without glycemic control by diet and oral hypoglycemic agents to their maximum tolerated dosage and who also had metabolic syndrome."( Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S, 2005)		0.57
" Insulin dosage in each group was titrated to target fasting blood glucose (FBG) of 100 mg/dL or less (( Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Busch, K; Janka, HU; Plewe, G, 2007)		0.34
" There was considerable overlapping in the AUC(infinity) values, making gender-dependent dosing unnecessary."( Replicate study design in bioequivalency assessment, pros and cons: bioavailabilities of the antidiabetic drugs pioglitazone and glimepiride present in a fixed-dose combination formulation.
Bradford, D; Karim, A; Laurent, A; Schuster, J; Slater, M; Zhao, Z, 2007)		0.54
"To compare the pharmacokinetic and pharmacodynamic effects of glimepiride between once- and twice-daily dosing in type 2 diabetic patients."( Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing.
Kaku, K; Kanda, Y; Kawasaki, F; Kohara, K; Kotani, K; Matsuda, M; Matsuki, M; Shigetoh, M; Shimoda, M; Tawaramoto, K, 2007)		0.85
"This study assessed the efficacy and safety of two different dosing regimens of fixed-dose combination (FDC) rosiglitazone (RSG) plus glimepiride (GLIM) compared with RSG or GLIM monotherapy in drug-naive subjects with type 2 diabetes mellitus (T2DM)."( Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.
Chou, HS; Ferreira-Cornwell, C; Goldstein, BJ; Jones, AR; Krebs, J; Palmer, JP; Waterhouse, B, 2008)		0.79
"A simple, precise, rapid, and reproducible reversed-phase high-performance liquid chromatography method is developed for the simultaneous estimation of metformin hydrochloride (MET), pioglitazone hydrochloride (PIO), and glimepiride (GLP) present in multicomponent dosage forms."( Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and glimepiride by RP-HPLC in tablet formulation.
Amin, M; Jain, D; Jain, S, 2008)		0.76
" Dosage was increased to a maximum of four pills in order to reach the glycemic control goals (fasting glucose ( Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
Aguilar-Salinas, C; Arechavaleta-Granell, R; Beltrán-Jaramillo, TJ; González-Canudas, J; González-Ortiz, M; Guerrero-Romero, JF; Islas-Andrade, S; Martínez-Abundis, E; Metha, R; Ramos-Zavala, MG; Revilla-Monsalve, C; Rodríguez-Morán, M; Violante-Ortiz, R; Wacher-Rodarte, N; Zavala-Suárez, E, )		0.51
"A simple, fast, and precise reverse phase, isocratic HPLC method was developed for the separation and quantification of pioglitazone and glimepiride in bulk drug and pharmaceutical dosage form."( Simultaneous determination of pioglitazone and glimepiride in bulk drug and pharmaceutical dosage form by RP-HPLC method.
A, K; A, R; Bhat, K; C, MR; G, S; K, K; M, S; N, U; P, M, 2008)		0.81
" Healthy fasting Korean men were randomized to 1 of 2 dosing sequences: a single oral administration of a fixed-dose glimepiride 1-mg + metformin 500-mg combination tablet (test) followed by single oral administration of a fixed-dose glimepiride 2 mg + metformin 500 mg combination tablet (reference), separated by a 1-week washout period between doses; or a single oral administration of a fixed-dose glimepiride 2-mg + metformin 500-mg combination tablet followed by single oral administration of a fixed-dose glimepiride 1 mg + metformin 500-mg combination tablet, separated by a 1-week washout period between doses."( Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in
Cho, JY; Jang, IJ; Kim, BH; Kim, J; Kim, JR; Kim, KP; Lim, KS; Shin, KH; Shin, SG; Yu, KS, 2009)		0.84
"0%), even at maximal dosage levels of one or two oral agents, and are at increased risk for diabetes-related complications."( Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
Conner, C; Hammer, M; Lee, WC, 2011)		0.6
" In resistance vessels, venous occlusion plethysmography was used to measure the dilator response to acetylcholine (ACh) [area under ACh dose-response curve (ACh AUC)]."( Postconditioning protects against human endothelial ischaemia-reperfusion injury via subtype-specific KATP channel activation and is mimicked by inhibition of the mitochondrial permeability transition pore.
Bhavsar, DD; Charakida, M; Deanfield, JE; Loukogeorgakis, SP; MacAllister, RJ; Okorie, MI; Ridout, D, 2011)		0.37
" Longer-acting GLP-1 agonists are dosed less frequently, appear to be associated with less nausea, and may be associated with better rates of adherence than shorter-acting agents."( Optimizing outcomes for GLP-1 agonists.
Freeman, JS, 2011)		0.37
"Using 96% ethanol as solvent, a less toxic and cost-effective spectrophotometric method for the determination of glimepiride in solid dosage forms was developed and validated."( An ultraviolet-spectrophotometric method for the determination of glimepiride in solid dosage forms.
Afieroho, OE; Okonkwo, TJ; Okorie, O, 2011)		0.82
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)		0.37
" Serial blood sampling for 12h after oral dosing was performed for determination of plasma glimepiride, glucose and insulin levels."( Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population.
Cho, HJ; Huh, W; Huh, WS; Kim, HG; Kim, JW; Kim, YG; Ko, JW; Lee, SY; Oh, SY, 2011)		0.82
" To accommodate the various dosing regimens of glimepiride, a glimepiride/metformin 1/500 mg SR tablet was also developed."( Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized
Cho, JY; Jang, IJ; Kim, SE; Shin, KH; Shin, SG; Yoon, SH; Yu, KS, 2011)		0.86
" Serial blood samples were collected immediately before and after dosing for 30 hours, and plasma concentrations were determined by using LC-MS/MS with validated methods."( Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized
Cho, JY; Jang, IJ; Kim, SE; Shin, KH; Shin, SG; Yoon, SH; Yu, KS, 2011)		0.6
" Primary endpoints were the area under the curve from the time of dosing to infinity (AUC(inf)) and the maximum observed plasma concentration (C(max)) of each drug."( No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Kadokura, T; Keirns, J; Krauwinkel, WJ; Smulders, RA; van Dijk, J; Veltkamp, SA; Zhang, W, 2012)		0.6
" As a conclusion, dissolution enhancement and hypoglycemic potentiation by 1:20 PM of Gmp/Tris, being simple and easy to prepare, may enable development of a reduced-dose and fast-release oral dosage form of Gmp."( Improvement of dissolution and hypoglycemic efficacy of glimepiride by different carriers.
Borg, TM; Foda, AM; Meshali, MM; Mohamed, EA, 2012)		0.63
" After four months, the patients were crossed over with no washout period to the alternative treatment for an additional four-month period on similar dosage schedules."( Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus.
Correia, MR; Cunha, MR; Fukui, RT; Lage, SG; Machado, HA; Rocha, DM; Santos, RF; Silva, ME; Vieira, M; Wajchenberg, BL, 2012)		0.71
" The effective dosage range is 1 to 8 mg/day; however, there is no significant difference between 4 and 8 mg/day, but it should be used with caution in the elderly and in patients with renal or hepatic disease."( Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].
Basit, A; Fawwad, A; Riaz, M, 2012)		1.82
" For the colesevelam coadministration periods, 3,750 mg once daily was dosed throughout the pharmacokinetic sampling period."( The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil.
He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)		0.64
" Insulin dosage and weight-gain were similar."( Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections.
Gao, L; Riddle, MC; Rosenstock, J; Vlajnic, A, 2014)		0.4
"To evaluate the antidiabetic drug dosage differences between geriatric and nongeriatric diabetics with reference to duration of disease and creatinine clearance (Crcl)."( Do geriatrics require dose titration for antidiabetic agents?
Adhikari, P; Chowta, M; Kamath, A; Pai, MR; Shastry, R; Ullal, S, )		0.13
" Further extensive pre/clinical studies are necessary prior to use transdermal GMD as a valuable alternative to peroral dosage forms with improved bioavailability, longer duration of action and more patient convenience."( Optimization of self-nanoemulsifying systems for the enhancement of in vivo hypoglycemic efficacy of glimepiride transdermal patches.
Abdel-Naim, AB; Afouna, MI; Ahmed, OA; Banjar, ZM; El-Say, KM; Khedr, A, 2014)		0.62
" The insulin dosing algorithm was not sufficient to equalize nocturnal hypoglycaemia between the two insulins."( Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Bolli, GB; Candelas, C; Dain, MP; Deerochanawong, C; Home, PD; Landgraf, W; Mathieu, C; Pilorget, V; Riddle, MC, 2015)		0.42
" Each subject received the following treatments (A and B) with a 7-day washout period: treatment A consisted of gemigliptin 50 mg once daily administered orally for 6 days, followed by concomitant oral dosing of glimepiride 4 mg and gemigliptin 50 mg on day 7; treatment B consisted of a single dose of glimepiride 4 mg."( Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Bae, KS; Bang, K; Choi, HY; Han, S; Kim, MJ; Kim, YH; Lee, SH; Lim, HS, 2014)		0.8
"A simple and convenient method was developed for the simultaneous determination of metformin HCl and glimepiride in tablet dosage form of different pharmaceuticals companies."( A simple and convenient method for the simultaneous in vitro study of metformin and glimepiride tablets.
Ahmed, R, 2014)		0.84
" There were no significant differences between self-monitored blood glucose measured at each time-point among different glimepiride dosages, or during the 14 weeks when glimepiride was used at its maximal dosage (6 mg/day)."( Glimepiride treatment in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene.
He, X; Huang, Z; Li, Y; Liao, Z; Liu, J; Ng, K; Wan, X; Xu, L, 2018)		2.13
" The significance of inkjet printing in producing amorphous dosage forms from solution based inks and personalised dosage forms of drugs susceptible to processing conditions was demonstrated using ramipril."( Valvejet Technology for the Production of a Personalised Fixed Dose Combination of Ramipril and Glimepiride: an Investigative Study on the Stability of Ramipril.
Croker, DM; Faucher, A; Kollamaram, G; Walker, GM, 2018)		0.7
" In conclusion, the potential cost of CYP2C9 genotype-guided dosing for glimepiride therapy is relatively high, and associated with modest improvements with respect to the number of hypoglycaemia avoided, as compared with standard dosing."( Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study.
Bourguignon, L; Fokoun, C; Goutelle, S; Rabier, H; Serrier, H; Tod, M, 2021)		1.16
"We aimed to investigate the effect of dosage reduction of four hypoglycemic multidrug regimens on the incidences of acute glycemic complications in people with type 2 diabetes who fast during Ramaḍān."( Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial.
Amarin, JZ; Beirat, AF; Hasan, YY; Hassoun Al Najar, AM; Qtaishat, A; Tierney, ME; Zaghlol, LY; Zaghlol, RY; Zayed, AA, 2021)		0.62
" The developed methods were successfully applied for the determination of glimepiride and pioglitazone hydrochloride in pure powder and dosage form."( Spectrophotometric methods for determination of glimepiride and pioglitazone hydrochloride mixture and application in their pharmaceutical formulation.
Atta, MY; Ghoniem, NS; Hegazy, MA; Hussien, EM, 2022)		1.21
" Hypoglycemic activity of a combination of glimepiride + metformin was enhanced when losartan was co-administered as a single dosage schedule as well as a multiple dose schedule as indicated by a reduced blood glucose level and enhanced levels of insulin in rats as well as in rabbits."( Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits.
Anilkumar, KV; Nagaraju, B, )		0.63
"It can therefore be concluded, that in diabetics with hypertension as a comorbidity condition, co-administration of losartan with glimepiride + metformin should be avoided or the dosage of a combination of glimepiride + metformin needs to be tittered to avoid recurrence of hypoglycemic episodes."( Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits.
Anilkumar, KV; Nagaraju, B, )		0.57
"A reversed-phase RP-HPLC method was developed for the simultaneous determination of metformin hydrochloride (MET), pioglitazone (PIO), and glimepiride (GLM) in their combined dosage forms and spiked human plasma."( Deduction of the operable design space of RP-HPLC technique for the simultaneous estimation of metformin, pioglitazone, and glimepiride.
Elkhodary, MM; Hammad, SF; Kamal, AH; Marie, AA; Salim, MM, 2023)		1.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1551 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements362
Household Essentials86
Beauty & Personal Care418
Pet Supplies61
Herbs, Botanicals & Homeopathy28
Professional Supplements69
Active Lifestyle & Fitness112
Weight Management75
Baby & Kids Products117
Food & Beverages223

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
1Life Science NMN+ Serum Platinum -- 1.7 oz1Life ScienceVitamins & Supplementscarbomer, vitamin E, vitamin E, nicotinamide mononucleotide, resveratrol, sodium hydroxide2024-11-29 10:47:42
8Greens Super Greens Gummies - Beauty Strawberry -- 50 Gummies8GreensVitamins & SupplementsVitamin C, Biotin, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
A La Maison French Liquid Hand Soap Refill - Lavender Aloe -- 33.8 fl ozA La MaisonHousehold Essentialstocopherol, tocopherol, vitamin E2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - Cherry Blossom -- 16.9 fl ozA La MaisonHousehold Essentialstocopherol, tocopherol, vitamin E2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - Citrus Blossom -- 16.9 fl ozA La MaisonHousehold Essentialstocopherol, tocopherol, vitamin E2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - Fresh Sea Salt -- 16.9 fl ozA La MaisonHousehold Essentialstocopherol, tocopherol, vitamin E2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - Heirloom Peach -- 16.9 fl ozA La MaisonHousehold Essentialsbenzyl salicylate, tocopherol, tocopherol, vitamin E, glycerin, hydroxyethylcellulose, linalool2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - Honeysuckle -- 16.9 fl ozA La MaisonHousehold Essentialstocopherol, tocopherol, vitamin e2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - Lavender Aloe -- 16.9 fl ozA La MaisonHousehold Essentialstocopherol, tocopherol, vitamin E2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - Plumeria -- 16.9 fl ozA La MaisonHousehold Essentialstocopherol, tocopherol, vitamin E, glycerin, hydroxyethylcellulose2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - Provence Lemon -- 16.9 fl ozA La MaisonHousehold Essentialscitral, tocopherol, decyl glucoside, tocopherol, vitamin E, glycerin, hydroxyethylcellulose2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - Pure Coconut -- 16.9 fl ozA La MaisonHousehold EssentialsTocopherol, Tocopherol, Vitamin E2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - Rose Lilac -- 16.9 fl ozA La MaisonHousehold Essentialstocopherol, tocopherol, vitamin E2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - White Tea -- 16.9 fl ozA La MaisonHousehold EssentialsTocopherol, Tocopherol, Vitamin E2024-11-29 10:47:42
A La Maison French Liquid Hand Soap - Yuzu Lime -- 16.9 fl ozA La MaisonHousehold Essentialstocopherol, tocopherol, vitamin E2024-11-29 10:47:42
A La Maison French Liquid Hand Soap Refill - Provence Lemon -- 33.8 fl ozA La MaisonHousehold Essentialscitral, tocopherol, decyl glucoside, tocopherol, vitamin E, glycerin, hydroxyethylcellulose2024-11-29 10:47:42
A La Maison French Liquid Hand Soap Refill - Pure Coconut -- 33.8 fl ozA La MaisonHousehold Essentialstocopherol, tocopherol, vitamin E2024-11-29 10:47:42
A La Maison French Milled Hand & Body Bar Soap Unscented -- 4 BarsA La MaisonBeauty & Personal CarePalm, Tocopherol, Tocopherol, Vitamin E2024-11-29 10:47:42
Abound Dry Dog Food Wild Beginnings Beef Venison & Lamb -- 4 lbsAboundPet SuppliesVitamin E, Docosahexaenoic Acid, Vitamin E, L-Carnitine, Phosphorus, Vitamin A, Selenium, Taurine2024-11-29 10:47:42
Abound Dry Dog Food Wild Beginnings Salmon Whitefish & Trout -- 4 lbsAboundPet SuppliesVitamin E, Docosahexaenoic Acid, Vitamin E, L-Carnitine, Phosphorus, Vitamin A, Selenium, Taurine2024-11-29 10:47:42
Abound Grain Free Jerky Bites for Dog & Puppy Lamb Chickpea Squash -- 12 ozAboundPet SuppliesVitamin E, Vitamin E2024-11-29 10:47:42
Abound Grain Free Jerky Bites for Dog & Puppy Salmon & Sweet Potato -- 12 ozAboundPet SuppliesVitamin E, Vitamin E2024-11-29 10:47:42
Abound Pro Dry Dog Food Vet Formulated Healthy Weight Chicken Oatmeal -- 8 lbsAboundPet SuppliesVitamin C, Chondroitin, Vitamin E, Vitamin E, Glucosamine, L-Carnitine, Phosphorus, Vitamin A2024-11-29 10:47:42
Abound Pro Dry Dog Food Vet Formulated Senior Salmon Pea -- 8 lbsAboundPet SuppliesVitamin C, Chondroitin, Vitamin E, Docosahexaenoic Acid, Vitamin E, Glucosamine, L-Carnitine, Phosphorus2024-11-29 10:47:42
Abound Pro Dry Dog Food Vet Formulated Sensitive Stomach Lamb Brown Rice -- 8 lbsAboundPet SuppliesVitamin C, Vitamin E, Vitamin E, Phosphorus, Selenium, Taurine2024-11-29 10:47:42
Abound Pro Dry Dog Food Vet Formulated Skin & Coat Salmon Brown Rice -- 8 lbsAboundPet SuppliesVitamin C, Vitamin E, Docosahexaenoic Acid, Vitamin E, Linoleic Acid, Phosphorus, Selenium2024-11-29 10:47:42
Abound Pro Dry Puppy Food Vet Formulated Chicken Brown Rice -- 8 lbsAboundPet SuppliesVitamin C, Vitamin E, EPA, Vitamin E, Phosphorus, Vitamin A, Taurine2024-11-29 10:47:42
Abound Pro Wet Dog Food Vet Formulated Healthy Weight Support Turkey Recipe -- 13.2 ozAboundPet SuppliesVitamin E, Vitamin E, L-Carnitine2024-11-29 10:47:42
Abound Pro Wet Dog Food Vet Formulated Joint Health Support Chicken Duck Turkey Recipe -- 13.2 ozAboundPet SuppliesVitamin E, Vitamin E2024-11-29 10:47:42
Abound Pro Wet Dog Food Vet Formulated Skin & Coat Support Salmon Sweet Potato Pate -- 13.2 ozAboundPet SuppliesVitamin E, Vitamin E2024-11-29 10:47:42
Abound Pro Wet Puppy Food Vet Formulated Chicken Vegetable Stew -- 13.2 ozAboundPet SuppliesVitamin E, Docosahexaenoic Acid, Vitamin E, L-Carnitine2024-11-29 10:47:42
Abound Pro+ Dry Cat Food Indoor Weight Hairball Care Chicken & Turkey -- 7 lbsAboundPet SuppliesVitamin C, Vitamin E, Vitamin E, L-Carnitine, Phosphorus, Taurine2024-11-29 10:47:42
Abound Pro+ Dry Cat Food Senior Formula Chicken & Brown Rice -- 7 lbsAboundPet SuppliesVitamin C, Chondroitin, Vitamin E, Vitamin E, Glucosamine, Phosphorus2024-11-29 10:47:42
Abound Pro+ Dry Cat Food Sensitive Skin & Stomach Salmon & Brown Rice -- 7 lbsAboundPet SuppliesVitamin C, Vitamin E, Vitamin E, Phosphorus, Taurine2024-11-29 10:47:42
Abound Wet Dog Food Dinner Pate Turkey & Sweet Potato -- 3.5 ozAboundPet SuppliesVitamin E, Vitamin E, L-Carnitine2024-11-29 10:47:42
Abound Wild Beginnings Dry Cat Food Salmon -- 7 lbsAboundPet SuppliesVitamin E, Vitamin E, Phosphorus, Vitamin A, Selenium, Taurine2024-11-29 10:47:42
Abra Therapeutics Detox Complexion Wash Lavender & Grapefruit -- 4 fl ozAbra TherapeuticsBeauty & Personal Carecitric acid, citric acid, vitamin E, tocopherol, vitamin E, cane sugar2024-11-29 10:47:42
Abra Therapeutics Green Tea Therapeutic Lotion Green Tea & Lemongrass -- 16 fl ozAbra TherapeuticsBeauty & Personal Carevitamin E, tocopherol, vitamin E, phenoxyethanol, sodium hydroxide2024-11-29 10:47:42
AC Grace Unique E -- 120 SoftgelsAC GraceVitamins & SupplementsVitamin E, Vitamin E, Fat2024-11-29 10:47:42
AC Grace Unique E -- 60 SoftgelsAC GraceVitamins & Supplements astaxanthin, Vitamin D3, Coenzyme Q10, Vitamin E, EPA, Vitamin E, lycopene2024-11-29 10:47:42
Acure Seriously Soothing Blue Tansy Night Oil -- 1 fl ozAcureBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Acure Seriously Soothing Solid Serum 3 in1 -- 1.7 fl ozAcureBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
AH! YES Organic Oil Based Personal Lubricant -- 4.7 fl ozAH! YESBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Airborne Immune Support Vitamin C & D + Zinc Elderberry -- 50 GummiesAirborneHerbs, Botanicals & HomeopathyVitamin C, Vitamin E, Vitamin E2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 13 Vitamins Minerals & Herbs Citrus -- 200 Chewable TabletsAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 13 Vitamins Minerals & Herbs Citrus -- 64 Chewable TabletsAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 13 Vitamins Minerals & Herbs Citrus -- 96 Chewable TabletsAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 13 Vitamins Minerals & Herbs Very Berry -- 10 Effervescent TabletsAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, L-glutamine, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 13 Vitamins Minerals & Herbs Very Berry -- 32 Chewable TabletsAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 13 Vitamins Minerals & Herbs Very Berry -- 64 Chewable TabletsAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, L-Glutamine, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 13 Vitamins Minerals & Herbs Very Berry -- 96 Chewable TabletsAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 13 Vitamins Minerals & Herbs Zesty Orange -- 30 Effervescent TabletsAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Riboflavin, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 9 Vitamins Minerals & Herbs Assorted Fruit -- 42 GummiesAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 9 Vitamins Minerals & Herbs Assorted Fruit -- 63 GummiesAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 9 Vitamins Minerals & Herbs Blueberry Pomegranate -- 63 GummiesAirborneHerbs, Botanicals & HomeopathyVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + 9 Vitamins Minerals & Herbs Zesty Orange -- 63 GummiesAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Immune Support Vitamin C + Zinc Elderberry -- 20 Effervescent TabletsAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Kids Immune Support Vitamin C & D + Zinc Elderberry -- 50 GummiesAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E2024-11-29 10:47:42
Airborne Kids Immune Support Vitamin C + 9 Vitamins Minerals & Herbs Assorted Fruit -- 42 GummiesAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Airborne Kids Immune Support Vitamin C + 9 Vitamins Minerals & Herbs Assorted Fruit -- 63 GummiesAirborneVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Selenium2024-11-29 10:47:42
Alba Botanica Hawaiian Body Cream Kukui Nut -- 6.5 ozAlbaBeauty & Personal Carebeta carotene, carbomer, vitamin E, ethylhexylglycerin, vitamin E, glyceryl stearate, dimethicone, phenoxyethanol, stearic acid, stearyl alcohol2024-11-29 10:47:42
All Good Assorted Lip Balm 3 Pack Original - Spearmint - Coconut SPF 15 -- 3 Lip BalmAll GoodBeauty & Personal Carecalendula, comfrey, vitamin E, vitamin E2024-11-29 10:47:42
All Good Mineral Sport Sunscreen Butter Tin SPF 50 -- 1 fl ozAll GoodBeauty & Personal Carevitamin E, vitamin E2024-11-29 10:47:42
All Good Organic Lip Balm - SPF 15 Original -- 0.15 ozAll GoodBeauty & Personal Carecalendula, comfrey, vitamin E, vitamin E2024-11-29 10:47:42
All Good Organic Lip Balm - SPF 15 Spearmint -- 0.15 ozAll GoodBeauty & Personal Carecalendula, comfrey, vitamin E, vitamin E2024-11-29 10:47:42
All Good Organic Lip Balm - SPF 15 Tangerine -- 0.15 ozAll GoodBeauty & Personal Carecalendula, comfrey, vitamin E, vitamin E2024-11-29 10:47:42
All Good Sport Sunscreen Butter Stick SPF 50+ -- 2.75 ozAll GoodBeauty & Personal Carecalendula, vitamin E, vitamin E2024-11-29 10:47:42
All Good Tinted Mineral Sunscreen Butter Tin SPF 50 -- 1 fl ozAll GoodBeauty & Personal Carevitamin E, vitamin E, octyldodecanol2024-11-29 10:47:42
Allergy Research Group Multi-Vi-Min -- 150 CapsulesAllergy Research GroupProfessional SupplementsBiotin, Boron, Vitamin D3, Chromium, Vitamin E, Folic Acid, Vitamin E, Glutamic Acid, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Allergy Research Group Multi-Vi-Min without Copper & Iron -- 150 Vegetarian CapsulesAllergy Research GroupProfessional SupplementsPABA, Vitamin C, Biotin, Boron, Vitamin D3, Chromium, Vitamin E, Folic Acid, Vitamin E, Glutamic Acid, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Allergy Research Group Quercetin 300 -- 300 mg - 60 CapsulesAllergy Research GroupProfessional SupplementsVitamin C, Vitamin E, Vitamin E, Quercetin2024-11-29 10:47:42
Allergy Research Group Stabilium 200 -- 30 CapsulesAllergy Research GroupProfessional SupplementsVitamin E, Vitamin E, Vitamin B6, Vitamin A, Beta, Vitamin B62024-11-29 10:47:42
Allergy Research Group Super D3 -- 60 Vegetarian CapsulesAllergy Research GroupProfessional SupplementsVitamin C, Vitamin D3, Vitamin E, Vitamin E, Tocotrienols2024-11-29 10:47:42
Allergy Research Group Super EPA Fish Oil Concentrate -- 200 SoftgelsAllergy Research GroupProfessional SupplementsVitamin E, Docosahexaenoic Acid, Vitamin E2024-11-29 10:47:42
ALLMAX Nutrition Liver D-Tox Ultimate Liver Protection -- 42 CapsulesALLMAX NutritionActive Lifestyle & FitnessNAC, Vitamin C, Vitamin E, Vitamin E, Selenium2024-11-29 10:47:42
Almased Dietary Supplement for Weight Management Almond Vanilla -- 17.6 ozAlmasedWeight ManagementVitamin C, L-Cystine, Vitamin E, Vitamin E, L-Histidine, L-Isoleucine, L-Lysine, Niacin, L-Phenylalanine, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B62024-11-29 10:47:42
Almased Dietary Supplement for Weight Management -- 17.6 ozAlmasedWeight ManagementVitamin C, L-Cystine, Vitamin E, Vitamin E, L-Histidine, L-Isoleucine, L-Lysine, L-Phenylalanine, Vitamin B6, Vitamin A, Riboflavin, Thiamin, L-Valine, Vitamin B62024-11-29 10:47:42
Aloe Life Personal Gel Intimate Moisturizer Unscented -- 4 ozAloe LifeBeauty & Personal Careallantoin, cholecalciferol, vitamin E, panthenol, vitamin E, glycerin, retinyl palmitate, vitamin A2024-11-29 10:47:42
Aloe Life Skin Gel Ultimate Skin Treatment Unscented -- 1 ozAloe LifeBeauty & Personal Carecitric acid, allantoin, ascorbic acid, azulene, citric acid, tocopherol, tocopherol, vitamin E, glycerin, retinol2024-11-29 10:47:42
Amazing Grass Fizzy Green Tablets Superfood Lemon Lime -- 60 ServingsAmazing GrassVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Thiamin, Vitamin B122024-11-29 10:47:42
Amazing Nutrition Amazing Formulas Daily Multivitamin -- 500 TabletsAmazing NutritionVitamins & SupplementsVitamin C, Biotin, Boron, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Nickel, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Amazing Nutrition Amazing Omega - Norwegian Fish Oil Orange -- 1250 mg - 120 SoftgelsAmazing NutritionVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Amberen Advanced Perimenopause Relief -- 60 CapsulesAmberenVitamins & SupplementsVitamin E, Vitamin B9, Vitamin E, Glycine, Vitamin B6, Vitamin B2, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
AMEN Biotin Collagen Peptides - Vitamins C & E Folate Keratin Hyaluronic Acid -- 90 Vegetable CapsulesAMENVitamins & SupplementsVitamin C, Biotin, Vitamin E, Folate, Vitamin E2024-11-29 10:47:42
American Biotech Labs Silver Biotics™ Advanced Healing Skin Cream Unscented -- 3.4 ozAmerican Biotech LabsBeauty & Personal Carevitamin E, tocopherol, vitamin E, glycerin, silver, stearic acid2024-11-29 10:47:42
Amy Myers MD Liposomal Vitamin C -- 15.2 fl ozAmy Myers MDProfessional SupplementsVitamin C, Vitamin E, Vitamin E2024-11-29 10:47:42
Amy Myers MD The Myers Way Multivitamin -- 180 CapsulesAmy Myers MDProfessional SupplementsVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, myo-Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ancient Nutrition Multi Prenatal -- 90 CapsulesAncient NutritionVitamins & SupplementsVitamin E, Folate, Vitamin E, Niacin, Vitamin B6, Vitamin A, Riboflavin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Andalou Naturals Age Defying Apricot Probiotic Cleansing Milk -- 6 fl ozAndalou NaturalsBeauty & Personal Careorange, allantoin, cetyl alcohol, CoQ10, tocopherol, ethylhexylglycerin, tocopherol, vitamin e, glyceryl stearate, glyceryl monolaurate, phenethyl alcohol, resveratrol, ubiquinone2024-11-29 10:47:42
Andalou Naturals Brighten & Tighten Hydro Serum Facial Sheet Mask -- 6 fl ozAndalou NaturalsBeauty & Personal Careallantoin, vitamin C, bisabolol, tocopherol, ethylhexylglycerin, tocopherol, vitamin E, phenethyl alcohol2024-11-29 10:47:42
Andalou Naturals Pure Pore Hydro Serum Facial Sheet Mask -- 0.6 fl ozAndalou NaturalsBeauty & Personal Careallantoin, bisabolol, tocopherol, tocopherol, palmarosa, vitamin E, phenethyl alcohol2024-11-29 10:47:42
Animal Advanced Omega -- 30 PacksAnimalActive Lifestyle & FitnessAlpha-Linolenic Acid, Vitamin E, Docosahexaenoic Acid, Gamma Linolenic Acid, Vitamin E2024-11-29 10:47:42
Animal Flex Joint Support -- 44 PacketsAnimalActive Lifestyle & FitnessVitamin C, cetyl myristoleate, cetyl palmitate, Vitamin E, Methylsulfonylmethane, Vitamin E, Glucosamine, HCl, Manganese, cetyl oleate, Quercetin, Selenium2024-11-29 10:47:42
Animal PAK - The Ultimate Training Pack -- 30 PacksAnimalActive Lifestyle & FitnessLipase, Alanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Carnitine, Choline, Chromium, Coenzyme Q10, Cystine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glutamine, Glycine, Histidine, Hydroxyproline, Inositol, Iodine, Isoleucine, Leucine, Lutein, Lycopene, Lysine, Manganese, menaquinone-4, Methionine, Niacin, Ornithine, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Selenium, Serine, L-Taurine, Thiamin, Alpha Lipoic Acid, Threonine, Tryptophan, Tyrosine, Valine, Vitamin B12, Vitamin B6, phytonadione, Vitamin K2024-11-29 10:47:42
Animal PAK - The Ultimate Training Pack -- 44 PacksAnimalActive Lifestyle & FitnessLipase, Alanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Carnitine, Choline, Chromium, Coenzyme Q10, Cystine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glutamine, Glycine, Histidine, Hydroxyproline, Inositol, Iodine, Isoleucine, Leucine, Lutein, Lycopene, Lysine, Manganese, menaquinone-4, Methionine, Niacin, Ornithine, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Selenium, Serine, L-Taurine, Thiamin, Alpha Lipoic Acid, Threonine, Tryptophan, Tyrosine, Valine, Vitamin B12, Vitamin B6, phytonadione, Vitamin K2024-11-29 10:47:42
Animal Pak Ultimate Foundation Powder Cherry Bomb -- 30 ServingsAnimalActive Lifestyle & FitnessLipase, Vitamin C, Betaine Anhydrous, Biotin, dicalcium phosphate, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, L-Glutamine, L-Histidine, Inositol, Iodine, L-Isoleucine, calcium carbonate, Lutein, Lycopene, Manganese, menaquinone-4, Niacin, Pantothenic Acid, L-Phenylalanine, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, L-Taurine, Thiamin, L-Valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Animal Pak Ultimate Foundation Powder Fruit Punch -- 14.7 ozAnimalActive Lifestyle & FitnessLipase, Vitamin C, Betaine Anhydrous, Biotin, dicalcium phosphate, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, L-Glutamine, L-Histidine, Inositol, Iodine, L-Isoleucine, calcium carbonate, Lutein, Lycopene, Manganese, menaquinone-4, Niacin, Pantothenic Acid, L-Phenylalanine, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, L-Taurine, Thiamin, L-Valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Animal Pak Ultimate Foundation Powder Orange Crushed -- 14.5 ozAnimalActive Lifestyle & FitnessLipase, Vitamin C, Betaine Anhydrous, Biotin, dicalcium phosphate, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, L-Glutamine, L-Histidine, Inositol, Iodine, L-Isoleucine, calcium carbonate, Lutein, Lycopene, Manganese, menaquinone-4, Niacin, Pantothenic Acid, L-Phenylalanine, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, L-Taurine, Thiamin, L-Valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Arthur Andrew Medical Inc. Femesse Breast and Balance -- 240 CapsulesArthur Andrew Medical Inc.Professional SupplementsVitamin E, Folate, Vitamin E, Vitamin B6, Selenium, Vitamin B62024-11-29 10:47:42
Atkins Iced Coffee Protein Shake Vanilla Latte -- 11 fl oz Each / Pack of 4AtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins Peanut Butter Granola Bar Meal Peanut Butter -- 5 BarsAtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins Protein Meal Bar Chocolate Chip Cookie Dough -- 5 BarsAtkinsWeight ManagementVitamin C, Biotin, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins Protein Plus RTD Creamy Milk Chocolate -- 4 BottlesAtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins Protein Plus RTD Creamy Vanilla -- 4 BottlesAtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins Protein Rich Shake Cafe Caramel -- 4 ShakesAtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins Protein Rich Shake Creamy Caramel -- 4 Bottles Each / Pack of 4AtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins Protein Shake Chai Tea Latte -- 11 fl oz Each / Pack of 4AtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins Protein-Rich Shake Dark Chocolate Royale -- 8 ShakesAtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins RTD Protein Shake Creamy Vanilla -- 8 ShakesAtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins RTD Protein-Rich Meal Shake Creamy Chocolate -- 16.9 fl oz Each / Pack of 4AtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins RTD Shake Creamy Root Beer Float -- 4 ShakesAtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins RTD Shake Milk Chocolate Delight -- 8 ShakesAtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins RTD Shake Mocha Latte -- 11 fl oz Each / Pack of 4AtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins RTD Shake Pumpkin Spice Latte -- 11 fl oz Each / Pack of 4AtkinsActive Lifestyle & FitnessVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins RTD Shake Strawberry -- 11 fl oz Each / Pack of 4AtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins Snack Bar Caramel Chocolate Nut Roll -- 5 BarsAtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Atkins Snack Bar Caramel Chocolate Peanut Nougat -- 5 BarsAtkinsWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Aura Cacia Essential Oil Blend Relaxing Roll-On Chill Pill -- 0.31 fl ozAura CaciaBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Aura Cacia Essential Oil Blend Soothing Roll-On Lavender -- 0.31 fl ozAura CaciaBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Auromere Ayurvedic Bar Soap Himalayan Rose -- 2.75 ozAuromereBeauty & Personal Carevitamin E, vitamin E, henna2024-11-29 10:47:42
Auromere Ayurvedic Bar Soap Lavender Neem -- 2.75 ozAuromereBeauty & Personal Carevitamin E, vitamin E2024-11-29 10:47:42
Auromere Ayurvedic Bar Soap Sandalwood-Turmeric -- 2.75 ozAuromereBeauty & Personal Carevitamin E, vitamin E2024-11-29 10:47:42
Auromere Ayurvedic Bar Soap Tulsi-Neem -- 2.75 ozAuromereBeauty & Personal Carevitamin E, vitamin E2024-11-29 10:47:42
Auromere Ayurvedic Bar Soap Vanilla Neem -- 2.75 ozAuromereBeauty & Personal Carevitamin E, vitamin E, henna2024-11-29 10:47:42
Auromere Ayurvedic Conditioner Bar with Neem -- 2.12 ozAuromereBeauty & Personal Carecetyl alcohol, vitamin E, D-panthenol, vitamin E, glycerine, vitamin B52024-11-29 10:47:42
Auromere Ayurvedic Exfoliating Body Bar Soap With Neem Herbal Spice -- 4.23 ozAuromereBeauty & Personal Carevitamin E, vitamin E2024-11-29 10:47:42
Auromere Ayurvedic Shampoo Bar with Organic Neem Tulsi-Spice -- 4.23 ozAuromereBeauty & Personal Carevitamin E, vitamin E, henna2024-11-29 10:47:42
Aussie Bubs Australian Grass Fed Nutritional Milk-Based Toddler Formula -- 28.2 ozAussie BubsBaby & Kids ProductsVitamin C, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Babo Botanicals Body Lotion Calming Lavender -- 8 fl ozBabo BotanicalsBaby & Kids Productschamomile, calendula, cetyl alcohol, vitamin E, vitamin E2024-11-29 10:47:42
Babo Botanicals Daily Sheer Tinted Sunscreen Extra Sensitive For Face SPF 30 -- 1.7 fl ozBabo BotanicalsBeauty & Personal Caretocopherol, decyl glucoside, tocopherol, vitamin E, glyceryl stearate, glyceryl caprylate, stearic acid2024-11-29 10:47:42
Babo Botanicals Moisturizing Body Lotion Oat & Calendula -- 8 fl ozBabo BotanicalsBeauty & Personal Carecetyl alcohol, vitamin E, vitamin E, glycerine, glyceryl caprylate, oat2024-11-29 10:47:42
Babo Botanicals Moisturizing Shampoo & Wash Oat & Calendula -- 16 fl ozBabo BotanicalsBaby & Kids Productscaprylyl glycol, glyceryl oleate, citric acid, ascorbyl palmitate, annatto, vitamin c, gluconolactone, citric acid, tocopherol, tocopherol, vitamin e, sodium gluconate, glycerin, sorbic acid2024-11-29 10:47:42
Babo Botanicals Sensitive Baby 2-in-1 Baby Shampoo & Wash Fragrance-Free -- 16 fl ozBabo BotanicalsBaby & Kids Productsvitamin e, ethylhexylglycerin, basil, vitamin e, sodium benzoate2024-11-29 10:47:42
Babo Botanicals Sensitive Baby Daily Hydrating Lotion Fragrance Free -- 8 fl ozBabo BotanicalsBaby & Kids Productscetearyl alcohol, cetyl alcohol, vitamin E, vitamin E, glycerin, glyceryl caprylate, oat2024-11-29 10:47:42
Babo Botanicals Smoothing Detangling Conditioner Spray Berry & Primrose -- 8 fl ozBabo BotanicalsBeauty & Personal Careisopropyl alcohol, cetearyl alcohol, tocopherol, ethylhexylglycerin, tocopherol, vitamin e, glycerin, phenethyl alcohol2024-11-29 10:47:42
Baby Cozy Baby Wipes Cleansing & Moisturizing 2-in-1 Formula - 6 Packs with 40 Wipes Per Pack -- 240 WipesBaby CozyBaby & Kids Productsvitamin E, vitamin E2024-11-29 10:47:42
Baebody Eye Cream -- 1.7 fl ozBaebodyBeauty & Personal Careprovitamin A, vitamin E, provitamin B5, vitamin E, glycerin, vitamin B3, phenoxyethanol, propylene glycol, stearic acid2024-11-29 10:47:42
Baebody Eye Gel -- 1.7 fl ozBaebodyBeauty & Personal Carebutylene glycol, alanine, arginine, aspartic acid, carbomer, vitamin E, dimethyl sulfone, vitamin E, glycerin, glycine, histidine, isoleucine, phenylalanine, proline, serine, sodium benzoate, sodium lactate, threonine, valine2024-11-29 10:47:42
Baebody Eye Gel Travel Size -- 0.5 fl ozBaebodyBeauty & Personal Carebutylene glycol, alanine, arginine, aspartic acid, carbomer, vitamin E, dimethyl sulfone, vitamin E, glycerin, glycine, histidine, isoleucine, phenylalanine, proline, serine, sodium benzoate, sodium lactate, threonine, valine2024-11-29 10:47:42
Baebody Retinol Facial Serum -- 1.01 fl ozBaebodyBeauty & Personal Carevitamin E, vitamin E, glycerin, retinol, sodium benzoate2024-11-29 10:47:42
Baebody Retinol Moisturizer -- 1.7 fl ozBaebodyBeauty & Personal Carecetyl alcohol, tocopherol, panthenol, tara, ethylhexylglycerin, tocopherol, vitamin E, glyceryl stearate, glycerin, isopropyl palmitate, vitamin B5, phenoxyethanol, potassium phosphate, retinol, stearic acid2024-11-29 10:47:42
Baebody Tea Tree Serum -- 1.01 fl ozBaebodyBeauty & Personal Carevitamin C, tocopherol, tara, dimethyl sulfone, ethylhexylglycerin, tocopherol, vitamin E, glycerin, vitamin B3, niacinamide, phenoxyethanol, retinol, salicylic acid, squalane2024-11-29 10:47:42
Baebody Vitamin C Facial Serum -- 1.01 fl ozBaebodyBeauty & Personal Carevitamin C, vitamin E, tara, dimethyl sulfone, ethylhexylglycerin, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Baebody Vitamin C Moisturizer -- 1.7 fl ozBaebodyBeauty & Personal Carevitamin C, cetyl alcohol, vitamin E, panthenol, dimethyl sulfone, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, isopropyl palmitate, vitamin B5, phenoxyethanol, stearic acid2024-11-29 10:47:42
Balanced Breed Dog All-in-1 Canine Multivitamin Vet Pharmacist Approved Peanut & Butter Banana -- 60 Soft ChewsBalanced BreedPet SuppliesVitamin C, Vitamin E, Folic Acid, Vitamin E, Vitamin B6, Vitamin B2, Taurine, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Balanced Greens Plant Protein Chocolate -- 34 ServingsBalanced GreensWeight ManagementVitamin C, Vitamin E, Folate, Vitamin E, Niacin, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Balanced Greens Plant Protein Unflavored -- 34 ServingsBalanced GreensWeight ManagementVitamin C, Vitamin E, Folate, Vitamin E, Niacin, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Balanced Greens Plant Protein Vanilla -- 34 ServingsBalanced GreensWeight ManagementVitamin C, Vitamin E, Folate, Vitamin E, Niacin, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Balanceuticals Seabuckthorn Seed Oil -- 500 mg - 60 SoftgelsBalanceuticalsHerbs, Botanicals & HomeopathyLinolenic Acid, Vitamin E, Vitamin E, Linoleic acid, Oleic Acid, Vitamin A2024-11-29 10:47:42
Bark & Whiskers Wild Alaskan Cod Liver Oil Vet Formulated for Dogs & Cats -- 6.8 fl ozBark & WhiskersPet SuppliesVitamin E, Docosahexaenoic Acid, Vitamin E, Vitamin A2024-11-29 10:47:42
Barney Butter Non-GMO Almond Butter Cocoa and Coconut -- 10 ozBarney ButterFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Barney Butter Non-GMO Almond Butter Bare Crunchy -- 10 ozBarney ButterFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Barney Butter Non-GMO Almond Butter Crunchy -- 16 ozBarney ButterFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Barney Butter Non-GMO Almond Butter Smooth -- 10 ozBarney ButterFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Barney Butter Non-GMO Almond Butter Smooth -- 16 ozBarney ButterFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Bausch & Lomb Ocuvite Eye Vitamin and Mineral Supplement Adult 50 Plus -- 50 SoftgelsBausch & LombVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Lutein, Zeaxanthin2024-11-29 10:47:42
Bausch & Lomb Ocuvite® Eye Vitamin & Mineral Supplement -- 120 TabletsBausch & LombVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Lutein, Vitamin A, Selenium2024-11-29 10:47:42
Bausch & Lomb PreserVision Eye Vitamin & Mineral Supplement AREDS 2 Patented Formula -- 120 SoftgelsBausch & LombVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Lutein, Zeaxanthin2024-11-29 10:47:42
Bausch & Lomb PreserVision Eye Vitamin & Mineral Supplement AREDS Lutein -- 120 SoftgelsBausch & LombVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Lutein2024-11-29 10:47:42
Bausch & Lomb PreserVision Eye Vitamin and Mineral Supplement AREDS Softgel Formula -- 60 SoftgelsBausch & LombVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Bausch & Lomb PreserVision® Eye Vitamin & Mineral Supplement AREDS Formula -- 120 SoftgelsBausch & LombVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Beauty Without Cruelty Facial Balancing Toner -- 8.5 fl ozBeauty Without CrueltyBeauty & Personal Carecitric acid, allantoin, benzyl alcohol, calendula, citric acid, vitamin E, panthenol, pro-vitamin B-5, Palmarosa, vitamin E, phenoxyethanol, retinyl palmitate, vitamin A, sorbitol2024-11-29 10:47:42
Beauty Without Cruelty Ultimate Conditioning Mascara Walnut -- 0.27 fl ozBeauty Without CrueltyBeauty & Personal Carebutylene glycol, benzyl alcohol, biotin, tocopherol, ethylhexylglycerin, tocopherol, vitamin E, phenoxyethanol, titanium dioxide2024-11-29 10:47:42
Because Extra Large Cleansing Wipes -- 48 WipesBecauseBeauty & Personal Carevitamin E, vitamin E, phenoxyethanol, propylene glycol, sodium citrate2024-11-29 10:47:42
Because No-Rinse Cleansing Spray -- 6 fl ozBecauseBeauty & Personal CareDMDM hydantoin, allantoin, betaine, vitamin E, D-panthenol, disodium EDTA, tocopherol, vitamin E, propylene glycol2024-11-29 10:47:42
Beech-Nut Mini Waffles with Hidden Veggies 12+ Months Butternut Berry -- 3.2 ozBeech-NutBaby & Kids ProductsVitamin E, Folate, Vitamin E, Niacin, Thiamin2024-11-29 10:47:42
Beech-Nut Whole Grain Baby Cereal Oatmeal -- 6 PackBeech-NutBaby & Kids ProductsVitamin E, Folate, Vitamin E, Niacin, Vitamin B, Pantothenic Acid, Phosphorus, Riboflavin, Thiamin2024-11-29 10:47:42
Best Naturals Cranberry Concentrate -- 12600 mg - 180 Vegetarian CapsulesBest NaturalsHerbs, Botanicals & HomeopathyVitamin C, Vitamin E, Vitamin E2024-11-29 10:47:42
Better Life Dish Soap Pomegranate -- 22 fl ozBetter LifeHousehold Essentialsorange, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Better Life Dish Soap Unscented -- 22 fl ozBetter LifeHousehold Essentialstocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Better Life Liquid Soap Naturally Skin-Soothing Citrus Mint -- 12 fl ozBetter LifeHousehold Essentialsorange, vitamin E, decyl glucoside, ethylhexylglycerin, vitamin E, glycerin, phenoxyethanol, PEG-150 stearate2024-11-29 10:47:42
Better Life Liquid Soap Naturally Skin-Soothing Clary Sage -- 12 fl ozBetter LifeHousehold Essentialsorange, vitamin E, decyl glucoside, ethylhexylglycerin, vitamin E, glycerin, phenoxyethanol, retinol palmitate, vitamin A2024-11-29 10:47:42
Better Life Liquid Soap Naturally Skin-Soothing Scent Free -- 12 fl ozBetter LifeHousehold Essentialsvitamin E, decyl glucoside, ethylhexylglycerin, vitamin E, glycerin, phenoxyethanol, PEG-150 stearate2024-11-29 10:47:42
Beverly International Super Pak -- 30 PacketsBeverly InternationalActive Lifestyle & FitnessPara-Aminobenzoic Acid, Vitamin C, Betaine HCl, Biotin, Chloride, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, L-Glutamic Acid, Pepsin, Inositol, Iodine, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Biggs & Featherbelle Handmade Natural Soap Bar Barbados Grapefruit and Orange -- 3.5 ozBiggs & FeatherbelleBeauty & Personal Carepalm, vitamin E, vitamin E2024-11-29 10:47:42
Bio Nutrition Testosterone Wellness for Men -- 60 TabletsBio NutritionVitamins & SupplementsVitamin E, DHEA, Gamma Oryzanol, Vitamin E, Gamma Oryzanol2024-11-29 10:47:42
Biocare Dietary GLP-1 Beverage - Pack of 14 Chocolate -- 14 PacketsBiocareProfessional SupplementsVitamin C, Biotin, L-Carnosine, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Leucine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Biocare Dietary GLP-1 Beverage - Pack of 14 Chocolate Salted Caramel -- 14 PacketsBiocareProfessional SupplementsVitamin C, Biotin, L-Carnosine, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Leucine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Biocare Dietary GLP-1 Beverage - Pack of 14 Mixed Fruit -- 14 PacketsBiocareProfessional SupplementsVitamin C, Biotin, L-Carnosine, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Leucine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Biocare Dietary GLP-1 Beverage - Pack of 14 Strawberries & Cream -- 14 PacketsBiocareProfessional SupplementsVitamin C, Biotin, L-Carnosine, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Leucine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Biohoney Avocado and Rosehip Cream Cleanser -- 5.9 fl ozBiohoneyBeauty & Personal Carecetearyl alcohol, vitamin E, vitamin E, glycerine, phenoxyethanol, stearic acid2024-11-29 10:47:42
Biohoney Certified Organic Bee Venom Mask -- 1.76 ozBiohoneyBeauty & Personal Carecetyl alcohol, vitamin E, tocopherol, vitamin E, glyceryl stearate2024-11-29 10:47:42
Biohoney Hydrating Mist Toner -- 3.3 fl ozBiohoneyBeauty & Personal Caregluconolactone, vitamin E, tocopherol, vitamin E, glycerine2024-11-29 10:47:42
Biohoney Natural Acne Cream -- 1.76 ozBiohoneyBeauty & Personal Carechamomile, calendula, vitamin e, tocopherol, vitamin e2024-11-29 10:47:42
Biohoney Natural Vitamin E Cream -- 1.76 ozBiohoneyBeauty & Personal Carevitamin E, tocopherol, vitamin E2024-11-29 10:47:42
BioSchwartz Immunity Boost -- 90 CapsulesBioSchwartzVitamins & SupplementsVitamin C, Goldenseal, Vitamin E, Vitamin E, Vitamin A, Selenium2024-11-29 10:47:42
Blue Diamond Almond Milk Chocolate -- 4 PackBlue DiamondFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Blue Diamond Almond Milk Original -- 64 fl ozBlue DiamondFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Blue Diamond Almonds Snickerdoodle -- 6 ozBlue DiamondFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Blue Diamond Kosher Almond Breeze Almond Coconut Blend Original -- 32 fl ozBlue DiamondFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Blue Diamond Kosher Almond Breeze Almond Coconut Blend Unsweetened Original -- 32 fl ozBlue DiamondFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Blue Diamond Kosher Almond Breeze Almond Coconut Blend Unsweetened Vanilla -- 32 fl ozBlue DiamondFood & BeveragesVitamin C, Vitamin E, Vitamin E, Manganese, Phosphorus, Vitamin A, Riboflavin2024-11-29 10:47:42
Blue Diamond Kosher Almond Breeze Almondmilk Chocolate -- 32 fl ozBlue DiamondFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Blue Diamond Kosher Almond Breeze Almondmilk Original -- 32 fl ozBlue DiamondFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Blue Diamond Kosher Almond Breeze Almondmilk Vanilla -- 32 fl ozBlue DiamondFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Blue Diamond Kosher Almond Breeze Almondmilk Unsweetened Chocolate -- 32 fl ozBlue DiamondFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Blue Diamond Kosher Almond Breeze Almondmilk Unsweetened Original -- 32 fl ozBlue DiamondFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Blue Diamond Kosher Almond Breeze Almondmilk Unsweetened Original -- 64 fl ozBlue DiamondFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Blue Diamond Kosher Almond Breeze Almondmilk Unsweetened Vanilla -- 32 fl ozBlue DiamondFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Blue Diamond Kosher Almond Breeze Almondmilk Unsweetened Vanilla -- 64 fl ozBlue DiamondFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Blue Diamond Kosher Almonds Roasted Salted -- 1.5 oz Each / Pack of 12Blue DiamondFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Blue Diamond Kosher Almonds Roasted Salted -- 12 ozBlue DiamondFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Blue Diamond Kosher Almonds Roasted Salted -- 6 ozBlue DiamondFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Blue Diamond Kosher Almonds Smokehouse -- 6 ozBlue DiamondFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Blue Diamond Kosher Almonds Whole Natural -- 12 ozBlue DiamondFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Blue Diamond Kosher Almonds Whole Natural -- 16 ozBlue DiamondFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Blue Diamond Kosher Almonds Bold Habanero BBQ -- 16 ozBlue DiamondFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Blue Diamond Kosher Almonds Lightly Salted - LowSodium -- 12 ozBlue DiamondFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Blue Diamond Kosher Almonds Lightly Salted -- 16 ozBlue DiamondFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Blue Diamond Kosher Almonds Whole Natural -- 1.5 oz Each / Pack of 12Blue DiamondFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Blue Diamond Kosher Oven Roasted Almonds Dark Chocolate -- 14 ozBlue DiamondFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Blue-Emu Arthritis Cream -- 3 FileBlue-EmuBeauty & Personal Careallantoin, tocopherol acetate, cetyl alcohol, vitamin E, D-panthenol, methylsulfonylmethane, disodium EDTA, ethylhexylglycerin, vitamin E, D-glucosamine, glycerin, dimethicone, phenoxyethanol, stearic acid, triethanolamine2024-11-29 10:47:42
Blue-Emu Lidocaine Cream -- 2.7 ozBlue-EmuBeauty & Personal Careallantoin, tocopherol acetate, cetyl alcohol, vitamin E, dl-panthenol, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, dimethicone, phenoxyethanol, stearic acid2024-11-29 10:47:42
Bluebonnet Nutrition Maxi ONE® Whole Food-Based Multiple -- 90 Vegetable CapsulesBluebonnet NutritionVitamins & SupplementsVitamin C, Biotin, Boron, Vitamin D3, Choline, Chromium, Vitamin E, riboflavin 5' phosphate, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Vitamin B3, Pantothenic Acid, pyridoxine 5' phosphate, pyridoxine HCl, Vitamin B6, Vitamin A, Vitamin B2, Selenium, citrate, citrate, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Bluebonnet Nutrition Multi One Single Daily Multiple -- 120 Vegetable CapsulesBluebonnet NutritionVitamins & SupplementsPABA, Vitamin C, Biotin, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Manganese, Molybdenum, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Bluebonnet Nutrition Natural Vitamin E -- 400 IU - 100 SoftgelsBluebonnet NutritionVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Bluebonnet Nutrition Targeted Choice EyeCare Macular & Blue -- 60 Vegetable CapsulesBluebonnet NutritionVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Lutein, Zeaxanthin2024-11-29 10:47:42
Caboo Baby Wipes Jumbo Unscented -- 432 WipesCabooBaby & Kids Productscitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin, sodium citrate2024-11-29 10:47:42
Caboo Baby Wipes Jumbo Unscented -- 72 WipesCabooBaby & Kids Productscitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin, sodium citrate2024-11-29 10:47:42
Caboo Flushable Wipes Bamboo Unscented Hypoallergenic -- 60 WipesCabooHousehold Essentialstocopherol, tocopherol, vitamin E, glycerin, sodium citrate2024-11-29 10:47:42
Carlson Cod Liver Oil Gems Super -- 1000 mg - 250 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Cod Liver Oil Gems™ Super -- 1000 mg - 100 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Elite Omega-3 Gems Lemon -- 1600 mg - 240 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Elite Omega-3 Gems® Fish Oil Wild Caught Lemon -- 1600 mg - 90 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Fish Oil BOGO Lemon -- 120 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Norwegian Cod Liver Oil Lemon -- 460 mg - 150 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Norwegian Cod Liver Oil Lemon -- 8.4 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Norwegian Cod Liver Oil Unflavored -- 16.9 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Norwegian Cod Liver Oil Dietary Supplement Unflavored -- 8.4 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Norwegian Cod Liver Oil Gems Natural Lemon -- 460 mg - 300 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Norwegian MedOmega™ Fish Oil Concentrate Lemon Lime -- 3.3 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Norwegian Salmon Oil BOGO 180 Ct + 50 Ct -- 500 mg - 180 Softgels Each / Pack of 2CarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Norwegian The Very Finest Fish Oil Natural Orange -- 16.9 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Solar D Gems Natural Lemon -- 4000 IU - 120 SolidCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Super D Omega-3 Lemon -- 8.4 fl ozCarlsonVitamins & SupplementsVitamin D3, Vitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Super DHA Gems® -- 500 mg - 180 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Super Omega-3 Gems® -- 250 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Super Omega-3 Gems® 30 FREE Soft Gels -- 100 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson The Very Finest Fish Oil Lemon -- 1600 mg - 6.7 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson The Very Finest Fish Oil Orange -- 240 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson The Very Finest Fish Oil- Omega-3s Natural Orange -- 700 mg - 150 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Wild Norwegian Cod Liver Oil Natural Lemon -- 1100 mg - 16.9 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
CeliAct Optimizing Nutrition for People with Celiac Disease -- 180 TabletsCeliActVitamins & Supplements Lipase, Para Aminobenzoic Acid, Vitamin C, Biotin, Boron, Chromium, Vitamin E, Folic Acid, Vitamin E, L-Glutamic Acid, Inositol, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Centrum Adult Multivitamin and Multimineral Supplement -- 60 TabletsCentrumVitamins & SupplementsVitamin C, Biotin, Chloride, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Centrum Men Multi-Vitamin Tablets -- 200 TabletsCentrumVitamins & SupplementsVitamin C, Biotin, Chloride, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Centrum MultiGummies Men 50 Plus Multivitamin Supplement Assorted Natural Fruit -- 140 GummiesCentrumVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Vitamin E, Folate, Vitamin E, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Centrum MultiGummies Men 50 Plus Multivitamin Supplement Assorted Natural Fruit -- 80 GummiesCentrumVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Vitamin E, Folate, Vitamin E, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Centrum MultiGummies Women 50 Plus Multivitamin Supplement Assorted Fruit -- 140 GummiesCentrumVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Vitamin E, Folate, Vitamin E, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Centrum MultiGummies Women 50 Plus Multivitamin Supplement Assorted Fruit -- 80 GummiesCentrumVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Vitamin E, Folate, Vitamin E, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Centrum Multivitamin for Men Multivitamin/Multimineral Supplement -- 120 TabletsCentrumVitamins & SupplementsVitamin C, Biotin, Chloride, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Centrum Multivitamin for Men Multivitamin/Multimineral Supplement -- 65 TabletsCentrumVitamins & SupplementsVitamin C, Biotin, Chloride, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Centrum Silver Adults 50 Plus Multivitamin Tablets -- 220 TabletsCentrumVitamins & SupplementsVitamin C, Biotin, Chloride, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Centrum Silver Men 50 Plus Multivitamin-Multimineral Tablets -- 200 TabletsCentrumVitamins & SupplementsVitamin C, Biotin, Chloride, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Centrum Silver Women 50 Plus Multivitamin-Multimineral Tablets -- 100 TabletsCentrumVitamins & SupplementsVitamin C, Biotin, Chloride, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Centrum Women MultiVitamin -- 65 TabletsCentrumVitamins & SupplementsVitamin C, Biotin, Chloride, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Centrum Women Multivitamin-Multimineral -- 200 TabletsCentrumVitamins & SupplementsVitamin C, Biotin, Chloride, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Centrum Women Multivitamin-Multimineral Tablets -- 120 TabletsCentrumVitamins & SupplementsVitamin C, Biotin, Chloride, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Cerebelly Organic Baby Food Dairy Free Smoothie Celery Apple Kiwi -- 6 PouchesCerebellyBaby & Kids ProductsVitamin C, Choline, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin B6, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Dairy Free Smoothie Purple Carrot Blueberry -- 6 PackCerebellyBaby & Kids ProductsVitamin C, Choline, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Dairy Free Smoothie Sweet Potato Peach -- 6 PouchesCerebellyBaby & Kids ProductsVitamin C, Choline, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Black Bean Sweet Potato with Avocado Oil -- 6 PouchesCerebellyBaby & Kids ProductsCholine, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Butternut Squash White Bean -- 6 PouchesCerebellyBaby & Kids ProductsCholine, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Beet Carrot Blueberry -- 6 PouchesCerebellyBaby & Kids ProductsCholine, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Broccoli Pear -- 6 PouchesCerebellyBaby & Kids ProductsVitamin C, Choline, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Butternut Squash Chicken Broth -- 6 PouchesCerebellyBaby & Kids ProductsCholine, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Carrot Beef Broth -- 6 PouchesCerebellyBaby & Kids ProductsCholine, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Carrot Pumpkin -- 6 PouchesCerebellyBaby & Kids ProductsCholine, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Green Bean Pumpkin -- 6 PouchesCerebellyBaby & Kids ProductsCholine, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Kale Sweet Potato Apple -- 6 PouchesCerebellyBaby & Kids ProductsCholine, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Spinach Apple Sweet Potato -- 6 PouchesCerebellyBaby & Kids ProductsVitamin C, Choline, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Sweet Potato Mango -- 6 PouchesCerebellyBaby & Kids ProductsVitamin C, Choline, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees Sweet Potato Pinto Bean -- 6 PouchesCerebellyBaby & Kids ProductsCholine, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Baby Food Purees White Bean Pumpkin Apple -- 6 PouchesCerebellyBaby & Kids ProductsVitamin C, Choline, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cerebelly Organic Smart Toddler Snack Bars Apple Kale -- 5 BarsCerebellyBaby & Kids ProductsVitamin C, Choline, Vitamin E, Vitamin E, Iodine, Manganese, Phosphorus, Vitamin A, Selenium, Vitamin B122024-11-29 10:47:42
Cerebelly Organic Smart Toddler Snack Bars Blueberry Banana Sweet Potato -- 5 BarsCerebellyBaby & Kids ProductsVitamin C, Choline, Vitamin E, Vitamin E, Iodine, Manganese, Phosphorus, Vitamin A, Selenium2024-11-29 10:47:42
Cerebelly Organic Smart Toddler Snack Bars Carrot Date -- 5 BarsCerebellyBaby & Kids ProductsVitamin C, Choline, Vitamin E, Vitamin E, Iodine, Manganese, Phosphorus, Vitamin A, Selenium2024-11-29 10:47:42
Cerebelly Organic Smart Toddler Snack Bars Strawberry Beet -- 5 BarsCerebellyBaby & Kids ProductsCholine, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Chapter One One Multi Gummies -- 60 GummiesChapter OneVitamins & SupplementsVitamin C, Biotin, Choline, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Chapter Six Prenatal -- 60 GummiesChapter SixVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Childlife Multi Vitamin and Mineral Natural Orange Mango -- 8 fl ozChildlifeVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Childlife Multi Vitamin SoftMelts Natural Orange -- 27 GummiesChildlifeVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Vitamin E, Folate, Vitamin E, Niacin, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Childlife MultiVitamin Gummy Gluten Free Sugar Free Strawberry Lemon -- 90 GummiesChildlifeVitamins & SupplementsVitamin C, Biotin, Boron, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Childlife Pure DHA Chewable Berry -- 90 SoftgelsChildlifeVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Clearly Natural Essentials - Foaming Glycerin Hand Soap Aloe Vera -- 8 fl ozClearly NaturalHousehold Essentialsglyceryl oleate, tocopherol, decyl glucoside, tocopherol, vitamin E, glycerin, glycine, phenoxyethanol2024-11-29 10:47:42
Clearly Natural Essentials - Foaming Glycerin Hand Soap Unscented -- 8 fl ozClearly NaturalHousehold Essentialsglyceryl oleate, tocopherol, decyl glucoside, tocopherol, vitamin E, glycerin, glycine, phenoxyethanol2024-11-29 10:47:42
Clearly Natural Essentials - Foaming Glycerin Hand Soap Vitamin E -- 8 fl ozClearly NaturalHousehold Essentialsglyceryl oleate, annatto, tocopherol, decyl glucoside, tocopherol, vitamin E, glycerin, glycine, phenoxyethanol2024-11-29 10:47:42
Clearly Natural Essentials Glycerin Bar Soap Vitamin E -- 4 oz Each / 3 PackClearly NaturalBeauty & Personal Careannatto, tocopherol, tocopherol, vitamin E, Glycerin, sodium citrate2024-11-29 10:47:42
Clearly Natural Essentials Glycerin Liquid Hand Soap Aloe Vera -- 12 fl ozClearly NaturalHousehold Essentialstocopherol, decyl glucoside, tocopherol, vitamin E, glycerin, glycine, phenoxyethanol2024-11-29 10:47:42
Clearly Natural Essentials Glycerin Liquid Hand Soap Orange -- 12 fl ozClearly NaturalHousehold Essentialsannatto, tocopherol, decyl glucoside, tocopherol, saffron, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Clearly Natural Essentials Glycerin Liquid Hand Soap Tea Tree -- 12 fl ozClearly NaturalHousehold Essentialsvitamin E, vitamin E, glycerine, glycine, oleic acid, potassium hydroxide2024-11-29 10:47:42
Clearly Natural Essentials Glycerin Liquid Hand Soap Unscented -- 12 fl ozClearly NaturalHousehold Essentialstocopherol, decyl glucoside, tocopherol, vitamin E, glycerin, glycine, phenoxyethanol2024-11-29 10:47:42
Clearly Natural Essentials Glycerin Liquid Hand Soap Unscented -- 32 fl ozClearly NaturalHousehold Essentialstocopherol, decyl glucoside, tocopherol, vitamin E, glycerin, glycine, phenoxyethanol2024-11-29 10:47:42
Clearly Natural Essentials Glycerin Liquid Hand Soap with Vitamin E -- 12 fl ozClearly NaturalHousehold Essentialstocopherol acetate, vitamin E, vitamin E, glycerine, glycine, oleic acid, phenylethyl alcohol, potassium hydroxide2024-11-29 10:47:42
Clif Bar Builders Plant-Based Protein Chocolate Chip Cookie Dough -- 12 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Builders Plant-Based Protein Bars Cookies and Cream -- 12 BarsClifActive Lifestyle & FitnessVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Clif Bar Builders Plant-Based Protein Bars Vanilla Almond -- 12 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Builders Plant-Based Protein Bars Cookies Chocolate -- 12 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Builders Plant-Based Protein Bars Chocolate -- 6 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Builders Plant-Based Protein Bars Chocolate Mint -- 12 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Builders Plant-Based Protein Bars Chocolate Mint -- 6 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Builders Plant-Based Protein Bars Chocolate Peanut Butter -- 12 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Builders Plant-Based Protein Bars Vanilla Almond -- 6 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Builders Plant-Based Protein Mini Bars Chocolate Mint -- 10 PackClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Builders Plant-Based Protein Mini Bars Chocolate Peanut Butter -- 10 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Builders Plant-Based Protein Plus Caffeine Bars Chocolate Chip Cookie Dough -- 6 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Kid ZBar Protein Bars Chocolate Chip -- 10 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Kid ZBar Protein Bars Chocolate Chip -- 15 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Kid ZBar Protein Bars Chocolate Chip -- 5 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Kid ZBar Protein Bars Chocolate Mint -- 10 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Kid ZBar Protein Bars Chocolate Mint -- 15 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Gluten Free Kid ZBar Protein Bars Cookies N Creme -- 5 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Kid Zbar Organic Protein Bars Smores -- 6 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Non-GMO Energy Bars Blueberry Almond Crisp -- 6 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Non-GMO Energy Bars Chocolate Chip Peanut Crunch -- 12 BarsClifActive Lifestyle & FitnessVitamin C, Vitamin E, Vitamin E, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Clif Bar Non-GMO Energy Mini Bars Chocolate Brownie -- 20 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Non-GMO Energy Mini Bars Crunchy Peanut Butter -- 10 BarsClifActive Lifestyle & FitnessVitamin C, Vitamin E, Vitamin E, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Clif Bar Non-GMO Energy Mini Bars White Chocolate Macadamia Nut -- 20 BarsClifActive Lifestyle & FitnessVitamin C, Vitamin E, Vitamin E, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Clif Bar Organic Kid ZBar Blueberry Muffin -- 12 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Kid ZBar Chocolate Brownie -- 12 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Kid ZBar Chocolate Brownie -- 18 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Kid ZBar Chocolate Brownie -- 24 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Kid ZBar Chocolate Brownie -- 6 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Kid ZBar Chocolate Chip -- 12 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Kid ZBar Chocolate Chip -- 18 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Kid ZBar Chocolate Chip -- 24 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Kid ZBar Iced Oatmeal Cookie -- 12 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Kid ZBar Iced Oatmeal Cookie -- 18 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Kid ZBar Iced Oatmeal Cookie -- 24 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Kid ZBar - Chocolate Chip & Oatmeal Cookie Variety Pack -- 24 BarsClifFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Nut Butter Bar Chocolate Chip & Peanut Butter -- 5 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Nut Butter Bars Chocolate & Peanut Butter -- 5 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Bar Organic Nut Butter Bars Peanut Butter -- 5 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Energy Bar Minis Chocolate Chip -- 20 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Gluten Free Builders Plant-Based Protein Bars Chocolate Peanut Butter -- 6 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Non-GMO Energy Mini Bars Chocolate Chip -- 10 BarsClifActive Lifestyle & FitnessVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Clif Organic Nut Butter Filled Energy Bars Chocolate Peanut Butter -- 12 BarsClifActive Lifestyle & FitnessVitamin C, Vitamin E, Vitamin E, Phosphorus, Vitamin A2024-11-29 10:47:42
Clif Organic Nut Butter Filled Energy Bars Peanut Butter -- 12 BarsClifActive Lifestyle & FitnessVitamin C, Vitamin E, Vitamin E, Phosphorus, Vitamin A2024-11-29 10:47:42
Codeage Eye Vitamins - Macular Health Complex AREDS 2 - Vision Support Formula -- 120 CapsulesCodeageProfessional SupplementsVitamin C, Omega-3, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Codeage Hair Vitamins - Biotin 10000 mcg Keratin Collagen Zinc Inositol Supplement -- 120 CapsulesCodeageProfessional SupplementsVitamin C, Biotin, Omega-3, Vitamin D3, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Codeage Liposomal Vitamin C 1000 mg with Vitamin E - Liquid Vitamin C Supplement for Women Immune Support Citrus Vanilla -- 32 PouchesCodeageProfessional SupplementsVitamin C, Vitamin E, Vitamin E2024-11-29 10:47:42
Codeage Teen Daily Multivitamin - Vitamins A B C D E K Zinc Biotin & Probiotics Vegan Supplement -- 60 CapsulesCodeageProfessional SupplementsVitamin C, Astaxanthin, Biotin, Boron, Omega-3, Vitamin D3, Chromium, Coenzyme Q10, Vitamin E, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Codeage Teen Daily Multivitamin - Vitamins A B C D E K Zinc Biotin & Probiotics Vegan Supplement -- 60 Capsules Each / Pack of 2CodeageProfessional SupplementsVitamin C, Astaxanthin, Biotin, Boron, Omega-3, Vitamin D3, Chromium, Coenzyme Q10, Vitamin E, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Codeage Wonder-C Liposomal Liquid Vitamin C 1000 mg with D3 Zinc Rose Hips & Quercetin -- 16 fl ozCodeageProfessional SupplementsVitamin C, Vitamin E, Vitamin E, Quercetin2024-11-29 10:47:42
Comforts Advantage Premium Milk-Based Infant Formula -- 34 ozComfortsBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, Fat, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Comforts Baby Oil with Aloe -- 20 fl ozComfortsBaby & Kids Productstocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Comforts Gentle Premium Milk Based Infant Formula -- 33.2 ozComfortsBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, Fat, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Comforts Infant Premium Milk Based Formula with Iron -- 34 ozComfortsBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, Fat, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Comforts Pediatric Shake Chocolate -- 6 ShakesComfortsBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Comforts Pediatric Shake Strawberry -- 6 ShakesComfortsBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Comforts Pediatric Shake Vanilla -- 16 ShakesComfortsBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Comforts Pediatric Shake Vanilla -- 6 ShakesComfortsBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Comforts Yogurt Bites Baby Snacks Mixed Berry -- 1 ozComfortsBaby & Kids ProductsVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Comforts Yogurt Bites Baby Snacks Strawberry -- 1 ozComfortsBaby & Kids ProductsVitamin C, Vitamin E, Vitamin E2024-11-29 10:47:42
Coromega Kids Omega 3 +Vitamin D Tropical Orange -- 30 PacketsCoromegaVitamins & SupplementsVitamin C, Vitamin D3, Vitamin E, EPA, Vitamin E2024-11-29 10:47:42
Coromega Omega-3 Squeeze Orange -- 90 PacketsCoromegaVitamins & SupplementsVitamin C, Vitamin E, EPA, Vitamin E2024-11-29 10:47:42
Country Life Chewable Adult Multi -- 60 WafersCountry LifeVitamins & SupplementsPABA, Vitamin C, Biotin, calcium ascorbate, calcium citrate, Choline, Chromium, Vitamin E, riboflavin 5' phosphate, Folic Acid, Vitamin E, Inositol, Manganese, Niacin, niacinamide, PABA, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Country Life Core Daily-1 for Men 50 + -- 60 TabletsCountry LifeVitamins & SupplementsLipase, Vitamin C, beta carotene, Betaine, Biotin, Calcium fructoborate, d-calcium pantothenate, Cellulase, Choline, Chromium, Vitamin E, riboflavin 5' phosphate, Folic Acid, Vitamin E, inositol hexanicotinate, Inositol, Lactose, Manganese, Molybdenum, Niacin, pantethine, Pantothenic Acid, Phosphorus, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, citrate, citrate, thiamine hydrochloride, Thiamin, cyanocobalamin, Vitamin B6, Vitamin K2024-11-29 10:47:42
Country Life Core Daily™ 1 for Women 50 Plus -- 60 TabletsCountry LifeVitamins & SupplementsLipase, Vitamin C, beta carotene, Betaine, Biotin, Calcium fructoborate, d-calcium pantothenate, Cellulase, Choline, Chromium, Vitamin E, riboflavin 5' phosphate, Folic Acid, Vitamin E, inositol hexanicotinate, Inositol, Lactose, Manganese, Molybdenum, Niacin, pantethine, Pantothenic Acid, Phosphorus, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, citrate, citrate, thiamine hydrochloride, Thiamin, cyanocobalamin, Vitamin B6, Vitamin K2024-11-29 10:47:42
Country Life Daily Total One™ Iron Free -- 60 Vegetarian CapsulesCountry LifeVitamins & Supplements ascorbyl palmitate, Vitamin C, beta carotene, Betaine, Biotin, Boron, calcium ascorbate, calcium citrate, d-calcium pantothenate, di-calcium phosphate, Chromium, Vitamin E, riboflavin 5' phosphate, Folate, Vitamin E, inositol hexanicotinate, Inositol, magnesium citrate, Manganese, Molybdenum, Niacin, niacinamide, pantethine, Pantothenic Acid, Phosphorus, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, retinyl palmitate, Vitamin A, Riboflavin, Selenium, thiamine hydrochloride, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Country Life Natural E-Complex with Mixed Tocopherols -- 400 IU - 90 SoftgelsCountry LifeVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Country Life Ultra Concentrated Omega™ 3 6 9 -- 90 SoftgelsCountry LifeVitamins & SupplementsAlpha-Linolenic Acid, Vitamin E, Docosahexaenoic Acid, Vitamin E, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
Crystal Magnesium Enriched Deodorant Stick Charcoal & Tea Tree -- 2.5 ozCrystalBeauty & Personal Carechamomile, tocopherol, triethyl citrate, tocopherol, vitamin E, glyceryl caprylate, ozokerite2024-11-29 10:47:42
Crystal Magnesium Enriched Deodorant Stick Clean & Fresh -- 2.5 ozCrystalBeauty & Personal Carechamomile, tocopherol, triethyl citrate, tocopherol, vitamin E, glyceryl caprylate, ozokerite2024-11-29 10:47:42
Crystal Magnesium Enriched Deodorant Stick Coconut & Vanilla -- 2.5 ozCrystalBeauty & Personal Carechamomile, tocopherol, triethyl citrate, tocopherol, vitamin E, glyceryl caprylate, ozokerite2024-11-29 10:47:42
Crystal Magnesium Enriched Deodorant Stick Cucumber & Mint -- 2.5 ozCrystalBeauty & Personal Carechamomile, tocopherol, triethyl citrate, tocopherol, vitamin E, glyceryl caprylate, ozokerite2024-11-29 10:47:42
Crystal Magnesium Enriched Deodorant Stick Lavender + Rosemary -- 2.5 ozCrystalBeauty & Personal Carechamomile, tocopherol, triethyl citrate, tocopherol, vitamin E, glyceryl caprylate, ozokerite2024-11-29 10:47:42
Crystal Magnesium Enriched Deodorant Stick Sea Salt & Sage -- 2.5 ozCrystalBeauty & Personal Carechamomile, tocopherol, triethyl citrate, tocopherol, vitamin E, glyceryl caprylate, ozokerite2024-11-29 10:47:42
Culturelle Kids Probiotic Plus Multivitamin Chewables Natural Fruit Punch -- 30 Chewable TabletsCulturelleVitamins & SupplementsVitamin C, Biotin, Vitamin E, Folate, Vitamin E, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Culturelle Kids Probiotics Multivitamin Plus Probiotic -- 60 GummiesCulturelleVitamins & SupplementsVitamin C, Biotin, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cymbiotika Elderberry Immune Support -- 26 PouchesCymbiotikaHerbs, Botanicals & HomeopathyCitrus Pectin, Vitamin E, Vitamin E2024-11-29 10:47:42
Cymbiotika Liposomal Magnesium L-Threonate Vanilla Creme -- 30 ServingsCymbiotikaVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Cymbiotika Plant Protein Powder Vanilla -- 30 ozCymbiotikaWeight Management Lipase, Alanine, Arginine, Aspartic Acid, Cellulase, Cystine, Vitamin E, Vitamin E, L-Glutamine, Alpha GPC, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Niacin, Phenylalanine, Phosphorus, Proline, Serine, Threonine, Tryptophan, Tyrosine, Valine, Vitamin K2024-11-29 10:47:42
DaVinci Laboratories Coenzyme Q10 ChewMelt -- 100 mg - 60 Chewable TabletsDaVinci LaboratoriesProfessional SupplementsCoenzyme Q10, Vitamin E, Vitamin E2024-11-29 10:47:42
DaVinci Laboratories Daily Best™ Ultra Multivitamin -- 60 CapsulesDaVinci LaboratoriesProfessional SupplementsVitamin C, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
DaVinci Laboratories Healthy Eyes -- 90 CapsulesDaVinci LaboratoriesProfessional SupplementsVitamin C, Vitamin E, Vitamin E, Lutein, Lycopene, Quercetin, Vitamin A, Riboflavin, Selenium, Taurine, Alpha-Lipoic Acid, Vitamin B12, Zeaxanthin2024-11-29 10:47:42
DaVinci Laboratories Immuno-DMG with Elderberry & Vitamin D3 -- 120 Chewable TabletsDaVinci LaboratoriesProfessional SupplementsVitamin C, Vitamin D3, Vitamin E, N, Vitamin E, Beta 1,3 Glucan2024-11-29 10:47:42
DaVinci Laboratories Omega-3 1000™ -- 90 Enteric Coated SoftgelsDaVinci LaboratoriesProfessional SupplementsVitamin E, Docosahexaenoic Acid, Vitamin E2024-11-29 10:47:42
DaVinci Laboratories Prostate Health -- 60 CapsulesDaVinci LaboratoriesProfessional SupplementsVitamin C, R-Alpha-Lipoic Acid, Vitamin E, Folate, Vitamin E, Lycopene, Vitamin B6, Resveratrol, Vitamin B62024-11-29 10:47:42
DaVinci Laboratories Spectra Man Multi -- 120 TabletsDaVinci LaboratoriesProfessional Supplements Lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Multivitamins for Adults -- 240 TabletsDaVinci LaboratoriesProfessional Supplements Lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Linoleic Acid, Manganese, Molybdenum, Niacin, Nickel, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Senior Multi -- 180 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, Glutamic Acid, Hesperidin, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Woman -- 120 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Manganese, Molybdenum, Niacin, Nickel, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Ultimate Prenatal Multi -- 150 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Linoleic Acid, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Dead Sea Naturals Cleansing Gel -- 3.4 fl ozDead Sea NaturalsBeauty & Personal Careallantoin, cocamidopropyl betaine, vitamin E, ethylhexylglycerin, vitamin E, glycerin, lactic acid, linalool, phenoxyethanol2024-11-29 10:47:42
Dead Sea Naturals Facial Cleanser -- 6.8 fl ozDead Sea NaturalsBeauty & Personal Careallantoin, cocamidopropyl betaine, vitamin E, ethylhexylglycerin, vitamin E, glycerin, lactic acid, linalool, phenoxyethanol2024-11-29 10:47:42
Dead Sea Naturals Facial Day Cream -- 1.7 fl ozDead Sea NaturalsBeauty & Personal Carecaprylyl glycol, alanine, allantoin, cetyl alcohol, chlorphenesin, tocopherol, tocopherol, vitamin E, glyceryl stearate, glycerin, glycine, dimethicone, hexyl cinnamal, isopropyl myristate, lactic acid, linalool, phenoxyethanol, peg-40 stearate, propanediol, sodium benzoate, urea2024-11-29 10:47:42
Dead Sea Naturals Facial Moisturizer Broad Spectrum SPF 20 -- 1.7 fl ozDead Sea NaturalsBeauty & Personal Carebutylene glycol, aminomethyl propanol, citric acid, ascorbyl palmitate, ascorbyl glucoside, ascorbic acid, cetearyl alcohol, citric acid, tocopherol, ethylhexylglycerin, tocopherol, vitamin E, glyceryl stearate, glycerin, dimethicone, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, lactic acid, niacinamide, phenoxyethanol, propylene glycol, salicylic acid, beta-sitosterol, sodium benzoate, sodium citrate, sodium hydroxide, squalene, stearyl alcohol2024-11-29 10:47:42
Dead Sea Naturals Foot Cream -- 3.4 fl ozDead Sea NaturalsBeauty & Personal Careallantoin, benzoic acid, cetearyl alcohol, tocopherol, dehydroacetic acid, ethylhexylglycerin, tocopherol, vitamin E, dimethicone, limonene, linalool, menthol, phenoxyethanol, potassium phosphate, salicylic acid, sodium benzoate2024-11-29 10:47:42
Dead Sea Naturals Purifying Mud Mask -- 3.4 fl ozDead Sea NaturalsBeauty & Personal Carecaprylyl glycol, citric acid, ascorbyl palmitate, allantoin, cetearyl alcohol, chlorphenesin, citric acid, tocopherol, panthenol, pro vitamin B5, tocopherol, vitamin E, glyceryl stearate, glycerin, dimethicone, hydroxyethylcellulose, kaolin, lactic acid, phenoxyethanol, PEG-40 stearate, propylene glycol, beta-sitosterol, sodium benzoate, sodium lactate, squalene, stearyl alcohol, zinc oxide2024-11-29 10:47:42
Dead Sea Naturals Skincare Starter Kit -- 1 KitDead Sea NaturalsBeauty & Personal Carecaprylyl glycol, butylene glycol, aminomethyl propanol, methylpropanediol, citric acid, ascorbyl palmitate, alanine, allantoin, ascorbyl glucoside, ascorbic acid, bisabolol, cetearyl alcohol, cetyl alcohol, cetyl palmitate, chlorphenesin, citric acid, cocamidopropyl betaine, tocopherol, panthenol, pro vitamin B5, ethylhexylglycerin, farnesol, tocopherol, vitamin E, glyceryl stearate, glycerin, glycine, dimethicone, hexyl cinnamal, hydroxyethylcellulose, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, isopropyl myristate, kaolin, lactic acid, linalool, niacinamide, phenoxyethanol, peg-40 stearate, propylene glycol, salicylic acid, beta-sitosterol, sodium benzoate, sodium citrate, sodium hydroxide, sodium lactate, squalene, stearyl alcohol, trehalose, urea, zinc oxide2024-11-29 10:47:42
Dead Sea Naturals Soothing Body Cream -- 6.8 fl ozDead Sea NaturalsBeauty & Personal Carecaprylyl glycol, allantoin, cetearyl alcohol, cetyl alcohol, chlorphenesin, cinnamyl alcohol, coumarin, coumarin, tocopherol, tocopherol, vitamin E, glyceryl stearate, glycerin, dimethicone, lactic acid, limonene, linalool, phenoxyethanol, PEG -40 stearate, propylene glycol, zinc oxide2024-11-29 10:47:42
Dead Sea Naturals Soothing Hand Cream -- 3.4 fl ozDead Sea NaturalsBeauty & Personal Carecaprylyl glycol, ascorbyl palmitate, allantoin, cetearyl alcohol, chlorphenesin, cinnamyl alcohol, coumarin, coumarin, tocopherol, tocopherol, vitamin E, glyceryl stearate, glycerin, dimethicone, lactic acid, limonene, linalool, phenoxyethanol, PEG-40 stearate, propylene glycol, beta-sitosterol, sodium lactate, squalene, stearyl alcohol, zinc oxide2024-11-29 10:47:42
Derma E Advanced Peptides & Collagen Eye Cream -- 0.5 ozDerma EBeauty & Personal Careascorbyl palmitate, allantoin, cetyl alcohol, vitamin e, panthenol, provitamin B5, vitamin e, glyceryl stearate, glycerin, dimethicone, phenoxyethanol, retinyl palmitate, vitamin A, stearic acid, zinc oxide2024-11-29 10:47:42
Derma E Advanced Peptides & Collagen Serum -- 2 fl ozDerma EBeauty & Personal Careascorbyl palmitate, alanine, allantoin, vitamin E, panthenol, provitamin B5, ethylhexylglycerin, vitamin E, glycerin, microcrystalline cellulose, leucine, phenoxyethanol, propanediol, sodium citrate, tyrosine2024-11-29 10:47:42
Derma E Advanced Peptides & Flora-Collagen Night Moisturizer -- 2 ozDerma EBeauty & Personal Careallantoin, cetyl alcohol, vitamin E, panthenol, provitamin B5, ethylhexylglycerin, vitamin E, glycerin, dimethicone, melatonin, phenoxyethanol, sodium hydroxide, stearic acid2024-11-29 10:47:42
Derma E Anti-Aging Regenerative Day Cream -- 2 ozDerma EBeauty & Personal Careallantoin, astaxanthin, cetyl alcohol, vitamin E, panthenol, provitamin B5, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, dimethicone, phenoxyethanol, retinyl palmitate, vitamin A, stearic acid2024-11-29 10:47:42
Derma E Anti-Aging Regenerative Night Cream -- 2 ozDerma EBeauty & Personal Careallantoin, astaxanthin, cetyl alcohol, vitamin E, panthenol, provitamin B5, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, dimethicone, phenoxyethanol, retinyl palmitate, vitamin A, stearic acid2024-11-29 10:47:42
Derma E Anti-Aging Shea Body Lotion Rosehip & Almond -- 8 ozDerma EBeauty & Personal Careallantoin, bakuchiol, cetearyl alcohol, cetyl alcohol, vitamin e, panthenol, provitamin b5, ethylhexylglycerin, vitamin e, glyceryl stearate, glycerin, phenoxyethanol, retinol, sodium hydroxide, stearic acid2024-11-29 10:47:42
Derma E Anti-Wrinkle Renewal Cream -- 4 ozDerma EBeauty & Personal Careallantoin, cetyl alcohol, vitamin E, panthenol, provitamin B5, ethylhexylglycerin, vitamin E, glycerin, microcrystalline cellulose, phenoxyethanol, retinyl palmitate, vitamin A, stearic acid2024-11-29 10:47:42
Derma E Anti-Wrinkle Scrub -- 4 ozDerma EBeauty & Personal Careascorbyl palmitate, cetearyl alcohol, cetyl alcohol, vitamin E, decyl glucoside, panthenol, provitamin B5, ethylhexylglycerin, vitamin E, glycerin, glycolic acid, phenoxyethanol, retinyl palmitate, vitamin A, stearic acid2024-11-29 10:47:42
Derma E Essentials Microdermabrasion Scrub -- 2 ozDerma EBeauty & Personal Careorange, aluminum oxide, clay, vitamin E, vitamin E, glycerin, kaolin, phenoxyethanol, stearic acid, stearyl alcohol2024-11-29 10:47:42
Derma E Hydrating Cleanser -- 6 fl ozDerma EBeauty & Personal Careallantoin, cocamidopropyl betaine, vitamin E, panthenol, provitamin B5, ethylhexylglycerin, vitamin E, glyceryl laurate, phenoxyethanol, retinyl palmitate, vitamin A2024-11-29 10:47:42
Derma E Hydrating Day Cream -- 2 ozDerma EBeauty & Personal Careascorbyl palmitate, allantoin, cetyl alcohol, vitamin E, panthenol, Provitamin B5, ethylhexylglycerin, vitamin E, glycerin, dimethicone, phenoxyethanol, retinyl palmitate, vitamin A, stearic acid, titanium dioxide2024-11-29 10:47:42
Derma E Hydrating Eye Cream -- 0.5 ozDerma EBeauty & Personal Careascorbyl palmitate, allantoin, cetyl alcohol, vitamin E, provitamin B5, vitamin E, dimethicone, phenoxyethanol, retinyl palmitate, vitamin A, stearic acid, titanium dioxide2024-11-29 10:47:42
Derma E Hydrating Shea Body Lotion Jasmine & Vanilla -- 8 ozDerma EBeauty & Personal Careallantoin, cetyl alcohol, tocopherol, panthenol, provitamin B5, tocopherol, vitamin E, glycerin, stearyl alcohol2024-11-29 10:47:42
Derma E Nourishing Conditioner Apricot Seed & Argan Oils -- 10 fl ozDerma EBeauty & Personal Carearginine, cetyl alcohol, tocopherol, panthenol, provitamin B5, ethylhexylglycerin, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Derma E Scalp Relief Shampoo -- 8 fl ozDerma EBeauty & Personal Carevitamin E, panthenol, provitamin B5, vitamin E, glycerin, menthol, phenoxyethanol, retinyl palmitate, vitamin A, salicylic acid2024-11-29 10:47:42
Derma E Skin Restore Peptide Moisturizer -- 2 ozDerma EBeauty & Personal Carecetyl alcohol, vitamin E, panthenol, provitamin B5, vitamin E, glyceryl stearate, glycerin, phenoxyethanol, retinyl palmitate, vitamin A, stearic acid, zinc oxide2024-11-29 10:47:42
Derma E Styling Hair Repair Oil -- 1 fl ozDerma EBeauty & Personal Carebeta-carotene, vitamin E, vitamin E2024-11-29 10:47:42
Derma E Tea Tree and Vitamin E Relief Cream -- 4 ozDerma EBeauty & Personal Careallantoin, cetyl alcohol, vitamin E, panthenol, provitamin B5, vitamin E, glyceryl stearate, glycerin, phenoxyethanol, stearic acid2024-11-29 10:47:42
Derma E Ultra Hydrating Advanced Repair Night Cream -- 2 ozDerma EBeauty & Personal Careascorbyl palmitate, allantoin, cetyl alcohol, vitamin E, panthenol, provitamin B5, ethylhexylglycerin, vitamin E, glycerin, dimethicone, phenoxyethanol, squalane, stearic acid, stearyl alcohol2024-11-29 10:47:42
Derma E Vitamin C Concentrated Serum -- 2 fl ozDerma EBeauty & Personal Care allantoin, vitamin C, vitamin E, panthenol, provitamin B5, vitamin E, glycerin, microcrystalline cellulose, maltodextrin, probiotic, phenoxyethanol, propanediol, sodium citrate2024-11-29 10:47:42
Derma E Vitamin C Gentle Daily Cleansing Paste -- 4 ozDerma EBeauty & Personal Carebehenic acid, vitamin E, panthenol, vitamin E, glycerin, hydroxyethylcellulose, kaolin, lauric acid, myristic acid, palmitic acid, palmitic acid, potassium hydroxide, stearic acid, titanium dioxide2024-11-29 10:47:42
Derma E Vitamin C Intense Night Cream -- 2 ozDerma EBeauty & Personal CareVitamin C, cetearyl alcohol, cetyl alcohol, cetyl palmitate, vitamin E, panthenol, provitamin B5, vitamin E, glycerin, phenoxyethanol, propanediol, vitamin A2024-11-29 10:47:42
Derma E Vitamin C No Dark Circles Perfecting Eye Cream -- 0.5 ozDerma EBeauty & Personal Careorange, benzyl acetate, caffeine, citral, vitamin E, decanal, panthenol, provitamin B5, geraniol, vitamin E, glycerin, microcrystalline cellulose, kaolin, linalool, niacinamide, sorbitol, tin oxide, titanium dioxide, triheptanoin2024-11-29 10:47:42
Derma E Vitamin C Renewing Moisturizer -- 2 fl ozDerma EBeauty & Personal Careallantoin, vitamin C, cetyl alcohol, vitamin E, panthenol, provitamin B5, vitamin E, glycerin, phenoxyethanol, propanediol, retinyl palmitate, vitamin A2024-11-29 10:47:42
Derma E Vitamin C Weightless Moisturizer SPF 45 -- 2 fl ozDerma EBeauty & Personal Carevitamin E, panthenol, ethylhexylglycerin, vitamin E, glycerin, isostearic acid, niacinamide, phenoxyethanol, titanium dioxide2024-11-29 10:47:42
Derma E Vitamin E Fragrance-Free Therapeutic Shea Body Lotion -- 8 ozDerma EBeauty & Personal Careallantoin, cetyl alcohol, vitamin E, panthenol, provitamin B5, vitamin E, glyceryl stearate, glycerin, phenoxyethanol, stearic acid2024-11-29 10:47:42
Derma E Vitamin E Skin Oil -- 14000 IU - 2 fl ozDerma EBeauty & Personal Carevitamin E, vitamin E2024-11-29 10:47:42
Derma E Vitamin E Therapeutic Moisture Shea Hand Cream Lavender & Neroli -- 2 ozDerma EBeauty & Personal Careallantoin, cetyl alcohol, vitamin E, panthenol, provitamin B5, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Desert Essence Hand & Body Lotion Sweet Almond -- 8 fl ozDesert EssenceBeauty & Personal Carebenzyl alcohol, tocopherol, dehydroacetic acid, tocopherol, Vitamin E, glycerin, stearic acid2024-11-29 10:47:42
Desert Essence Organic Relaxing Hand and Body Lotion Tropical Coconut -- 8 fl ozDesert EssenceBeauty & Personal Carecetyl alcohol, palm, tocopherol, tocopherol, vitamin E, glycerin, stearic acid2024-11-29 10:47:42
Desert Essence Organics Uplifting Hand and Body Lotion Spicy Vanilla Chai -- 8 fl ozDesert EssenceBeauty & Personal Carecetyl alcohol, palm, eugenia caryophyllata, tocopherol, tocopherol, vitamin E, glycerin, stearic acid2024-11-29 10:47:42
Desert Essence Tea Tree Replenishing Conditioner -- 12.7 fl ozDesert EssenceBeauty & Personal Caregluconolactone, cetearyl alcohol, tocopherol, behenyl alcohol, tocopherol, vitamin e, glycerin, menthol, glyceryl caprylate2024-11-29 10:47:42
Designer Wellness Designer Whey - Meal Replacement Protein Powder Milk Chocolate -- 1.72 lbsDesigner WellnessWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Designer Wellness Designer Whey - Meal Replacement Protein Powder Vanilla Bean -- 1.72 lbsDesigner WellnessWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Deva Omega-3 DHA-EPA Liquid Lemon -- 2 fl ozDevaVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Deva Vegan Hair Nails and Skin -- 90 TabletsDevaVitamins & SupplementsPABA, Vitamin C, Biotin, Choline, L-cysteine, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin B3, PABA, Vitamin B5, Vitamin B6, Vitamin B2, Beta Sitosterol, Vitamin B1, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Multivitamin & Mineral Supplement -- 90 Coated TabletsDevaVitamins & SupplementsVitamin C, Beta Carotene, Betaine HCL, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Calcium Carbonate, Lutein, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Rutin, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Multivitamin & Mineral Tiny Tablets -- 90 TabletsDevaVitamins & SupplementsVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Multivitamin and Mineral Supplement Iron Free -- 90 Coated TabletsDevaVitamins & SupplementsVitamin C, Beta Carotene, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Lutein, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Rutin, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Omega-3 DHA from Algae Lemon -- 2 fl ozDevaVitamins & SupplementsVitamin E, Docosahexaenoic Acid, Vitamin E2024-11-29 10:47:42
Deva Vegan Prenatal One Daily Multivitamin and Mineral -- 90 Coated TabletsDevaVitamins & SupplementsChamomile, Vitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Deva Vegan Vitamin E with Mixed Tocopherols -- 400 IU - 90 Vegan CapsDevaVitamins & Supplements d-beta, Vitamin E, Vitamin E2024-11-29 10:47:42
Douglas Laboratories Ultra Preventive® Kids Natural Grape -- 60 TabletsDouglas LaboratoriesProfessional SupplementsVitamin C, Biotin, Boron, Vitamin D3, Choline, Vitamin E, Folic Acid, Vitamin E, Iodine, Lutein, Manganese, Molybdenum, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, beta, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Douglas Laboratories Ultra Preventive® Kids Natural Orange -- 60 TabletsDouglas LaboratoriesProfessional SupplementsVitamin C, Biotin, Boron, Vitamin D3, Choline, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Molybdenum, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, beta, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Dr. Botanical Health Organic Green Spirulina Powder -- 3.5 ozDr. Botanical HealthVitamins & SupplementsAlanine, Arginine, Vitamin C, Aspartic Acid, Chlorophyll, Cysteine, Vitamin E, Vitamin E, Glutamic Acid, Glycine, Histidine, Isoleucine, Leucine, Lysine, Manganese, Methionine, Niacin, Phosphorus, Proline, Riboflavin, Serine, Thiamin, Threonine, Tryptophan, Tyrosine, Valine2024-11-29 10:47:42
Dr. Goodpet Bena Fish Oil™ for Pets -- 45 SoftgelsDr. GoodpetPet SuppliesVitamin E, Docosahexaenoic Acid, Vitamin E, Fat2024-11-29 10:47:42
Dr. Jacobs Naturals African Black Soap Body Wash + Lavender & Clary Sage -- 16 fl ozDr. JacobsBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals African Black Soap Body Wash + Raw Black -- 16 fl ozDr. JacobsBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals African Black Soap Body Wash + Sensual Monoi -- 16 fl ozDr. JacobsBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals Pure Castile All-In-1 Soap Almond -- 32 fl ozDr. JacobsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals Pure Castile All-In-1 Soap Eucalyptus -- 32 fl ozDr. JacobsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals Pure Castile All-In-1 Soap Fragrance Free -- 32 fl ozDr. JacobsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals Pure Castile All-In-1 Soap Lavender -- 32 fl ozDr. JacobsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals Pure Castile All-In-1 Soap Orange & Ginger -- 32 fl ozDr. JacobsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals Pure Castile All-In-1 Soap Peppermint -- 32 fl ozDr. JacobsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals Rich Castile Body Wash + Fair Trade Organic Shea Butter -- 16 fl ozDr. JacobsBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals Rich Castile Body Wash + Lavender Essential Oil -- 16 fl ozDr. JacobsBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals Rich Castile Body Wash + Nourishing Almond -- 16 fl ozDr. JacobsBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals Rich Castile Body Wash + Orange & Ginger Oil -- 16 ozDr. JacobsBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Jacobs Naturals Rich Castile Body Wash + Soothing Sandalwood -- 16 fl ozDr. JacobsBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
Dr. Mercola Vitamin E -- 30 CapsulesDr. MercolaProfessional Supplementsd-Beta Tocopherol, d-Alpha-Tocopherol, d-delta tocopherol, d-Gamma Tocopherol, d-Gamma Tocotrienol, Vitamin E, d-Alpha Tocotrienol, d-Beta Tocotrienol, d-Delta Tocotrienol2024-11-29 10:47:42
Dr. Woods Naturally Bar Soap Baby Mild Unscented -- 5.25 ozDr. WoodsBaby & Kids Productsvitamin E, vitamin E, sodium gluconate2024-11-29 10:47:42
Dr. Woods Naturally Bar Soap Exfoliating Raw Black -- 5.25 ozDr. WoodsBeauty & Personal Carevitamin E, palma rosa, vitamin E, sodium gluconate2024-11-29 10:47:42
Dr. Woods Naturally Bar Soap Moisturizing Ginger Citrus -- 5.25 ozDr. WoodsBeauty & Personal Carevitamin E, vitamin E, sodium gluconate, glycerin2024-11-29 10:47:42
Dr. Woods Naturally Bar Soap Relaxing Lavender -- 5.25 ozDr. WoodsBeauty & Personal Carevitamin E, vitamin E, sodium gluconate2024-11-29 10:47:42
Dr. Woods Naturally Castile Baby Mild Soap With Fair Trade Shea Butter Unscented -- 16 fl ozDr. WoodsBaby & Kids ProductsCitric Acid, Citric Acid, Tocopherol, Tocopherol, Vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Baby Mild Soap With Fair Trade Shea Butter Unscented -- 32 fl ozDr. WoodsBaby & Kids ProductsCitric Acid, Citric Acid, Tocopherol, Tocopherol, Vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap with Fair Trade Shea Butter Almond -- 32 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, vitamin E, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap Almond -- 32 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap Baby Mild Unscented -- 32 fl ozDr. WoodsBaby & Kids Productscitric acid, citric acid, tocopherol, tocopherol, vitamin e2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap Peppermint -- 32 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap Peppermint with Fair Trade Shea Butter -- 16 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, vitamin E, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap Tea Tree -- 32 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, vitamin E, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap with Fair Trade Shea Butter - Lavender - -- 32 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, Vitamin E, Vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap with Fair Trade Shea Butter Almond -- 8 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, vitamin E, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap with Fair Trade Shea Butter Lavender -- 8 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap with Fair Trade Shea Butter Tea Tree -- 16 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap with Fair Trade Shea Butter Tea Tree -- 32 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, Vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Castile Soap with Fair Trade Shea Butter Tea Tree -- 8 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, Vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Exfoliating Bar Soap English Rose -- 5.25 ozDr. WoodsBeauty & Personal CareVitamin E, Vitamin E, Sodium Gluconate, Glycerin, Niacinamide, Retinyl Palmitate, Vitamin A2024-11-29 10:47:42
Dr. Woods Naturally Facial Cleanser Black Soap -- 8 fl ozDr. WoodsBeauty & Personal Carecitric acid, chamomile, ascorbic acid, citric acid, tocopherol, panthenol, pro vitamin b5, tocopherol, vitamin E, glycerin, hydroxyethylcellulose2024-11-29 10:47:42
Dr. Woods Naturally Facial Cleanser Tea Tree -- 8 fl ozDr. WoodsBeauty & Personal Carecitric acid, allantoin, ascorbic acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin, hydroxyethylcellulose2024-11-29 10:47:42
Dr. Woods Naturally Raw Black Soap Original -- 32 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, panthenol, pro vitamin B5, tocopherol, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Raw Black Soap Unscented -- 32 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, panthenol, pro vitamin B5, tocopherol, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Raw Black Soap With Fair Trade Shea Butter Coconut Papaya -- 32 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, panthenol, pro vitamin B5, tocopherol, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Raw Black Soap with Fair Trade Shea Butter Coconut Papaya -- 8 ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, panthenol, pro vitamin B5, tocopherol, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Raw Black Soap with Fair Trade Shea Butter Original -- 16 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, panthenol, pro vitamin B5, tocopherol, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Raw Black Soap with Fair Trade Shea Butter Original -- 32 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, panthenol, pro vitamin B5, tocopherol, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Raw Black Soap with Fair Trade Shea Butter Original -- 8 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, panthenol, Pro vitamin B5, tocopherol, vitamin E2024-11-29 10:47:42
Dr. Woods Naturally Raw Black Soap With Fair Trade Shea Butter Peppermint -- 32 fl ozDr. WoodsHousehold Essentialscitric acid, citric acid, tocopherol, panthenol, pro vitamin B5, tocopherol, vitamin E2024-11-29 10:47:42
Duke Cannon Best Damn Beard Balm Redwood -- 1.6 ozDuke CannonBeauty & Personal CareVitamin E, Vitamin E2024-11-29 10:47:42
Dymatize Super Mass Gainer Gourmet Vanilla -- 6 lbsDymatizeActive Lifestyle & FitnessVitamin C, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Dymatize Super Mass Gainer Rich Chocolate -- 6 lbsDymatizeActive Lifestyle & FitnessVitamin C, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Earth Therapeutics Foot Repair Therapeutic Balm -- 4 ozEarth TherapeuticsBeauty & Personal CareAllantoin, Butylparaben, Carbomer, Cetyl Alcohol, Cholecalciferol, Vitamin E, Vitamin E, Isopropyl Palmitate, Lactic Acid, Methylparaben, Phenoxyethanol, Propylparaben, Retinyl Palmitate, Vitamin A, Stearic Acid, Triethanolamine, Urea2024-11-29 10:47:42
Earth Therapeutics Intensive Heel Repair -- 4 fl ozEarth TherapeuticsBeauty & Personal Carecitric acid, citric acid, vitamin E, vitamin E, glycerin, isopropyl palmitate, methylparaben, phenoxyethanol, propylparaben, retinyl palmitate, vitamin A, stearic acid, urea2024-11-29 10:47:42
Ecco Bella FlowerColor Natural Cover Up Concealer - Medium Beige -- 0.13 ozEcco BellaBeauty & Personal Carevitamin E, vitamin E, isopropyl palmitate2024-11-29 10:47:42
Eco Lips Lipscrub Vanilla Bean -- 0.5 ozEco LipsBeauty & Personal CareCalendula, Vitamin E, Vitamin E, Stevia, Sugar2024-11-29 10:47:42
Eco Lips Organic Mongo Kiss Lip Balm Blood Orange -- 0.25 ozEco LipsBeauty & Personal Carevitamin e, vitamin e, stevia2024-11-29 10:47:42
Eco Lips Organic Mongo Kiss Lip Balm Vanilla Honey -- 0.25 ozEco LipsBeauty & Personal Carecalendula, vitamin E, vitamin E2024-11-29 10:47:42
Eco Lips Organic Mongo Kiss Lip Balm Yumberry -- 0.25 ozEco LipsBeauty & Personal Carecalendula, vitamin E, vitamin E, stevia2024-11-29 10:47:42
Eczema Honey Body Lotion -- 16 ozEczema HoneyBeauty & Personal Carecaprylyl glycol, citric acid, cetearyl alcohol, citric acid, vitamin E, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, phenoxyethanol, stearic acid, caprylic triglyceride2024-11-29 10:47:42
Eden Foods Organic EdenSoy Extra Soy Milk Vanilla -- 32 fl ozEden FoodsFood & BeveragesBiotin, Omega-3, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Pantothenic Acid, Phosphorus, Pyridoxine, Vitamin A, Riboflavin, Thiamin, Vitamin B122024-11-29 10:47:42
Eidon Ionic Minerals Silica & MSM Moisturizing Lotion -- 16 fl ozEidon Ionic MineralsBeauty & Personal Carevitamin E, vitamin E, glycerin, stearic acid2024-11-29 10:47:42
Else Kids Complete Nutrition Shake RTD Plant Powered 2+ Years Chocolate -- 4 PackElseBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Else Kids Nutritional Shake Plant Protein Powder 2+ Year Vanilla -- 16 ozElseBaby & Kids ProductsVitamin C, Biotin, Choline, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Else Kids Nutritional Shake Plant Protein Powder 2+ Years Chocolate -- 16 ozElseBaby & Kids ProductsVitamin C, Biotin, Choline, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Else Organic Plant-Powered Super Cereal 6+ Months Banana -- 7 ozElseBaby & Kids ProductsVitamin C, Biotin, Choline, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Else Organic Plant-Powered Super Cereal Baby 6+ Months Mango -- 7 ozElseBaby & Kids ProductsVitamin C, Biotin, Choline, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Else Organic Plant-Powered Super Cereal Baby 6+ Months Original -- 7 ozElseBaby & Kids ProductsVitamin C, Biotin, Choline, Vitamin E, Folate, Vitamin E, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Else Organic Plant-Powered Super Cereal Baby 6+ Months Vanilla -- 7 ozElseBaby & Kids ProductsVitamin C, Biotin, Choline, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Else Toddler Omega 3&6 Complete Nutrition Formula Plant-Based 12+ Months -- 22 ozElseBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Else Toddler Organic Complete Nutrition Formula Plant-Based 12+ Months -- 22 ozElseBaby & Kids ProductsVitamin C, Biotin, Choline, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Emerald Cove Organic Toasted Shushi Nori -- 50 SheetsEmerald CoveFood & BeveragesVitamin C, Biotin, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Emerald Forest Botanical Moisturizing Conditioner Lavender Mint -- 12 fl ozEmerald ForestBeauty & Personal Caregluconolactone, cetyl alcohol, vitamin E, panthenol, vitamin E, vitamin B52024-11-29 10:47:42
Emerald Forest Botanical Moisturizing Shampoo Lavender Mint -- 12 fl ozEmerald ForestBeauty & Personal Caregluconolactone, vitamin E, panthenol, vitamin E, vitamin B52024-11-29 10:47:42
Emerald Forest Botanical Shampoo with Sapayul Citrus Blossom -- 12 fl ozEmerald ForestBeauty & Personal Careorange, gluconolactone, vitamin E, panthenol, vitamin E, vitamin B52024-11-29 10:47:42
Emerald Labs Prenatal 1-Daily Multi -- 60 Vegetable CapsulesEmerald LabsVitamins & SupplementsLipase, Beta Carotene, Biotin, Boron, cellulase, Vitamin D3, Chromium, Vitamin E, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Rutin, Selenium, Vitamin B1, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Emergen-C Immune Plus with Vitamin D Chewables Orange Blast -- 14 Chewable TabletsEmergen-CVitamins & SupplementsVitamin C, Biotin, Vitamin E, Vitamin E, Vitamin B6, Vitamin B62024-11-29 10:47:42
Emergen-C Immune Plus with Vitamin D Chewables Orange Blast -- 42 Chewable TabletsEmergen-CVitamins & SupplementsVitamin C, Biotin, Vitamin E, Vitamin E, Vitamin B6, Vitamin B62024-11-29 10:47:42
Emerita Pro-Gest® Cream -- 2 ozEmeritaVitamins & Supplementscaprylyl glycol, carbomer, cetyl alcohol, vitamin E, panthenol, vitamin E, glyceryl stearate, glycerin, phenoxyethanol, sorbic acid, stearic acid2024-11-29 10:47:42
Ener-C Vitamin C Raspberry -- 1000 mg - 30 PacketsEner-CVitamins & SupplementsVitamin C, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin B3, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Ener-C Vitamin C Multivitamin Drink Mix Lemon Lime -- 1000 mg - 30 PacketsEner-CVitamins & SupplementsVitamin C, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Vitamin B3, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Ener-C Vitamin C Multivitamin Drink Mix Orange -- 1000 mg - 30 PacketsEner-CVitamins & SupplementsVitamin C, Beta Carotene, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Vitamin B3, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Ener-C Vitamin C Multivitamin Drink Mix Peach Mango -- 1000 mg - 30 PacketsEner-CVitamins & SupplementsVitamin C, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Vitamin B3, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Ener-C Vitamin C Multivitamin Drink Mix Tangerine Grapefruit -- 1000 mg - 30 PacketsEner-CVitamins & SupplementsVitamin C, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Vitamin B3, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Ener-C Vitamin C Multivitamin Drink Mix Variety Pack -- 1000 mg - 30 PacketsEner-CVitamins & SupplementsVitamin C, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Vitamin B3, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Ener-C Vitamin C Multivitamin Drink Mix Sugar Free Mixed Berry -- 1000 mg - 30 PacketsEner-CVitamins & SupplementsVitamin C, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacinamide, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin B12, Vitamin B62024-11-29 10:47:42
Ener-C Vitamin C Multivitamin Drink Mix Sugar Free Orange -- 1000 mg - 30 PacketsEner-CVitamins & SupplementsVitamin C, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacinamide, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin B12, Vitamin B62024-11-29 10:47:42
Ensure Clear Nutrition Drink Mixed Fruit -- 4 PackEnsureWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure Complete Nutrition Shake Milk Chocolate -- 4 ShakesEnsureWeight ManagementVitamin C, Biotin, Chloride, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure Complete Nutrition Shake Vanilla -- 4 ShakesEnsureWeight ManagementVitamin C, Biotin, Chloride, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure High Protein Nutrition Shake Milk Chocolate -- 8 fl oz Each / Pack of 6EnsureWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure High Protein Nutrition Shake Vanilla 8 fl oz -- 6 BottlesEnsureWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure Max Protein Nutrition Shake Cafe Mocha -- 11 fl ozEnsureWeight ManagementVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure Max Protein Nutrition Shake French Vanilla -- 4 ShakesEnsureWeight ManagementVitamin C, Biotin, Chloride, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure Max Protein Nutrition Shake Milk Chocolate -- 11 fl ozEnsureWeight ManagementVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure Original Nutrition Shake Strawberry -- 8 fl oz Each / Pack of 6EnsureWeight ManagementVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure Plus Nutrition Shake Strawberry -- 6 BottlesEnsureWeight ManagementVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure Plus Nutrition Shake Milk Chocolate -- 6 BottlesEnsureWeight ManagementVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure Plus Nutrition Shake Vanilla 8oz -- 6 BottlesEnsureWeight ManagementVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure Original Milk Chocolate Ready-to-Drink Nutrition Shakes -- Pack of 6EnsureWeight ManagementVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Ensure Original Vanilla Ready-to-Drink Nutrition Shakes -- Pack of 6EnsureWeight ManagementVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
EO Body Oil French Lavender -- 8 fl ozEOBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Equazen VitaSpectrum Powder Unflavored -- 5.04 ozEquazenProfessional SupplementsVitamin C, Trimethylglycine, Trimethylglycine, Biotin, Boron, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, vitamin A acetate, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Every Man Jack Hand & Body Lotion - Sandalwood -- 13.5 fl ozEvery Man JackBeauty & Personal Carecitric acid, cetyl alcohol, citric acid, tocopherol, panthenol, ethylhexylglycerin, tocopherol, vitamin E, glycerin, phenoxyethanol, squalane2024-11-29 10:47:42
Every Man Jack Hand & Body Lotion - Sea Salt -- 13.5 fl ozEvery Man JackBeauty & Personal Carecitric acid, cetyl alcohol, citric acid, tocopherol, panthenol, ethylhexylglycerin, tocopherol, vitamin E, glycerin, phenoxyethanol, squalane2024-11-29 10:47:42
Evlution Nutrition VitaMode -- 120 TabletsEvlution NutritionActive Lifestyle & Fitness Lipase, PABA, Vitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Evolve Plant Based Protein Shake Chocolate Caramel -- 11.16 fl oz Each / Pack of 4EvolveWeight ManagementVitamin C, Vitamin E, Vitamin E, Vitamin B122024-11-29 10:47:42
Fearn Lecithin Granules -- 16 ozFearnVitamins & SupplementsLinolenic Acid, Choline, Vitamin E, Folic Acid, Vitamin E, Linoleic Acid, Niacin, Fat, Phosphorus, Riboflavin, Thiamine, Vitamin B122024-11-29 10:47:42
Fearn Raw Wheat Germ -- 10 ozFearnHerbs, Botanicals & HomeopathyVitamin E, Vitamin E, Niacin, Phosphorus, Thiamine2024-11-29 10:47:42
Fitcode Fit Multi Complete Multivitamin Complex -- 90 TabletsFitcodeVitamins & SupplementsVitamin C, Biotin, Chloride, Choline, Vitamin E, Folate, Vitamin E, Inositol, Lutein, Lycopene, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Flora Stressveda with KSM-66 Ashwagandha + Plant-Sourced B-Complex -- 30 Vegetarian CapsulesFloraHerbs, Botanicals & HomeopathyVitamin C, Biotin, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B6, Vitamin K2024-11-29 10:47:42
Floradix Epresat Liquid Adult Multivitamin -- 8.5 fl ozFloradixVitamins & SupplementsVitamin E, Vitamin E, Niacin, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B62024-11-29 10:47:42
Floradix Epresat® Liquid Adult Multivitamin -- 17 fl ozFloradixVitamins & SupplementsVitamin E, Vitamin E, Niacin, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B62024-11-29 10:47:42
Flower Essence Self Heal Skin Creme -- 4 fl ozFlower EssenceBeauty & Personal Cared-limonene, orange, cetyl alcohol, tocopherol, tocopherol, vitaminE, glycerin, linalool, totarol2024-11-29 10:47:42
Foods Alive Organic Black Sesame Seeds Superfood -- 12 ozFoods AliveFood & BeveragesVitamin C, Vitamin E, Folate, Vitamin E, Manganese, Niacin, Phosphorus, Vitamin A, Riboflavin, Thiamin2024-11-29 10:47:42
Foods Alive Organic Superfoods Toasted Hemp Seed with Sea Salt -- 14 ozFoods AliveFood & BeveragesVitamin C, Vitamin E, Vitamin E, Manganese, Niacin, Phosphorus, Vitamin A, Riboflavin, Thiamin2024-11-29 10:47:42
Force Factor AREDS 2+ Eye Health Formula Tropical Fruit -- 60 Soft ChewsForce FactorVitamins & SupplementsVitamin C, Vitamin E, Saffron, Vitamin E, Lutein, Zeaxanthin2024-11-29 10:47:42
Force Factor Better Turmeric Extra Strength Curcumin Fruit Splash -- 60 Soft ChewsForce FactorActive Lifestyle & FitnessVitamin E, Vitamin E, Niacin, Vitamin B6, Vitamin B12, Vitamin B62024-11-29 10:47:42
Force Factor Collagen Boosting Superfoods Tropical Fruit -- 60 Soft ChewsForce FactorVitamins & SupplementsVitamin C, Biotin, Vitamin E, Vitamin E, Maltodextrin, Niacin, Quercetin2024-11-29 10:47:42
Force Factor Complete Eye Health - Advanced Vitamin & Mineral Formula -- 60 Vegetable CapsulesForce FactorVitamins & SupplementsVitamin E, Saffron, Vitamin E, Lutein, Vitamin A, Zeaxanthin2024-11-29 10:47:42
Force Factor Liquid Labs Beauty Rapid Hydration Electrolyte Drink Mix Tropical Berry -- 20 Stick PacksForce FactorActive Lifestyle & FitnessVitamin C, Biotin, Chloride, Vitamin E, Vitamin E, Niacin, Selenium2024-11-29 10:47:42
Force Factor Test X180 Multivitamin Daily Testosterone Booster + Male Vitality Enhancer -- 120 TabletsForce FactorActive Lifestyle & FitnessVitamin C, Biotin, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Four Paws Healthy Promise Ear Wipes for Cats and Dogs -- 35 WipesFour PawsPet Suppliesvitamin E, vitamin E, glycerin2024-11-29 10:47:42
Four Paws Healthy Promise Eye Wipes for Dogs & Cats -- 35 WipesFour PawsPet Suppliesvitamin E, vitamin E, glycerin2024-11-29 10:47:42
Fresh Press Farms Non-GMO Extra Virgin Olive Oil Bold -- 16.4 fl ozFresh Press FarmsFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Fresh Press Farms Non-GMO Extra Virgin Olive Oil Classic -- 16.4 fl ozFresh Press FarmsFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Fresh Press Farms Non-GMO Extra Virgin Olive Oil Mild -- 16.4 fl ozFresh Press FarmsFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Fresh Press Farms Non-GMO Sunflower Oil High Oleic Smooth and Buttery -- 16.4 fl ozFresh Press FarmsFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Frownies Rose Water Hydrator -- 2 fl ozFrowniesBeauty & Personal Carevitamin E, vitamin E, propanediol2024-11-29 10:47:42
Further Food Ultimate Immune Support -- 120 CapsulesFurther FoodHerbs, Botanicals & HomeopathyVitamin C, Vitamin E, Vitamin E, Vitamin A, Selenium2024-11-29 10:47:42
Futurebiotics Hair Skin & Nails -- 135 TabletsFuturebioticsVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Choline, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Hair Skin & Nails® for Men -- 135 TabletsFuturebioticsVitamins & Supplementspara-Aminobenzoic Acid, Vitamin C, Biotin, Vitamin D3, Choline, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Hair, Skin and Nails® -- 75 TabletsFuturebioticsVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Betaine, Biotin, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Manganese, Methionine, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Hi-Energy Multi For Men™ -- 120 TabletsFuturebioticsVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Hi-Energy Multi For Men™ -- 60 TabletsFuturebioticsVitamins & SupplementsVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics M.V. Teen™ Multi-Vitamin and Mineral Formula for Teens -- 180 CapsulesFuturebioticsVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics M.V. Teen™ Multivitamin -- 90 CapsulesFuturebioticsVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Multi Vitamin Energy Plus® For Women -- 60 TabletsFuturebioticsVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Biotin, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Garden of Life Mykind Organics Kids Multi Gummies Organic Cherry -- 120 Vegan GummiesGarden of LifeVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Garden of Life Raw Organic Meal Plant-Based Chocolate -- 38.03 ozGarden of LifeActive Lifestyle & FitnessVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Garden of Life Raw Organic Meal Plant-Based Vanilla -- 37.04 ozGarden of LifeActive Lifestyle & FitnessVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Garden of Life RAW Organic Protein Plant-Based Formula Chocolate -- 24.69 ozGarden of LifeActive Lifestyle & FitnessAlanine, Arginine, Aspartic Acid, Cystine, Vitamin E, Vitamin E, Glutamic Acid, Glycine, Histidine, Proline, Vitamin A, Serine, Tyrosine, Vitamin K2024-11-29 10:47:42
Garden of Life RAW Organic Protein Plant-Based Formula Unflavored -- 19.75 ozGarden of LifeActive Lifestyle & FitnessAlanine, Arginine, Aspartic Acid, Cystine, Vitamin E, Vitamin E, Glutamic Acid, Glycine, Histidine, Proline, Vitamin A, Serine, Tyrosine, Vitamin K2024-11-29 10:47:42
Garden of Life RAW Organic Protein Plant-Based Formula Vanilla -- 23.28 ozGarden of LifeActive Lifestyle & FitnessAlanine, Arginine, Aspartic Acid, Cystine, Vitamin E, Vitamin E, Glutamic Acid, Glycine, Histidine, Proline, Vitamin A, Serine, Tyrosine, Vitamin K2024-11-29 10:47:42
Garden of Life Vitamin Code RAW One Multivitamin for Women -- 75 Vegetarian CapsulesGarden of LifeVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Garden of Life Vitamin Code RAW Vitamin E -- 60 Vegetarian CapsulesGarden of LifeVitamins & SupplementsVitamin E, Vitamin E, Vitamin A, Selenium, Vitamin K2024-11-29 10:47:42
Garden of Life Vitamin Code® 50 & Wiser Women Whole Food Multivitamin -- 120 Vegetarian CapsulesGarden of LifeVitamins & SupplementsVitamin C, Biotin, Boron, Vitamin D3, Chromium, CoQ10, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Garden of Life Vitamin Code® 50 & Wiser Women Whole Food Multivitamin -- 240 Vegetarian CapsulesGarden of LifeVitamins & SupplementsVitamin C, Biotin, Boron, Vitamin D3, Chromium, CoQ10, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Garden of Life Vitamin Code® 50 and Wiser Men -- 240 Vegetarian CapsulesGarden of LifeVitamins & SupplementsVitamin C, Biotin, Boron, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Garden of Life Vitamin Code® RAW One™ Multivitamin for Men -- 75 Vegetarian CapsulesGarden of LifeVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
GEM Calm Essentials Bites Banana Cinnamon -- 28 BitesGEMVitamins & SupplementsVitamin E, Folate, Vitamin E, Vitamin B122024-11-29 10:47:42
Gerber Baby Food Stage 2 Snack Yogurt Melts Non-GMO Banana Vanilla -- 1 ozGerberBaby & Kids ProductsVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Gerber Baby Food Stage 2 Snack Yogurt Melts Non-GMO Mixed Berries -- 1 ozGerberBaby & Kids ProductsVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Gerber Baby Food Stage 2 Snack Yogurt Melts Non-GMO Variety Pack -- 1 oz Each / Pack of 4GerberBaby & Kids ProductsVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Gerber Baby Snacks Stage 2 Non-GMO Arrowroot Biscuits -- 5.5 ozGerberBaby & Kids ProductsVitamin C, Vitamin E, Vitamin E, Vitamin A, Sugar2024-11-29 10:47:42
Gerber Cereal for Baby Supported Sitter First Foods Oatmeal -- 16 ozGerberBaby & Kids ProductsVitamin C, Vitamin E, Folate, Vitamin E, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Gerber Cereal for Baby Supported Sitter First Foods Rice -- 8 ozGerberBaby & Kids ProductsVitamin C, Vitamin E, Folate, Vitamin E, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Gerber Grain & Grow Stage 2 Puff Snack Non-GMO Banana -- 1.48 ozGerberBaby & Kids ProductsVitamin E, Vitamin E, Niacin, Vitamin B6, Thiamin, Vitamin B62024-11-29 10:47:42
Gerber Grain & Grow Stage 2 Puff Snack Non-GMO Banana & Strawberry Apple -- 1.48 oz Each / Pack of 4GerberBaby & Kids ProductsVitamin E, Vitamin E, Niacin, Vitamin B6, Thiamine, Vitamin B62024-11-29 10:47:42
Gerber Grain & Grow Stage 2 Puff Snack Non-GMO Blueberry -- 1.48 ozGerberBaby & Kids ProductsVitamin C, Vitamin E, Vitamin E, Niacin, Vitamin B6, Vitamin A, Riboflavin, Sugar, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Gerber Grain & Grow Stage 2 Puff Snack Non-GMO Sweet Potato -- 1.48 ozGerberBaby & Kids ProductsVitamin E, Vitamin E, Niacin, Vitamin B6, Thiamine, Vitamin B62024-11-29 10:47:42
Gerber Grain & Grow Stage 3 Hearty Bits MultiGrain Non-GMO Cereal Banana Apple Strawberry -- 8 ozGerberBaby & Kids ProductsVitamin C, Vitamin E, Folate, Vitamin E, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Gerber Natural for Toddler Stage 3 Apple Pear Peach Puree Pouch -- 3.5 ozGerberBaby & Kids ProductsVitamin C, Vitamin E, Vitamin E2024-11-29 10:47:42
Gerber Toddler Snacks Non-GMO Fruit & Yogurt Variety Pack -- 9 PouchesGerberBaby & Kids ProductsVitamin C, Vitamin E, Vitamin E, Vitamin A, Riboflavin2024-11-29 10:47:42
Giovanni 2chic Repairing Conditioner with Blackberry & Coconut Milk -- 8 fl ozGiovanniBeauty & Personal Carecitric acid, cetyl alcohol, citric acid, vitamin E, dehydroacetic acid, panthenol, pro-vitamin B-5, vitamin E, glycerin, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Giovanni 2chic Ultra-Luxurious Conditioner with Cherry Blossom & Rose Petals -- 8.5 fl ozGiovanniBeauty & Personal Carecitric acid, benzyl alcohol, cetyl alcohol, citric acid, vitamin E, dehydroacetic acid, panthenol, pro-vitamin B-5, vitamin E, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Giovanni 2chic Ultra-Luxurious Leave-In Conditioning & Styling Elixir with Cherry Blossom & Rose Petals -- 4 fl ozGiovanniBeauty & Personal Carecitric acid, benzyl alcohol, cetearyl alcohol, citric acid, vitamin E, dehydroacetic acid, panthenol, pro-vitamin B5, vitamin E, dimethicone2024-11-29 10:47:42
Giovanni 2chic Ultra-Moist Dual Action Protective Leave-In Spray -- 4 fl ozGiovanniBeauty & Personal Carecitric acid, citric acid, vitamin E, panthenol, pro-vitamin B5, vitamin E, glycerin, phenoxyethanol, sodium benzoate2024-11-29 10:47:42
Giovanni 2chic Ultra-Moist Leave-In Conditioning & Styling Elixir with Avocado & Olive Oil -- 4 fl ozGiovanniBeauty & Personal Carecitric acid, cetyl alcohol, citric acid, vitamin E, panthenol, pro-vitamin B-5, vitamin E, glycerin, dimethicone, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Giovanni 2chic Ultra-Moist Super Potion Anti-Frizz & Binding Serum Oil with Avocado & Olive Oil -- 1.8 fl ozGiovanniBeauty & Personal Carebenzyl alcohol, vitamin E, vitamin E2024-11-29 10:47:42
Giovanni 2chic Ultra-Sleek Leave-In Conditioning and Styling Elixir with Brazilian Keratin and Argan Oil -- 4 fl ozGiovanniBeauty & Personal Carecitric acid, benzyl alcohol, cetyl alcohol, citric acid, vitamin E, panthenol, pro-vitamin B5, vitamin E, glycerin, phenoxyethanol, sodium benzoate, stearyl alcohol2024-11-29 10:47:42
Giovanni 2chic Ultra-Volume Leave-In Conditioning & Styling Elixir Tangerine & Papaya Butter -- 4 fl ozGiovanniBeauty & Personal Carecitric acid, cetyl alcohol, citric acid, vitamin E, panthenol, pro-vitamin B-5, vitamin E, glycerin, dimethicone, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Giovanni Deep Cleanse Shampoo Golden Wheat -- 8.5 fl ozGiovanniBeauty & Personal Carecocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, vitamin E, glycerin, menthol, sodium cocoyl glutamate2024-11-29 10:47:42
Giovanni Direct Leave-In Conditioner -- 2 fl ozGiovanniBeauty & Personal Carecitric acid, cetyl alcohol, citric acid, tocopherol, panthenol, pro-vitamin B5, tocopherol, vitamin E, phenoxyethanol2024-11-29 10:47:42
Giovanni Direct Leave-In Weightless Moisture Conditioner For All Hair Types -- 8.5 fl ozGiovanniBeauty & Personal Carecitric acid, cetyl alcohol, citric acid, tocopherol, panthenol, pro-vitamin b5, tocopherol, vitamin e, phenoxyethanol2024-11-29 10:47:42
Giovanni L.A. Natural Styling Gel -- 2 fl ozGiovanniBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, hydroxyethylcellulose, phenoxyethanol2024-11-29 10:47:42
Giovanni L.A. Natural Styling Gel Strong Hold -- 6.8 fl ozGiovanniBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, hydroxyethylcellulose, phenoxyethanol2024-11-29 10:47:42
Giovanni More Body Hair Thickener -- 6.8 fl ozGiovanniBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, hydroxyethylcellulose, phenoxyethanol2024-11-29 10:47:42
Giovanni Nutrafix Hair Reconstructor -- 6.8 fl ozGiovanniBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, phenoxyethanol2024-11-29 10:47:42
Giovanni Root 66 Max Volume Conditioner -- 8.5 fl ozGiovanniBeauty & Personal Carecitric acid, cetearyl alcohol, cetrimonium bromide, cetyl alcohol, citric acid, vitamin E, panthenol, pro-vitamin B5, vitamin E, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Giovanni Smooth As Silk Deeper Moisture Conditioner -- 8.5 fl ozGiovanniBeauty & Personal Carecetrimonium bromide, cetyl alcohol, vitamin e, vitamin e, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Giovanni Smooth As Silk Xtreme Protein Hair Infusion -- 5.1 ozGiovanniBeauty & Personal Careorange, cetrimonium bromide, cetyl alcohol, vitamin e, vitamin e, dimethicone2024-11-29 10:47:42
Giovanni Smoothing Castor Oil Conditioner -- 13.5 fl ozGiovanniBeauty & Personal Carecitric acid, biotin, cetrimonium bromide, cetyl alcohol, citric acid, vitamin E, panthenol, pro-vitamin B5, vitamin E, glycerin, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Giovanni Smoothing Castor Oil Leave-In Conditioner -- 11.5 ozGiovanniBeauty & Personal Carecitric acid, biotin, cetrimonium bromide, cetyl alcohol, citric acid, vitamin E, dehydroacetic acid, panthenol, pro-vitamin B5, vitamin E, glycerin, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Giovanni Smoothing Castor Oil Shampoo -- 13.5 fl ozGiovanniBeauty & Personal Carecitric acid, biotin, citric acid, cocamidopropyl betaine, vitamin E, decyl glucoside, dehydroacetic acid, panthenol, pro-vitamin B5, vitamin E, glycerin, phenoxyethanol, sodium lauroyl sarcosinate, sodium cocoyl glutamate2024-11-29 10:47:42
Giovanni Sugar Scrub Hot Chocolate -- 9 ozGiovanniBeauty & Personal Carevitamin E, vitamin E, Sucrose2024-11-29 10:47:42
Giovanni Vitapro Fusion Leave-In Hair Treatment -- 5.1 fl ozGiovanniBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, phenoxyethanol2024-11-29 10:47:42
Glucerna Hunger Smart Shake Homemade Vanilla -- 6 BottlesGlucernaWeight ManagementVitamin C, Biotin, Chloride, Choline, Chromium, Vitamin E, Folate, Vitamin E, Glycerin, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Glucerna Nutritional Shake Creamy Strawberry -- 6 BottlesGlucernaWeight ManagementVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Glucerna Nutritional Shake Homemade Vanilla -- 6 BottlesGlucernaWeight ManagementVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Glucerna Protein Smart Shakes Chocolate -- 4 ShakesGlucernaWeight ManagementVitamin C, Biotin, Chloride, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Glucerna Protein Smart Shakes Vanilla -- 4 ShakesGlucernaWeight ManagementVitamin C, Biotin, Chloride, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Glucerna Shake Rich Chocolate -- 8 fl ozGlucernaWeight ManagementVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Gnarly Nutrition Performance Greens - NSF Certified for Sport Blueberry Acai -- 12.8 ozGnarly NutritionVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Gnarly Nutrition Vegan Protein - NSF Certified for Sport Chocolate -- 36.8 ozGnarly NutritionActive Lifestyle & FitnessVitamin C, Biotin, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Gnarly Nutrition Vegan Protein - NSF Certified for Sport Vanilla -- 36.8 ozGnarly NutritionActive Lifestyle & FitnessVitamin C, Biotin, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Go Raw Organic Coconut & Sprouted Seed Clusters Sweet & Salty -- 3 ozGo RawFood & BeveragesVitamin E, Vitamin E, Manganese2024-11-29 10:47:42
Go Raw Organic Sprouted Snacking Seeds Sea Salt & Vinegar -- 4 ozGo RawFood & BeveragesVitamin E, Vitamin E, Manganese, Phosphorus, Selenium, Thiamin2024-11-29 10:47:42
Go Raw Organic Sprouted Sunflower Seeds Sea Salt -- 4 ozGo RawFood & BeveragesVitamin E, Folate, Vitamin E, Manganese, Phosphorus, Vitamin B6, Selenium, Vitamin B62024-11-29 10:47:42
Go Raw Snacking Seeds Organic Chili Lime -- 4 ozGo RawFood & BeveragesVitamin E, Vitamin E, Manganese, Phosphorus, Selenium2024-11-29 10:47:42
Go Raw Snacking Seeds Organic Everything Bagel -- 4 ozGo RawFood & BeveragesVitamin E, Vitamin E, Manganese, Phosphorus, Selenium2024-11-29 10:47:42
Go Raw Snacking Seeds Organic Sea Salt & Pepper -- 4 ozGo RawFood & BeveragesVitamin E, Vitamin E, Manganese, Phosphorus, Selenium2024-11-29 10:47:42
Go Raw Snacking Seeds Organic Sweet & Salty Kettle -- 4 ozGo RawFood & BeveragesVitamin E, Vitamin E, Manganese, Phosphorus, Selenium2024-11-29 10:47:42
Godefroy Double Lash & Brown Eyelash & Eyebrow Growth Serum -- 0.1 fl ozGodefroyBeauty & Personal Carecaprylyl glycol, vitamin E, ethylhexylglycerin, tocopherol, vitamin E, menthol, retinol palmitate2024-11-29 10:47:42
GoGo Squeez Active Electrolytes Blueberry Strawberry Lemon -- 4 PouchesGoGo SqueezFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
GoGo Squeez Active Electrolytes Strawberry Pineapple Orange -- 4 PouchesGoGo SqueezFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Goli Nutrition Kids Complete MultiVitamin Vegan -- 80 GummiesGoli NutritionVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K12024-11-29 10:47:42
Goli Nutrition Superfruits Gummies Fruit Blend -- 60 GummiesGoli NutritionVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Good Day Chocolate Kids Multivitamin -- 70 Chocolate PiecesGood Day ChocolateVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Choline, Vitamin E, Folate, Vitamin E, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Good Health Inc. Veggie Straws Sea Salt -- 6.75 ozGood Health Inc.Food & BeveragesVitamin C, Vitamin B7, Vitamin E, Folate, Vitamin E, Vitamin B6, Vitamin A, Vitamin B1, Vitamin B6, Vitamin K2024-11-29 10:47:42
Green + Lovely After Shower Body Oil Calendula Vanilla -- 8 fl ozGreen + LovelyBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Green + Lovely After Shower Body Oil Lavender Rose -- 8 fl ozGreen + LovelyBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Green + Lovely Better Than Butter Belly Oil Lavender -- 9 fl ozGreen + LovelyBaby & Kids Productstocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Green + Lovely Blue Arnica Salve -- 2 ozGreen + LovelyBeauty & Personal Carechamomile, vitamin E, vitamin E2024-11-29 10:47:42
Green + Lovely Lip Balm Favorites Variety Pack -- 4 Lip BalmsGreen + LovelyBeauty & Personal Carevitamin E, vitamin E2024-11-29 10:47:42
Green Foods Magma Plus® Powder -- 10.6 ozGreen FoodsHerbs, Botanicals & HomeopathyVitamin C, Chlorophyll, Vitamin E, Vitamin E, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Thiamin, Vitamin B6, Vitamin K2024-11-29 10:47:42
Green Foods Magma Plus® Powder -- 5.3 ozGreen FoodsHerbs, Botanicals & Homeopathy Lipase, Vitamin C, Chlorophyll, Vitamin E, Vitamin E, Pantothenic Acid, Phosphorus, Vitamin B6, Stevia, Vitamin A, Thiamine, Vitamin B6, Vitamin K2024-11-29 10:47:42
Green Foods True Vitality Plant Protein Shake with DHA Vanilla -- 25.2 ozGreen FoodsActive Lifestyle & FitnessVitamin C, Biotin, Boron, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Nickel, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Silicon, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Green Goo 100% All Natural Skin Repair - 1.82 oz -- 1 TinGreen GooBeauty & Personal CareVitamin E, Vitamin E2024-11-29 10:47:42
Green Goo Clarity + Focus Herbal Deodorant -- 2.25 ozGreen GooBeauty & Personal Carecalendula, vitamin E, vitamin E, stearyl alcohol2024-11-29 10:47:42
Green Goo First Aid Salve Large Tin -- 1.82 ozGreen GooBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Green Goo Free To Breathe Salve Large Tin -- 1.82 ozGreen GooVitamins & Supplementscalendula, tocopherol, tocopherol, vitamin e2024-11-29 10:47:42
Green Goo Natural Deodorant Immunity + Defense - Cedarwood & Siberian Fir -- 2.25 ozGreen GooBeauty & Personal Carecalendula, vitamin E, vitamin E, stearyl alcohol2024-11-29 10:47:42
Green Goo Natural Deodorant Relax + Adapt - Lavender & Bergamot -- 2.25 ozGreen GooBeauty & Personal Carecalendula, vitamin E, vitamin E, stearyl alcohol, ashwagandha, withania somnifera2024-11-29 10:47:42
Green Goo Plants For Your Face All Over Face + Body Serum Repairing -- 1 fl ozGreen GooBeauty & Personal Carevitamin e, palmarosa, vitamin e2024-11-29 10:47:42
Green Goo Plants For Your Face All Over Face + Body Wash -- 4 fl ozGreen GooBeauty & Personal Carecalendula, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Green Goo Plants For Your Face All Over Face + Body Wash Eczema -- 4 fl ozGreen GooBeauty & Personal Caregeranium, chamomile, calendula, vitamin E, palmarosa, vitamin E, tocopherols2024-11-29 10:47:42
Green Goo Plants For Your Face Hydrating All Over Face + Body Serum -- 1 fl ozGreen GooBeauty & Personal Carevitamin E, vitamin E2024-11-29 10:47:42
Green Goo Plants For Your Face Hydrating All Over Face + Body Stick -- 0.6 ozGreen GooBeauty & Personal Carecalendula, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Green Goo Poison Ivy Salve Large Tin -- 1.82 ozGreen GooBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Greens First Boost Dutch Chocolate -- 10.5 ozGreens FirstVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Magnesium Phosphate, Manganese, Molybdenum, Niacin, Vitamin B5, Phosphorus, Potassium Phosphate, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Greens First Boost French Vanilla -- 10.5 ozGreens FirstVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Magnesium Phosphate, Manganese, Molybdenum, Niacin, Vitamin B5, Phosphorus, Potassium Phosphate, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Greens First Female - MenoSolve Plus Probiotics -- 60 Vegetable CapsulesGreens FirstVitamins & SupplementsChromium, Vitamin E, Vitamin E, Microcrystalline cellulose, Niacin, Pantothenic Acid2024-11-29 10:47:42
Greens First Female - MenoSolve Plus Probiotics Powder Original Mint -- 30 ServingsGreens FirstVitamins & SupplementsChromium, Vitamin E, Vitamin E, Niacin, Quercetin Dihydrate2024-11-29 10:47:42
Greens First Female - Prenatal with Vegan DHA Plus Probiotics -- 90 Vegetable CapsulesGreens FirstVitamins & SupplementsVitamin C, dextrin, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Vitamin B3, potassium bicarbonate, Vitamin B6, rebaudioside A, Vitamin A, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Greens Plus +plusbar Protein Chocolate -- 12 BarsGreens PlusActive Lifestyle & Fitnessd-alpha tocopheryl succinate, beta-carotene, Biotin, vitamin d3, vitamin e, vitamin e, Pantothenic Acid, Vitamin B6, vitamin a, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Greens Plus Dairy Free Plusbar Energy Chocolate -- 12 BarsGreens PlusFood & BeveragesD-Alpha tocopheryl succinate, beta-carotene, Biotin, vitamin D3, vitamin E, vitamin E, Pantothenic Acid, Vitamin B6, vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Greens Plus Meal Replacement PlusShake™ Raw Chocolate -- 1.5 lbsGreens PlusActive Lifestyle & FitnessVitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Greens Plus Original Superfood -- 240 Veggie CapsulesGreens PlusVitamins & SupplementsVitamin C, Vitamin E, Folate, Vitamin E, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
GuruNanda Mouthwash Oral Rinse Wild Mint -- 2 fl ozGuruNandaBeauty & Personal Carevitamin e, vitamin e, stevia2024-11-29 10:47:42
Hain Pure Foods Safflower Mayonnaise -- 12 ozHain Pure FoodsFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A, spice2024-11-29 10:47:42
Hand in Hand Foaming Shave Cream Almond Crème -- 8 fl ozHand in HandBeauty & Personal Caretocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Hand in Hand Foaming Shave Cream Cactus Blossom -- 8 fl ozHand in HandBeauty & Personal Caretocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Hand in Hand Foaming Shave Cream Island Mimosa -- 8 fl ozHand in HandBeauty & Personal Caretocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Happy Baby Organic Infant Formula A2 Milk Powder 0-12 Months Stage 1 -- 22.9 ozHappy BabyBaby & Kids Productsascorbyl palmitate, Vitamin C, beta-carotene, Biotin, calcium pantothenate, Chloride, cholecalciferol, Choline, cupric sulfate, Vitamin E, ferrous sulfate, folic acid, vitamin e, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, niacinamide, Fat, Pantothenic Acid, Phosphorus, potassium chloride, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, sodium citrate, Vitamin B1, calcium phosphate, Vitamin B12, phytonadione, Vitamin K, zinc sulfate2024-11-29 10:47:42
Happy Baby Organic Infant Formula Powder 0-12 Months Stage 1 -- 21 ozHappy BabyBaby & Kids Productsascorbyl palmitate, dl-alpha tocopheryl acetate, Vitamin C, betacarotene, Biotin, calcium pantothenate, Chloride, cholecalciferol, Choline, cupric sulfate, Vitamin E, ferrous sulfate, folic acid, vitamin E, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, niacinamide, Fat, Pantothenic Acid, Phosphorus, potassium bicarbonate, potassium chloride, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, sodium citrate, sodium selenite, thiamine hydrochloride, Thiamine, calcium phosphate, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, zinc sulfate2024-11-29 10:47:42
Happy Baby Organic Infant Formula Powder 6-12 Months Stage 2 -- 21 ozHappy BabyBaby & Kids Productsascorbyl palmitate, dl-alpha tocopheryl acetate, Vitamin C, betacarotene, Biotin, calcium pantothenate, Chloride, cholecalciferol, Choline, cupric sulfate, Vitamin E, ferrous sulfate, folic acid, vitamin E, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, niacinamide, Fat, Pantothenic Acid, Phosphorus, potassium bicarbonate, potassium chloride, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, sodium citrate, sodium selenite, thiamine hydrochloride, Thiamine, calcium phosphate, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, zinc sulfate2024-11-29 10:47:42
Happy Baby Organic Superfood Puffs Crawling Baby Snack Kale & Spinach -- 2.1 ozHappy BabyBaby & Kids ProductsDL-alpha-tocopherol acetate, Vitamin C, cholecalciferol, choline, Vitamin E, ferric pyrophosphate, Folate, vitamin E, calcium carbonate, Niacin, niacinamide, vitamin B5, Phosphorus, potassium chloride, pyridoxine hydrochloride, Vitamin B6, vitamin A acetate, Vitamin A, vitamin B2, Thiamin, vitamin B1, tricalcium phosphate, cyanocobalamin, vitamin B6, zinc oxide2024-11-29 10:47:42
Happy Baby Organic Superfood Puffs Crawling Baby Snack Purple Carrot & Blueberry -- 2.1 ozHappy BabyBaby & Kids ProductsDL-alpha-tocopherol acetate, Vitamin C, cholecalciferol, choline, Vitamin E, ferric pyrophosphate, vitamin E, calcium carbonate, Niacin, niacinamide, vitamin B5, Phosphorus, potassium chloride, pyridoxine hydrochloride, Vitamin B6, vitamin A acetate, Vitamin A, vitamin B2, Thiamin, vitamin B1, tricalcium phosphate, cyanocobalamin, vitamin B6, zinc oxide2024-11-29 10:47:42
Havasu Nutrition Collagen Gummies Lemon -- 60 GummiesHavasu NutritionVitamins & Supplementscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Vitamin E2024-11-29 10:47:42
Havasu Nutrition Premium Multivitamin Gummies Natural Fruit -- 60 GummiesHavasu NutritionVitamins & Supplementscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Folate, Vitamin E, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Healright Daily Micronutrient Bar Caramel Apple Fig -- 2.19 ozHealrightProfessional SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, L-glutamine, glycerin, maltitol, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Healright Daily Micronutrient Bar Chocolate Cherry Pomegranate -- 14 BarsHealrightProfessional SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, L-glutamine, glycerin, Maltitol, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Healright Daily Micronutrient Bar Chocolate Cherry Pomegranate -- 2.19 ozHealrightProfessional SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, L-glutamine, glycerin, Maltitol, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Healright Daily Micronutrient Bar Lemon Blueberry -- 2.19 ozHealrightProfessional SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, L-glutamine, glycerin, Maltitol, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Healright Daily Micronutrient Bar Peanut Butter Banana -- 2.19 ozHealrightProfessional SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, L-glutamine, glycerin, Maltitol, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Healths Harmony Blood Sugar Capsules with Cinnamon Bitter Melon and Chromium -- 120 CapsulesHealths HarmonyHerbs, Botanicals & HomeopathyVitamin C, Biotin, Chromium, Vitamin E, Vitamin E, microcrystalline cellulose, Manganese, Taurine, Alpha Lipoic Acid, Vanadium2024-11-29 10:47:42
Healths Harmony Kids Vitamin Gummies Organic Strawberry Orange Lemon -- 60 GummiesHealths HarmonyVitamins & SupplementsVitamin C, Biotin, Vitamin E, Folate, Vitamin E, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, sodium citrate, Vitamin B12, Vitamin B62024-11-29 10:47:42
Healthy Origins Astaxanthin -- 4 mg - 150 SoftgelsHealthy OriginsVitamins & SupplementsVitamin E, Vitamin E, glycerin, Lutein, Vitamin A2024-11-29 10:47:42
Healthy Origins Astaxanthin Triple Strength -- 12 mg - 150 SoftgelsHealthy OriginsVitamins & SupplementsAstaxanthin, Vitamin E, Vitamin E, glycerin, Lutein, Vitamin A2024-11-29 10:47:42
Healthy Origins Astaxanthin Triple Strength -- 12 mg - 60 SoftgelsHealthy OriginsVitamins & SupplementsVitamin E, Vitamin E, glycerin, Lutein, Vitamin A2024-11-29 10:47:42
Healthy Origins Natural Sunflower E - SunE900™ -- 400 IU - 120 SoftgelsHealthy OriginsVitamins & SupplementsVitamin E, Vitamin E, glycerin2024-11-29 10:47:42
Healthy Origins Vitamin E -- 400 IU - 360 SoftgelsHealthy OriginsVitamins & SupplementsVitamin E, Vitamin E, glycerin2024-11-29 10:47:42
Healthy Pup Multi Max for Dogs -- 120 Soft ChewsHealthy PupPet Suppliescitric acid, alpha-Linolenic Acid, Biotin, Calcium Ascorbate, dicalcium phosphate, Vitamin D3, Choline, citric acid, Cobalt, copper carbonate, Vitamin E, ferrous sulfate, folic acid, Vitamin E, glycerin, Iodine, Linoleic Acid, maltodextrin, Manganese, Niacin, Oleic Acid, d-Pantothenic Acid, Phosphorus, potassium iodide, pyridoxine hydrochloride, Pyridoxine, vitamin A palmitate, Vitamin A, Riboflavin, sorbic acid, Thiamine, Vitamin B12, Menadione, zinc sulfate2024-11-29 10:47:42
Heaven Sent Wellgenix Balanced Essentials + Plus Liquid Vitamins Berry -- 32 fl ozHeaven SentVitamins & Supplementscitric acid, Antimony, Arginine, Vitamin C, Aspartic Acid, Kelp, Barium, Beryllium, Biotin, Bismuth, Boron, Bromide, Omega 3, Cerium, Cesium, Chromium, citric acid, Cobalt, Cystine, Vitamin E, fructose, Dysprosium, Erbium, Europium, Fluoride, Folate, Gadolinium, Gallium, Vitamin E, Glycine, Gold, Hafnium, Histidine, Holmium, Inositol, Iodine, Iodine, Isoleucine, Lanthanum, Leucine, Calcium Carbonate, Lithium, Lutetium, Lysine, Manganese, Methionine, Molybdenum, Neodymium, Niacin, Nickel, Niobium, Pantothenic Acid, Phenylalanine, Phosphorus, Praseodymium, Proline, Vitamin B6, Vitamin A, Rhenium, Riboflavin, Rubidium, Samarium, Scandium, Selenium, Serine, Silicon, Silver, Strontium, Tantalum, Tellurium, Terbium, Thallium, Thiamin, Thorium, Threonine, Thulium, Tin, Titanium, Tryptophan, Tungsten, Tyrosine, Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Ytterbium, Yttrium, Zirconium2024-11-29 10:47:42
Herbion Naturals - All Natural Chest Rub Soothing Ointment -- 3.53 ozHerbionVitamins & Supplementsvitamin E, vitamin E2024-11-29 10:47:42
Heritage Store Egyptian Gold Body Butter -- 4 ozHeritage StoreBeauty & Personal Carea-tocopherol, vitamin E, glyceryl stearate2024-11-29 10:47:42
Heritage Store Grapeseed Oil -- 16 fl ozHeritage StoreBeauty & Personal CareVitamin E, Vitamin E2024-11-29 10:47:42
Home Health Almond Glow Body Lotion Massage Oil Unscented -- 8 fl ozHome HealthBeauty & Personal CareTocopherol Acetate, Vitamin E, Vitamin E2024-11-29 10:47:42
Honey Stinger Almond Pumpkin Seed Nut + Seed Bar -- 12 BarsHoney StingerActive Lifestyle & Fitnessorange, Vitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, cane sugar, Thiamin, Vitamin B62024-11-29 10:47:42
Honey Stinger Peanut & Sunflower Nut + Seed Bars -- 12 BarsHoney StingerActive Lifestyle & Fitnessorange, Vitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, cane sugar, Thiamin, Vitamin B62024-11-29 10:47:42
Honey Stinger Protein Bar Dark Chocolate Coconut Almond -- 15 BarsHoney StingerActive Lifestyle & Fitnessdl-alpha tocopheryl acetate, Vitamin C, Biotin, d-calcium pantothenate, dicalcium phosphate, Chloride, cholecalciferol, Chromium, copper gluconate, Vitamin E, ferric orthophosphate, Vitamin E, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, niacinamide, Pantothenic Acid, Phosphorus, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, zinc oxide2024-11-29 10:47:42
Honey Stinger Protein Bar Milk Chocolate Peanut Butta -- 15 BarsHoney StingerActive Lifestyle & Fitnessd,l-alpha tocopheryl acetate, Vitamin C, Biotin, d-calcium pantothenate, dicalcium phosphate, Chlorine, cholecalciferol, Chromium, copper gluconate, Vitamin E, Vitamin E, Iodide, maltodextrin, Manganese, Molybdenum, Niacin, niacinamide, Pantothenic Acid, Phosphorus, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin a palmitate, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, zinc oxide2024-11-29 10:47:42
Honeybee Gardens Truly Natural Lipstick Goddess -- 0.13 ozHoneybee GardensBeauty & Personal Carecarmine, golden seal, tocopherol, tocopherol, vitamin e2024-11-29 10:47:42
Honeybee Gardens Truly Natural Lipstick Seduction -- 0.13 ozHoneybee GardensBeauty & Personal Caregolden seal, tocopherol, tocopherol, vitamin e2024-11-29 10:47:42
Human Beanz Multivitamin Jelly Beans Essential Vitamins Plus Zinc Berry Blast -- 120 Jelly BeansHuman BeanzVitamins & Supplementscitric acid, Vitamin C, Biotin, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Iodine, maltodextrin, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, sodium citrate, Sugar, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Humble Potato Chips Gluten Free Organic Light & Crispy Creamy Dill -- 5 ozHumbleFood & Beveragescitric acid, citric acid, vitamin E, vitamin E, malic acid2024-11-29 10:47:42
I and Love and You Naked Essentials Dry Cat Food Chicken + Duck -- 3.4 lbsI and Love and YouPet Suppliesbiotin, D-calcium pantothenate, copper sulfate, Vitamin E, ferrous sulfate, Vitamin E, calcium carbonate, Linoleic, potassium chloride, pyridoxine hydrochloride, Vitamin A, sodium selenite, Taurine, zinc sulfate2024-11-29 10:47:42
I and Love and You Naked Essentials Dry Cat Food Salmon + Trout -- 3.4 lbsI and Love and YouPet SuppliesBiotin, Calcium Pantothenate, Dicalcium Phosphate, Choline Chloride, Copper Sulfate, Vitamin E, Ferrous Sulfate, Folic Acid, Vitamin E, Calcium Carbonate, Pyridoxine Hydrochloride, Sodium Selenite, Taurine, Zinc Sulfate2024-11-29 10:47:42
I and Love and You Naked Essentials Dry Dog Food Chicken + Duck -- 4 lbsI and Love and YouPet Suppliescitric acid, d-calcium pantothenate, choline chloride, citric acid, copper sulfate, Vitamin E, ferrous sulfate, folic acid, Vitamin E, potassium chloride, pyridoxine hydrochloride, sodium selenite, Taurine, zinc oxide2024-11-29 10:47:42
I and Love and You Naked Essentials Dry Dog Food Duck & Chicken -- 11 lbsI and Love and YouPet SuppliesBiotin, Calcium Pantothenate, Choline Chloride, Copper Sulfate, Vitamin E, Ferrous Sulfate, Folic Acid, Vitamin E, Calcium Carbonate, Potassium Chloride, Pyridoxine Hydrochloride, Sodium Selenite, Zinc Sulfate2024-11-29 10:47:42
I and Love and You Naked Essentials Dry Dog Food Lamb + Bison -- 11 lbsI and Love and YouPet Suppliesd-calcium pantothenate, choline chloride, copper sulfate, Vitamin E, folic acid, Vitamin E, calcium carbonate, potassium chloride, pyridoxine hydrochloride, sodium selenite2024-11-29 10:47:42
I and Love and You Naked Essentials Dry Dog Food Lamb + Bison -- 4 lbsI and Love and YouPet Suppliescitric acid, d-calcium pantothenate, choline chloride, citric acid, copper sulfate, Vitamin E, ferrous sulfate, folic acid, Vitamin E, potassium chloride, pyridoxine hydrochloride, sodium selenite, Taurine, zinc oxide2024-11-29 10:47:42
I and Love and You Naked Essentials Puppy Dry Dog Food Chicken + Lentils -- 4 lbsI and Love and YouPet Suppliesd-calcium pantothenate, choline chloride, copper sulfate, Vitamin E, Docosahexaenoic Acid, iron sulfate, folic acid, Vitamin E, niacin, Phosphorus, pyridoxine hydrochloride, Vitamin A, sodium selenite, Taurine, zinc sulfate2024-11-29 10:47:42
I and Love and You Nude Super Food Dry Cat Food Poultry a Plenty -- 5 lbI and Love and YouPet Suppliesbiotin, calcium pantothenate, choline chloride, copper sulfate, Vitamin E, ferrous sulfate, folic acid, Vitamin E, calcium carbonate, pyridoxine hydrochloride, sodium selenite, Taurine, zinc sulfate2024-11-29 10:47:42
I and Love and You Treat Meow Squeeze & Thank You Moist Cat Treats Variety Pack Seafood Chicken Tuna -- 12 PouchesI and Love and YouPet SuppliesVitamin E, Vitamin E, potassium iodide, Vitamin A, sodium selenite, zinc oxide2024-11-29 10:47:42
Igennus Pharmepa Complete EPA - DHA - GLA Ultra Pure rTG Wild Fish Oil Lemon -- 1000 mg - 60 SoftgelsIgennusVitamins & SupplementsVitamin E, rTG, Vitamin E, linoleic acid2024-11-29 10:47:42
Igennus Pharmepa Restore - Ultra Pure EPA-Super Strength rTG Wild Fish Oil Lemon -- 1000 mg - 60 SoftgelsIgennusVitamins & SupplementsVitamin E, EPA, vitamin E2024-11-29 10:47:42
Igennus VESIsorb Ubiquinol-QH - Premium Absorption Activated CoQ10 - Kaneka Ubiquinol -- 30 SoftgelsIgennusVitamins & SupplementsVitamin E, Vitamin E, Ubiquinol2024-11-29 10:47:42
Inaba Grain Free Churu Cat Treats Chicken Recipe -- 2 oz Each / Pack of 8InabaPet SuppliesVitamin E, Vitamin E2024-11-29 10:47:42
Inaba Grain Free Churu Cat Treats Tuna Recipe -- 2 oz Each / Pack of 8InabaPet SuppliesVitamin E, Vitamin E2024-11-29 10:47:42
Inaba Grain Free Churu Puree Cat Treats Chicken with Scallop Recipe -- 2 oz Each / Pack of 8InabaPet SuppliesVitamin E, Vitamin E2024-11-29 10:47:42
Inholtra Premium Lubri-Joint -- 120 Liquid SoftgelsInholtraVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, glycerin, Manganese2024-11-29 10:47:42
Innate Formulas One Daily Iron Free Multivitamin -- 90 TabletsInnateProfessional SupplementsVitamin C, Biotin, Boron, Vitamin D3, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Innate Response Formulas Baby & Me Multivitamin -- 120 TabletsInnateProfessional SupplementsVitamin C, Biotin, Vitamin D3, Vitamin E, Folate, Vitamin E, Microcrystalline cellulose, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Innate Response Formulas Baby & Me Multivitamin -- 60 TabletsInnateProfessional SupplementsVitamin C, Biotin, Vitamin D3, Vitamin E, Folate, Vitamin E, Microcrystalline cellulose, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Innate Response Formulas Men Over 40 One Daily Iron Free -- 60 TabletsInnateProfessional SupplementsVitamin C, Biotin, Boron, Vitamin D3, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Innate Response Formulas One Daily -- 90 TabletsInnateProfessional SupplementsVitamin C, Biotin, Boron, Vitamin D3, Vitamin E, Folate, Vitamin E, Microcrystalline cellulose, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Innate Response Formulas Women Over 40 One Daily -- 60 TabletsInnateProfessional SupplementsVitamin C, Biotin, Boron, Vitamin D3, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
IQBAR Brain & Body Bars Almond Butter Chip -- 4 BarsIQBARWeight ManagementVitamin E, Vitamin E2024-11-29 10:47:42
IQBAR Brain & Body Bars Chocolate Sea Salt -- 4 BarsIQBARWeight ManagementVitamin E, Vitamin E2024-11-29 10:47:42
IQBAR Brain & Body Bars Peanut Butter Chip -- 4 BarsIQBARWeight ManagementVitamin E, Vitamin E2024-11-29 10:47:42
Irwin Naturals Immuno-Shield™ -- 100 Liquid SoftgelsIrwin NaturalsVitamins & SupplementsVitamin C, Vitamin E, Beta Glucan, Vitamin E, glycerin, Selenium2024-11-29 10:47:42
Irwin Naturals Living Green Liquid-Gel Multi For Men Economy Size -- 120 SoftgelsIrwin NaturalsVitamins & Supplements L-5-Hydroxytryptophan, Vitamin C, Biotin, Chromium, Vitamin E, Folic Acid, Vitamin E, glycerin, L-Isoleucine, Manganese, Molybdenum, Niacin, Pantothenic Acid, L-Phenylalanine, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, L-Valine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Irwin Naturals Living Green Liquid-Gel Multi For Women -- 120 Liquid SoftgelsIrwin NaturalsVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folic Acid, Vitamin E, glycerin, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, titanium dioxide, Vitamin B12, Vitamin B62024-11-29 10:47:42
Irwin Naturals Living Green Liquid-Gel Multi™ For Men -- 90 Liquid SoftgelsIrwin NaturalsVitamins & Supplements L-5-Hydroxytryptophan, Vitamin C, Biotin, dicalcium phosphate, Chromium, Vitamin E, Folate, Vitamin E, L-Isoleucine, Manganese, Molybdenum, Niacin, Pantothenic Acid, L-Phenylalanine, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, titanium dioxide, L-Valine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Irwin Naturals Triple-Tea Fat Burner -- 75 Liquid SoftgelsIrwin NaturalsWeight ManagementVitamin C, Vitamin E, Folic Acid, Vitamin E, Niacin, Vitamin B6, Vitamin B12, Vitamin B62024-11-29 10:47:42
Irwin Naturals Vision Sharp® Multi-Nutrient Eye Health -- 42 Liquid SoftgelsIrwin NaturalsVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, glycerin, Lutein, Manganese, Vitamin A, Citrus, titanium dioxide, Zeaxanthin2024-11-29 10:47:42
Jarrow Formulas Famil-E -- 60 SoftgelsJarrow FormulasVitamins & Supplements d-Alpha, Vitamin E, d-Gamma Tocopherol, Vitamin E, glycerin2024-11-29 10:47:42
Jarrow Formulas Toco-Sorb -- 60 SoftgelsJarrow FormulasVitamins & Supplementsd-Alpha, d-Beta, Vitamin E, Vitamin E, glycerin, Tocotrienols2024-11-29 10:47:42
Juven Therapeutic Nutrition Drink Powder Mix Fruit Punch -- 30 PacketsJuvenProfessional Supplementscitric acid, acesulfame potassium, acesulfame potassium, dl-alpha-tocopheryl acetate, Vitamin C, citric acid, Vitamin E, Vitamin E, L-Glutamine, sugar, sucralose, Vitamin B12, zinc sulfate2024-11-29 10:47:42
Juven Therapeutic Nutrition Drink Powder Mix Orange -- 30 PacketsJuvenProfessional Supplementscitric acid, acesulfame potassium, acesulfame potassium, dl-alpha-tocopheryl acetate, Vitamin C, citric acid, Vitamin E, Vitamin E, L-Glutamine, sugar, sucralose, Vitamin B12, zinc sulfate2024-11-29 10:47:42
Juven Therapeutic Nutrition Drink Powder Mix Unflavored -- 30 PacketsJuvenProfessional Supplementscitric acid, dl-alpha-tocopheryl acetate, Vitamin C, citric acid, Vitamin E, Vitamin E, L-Glutamine, Vitamin B12, zinc sulfate2024-11-29 10:47:42
Kabrita Goat Milk Toddler Formula 12-24 Months -- 14 ozKabritaBaby & Kids Productsvitamin E acetate, Vitamin C, Biotin, tri calcium citrate, calcium pantothenate, dicalcium phosphate, vitamin D3, choline chloride, copper sulfate, Vitamin E, ferrous sulfate, folic acid, Vitamin E, inositol, Iodine, Lactose, L-carnitine, calcium carbonate, Niacin, niacinamide, Pantothenic Acid, Phosphorus, vitamin B6 hydrochloride, Vitamin B6, retinyl acetate, Vitamin A, Riboflavin, sodium selenite, taurine, thiamine hydrochloride, Thiamin, tri calcium phosphate, Vitamin B12, Vitamin B6, vitamin K1, zinc sulfate2024-11-29 10:47:42
Kaged Plant Based Whole Food Multivitamin -- 60 Veggie CapsKagedActive Lifestyle & FitnessVitamin C, kelp, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Kashi Fiber Cereal Organic Warm Cinnamon -- 10.6 ozKashiFood & Beveragesvitamin E, ferric phosphate, vitamin E, Phosphorus2024-11-29 10:47:42
Kashi Go Breakfast Cereal Toasted Berry Crumble -- 14 ozKashiFood & Beveragesvitamin E, vitamin E, Phosphorus, baking soda, cane sugar2024-11-29 10:47:42
Kashi Organic Honey Toasted Oat Cereal -- 10.6 ozKashiFood & Beveragesvitamin E, ferric phosphate, vitamin E, Phosphorus2024-11-29 10:47:42
Kashi Strawberry Banana Smoothie Loops -- 10 ozKashiFood & Beveragesvitamin E, vitamin E, cane sugar2024-11-29 10:47:42
KIND Chewy Gluten Free Granola Oat Bars Chocolate Chip -- 10 BarsKINDFood & Beveragesvitamin E, vitamin E, cane sugar2024-11-29 10:47:42
KIND Chewy Gluten Free Granola Oat Bars Variety Pack Chocolate Chip & Peanut Butter Chocolate Chip -- 20 BarsKINDFood & Beveragesvitamin E, vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Almond Flour Soft Baked Squares Chocolate Brownie -- 6 BarsKINDFood & Beveragesvitamin E, vitamin E, baking soda, cane sugar2024-11-29 10:47:42
KIND Gluten Free Breakfast Protein Bars Almond Butter -- 6 PacksKINDFood & Beveragesamaranth, vitamin E, vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Breakfast Protein Bars Blueberry Almond -- 6 PacksKINDFood & Beveragesamaranth, Vitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Breakfast Protein Bars Dark Chocolate Cocoa -- 6 PacksKINDFood & Beveragesamaranth, Vitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Breakfast Protein Bars Honey Oat -- 6 PacksKINDFood & Beveragesamaranth, Vitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Breakfast Protein Bars Peanut Butter -- 6 PacksKINDFood & Beveragesamaranth, Vitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Breakfast Protein Bars Peanut Butter Banana Dark Chocolate -- 6 PacksKINDFood & Beveragesamaranth, Vitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Cereal Oats Bars Peanut Butter -- 6 BarsKINDFood & Beveragesamaranth, Vitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Chewy Minis Oat Bars Peanut Butter -- 10 BarsKINDFood & Beveragesvitamin E, vitamin E, sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Grains Granola Clusters Cinnamon Oat -- 11 ozKINDFood & Beveragesamaranth, Vitamin C, vitamin E, vitamin E, Vitamin A2024-11-29 10:47:42
KIND Gluten Free Healthy Grains Granola Clusters Dark Chocolate -- 11 ozKINDFood & Beveragesamaranth, Vitamin C, vitamin E, vitamin E, Vitamin A, sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Grains Granola Clusters Oats & Honey with Toasted Coconut -- 11 ozKINDFood & Beveragesamaranth, vitamin E, vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Grains Granola Clusters Raspberry with Chia Seeds -- 11 ozKINDFood & Beveragesamaranth, vitamin E, vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Grains Granola Clusters Vanilla Blueberry -- 11 ozKINDFood & Beveragescitrus pectin, amaranth, Vitamin C, vitamin E, vitamin E, glycerine, Vitamin A, cane sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Grains Granola Clusters Family Size Peanut Butter -- 17 ozKINDFood & Beveragesamaranth, Vitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Grains Granola Drizzled Bars Salted Caramel -- 5 BarsKINDFood & Beveragesamaranth, annatto, vitamin E, vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Grains Oat Granola Bars Dark Chocolate Chunk -- 15 BarsKINDFood & Beveragesamaranth, vitamin E, vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Grains Oat Granola Bars Oats & Honey -- 15 BarsKINDFood & Beveragesamaranth, Vitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Grains Oat Granola Bars Peanut Butter Dark Chocolate -- 15 BarsKINDFood & Beveragesamaranth, Vitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Grains Oat Granola Bars Vanilla Blueberry -- 15 BarsKINDFood & Beveragesamaranth, Vitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Snack Bars Blueberry Vanilla & Cashew -- 12 BarsKINDFood & BeveragesBiotin, Vitamin E, Vitamin E, Manganese, Phosphorus, sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Snack Bars Caramel Almond & Sea Salt -- 12 BarsKINDFood & BeveragesVitamin C, Vitamin E, Vitamin E, Manganese, Phosphorus, Vitamin A, Vitamin B2, sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Snack Bars Dark Chocolate Almond Mint -- 12 BarsKINDFood & BeveragesBiotin, Vitamin E, Vitamin E, Manganese, Molybdenum, Vitamin B2, sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Snack Bars Dark Chocolate Cherry Cashew -- 12 BarsKINDFood & Beveragesvitamin C, vitamin E, vitamin E, vitamin A, sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Snack Bars Dark Chocolate Mocha Almond -- 12 BarsKINDFood & BeveragesBiotin, Vitamin E, Vitamin E, Manganese, Molybdenum, Vitamin B3, Phosphorus, Vitamin B2, sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Snack Bars Dark Chocolate Nuts & Sea Salt -- 12 BarsKINDFood & BeveragesBiotin, Vitamin E, Vitamin E, Manganese, Molybdenum, Vitamin B3, Phosphorus, Vitamin B2, sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Snack Bars Honey Roasted Nuts & Sea Salt -- 12 BarsKINDFood & BeveragesVitamin E, Vitamin E, Manganese, Molybdenum, Vitamin B3, Phosphorus2024-11-29 10:47:42
KIND Gluten Free Healthy Snack Bars Madagascar Vanilla Almond -- 12 BarsKINDFood & BeveragesBiotin, Vitamin E, Vitamin E, Manganese, Molybdenum, Vitamin B3, Phosphorus, Vitamin B2, sugar2024-11-29 10:47:42
KIND Gluten Free Healthy Snack Bars Maple Glazed Pecan & Sea Salt -- 12 BarsKINDFood & BeveragesVitamin C, Vitamin E, Vitamin E, Manganese, Phosphorus, Vitamin A, Sugar2024-11-29 10:47:42
KIND Gluten Free Nut Butter Filled Snack Bars Chocolate Peanut Butter -- 6 BarsKINDFood & BeveragesVitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
KIND Gluten Free Plant Protein Bars Double Dark Chocolate Nut -- 12 BarsKINDFood & BeveragesBiotin, Vitamin E, Vitamin E, Manganese, Vitamin B3, Phosphorus, sugar2024-11-29 10:47:42
KIND Kids Bar Tree Nut Free Peanut Free Gluten Free Chocolate Chip -- 5 BarsKINDFood & BeveragesVitamin E, Vitamin E, baking soda, cane sugar2024-11-29 10:47:42
KIND Trail Mix Cashew Cranberry Walnut -- 7.5 ozKINDFood & Beveragesvitamin E, vitamin E, cane sugar2024-11-29 10:47:42
KIND Trail Mix Pecan Cranberry Cashew -- 9 ozKINDFood & Beveragesvitamin E, vitamin E, cane sugar2024-11-29 10:47:42
King Arthur Baking Company Almond Flour -- 16 ozKing Arthur Baking CompanyFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Kiss My Face Anti-Stress Shower Gel - Woodland Pine & Ginseng -- 16 fl ozKiss My FaceBeauty & Personal Careallantoin, vitamin E, decyl glucoside, vitamin E, retinyl palmitate, vitamin A, sodium cocoyl glutamate2024-11-29 10:47:42
Kiss My Face Body Lotion Tropical Coconut -- 16 fl ozKiss My FaceBeauty & Personal Carecetyl alcohol, vitamin E, panthenol, ethylhexylglycerin, vitamin E, glycerin, phenoxyethanol, squalane, stearic acid, stearyl alcohol2024-11-29 10:47:42
Kiss My Face Face Factor Mineral Sunscreen SPF 50 -- 2 fl ozKiss My FaceBeauty & Personal Carebutylene glycol, citric acid, chamomile, ascorbic acid, citric acid, vitamin E, decyl glucoside, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, hydroxyethylcellulose, lutein, phenoxyethanol2024-11-29 10:47:42
Kiss My Face Moisturizing Hand Soap Coconut -- 9 fl ozKiss My FaceHousehold Essentialsorange, citric acid, allantoin, citric acid, vitamin E, vitamin E, glyceryl stearate, glycerin, cocobetaine2024-11-29 10:47:42
Kiss My Face Moisturizing Hand Soap Fragrance Free -- 9 fl ozKiss My FaceHousehold Essentialsorange, citric acid, allantoin, citric acid, vitamin E, vitamin E, glyceryl stearate, glycerin, cocobetaine2024-11-29 10:47:42
Kiss My Face Moisturizing Hand Soap Olive & Aloe -- 9 fl ozKiss My FaceHousehold Essentialsorange, citric acid,, allantoin, cocamidopropyl betaine, vitamin e, decyl glucoside, vitamin e, glycerin, phenoxyethanol, glycol stearate, sodium benzoate2024-11-29 10:47:42
Klean Athlete Gummy Multivitamin - NSF Certified for Sport Raspberry Lemonade -- 100 GummiesKlean AthleteProfessional Supplementscitric acid, Vitamin C, Biotin, Vitamin D3, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, sodium citrate, cane sugar, Thiamin, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Klean Athlete Klean Multivitamin - NSF Certified for Sport -- 60 TabletsKlean AthleteProfessional SupplementsL-methylfolate, Vitamin C, Astaxanthin, Biotin, Cellulose, Vitamin D3, Choline, Chromium, leaf, Vitamin E, Folate, Vitamin E, glycerin, Inositol, Iodine, Lutein, Lycopene, Molybdenum, Pantothenic Acid, Pterostilbene, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamine, titanium dioxide, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
KOS Organic Plant Protein Powder Chocolate -- 20.6 ozKOSWeight Managementlipase, cellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Riboflavin, Selenium, Vitamin B12, Vitamin K2024-11-29 10:47:42
KOS Organic Plant Protein Powder Chocolate Peanut Butter -- 20.56 ozKOSWeight Managementlipase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Riboflavin, Selenium, Vitamin B12, Vitamin K2024-11-29 10:47:42
KOS Organic Plant Protein Powder Vanilla -- 19.6 ozKOSWeight Managementlipase, cellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Riboflavin, Selenium, Vitamin B12, Vitamin K2024-11-29 10:47:42
KOS Organic Plant Protein with Blue Spirulina & Immunity Blueberry Muffin -- 20.6 ozKOSWeight Managementlipase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Riboflavin, Selenium, Vitamin B12, Vitamin K2024-11-29 10:47:42
KOS Organic Superfood Plant Protein Powder Chocolate -- 28 ServingsKOSWeight Managementcellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, niacinamide, potassium iodide, Riboflavin, Selenium, DL-alpha tocopherol, cyanocobalamin, zinc oxide2024-11-29 10:47:42
KOS Organic Superfood Plant Protein Powder Vanilla -- 28 ServingsKOSWeight Managementcellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, niacinamide, potassium iodide, Riboflavin, Selenium, DL-alpha tocopherol, cyanocobalamin, zinc oxide2024-11-29 10:47:42
KOS Organic Superfood Plant Protein Powder - 15 Servings Strawberries & Cream -- 20.1 ozKOSWeight Managementcellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, niacinamide, potassium iodide, Riboflavin, Selenium, DL-alpha tocopherol, cyanocobalamin, zinc oxide2024-11-29 10:47:42
KOS Organic Superfood Plant Protein Powder - 28 Servings Chocolate Peanut Butter -- 38.5 ozKOSWeight Managementcellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, niacinamide, potassium iodide, Riboflavin, Selenium, DL-alpha tocopherol, cyanocobalamin, zinc oxide2024-11-29 10:47:42
KOS Organic Superfood Plant Protein Powder - 28 Servings Salted Caramel Coffee -- 36.54 ozKOSWeight Managementlipase, cellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, niacinamide, potassium iodide, Riboflavin, Selenium, DL-alpha tocopherol, Vitamin B12, phylloquinone, zinc oxide2024-11-29 10:47:42
KOS Organic Superfood Plant Protein Powder - 28 Servings Strawberries & Cream -- 37.5 ozKOSWeight Managementcellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, niacinamide, potassium iodide, Riboflavin, Selenium, DL-alpha tocopherol, cyanocobalamin, zinc oxide2024-11-29 10:47:42
KOS Organic Superfood Plant Protein Powder - 28 Servings Unflavored -- 33.6 ozKOSWeight Managementcellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, niacinamide, potassium iodide, Riboflavin, Selenium, DL-alpha tocopherol, cyanocobalamin, zinc oxide2024-11-29 10:47:42
Kuli Kuli Green Power Superfood -- 6 ozKuli KuliHerbs, Botanicals & HomeopathyVitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Kuli Kuli Gut Bliss Superfood -- 6 ozKuli KuliHerbs, Botanicals & HomeopathyVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Kuli Kuli Pure Moringa Vegetable Powder -- 7.4 ozKuli KuliHerbs, Botanicals & HomeopathyVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Kyolic Aged Garlic Extract Detox and Anti-Aging Formula 105 -- 100 CapsulesKyolicHerbs, Botanicals & HomeopathyVitamin C, Vitamin E, Vitamin E, Microcrystalline cellulose, Vitamin A, Selenium2024-11-29 10:47:42
Kyolic Aged Garlic Extrac™ Detox and Anti-Aging Formula 105 -- 200 CapsulesKyolicHerbs, Botanicals & HomeopathyVitamin C, Cellulose, Vitamin E, Vitamin E, Vitamin A, Selenium2024-11-29 10:47:42
Kyolic Aged Garlic Extract™ Circulation Formula 106 -- 100 CapsulesKyolicVitamins & Supplementscellulose, Vitamin E, Vitamin E2024-11-29 10:47:42
Kyolic Aged Garlic Extract™ Circulation Formula 106 -- 200 CapsulesKyolicVitamins & Supplementscellulose, Vitamin E, Vitamin E2024-11-29 10:47:42
Kyolic Aged Garlic Extract™ Circulation Formula 106 -- 300 CapsulesKyolicHerbs, Botanicals & Homeopathycellulose, Vitamin E, Vitamin E2024-11-29 10:47:42
Kyolic Aged Garlic Extract™ Omega 3 Cholesterol & Circulation -- 180 SoftgelsKyolicVitamins & SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
Lakewood Juice Not From Concentrate Organic Non-GMO Pure Blueberry -- 32 fl ozLakewoodFood & BeveragesVitamin E, Vitamin E, Manganese, Niacin, Vitamin B6, Vitamin B62024-11-29 10:47:42
Lakewood Organic Pure Juice Fresh Pressed Carrot -- 32 fl ozLakewoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B62024-11-29 10:47:42
Lakewood Organic Pure Juice Fresh Pressed Cranberry -- 32 fl ozLakewoodFood & BeveragesVitamin E, Vitamin E, Manganese, Pantothenic Acid, Vitamin B6, Vitamin B62024-11-29 10:47:42
Lakewood Premium Pure Fruit Juice Pressed Cranberry -- 32 fl ozLakewoodFood & BeveragesVitamin E, Vitamin E, Manganese, Pantothenic Acid, Vitamin B6, Vitamin B62024-11-29 10:47:42
Larabar Gluten Free Fruit & Nut Bar Chocolate Chip Brownie -- 16 BarsLarabarFood & BeveragesVitamin C, Vitamin E, Vitamin E, chocolate chips, Vitamin A2024-11-29 10:47:42
Lean1 Nutrition 53 Fat Burning Meal Replacement Chocolate -- 2 lbsLean1Weight ManagementD-alpha-tocopherol acetate, Vitamin C, Biotin, D-calcium pantothenate, Chloride, vitamin D3, Chromium, copper gluconate, Vitamin E, beta glucans, ferrous fumarate, Folate, Vitamin E, L-glutamine, Iodine, Manganese, Molybdenum, Niacin, niacinamide, Pantothenic Acid, Phosphorus, phytosterols, potassium chloride, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, sodium molybdate, sodium selenate, taurine, thiamine hydrochloride, Thiamin, alpha lipoic acid, calcium phosphate, cyanocobalamin, Vitamin B6, phytonadione, Vitamin K, zinc oxide2024-11-29 10:47:42
Lean1 Nutrition 53 Fat Burning Meal Replacement Vanilla -- 1.72 lbsLean1Weight ManagementLipase, Vitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, L-Glutamine, Iodine, Maltodextrin, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Potassium Chloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, Taurine, Thiamin, Sucralose, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Lean1 Nutrition 53 Original Fat Burning Protein Shake Chocolate Peanut Butter -- 2 lbsLean1Weight Managementlipase, DL-alpha tocopheryl acetate, Vitamin C, Biotin, D-calcium pantothenate, dicalcium phosphate, cholecalciferol, Chromium, copper gluconate, Vitamin E, ferrous fumarate, Folate, Vitamin E, glutamine, Iodine, calcium carbonate, maltodextrin, Manganese, Molybdenum, Niacin, Pantothenic Acid, potassium chloride, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, sodium molybdate, sodium selenate, cane sugar, taurine, Thiamin, sucralose, cyanocobalamin, Vitamin B6, phytonadione, Vitamin K, zinc oxide2024-11-29 10:47:42
Life Extension Gamma E Mixed Tocopherols & Tocotrienols -- 60 SoftgelsLife ExtensionVitamins & SupplementsVitamin E, Vitamin E, glycerin2024-11-29 10:47:42
Life Extension Super Selenium Complex -- 200 mcg - 100 Vegetarian CapsulesLife ExtensionVitamins & SupplementsVitamin E, Vitamin E, Selenium, Se-Methyl L-Selenocysteine, sodium selenite2024-11-29 10:47:42
Life Extension Two-Per-Day Capsules -- 120 CapsulesLife ExtensionVitamins & SupplementsD-alpha tocopheryl succinate, Apigenin, Vitamin C, Biotin, Boron, dicalcium phosphate, Vitamin D3, Vitamin E, riboflavin 5'-phosphate, Folate, Vitamin E, gluconate, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, niacinamide, Pantothenic Acid, pyridoxal 5'-phosphate, pyridoxine HCl, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Alpha-Lipoic Acid, beta, Vitamin B12, Vitamin B62024-11-29 10:47:42
Life Extension Two-Per-Day Tablets -- 120 TabletsLife ExtensionVitamins & SupplementsD-alpha tocopheryl succinate, Apigenin, Vitamin C, Biotin, Boron, dicalcium phosphate, Vitamin D3, Vitamin E, riboflavin 5'-phosphate, Folate, Vitamin E, gluconate, glycerin, Microcrystalline cellulose, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, niacinamide, Pantothenic Acid, pyridoxal 5'-phosphate, pyridoxine HCI, Vitamin B6, Vitamin A, Riboflavin, stearic acid, Thiamine, Alpha-Lipoic Acid, beta, Vitamin B12, Vitamin B62024-11-29 10:47:42
Life-Flo Organic Pure Sea Buckthorn Oil -- 1 fl ozLife-FloBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Life-Flo Organic Pure Sesame Oil -- 16 fl ozLife-FloBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Life-Flo Organic Pure Shea Butter -- 9 fl ozLife-FloBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Life-Flo Organic Pure Sunflower Oil -- 16 fl ozLife-FloBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Life-Flo Pure Avocado Oil -- 16 fl ozLife-FloBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Life-Flo Pure Mango Butter -- 9 fl ozLife-FloBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Life-Flo Pure Organic Safflower Oil -- 16 fl ozLife-FloBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Life-Flo Pure Raspberry Seed Oil -- 2 fl ozLife-FloBeauty & Personal Carevitamin E, vitamin E2024-11-29 10:47:42
Life-Flo Pure Rosehip Seed Oil -- 1 fl ozLife-FloBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Life-Flo Super Vitamin E Oil -- 5000 IU - 4 fl ozLife-FloBeauty & Personal Careascorbyl palmitate, vitamin C, tocopherol, tocopherol, vitamin E, tocotrienols2024-11-29 10:47:42
Lifetime All One Rice Base Multiple Vitamin & Mineral Powder Unflavored -- 2.2 lbsLifetimeVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Kelp, Beta Carotene, Betaine HCl, Biotin, Calcium Pantothenate, Dicalcium Phosphate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Calcium Carbonate, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Potassium Iodide, Vitamin B6, Retinol Acetate, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Lifetime Brite Eyes™ Antioxidant Formula -- 60 CapsulesLifetimeVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Lutein, Vitamin A, Zeaxanthin2024-11-29 10:47:42
Lifetime Multiple Vitamin & Mineral Powder Unflavored -- 2.2 lbsLifetimeVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Kelp, Biotin, Calcium Pantothenate, Dicalcium Phosphate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Calcium Carbonate, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Lily of the Desert Aloe Vera Gelly Soothing Moisturizer -- 12 fl ozLily of the DesertBeauty & Personal Carecaprylyl glycol, ascorbic acid, vitamin E, vitamin E, retinyl palmitate, vitamin A2024-11-29 10:47:42
Lily of the Desert Aloe Vera Gelly Soothing Moisturizer -- 4 ozLily of the DesertBeauty & Personal Careascorbic acid, carbomer, vitamin E, vitamin E, vitamin A, sodium hydroxide2024-11-29 10:47:42
Lily of the Desert Aloe Vera Gelly Soothing Moisturizer -- 8 ozLily of the DesertBeauty & Personal Carecaprylyl glycol, ascorbic acid, benzyl alcohol, vitamin E, ethylhexylglycerin, vitamin E, retinyl palmitate, vitamin A2024-11-29 10:47:42
Lily of the Desert Drink Mix EcoSport Hydration Blueberry Acai -- 24 Stick PacksLily of the DesertActive Lifestyle & Fitness Citric acid, Vitamin C, Biotin, Boron, Chromium, Citric acid, Vitamin E, Folic Acid, Vitamin E, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Lily of the Desert Drink Mix EcoSport Hydration Lemon Lime -- 24 Stick PacksLily of the DesertActive Lifestyle & Fitness Citric acid, Vitamin C, Biotin, Boron, Chromium, Citric acid, Vitamin E, Folic Acid, Vitamin E, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Lily of the Desert Drink Mix EcoSport Hydration Watermelon -- 24 Stick PacksLily of the DesertActive Lifestyle & Fitness Citric acid, Vitamin C, Biotin, Boron, Chromium, Citric acid, Vitamin E, Folic Acid, Vitamin E, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Lily of the Desert EcoDrink Nutrient Support Caffeine Free Blueberry Pomegranate -- 24 Stick PacksLily of the DesertActive Lifestyle & Fitness Citric acid, Vitamin C, Biotin, Boron, Chromium, Citric acid, Vitamin E, Folic Acid, Vitamin E, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Lily of the Desert EcoDrink Nutrient Support Caffeine Free Fruit Punch -- 24 Stick PacksLily of the DesertActive Lifestyle & Fitness Citric acid, Vitamin C, Biotin, Boron, Chromium, Citric acid, Vitamin E, Folic Acid, Vitamin E, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Lily of the Desert EcoDrink Nutrient Support Caffeine Free Peach Mango -- 24 Stick PacksLily of the DesertActive Lifestyle & Fitness Citric acid, Vitamin C, Biotin, Boron, Chromium, Citric acid, Vitamin E, Folic Acid, Vitamin E, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Lily of the Desert EcoDrink Nutrient Support Caffeine Free Strawberry Lemomade -- 24 Stick PacksLily of the DesertActive Lifestyle & Fitness Citric acid, Vitamin C, Biotin, Boron, Chromium, Citric acid, Vitamin E, Folic Acid, Vitamin E, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Liquid Health Complete Multiple Natural Berry -- 32 fl ozLiquid HealthVitamins & Supplementscitric acid, Vitamin C, Biotin, Boron, d-calcium pantothenate, Choline, Chromium, citric acid, Vitamin E, erythritol, Riboflavin 5 phosphate, Folate, Vitamin E, malic acid, Manganese, Molybdenum, Niacin Vitamin B3, Pantothenic Acid, allulose, pyridoxal 5 phosphate, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Little DaVinci Kids Mightiest Vite Multivitamin Powder Fruit Punch -- 30 ServingsLittle DaVinciProfessional Supplementscitric acid, Vitamin C, Vitamin D3, citric acid, Vitamin E, Folate, Vitamin E, Niacinamide, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Little Twig Baby Detangling Conditioner Berry Pomegranate -- 8.5 fl ozLittle TwigBaby & Kids Productscitric acid, allantoin, chamomile, cetyl alcohol, citric acid, vitamin e, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin e, glycerin, isopropyl palmitate, sodium benzoate2024-11-29 10:47:42
Little Twig Baby Detangling Conditioner Calming Lavender -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cetyl alcohol, vitamin E, panthenol, pro vitamin B5, vitamin E, isopropyl palmitate, sodium benzoate2024-11-29 10:47:42
Little Twig Baby Detangling Conditioner Fragrance Free -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cetyl alcohol, vitamin E, panthenol, pro vitamin B5, vitamin E, glycerin, isopropyl palmitate, sodium benzoate2024-11-29 10:47:42
Little Twig Baby Detangling Conditioner Happy Tangerine -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cetyl alcohol, vitamin E, panthenol, pro vitamin B5, vitamin E, isopropyl palmitate, sodium benzoate2024-11-29 10:47:42
Little Twig Baby Shampoo Berry Pomegranate -- 8.5 fl ozLittle TwigBaby & Kids Productscitric acid, allantoin, chamomile, citric acid, cocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, glycerin, sodium benzoate, sodium cocoyl glutamate2024-11-29 10:47:42
Little Twig Baby Shampoo Calming Lavender -- 8.5 fl ozLittle TwigBaby & Kids Productscocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, sodium benzoate, sodium cocoyl glutamate2024-11-29 10:47:42
Little Twig Baby Shampoo Fragrance Free -- 8.5 fl ozLittle TwigBaby & Kids Productscocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, sodium benzoate, sodium cocoyl glutamate2024-11-29 10:47:42
Little Twig Baby Shampoo Happy Tangerine -- 8.5 fl ozLittle TwigBaby & Kids Productscocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, sodium benzoate, sodium cocoyl glutamate2024-11-29 10:47:42
Little Twig Baby Wash Berry Pomegranate -- 8.5 fl ozLittle TwigBaby & Kids Productscitric acid, allantoin, chamomile, citric acid, cocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, sodium benzoate2024-11-29 10:47:42
Little Twig Baby Wash Calming Lavender -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, sodium benzoate2024-11-29 10:47:42
Little Twig Baby Wash Fragrance Free -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, sodium benzoate2024-11-29 10:47:42
Little Twig Baby Wash Happy Tangerine -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, sodium benzoate2024-11-29 10:47:42
Little Twig Body Lotion Berry Pomegranate -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cetyl alcohol, vitamin E, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, stearic acid2024-11-29 10:47:42
Little Twig Body Lotion Calming Lavender -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cetyl alcohol, vitamin E, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, glyceryl stearate, stearic acid2024-11-29 10:47:42
Little Twig Body Lotion Fragrance Free -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cetyl alcohol, vitamin E, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, glyceryl stearate, stearic acid2024-11-29 10:47:42
Little Twig Body Lotion Happy Tangerine -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cetyl alcohol, vitamin E, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, glyceryl stearate, stearic acid2024-11-29 10:47:42
Little Twig Bubble Bath Berry Pomegranate -- 8.5 fl ozLittle TwigBaby & Kids Productscitric acid, allantoin, chamomile, citric acid, cocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, glycerin, sodium lauroyl sarcosinate, sodium benzoate2024-11-29 10:47:42
Little Twig Bubble Bath Calming Lavender -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, sodium benzoate2024-11-29 10:47:42
Little Twig Bubble Bath Fragrance Free -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, sodium benzoate2024-11-29 10:47:42
Little Twig Bubble Bath Happy Tangerine -- 8.5 fl ozLittle TwigBaby & Kids Productsallantoin, chamomile, cocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, pro vitamin B5, ethylhexylglycerin, vitamin E, glycerin, sodium benzoate2024-11-29 10:47:42
Living Intentions Activated Sprouted Nuts Unsalted Almonds -- 16 ozLiving IntentionsFood & BeveragesVitamin C, Vitamin E, Vitamin E, Manganese, Vitamin A, Riboflavin2024-11-29 10:47:42
Living Intentions Activated Sprouted Seeds Jalapeno Mojo -- 8 ozLiving IntentionsFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars Blueberry Bliss -- 15 BarsLunaFood & BeveragesVitamin C, Vitamin E, Folate, Vitamin E, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars Chocolate Cupcake -- 15 BarsLunaFood & BeveragesVitamin C, Vitamin E, Folate, Vitamin E, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars Chocolate Dipped Coconut -- 15 BarsLunaFood & BeveragesVitamin C, Vitamin E, Vitamin E, Phosphorus, Vitamin A2024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars Chocolate Dipped Coconut -- 6 BarsLunaFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars Chocolate Peppermint Stick -- 12 BarsLunaFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars Chocolate Peppermint Stick -- 15 BarsLunaFood & BeveragesVitamin C, Vitamin E, Folate, Vitamin E, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars Chocolate Peppermint Stick -- 6 BarsLunaFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars Lemon Zest -- 6 BarsLunaFood & Beveragescitric acid, citric acid, Vitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars LemonZest -- 12 BarsLunaFood & Beveragescitric acid, citric acid, Vitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars LemonZest -- 15 BarsLunaFood & BeveragesVitamin C, Vitamin E, Folate, Vitamin E, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars Nutz Over Chocolate -- 15 BarsLunaFood & BeveragesVitamin C, Vitamin E, Vitamin E, Phosphorus, Vitamin A2024-11-29 10:47:42
Luna Gluten Free Whole Nutrition Bars for Women Nutz Over Chocolate -- 6 BarsLunaFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Luna Whole Nutrition Mash-Ups Bars LemonZest + Blueberry -- 15 BarsLunaFood & Beveragescitric acid, citric acid, Vitamin E, Vitamin E, Phosphorus, sodium bicarbonate2024-11-29 10:47:42
Luna Whole Nutrition Mash-Ups Bars LemonZest + Blueberry -- 6 BarsLunaFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Luna Whole Nutrition Mash-Ups Bars LemonZest + Raspberry -- 15 BarsLunaFood & Beveragescitric acid, citric acid, Vitamin E, Vitamin E, Phosphorus, sodium bicarbonate2024-11-29 10:47:42
Luna Whole Nutrition Mash-Ups Bars Lemonzest + Raspberry -- 6 BarsLunaFood & BeveragesVitamin E, Vitamin E, Phosphorus2024-11-29 10:47:42
Macro Life Naturals Kids Macro Coco-Greens Superfood Chocolate -- 32 ServingsMacro Life NaturalsVitamins & Supplements Lipase, Vitamin C, calcium citrate, Cellulase, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
Macro Life Naturals Macro Greens Superfood -- 10 ozMacro Life NaturalsVitamins & SupplementsLipase, Policosanol, Vitamin C, Cellulase, Vitamin E, Vitamin E, Stevia, Vitamin A, Rutin, Vitamin B122024-11-29 10:47:42
Mad Hippie Antioxidant Facial Oil -- 1.02 fl ozMad HippieBeauty & Personal Carevitamin E, tocopherol, vitamin E2024-11-29 10:47:42
Mad Hippie Cream Cleanser Normal to Dry Skin -- 118 mLMad HippieBeauty & Personal Carecaprylyl glycol, vitamin E, vitamin E, retinyl palmitate, vitamin A, squalene2024-11-29 10:47:42
Mad Hippie Day-Night Vitamin C and Super A Serum Dual Pack -- 0.5 fl ozMad HippieBeauty & Personal Carecaprylyl glycol, dimethyl isosorbide, acetyl glucosamine, vitamin c, vitamin e, ethylhexyl glycerin, ferulic acid, vitamin e, glycerin, phenethyl alcohol, stearyl alcohol, tocotrienol2024-11-29 10:47:42
Mad Hippie Holiday Skin Care Gift Bag -- 1 SetMad HippieBeauty & Personal Carecaprylyl glycol, orange, allantoin, ascorbyl glucoside, vitamin C, ceramide 3, cetyl alcohol, vitamin E, and, ethylhexyl glycerin, ferulic acid, vitamin E, glyceryl stearate, glycerin, hydroxyethylcellulose, isopropyl palmitate, oat, phenethyl alcohol, propanediol, vitamin B2, squalane, stearic acid, stearyl alcohol, tocotrienol2024-11-29 10:47:42
Mad Hippie Triple C Night Cream -- 2.1 ozMad HippieBeauty & Personal Carecaprylyl glycol, allantoin, ascorbyl glucoside, vitamin C, ceramide 3, cetyl alcohol, vitamin E, and, ethylhexyl glycerin, vitamin E, glyceryl stearate, glycerin, isopropyl palmitate, phenethyl alcohol, vitamin B2, squalane, stearic acid, tocotrienol2024-11-29 10:47:42
Mad Hippie Vitamin C Serum -- 30 mLMad HippieBeauty & Personal Carevitamin C, vitamin E, ferulic acid, vitamin E, glycerin, tocotrienol2024-11-29 10:47:42
Mad Hippie Vitamin C Serum Travel Size -- 0.5 ozMad HippieBeauty & Personal Carevitamin C, vitamin E, ferulic acid, vitamin E, glycerin, tocotrienol2024-11-29 10:47:42
MadeGood Chocolate Drizzled Birthday Cake Granola Bars -- 5 BarsMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Drizzled Granola Bars Cookie Crumble Chocolate -- 5 BarsMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Drizzled Granola Bars Vanilla Chocolate -- 5 BarsMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Cookies Chocolate Chip -- 7 ozMadeGoodFood & BeveragesVitamin E, Vitamin E, baking soda, Thiamin2024-11-29 10:47:42
MadeGood Organic Gluten Free Cookies Snickerdoodle -- 7 ozMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, baking soda, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Cookies Vanilla -- 7 ozMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, baking soda, cane sugar, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Crispy Light Granola Cocoa Crunch -- 10 ozMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Crispy Light Granola Strawberry -- 10 ozMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Crispy Squares Chocolate Chip -- 6 BarsMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Crispy Squares Strawberry -- 6 BarsMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Crispy Squares Vanilla -- 6 BarsMadeGoodFood & BeveragesVitamin E, Vitamin E, Thiamin2024-11-29 10:47:42
MadeGood Organic Gluten Free Granola Bars Chocolate Banana -- 6 BarsMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Granola Bars Chocolate Chip -- 6 BarsMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Granola Bars Cookies & Creme -- 6 BarsMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Granola Bars Mixed Berry -- 6 BarsMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamine, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Granola Minis Chocolate Banana -- 3.5 ozMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamine, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Granola Minis Chocolate Chip -- 3.5 ozMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamine, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Granola Minis Mixed Berry -- 3.5 ozMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Soft Baked Mini Cookies Chocolate Chip -- 5 PouchesMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Soft Baked Mini Cookies Double Chocolate -- 5 PouchesMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, cane sugar, Thiamin, vanilla, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Soft Baked Mini Cookies Red Velvet -- 5 PouchesMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, cane sugar, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Gluten Free Soft Baked Mini Cookies Snickerdoodle -- 5 PouchesMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Mornings Soft Baked Oat Bars Blueberry -- 5 BarsMadeGoodFood & Beveragesorange, Vitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Organic Mornings Soft Baked Oat Bars Cinnamon Bun -- 5 BarsMadeGoodFood & Beveragesorange, Vitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Star Puffed Cheddar Cracker -- 4.26 ozMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
MadeGood Star Puffed Sea Salt Crackers -- 4.26 ozMadeGoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Thiamin, Vitamin B62024-11-29 10:47:42
Manitoba Harvest Instant Superseed Oatmeal Apple & Cinnamon -- 9 ozManitoba HarvestFood & BeveragesVitamin E, Folate, Vitamin E, Manganese, Niacin, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B62024-11-29 10:47:42
Manitoba Harvest Instant Superseed Oatmeal Maple & Brown Sugar -- 9 ozManitoba HarvestFood & BeveragesVitamin E, Folate, Vitamin E, Manganese, Niacin, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B62024-11-29 10:47:42
Manitoba Harvest Organic Hemp + Chia & Flax -- 7 ozManitoba HarvestVitamins & SupplementsVitamin E, Folate, Vitamin E, Manganese, Niacin, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B62024-11-29 10:47:42
Mason Natural Daily Multiple Vitamins With Iron -- 365 TabletsMason NaturalVitamins & SupplementsPABA, Vitamin C, Vitamin E, Folate, Vitamin E, Microcrystalline cellulose, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, stearic acid, Vitamin B1, titanium dioxide, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Mason Natural Glucosamine & Fish Oil -- 90 SoftgelsMason NaturalVitamins & SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
Mason Natural Immune Defense Powder Mixed Berry -- 14 Stick PacksMason NaturalVitamins & Supplements Citric acid, Vitamin C, beta carotene, Citric acid, Vitamin E, Vitamin E, maltodextrin, Manganese, rebaudioside A, Selenium2024-11-29 10:47:42
Mason Natural Immunity Plus Hydration Power -- 10 Effervescent TabletsMason NaturalVitamins & Supplements Citric acid, Vitamin C, Citric acid, Vitamin E, Vitamin E, microcrystalline cellulose, Manganese, rebaudioside a, Selenium2024-11-29 10:47:42
Mason Natural Marine Collagen Powder Pomegranate Blueberry -- 14 PacksMason NaturalVitamins & Supplementscitric acid, N-Acetyl L-Cysteine, Vitamin C, Biotin, citric acid, Vitamin E, Vitamin E, Malic acid, Niacin2024-11-29 10:47:42
Mason Natural Mini Multi Vitamins -- 365 Mini TabletsMason NaturalVitamins & SupplementsVitamin C, Vitamin D3, Vitamin E, Vitamin E, Microcrystalline cellulose, Pantothenic Acid, Vitamin B6, Vitamin B2, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Mason Natural Prenatal Multivitamin with DHA & Zinc Banana Orange -- 60 GummiesMason NaturalVitamins & Supplementscitrus pectin, citric acid, Vitamin C, beta carotene, Vitamin D3, citric acid, Vitamin E, Folate, Vitamin E, Niacin, Vitamin B6, Vitamin A, sodium citrate, Vitamin B12, Vitamin B62024-11-29 10:47:42
Mason Natural Stress B-Complex with Antioxidants + Zinc -- 60 TabletsMason NaturalVitamins & SupplementsVitamin C, Biotin, Vitamin E, Folate, Vitamin E, Microcrystalline cellulose, Niacin, Pantothenic Acid, Vitamin B6, Vitamin B2, stearic acid, Vitamin B1, titanium dioxide, glyceryl triacetate, Vitamin B12, Vitamin B62024-11-29 10:47:42
Mason Natural Vitamin E 1000 IU -- 450 mg - 50 SoftgelsMason NaturalVitamins & SupplementsVitamin E, Vitamin E, glycerin2024-11-29 10:47:42
Mason Natural Vitamin E C & Beta Carotene Antioxidant Formula -- 60 TabletsMason NaturalVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Microcrystalline cellulose, stearic acid, sucrose, tricalcium phosphate2024-11-29 10:47:42
MediNatura T-Relief Homeopathic Cream -- 2 ozMediNaturaHerbs, Botanicals & Homeopathyvitamin E, vitamin E, phenoxyethanol2024-11-29 10:47:42
MediNatura T-Relief Natural Arthritis Pain Relief Arnica +12 Cream -- 2 ozMediNaturaHerbs, Botanicals & Homeopathyvitamin E, vitamin E, phenoxyethanol2024-11-29 10:47:42
MediNatura T-Relief™ Arnica + 12 -- 4 ozMediNaturaHerbs, Botanicals & Homeopathyvitamin E, vitamin E, phenoxyethanol2024-11-29 10:47:42
Mediterra Wellness Boosters Detox & Cleanse Liquid Lemon Cream -- 20 PouchesMediterraVitamins & Supplementsvitamin E, vitamin E2024-11-29 10:47:42
Mediterra Wellness Boosters Healthy Aging Liquid Citrus Vanilla -- 20 Liquid PouchesMediterraVitamins & Supplementsbeta carotene, Vitamin E, Vitamin E, Glycerin, potassium bicarbonate, vanilla2024-11-29 10:47:42
Medterra Wellness Boosters Mending Mushrooms Liquid Chocolate -- 20 Liquid PouchesMedterraHerbs, Botanicals & HomeopathyVitamin E, Vitamin E2024-11-29 10:47:42
MegaFood Baby & Me 2 Prenatal Multivitamin with Folate and Choline -- 120 TabletsMegaFoodVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Choline, Vitamin E, Folate, Vitamin E, Microcrystalline cellulose, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
MegaFood Kids Multivitamin Brain & Immune Support Berrylicious -- 60 GummiesMegaFoodVitamins & Supplementscitric acid, Vitamin C, Biotin, Vitamin D3, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, sodium citrate, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
MegaFood Kids One Daily Multivitamin Grape -- 30 Soft ChewsMegaFoodVitamins & Supplementscitric acid, Vitamin C, Biotin, Vitamin D3, Chromium, citric acid, Vitamin E, Folate, Vitamin E, glycerin, malic acid, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
MegaFood Kids One Daily Multivitamin Bone Health Immune Support -- 60 Mini TabletsMegaFoodVitamins & SupplementsVitamin C, Biotin, Boron, Vitamin D3, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Stearic acid, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
MegaFood Multivitamin for Men - Gummy Vitamins Wild Blueberry -- 60 GummiesMegaFoodVitamins & Supplementscitric acid, Vitamin C, Biotin, Vitamin D3, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Iodine, Lycopene, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
MegaFood Multivitamin for Women - Gummy Vitamins Tangerine -- 60 GummiesMegaFoodVitamins & Supplementscitric acid, Vitamin C, Biotin, Boron, Vitamin D3, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Vitamin B6, Vitamin A, Vitamin B2, Selenium, sodium citrate, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
MegaFood Skin Nails & Hair 2 with Biotin Vitamin A Vitamin C -- 90 TabletsMegaFoodVitamins & SupplementsVitamin C, Biotin, Vitamin E, Vitamin E, Microcrystalline cellulose, Pantothenic Acid, Vitamin B6, Vitamin A, Selenium, stearic acid, Vitamin B62024-11-29 10:47:42
MegaFood Women Over 55+ One Daily Multivitamin -- 120 TabletsMegaFoodVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Vitamin E, Folate, Vitamin E, Microcrystalline cellulose, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
MegaFood Women Over 55+ One Daily Multivitamin -- 60 TabletsMegaFoodVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Vitamin E, Folate, Vitamin E, Microcrystalline cellulose, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
MegaFood Women Over 55+ One Daily Multivitamin -- 90 TabletsMegaFoodVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Vitamin E, Folate, Vitamin E, Microcrystalline cellulose, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Method Foaming Hand Wash Holiday Scent Juniper + Joy -- 10 fl ozMethodHousehold Essentialsvitamin E, vitamin E, sodium benzoate2024-11-29 10:47:42
Method Foaming Hand Wash Lemon Mint -- 10 fl ozMethodHousehold Essentialsmethylisothiazolinone, citric acid, methylchloroisothiazolinone, citric acid, cocamidopropyl betaine, vitamin E, vitamin E, glycerin, limonene, sodium citrate, sodium lauryl sulfate, benzophenone-4, yellow 52024-11-29 10:47:42
Method Foaming Hand Wash Refill Coconut Water -- 28 fl ozMethodHousehold Essentialsmethylisothiazolinone, methylchloroisothiazolinone, vitamin E, vitamin E2024-11-29 10:47:42
Method Foaming Hand Wash Refill French Lavender -- 28 fl ozMethodHousehold Essentialsmethylisothiazolinone, methylchloroisothiazolinone, vitamin E, vitamin E, linalool2024-11-29 10:47:42
Method Foaming Hand Wash Refill Pink Grapefruit -- 28 fl ozMethodHousehold Essentialsmethylisothiazolinone, methylchloroisothiazolinone, vitamin E, red 33, vitamin E, hexyl cinnamic aldehyde, limonene, linalool2024-11-29 10:47:42
Method Foaming Hand Wash Refill Sea Minerals -- 28 fl ozMethodHousehold EssentialsVitamin E, Vitamin E, sodium benzoate2024-11-29 10:47:42
Method Foaming Hand Wash Refill Sweet Water -- 28 fl ozMethodHousehold Essentialsvitamin E, vitamin E, sodium benzoate2024-11-29 10:47:42
Method Gel Hand Wash Pink Grapefruit -- 12 fl ozMethodHousehold Essentialsmethylisothiazolinone, citric acid, methylchloroisothiazolinone, citric acid, cocamidopropyl betaine, vitamin E, red 33, vitamin E, glycerin, sodium citrate, sodium lauryl sulfate, benzophenone-42024-11-29 10:47:42
Method Gel Hand Wash Refill - French Lavender -- 34 fl ozMethodHousehold Essentialsmethylisothiazolinone, methylchloroisothiazolinone, vitamin e, vitamin e, linalool2024-11-29 10:47:42
Method Gel Hand Wash Refill - Pink Grapefruit -- 34 fl ozMethodHousehold Essentialsmethylisothiazolinone, methylchloroisothiazolinone, vitamin E, red 33, vitamin E, hexyl cinnamic aldehyde, limonene, linalool2024-11-29 10:47:42
Method Gel Hand Wash Refill - Sea Minerals -- 34 fl ozMethodHousehold Essentialsmethylisothiazolinone, methylchloroisothiazolinone, vitamin E, vitamin E, hexyl cinnamal, linalool2024-11-29 10:47:42
Method Gel Hand Wash Refill - Sweet Water -- 34 fl ozMethodHousehold Essentialsmethylisothiazolinone, methylchloroisothiazolinone, benzyl salicylate, vitamin E, vitamin E, butylphenyl methylpropional2024-11-29 10:47:42
Method Gel Hand Wash Refill - Vetiver + Amber -- 34 fl ozMethodHousehold Essentialsvitamin e, vitamin e, sodium benzoate2024-11-29 10:47:42
Method Gel Hand Wash Refill - Waterfall -- 34 fl ozMethodHousehold Essentialsvitamin E, vitamin E, sodium benzoate2024-11-29 10:47:42
Method Gel Hand Wash Rosemary -- 11.5 fl ozMethodHousehold Essentialsmethylisothiazolinone, methylchloroisothiazolinone, vitamin E, vitamin E2024-11-29 10:47:42
Method Premium Foaming Hand Wash Soap Refill - Vanilla + Raspberry -- 28 fl ozMethodHousehold Essentialsvitamin e, vitamin e, sodium benzoate2024-11-29 10:47:42
Mikanaturals Arnica Montana & Yucca Gel Bruising & Pain Relief Homeopathic Remedy -- 8 fl ozMikanaturalsHerbs, Botanicals & HomeopathyTocopherol acetate, chamomile, carbomer, vitamin E, vitamin E, retinyl palmitate, vitamin A2024-11-29 10:47:42
Mikanaturals Arnica Montana & Yucca Gel Plus with Menthol and Peppermint -- 8 fl ozMikanaturalsHerbs, Botanicals & Homeopathytocopherol acetate, chamomile, camphor, carbomer, Vitamin E, Vitamin E, menthol, retinyl palmitate, Vitamin A2024-11-29 10:47:42
Mill Creek Botanicals Aloe Vera & PABA Body Lotion -- 14 fl ozMill CreekBeauty & Personal Careallantoin, calendula, tocopherol, panthenol, provitamin B5, tocopherol, vitamin E, glyceryl stearate, glycerin, octyl dimethyl PABA, retinyl palmitate, vitamin A, sodium benzoate, stearic acid2024-11-29 10:47:42
Mill Creek Botanicals Aloe Vera Conditioner Mild Formula -- 14 fl ozMill CreekBeauty & Personal Carecitric acid, tocopherol acetate, biotin, calendula, cetearyl alcohol, citric acid, goldenseal, vitamin E, panthenol, provitamin B5, vitamin E, glycerin, retinyl palmitate, vitamin A, sodium benzoate2024-11-29 10:47:42
Mill Creek Botanicals Aloe Vera Cream -- 4 ozMill CreekBeauty & Personal Careallantoin, cetearyl alcohol, cetyl alcohol, tocopherol, panthenol, provitamin B5, tocopherol, vitamin E, glycerin, phenoxyethanol, retinyl palmitate, vitamin A, stearic acid, triethanolamine2024-11-29 10:47:42
Mill Creek Botanicals Aloe Vera Shampoo Mild Formula -- 14 fl ozMill CreekBeauty & Personal Carecitric acid, tocopherol acetate, biotin, chlorophyll, citric acid, cocamidopropyl betaine, goldenseal, Vitamin E, panthenol, provitamin B5, Vitamin E, glycerin, sodium benzoate2024-11-29 10:47:42
Mill Creek Botanicals Baby Calendula Cream -- 4 fl ozMill CreekBaby & Kids Productschamomile, calendula, cetyl alcohol, vitamin E, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, phenoxyethanol2024-11-29 10:47:42
Mill Creek Botanicals Dandruff Control Shampoo -- 16 fl ozMill CreekBeauty & Personal Carecitric acid, vitamin C, cholecalciferol, citric acid, cocamidopropyl betaine, tocopherol, panthenol, provitamin B5, disodium-EDTA, tocopherol, vitamin E, retinyl palmitate, vitamin A, sodium benzoate2024-11-29 10:47:42
Mill Creek Botanicals Keratin Repair Formula Conditioner -- 14 fl ozMill CreekBeauty & Personal Carecitric acid, tocopherol acetate, biotin, calendula, cetearyl alcohol, citric acid, goldenseal, vitamin E, panthenol, provitamin B5, vitamin E, glycerin, retinyl palmitate, vitamin A, sodium benzoate2024-11-29 10:47:42
Mill Creek Botanicals Keratin Repair Formula Shampoo -- 14 fl ozMill CreekBeauty & Personal Carecitric acid, allantoin, tocopherol acetate, biotin, calendula, citric acid, cocamidopropyl betaine, comfrey, goldenseal, vitamin E, panthenol, provitamin B5, vitamin E, glycerin, henna, sodium benzoate2024-11-29 10:47:42
Mill Creek Botanicals Vitamin E Cream -- 20000 IU - 4 ozMill CreekBeauty & Personal Carecitric acid, allantoin, tocopherol acetate, cetyl alcohol, citric acid, tocopherol, panthenol, provitamin B5, tocopherol, vitamin E, dimethicone, retinyl palmitate, vitamin A, sodium benzoate, stearic acid, triethanolamine2024-11-29 10:47:42
Mineral Fusion Sheer Moisture Lip Tint - Blush -- 0.1 ozMineral FusionBeauty & Personal CareCarmine, vitamin E, ethylhexylglycerin, vitamin E, ozokerite, phenoxyethanol, Yellow 5, Titanium Dioxide2024-11-29 10:47:42
Mineral Fusion Sheer Moisture Lip Tint - Flicker -- 0.1 ozMineral FusionBeauty & Personal CareCarmine, vitamin E, ethylhexylglycerin, vitamin E, ozokerite, phenoxyethanol, Yellow 5, Titanium Dioxide2024-11-29 10:47:42
Mineral Fusion Sheer Moisture Lip Tint - Glisten -- 0.1 ozMineral FusionBeauty & Personal CareCarmine, vitamin E, ethylhexylglycerin, vitamin E, ozokerite, phenoxyethanol, Yellow 5, Titanium Dioxide2024-11-29 10:47:42
Mineral Fusion Sheer Moisture Lip Tint - Smolder -- 0.1 ozMineral FusionBeauty & Personal CareCarmine, vitamin E, ethylhexylglycerin, vitamin E, ozokerite, phenoxyethanol, Yellow 5, Titanium Dioxide2024-11-29 10:47:42
Monoi Tiki Tahiti Coconut Oil Coconut -- 4 fl ozMonoiBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Monoi Tiki Tahiti Coconut Oil Original -- 4 fl ozMonoiBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Monoi Tiki Tahiti Coconut Oil Tipanie -- 4 fl ozMonoiBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Monoi Tiki Tahiti Coconut Oil Vanilla -- 4 fl ozMonoiBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Monoi Tiki Tahiti Coconut Oil Ylang Ylang -- 4 fl ozMonoiBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Monoi Tiki Tahiti Coconut Suntan Oil SPF 6 -- 4 fl ozMonoiBeauty & Personal Caretocopherol acetate, vitamin E, vitamin E, oxybenzone2024-11-29 10:47:42
Monoi Tiki Tahiti Sandalwood -- 4 fl ozMonoiBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
MRM Complete E -- 60 SoftgelsMRMVitamins & SupplementsVitamin C, d-Beta Tocopherol, Coenzyme Q10, d-Alpha-Tocopherol, d-delta tocopherol, d-Gamma Tocopherol, d-Gamma Tocotrienol, Vitamin E, glycerin, Phytosterols, Alpha-Lipoic Acid, d-Alpha Tocotrienol2024-11-29 10:47:42
MRM CoQ-10 -- 100 mg - 60 SoftgelsMRMVitamins & SupplementsCoenzyme Q10, Vitamin E, Vitamin E, glycerin2024-11-29 10:47:42
MRM Liver X™ -- 60 Vegan CapsulesMRMVitamins & SupplementsBetaine Anhydrous, Vitamin E, Vitamin E, Alpha-Lipoic Acid, Vitamin B122024-11-29 10:47:42
MRM Veggie Meal Replacement Vanilla Bean -- 3 lbsMRMActive Lifestyle & FitnessAlanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Cysteine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glycine, Histidine, Iodine, Isoleucine, Leucine, Lysine, Methionine, Niacin, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Serine, Thiamin, Threonine, trehalose, Tryptophan, Tyrosine, Valine, Vitamin B6, Vitamin D22024-11-29 10:47:42
Munk Pack Chewy Granola Bar Gluten Free Keto Blueberry Almond Vanilla -- 4 BarsMunk PackFood & Beveragesvitamin E, vitamin E, Glycerin, allulose2024-11-29 10:47:42
Munk Pack Chewy Granola Bar Gluten Free Keto Dark Chocolate Drizzle -- 4 BarsMunk PackFood & Beveragesvitamin E, vitamin E, Glycerin, allulose2024-11-29 10:47:42
Munk Pack Chewy Granola Bar Gluten Free Keto Peanut Butter Chocolate Chip -- 4 BarsMunk PackFood & Beveragesvitamin E, vitamin E, Glycerin, allulose2024-11-29 10:47:42
Munk Pack Keto Granola Bar Almond Butter Cocoa Chip -- 4 BarsMunk PackFood & Beveragesvitamin E, vitamin E, Glycerin, Allulose2024-11-29 10:47:42
Munk Pack Keto Granola Bar Coconut Cocoa Chip -- 1.12 oz Each / Pack of 4Munk PackFood & Beveragesvitamin E, vitamin E, Glycerin, allulose2024-11-29 10:47:42
Munk Pack Keto Nut & Seed Bars Peanut Butter Dark Chocolate -- 12 BarsMunk PackFood & Beveragesvitamin E, vitamin E, Allulose2024-11-29 10:47:42
Munk Pack Keto Nut & Seed Bars Sea Salt Dark Chocolate -- 12 BarsMunk PackFood & Beveragesvitamin e, vitamin e, allulose2024-11-29 10:47:42
Munk Pack Nut & Seed Bar Gluten Free Keto Caramel Sea Salt -- 12 BarsMunk PackFood & Beveragesannatto, vitamin E, vitamin E, allulose2024-11-29 10:47:42
Munk Pack Nut & Seed Bar Gluten Free Keto Caramel Sea Salt -- 4 BarsMunk PackFood & Beveragesannatto, vitamin E, vitamin E, allulose2024-11-29 10:47:42
Munk Pack Nut & Seed Bar Gluten Free Keto Coconut Almond Dark Chocolate -- 12 BarsMunk PackFood & Beveragesvitamin E, vitamin E, allulose2024-11-29 10:47:42
Munk Pack Nut & Seed Bar Gluten Free Keto Dark Chocolate Pretzel -- 12 BarsMunk PackFood & Beveragesvitamin E, vitamin E, allulose2024-11-29 10:47:42
Munk Pack Nut & Seed Bar Gluten Free Keto Macadamia White Chocolate -- 12 BarsMunk PackFood & Beveragesvitamin E, vitamin E, allulose2024-11-29 10:47:42
Munk Pack Nut & Seed Bar Gluten Free Keto Peanut Butter Dark Chocolate -- 4 BarsMunk PackFood & Beveragesvitamin E, vitamin E, allulose2024-11-29 10:47:42
Munk Pack Nut & Seed Bar Gluten Free Keto Sea Salt Dark Chocolate -- 4 BarsMunk PackFood & Beveragesvitamin E, vitamin E, allulose2024-11-29 10:47:42
Napa Valley Naturals High Heat Cooking Grapeseed Oil -- 25.4 fl ozNapa Valley NaturalsFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Napa Valley Naturals Organic Extra Virgin Olive Oil -- 25.4 fl ozNapa Valley NaturalsFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
Natrol Extreme Omega Lemon -- 2400 mg - 60 SoftgelsNatrolVitamins & SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
Naturade Total Soy® Meal Replacement Strawberry Creme -- 17.88 ozNaturadeWeight Managementd-alpha tocopheryl succinate, Vitamin C, beta carotene, Biotin, calcium pantothenate, Vitamin D3, Chromium, Vitamin E, Fructose, ferrous sulfate, Folate, Vitamin E, Iodine, maltodextrin, Manganese, Niacin, niacinamide, Pantothenic Acid, Phosphorus, potassium chloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, cyanocobalamin, Vitamin B62024-11-29 10:47:42
Naturade Weight Gain Vanilla -- 20.3 ozNaturadeActive Lifestyle & Fitnessd-alpha-tocopheryl acetate, Vitamin C, vitamin E, egg white, vitamin E, glyceryl monostearate, maltodextrin, Vitamin A2024-11-29 10:47:42
Naturade Weight Gain Vanilla -- 40 ozNaturadeActive Lifestyle & Fitnessd-alpha-tocopheryl acetate, Vitamin C, vitamin E, egg white, vitamin E, maltodextrin, Vitamin A2024-11-29 10:47:42
Natural Balance Ladies Choice™ -- 60 VegCapsNatural BalanceVitamins & SupplementsCellulose, Vitamin E, Vitamin E2024-11-29 10:47:42
Natural Care OptiAll® -- 60 CapsulesNatural CareHerbs, Botanicals & HomeopathyVitamin C, cellulose, Vitamin E, Vitamin E, glycerin, Vitamin B6, Vitamin A, Vitamin B2, Selenium, titanium dioxide, Vitamin B12, Vitamin B62024-11-29 10:47:42
Natural Care VeinGard Cream -- 2 ozNatural CareHerbs, Botanicals & Homeopathycitric acid, ascorbyl palmitate, vitamin C, calcium lactate, carbomer, cetearyl alcohol, cetyl alcohol, citric acid, vitamin E, methylsulfonylmethane, vitamin E, glyceryl stearate, glycerin, calcium carbonate, phenoxyethanol, sodium benzoate, sodium cocoyl glutamate, stearic acid2024-11-29 10:47:42
Natural Dog Company Calming Chew For Dogs -- 90 Soft ChewsNatural Dog CompanyPet SuppliesChamomile, Ascorbic acid, vitamin E, vitamin E, Melatonin, Thiamine2024-11-29 10:47:42
Natural Dog Company Multivitamin Supplements For Dogs -- 90 Soft ChewsNatural Dog CompanyPet Suppliesascorbic acid, beta carotene, vitamin B7, Choline, Vitamin E, ferrous gluconate, Folic Acid, vitamin E, inositol, Iodine, Manganese, Niacin, Pantothenic Acid, potassium iodate, pyridoxine hydrochloride, vitamin B6, vitamin A acetate, Vitamin A, vitamin B2, Selenium, vitamin B1, Vitamin B12, vitamin B6, vitamin K2024-11-29 10:47:42
Natural Dog Company Sensitive Skin Oatmeal Hypoallergenic Shampoo For Dogs -- 12 fl ozNatural Dog CompanyPet Suppliescitric acid, chamomile, citric acid, cocamidopropyl betaine, vitamin E, lauramine oxide, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Natural Dog Company Skin & Coat High Omega-3 Liquid Supplement Oil For Dogs -- 16 fl ozNatural Dog CompanyPet Suppliesascorbic acid, Vitamin E, Docosahexaenoic Acid, Vitamin E, sorbic acid2024-11-29 10:47:42
Natural Dog Company Skin and Coat Supplements For Dogs -- 90 Soft ChewsNatural Dog CompanyPet SuppliesAscorbic Acid, Vitamin E, Docosahexaenoic Acid, Vitamin E2024-11-29 10:47:42
Natural Factors Ubiquinol Active CoQ10 -- 100 mg - 120 SoftgelsNatural FactorsVitamins & Supplementsvitamin E, vitamin E, glycerin2024-11-29 10:47:42
Natural Factors Whole Earth & Sea® Sunflower Vitamin E -- 268 mg - 90 SoftgelsNatural FactorsVitamins & SupplementsVitamin E, Vitamin E, glycerin2024-11-29 10:47:42
Natural Path Silver Wings Silver Herbal Ointment -- 250 ppm - 1.5 ozNatural Path Silver WingsVitamins & SupplementsGoldenseal, Vitamin E, Vitamin E, Colloidal Silver2024-11-29 10:47:42
Natural Sources Raw Male -- 60 CapsulesNatural SourcesVitamins & SupplementsVitamin E, Vitamin E, maltodextrin, Vitamin A2024-11-29 10:47:42
Nature Made Multi For Her -- 90 TabletsNature MadeVitamins & SupplementsVitamin C, Biotin, Vitamin D 3, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Nature Made Multi For Her 50+ -- 90 TabletsNature MadeVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Nature Made Stress B-Complex -- 75 TabletsNature MadeVitamins & Supplementsdl-alpha tocopheryl acetate, Vitamin C, Biotin, d-calcium pantothenate, Vitamin E, folic acid, Vitamin E, Niacin, niacinamide, Pantothenic Acid, pyridoxine hydrochloride, Vitamin B6, Riboflavin, stearic acid, Thiamin, Vitamin B12, Vitamin B6, zinc sulfate2024-11-29 10:47:42
Nubian Heritage African Black Soap with Shea Butter Hand Cream for Dry Skin -- 4 fl ozNubian HeritageBeauty & Personal Carecarbomer, tocopherol, tocopherol, vitamin E, oat, salicylic acid, stearyl alcohol2024-11-29 10:47:42
Nubian Heritage Cruelty-Free Indian Hemp & Haitian Vetiver Hand Cream with Shea Butter for All Skin -- 4 ozNubian HeritageBeauty & Personal Careallantoin, tocopherol, tocopherol, vitamin E, hemp, stearyl alcohol2024-11-29 10:47:42
Nubian Heritage Natural Deodorant 24 hour Aluminum Free African Black Soap -- 2.25 ozNubian HeritageBeauty & Personal CareAllantoin, Tocopherol, Tocopherol, Vitamin E, Glycerin2024-11-29 10:47:42
NuGo Nutrition Original Protein Bar Churro -- 1.76 oz Each / Pack of 15NuGo NutritionWeight ManagementVitamin C, Vitamin E, Folate, Vitamin E, Niacin, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, cane sugar, Thiamin, vanilla, Vitamin B12, Vitamin B62024-11-29 10:47:42
NuGo Nutrition Protein Bars Orange Smoothie -- 15 BarsNuGo NutritionWeight ManagementVitamin C, Vitamin E, Folate, vitamin E, calcium carbonate, Niacin, niacinamide, palmitate, Phosphorus, Vitamin B6, Vitamin A, vitamin B2, cane sugar, Thiamin, vitamin B1, cyanocobalamin, vitamin B62024-11-29 10:47:42
NuGo Nutrition To Go Bars Chocolate -- 15 BarsNuGo NutritionWeight Managementd-alpha tocopheryl acetate, Vitamin C, dicalcium phosphate, Vitamin E, fructose, Folic Acid, vitamin E, calcium carbonate, maltodextrin, Niacin, niacinamide, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, cane sugar, Thiamin, cyanocobalamin, vitamin B-62024-11-29 10:47:42
NuGo Nutrition To Go Bars Chocolate Banana -- 15 BarsNuGo NutritionWeight ManagementVitamin C, dicalcium phosphate, Vitamin E, fructose, vitamin B9, Vitamin E, microcrystalline cellulose, maltodextrin, Niacin, niacinamide, palmitate, pyridoxine hydrochloride, Vitamin B6, Vitamin A, vitamin B2, cane sugar, Thiamin, cyanocobalamin, vitamin B62024-11-29 10:47:42
NuGo Nutrition To Go Bars Coffee -- 15 BarsNuGo NutritionWeight ManagementD-alpha tocopheryl acetate, Vitamin C, dicalcium phosphate, Vitamin E, fructose, folic acid, vitamin E, microcrystalline cellulose, calcium carbonate, maltodextrin, Niacin, niacinamide, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, cane sugar, Thiamin, cyanocobalamin, vitamin B-62024-11-29 10:47:42
NuGo Nutrition To Go Bars Peanut Butter Chocolate -- 15 BarsNuGo NutritionWeight Managementd-alpha tocopheryl acetate, Vitamin C, dicalcium phosphate, Vitamin E, fructose, folic acid, vitamin E, microcrystalline cellulose, calcium carbonate, Niacin, niacinamide, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, sugar, Thiamin, cyanocobalamin, vitamin B-62024-11-29 10:47:42
NuGo Nutrition To Go Bars Vanilla Yogurt -- 15 BarsNuGo NutritionWeight Managementd-alpha tocopheryl acetate, Vitamin C, dicalcium phosphate, Vitamin E, fructose, folic acid, vitamin E, microcrystalline cellulose, maltodextrin, Niacin, niacinamide, Phosphorus, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, beet sugar, Thiamin, Vitamin B12, vitamin B62024-11-29 10:47:42
NutraBio Extreme Mass Chocolate -- 15.6 ServingsNutraBioActive Lifestyle & FitnessVitamin C, Biotin, cholecalciferol, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Maltodextrin, Vitamin B3, niacinamide, Pantothenic Acid, Phosphorus, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Riboflavin, Selenium, Thiamin, sucralose, Vitamin B12, Vitamin B6, vitamin K1, Vitamin K2024-11-29 10:47:42
NutraBio Extreme Mass Vanilla -- 15.6 ServingsNutraBioActive Lifestyle & FitnessVitamin C, Biotin, cholecalciferol, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Maltodextrin, Vitamin B3, niacinamide, Pantothenic Acid, Phosphorus, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Riboflavin, Selenium, Thiamin, sucralose, Vitamin B12, Vitamin B6, vitamin K1, Vitamin K2024-11-29 10:47:42
NutraBio MultiSport for Men -- 120 CapsulesNutraBioActive Lifestyle & FitnessVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
NutraBio MultiSport for Women -- 120 CapsulesNutraBioActive Lifestyle & FitnessVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Nutrex Hawaii BioAstin EyeAstin Hawaiian Astaxanthin -- 6 mg - 60 SoftgelsNutrex HawaiiVitamins & Supplementsvitamin E, vitamin E, glycerin, Lutein, Quercetin, Zeaxanthin2024-11-29 10:47:42
Nutrex Hawaii BioAstin Hawaiian Astaxanthin -- 12 mg - 25 SoftgelsNutrex HawaiiVitamins & Supplementsvitamin E, vitamin E, glycerin2024-11-29 10:47:42
Nutrex Hawaii BioAstin Hawaiian Astaxanthin -- 4 mg - 60 SoftgelsNutrex HawaiiVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Nutrex Hawaii BioAstin Hawaiian Astaxanthin Vegan Formula -- 12 mg - 50 Vegan SoftgelsNutrex HawaiiVitamins & SupplementsVitamin E, Vitamin E, glycerine, sorbitol2024-11-29 10:47:42
Nutrex Hawaii BioAstin Hawaiian Astaxanthin Vegan Formula -- 12 mg - 75 Vegan SoftgelsNutrex HawaiiVitamins & SupplementsVitamin E, Vitamin E, glycerine, sorbitol2024-11-29 10:47:42
Nutrex Hawaii BioAstin Hawaiian Astaxanthin Vegan Formula -- 4 mg - 120 Vegan SoftgelsNutrex HawaiiVitamins & SupplementsVitamin E, Vitamin E, glycerine, sorbitol2024-11-29 10:47:42
Nutrex Hawaii BioAstin Supreme Hawaiian Astaxanthin Vegan Formula -- 6 mg - 60 Vegan SoftgelsNutrex HawaiiVitamins & SupplementsVitamin E, Vitamin E, glycerin, sorbitol2024-11-29 10:47:42
Nutri Lutein Zeaxanthin & Meso-Zeaxantin Triple Caretenoid Vision Complex -- 20/12 mg - 60 Vegan CapsulesNutriVitamins & SupplementsVitamin C, Vitamin D3, Copper Gluconate, Vitamin E, Folate, Vitamin E, Lutein, Meso-Zeaxanthin, Vitamin A, Selenium, Zeaxanthin2024-11-29 10:47:42
NutriBiotic Face Creme -- 2 fl ozNutriBioticBeauty & Personal Careallantoin, vitamin C, benzyl alcohol, vitamin D3, tocopherol, dimethylaminoethanol, panthenol, ethylhexylglycerin, farnesol, tocopherol, vitamin E, glyceryl stearate, glycerin, glycerol monolaurate, phenoxyethanol, retinyl palmitate, squalene, stearic acid, stearyl alcohol, alpha lipoic acid, tocotrienol, tromethamine2024-11-29 10:47:42
NutriBiotic Hand & Body Lotion Citrus -- 8 fl ozNutriBioticBeauty & Personal Careascorbic acid, carbomer, tocopherol, ethyl hexyl glycerin, tocopherol, vitamin E, glyceryl stearate, glycerin, retinyl palmitate, vitamin A, stearic acid2024-11-29 10:47:42
NutriBiotic Multi Vitamins & Minerals -- 180 CapsulesNutriBioticVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Glucono delta lactone, Biotin, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, calcium carbonate, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, Selenium, montmorillonite, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
NutriBiotic Skin Ointment with Lysine -- 0.5 fl ozNutriBioticHerbs, Botanicals & Homeopathyvitamin C, cholecalciferol, goldenseal, tocopherol, tocopherol, vitamin E, retinyl palmitate, vitamin A2024-11-29 10:47:42
NutriBiotic Super Shower Gel Fresh Fruit -- 12 fl ozNutriBioticBeauty & Personal Carecocamidopropyl betaine, vitamin E, diazolidinyl urea, sodium laureth sulfate, vitamin E, methylparaben, propylparaben, TRP2024-11-29 10:47:42
NutriCology Multi-Vi-Min -- 150 CapsulesNutriCologyVitamins & Supplements5-Methyltetrahydrofolate, Biotin, Boron, Vitamin D3, Chromium, Vitamin E, Vitamin E, Glutamic Acid, microcrystalline cellulose, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
NutriCology Ocudyne II -- 200 CapsulesNutriCologyVitamins & SupplementsN-Acetyl L-Cysteine, Vitamin C, Boron, Vitamin D3, Chromium, Vitamin E, Folic Acid, Vitamin E, Glutamic Acid, Glycine, microcrystalline cellulose, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Taurine, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
NutriCology Pro Greens With Advanced Probiotic Formula -- 9.27 ozNutriCologyVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
NutriCology Quercetin 300 -- 60 CapsulesNutriCologyVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Quercetin2024-11-29 10:47:42
NutriCology Tocomin SupraBio Tocotrienols -- 200 mg - 60 SoftgelsNutriCologyVitamins & SupplementsVitamin E, d-Gamma Tocotrienol, Vitamin E, glycerin, d-Alpha Tocotrienol, d-Beta Tocotrienol, d-delta tocotrienol2024-11-29 10:47:42
NutriCology Vitamin E Succinate -- 100 Vegetarian CapsulesNutriCologyVitamins & Supplementscellulose, Vitamin E, Vitamin E2024-11-29 10:47:42
Nutricost Vitamin E -- 400 IU - 240 SoftgelsNutricostVitamins & SupplementsVitamin E, Vitamin E, glycerin2024-11-29 10:47:42
NUUN Immunity Hydration Single Tube Blueberry Tangerine -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, vitamin E, calcium carbonate, magnesium carbonate, potassium bicarbonate, retinyl acetate, Vitamin A, Selenium, sodium carbonate, ergocalciferol, zinc sulfate2024-11-29 10:47:42
NUUN Vitamins + Caffeine Hydration Single Tube Blackberry Citrus -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, folic acid, vitamin E, calcium carbonate, potassium bicarbonate, pyridoxal 5-phosphate, Vitamin B6, retinyl acetate, Vitamin A, riboflavin, sodium carbonate, vitamin B6, ergocalciferol2024-11-29 10:47:42
NUUN Vitamins + Caffeine Hydration Single Tube Ginger Lemonade -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, folic acid, vitamin E, calcium carbonate, potassium bicarbonate, pyridoxal 5-phosphate, Vitamin B6, retinyl acetate, Vitamin A, riboflavin, sodium carbonate, vitamin B6, ergocalciferol2024-11-29 10:47:42
NUUN Vitamins Hydration Single Tube Blueberry Pomegranate -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, Vitamin C, Chloride, citric acid, Vitamin E, Folic Acid, Vitamin E, Vitamin B6, Vitamin A, riboflavin, sodium carbonate, Sugar, Vitamin B62024-11-29 10:47:42
NUUN Vitamins Hydration Single Tube Grapefruit Orange -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, folic acid, vitamin E, calcium carbonate, potassium bicarbonate, pyridoxal 5-phosphate, Vitamin B6, retinyl acetate, Vitamin A, riboflavin, sodium carbonate, vitamin B6, ergocalciferol2024-11-29 10:47:42
NUUN Vitamins Hydration Single Tube Strawberry Melon -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, folic acid, vitamin E, calcium carbonate, potassium bicarbonate, pyridoxal 5-phosphate, Vitamin B6, retinyl acetate, Vitamin A, riboflavin, sodium carbonate, vitamin B6, ergocalciferol2024-11-29 10:47:42
NUUN Vitamins Hydration Single Tube Tangerine Lime -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, folic acid, vitamin E, calcium carbonate, potassium bicarbonate, pyridoxal 5-phosphate, Vitamin B6, retinyl acetate, Vitamin A, riboflavin, sodium carbonate, vitamin B6, ergocalciferol2024-11-29 10:47:42
OceanBlue Professional Omega-3 2100 High Potency Natural Orange -- 120 SoftgelsOceanBlueProfessional SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
OceanBlue Professional Omega-3 2100 with Vitamin D Natural Vanilla -- 120 SoftgelsOceanBlueProfessional SupplementsVitamin D3, Vitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
Octonuts Almond Protein Powder Chocolate -- 21 ozOctonutsActive Lifestyle & FitnessVitamin E, Vitamin E, Riboflavin2024-11-29 10:47:42
Octonuts Almond Protein Powder Vanilla -- 21 ozOctonutsActive Lifestyle & FitnessVitamin E, Vitamin E, Riboflavin2024-11-29 10:47:42
Octonuts Almond Protein Powder -- 21 ozOctonutsActive Lifestyle & FitnessVitamin E, Vitamin E, Riboflavin2024-11-29 10:47:42
Ocuvite Adult 50+ Eye Vitamin & Mineral -- 90 Mini SoftgelsOcuviteVitamins & SupplementsVitamin C, carmine, Vitamin E, EPA, Vitamin E, glycerin, Lutein2024-11-29 10:47:42
Oilogic Baby Slumber & Sleep Essential Oil Vapor Roll-On -- 2 fl ozOilogicBaby & Kids Productschamomile, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Oilogic Baby Stuffy Nose & Cough Essential Oil Vapor Chest Roll-On -- 2 fl ozOilogicBaby & Kids Productsorange, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Olly Adult Multi Probiotic Gummy Tropical Twist -- 70 GummiesOllyVitamins & Supplementscitric acid, Vitamin C, Biotin, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Selenium, Cane sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Olly Flawless Complexion - Berry Fresh -- 50 GummiesOllyVitamins & SupplementsCitric Acid, Vitamin D3, Chromium, Citric Acid, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Selenium, Beet Sugar, Vitamin B62024-11-29 10:47:42
Olly Kids Multi Gummy Worms Sour Fruity Punch -- 70 GummiesOllyVitamins & Supplementscitric acid, Vitamin C, Biotin, Choline, citric acid, Vitamin E, Folate, Vitamin E, Iodine, lactic acid, Pantothenic Acid, Vitamin B6, Vitamin A, beet sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Olly Kids Multi Plus Probiotic Yum Berry Punch -- 100 GummiesOllyVitamins & Supplementscitric acid, Vitamin C, Biotin, Choline, citric acid, Vitamin E, Folate, Vitamin E, Iodine, lactic acid, Pantothenic Acid, Vitamin B6, Vitamin A, Cane sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Olly Kids Multi plus Probiotic Yum Berry Punch -- 70 GummiesOllyVitamins & Supplementscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Folic Acid, Vitamin E, Iodine, lactic acid, Pantothenic Acid, Vitamin B6, Vitamin A, Cane sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Olly Teen Girl Multi Berry Melon Besties -- 70 GummiesOllyVitamins & Supplementscitric acid, Vitamin C, Biotin, Vitamin D3, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Iodine, lactic acid, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Selenium, beet sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Olly The Essential Prenatal Sweet Citrus -- 60 GummiesOllyVitamins & Supplementscitric acid, ascorbyl palmitate, Vitamin C, Choline, citric acid, Vitamin E, EPA, Folate, Vitamin E, lactic acid, Niacin, Vitamin B6, Vitamin A, sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Olly Ultra Strength Prenatal Folic Acid + DHA Multivitamin -- 60 SoftgelsOllyVitamins & SupplementsVitamin C, Biotin, Vitamin E, EPA, Folate, Vitamin E, glycerin, Iodine, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Thiamin, titanium dioxide, Vitamin B12, Vitamin B62024-11-29 10:47:42
Olly Undeniable Beauty Graprefruit Glam -- 60 GummiesOllyVitamins & Supplementscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Vitamin E, beet sugar2024-11-29 10:47:42
Olympian Labs Enteric Coated Omega-3 Fish Oil -- 2000 mg - 120 SoftgelsOlympian LabsVitamins & SupplementsVitamin E, EPA, triethyl citrate, Vitamin E, glyceryl monostearate, glycerin, propylene glycol, triacetin, vanillin2024-11-29 10:47:42
Olympian Labs Omega-3 Fish Oils -- 2000 mg - 240 SoftgelsOlympian LabsVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Olympian Labs Sea Nourishment Cran-Raspberry -- 32 fl ozOlympian LabsVitamins & SupplementsLipase, citric acid, Alanine, Arginine, Vitamin C, Aspartic Acid, Barium, Beta Carotene, Bismuth, Boron, Bromine, Cadmium, Cellulase, Cesium, Chloride, Chromium, citric acid, Citrulline, Cobalt, Cysteine, Cystine, Vitamin E, fructose, Germanium, Vitamin E, Glutamine, Glycine, Gold, Histidine, Hydrogen, Indium, Iodine, Iridium, Lanthanum, Lithium, Manganese, Molybdenum, Vitamin B, Nickel, Niobium, Ornithine, Osmium, Palladium, Phosphorus, Platinum, Proline, Rhodium, Rubidium, Selenium, Serine, Silver, Strontium, Sulfur, Taurine, Tellurium, Thallium, Tin, Titanium, Tungsten, CoQ7, CoQ8, CoQ9, Uranium, Vanadium2024-11-29 10:47:42
Olympian Labs Tocomin Vitamin E Complete -- 60 SoftgelsOlympian LabsVitamins & Supplementsd-Beta Tocopherol, Vitamin E, d-delta tocopherol, d-Gamma Tocopherol, d-Gamma Tocotrienol, Vitamin E, Phytosterols, d-Alpha Tocotrienol, d-Beta Tocotrienol, d-delta tocotrienol2024-11-29 10:47:42
Omax3 Ultra Pure Omega-3 -- 1500 mg - 60 SoftgelsOmax3Professional SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
Omax3 Ultra Pure Pro-Strength Omega-3 - NSF Certified for Sport -- 3000 mg - 60 SoftgelsOmax3Professional SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
Once Upon a Farm Organic Coconut Melts Mango Ba-nilla -- 1 ozOnce Upon a FarmBaby & Kids Productsvitamin E, vitamin E, probiotic2024-11-29 10:47:42
Once Upon a Farm Organic Coconut Melts Mixed Berry -- 1 ozOnce Upon a FarmBaby & Kids Productsvitamin E, vitamin E, probiotic2024-11-29 10:47:42
Once Upon a Farm Organic Coconut Melts Strawberry Banana -- 1 ozOnce Upon a FarmBaby & Kids Productsvitamin E, vitamin E, probiotic2024-11-29 10:47:42
One Degree Organic Foods Gluten Free Sprouted Granola Vanilla Chia -- 11 ozOne Degree Organic FoodsFood & Beveragesvitamin E, Folate, vitamin E, Manganese, Phosphorus, Thiamin, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Gluten Free Tea Infused Granola Sprouted Cacao Mint -- 10 ozOne Degree Organic FoodsFood & Beveragesvitamin E, vitamin E, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Gluten Free Tea Infused Granola Sprouted Coconut Hibiscus -- 10 ozOne Degree Organic FoodsFood & BeveragesVitamin E, Vitamin E, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Gluten Free Tea Infused Granola Sprouted Honey Bergamot -- 10 ozOne Degree Organic FoodsFood & BeveragesVitamin E, Vitamin E, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Organic Sprouted Granola Cinnamon Flax -- 11 ozOne Degree Organic FoodsFood & Beveragesvitamin E, Folate, vitamin E, Manganese, Phosphorus, Thiamin, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Organic Sprouted Oat Granola Honey Hemp -- 11 ozOne Degree Organic FoodsFood & Beveragesvitamin E, Folate, vitamin E, Manganese, Phosphorus, Thiamin, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Organic Sprouted Oat Granola Quinoa Cacao -- 11 ozOne Degree Organic FoodsFood & Beveragesvitamin E, vitamin E, Manganese, Phosphorus, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Sprouted Brown Rice Cacao Crisps Cacao -- 10 ozOne Degree Organic FoodsFood & Beveragesvitamin E, Folate, vitamin E, Manganese, Niacin, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, tocopherols, Vitamin B62024-11-29 10:47:42
One Degree Organic Foods Sprouted Brown Rice Crisps Cereal -- 8 ozOne Degree Organic FoodsFood & Beveragesvitamin E, Folate, vitamin E, Manganese, Niacin, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, tocopherols, Vitamin B62024-11-29 10:47:42
One Degree Organic Foods Sprouted Instant Oatmeal Apple Cinnamon -- 18 ozOne Degree Organic FoodsFood & Beveragestocopherol, tocopherol, vitamin E, Phosphorus2024-11-29 10:47:42
One Degree Organic Foods Sprouted Instant Oatmeal Cacao Nib -- 18 ozOne Degree Organic FoodsFood & Beveragestocopherol, tocopherol, vitamin E2024-11-29 10:47:42
One Degree Organic Foods Sprouted Instant Oatmeal Coconut Sugar & Spice -- 18 ozOne Degree Organic FoodsFood & Beveragestocopherol, tocopherol, vitamin E2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Activated Charcoal -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Almond -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Dead Sea Mud -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Dead Sea Salt -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, Vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Eucalyptus -- 7 ozOne With NatureBeauty & Personal Carecitric acid, chlorophyll, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap French Green Clay -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin, montmorillonite2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Grapefruit Guava -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Lavender -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, vitamin E, vitamin E2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Lemon Sage -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Lemon Verbena -- 6 BarsOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Lilac -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Olive Oil -- 7 ozOne With NatureBeauty & Personal Carecitric acid, chlorophyll, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Peppermint -- 7 ozOne With NatureBeauty & Personal Carecitric acid, chlorophyll, citric acid, tocopherol, tocopherol, vitamin E, glycerin, sorbitol2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Rose Petal -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Sulfur & Chamomile -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin, sulfur2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Vanilla Oatmeal -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Dead Sea Mineral Bar Soap Volcanic Mud -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, and, tocopherol, vitamin E, glycerin, illite2024-11-29 10:47:42
One With Nature Dead Sea Minerals Bar Soap Blackberry Pear -- 7 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin2024-11-29 10:47:42
One With Nature Down There Feminine Cleansing Bar Soap Fragrance Free -- 3.5 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin, kaolin2024-11-29 10:47:42
One With Nature One Bar - Shampoo-Shave & Shower Soap - Activated Charcoal -- 3.5 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamine, glycerin, kaolin2024-11-29 10:47:42
One With Nature One Bar - Shampoo-Shave & Shower Soap - Stimulating Sandalwood -- 3.5 ozOne With NatureBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin e, glycerin, kaolin2024-11-29 10:47:42
One-A-Day Mens 50 Plus Complete Multivitamin -- 65 TabletsOne-A-DayVitamins & Supplementsdl-alpha-tocopheryl acetate, Vitamin C, Biotin, d-calcium pantothenate, cholecalciferol, Chromium, copper sulfate, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Iodine, Calcium carbonate, Lycopene, Manganese, Molybdenum, Niacin, niacinamide, Pantothenic Acid, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, sodium molybdate, sodium selenite, stearic acid, Thiamin, titanium dioxide, cyanocobalamin, Vitamin B6, phylloquinone, Vitamin K, zinc oxide2024-11-29 10:47:42
One-A-Day VitaCraves Adult Multi Gummies -- 150 GummiesOne-A-DayVitamins & Supplementscitric acid, vitamin E acetate, Vitamin C, d-biotin, d-calcium pantothenate, vitamin D3, Choline, citric acid, Vitamin E, folic acid, Vitamin E, Inositol, Iodine, Pantothenic Acid, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A acetate, Vitamin A, sucrose, vitamin B12, Vitamin B62024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 150 TabletsOptimum NutritionActive Lifestyle & Fitness Lipase, PABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Choline, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, L-Lysine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 240 TabletsOptimum NutritionActive Lifestyle & Fitness Lipase, PABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Choline, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folate, Vitamin E, L-Glutamine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 90 TabletsOptimum NutritionActive Lifestyle & FitnessPABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folate, Vitamin E, L-Glutamine, glycerine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, L-Lysine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Women Multivitamin for Women -- 120 CapsulesOptimum NutritionActive Lifestyle & FitnessAlpha-Carotene, Vitamin C, kelp, Biotin, Chromium, Cryptoxanthin, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Iodine, Isoflavone, calcium carbonate, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, citrate, sodium selenate, citrate, Thiamin, Alpha-Lipoic Acid, calcium phosphate, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Women Multivitamin for Women -- 60 CapsulesOptimum NutritionActive Lifestyle & FitnessAlpha-Carotene, Vitamin C, kelp, Biotin, Chromium, Cryptoxanthin, Vitamin E, Folic Acid, Vitamin E, microcrystalline cellulose, Iodine, calcium carbonate, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, potassium iodide, Vitamin B6, Vitamin A, Riboflavin, Selenium, citrate, citrate, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Serious Mass Protein Powder Supplement Chocolate -- 16 ServingsOptimum NutritionActive Lifestyle & FitnessPABA, acesulfame potassium, acesulfame potassium, d-alpha tocopheryl succinate, Vitamin C, beta carotene, Biotin, calcium citrate, d-calcium pantothenate, di-calcium phosphate, cholecalciferol, Choline, Chromium, copper gluconate, Vitamin E, ferrous fumarate, folic acid, Vitamin E, L-Glutamine, Inositol, Iodine, Maltodextrin, Manganese, Molybdenum, Niacin, niacinamide, PABA, Pantothenic Acid, Phosphorus, potassium iodide, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, selenomethionine, Thiamin, cyanocobalamin, Vitamin B62024-11-29 10:47:42
Orgain Organic Kids Nutritional Shake 22 Vitamins & Minerals Chocolate -- 12 ShakesOrgainBaby & Kids ProductsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Orgain Organic Kids Nutritional Shake 22 Vitamins & Minerals Strawberry -- 12 ShakesOrgainBaby & Kids ProductsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Orgain Organic Kids Nutritional Shake 22 Vitamins & Minerals Vanilla -- 12 ShakesOrgainBaby & Kids ProductsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Orgain Organic Kids Vegan Nutritional Shake - 23 Vitamins & Minerals Chocolate -- 12 ShakesOrgainBaby & Kids ProductsVitamin C, Biotin, Chromium, Vitamin E, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Orgain Organic Kids Vegan Nutritional Shake - 23 Vitamins & Minerals Vanilla -- 12 ShakesOrgainBaby & Kids ProductsVitamin C, Biotin, Chromium, Vitamin E, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Orgain Organic Nutrition Grass Fed Protein Shake Creamy Chocolate Fudge -- 12 ShakesOrgainActive Lifestyle & FitnessVitamin C, Biotin, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Orgain Organic Nutrition Shake Creamy Chocolate Fudge -- 12 ShakesOrgainActive Lifestyle & FitnessDL-alpha tocopheryl acetate, Vitamin C, Biotin, cholecalciferol, copper gluconate, Vitamin E, Folate, Vitamin E, Iodine, magnesium sulfate, Niacin, niacinamide, Pantothenic Acid, trisodium phosphate, Phosphorus, potassium chloride, tripotassium citrate, potassium iodide, tripotassium phosphate, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, thiamine hydrochloride, Thiamin, tricalcium phosphate, cyanocobalamin, Vitamin B62024-11-29 10:47:42
Orgain Organic Nutrition Shake Sweet Vanilla Bean -- 12 ShakesOrgainActive Lifestyle & FitnessDL-alpha tocopheryl acetate, Vitamin C, Biotin, cholecalciferol, copper gluconate, Vitamin E, Folate, Vitamin E, Iodine, magnesium sulfate, Niacin, niacinamide, Pantothenic Acid, trisodium phosphate, Phosphorus, potassium chloride, tripotassium citrate, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, thiamine hydrochloride, Thiamin, tricalcium phosphate, cyanocobalamin, Vitamin B62024-11-29 10:47:42
Orgain Organic Nutrition Shake Grass Fed Protein Iced Cafe Mocha -- 12 ShakesOrgainActive Lifestyle & FitnessVitamin C, Biotin, Vitamin E, Folate, Vitamin E, Iodine, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Orgain Organic Nutrition Vegan Protein Shake Plant Based Smooth Chocolate -- 12 ShakesOrgainWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Orgain Organic Nutrition Vegan Protein Shake Plant Based Vanilla Bean -- 12 ShakesOrgainWeight ManagementVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Organic Excellence Balance Plus Therapy -- 2 ozOrganic ExcellenceVitamins & Supplementsvitamin e, tocopherol, vitamin e2024-11-29 10:47:42
Organic Excellence Feminine Balance Therapy -- 2 ozOrganic ExcellenceVitamins & Supplementsvitamin E, tocopherol, vitamin E, stearic acid2024-11-29 10:47:42
Organic Excellence Progesterone Cream - Balance Plus Therapy -- 3.3 ozOrganic ExcellenceBeauty & Personal Carevitamin E, tocopherol, vitamin E2024-11-29 10:47:42
Organic Excellence Progesterone Cream - Feminine Balance Therapy -- 3.3 ozOrganic ExcellenceBeauty & Personal Carevitamin E, tocopherol, vitamin E, stearic acid2024-11-29 10:47:42
Outstanding Foods Cheese Balls Bacon Chedda -- 3 ozOutstanding FoodsFood & BeveragesVitamin C, Chromium, Vitamin E, Vitamin E, Iodine, lactic acid, Molybdenum, Niacin, Vitamin B6, Vitamin A, Riboflavin, Selenium, cane sugar, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Outstanding Foods Cheese Balls Cheddar -- 3 ozOutstanding FoodsFood & BeveragesVitamin C, Chromium, Vitamin E, Vitamin E, Iodine, lactic acid, Manganese, Molybdenum, Niacin, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Outstanding Foods Cheese Balls Garlic Parmesan -- 3 ozOutstanding FoodsFood & BeveragesVitamin C, Chromium, Vitamin E, Vitamin E, Iodine, lactic acid, Molybdenum, Niacin, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Outstanding Foods Cheese Balls Jalapeno -- 3 ozOutstanding FoodsFood & Beveragescitric acid, Vitamin C, Chromium, citric acid, Vitamin E, Vitamin E, Iodine, lactic acid, Molybdenum, Niacin, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Pacha Soap Co Holiday Bar Soap - Balsam & Pine -- 4 ozPacha Soap CoBeauty & Personal Carebeta carotene, palm, tocopherol, tocopherol, vitamin E, titanium dioxide2024-11-29 10:47:42
Pacha Soap Co Pacha Peaces Bar Soap Variety Pack - Earthy Essentials -- 7 ozPacha Soap CoBeauty & Personal Carekelp, beta-carotene, palm, tocopherol, tocopherol, vitamin E, oat, titanium dioxide2024-11-29 10:47:42
Pacha Soap Co Pacha Peaces Bar Soap Variety Pack - Signature Scents -- 7 ozPacha Soap CoBeauty & Personal Carekelp, beta-carotene, palm, clay, tocopherol, tocopherol, vitamin E, oat, titanium dioxide2024-11-29 10:47:42
Pacific Foods Ultra Soy Non-Dairy Beverage Original -- 32 fl ozPacific FoodsFood & BeveragesB2, D-alpha-tocopherol acetate, Vitamin C, Vitamin E, vitamin E, palmitate, Phosphorus, pyridoxine HCL, Vitamin B6, Vitamin A, Riboflavin, tricalcium phosphate, Vitamin B12, vitamin B6, vitamin D22024-11-29 10:47:42
Pacifica Conditioner Salty Waves Texturizing -- 8 fl ozPacificaBeauty & Personal Carekelp, cetearyl alcohol, cetyl alcohol, vitamin E, panthenol, ethylhexylglycerin, vitamin E, dimethicone, sodium benzoate, sorbitol, stearyl alcohol2024-11-29 10:47:42
Pacifica Dreamy Youth Day and Night Face Cream -- 1.7 fl ozPacificaBeauty & Personal Caregeranium, allantoin, tocopherol acetate, kelp, cetyl alcohol, vitamin E, panthenol, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, oat, vitamin B5, phenoxyethanol2024-11-29 10:47:42
Pacifica Fluffy Blushy Bloom -- 0.28 ozPacificaBeauty & Personal Caretocopherol, tocopherol, vitamin E, tin oxide, CI 778912024-11-29 10:47:42
Pacifica Glow Baby Vitaglow Face Lotion -- 1.7 fl ozPacificaBeauty & Personal Careorange, ascorbic acid, bisabolol, cetyl alcohol, tocopherol, ethylhexylglycerin, tocopherol, vitamin E, glyceryl stearate, glycerin, phenoxyethanol, stearic acid2024-11-29 10:47:42
Pacifica Natural Beauty Face Wash Kale Detox Deep Cleaning -- 5 fl ozPacificaBeauty & Personal Carecitric acid, chlorophyll, citric acid, vitamin E, decyl glucoside, panthenol, vitamin E, glycerin, kaolin, vitamin B5, sodium benzoate2024-11-29 10:47:42
Pacifica Rosemary Purify Invigorating Conditioner -- 8 fl ozPacificaBeauty & Personal Carecetearyl alcohol, cetyl alcohol, vitamin E, panthenol, ethylhexylglycerin, vitamin E, glycerin, menthol, vitamin B5, sodium benzoate, sorbitol, stearyl alcohol, tocopherols2024-11-29 10:47:42
Pacifica Salty Waves Texturizing Shampoo -- 12 fl ozPacificaBeauty & Personal Carekelp, cocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, vitamin E, vitamin B, sodium benzoate, sorbitol2024-11-29 10:47:42
Pacifica Stellar Gaze Length & Strength Mineral Mascara - Supernova -- 0.25 fl ozPacificaBeauty & Personal Carechamomile, vitamin E, panthenol, vitamin E, vitamin B2024-11-29 10:47:42
Pacifica Vegan Ceramide Barrier Face Lotion -- 1.7 fl ozPacificaBeauty & Personal Careallantoin, tocopherol acetate, carbomer, ceramide NP, vitamin E, panthenol, beta-glucan, vitamin E, glyceryl stearate, glycerin, glyceryl laurate, vitamin B5, phenoxyethanol, phytosphingosine, stearic acid2024-11-29 10:47:42
Pacifica Vegan Collagen Lip Plumping Gloss -- 0.22 fl ozPacificaBeauty & Personal Carecaprylyl glycol, tocopherol, tocopherol, vitamin E, lactic acid, tin oxide2024-11-29 10:47:42
Pacifica Vegan Collagen Overnight Recovery Cream -- 1.7 fl ozPacificaBeauty & Personal Careorange, allantoin, vitamin C, cetyl alcohol, vitamin E, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, phenoxyethanol, stearic acid, stearyl alcohol2024-11-29 10:47:42
Pacifica Vegan Collagen Recovery Eye Cream -- 0.5 fl ozPacificaBeauty & Personal Careorange, allantoin, arginine, caffeine, cetearyl alcohol, tocopherol, panthenol, tocopherol, vitamin E, glycerin, maltodextrin, glyceryl caprylate, phenoxyethanol, stearic acid2024-11-29 10:47:42
Pacifica Vegan Waterproof Eyeliner Fringe Brown -- 0.04 ozPacificaBeauty & Personal Caretocopherol, tocopherol, vitamin E, glyceryl caprylate, CI 778912024-11-29 10:47:42
Pacifica Vegan Waterproof Eyeliner Jet Black -- 0.04 ozPacificaBeauty & Personal Caretocopherol, tocopherol, vitamin E, glyceryl caprylate, CI 778912024-11-29 10:47:42
Pacifica Wake Up Beautiful Overnight Retinoid Cream -- 1.7 fl ozPacificaBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin, melatonin, phenoxyethanol, sodium benzoate2024-11-29 10:47:42
Penetrex Joint & Muscle Therapy Cream -- 2 ozPenetrexBeauty & Personal CareDMDM hydantoin, camphor, ethoxydiglycol, cetyl myristoleate, tocopherol, methylsulfonylmethane, tocopherol, vitamin E, glucosamine, glyceryl stearate, glycerin, dimethicone, phenoxyethanol, pyridoxine hydrochloride, vitamin B6, vitamin B62024-11-29 10:47:42
Penetrex Joint & Muscle Therapy Cream -- 4 ozPenetrexBeauty & Personal CareDMDM hydantoin, camphor, ethoxydiglycol, cetyl myristoleate, tocopherol, methylsulfonylmethane, tocopherol, vitamin E, glucosamine, glyceryl stearate, glycerin, dimethicone, phenoxyethanol, pyridoxine hydrochloride, vitamin B6, vitamin B62024-11-29 10:47:42
Petal Fresh Anti-Frizz Conditioner Lavender -- 16 fl ozPetal FreshBeauty & Personal Carechamomile, cetearyl alcohol, cetyl alcohol, vitamin E, dehydroacetic acid, panthenol, behenyl alcohol, ethylhexylglycerin, vitamin E, glycerin, vitamin B5, stearyl alcohol2024-11-29 10:47:42
Petal Fresh Anti-Frizz Shampoo Lavender -- 16 fl ozPetal FreshBeauty & Personal Carecitric acid, chamomile, betaine, citric acid, vitamin e, dehydroacetic acid, panthenol, ethylhexylglycerin, vitamin e, glycerin, vitamin B52024-11-29 10:47:42
Petal Fresh Body Butter Restoring Honey & Coconut -- 8 ozPetal FreshBeauty & Personal Carebenzyl benzoate, cetyl alcohol, vitamin E, dehydroacetic acid, panthenol, ethylhexylglycerin, vitamin E, glycerin, isopropyl myristate, vitamin B5, sodium hydroxide, stearic acid, stearyl alcohol2024-11-29 10:47:42
Petal Fresh Body Scrub Reviving Argan Oil & Shea -- 16 fl ozPetal FreshBeauty & Personal Carekelp, cetyl alcohol, vitamin E, dehydroacetic acid, panthenol, ethylhexylglycerin, vitamin E, glycerin, vitamin B5, stearic acid2024-11-29 10:47:42
Petal Fresh Body Scrub Smoothing Coconut -- 16 fl ozPetal FreshBeauty & Personal Carekelp, cetyl alcohol, vitamin E, dehydroacetic acid, panthenol, ethylhexylglycerin, vitamin E, glycerin, vitamin B5, stearic acid2024-11-29 10:47:42
Petal Fresh Conditioner Strengthening Seaweed & Argan Oil -- 16 fl ozPetal FreshBeauty & Personal Carechamomile, kelp, cetearyl alcohol, cetyl alcohol, vitamin E, dehydroacetic acid, panthenol, behenyl alcohol, ethylhexylglycerin, vitamin E, glycerin, vitamin B5, stearyl alcohol2024-11-29 10:47:42
Petal Fresh Conditioner Volumizing Rosemary & Mint -- 16 fl ozPetal FreshBeauty & Personal Carechamomile, benzyl benzoate, cetearyl alcohol, cetyl alcohol, vitamin E, dehydroacetic acid, panthenol, behenyl alcohol, ethylhexylglycerin, vitamin E, glycerin, vitamin B5, stearyl alcohol2024-11-29 10:47:42
Petal Fresh Hair ResQ Thickening Follicle Stimulator Serum with Biotin -- 2 fl ozPetal FreshBeauty & Personal Carebenzyl salicylate, vitamin B7, caffeine, citronellol, coumarin, coumarin, tocopherol, panthenol, tocopherol, geraniol, vitamin E, glycerin, hexyl cinnamal, limonene, menthol, niacin, vitamin B5, vitamin B6, vitamin B62024-11-29 10:47:42
Petal Fresh Makeup Removing Wipes Refreshing Cucumber -- 60 WipesPetal FreshBeauty & Personal Carecitric acid, citric acid, vitamin E, vitamin E, phenoxyethanol, propanediol2024-11-29 10:47:42
Petal Fresh Scalp Treatment Conditioner Tea Tree -- 16 fl ozPetal FreshBeauty & Personal Carechamomile, cetearyl alcohol, cetyl alcohol, vitamin E, dehydroacetic acid, panthenol, behenyl alcohol, ethylhexylglycerin, vitamin E, glycerin, vitamin B5, stearyl alcohol2024-11-29 10:47:42
Petal Fresh Scalp Treatment Shampoo Tea Tree -- 16 fl ozPetal FreshBeauty & Personal Carecitric acid, chamomile, betaine, citric acid, vitamin E, dehydroacetic acid, panthenol, ethylhexylglycerin, vitamin E, glycerin, vitamin B52024-11-29 10:47:42
Petal Fresh Shampoo Strengthening Seaweed & Argan Oil -- 16 fl ozPetal FreshBeauty & Personal Carecitric acid, chamomile, kelp, betaine, citric acid, vitamin E, dehydroacetic acid, panthenol, ethylhexylglycerin, vitamin E, glycerin, vitamin B52024-11-29 10:47:42
Petal Fresh Shampoo Volumizing Rosemary & Mint -- 16 fl ozPetal FreshBeauty & Personal Carecitric acid, chamomile, betaine, citric acid, vitamin E, dehydroacetic acid, panthenol, ethylhexylglycerin, vitamin E, glycerin, vitamin B52024-11-29 10:47:42
Phion pH Balance Master Cleanse Lemonade Diet -- 32 fl ozPhion pH BalanceVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, magnesium sulfate, Niacin, Vitamin B6, Vitamin A, Riboflavin, sodium benzoate, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Pirq Electrolyte Drink Mix - Hydration Powder Packets Fruit Punch -- 10 PacketsPirqActive Lifestyle & Fitness Citric acid, calcium ascorbate, D-calcium pantothenate, Chloride, Citric acid, curcumin, Vitamin E, Vitamin E, magnesium citrate, malic acid, Niacin, niacinamide, Pantothenic Acid, potassium citrate, Vitamin B122024-11-29 10:47:42
Pirq Electrolyte Drink Mix - Hydration Powder Packets Lemon Lime -- 10 PacketsPirqActive Lifestyle & Fitnesscitric acid, calcium ascorbate, D-calcium pantothenate, Chloride, citric acid, curcumin, Vitamin E, Vitamin E, magnesium citrate, malic acid, Niacin, niacinamide, Pantothenic Acid, potassium citrate, Vitamin B122024-11-29 10:47:42
Pirq Electrolyte Drink Mix - Hydration Powder Packets Orange -- 10 PacketsPirqActive Lifestyle & Fitness Citric acid, beta carotene, calcium ascorbate, D-calcium pantothenate, Chloride, Citric acid, curcumin, Vitamin E, vitamin E, magnesium citrate, malic acid, Niacin, niacinamide, Pantothenic Acid, potassium citrate, Vitamin B122024-11-29 10:47:42
Pirq Electrolyte Drink Mix - Hydration Powder Packets Watermelon -- 10 PacketsPirqActive Lifestyle & Fitness Citric acid, calcium ascorbate, D-calcium pantothenate, Chloride, Citric acid, curcumin, Vitamin E, Vitamin E, magnesium citrate, malic acid, Niacin, niacinamide, Pantothenic Acid, potassium citrate, Vitamin B122024-11-29 10:47:42
PlantFusion Complete Meal Shake Chocolate Caramel -- 32.1 ozPlantFusionActive Lifestyle & FitnessVitamin C, Biotin, Chromium, Vitamin E, Erythritol, Folate, Vitamin E, L-Glutamine, L-Isoleucine, Niacin, Phosphorus, Vitamin B6, Reb A, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
PlantFusion Complete Meal Shake Creamy Vanilla Bean -- 32.1 ozPlantFusionActive Lifestyle & FitnessVitamin C, Biotin, Chromium, Vitamin E, erythritol, Folate, Vitamin E, L-glutamine, L-isoleucine, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, reb A, Vitamin A, Riboflavin, Selenium, Thiamin, L-valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Plantlife Foaming Hand & Body Soap Refill - Vanilla Orange -- 16 fl ozPlantlifeHousehold Essentialsvitamin E, vitamin E, vanilla2024-11-29 10:47:42
Plantlife Foaming Hand & Body Soap - Lemongrass -- 8.5 fl ozPlantlifeHousehold Essentialsvitamin E, vitamin E2024-11-29 10:47:42
Plantlife Foaming Hand & Body Soap - Vanilla Orange -- 8.5 fl ozPlantlifeHousehold Essentialsvitamin E, vitamin E, vanilla2024-11-29 10:47:42
Plantlife Foaming Hand & Body Soap Refill - Lemongrass -- 16 fl ozPlantlifeHousehold Essentialsvitamin E, vitamin E2024-11-29 10:47:42
Plantlife Herbal Insect Body Oil Deet Free -- 4 fl ozPlantlifeBeauty & Personal Carecitronella, vitamin E, vitamin E2024-11-29 10:47:42
Plum Organics Baby Food Puree 6+ Months Apple Spinach & Avocado -- 6 PouchesPlum OrganicsBaby & Kids ProductsVitamin E, Folate, Vitamin E, Vitamin A2024-11-29 10:47:42
Plum Organics Mighty Puffs Baby Snacks 9+ Months Beet + Strawberry -- 1.85 ozPlum OrganicsBaby & Kids ProductsDL-alpha tocopherol acetate, Choline, Vitamin E, Folate, vitamin E, Niacin, niacinamide, Vitamin B6, vitamin B2, thiamine hydrochloride, Thiamin, vitamin B1, cyanocobalamin, vitamin B6, zinc sulphate2024-11-29 10:47:42
Plum Organics Super Smoothie 2+ Years Pear Sweet Potato Spinach Blueberry Bean & Oat -- 4 PouchesPlum OrganicsBaby & Kids ProductsDL-alpha-tocopheryl acetate, Vitamin C, Choline, Vitamin E, vitamin E, Vitamin B6, Vitamin A, Vitamin B62024-11-29 10:47:42
Santa Cruz Organic Creamy Dark Roasted Peanut Butter -- 16 ozSanta CruzFood & BeveragesVitamin E, Vitamin E, Niacin2024-11-29 10:47:42
Santa Cruz Organic Crunchy Dark Roasted Peanut Butter -- 16 ozSanta CruzFood & BeveragesVitamin E, Vitamin E, Niacin2024-11-29 10:47:42
Second Nature Antioxidant+ Smart Mix Nut Medley -- 10 ozSecond NatureFood & BeveragesVitamin E, Vitamin E, sugar2024-11-29 10:47:42
Second Nature Keto Crunch Smart Mix Nut Medley -- 10 ozSecond NatureFood & Beveragesdextrin, Vitamin E, erythritol, Vitamin E2024-11-29 10:47:42
Second Nature Nut Medley Mix Dark Chocolate -- 1.25 oz Each / Pack of 10Second NatureFood & BeveragesVitamin E, Vitamin E, sugar2024-11-29 10:47:42
Second Nature Nut Medley Mix Dark Chocolate Cherry -- 12 ozSecond NatureFood & BeveragesVitamin E, Vitamin E, sugar2024-11-29 10:47:42
Second Nature Super Omega Smart Mix Nut Medley -- 10 ozSecond NatureFood & Beveragesdextrin, Vitamin E, erythritol, Vitamin E2024-11-29 10:47:42
Serenity Kids Grass Fed A2 Whole Milk Toddler Formula Powder 12-36 Months -- 21 ozSerenity KidsBaby & Kids ProductsL-methylfolate, ascorbyl palmitate, adenosine-5-monophosphate, alpha-tocopheryl acetate, Vitamin C, Biotin, calcium pantothenate, dicalcium phosphate, Chloride, vitamin D3, Choline, copper sulfate, cytidine-5-monophosphate, Vitamin E, ferrous sulfate, Folate, Vitamin E, inositol, Iodine, lacto-n-neotetraose, calcium carbonate, magnesium phosphate, Niacin, niacinamide, Pantothenic Acid, Phosphorus, potassium chloride, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, sodium selenite, Thiamin, Vitamin B12, Vitamin B6, phylloquinone, Vitamin K, zinc sulfate2024-11-29 10:47:42
SFI Health VitaSpectrum -- 180 Vegetarian CapsulesSFI HealthProfessional SupplementsVitamin C, beta-carotene, Biotin, Boron, cellulose, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
SheaMoisture Coconut & Hibiscus Bath Massage & Body Oil for Dull Skin -- 8 fl ozSheaMoistureBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
SheaMoisture Cruelty-Free Coconut & Hibiscus Illuminating Hand & Body Scrub for Dull Skin -- 12 ozSheaMoistureBeauty & Personal Careallantoin, vitamin e, vitamin e2024-11-29 10:47:42
SheaMoisture Olive Oil & Green Tea Extract Shea Butter Soap Bar for Dry Aging Skin -- 8 ozSheaMoistureBeauty & Personal Carevitamin e, vitamin e2024-11-29 10:47:42
SheaMoisture Raw Shea Butter Moisture Retention Shampoo to Hydrate Dry & Damaged Hair -- 13 fl ozSheaMoistureBeauty & Personal Carecaprylyl glycol, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Shikai Magnesium & Hemp Oil Body Cream -- 4.5 fl ozShikaiBeauty & Personal Carevitamin E, and, vitamin E, glycerin, hemp, phenoxyethanol, sodium citrate, stearic acid, tocotrienols2024-11-29 10:47:42
Shikai Very Clean Body Barrier Cream Honey Almond -- 4.5 fl ozShikaiBeauty & Personal Carebisabolol, cetyl alcohol, tocopherol, and, panthenol, pro-vitamin B5, behenyl alcohol, tocopherol, vitamin E, glyceryl stearate, glycerin, vitamin B3, niacinamide, phenoxyethanol2024-11-29 10:47:42
Shikai Very Clean Hand Cream Milk & Honey -- 2 fl ozShikaiBeauty & Personal Carebutylene glycol, allantoin, vitamin C, cetyl alcohol, tocopherol, and, beta-glucan, tocopherol, vitamin E, glyceryl stearate, glycerin, oat, phenoxyethanol2024-11-29 10:47:42
Silk Almondmilk Vanilla -- 6 ContainersSilkFood & Beveragesvitamin E acetate, Vitamin E, Vitamin E, calcium carbonate, vitamin A palmitate, Vitamin A, cane sugar, vitamin D22024-11-29 10:47:42
Silk Almondmilk Unsweetened Vanilla -- 1 qtSilkFood & Beveragesvitamin E acetate, Vitamin E, Vitamin E, calcium carbonate, vitamin A palmitate, Vitamin A, vitamin D22024-11-29 10:47:42
Simple Truth Immunity Support Juice -- 32 fl ozSimple TruthFood & BeveragesD-alpha-tocopheryl acetate, Vitamin C, Vitamin E, vitamin E, vitamin A palmitate, Vitamin A2024-11-29 10:47:42
Sky Organics African Black Soap Bar -- 16 ozSky OrganicsBeauty & Personal Carepalm, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Sky Organics Flaxseed & Castor Oil Essential Scalp Elixir -- 6 fl ozSky OrganicsBeauty & Personal Caretocopherol, tocopherol, vitamin e2024-11-29 10:47:42
Sky Organics Organic Age Embrace Oil Serum -- 1 fl ozSky OrganicsBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Sky Organics Organic Castor Oil GroPotion -- 6 fl ozSky OrganicsBeauty & Personal Carevitamin B-7, tocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Sky Organics Organic Coconut Oil Vitamin E Infused -- 16.9 fl ozSky OrganicsBeauty & Personal Carevitamin E, vitamin E2024-11-29 10:47:42
Sky Organics Organic Shea Butter Stick -- 2.3 ozSky OrganicsBeauty & Personal Caretocopherol, tocopherol, vitamin e2024-11-29 10:47:42
Sky Organics Vitamin C Bright Glow Oil Serum -- 1 fl ozSky OrganicsBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42
Sky Organics Vitamin E Oil -- 36,000 IU - 4 fl ozSky OrganicsBeauty & Personal Caretocopherol, tocopherol, vitamin e2024-11-29 10:47:42
SmartyPants Adult Complete and Fiber -- 180 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, annatto, Vitamin C, Choline, citric acid, Vitamin E, EPA, Folate, Vitamin E, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
SmartyPants Adult Fomula Multivitamin -- 180 GummiesSmartyPantsVitamins & Supplementscitric acid, Vitamin C, Choline, citric acid, Vitamin E, Folate, Vitamin E, Iodine, Vitamin K2, Vitamin K2, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
SmartyPants Adult Mineral Complete Mixed Berry -- 60 ChewablesSmartyPantsVitamins & Supplementscitric acid, Vitamin C, Boron, Chromium, citric acid, Vitamin E, Vitamin E, glycerin, Manganese, Molybdenum, Selenium, Vitamin K2024-11-29 10:47:42
SmartyPants Kids Formula Cherry Berry -- 120 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Choline, citric acid, Vitamin E, EPA, Folate, Vitamin E, Inositol, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
SmartyPants Kids Mineral Complete Mixed Berry -- 60 ChewablesSmartyPantsVitamins & SupplementsVitamin C, Chromium, Vitamin E, Vitamin E, Manganese, Molybdenum, Selenium2024-11-29 10:47:42
SmartyPants Kids Multi and Fiber Gummies -- 120 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Biotin, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
SmartyPants Organic Prenatal Multi & Omegas Gummies -- 120 Vegetarian GummiesSmartyPantsVitamins & SupplementsL-methylfolate, Vitamin C, Biotin, Omega-3, Choline, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin K2, Vitamin K2, Niacin, Vitamin B6, retinyl palmitate, Vitamin A, Riboflavin, Selenium, sodium citrate, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
SmartyPants Organics Kids Formula -- 120 Vegetarian GummiesSmartyPantsVitamins & SupplementsL-methylfolate, Vitamin C, Omega-3, Vitamin E, Folate, Vitamin E, Iodine, Vitamin K2, Vitamin K2, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, sodium citrate, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
SmartyPants Organics Toddler Formula -- 60 Vegetarian GummiesSmartyPantsVitamins & SupplementsL-methylfolate, Vitamin C, Omega-3, Choline, Vitamin E, Folate, Vitamin E, Iodine, Vitamin K2, Vitamin K2, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, sodium citrate, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
SmartyPants Prenatal Multi & Omegas Gummies -- 120 GummiesSmartyPantsVitamins & Supplementscitric acid, Vitamin C, Biotin, Choline, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Niacin, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
SmartyPants Sugar Free Kids Multi & Omegas -- 44 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Biotin, Omega-3, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, allulose, Vitamin B6, Vitamin A, Riboflavin, sodium citrate, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
SmartyPants Teen Girl Multi & Omegas Gummies -- 120 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Biotin, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Vitamin B6, retinyl palmitate, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
SmartyPants Teen Guy Multi & Omegas Gummies -- 120 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Biotin, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Vitamin B6, retinyl palmitate, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
SmartyPants Toddler Multi & Omegas Gummies -- 90 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Biotin, Choline, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin K2, Vitamin K2, Pantothenic Acid, Vitamin B6, retinyl palmitate, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Snap Supplements Liver Health -- 60 CapsulesSnap SupplementsVitamins & SupplementsVitamin C, Choline, Vitamin E, Vitamin E, Selenium2024-11-29 10:47:42
So Delicious Dairy Free Almond Milk Unsweetened -- 32 fl ozSo DeliciousFood & Beveragesvitamin E acetate, ascorbic acid, Vitamin E, Vitamin E, calcium carbonate, vitamin A palmitate, Vitamin A, vitamin D22024-11-29 10:47:42
So Delicious Dairy Free Almond Milk Vanilla -- 32 fl ozSo DeliciousFood & Beveragesvitamin E acetate, Vitamin C, Vitamin E, Vitamin E, calcium carbonate, vitamin A palmitate, Vitamin A, cane sugar, vitamin D22024-11-29 10:47:42
SoapBox Body Wash Coconut & Goji Berry -- 20 fl ozSoapBoxBeauty & Personal Careacetic acid, benzyl alcohol, cocamidopropyl betaine, vitamin E, dehydroacetic acid, vitamin E, glycerin, niacinamide, phenoxyethanol2024-11-29 10:47:42
SoapBox Body Wash Cucumber & Yuzu Lemon -- 20 fl ozSoapBoxBeauty & Personal Careacetic acid, benzyl alcohol, cocamidopropyl betaine, vitamin e, dehydroacetic acid, vitamin e, glycerin, niacinamide, phenoxyethanol2024-11-29 10:47:42
SoapBox Body Wash Oat Milk & Lavender -- 20 fl ozSoapBoxBeauty & Personal Careacetic acid, benzyl alcohol, cocamidopropyl betaine, vitamin e, dehydroacetic acid, vitamin e, glycerin, niacinamide, oat, phenoxyethanol2024-11-29 10:47:42
SoapBox Body Wash Vanilla Bean & Fig -- 20 fl ozSoapBoxBeauty & Personal Careacetic acid, benzyl alcohol, cocamidopropyl betaine, vitamin E, dehydroacetic acid, vitamin E, glycerin, hexyl cinnamal, limonene, niacinamide, phenoxyethanol2024-11-29 10:47:42
SoapBox Body Wash Watermelon & Peony -- 20 fl ozSoapBoxBeauty & Personal Careacetic acid, benzyl alcohol, cocamidopropyl betaine, vitamin e, dehydroacetic acid, peony, vitamin e, glycerin, niacinamide, phenoxyethanol2024-11-29 10:47:42
SoapBox Conditioner Control & Soften Argan Oil -- 16 fl ozSoapBoxBeauty & Personal Carecitric acid, benzyl alcohol, cetyl alcohol, citric acid, vitamin E, panthenol, vitamin E, glycerin, stearyl alcohol2024-11-29 10:47:42
SoapBox Conditioner Moisture & Nourish Coconut Oil -- 16 fl ozSoapBoxBeauty & Personal Carecitric acid, benzyl alcohol, cetyl alcohol, citric acid, vitamin E, dehydroacetic acid, panthenol, vitamin E, glycerin, stearyl alcohol2024-11-29 10:47:42
SoapBox Conditioner Tea Tree -- 16 fl ozSoapBoxBeauty & Personal Carecitric acid, benzyl alcohol, cetyl alcohol, citric acid, vitamin E, dehydroacetic acid, panthenol, vitamin E, glycerin, stearyl alcohol2024-11-29 10:47:42
Solgar Formula VM-75® Iron-Free -- 180 TabletsSolgarVitamins & Supplementsalpha carotene, Vitamin C, Betaine HCl, Biotin, Boron, Choline, Chromium, cryptoxanthin, Vitamin E, Folic Acid, Vitamin E, Hesperidin, Microcrystalline cellulose, Inositol, Iodine, calcium carbonate, lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, titanium dioxide, Vitamin B12, Vitamin B6, zeaxanthin, zinc oxide2024-11-29 10:47:42
Solgar Natural Source Vitamin E -- 670 mg (1000 IU) - 100 SoftgelsSolgarVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Solgar Vitamin E -- 67 mg - 100 SoftgelsSolgarVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Solgar Vitamin E Complex -- 200 IU - 100 SoftgelsSolgarVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Solgar Vitamin E Complex -- 400 IU - 250 SoftgelsSolgarVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Solgar Vitamin E D-Alpha Tocopherol plus D-Beta, D-Delta and D-Gamma Tocopherols -- 268 mg - 100 SoftgelsSolgarVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Solgar Vitamin E Liquid -- 2 fl ozSolgarVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Solgar Vitamin E Pure D-Alpha Tocopherol -- 268 mg (400 IU) - 100 SoftgelsSolgarVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Soothing Touch Ayurveda Body Lotion Desert Sage -- 32 fl ozSoothing TouchBeauty & Personal Caregeranium, allantoin, chamomile, vitamin E, and, tocopherol, vitamin E, glycerin, phenoxyethanol, stearic acid2024-11-29 10:47:42
Soothing Touch Ayurveda Body Lotion Fresh Citrus -- 32 fl ozSoothing TouchBeauty & Personal Careallantoin, chamomile, vitamin E, and, tocopherol, vitamin E, glycerin, phenoxyethanol, stearic acid2024-11-29 10:47:42
Soothing Touch Ayurveda Body Lotion Island Coconut -- 32 fl ozSoothing TouchBeauty & Personal Careallantoin, chamomile, vitamin E, and, tocopherol, vitamin E, glycerin, phenoxyethanol, stearic acid2024-11-29 10:47:42
Soothing Touch Ayurveda Body Lotion Naked -- 32 fl ozSoothing TouchBeauty & Personal Careallantoin, chamomile, vitamin E, and, tocopherol, vitamin E, glycerin, phenoxyethanol, stearic acid2024-11-29 10:47:42
Soothing Touch Ayurveda Body Lotion Rose Petal -- 32 fl ozSoothing TouchBeauty & Personal Careallantoin, chamomile, vitamin E, and, tocopherol, vitamin E, glycerin, phenoxyethanol, stearic acid2024-11-29 10:47:42
Soothing Touch Lip Balm - Coconut Lime -- 0.25 ozSoothing TouchBeauty & Personal CareVitamin E, Tocopherol, Vitamin E2024-11-29 10:47:42
Soothing Touch Lip Balm - Grapefruit & Vitamin C -- 0.25 ozSoothing TouchBeauty & Personal CareVitamin E, Tocopherol, Vitamin E2024-11-29 10:47:42
Soothing Touch Lip Balm - Lavender Coconut -- 0.25 ozSoothing TouchBeauty & Personal Carevitamin e, tocopherol, vitamin e2024-11-29 10:47:42
Soothing Touch Lip Balm - Lemon Cardamom -- 0.25 ozSoothing TouchBeauty & Personal CareVitamin E, Tocopherol, Vitamin E2024-11-29 10:47:42
Soothing Touch Lip Balm - Peppermint -- 0.25 ozSoothing TouchBeauty & Personal CareVitamin E, Tocopherol, Vitamin E2024-11-29 10:47:42
Soothing Touch Lip Balm - Pomegranate -- 0.25 ozSoothing TouchBeauty & Personal CareVitamin E, Tocopherol, Vitamin E2024-11-29 10:47:42
Soothing Touch Lip Balm - Unscented -- 0.25 ozSoothing TouchBeauty & Personal CareVitamin E, Tocopherol, Vitamin E2024-11-29 10:47:42
Soothing Touch Lip Balm - Vanilla Chai -- 0.25 ozSoothing TouchBeauty & Personal Carevitamin e, tocopherol, vitamin e2024-11-29 10:47:42
Soothing Touch Lip Balm - Vanilla Rose -- 0.25 ozSoothing TouchBeauty & Personal Carevitamin e, tocopherol, vitamin e2024-11-29 10:47:42
Source Naturals DIM -- 200 mg - 120 TabletsSource NaturalsVitamins & SupplementsDiindolylmethane, Vitamin E, Vitamin E, Microcrystalline cellulose, stearic acid2024-11-29 10:47:42
Source Naturals DIM -- 200 mg - 60 TabletsSource NaturalsVitamins & SupplementsDiindolylmethane, Vitamin E, Vitamin E, Microcrystalline cellulose, stearic acid2024-11-29 10:47:42
Source Naturals Life Force™ Multiple No Iron -- 180 CapsulesSource NaturalsVitamins & SupplementsN-Acetyl L-Cysteine, Vitamin C, Astaxanthin, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, Vitamin E, DMAE, Folate, Vitamin E, microcrystalline cellulose, Inositol, Iodine, calcium carbonate, Lutein, Lycopene, Manganese, Molybdenum, N-Acetyl-L-Tyrosine, Niacin, Pantethine, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Source Naturals Wellness Fizz™ Natural Berry -- 10 WafersSource NaturalsVitamins & Supplementscitric acid, Vitamin C, citric acid, Vitamin E, Vitamin E, Vitamin A, Selenium, tartaric acid2024-11-29 10:47:42
Southern Butter Backdoor Balm -- 1.82 ozSouthern ButterBeauty & Personal Carecalendula, comfrey, vitamin E, vitamin E2024-11-29 10:47:42
Southern Butter Enhance Stimulating Butter -- 1.82 ozSouthern ButterBeauty & Personal Carecalendula, vitamin E, vitamin E2024-11-29 10:47:42
Southern Butter Intimate Body Butter - Fragrance Free -- 1.82 ozSouthern ButterBeauty & Personal Carecalendula, vitamin E, vitamin E2024-11-29 10:47:42
Southern Butter Intimate Body Butter - Rose + Lavender -- 1.82 ozSouthern ButterBeauty & Personal Caregeranium, calendula, vitamin E, vitamin E2024-11-29 10:47:42
Southern Butter Intimate Body Butter - Sandalwood + Cinnamon -- 1.82 ozSouthern ButterBeauty & Personal Carecalendula, vitamin E, vitamin E, vanilla2024-11-29 10:47:42
Spinster Sisters Co. Body Butter Lavender -- 2 ozSpinster Sisters Co.Beauty & Personal Carevitamin E, vitamin E, stearic acid2024-11-29 10:47:42
Spinster Sisters Co. Body Butter Lemon Grass & Sage -- 2 ozSpinster Sisters Co.Beauty & Personal Caretocopherol, tocopherol, vitamin E, stearic acid2024-11-29 10:47:42
Spinster Sisters Co. Body Butter Oatmeal Milk & Honey -- 2 ozSpinster Sisters Co.Beauty & Personal Carevitamin E, vitamin E, stearic acid2024-11-29 10:47:42
Spinster Sisters Co. Body Butter Pomegranate -- 2 ozSpinster Sisters Co.Beauty & Personal Caretocopherol, tocopherol, vitamin E, stearic acid2024-11-29 10:47:42
Spinster Sisters Co. Vitamin E & Sea Buckthorn Face Cream -- 2 ozSpinster Sisters Co.Beauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin, stearic acid2024-11-29 10:47:42
Sprout Organic Baby Food Wafflez Blueberry Apple -- 5 PiecesSprout Organic Baby FoodBaby & Kids ProductsVitamin E, Folate, Vitamin E, Niacin, Thiamin2024-11-29 10:47:42
Sprout Organic Baby Food Wafflez Oatmeal Chocolate Chip -- 5 PiecesSprout Organic Baby FoodBaby & Kids ProductsVitamin E, Folate, Vitamin E, Niacin, Thiamin2024-11-29 10:47:42
Sprout Organic Baby Food Wafflez Pumpkin Butter & Jelly -- 5 PiecesSprout Organic Baby FoodBaby & Kids ProductsVitamin E, Folate, Vitamin E, Niacin, Thiamin2024-11-29 10:47:42
Sprout Revolution Organic Sprouted Ground Flax Blueberry -- 16 ozSprout RevolutionFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Sprout Revolution Organic Sprouted Ground Flax Original -- 16 ozSprout RevolutionFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B, Vitamin B6, Vitamin A, Vitamin B62024-11-29 10:47:42
Sprout Revolution Premium Organic Sprouted Ground Flax -- 8 ozSprout RevolutionFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Stonewall Home Liquid Hand Soap - Balsam Woods -- 17.5 fl ozStonewall HomeHousehold Essentialsvitamin E, vitamin E, coco betaine2024-11-29 10:47:42
Stonewall Home Liquid Hand Soap - Cashmere -- 17.5 fl ozStonewall HomeHousehold Essentialsvitamin E, vitamin E, coco betaine2024-11-29 10:47:42
Stonewall Home Liquid Hand Soap - Honey Vanilla -- 17.5 fl ozStonewall HomeHousehold Essentialsvitamin E, vitamin E, coco betaine2024-11-29 10:47:42
Stonewall Kitchen Liquid Hand Soap Coastal Breeze -- 16.9 fl ozStonewall KitchenHousehold Essentialsvitamin E, vitamin E, coco betaine2024-11-29 10:47:42
Stonewall Kitchen Liquid Hand Soap Herbes de Provence -- 16.9 fl ozStonewall KitchenHousehold Essentialsgreen 5, vitamin E, vitamin E, coco betaine2024-11-29 10:47:42
Stonewall Kitchen Liquid Hand Soap Lake House -- 16.9 fl ozStonewall KitchenHousehold Essentialsgreen 5, red 40, vitamin E, vitamin E, coco betaine2024-11-29 10:47:42
Stur Water Enhancer with Stevia Honestly Lemonade -- 1.9 fl ozSturFood & Beveragescitric acid, citric acid, Vitamin E, Vitamin E, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, sodium benzoate, sodium citrate, Sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Sukin Antioxidant Eye Serum -- 1.01 fl ozSukinBeauty & Personal Carecitric acid, cetearyl alcohol, cetyl alcohol, citric acid, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Sukin Botanical Body Wash Bergamot & Patchouli -- 16.9 fl ozSukinBeauty & Personal Carecitric acid, chamomile, benzyl alcohol, citric acid, cocamidopropyl betaine, tocopherol, decyl glucoside, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Sukin Botanical Body Wash Lime & Coconut -- 16.9 fl ozSukinBeauty & Personal Carecitric acid, chamomile, benzyl alcohol, citric acid, cocamidopropyl betaine, tocopherol, decyl glucoside, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Sukin Botanical Body Wash Original Signature Scent -- 16.9 fl ozSukinBeauty & Personal Carechamomile, benzyl alcohol, cocamidopropyl betaine, tocopherol, decyl glucoside, tocopherol, vitamin e, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Cream Cleanser Pump Signature -- 4.23 fl ozSukinBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Deep Cleanse Shampoo - Hair Care -- 16.9 fl ozSukinBeauty & Personal Carecitric acid, benzyl alcohol, citric acid, cocamidopropyl betaine, tocopherol, tocopherol, vitamin E, glycerin, lactic acid, menthol, phenoxyethanol, sodium benzoate, sorbitol2024-11-29 10:47:42
Sukin Facial Moisturizer Pump Signature -- 4.23 fl ozSukinBeauty & Personal Carecitric acid, benzyl alcohol, cetearyl alcohol, cetyl alcohol, citric acid, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Foaming Facial Cleanser Pump Signature -- 4.23 flSukinBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Hydrating Body Lotion Bergamot & Patchouli -- 16.9 fl ozSukinBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Sukin Hydrating Body Lotion Lime & Coconut -- 16.9 fl ozSukinBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin e, glycerin, phenoxyethanol2024-11-29 10:47:42
Sukin Hydrating Body Lotion Original Signature Scent -- 16.91 fl ozSukinBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Hydrating Conditioner -- 16.9 fl ozSukinBeauty & Personal Careisopropyl alcohol, citric acid, benzyl alcohol, cetyl alcohol, citric acid, tocopherol, tocopherol, vitamin e, glycerin, phenoxyethanol2024-11-29 10:47:42
Sukin Hydrating Replenishing Hair Masque -- 6.7 fl ozSukinBeauty & Personal Carecitric acid, benzyl alcohol, cetearyl alcohol, citric acid, tocopherol, tocopherol, vitamin E, phenoxyethanol2024-11-29 10:47:42
Sukin Hydrating Shampoo -- 16.9 fl ozSukinBeauty & Personal Carecitric acid, benzyl alcohol, citric acid, cocamidopropyl betaine, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Sukin Moisture Restoring Night Cream Signature -- 4.06 fl ozSukinBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin e, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Natural Balance Conditioner -- 16.9 fl ozSukinBeauty & Personal Careisopropyl alcohol, citric acid, benzyl alcohol, cetyl alcohol, citric acid, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Natural Balance Shampoo -- 16.9 fl ozSukinBeauty & Personal Carecitric acid, benzyl alcohol, citric acid, cocamidopropyl betaine, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Purely Ageless Rejuvenating Day Cream -- 4.06 fl ozSukinBeauty & Personal Carebenzyl alcohol, cetyl alcohol, tocopherol, ethylhexylglycerin, tocopherol, vitamin e, glyceryl stearate, glycerin, lactic acid, phenoxyethanol, ribose, sodium benzoate, vanillin2024-11-29 10:47:42
Sukin Purely Ageless Restorative Night Cream -- 4.06 fl ozSukinBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin e, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Rosehip Enriching Night Cream -- 4.06 fl ozSukinBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Rosehip Hydrating Day Cream -- 4.06 fl ozSukinBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Sensitive Calming Night Cream -- 4.06 fl ozSukinBeauty & Personal Carechamomile, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Sensitive Facial Moisturizer -- 4.23 fl ozSukinBeauty & Personal Carechamomile, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Signature Revitalising Facial Scrub -- 4.23 fl ozSukinBeauty & Personal Carecitric acid, chamomile, benzyl alcohol, cetearyl alcohol, cetyl alcohol, citric acid, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol, vanillin2024-11-29 10:47:42
Sukin Super Greens Detoxifying Facial Scrub -- 4.23 fl ozSukinBeauty & Personal Carecitric acid, cetearyl alcohol, cetyl alcohol, citric acid, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Sukin Super Greens Facial Recovery Serum -- 1.01 fl ozSukinBeauty & Personal Carebenzyl alcohol, tocopherol, tocopherol, vitamin E, glyceryl stearate, glycerin, lactic acid, phenoxyethanol2024-11-29 10:47:42
Sukin Super Greens Nutrient Rich Facial Moisturizer -- 4.23 fl ozSukinBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Sukin Volumising Conditioner -- 16.9 fl ozSukinBeauty & Personal Careisopropyl alcohol, citric acid, cetyl alcohol, citric acid, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
Sukin Volumising Shampoo -- 16.9 fl ozSukinBeauty & Personal Carecitric acid, citric acid, cocamidopropyl betaine, tocopherol, tocopherol, vitamin E, glycerin, phenoxyethanol2024-11-29 10:47:42
SUKU Vitamins Luscious Hair -- 50 GummiesSUKU VitaminsVitamins & Supplementscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Folate, Vitamin E, Silicon, sodium citrate2024-11-29 10:47:42
SUKU Vitamins Teen Boy Total Multi Blueberry & Grape -- 60 Pectin GummiesSUKU VitaminsVitamins & Supplementscitric acid, L-5-Methyltetrahydrofolate, agar, Vitamin C, Biotin, Vitamin D3, Choline, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin K2, Vitamin K2, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
SUKU Vitamins Teen Girl Total Multi Wild Cherry -- 60 Pectin GummiesSUKU VitaminsVitamins & Supplementscitric acid, L-5-Methyltetrahydrofolate, agar, Vitamin C, Biotin, Vitamin D3, Choline, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin K2, Vitamin K2, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
SUKU Vitamins The Complete Kids Multi Gummy Vitamin Tropical Bonanza -- 60 GummiesSUKU VitaminsVitamins & Supplementscitric acid, agar, Vitamin C, beta-carotene, Biotin, Choline, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, sodium citrate, Vitamin B12, Vitamin B62024-11-29 10:47:42
SUKU Vitamins The Complete Prenatal Multi Pineapple & Peach -- 60 Pectin GummiesSUKU VitaminsVitamins & Supplementscitric acid, L-5-Methyltetrahydrofolate, agar, Vitamin C, Biotin, Vitamin D3, Choline, citric acid, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin K2, Vitamin K2, Niacinamide, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
SunButter Sunflower Butter On the Go Cups Creamy -- 6 CupsSunButterFood & BeveragesVitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Sugar, Vitamin B62024-11-29 10:47:42
Sundown Naturals Vitamin E -- 180 mg - 100 SoftgelsSundown NaturalsVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
SunFood Organic Black Peruvian Botija Olives Pitted -- 8 ozSunFoodFood & BeveragesVitamin C, Vitamin E, Vitamin E, Vitamin A2024-11-29 10:47:42
SunFood Raw Organic Heirloom Almonds -- 8 ozSunFoodFood & BeveragesVitamin E, Vitamin E2024-11-29 10:47:42
SunFood Raw Organic Maca Extreme -- 8 ozSunFoodHerbs, Botanicals & HomeopathyVitamin C, Vitamin E, Vitamin E, Phosphorus, Vitamin A, Vitamin B2, Vitamin B12024-11-29 10:47:42
Sunshine Beverages Sparkling Energy Drink Clementine Twist -- 4 CansSunshine BeveragesFood & Beveragescitric acid, alpha tocopheryl acetate, Vitamin C, beta carotene, calcium pantothenate, citric acid, Vitamin E, Vitamin E, malic acid, maltodextrin, Niacin, niacinamide, Pantothenic Acid, potassium citrate, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, cane sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Sunwarrior Harvest Hemp Protein Powder Unflavored -- 26.4 ozSunwarriorVitamins & SupplementsAlanine, Arginine, Aspartic Acid, Cystine, Vitamin E, Vitamin E, Glutamic Acid, Glycine, Histidine, Isoleucine, Leucine, Lysine, Manganese, Methionine, Niacin, Phenylalanine, Phosphorus, Proline, Vitamin B6, Serine, Thiamin, Threonine, Tryptophan, Tyrosine, Vitamin B62024-11-29 10:47:42
Sunwarrior Illumni8 Lean Meal Superfood Shake Chocolate -- 25.3 ozSunwarriorWeight Managementorange, Vitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, vitamin B12, Vitamin B62024-11-29 10:47:42
Sunwarrior Vitamin Mineral Rush In Aloe Superjuice -- 30 fl ozSunwarriorHerbs, Botanicals & Homeopathy Orange, Vitamin C, Biotin, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Vitamin B6, stevia, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Swolverine Multivitamin -- 60 CapsulesSwolverineActive Lifestyle & FitnessVitamin C, Biotin, Boron, Chloride, Vitamin D3, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Tartar Shield Dog Biscuits Daily Dental Treat Chicken -- 26 ozTartar ShieldPet Suppliescalcium pantothenate, vitamin d3, choline chloride, copper sulfate, vitamin e, ferrous sulfate, folic acid, vitamin e, calcium carbonate, malic acid, niacin, potassium chloride, pyridoxine hydrochloride, vitamin a, riboflavin, sodium selenite, vitamin b12, zinc oxide2024-11-29 10:47:42
Tartar Shield PRO CARE Natural Enzymatic Toothpaste for Dogs & Cats Coconut -- 3 ozTartar ShieldPet Suppliestocopherol, tocopherol, vitamin E, glycerin, kaolin, malic acid2024-11-29 10:47:42
Tartar Shield PRO CARE Natural Enzymatic Toothpaste Kit for Dogs & Cats Coconut -- 1 SetTartar ShieldPet Suppliestocopherol, tocopherol, vitamin E, glycerin, kaolin, malic acid2024-11-29 10:47:42
Terry Naturally Clinical Essentials Multi-Vitamin & Minerals -- 60 TabletsTerry NaturallyVitamins & SupplementsPABA, citric acid, Vitamin C, Benfotiamine, Biotin, Boron, calcium ascorbate, calcium fructoborate, dicalcium phosphate, Vitamin D3, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, glycerol monostearate, glycine, Microcrystalline cellulose, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Terry Naturally DIM Complex -- 30 CapsulesTerry NaturallyVitamins & Supplements Vitamin E, Vitamin E, Cellulose powder2024-11-29 10:47:42
Terry Naturally Sucontral D Blood Sugar Balance -- 120 CapsulesTerry NaturallyVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Cellulose powder, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Terry Naturally Sucontral D Blood Sugar Balance -- 60 CapsulesTerry NaturallyVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Cellulose powder, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
The Good Crisp Company Gluten Free Potato Crisp Aged White Cheddar -- 5.6 ozThe Good Crisp CompanyFood & Beveragescitric acid, citric acid, vitamin E, vitamin E, lactic acid, maltodextrin2024-11-29 10:47:42
The Good Crisp Company Gluten Free Potato Crisp Classic Original -- 5.6 ozThe Good Crisp CompanyFood & Beveragesvitamin E, vitamin E, sugar2024-11-29 10:47:42
The Good Crisp Company Gluten Free Potato Crisp Outback BBQ -- 5.6 ozThe Good Crisp CompanyFood & Beveragescitric acid, citric acid, vitamin e, vitamin e, sugar2024-11-29 10:47:42
The Good Crisp Company Gluten Free Potato Crisps Sea Salt & Vinegar -- 5.6 ozThe Good Crisp CompanyFood & Beveragescitric acid, vinegar, citric acid, vitamin E, vitamin E, lactic acid, maltodextrin, sugar, tartaric acid2024-11-29 10:47:42
The Good Crisp Company Gluten Free Potato Crisps Sour Cream & Onion -- 5.6 ozThe Good Crisp CompanyFood & Beveragescitric acid, citric acid, vitamin E, vitamin E, malic acid, sugar2024-11-29 10:47:42
The Good Crisp Company Gluten Free Potato Crisps Spicy Jalapeno -- 5.6 ozThe Good Crisp CompanyFood & Beveragesvitamin E, vitamin E, sugar2024-11-29 10:47:42
The Honey Pot Boric Acid & Herbs Suppositories plus Applicator -- 14 SuppositoriesThe Honey PotBeauty & Personal Careboric acid, vitamin E, vitamin E, glyceryl behenate2024-11-29 10:47:42
The Honey Pot Sensual Stimulating Serum -- 1 fl ozThe Honey PotBeauty & Personal Careiodopropynyl butylcarbamate, allantoin, bisabolol, chlorphenesin, vitamin E, vitamin E, dimethicone, hydroxyethylcellulose, propylene glycol2024-11-29 10:47:42
The Seaweed Bath Co Active Defense Cream SPF 50 -- 3.4 fl ozThe Seaweed Bath CoBeauty & Personal Careoctisalate, citric acid, benzyl alcohol, cetearyl alcohol, citric acid, vitamin E, decyl glucoside, dehydroacetic acid, vitamin E, glyceryl stearate, glycerin, hydroxyethylcellulose, zinc oxide2024-11-29 10:47:42
The Seaweed Bath Co Clear Guard SPF 40 Sport -- 6 fl ozThe Seaweed Bath CoBeauty & Personal Careoctisalate, vitamin E, vitamin E, methyl abietate, octocrylene2024-11-29 10:47:42
The Seaweed Bath Co Collagen Hand Cream -- 2 fl ozThe Seaweed Bath CoBeauty & Personal Careallantoin, cetyl alcohol, tocopherol, panthenol, triethyl citrate, tocopherol, vitamin E, glyceryl stearate, glycerin, sodium benzoate, stearyl alcohol2024-11-29 10:47:42
The Seaweed Bath Co Daily Protection Cream SPF 30 -- 3.4 fl ozThe Seaweed Bath CoBeauty & Personal Careoctisalate, citric acid, benzyl alcohol, cetearyl alcohol, citric acid, vitamin E, decyl glucoside, dehydroacetic acid, vitamin E, glyceryl stearate, glycerin, hydroxyethylcellulose, zinc oxide2024-11-29 10:47:42
The Seaweed Bath Co Detox Body Scrub - Rosemary Mint -- 1.5 fl ozThe Seaweed Bath CoBeauty & Personal Carecocamidopropyl betaine, vitamin e, triethyl citrate, ethylhexylglycerin, vitamin e, glycerin, illite, kaolin, phenethyl alcohol, montmorillonite, sodium hydroxide2024-11-29 10:47:42
The Seaweed Bath Co Everyday Mineral SPF 40 -- 3.4 fl ozThe Seaweed Bath CoBeauty & Personal Carecitric acid, benzyl alcohol, cetearyl alcohol, citric acid, vitamin E, decyl glucoside, dehydroacetic acid, vitamin E, glyceryl stearate, glycerin, hydroxyethylcellulose, dodecane, propanediol2024-11-29 10:47:42
The Seaweed Bath Co Firming Body Cream with chlorella & Green Coffee -- 1.5 fl ozThe Seaweed Bath CoBeauty & Personal Careallantoin, benzyl alcohol, carbomer, tocopherol, dehydroacetic acid, panthenol, triethyl citrate, tocopherol, vitamin E, glyceryl stearate, glycerin, vitamin B-5, stearic acid, stearyl alcohol, tromethamine2024-11-29 10:47:42
The Seaweed Bath Co Fortify & Protect Super Sheer Face Serum SPF 50 -- 1.1 fl ozThe Seaweed Bath CoBeauty & Personal Carecaprylyl glycol, citric acid, chamomile, ascorbic acid, cetearyl alcohol, citric acid, cocamidopropyl betaine, tocopherol, tocopherol, vitamin E, glycerin, glyceryl laurate, dodecane, squalane2024-11-29 10:47:42
The Seaweed Bath Co Gentle Conditioner - Unscented -- 12 fl ozThe Seaweed Bath CoBeauty & Personal Carecetylalcohol, tocopherol, ethylhexylglycerin, tocopherol, vitamin E, glyceryl stearate, glycerin, sodium benzoate, sorbitol, stearyl alcohol2024-11-29 10:47:42
The Seaweed Bath Co Heat Care Conditioner - Lime Papaya -- 12 fl ozThe Seaweed Bath CoBeauty & Personal Carecitric acid, ascorbic acid, astaxanthin, cetearyl alcohol, cetyl alcohol, citric acid, tocopherol, panthenol, ectoin, ethyl linoleate, ethyl oleate, ethylhexylglycerin, tocopherol, vitamin E, glyceryl stearate, glycerin, vitamin B5, sodium phosphate, sodium benzoate, trehalose, xylitol2024-11-29 10:47:42
The Seaweed Bath Co Heat Care Shampoo - Lime Papaya -- 12 fl ozThe Seaweed Bath CoBeauty & Personal Carecitric acid, ascorbic acid, astaxanthin, cetearyl alcohol, cetyl alcohol, citric acid, tocopherol, panthenol, ectoin, ethyl linoleate, ethyl oleate, ethylhexylglycerin, tocopherol, vitamin E, glyceryl stearate, glycerin, vitamin B5, sodium phosphate, sodium benzoate, trehalose, xylitol2024-11-29 10:47:42
The Seaweed Bath Co Hydrate & Protect Dewy Skin Face Lotion SPF 30 -- 2 fl ozThe Seaweed Bath CoBeauty & Personal Carecitric acid, allantoin, vitamin C, betaine, bisabolol, citric acid, vitamin E, basil, vitamin E, glyceryl stearate, glycerin, glyceryl caprylate, niacinamide, squalane2024-11-29 10:47:42
The Seaweed Bath Co Hydrate Body Cream - Unscented -- 1.5 fl ozThe Seaweed Bath CoBeauty & Personal Careallantoin, benzyl alcohol, carbomer, tocopherol, dehydroacetic acid, panthenol, tocopherol, vitamin E, glyceryl stearate, glycerin, vitamin B5, stearic acid, stearyl alcohol, tromethamine2024-11-29 10:47:42
TheraNeem Naturals Conditioner -- 12 fl ozTheraNeemBeauty & Personal Carecetearyl alcohol, tocopherol, panthenol, tocopherol, vitamin E2024-11-29 10:47:42
TheraNeem Naturals Neem Cream Orange & Ylang Ylang -- 2 ozTheraNeemBeauty & Personal Careorange, tocopherol, ethylhexyl glycerin, tocopherol, vitamin E, glycerin, phenoxyethanol, stearic acid2024-11-29 10:47:42
TheraNeem Neem Cream Original Vanilla -- 2 fl ozTheraNeemBeauty & Personal CareTocopherol, Ethylhexyl Glycerin, Tocopherol, Vitamin E, Glycerin, Phenoxyethanol, Stearic Acid2024-11-29 10:47:42
ThinkKids Sunscreen Lotion Clear Zinc SPF 50 -- 6 fl ozThinkKidsBaby & Kids Productsascorbic acid, vitamin E, vitamin E, magnesium sulfate, tocopherols2024-11-29 10:47:42
Thinksport Sunscreen SPF 50 plus -- 3 fl ozThinksportBeauty & Personal Careascorbic acid, vitamin E, vitamin E, dimethicone, magnesium sulfate, methyl abietate, tocopherols2024-11-29 10:47:42
Thompson All In One Multivitamin Iron Free -- 60 CapsulesThompsonVitamins & SupplementsVitamin C, Biotin, cellulose, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Thompson Multi Formula for Women -- 60 CapsulesThompsonVitamins & SupplementsVitamin C, Biotin, cellulose, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
Thompson Multi-Vitamin with Minerals -- 120 TabletsThompsonVitamins & SupplementsVitamin C, Cellulose, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, stearic acid, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Thompson Nuplex Multivitamin Multimineral with Iron -- 90 TabletsThompsonVitamins & SupplementsVitamin C, Cellulose, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, stearic acid, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Thompson Omega 3-6-9 -- 1200 mg - 120 CapsulesThompsonVitamins & SupplementsVitamin E, Vitamin E, glycerin2024-11-29 10:47:42
Thorne Research Basic Nutrient 2-Day -- 60 CapsulesThorne ResearchProfessional SupplementsVitamin C, Biotin, Boron, Calcium Pantothenate, dicalcium phosphate, Chromium, Vitamin E, Folate, d-Gamma Tocopherol, Vitamin E, Iodine, Lutein, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Thorne Research Basic Nutrients 2 Day - NSF Certified for Sport -- 60 CapsulesThorne ResearchProfessional SupplementsVitamin C, Biotin, Boron, Calcium Pantothenate, dicalcium phosphate, Chromium, Vitamin E, Folate, d-Gamma Tocopherol, Vitamin E, Iodine, Lutein, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Thorne Research Basic Prenatal -- 90 CapsulesThorne ResearchProfessional SupplementsVitamin C, Biotin, Boron, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Thorne Research D-1000 -- 90 CapsulesThorne ResearchProfessional Supplementsvitamin E, vitamin E, Microcrystalline cellulose, leucine2024-11-29 10:47:42
Thorne Research D-10000 -- 60 CapsulesThorne ResearchProfessional Supplementsvitamin E, vitamin E, Microcrystalline cellulose, leucine2024-11-29 10:47:42
Thorne Research D-5000 - NSF Certified for Sport -- 60 CapsulesThorne ResearchProfessional Supplementsvitamin E, vitamin E, Microcrystalline cellulose, leucine2024-11-29 10:47:42
Thorne Research Super EPA -- 90 Gel CapsThorne ResearchProfessional Supplementsvitamin E, EPA, vitamin E2024-11-29 10:47:42
Thorne Research Vitamin K -- 60 CapsulesThorne ResearchProfessional Supplementsvitamin E, vitamin E, Microcrystalline cellulose, Vitamin K2, Vitamin K2, Vitamin K1, Vitamin K2024-11-29 10:47:42
Timeless Skin Care Coenzyme Q10 Serum -- 1 fl ozTimeless Skin CareBeauty & Personal Carebenzylalcohol, vitamin E, vitamin E, glycerin, ubiquinone2024-11-29 10:47:42
Trace Minerals Research Liquid Multi Vitamin-Mineral Tropical Mixed Berry -- 30 fl ozTrace Minerals ResearchVitamins & Supplementscitric acid, Vitamin C, Biotin, Boron, Calcium Citrate, Vitamin D3, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Selenium, Thiamine, Tricalcium Phosphate, Vitamin B12, Vitamin B6, xylitol2024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 28 Servings Chocolate -- 2.6 lbsTransformHQActive Lifestyle & Fitnessd-alpha tocopheryl succinate, D-calcium pantothenate, vitamin D3, Vitamin E, Folate, vitamin E, Niacin, niacinamide, Pantothenic Acid, pyridoxine HCI, Vitamin B6, vitamin B2, Thiamin, vitamin B1, sucralose, vitamin B12, vitamin B62024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 28 Servings Chocolate Peanut Butter -- 2.5 lbsTransformHQActive Lifestyle & Fitnessd-alpha tocopheryl succinate, D-calcium pantothenate, vitamin D3, Vitamin E, Folate, vitamin E, Niacin, niacinamide, Pantothenic Acid, Phosphorus, pyridoxine HCI, Vitamin B6, vitamin B2, Thiamin, sucralose, vitamin B12, vitamin B62024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 28 Servings Cookies & Cream -- 2.7 lbsTransformHQActive Lifestyle & Fitnessd-alpha tocopheryl succinate, D-calcium pantothenate, vitamin D3, vitamin E, Folate, vitamin E, Niacin, niacinamide, Pantothenic Acid, Phosphorus, pyridoxine HCI, Vitamin B6, vitamin B2, Thiamin, sucralose, vitamin B12, vitamin B62024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 28 Servings Orange Cream -- 2.5 lbsTransformHQActive Lifestyle & Fitnessd-alpha tocopheryl succinate, D-calcium pantothenate, vitamin D3, Vitamin E, Folate, vitamin E, Niacin, niacinamide, Pantothenic Acid, Phosphorus, pyridoxine HCI, Vitamin B6, vitamin B2, Thiamin, sucralose, vitamin B12, vitamin B62024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 28 Servings Pineapple Whip -- 2.5 lbsTransformHQActive Lifestyle & Fitnessbeta-carotene, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, sucralose, Vitamin B12, Vitamin B62024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 28 Servings Strawberries & Cream -- 2.5 lbsTransformHQActive Lifestyle & Fitnessd-alpha tocopheryl succinate, D-calcium pantothenate, vitamin D3, vitamin E, Folate, vitamin E, Niacin, niacinamide, Pantothenic Acid, Phosphorus, pyridoxine HCI, Vitamin B6, vitamin B2, Thiamin, sucralose, vitamin B12, vitamin B62024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 28 Servings Vanilla -- 2.5 lbsTransformHQActive Lifestyle & Fitnessd-alpha tocopheryl succinate, D-calcium pantothenate, vitamin D3, Vitamin E, Folate, vitamin E, Niacin, niacinamide, Pantothenic Acid, pyridoxine HCI, Vitamin B6, vitamin B2, Thiamin, vitamin B1, sucralose, vitamin B12, vitamin B62024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 7 Servings Chocolate -- 10.5 ozTransformHQActive Lifestyle & Fitnessd-alpha tocopheryl succinate, D-calcium pantothenate, vitamin D3, Vitamin E, Folate, vitamin E, Niacin, niacinamide, Pantothenic Acid, pyridoxine HCI, Vitamin B6, vitamin B2, Thiamin, vitamin B1, sucralose, vitamin B12, vitamin B62024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 7 Servings Chocolate Peanut Butter -- 10.1 ozTransformHQActive Lifestyle & Fitnessd-alpha tocopheryl succinate, D-calcium pantothenate, vitamin D3, Vitamin E, Folate, vitamin E, Niacin, niacinamide, Pantothenic Acid, Phosphorus, pyridoxine HCI, Vitamin B6, vitamin B2, Thiamin, sucralose, vitamin B12, vitamin B62024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 7 Servings Cookies & Cream -- 11.1 ozTransformHQActive Lifestyle & Fitnessd-alpha tocopheryl succinate, D-calcium pantothenate, vitamin D3, vitamin E, Folate, vitamin E, Niacin, niacinamide, Pantothenic Acid, Phosphorus, pyridoxine HCI, Vitamin B6, vitamin B2, Thiamin, sucralose, vitamin B12, vitamin B62024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 7 Servings Strawberries & Cream -- 10.1 ozTransformHQActive Lifestyle & Fitnessd-alpha tocopheryl succinate, D-calcium pantothenate, vitamin D3, vitamin E, Folate, vitamin E, Niacin, niacinamide, Pantothenic Acid, Phosphorus, pyridoxine HCI, Vitamin B6, vitamin B2, Thiamin, sucralose, vitamin B12, vitamin B62024-11-29 10:47:42
TransformHQ Meal Replacement Shake - 7 Servings Vanilla -- 10 ozTransformHQActive Lifestyle & Fitnessd-alpha tocopheryl succinate, D-calcium pantothenate, vitamin D3, Vitamin E, Folate, vitamin E, Niacin, niacinamide, Pantothenic Acid, pyridoxine HCI, Vitamin B6, vitamin B2, Thiamin, vitamin B1, sucralose, vitamin B12, vitamin B62024-11-29 10:47:42
Tree to Tub Anti-Aging Retinol Body Lotion -- 8.5 fl ozTree to TubBeauty & Personal Carecaprylyl glycol, orange, cetearyl alcohol, palm, tocopherol, ethyl ferulate, tocopherol, vitamin E, glycerin, phenoxyethanol, propanediol, retinol, sodium benzoate, sodium hydroxide, succinic acid, urea2024-11-29 10:47:42
Tree to Tub Advanced Firming & Tightening Neck Cream -- 1.5 fl ozTree to TubBeauty & Personal Carecaprylyl glycol, betaine, palm, tocopherol, ethyl ferulate, tocopherol, vitamin E, glycerin, propanediol, retinol2024-11-29 10:47:42
Tree to Tub Anti Aging Hyaluronic Acid & Retinol Night Cream -- 1.7 ozTree to TubBeauty & Personal Carepalm, vitamin E, panthenol, vitamin E, glycerin, vitamin B5, retinol2024-11-29 10:47:42
Tree to Tub Anti-Aging Retinol Eye Cream for Sensitive Skin -- 0.5 fl ozTree to TubBeauty & Personal Carebetaine, palm, vitamin E, panthenol, vitamin E, glycerin, vitamin B5, retinol2024-11-29 10:47:42
Tree to Tub Biotin & Caffeine Volumizing Conditioner for Sensitive Scalp -- 8.5 fl ozTree to TubBeauty & Personal Carecaprylyl glycol, butylene glycol, citric acid, ascorbyl palmitate, vitamin c, vitamin B7, cetearyl alcohol, palm, citric acid, vitamin e, vitamin e, glycerin, lactic acid, menthol, glyceryl caprylate, pantothenic acid, propanediol, retinyl palmitate, vitamin A, sorbic acid, sugar2024-11-29 10:47:42
Tree to Tub Deep Hydrating Moisturizer for Sensitive Skin with Green Tea -- 1.7 ozTree to TubBeauty & Personal Careascorbic acid, vitamin E, panthenol, vitamin E, glycerin, vitamin b3, niacinamide, vitamin B52024-11-29 10:47:42
Tree to Tub Hydrating Hyaluronic Acid & Vegan Collagen Serum for Face -- 1 fl ozTree to TubBeauty & Personal Carecitric acid, citric acid, tocopherol, panthenol, triethyl citrate, tocopherol, vitamin E, glycerin, malic acid, pantolactone, vitamin b5, proline, propanediol, sodium benzoate, sodium citrate2024-11-29 10:47:42
Tree to Tub InstaGlow Vitamin C Face Moisturizer -- 1.5 fl ozTree to TubBeauty & Personal Care3-o-ethyl ascorbic acid, citric acid, ascorbyl glucoside, vitamin C, betaine, palm, citric acid, vitamin E, vitamin E, glycerin, trisodium ethylenediamine disuccinate, vitamin B3, niacinamide, sodium citrate2024-11-29 10:47:42
Tree to Tub Strengthening & Volumizing Caffeine and Biotin Shampoo and Conditioner Set -- 1 SetTree to TubBeauty & Personal Carecaprylyl glycol, butylene glycol, citric acid, ascorbyl palmitate, vitamin c, vitamin b7, cetearyl alcohol, palm, citric acid, cocamidopropyl betaine, vitamin e, decyl glucoside, vitamin e, glycerin, lactic acid, menthol, glyceryl caprylate, vitamin b3, niacinamide, pantothenic acid, propanediol, retinyl palmitate, vitamin a, sodium lauroyl sarcosinate, sodium benzoate, sorbic acid, sugar2024-11-29 10:47:42
Tree to Tub Volumizing Hair Spray Rice & Rosemary Water -- 3.4 fl ozTree to TubBeauty & Personal Carebutylene glycol, ascorbyl palmitate, allantoin, arginine, vitamin C, vitamin B7, caffeine, vitamin E, panthenol, ethylhexylglycerin, vitamin E, glycerin, pantothenic acid, propylene glycol, retinyl palmitate, vitamin A2024-11-29 10:47:42
Tree to Tub Witch Hazel Toner for Sensitive Skin with Green Tea & Ginseng -- 4 fl ozTree to TubBeauty & Personal Caregeranium, allantoin, chamomile, ascorbic acid, betaine, vitamin E, panthenol, vitamin E, glycerin, lactic acid, vitamin B5, sodium benzoate2024-11-29 10:47:42
Tropical Oasis Adult Multi-Vitamin Mineral -- 16 fl ozTropical OasisVitamins & SupplementsVitamin C, Biotin, Vitamin E, Folic Acid, Vitamin E, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Thiamin Hydrochloride, Vitamin B12, Vitamin B6, xylitol2024-11-29 10:47:42
Tropical Oasis Mega Premium Multi-Vitamin -- 32 fl ozTropical OasisVitamins & SupplementsPABA, Vitamin C, Biotin, Choline, CoQ10, Vitamin E, Folate, Vitamin E, Inositol, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Vitamin B2, Vitamin B1, Vitamin B12, Vitamin B6, xylitol2024-11-29 10:47:42
True Grace Prenatal Multivitamin -- 120 Vegan TabletsTrue GraceVitamins & SupplementsVitamin C, Biotin, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
True Grace Prenatal Multivitamin -- 60 Vegan TabletsTrue GraceVitamins & SupplementsVitamin C, Biotin, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
TruSkin Hyaluronic Acid Serum for Face -- 1 fl ozTruSkinBeauty & Personal Carevitamin C, vitamin E, vitamin E, hydroxyethyl cellulose, sodium benzoate2024-11-29 10:47:42
TruSkin Niacinamide (B3) Facial Serum -- 1 fl ozTruSkinBeauty & Personal Carevitamin E, tocopherol, vitamin E, glycerin, vitamin B3, niacinamide, phenoxyethanol2024-11-29 10:47:42
TruSkin Retinol Moisturizer -- 2 fl ozTruSkinBeauty & Personal Carecetyl alcohol, vitamin E, panthenol, vitamin E, glyceryl stearate, isopropyl palmitate, vitamin B5, phenoxyethanol, stearic acid2024-11-29 10:47:42
TruSkin Retinol Serum for Face -- 1 fl ozTruSkinBeauty & Personal Carevitamin E, vitamin E, retinol, sodium benzoate2024-11-29 10:47:42
TruSkin Serum Eye Gel -- 0.5 fl ozTruSkinBeauty & Personal Carebutylene glycol, alanine, arginine, aspartic acid, carbomer, vitamin E, vitamin E, glycine, histidine, isoleucine, phenylalanine, proline, serine, sodium benzoate, sodium lactate, threonine, valine2024-11-29 10:47:42
TruSkin Vitamin C Daily Face Cleanser -- 5 fl ozTruSkinBeauty & Personal Carecocamidopropyl betaine, vitamin E, decyl glucoside, dimethyl sulfone, vitamin E, phenoxyethanol2024-11-29 10:47:42
TruSkin Vitamin C Daily Facial Moisturizer -- 2 fl ozTruSkinBeauty & Personal Carevitamin c, cetyl alcohol, vitamin E, panthenol, vitamin E, glyceryl stearate, isopropyl palmitate, phenoxyethanol, stearic acid2024-11-29 10:47:42
TruSkin Vitamin C Facial Serum -- 1 fl ozTruSkinBeauty & Personal Cared-alpha tocopheryl acetate, (2s)-2-amino-5-guanidinopenta-noic acid, vitamin C, carbomer, vitamin E, vitamin E, phenoxyethanol2024-11-29 10:47:42
TruSkin Vitamin C Facial Serum -- 2 ozTruSkinBeauty & Personal Cared-alpha tocopheryl acetate, (2s)-2- amino-5-guanidinopentanoic acid, vitamin c, carbomer, vitamin e, methylsulfonylmethane, vitamin e, phenoxyethanol, sodium hydroxide2024-11-29 10:47:42
Twinlab Choline Cocktail™ -- 750 mg - 13.33 ozTwinlabVitamins & Supplementscitric acid, Vitamin C, Biotin, Choline, Chromium, citric acid, Coenzyme Q10, Vitamin E, fructose, DMAE, Folate, Vitamin E, L-Carnitine, Maltodextrin, Niacin, Pantothenic Acid, Vitamin B6, Reb A, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Twinlab Daily One Caps For Women -- 60 CapsulesTwinlabVitamins & Supplements Agnuside, Vitamin C, Biotin, Vitamin D3, Choline, Chromium, Vitamin E, riboflavin-5'-phosphate, Folate, Vitamin E, Inositol, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, pyridoxal-5'-phosphate, pyridoxine HCI, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Twinlab Daily One Caps without Iron -- 180 CapsulesTwinlabVitamins & SupplementsVitamin C, Biotin, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Twinlab OcuGuard Plus -- 120 Veggie CapsulesTwinlabVitamins & SupplementsVitamin C, Chromium, Vitamin E, eriocitrin, Vitamin E, hesperidin, Lutein, Quercetin Dihydrate, Vitamin A, Riboflavin, Rutin, Selenium, Taurine2024-11-29 10:47:42
Twinlab OcuGuard® Plus -- 60 Veggie CapsTwinlabVitamins & SupplementsN-Acetyl L-Cysteine, Vitamin C, Chromium, Vitamin E, eriocitrin, Vitamin E, Lutein, naringin, Quercetin Dihydrate, Vitamin A, Riboflavin, Rutin, Selenium, Taurine, Zeaxanthin2024-11-29 10:47:42
Uncle Crumbles Gluten Free Granola Brainberry -- 11 ozUncle CrumblesFood & Beveragesvitamin E, vitamin E, cane sugar2024-11-29 10:47:42
Vega Essentials Shake Plant-Based Powder Chocolate -- 30 ServingsVegaActive Lifestyle & FitnessB2, Vitamin C, Biotin, Vitamin E, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Vega Essentials Shake Plant-Based Powder Vanilla -- 30 ServingsVegaActive Lifestyle & FitnessB2, Vitamin C, Biotin, Vitamin E, Vitamin E, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
VegLife Vegan One Multiple with Iron -- 60 TabletsVegLifeVitamins & SupplementsPABA, Vitamin C, Biotin, calcium citrate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamine, calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
VegLife Vegan One™ Multiple Iron-Free -- 60 TabletsVegLifeVitamins & SupplementsPABA, Vitamin C, Biotin, calcium citrate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, montmorillonite clay, stearic acid, Thiamine, calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
VegLife Vital Teen™ Boys Multiple -- 60 Vegan CapsulesVegLifeVitamins & SupplementsPABA, Vitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, L-carnitine, maltodextrin, Manganese, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
VegLife Vital Teen™ Girls Multiple -- 60 Vegan CapsulesVegLifeVitamins & SupplementsPABA, Vitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, maltodextrin, Manganese, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vibrant Health Green Vibrance -- 240 Veggie CapsVibrant HealthVitamins & SupplementsLipase, Policosanol, Larch Arabinogalactan, Vitamin C, Cellulase, Vitamin D3, Vitamin E, Vitamin E, Vitamin A, Vitamin B12, Vitamin K2024-11-29 10:47:42
Vibrant Health Green Vibrance Pouch -- 23.83 ozVibrant HealthVitamins & SupplementsLipase, Vitamin C, Cellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Phosphorus, Vitamin A, Vitamin B12, Vitamin K2024-11-29 10:47:42
Vibrant Health Green Vibrance Powder -- 15 PacketsVibrant HealthVitamins & SupplementsVitamin C, Chromium, Vitamin E, Vitamin E, Iodide, Vitamin A, Selenium, Vitamin B12, Vitamin K2024-11-29 10:47:42
Vibrant Health Green Vibrance Powder -- 23.37 ozVibrant HealthVitamins & SupplementsLipase, Vitamin C, Cellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Phosphorus, Vitamin A, Selenium, Vitamin B12, Vitamin K2024-11-29 10:47:42
Vibrant Health Green Vibrance Powder -- 6.26 ozVibrant HealthVitamins & SupplementsLipase, Vitamin C, Cellulase, Chromium, Vitamin E, Vitamin E, Iodine, Vitamin A, Selenium, Vitamin B12, Vitamin K2024-11-29 10:47:42
Vibrant Health Green Vibrance Powder -- 83 ServingsVibrant HealthVitamins & SupplementsLipase, Vitamin C, Cellulase, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Phosphorus, Vitamin A, Vitamin B12, Vitamin K2024-11-29 10:47:42
Vibrant Health Green Vibrance® Powder -- 30 ServingsVibrant HealthVitamins & SupplementsLipase, Vitamin C, Cellulase, Vitamin D3, Chromium, Vitamin E, Vitamin E, Iodine, Mustard, Vitamin A, Selenium, Vitamin B12, Vitamin K2024-11-29 10:47:42
Vibrant Health Maximum Vibrance Chocolate -- 28.2 ozVibrant HealthVitamins & SupplementsLipase, Policosanol, Larch Arabinogalactan, Vitamin C, Astaxanthin, Biotin, Cellulase, Vitamin D3, Chromium, Vitamin E, Vitamin B9, Vitamin E, Iodine, Lycopene, L-Lysine, Manganese, Vitamin B3, Vitamin B5, Phosphorus, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Silicon, Vitamin B1, L-Valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Vibrant Health Maximum Vibrance™ Multi-Supplement Powder Vanilla Bean -- 20.74 ozVibrant HealthVitamins & SupplementsLipase, Vitamin C, Biotin, Cellulase, Vitamin D3, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Mustard, Nicotinic Acid, Pantothenic Acid, Phosphorus, Pyridoxine, Vitamin A, Riboflavin, Selenium, Silicon, Thiamin, Vitamin K2024-11-29 10:47:42
Vibrant Health Spectrum Vibrance® Antioxidant Superfood -- 6.5 ozVibrant HealthVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Vitamin A, Vitamin K2024-11-29 10:47:42
Vitabath Bar Soap Original Spring Green -- 8 ozVitabathBeauty & Personal Careascorbic acid, vitamin E, vitamin E, glycerin, pantothenic acid, retinyl palmitate, vitamin A, zinc oxide2024-11-29 10:47:42
Vitabath Men Soap On A Rope - Amber Woodland -- 9 ozVitabathBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin, hemp, oat, zinc oxide2024-11-29 10:47:42
Vitabath Men Soap On A Rope - Lime & Cedarleaf -- 9 ozVitabathBeauty & Personal Carecitric acid, citric acid, tocopherol, tocopherol, vitamin E, glycerin, hemp, oat, zinc oxide2024-11-29 10:47:42
Vitabath Plus For Dry Skin Bar Soap -- 8 ozVitabathBeauty & Personal Careascorbic acid, vitamin E, vitamin E, glycerin, pantothenic acid, retinyl palmitate, vitamin A, zinc oxide2024-11-29 10:47:42
Vitacost - globaby Baby Liquid Castile Soap Unscented -- 32 fl oz (946 mL)Vitacost - globabyBaby & Kids Productscitric acid, citric acid, tocopherol, tocopherol, vitamin E, hydroxyethylcellulose2024-11-29 10:47:42
Vitacost - Glonaturals Castile Liquid Soap - Lavender -- 32 fl ozVitacost - GlonaturalsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E, hydroxyethylcellulose2024-11-29 10:47:42
Vitacost - Glonaturals Castile Liquid Soap - Peppermint -- 32 fl ozVitacost - GlonaturalsHousehold Essentialscitric acid, citric acid, tocopherol, tocopherol, vitamin E, hydroxyethylcellulose2024-11-29 10:47:42
Vitacost Vitamin E & Tocotrienol Complex -- 60 Liquid CapsulesVitacost BrandVitamins & SupplementsVitamin E, Vitamin E2024-11-29 10:47:42
Vitacost-Synergy 3000 Multivitamin -- 180 CapsulesVitacost-SynergyVitamins & SupplementsVitamin C, d-beta tocopherol, Biotin, Boron, calcium citrate, cholecalciferol, Chromium, Coenzyme Q10, Vitamin E, d-delta tocopherol, Folate, Vitamin E, Iodine, Lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, retinyl palmitate, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Vitacost-Synergy Basic® Multivitamin -- 60 CapsulesVitacost-SynergyVitamins & Supplementsd-alpha tocopheryl succinate, Vitamin C, d-beta tocopherol, Biotin, dicalcium phosphate, Chromium, Coenzyme Q10, Vitamin E, d-delta tocopherol, Folate, Vitamin E, Iodine, Lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Vitacost-Synergy Eye Defense Formula† -- 120 CapsulesVitacost-SynergyVitamins & SupplementsN-Acetyl L-Cysteine, Vitamin C, Chromium, Vitamin E, Vitamin E, Lutein, Quercetin Dihydrate, Vitamin A, Riboflavin, Rutin, Selenium, Taurine, Zeaxanthin2024-11-29 10:47:42
Vitacost-Synergy Mitochondrial Energy Booster† 15-Nutrient Blend -- 120 CapsulesVitacost-SynergyVitamins & SupplementsBenfotiamine, cholecalciferol, Chromium, Coenzyme Q10, Vitamin E, Vitamin E, microcrystalline cellulose, D3, Niacin, Vitamin B6, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitacost-Synergy Once Daily® Multivitamin -- 60 CapsulesVitacost-SynergyVitamins & SupplementsVitamin C, Biotin, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Iodine, Lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Vitacost-Synergy ToCoQ10® -- 100 mg - 120 SoftgelsVitacost-SynergyVitamins & SupplementsCoenzyme Q10, Vitamin E, Vitamin E, Tocotrienols2024-11-29 10:47:42
Vitacost-Synergy Twice Daily Energy† Multivitamin -- 60 CapsulesVitacost-SynergyVitamins & SupplementsVitamin C, Benfotiamine, Biotin, cholecalciferol, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Manganese, Vitamin K2, Menaquinone-7, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Vitafusion Daily Wellness Multi Berry Fusion -- 30 Soft ChewsVitafusionVitamins & Supplementscitric acid, Vitamin C, Biotin, Vitamin D3, citric acid, Vitamin E, Folate, Vitamin E, glycerin, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Cane sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitafusion Gorgeous Hair Skin & Nails Multivitamin Natural Raspberry -- 135 GummiesVitafusionVitamins & Supplementscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Folate, Vitamin E, Iodine, lactic acid, Pantothenic Acid, Vitamin B6, Vitamin A, sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitafusion Hair Skin & Nails Multivitamin Natural Raspberry -- 100 GummiesVitafusionVitamins & Supplementscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Folate, Vitamin E, Iodine, lactic acid, Pantothenic Acid, Vitamin B6, Vitamin A, sucrose, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitafusion Lil Critters Omega-3 EPA-DHA & ALA Zesty Raspberry Lemonade -- 120 GummiesVitafusionVitamins & Supplementscitric acid, Vitamin C, citric acid, Vitamin E, fumaric acid, Vitamin E, lactic acid, Vitamin A, sugar2024-11-29 10:47:42
Vitafusion Multi + Energy Raspberry & Black Tea -- 90 GummiesVitafusionVitamins & Supplementscitric acid, Vitamin C, Biotin, Boron, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Iodine, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitafusion Multi Plus Immune Gummies -- 90 GummiesVitafusionVitamins & Supplementscitric acid, Vitamin C, Biotin, Boron, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Iodine, malic acid, Molybdenum, Pantothenic Acid, Vitamin B6, Vitamin A, sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitafusion MultiVites Adult Complete Multivitamin Gummy Assorted Fruit -- 70 GummiesVitafusionVitamins & SupplementsVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, lactic acid, Lutein, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, sucrose, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitafusion MultiVites™ Multivitamin Gummies Berry Peach and Orange -- 150 GummiesVitafusionVitamins & Supplementscitric acid, Vitamin C, Biotin, Boron, Chromium, citric acid, Vitamin E, Folic Acid, Vitamin E, Inositol, lactic acid, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, sucrose, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitafusion Omega 3 EPA DHA Natural Berry Lemonade -- 120 GummiesVitafusionVitamins & Supplementscitric acid, Vitamin C, citric acid, Vitamin E, fumaric acid, Vitamin E, lactic acid, Vitamin A, sugar2024-11-29 10:47:42
Vitafusion PreNatal Gummy Vitamins Natural Raspberry Lemonade -- 90 GummiesVitafusionVitamins & SupplementsVitamin C, Vitamin E, Folate, fumaric acid, Vitamin E, lactic acid, Niacin, Vitamin B6, Vitamin A, sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
VitaHustle Beauty Gummies Strawberry Colada -- 50 GummiesVitaHustleVitamins & Supplementscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Vitamin E, sodium citrate, cane sugar2024-11-29 10:47:42
VitaHustle ONE Superfood Greens Mixed Berry -- 25 ServingsVitaHustleVitamins & Supplementscitric acid, Vitamin C, citric acid, Vitamin E, Vitamin E, malic acid, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
VitaHustle ONE Superfood Protein + Greens Powder - 20g Plant Protein Dark Cacao -- 10 ServingsVitaHustleActive Lifestyle & FitnessVitamin C, Biotin, Chloride, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vital Nutrients Once Daily Multivitamin Complete Daily Vegan For Overall Wellness -- 60 Vegan CapsulesVital NutrientsProfessional SupplementsVitamin C, Biotin, Cellulose, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacinamide, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Vital Nutrients Minimal and Essential Multivitamin -- 90 CapsulesVital NutrientsProfessional Supplementsascorbyl palmitate, Vitamin C, Biotin, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Manganese, Niacinamide, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vital Nutrients Multi-Nutrients -Without Iron & Iodine- -- 180 Vegetarian CapsulesVital NutrientsProfessional SupplementsVitamin C, Biotin, Boron, cellulose, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vital Nutrients Multi-Nutrients 3 Citrate-Malate Formula without Copper and Iron -- 180 CapsulesVital NutrientsProfessional SupplementsVitamin C, Biotin, Boron, Chromium, Vitamin E, Riboflavin 5' Phosphate, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Niacinamide, Pantothenic Acid, Pyridoxal 5' Phosphate, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vital Nutrients Vitamin E 400 with Mixed Tocopherols -- 100 SoftgelsVital NutrientsProfessional Supplementsd-Beta, Vitamin E, Vitamin E, glycerin2024-11-29 10:47:42
Vital Planet Vital Dog™ Daily Multivitamin Beef -- 30 Chewable TabletsVital PlanetPet Suppliesascorbic acid, kelp, d-calcium pantothenate, dicalcium phosphate, Vitamin D3, Choline, Vitamin E, methylsulfonylmethane, iron citrate, Folic Acid, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, potassium chloride, potassium iodide, Pyridoxine, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamine, Vitamin B122024-11-29 10:47:42
Vitanica CandidaStat™ Yeast Balance Support -- 60 Vegetarian CapsulesVitanicaVitamins & SupplementsVitamin E, Vitamin E, Caprylic Acid2024-11-29 10:47:42
Vitanica Luminous® Hair Skin & Nails Support -- 60 Vegetarian CapsulesVitanicaVitamins & SupplementsVitamin C, Biotin, calcium ascorbate, Vitamin E, Vitamin E, Selenium, citrate, citrate, Vitamin D22024-11-29 10:47:42
Vitanica Maternal Symmetry™ OB Multivitamin -- 180 Vegetarian CapsulesVitanicaVitamins & SupplementsVitamin C, Biotin, Boron, calcium ascorbate, Chromium, Vitamin E, ferrous fumarate, ferrous succinate, riboflavin-5-phosphate, Folate, Vitamin E, Iodine, Manganese, Vitamin B3, Pantothenic Acid, Vitamin B6, Vitamin A, vitamin B2, Selenium, Thiamin, vitamin B1, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Vitanica ThyroFem™ Thyroid Support -- 60 Vegetarian CapsulesVitanicaVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Iodine, Selenium, Vitamin B122024-11-29 10:47:42
Viteyes Areds 2 Based Formula Zinc Free -- 60 CapsulesViteyesVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, Lutein, Zeaxanthin2024-11-29 10:47:42
Viteyes Classic Advanced Areds 2 Based Formula -- 60 CapsulesViteyesVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, microcrystalline cellulose, Selenium, Alpha-Lipoic Acid2024-11-29 10:47:42
Viteyes Classic Areds 2 Based Formula -- 60 CapsulesViteyesVitamins & SupplementsVitamin C, dicalcium phosphate, Vitamin E, Vitamin E, microcrystalline cellulose, Lutein, Zeaxanthin2024-11-29 10:47:42
Viteyes Classic AREDS 2 Based Formula -- 60 SoftgelsViteyesVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, glycerin, Lutein, Zeaxanthin2024-11-29 10:47:42
Viteyes Classic plus Omega-3 Ared 2 Based Formula -- 90 SoftgelsViteyesVitamins & SupplementsVitamin C, Omega-3, Vitamin E, Vitamin E, glycerin, Lutein, Zeaxanthin2024-11-29 10:47:42
Viteyes Complete Eye & Total Body Health Multivitamin -- 180 CapsulesViteyesVitamins & SupplementsN-Acetyl Cysteine, Vitamin C, Biotin, Boron, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Nickel, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Taurine, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Viteyes Optic Nerve Support -- 90 TabletsViteyesVitamins & SupplementsN-Acetyl Cysteine, Vitamin C, Dicalcium phosphate, Coenzyme Q10, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Quercetin Dihydrate, stearic acid, Taurine, Alpha-Lipoic Acid, Vitamin B122024-11-29 10:47:42
Viteyes Tear Support -- 30 SoftgelsViteyesVitamins & SupplementsVitamin E, Vitamin E, glycerin, Vitamin B6, Vitamin B62024-11-29 10:47:42
Voyage Foods Roasted Seed Spread Top 9 Allergen Free Non GMO Peanut-Free Spread Peanut -- 16 ozVoyage FoodsFood & BeveragesVitamin E, Vitamin E, cane sugar2024-11-29 10:47:42
Wellements Organic Baby Multivitamin Drops 2 Months+ Cherry -- 1 fl ozWellementsBaby & Kids Productscitric acid, Vitamin C, citric acid, Vitamin E, Folate, Vitamin E, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B62024-11-29 10:47:42
Wellness Dry Cat Food Complete Health Grain Free Indoor Recipe -- 5.5 lbsWellnessPet Suppliesascorbic acid, biotin, D-calcium pantothenate, choline chloride, copper sulfate, Vitamin E, ferrous sulfate, folic acid, Vitamin E, Glucosamine, L-carnitine, calcium carbonate, max, niacin, Phosphorus, potassium chloride, pyridoxine hydrochloride, Vitamin A, riboflavin, sodium selenite, Taurine, vitamin K, zinc sulfate2024-11-29 10:47:42
White Egret CoQ-10 Toning Creme -- 2 ozWhite EgretBeauty & Personal Careallantoin, cetyl alcohol, vitamin E, panthenol, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, phenoxyethanol, propanediol, vitamin A, stearyl alcohol2024-11-29 10:47:42
White Egret Magnesium Lotion -- 12 fl ozWhite EgretBeauty & Personal Careorange, allantoin, cetyl alcohol, vitamin E, DL panthenol, vitamin E, glyceryl stearate, glycerin, microcrystalline cellulose, stearic acid2024-11-29 10:47:42
White Egret Retinyl Night Creme -- 2 fl ozWhite EgretBeauty & Personal Careallantoin, cetyl alcohol, vitamin E, panthenol, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, phenoxyethanol, propanediol, vitamin A, stearyl alcohol2024-11-29 10:47:42
White Egret Vitamin C Hyaluronic Acid Serum -- 2 fl ozWhite EgretBeauty & Personal Careallantoin, vitamin C, cetyl alcohol, vitamin E, panthenol, provitamin b5, ethylhexylglycerin, vitamin E, glyceryl stearate, glycerin, phenoxyethanol, retinyl palmitate, vitamin A, stearyl alcohol2024-11-29 10:47:42
Wild Harvest Dry Cat Food Salmon & Brown Rice Recipe -- 3 lbsWild HarvestPet Suppliesbeta carotene, biotin, D-calcium pantothenate, choline chloride, Vitamin E, iron sulfate, folic acid, Vitamin E, powdered cellulose, Linoleic Acid, L-lysine, niacin, Phosphorus, pyridoxine hydrochloride, Vitamin A, sodium selenite, Taurine, zinc sulfate2024-11-29 10:47:42
Wild Harvest Grain Free Turkey, Sweet Potato & Cranberry Recipe Mini Jerky Dog Treats -- 6 ozWild HarvestPet Supplieskelp, copper sulfate, Vitamin E, Vitamin E, glycerin, phosphoric acid, potassium chloride, sodium selenite, sorbic acid, sugar, zinc sulfate2024-11-29 10:47:42
Youtheory Marine Collagen -- 2500 mg - 160 TabletsYoutheoryVitamins & SupplementsVitamin C, dicalcium phosphate, Vitamin E, Vitamin E, Calcium carbonate, Vitamin B6, Vitamin A, Selenium, stearic acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Youtheory Marine Collagen -- 2500 mg - 290 TabletsYoutheoryVitamins & SupplementsVitamin C, dicalcium phosphate, Vitamin E, Vitamin E, Calcium carbonate, Vitamin B6, Vitamin A, Selenium, stearic acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Yumi Organic Snack Bar Toddler Apple Cinnamon & Squash -- 5 BarsYumiBaby & Kids Productscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Vitamin E, Manganese, Niacin, Vitamin B6, Vitamin A, Riboflavin, Selenium, baking soda, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Yumi Organic Snack Bar Toddler Blueberry & Purple Carrot -- 5 BarsYumiBaby & Kids Productscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Vitamin E, Manganese, Niacin, Vitamin B6, Vitamin A, Riboflavin, Selenium, baking soda, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Yumi Organic Snack Bar Toddler Strawberry & Rhubarb -- 5 BarsYumiBaby & Kids Productscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Vitamin E, Manganese, Niacin, Vitamin B6, Vitamin A, Riboflavin, Selenium, baking soda, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Zahler Multivitamin Beauty -- 60 CapsulesZahlerVitamins & SupplementsVitamin C, Astaxanthin, Biotin, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantethine, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Zahler Multivitamin Brainfood -- 60 CapsulesZahlerVitamins & SupplementsVitamin C, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Zahler Multivitamin Metabolism -- 60 CapsulesZahlerVitamins & SupplementsVitamin C, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantethine, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Zahler Multivitamin One Daily -- 60 CapsulesZahlerVitamins & SupplementsVitamin C, Vitamin D3, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantethine, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Zahler Prenatal + DHA 300 Optimal Formula -- 120 SoftgelsZahlerVitamins & Supplementsannatto, Vitamin C, Biotin, Choline, Chromium, Vitamin E, Docosahexaenoic Acid, Folate, Vitamin E, glycerin, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Zahler Prenatal + DHA 300 Optimal Formula -- 180 SoftgelsZahlerVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Choline, Chromium, Vitamin E, Docosahexaenoic Acid, Riboflavin 5-Phosphate, Folate, Vitamin E, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Zahler Total One Prenatal -- 120 CapsulesZahlerVitamins & Supplementsascorbyl palmitate, Vitamin C, Biotin, dicalcium phosphate, Chromium, Vitamin E, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Zenwise Omega-3 Gummies -- 30 GummiesZenwiseVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Zesty Paws 8-in-1 Multivitamin Bites Supplement for Dogs Chicken -- 250 Soft ChewsZesty PawsPet Suppliescitric acid, Vitamin C, Biotin, calcium pantothenate, citric acid, Vitamin E, Docosahexaenoic Acid, Folic Acid, vitamin E, powdered cellulose, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B2, Vitamin B1, vitamin B12, Vitamin B62024-11-29 10:47:42
Zesty Paws 8-in-1 Multivitamin Bites Supplement for Dogs Chicken -- 90 Soft ChewsZesty PawsPet Supplies Lipase, Vitamin C, Biotin, Cellulase, Vitamin D3, Coenzyme Q10, Vitamin E, Folic Acid, Vitamin E, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin B2, sorbic acid, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Zesty Paws 8-in-1 Multivitamin Bites Supplement for Dogs Peanut Butter -- 90 Soft ChewsZesty PawsPet Suppliescitric acid, Vitamin C, Biotin, calcium pantothenate, citric acid, Vitamin E, Docosahexaenoic Acid, Folic Acid, vitamin E, powdered cellulose, manganese, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B2, Vitamin B1, vitamin B12, Vitamin B62024-11-29 10:47:42
Zesty Paws Hemp Elements 8-in-1 Multivitamin Supplement for Dogs Chicken -- 90 Soft ChewsZesty PawsPet Supplies Lipase, citric acid, Vitamin C, Biotin, Cellulase, Vitamin D3, citric acid, Coenzyme Q10, Vitamin E, Folic Acid, Vitamin E, powdered cellulose, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, Vitamin B1, Vitamin B-12, Vitamin B62024-11-29 10:47:42
Zesty Paws Mobility Hip & Joint Glucosamine Supplement for Dogs Bacon -- 90 Soft ChewsZesty PawsPet Suppliescitric acid, d-alpha tocopherol acetate, Ascorbic Acid, Kelp, citric acid, d-Alpha-Tocopherol, methylsulfonylmethane, vitamin E, powdered cellulose2024-11-29 10:47:42
Zesty Paws Mobility Hip & Joint Glucosamine Supplement for Dogs Duck -- 250 Soft ChewsZesty PawsPet SuppliesCitric acid, Vitamin C, Citric acid, Vitamin E, Methylsulfonylmethane, Vitamin E, powdered cellulose2024-11-29 10:47:42
Zesty Paws Mobility Hip & Joint Glucosamine Supplement for Dogs Duck -- 90 Soft ChewsZesty PawsPet Suppliescitric acid, d-alpha tocopherol acetate, Vitamin C, citric acid, Vitamin E, methylsulfonylmethane, vitamin E, Glucosamine, powdered cellulose, Zinc Sulfate2024-11-29 10:47:42
Zesty Paws Senior Advanced 11-in-1 Multivitamin Glucosamine Supplement for Dogs Chicken -- 90 Soft ChewsZesty PawsPet Supplieslipase, Vitamin C, Biotin, cellulase, Vitamin D3, Coenzyme Q10, Vitamin E, methylsulfonylmethane, folic acid, vitamin E, powdered cellulose, Lutein, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, sorbic acid, vitamin B1, vitamin B12, vitamin B62024-11-29 10:47:42
Zesty Paws Senior Advanced Mobility Glucosamine Hip & Joint Supplement for Dogs Chicken -- 90 Soft ChewsZesty PawsPet Suppliescitric acid, Vitamin C, citric acid, Vitamin E, methylsulfonylmethane, vitamin E, Glucosamine, powdered cellulose, Bio Perine2024-11-29 10:47:42
Zesty Paws Senior Advanced Vision Bites Supplement Dogs Chicken -- 90 Soft ChewsZesty PawsPet SuppliesVitamin C, Astaxanthin, Beta Carotene, Vitamin E, Docosahexaenoic Acid, Vitamin E, powdered cellulose, Lutein2024-11-29 10:47:42
Zesty Paws Skin & Coat Fish Oil & Omega-3 Supplement for Dogs Bacon -- 90 Soft ChewsZesty PawsPet SuppliesAscorbic Acid, Biotin, d-Alpha-Tocopherol, Docosahexaenoic Acid, vitamin E, sorbic acid2024-11-29 10:47:42
Zesty Paws Skin & Coat Fish Oil & Omega-3 Supplement for Dogs Chicken -- 90 Soft ChewsZesty PawsPet SuppliesAscorbic Acid, Biotin, Omega-3, Vitamin E, EPA, Vitamin E, sorbic acid2024-11-29 10:47:42
Zesty Paws Skin & Coat Salmon Fish Oil & Omega-3 Supplement for Dogs -- 90 Soft ChewsZesty PawsPet Suppliesvitamin C, kelp, biotin, D-alpha Tocopherol, vitamin E, Linoleic Acid, sorbic acid2024-11-29 10:47:42
Zhou Daily Boost -- 30 Vegetarian CapsulesZhouVitamins & SupplementsPABA, Vitamin C, Biotin, cellulose, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamine, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Zhou DIM Active™ with Activated Broccoli Extract -- 60 Veggie CapsulesZhouVitamins & SupplementsDIM, Vitamin C, Vitamin E, Vitamin E2024-11-29 10:47:42
Zion Health Adama Deep Cleansing Scalp & Hair Scrub Pear Blossom -- 4 ozZion HealthBeauty & Personal Carecaprylyl glycol, biotin, cocamidopropyl betaine, vitamin E, panthenol, vitamin E, glyceryl stearate, phenoxyethanol, sodium citrate2024-11-29 10:47:42
Zion Health Adama Face Charcoal Mask Deep Pore Cleanser -- 4 ozZion HealthBeauty & Personal Caretocopherol acetate, vitamin C, cholecalciferol, vitamin E, panthenol, vitamin E, glyceryl stearate, glycerin, glycolic acid, lactic acid, vitamin B, phenoxyethanol, retinol palmitate, salicylic acid, sorbic acid, zinc oxide2024-11-29 10:47:42
Zion Health Body Butter with Argan Oil - Moroccan Pear -- 4 ozZion HealthBeauty & Personal Carecaprylyl glycol, citric acid, citric acid, vitamin E, panthenol, vitamin E, phenoxyethanol, sodium citrate, stearic acid2024-11-29 10:47:42
Zum Hand & Body Lotion Almond -- 6 fl ozZumBeauty & Personal Caretocopherol, tocopherol, basil, vitamin E2024-11-29 10:47:42
Zum Hand & Body Lotion Frankincense & Myrrh -- 6 fl ozZumBeauty & Personal Carecarbomer, tocopherol, tocopherol, basil, vitamin E2024-11-29 10:47:42
Zum Hand & Body Lotion Patchouli -- 6 fl ozZumBeauty & Personal Carecarbomer, tocopherol, tocopherol, basil, vitamin E2024-11-29 10:47:42
Zum Kiss Lip Balm Vanilla -- 0.15 ozZumBeauty & Personal Carevitamin E, vitamin E2024-11-29 10:47:42
Zum Massage & Body Oil Frankincense and Myrrh -- 4 fl ozZumBeauty & Personal Caretocopherol, tocopherol, vitamin E2024-11-29 10:47:42

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (37)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.19950.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency18.82300.140911.194039.8107AID2451
SMAD family member 2Homo sapiens (human)Potency10.68220.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency10.68220.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency0.58050.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency13.33320.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency6.88320.000221.22318,912.5098AID1259243; AID743036
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency7.94330.00137.762544.6684AID914; AID915
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency27.07150.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency37.22120.001310.157742.8575AID1259252
estrogen nuclear receptor alphaHomo sapiens (human)Potency10.75310.000229.305416,493.5996AID743069; AID743075
GVesicular stomatitis virusPotency8.68380.01238.964839.8107AID1645842
glucocerebrosidaseHomo sapiens (human)Potency15.18610.01268.156944.6684AID2101
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency5.23610.001019.414170.9645AID743094; AID743191
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.31620.00636.904339.8107AID883
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency18.35640.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency28.18380.01789.637444.6684AID588834
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency33.48890.000627.21521,122.0200AID743202
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency10.00000.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency11.22020.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency32.19680.005612.367736.1254AID624032
Interferon betaHomo sapiens (human)Potency8.68380.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency8.68380.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency21.13170.002319.595674.0614AID651631
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency0.31620.00638.235039.8107AID883
Guanine nucleotide-binding protein GHomo sapiens (human)Potency31.62281.995325.532750.1187AID624288
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency8.68380.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency8.68380.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)6.39000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)64.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)18.85000.11007.190310.0000AID1443980; AID1443986; AID1449628; AID1473738
Aldo-keto reductase family 1 member C3Homo sapiens (human)IC50 (µMol)0.85000.05002.207010.0000AID1674109
Aldo-keto reductase family 1 member C2 Homo sapiens (human)IC50 (µMol)50.00000.37004.09519.2800AID1674110
Aldo-keto reductase family 1 member C1Homo sapiens (human)IC50 (µMol)6.86000.00603.12657.9000AID1674111
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (241)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
G protein-coupled receptor signaling pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
response to nutrientAldo-keto reductase family 1 member C3Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of cell population proliferationAldo-keto reductase family 1 member C3Homo sapiens (human)
male gonad developmentAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to starvationAldo-keto reductase family 1 member C3Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
cyclooxygenase pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
keratinocyte differentiationAldo-keto reductase family 1 member C3Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
retinal metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
macromolecule metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
regulation of retinoic acid receptor signaling pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
renal absorptionAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to calcium ionAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to prostaglandin stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to corticosteroid stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to prostaglandin D stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
negative regulation of retinoic acid biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
regulation of testosterone biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of endothelial cell apoptotic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
G protein-coupled receptor signaling pathwayAldo-keto reductase family 1 member C2 Homo sapiens (human)
digestionAldo-keto reductase family 1 member C2 Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
positive regulation of cell population proliferationAldo-keto reductase family 1 member C2 Homo sapiens (human)
epithelial cell differentiationAldo-keto reductase family 1 member C2 Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAldo-keto reductase family 1 member C2 Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C2 Homo sapiens (human)
cellular response to prostaglandin D stimulusAldo-keto reductase family 1 member C2 Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
xenobiotic metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
digestionAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid and bile salt transportAldo-keto reductase family 1 member C1Homo sapiens (human)
intestinal cholesterol absorptionAldo-keto reductase family 1 member C1Homo sapiens (human)
epithelial cell differentiationAldo-keto reductase family 1 member C1Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
retinal metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
cholesterol homeostasisAldo-keto reductase family 1 member C1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
response to organophosphorusAldo-keto reductase family 1 member C1Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (103)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C3Homo sapiens (human)
all-trans-retinol dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C3Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin D2 11-ketoreductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
ketoreductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin-F synthase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
15-hydroxyprostaglandin-D dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
Delta4-3-oxosteroid 5beta-reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C3Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C2 Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
carboxylic acid bindingAldo-keto reductase family 1 member C2 Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C2 Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C1Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C1Homo sapiens (human)
carboxylic acid bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
3beta-hydroxy-5beta-steroid dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorAldo-keto reductase family 1 member C1Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androsterone dehydrogenase (B-specific) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (45)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleusAldo-keto reductase family 1 member C3Homo sapiens (human)
cytoplasmAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C3Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C2 Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
cytosolAldo-keto reductase family 1 member C1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (174)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID194733Maximum % decrease of blood glucose (deltaBG) was observed within 4 hour after administration orally at 0.1 mg/kg dose to fasted adult female rats versus a control group; ND = 'not determined'1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Repaglinide and related hypoglycemic benzoic acid derivatives.
AID1407829Anti-hyperglycemic activity in Wistar albino rat sucrose loaded model assessed as reduction in blood glucose level at 4 mg/kg pretreated orally for 30 mins followed by sucrose challenge and measured up to 120 mins post sucrose challenge relative to contro2018European journal of medicinal chemistry, Sep-05, Volume: 157Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.
AID1407831Anti-hyperglycemic activity in streptozotocin-induced Wistar albino rat diabetic model assessed as reduction in blood glucose level at 4 mg/kg, po measured up to 6 hrs post dose by glucometric method relative to control2018European journal of medicinal chemistry, Sep-05, Volume: 157Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.
AID418879Effect on 2-deoxy-D-[1-3H]glucose transport in Sprague-Dawley rat adipocytes at 10 uM in presence of insulin by liquid scintillation counting2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents.
AID418877Effect on 2-deoxy-D-[1-3H]glucose transport in Sprague-Dawley rat adipocytes at 1 uM in presence of insulin by liquid scintillation counting2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents.
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID418876Effect on 2-deoxy-D-[1-3H]glucose transport in Sprague-Dawley rat adipocytes at 1 uM in absence of insulin by liquid scintillation counting2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents.
AID1290576Hypoglycemic activity in diabetic rat model assessed as decrease in blood glucose level at 20 mg/kg, ig administered for 12 days measured on ninth day of compound dosing by glucometer relative to control2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Study on the synthesis and biological activities of α-substituted arylacetates derivatives.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1674110Inhibition of N-terminal His-tagged human AKR1C2 expressed in Escherichia coli BL21 (Condon Plus) competent cells using 9,10-phenanthrenequinone as substrate in presence of NADPH2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Overview of AKR1C3: Inhibitor Achievements and Disease Insights.
AID418881Effect on 2-deoxy-D-[1-3H]glucose transport in Sprague-Dawley rat adipocytes at 100 uM in presence of insulin by liquid scintillation counting2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID418874Effect on insulin release in rat pancreatic cells at 100 umol/L after 6 hrs by radioimmunoassay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents.
AID1488557Displacement of fluormone-PPARgamma green from GST-tagged PPARgamma-LBD (unknown origin) by fluorescence polarization assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
AID194587Maximum % decrease of blood glucose (deltaBG) was observed within 0.5 hour after administration orally at 0.1 mg/kg dose to fasted adult female rats versus a control group1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Repaglinide and related hypoglycemic benzoic acid derivatives.
AID1494548Antihyperglycemic activity in established high fat diet-induced obese mouse assessed as reduction in blood glucose level at 10 mg/kg, iv administered once daily for 14 days measured at 1 hr post dose on day 7 and 14 during compound dosing in presence of r2018Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9
Synthesis, biological evaluation, and molecular docking investigation of benzhydrol- and indole-based dual PPAR-γ/FFAR1 agonists.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1290570Hypoglycemic activity in diabetic rat model assessed as decrease in blood glucose level at 20 mg/kg, ig administered for 12 days measured on third day of compound dosing by glucometer relative to control2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Study on the synthesis and biological activities of α-substituted arylacetates derivatives.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1473897AUC in human at 1 to 4 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1662163Antidiabetic activity in Sprague-Dawley rat assessed as reduction in glucose levels2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Anti-diabetic drugs recent approaches and advancements.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID194595Maximum % decrease of blood glucose (deltaBG) was observed within 2 hour after administration orally at 0.1 mg/kg dose to fasted adult female rats versus a control group1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Repaglinide and related hypoglycemic benzoic acid derivatives.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID418880Effect on 2-deoxy-D-[1-3H]glucose transport in Sprague-Dawley rat adipocytes at 100 uM in absence of insulin by liquid scintillation counting2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1473900Ratio of drug concentration at steady state in human at 1 to 4 mg, po QD after 24 hrs to IC50 for human MRP3 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1290573Hypoglycemic activity in diabetic rat model assessed as decrease in blood glucose level at 20 mg/kg, ig administered for 12 days measured on sixth day of compound dosing by glucometer relative to control2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Study on the synthesis and biological activities of α-substituted arylacetates derivatives.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID194598Maximum % decrease of blood glucose (deltaBG) was observed within 3 hour after administration orally at 0.1 mg/kg dose to fasted adult female rats versus a control group1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Repaglinide and related hypoglycemic benzoic acid derivatives.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID418878Effect on 2-deoxy-D-[1-3H]glucose transport in Sprague-Dawley rat adipocytes at 10 uM in absence of insulin by liquid scintillation counting2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211795Dissociation constant, pKa of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1674109Inhibition of N-terminal His-tagged human AKR1C3 expressed in Escherichia coli BL21(Condon Plus) competent cells using 9,10-phenanthrenequinone as substrate in presence of NADPH2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Overview of AKR1C3: Inhibitor Achievements and Disease Insights.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID699470Effect of glucose tolerance in fasted C57/BL6N mouse assessed as inhibition of glucose excursion at 30 mg/kg, po administered 2 mins before glucose challenge measured after 20 to 120 mins by IPGTT2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Synthesis and pharmacological evaluation of indolinone derivatives as novel ghrelin receptor antagonists.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1494546Antihyperglycemic activity in established high fat diet-induced obese mouse assessed as reduction in body weight at 10 mg/kg, iv administered once daily for 14 days2018Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9
Synthesis, biological evaluation, and molecular docking investigation of benzhydrol- and indole-based dual PPAR-γ/FFAR1 agonists.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID194737Maximum % decrease of blood glucose (deltaBG) was observed within 4 hour after administration orally at 0.3 mg/kg dose to fasted adult female rats versus a control group1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Repaglinide and related hypoglycemic benzoic acid derivatives.
AID1636422Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 103.5 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of 2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID418875Increase in insulin release in rat pancreatic cells at 100 umol/L after 6 hrs by radioimmunoassay relative to basal level2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1211792Hepatic clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473901Ratio of drug concentration at steady state in human at 1 to 4 mg, po QD after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211796Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID176587Half-maximal effective dose was measured on rat blood glucose after administrating at 4 hr1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Repaglinide and related hypoglycemic benzoic acid derivatives.
AID1488558Agonist activity at SUR in Wistar rat pancreatic islets assessed as increase in insulin secretion at 5 to 20 uM incubated for 1 hr followed by glucose addition for 30 mins by quantitative sandwich enzyme immunoassay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1473898Drug concentration at steady state in human at 1 to 4 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID418684Antidiabetic activity in po dosed type 2 diabetes mellitus patient assessed as reduction in HbA1C level in pancreas2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1636366Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 46 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NAD2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID194732Maximum % decrease of blood glucose (deltaBG) was observed within 4 hour after administration orally at 0.1 mg/kg dose to fasted adult female rats versus a control group1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Repaglinide and related hypoglycemic benzoic acid derivatives.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1211791Fraction unbound in human hepatocytes2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID194591Maximum % decrease of blood glucose (deltaBG) was observed within 1 hour after administration orally at 0.1 mg/kg dose to fasted adult female rats versus a control group1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Repaglinide and related hypoglycemic benzoic acid derivatives.
AID1211798Intrinsic clearance in human using well stirred liver model by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID302758Solubility by shake flask method2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Poorly soluble marketed drugs display solvation limited solubility.
AID1211794Fraction unbound in blood (not specified)2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1211797Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1488556Antihyperglycemic activity in streptozotocin-induced diabetic Swiss albino rat assessed as decrease in blood glucose level at 0.36 mg/kg, po measured up to 3 hrs post dose relative to control2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
AID418882Increase in glucose absorption in Sprague-Dawley rat adipocytes at 100 uM by liquid scintillation counting relative to basal level2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents.
AID1473899Ratio of drug concentration at steady state in human at 1 to 4 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1290579Hypoglycemic activity in diabetic rat model assessed as decrease in blood glucose level at 20 mg/kg, ig administered for 12 days measured on twelfth day by glucometer relative to control2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Study on the synthesis and biological activities of α-substituted arylacetates derivatives.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1674111Inhibition of N-terminal His-tagged human AKR1C1 expressed in Escherichia coli BL21 (Condon Plus) competent cells using 9,10-phenanthrenequinone as substrate in presence of NADPH2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Overview of AKR1C3: Inhibitor Achievements and Disease Insights.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1339407Displacement of fluormone-PPARgamma Green from recombinant human N-terminal GST-tagged PPARgamma-LBD by fluorescence polarization assay2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists.
AID1339406Antihyperglycemic activity in Swiss albino rat model of streptozotocin-induced hyperglycemia assessed as reduction in blood glucose level at 0.36 mg/kg, po measured after 3 hrs by glucometer relative to control2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists.
AID1339408Agonist activity at SUR in Wistar rat islets of pancreas assessed as induction of glucose-stimulated insulin secretion preincubated for 1 hr followed by glucose addition measured after 30 mins by sandwich ELISA2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (912)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.22)18.7374
1990's86 (9.43)18.2507
2000's302 (33.11)29.6817
2010's418 (45.83)24.3611
2020's104 (11.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 115.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index115.68 (24.57)
Research Supply Index7.17 (2.92)
Research Growth Index6.79 (4.65)
Search Engine Demand Index211.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (115.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials340 (35.56%)5.53%
Reviews91 (9.52%)6.00%
Case Studies45 (4.71%)4.05%
Observational5 (0.52%)0.25%
Other475 (49.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (222)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pilot Study to Assess the Difference in Glycemic Profiles Between Vildagliptin and Glimepiride Using Continuous Glucose Monitoring Device [NCT01262586]Phase 324 participants (Actual)Interventional2010-11-30Completed
Randomized, 2-way Crossover, Bioequivalence Study of Glimepiride 1 mg Tablets and Amaryl 1 mg Tablets in Healthy Subjects Under Fasting Condition [NCT01052909]Phase 144 participants (Actual)Interventional2003-12-31Completed
Randomized, 2-way Crossover, Bioequivalence Study of Glimepiride 1 mg Tablets and Amaryl 1 mg Tablets in Healthy Subjects Under Fed Condition [NCT01053689]Phase 144 participants (Actual)Interventional2003-12-31Completed
Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With [NCT00318461]Phase 31,091 participants (Actual)Interventional2006-05-31Completed
ADIponectin and ADMA Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination (Amaryl-M) [NCT01204580]Phase 440 participants (Actual)Interventional2010-12-31Completed
An Open-label, Randomized Crossover Study to Evaluate the Effect of ASP1941 on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glimepiride in Healthy Subjects and Vice Versa [NCT01302158]Phase 152 participants (Actual)Interventional2009-12-31Completed
AMIT Study - Amaryl M Initiation and Titration Study [NCT01144728]Phase 4172 participants (Actual)Interventional2010-05-31Completed
Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes [NCT01951339]36 participants (Actual)Interventional2013-10-31Completed
CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) [NCT00032487]Phase 31,791 participants (Actual)Interventional2000-12-01Completed
Effects of the DPP-4 or SGLT2 Inhibitors on the Metabolic Cardiovascular Systems in Patients With Type 2 Diabetes Mellitus. [NCT02528019]Phase 4100 participants (Anticipated)Interventional2015-08-31Recruiting
Open-labelled, Randomized, Active-controlled, Parallel-arm, Single-center Study on Effect of Sitagliptin on T2DM Patients on Treatment With Metformin and Insulin [NCT01341717]Phase 4440 participants (Actual)Interventional2012-02-29Completed
Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational Study [NCT02456428]1,499,650 participants (Actual)Observational2014-03-31Completed
A Multi-center, Double-blind, Placebo-controlled, Randomized Study to Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes Treated With Differing Baseline D [NCT01068860]Phase 2246 participants (Actual)Interventional2010-02-28Completed
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Placebo Added to Metformin in Patients With Type 2 Diabetes [NCT03332771]Phase 3954 participants (Actual)Interventional2017-12-01Completed
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes Inadequately Cont [NCT02089126]Phase 3230 participants (Anticipated)Interventional2014-06-30Not yet recruiting
A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes [NCT03060980]Phase 3245 participants (Actual)Interventional2017-03-03Terminated(stopped due to Decision by Sponsor)
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Sulfonylurea in Subjects With Type 2 Diabetes in Japan [NCT01318083]Phase 2/Phase 3312 participants (Actual)Interventional2008-08-31Completed
A Phase 4, Monocenter, Randomized, Double-blind, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Linagliptin Versus the Sulfonylurea (SU) Der [NCT02106104]Phase 448 participants (Actual)Interventional2014-03-31Completed
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes [NCT00106340]Phase 33,118 participants (Actual)Interventional2005-03-31Completed
Comparison in Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes Uncontrolled With Metformin [NCT05663736]Phase 480 participants (Anticipated)Interventional2020-01-01Recruiting
Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin: A 48-week Randomized, Open-label, Multicentre Phase IIIB Study to Compare the Effectiveness of Combination Therapy to Monotherapy in Type 2 Diabetes Mellitus Patients [NCT00131664]Phase 3391 participants (Actual)Interventional2005-09-30Completed
Relative Bioavailability of Both BI 10773 and Glimepiride After Co-administration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and a Single Dose of Glimepiride (1 mg) Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover [NCT02172261]Phase 116 participants (Actual)Interventional2009-04-30Completed
The Use of Incretin-based Drugs and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes [NCT02476760]1,417,914 participants (Actual)Observational2014-03-31Completed
The Effect of Omega 3 Fatty Acids on Blood Glucose, Lipids Profile, Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride [NCT03917940]70 participants (Actual)Interventional2019-01-31Completed
A Phase 2, Randomized, Double-Blind, Double-Dummy Placebo-and Active-Controlled, Multicenter Study to Determine the Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus [NCT01007097]Phase 2426 participants (Actual)Interventional2009-12-31Completed
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin [NCT00701090]Phase 31,035 participants (Actual)Interventional2008-05-31Completed
Dynamic Responsiveness of Insulin Secretory Parameters to Sitagliptin and Glimeperide Administration in Subjects With Type 2 Diabetes Mellitus: An Open Label Study [NCT02443922]100 participants (Anticipated)Interventional2015-06-30Not yet recruiting
A Phase IV, Multicenter, Randomized, Active Comparator Controlled Study of the Addition of Pioglitazone Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Alogliptin [NCT02426294]Phase 4154 participants (Anticipated)Interventional2015-02-28Recruiting
A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial With a Blinded 104-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in C [NCT02419612]Phase 3444 participants (Actual)Interventional2015-08-14Completed
Double-blinded Comparative Study to Investigate the Efficacy and Safety of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride in Patients With T2DM Inadequately Treated With Constant Dose of Glimepiride [NCT00924573]Phase 3189 participants (Actual)Interventional2009-05-31Completed
[NCT00939939]Phase 43 participants (Actual)Interventional2010-03-31Terminated(stopped due to Recruitment failure)
A Relative Bioavailability Study of Glimepiride 4 mg Tablets Under Non-Fasting Conditions [NCT00835172]Phase 132 participants (Actual)Interventional2003-03-31Completed
Effect of Inhaled Pre-Prandial Human Insulin Plus Metformin & Glimepiride Versus Rosiglitazone Plus Metformin & Glimepiride on HbA1c in Subjects With Type 2 Diabetes [NCT00427154]Phase 3227 participants (Actual)Interventional2007-01-10Terminated(stopped due to See termination reason in detailed description)
A Long-term, Open-label Extension Study to Investigate the Long-term Safety of Alogliptin When Used in Combination With Sulfonylurea or Metformin in Subjects With Type 2 Diabetes in Japan [NCT01318135]Phase 2/Phase 3576 participants (Actual)Interventional2009-01-31Completed
Comparison of the Effects of Rosiglitazone and Glimepiride, Both Given in Combination With Metformin, on 24-Hour Glycemia in Type 2 Diabetes Patients Not Controlled With Metformin Alone. A 3-Month Multicentre, Randomized, Parallel-Group, Open-Label Study. [NCT00318656]Phase 423 participants (Actual)Interventional2005-11-30Completed
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) [NCT02973477]Phase 445 participants (Actual)Interventional2017-01-12Completed
A Randomized, Prospective, Parallel Design Study to Compare the Effectiveness of Sitagliptin Versus Glimepiride on Endothelial Dysfunction During an Oral Glucose Loading in Drug Naive Patients With Type 2 Diabetes. [NCT02301806]Phase 430 participants (Anticipated)Interventional2015-01-31Recruiting
The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea [NCT03081676]20 participants (Actual)Interventional2017-03-08Completed
Efficacy and Safety of Saxagliptin and Glimepiride in Chinese Patients With Type 2 Diabetes Controlled Inadequately With Metformin Monotherapy (SPECIFY Study) : a 48-week, Multi-center, Randomized, Open-label Trial [NCT02280486]Phase 4388 participants (Actual)Interventional2015-01-31Completed
Comparative Study of Dapagliflozin Versus Glimepiride Effect on Insulin Regulated Aminopeptidase (IRAP) and Interleukin-34 (IL-34) in Patient With Type 2 Diabetes Mellitus [NCT04240171]60 participants (Actual)Observational [Patient Registry]2020-12-01Completed
Effect of Glimepiride, Vildagliptin, Pioglitazone and Canagliflozin on Durability of Glycemic Control After Metformin Failure in Type 2 Diabetes [NCT02142309]Phase 4450 participants (Anticipated)Interventional2005-10-31Recruiting
[NCT01585792]Phase 380 participants (Actual)Interventional2012-05-31Completed
A Relative Bioavailability Study of Glimepiride 4 mg Tablets Under Fasting Conditions [NCT00834340]Phase 132 participants (Actual)Interventional2003-02-28Completed
Comparison of Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination in Poorly Controlled Type 2 Diabetic Patients [NCT04470310]Phase 499 participants (Actual)Interventional2015-12-31Active, not recruiting
Clinical Study to Assess the Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea (Glimepiride) in Healthy Male Subjects: Single-blinded, Randomized, Crossover Study [NCT01133431]Phase 124 participants (Anticipated)Interventional2010-05-31Completed
[NCT00633425]Phase 443 participants (Actual)Interventional2002-10-31Completed
A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride [NCT01075282]Phase 3810 participants (Actual)Interventional2010-02-28Completed
A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Contr [NCT01006603]Phase 4957 participants (Actual)Interventional2009-10-31Completed
A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus [NCT00974090]Phase 3194 participants (Actual)Interventional2009-09-30Completed
A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess Glycemic Control With Rimonabant in Comparison With Glimepiride Over 1 Year in Overweight/Obese Type2 Diabetic Patients Not Adequately Controlled With Metformin [NCT00449605]Phase 3508 participants (Actual)Interventional2007-03-31Terminated(stopped due to Company decision taken in light of demands by certain national health authorities)
A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic [NCT01678820]Phase 3299 participants (Actual)Interventional2012-10-10Terminated(stopped due to Merck terminated the study for business reasons in November 2013.)
A 52-Week, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Active Controlled, Phase IV Study to Evaluate the Safety and Efficacy of Dapagliflozin or Dapagliflozin Plus Saxagliptin Compared With Sulphonylurea All Given as Add-on Therapy to Metformi [NCT02471404]Phase 4939 participants (Actual)Interventional2015-09-21Completed
A Phase 4, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Renal Protective Effect (UACR), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria [NCT03118713]Phase 433 participants (Actual)Interventional2017-04-25Terminated(stopped due to Business decision due to enrollment challenges)
A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin [NCT02769481]Phase 3426 participants (Actual)Interventional2016-08-15Completed
Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Advanced Type 2 Diabetes [NCT05975528]Phase 487 participants (Anticipated)Interventional2023-08-31Not yet recruiting
A Multicenter, Open, Randomized, 24 Weeks Study to Evaluate the Superiority of Glimepiride Over Sitagliptin for the Treatment of naïve Patients With Type 2 Diabetes Mellitus [NCT00957060]Phase 4400 participants (Actual)Interventional2009-07-31Completed
Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled [NCT00949442]Phase 4708 participants (Actual)Interventional2009-07-31Completed
Influence of Improving Glycaemic Control on Glucagon-Like-Peptide-1 Response to an Oral Glucose Load. Comparison of Sulphonylurea With DPP-4 Inhibition. [NCT00747383]74 participants (Actual)Interventional2008-09-30Completed
A Pilot Study of Intensive Insulin Regimen as a Primary Treatment of New Onset of Type 2 DM [NCT01087567]Phase 423 participants (Actual)Interventional2010-07-31Completed
Effect of Oral Combination Therapy of Metformin Extended Release Over Glimepiride in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus With Failure of Monotherapy [NCT00941161]Phase 428 participants (Anticipated)Interventional2009-02-28Completed
A Multicenter, Randomized, Parallel-group, Open Study to Compare the Efficacy and Safety of Early Combination Therapy With Amaryl M to Metformin Uptitration in Type 2 DM Patients Inadequately Controlled on Metformin HCL [NCT00612144]Phase 4192 participants (Anticipated)Interventional2007-12-31Completed
A 24 Week, Open-Label, Single Arm, Multi-Center Clinical Study to Document the Benefits of the Combination of Lantus and Amaryl in Ethnic Japanese Type 2 Diabetic Patients Living Outside of Japan (in US or Brazil), Who Failed Good Metabolic Control With O [NCT00642915]Phase 4100 participants (Actual)Interventional2003-06-30Completed
Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver [NCT02649465]Phase 440 participants (Actual)Interventional2015-11-11Completed
Effect of Dosage Reduction of Glucose-Lowering Multidrug Regimens on the Incidence of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan: An Open-Label, Parallel-Group, Randomized, Controlled Trial [NCT04237493]Phase 4687 participants (Actual)Interventional2017-02-14Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Glimepiride Tablets (1 mg; Mylan) to Amaryl® Tablets (1 mg; Aventis) in Healthy Volunteers [NCT00648362]Phase 140 participants (Actual)Interventional2004-11-30Completed
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy [NCT01565096]Phase 444 participants (Anticipated)Interventional2011-11-30Recruiting
Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono- Therapy in Chinese Type 2 Diabetes Mellitus (T2DM) [NCT00908921]Phase 4391 participants (Actual)Interventional2009-04-30Completed
An Open, Randomized, Two-Treatment, Crossover Study to Assess the Dose Proportionality of Glimepiride Between Amaryl M 1mg/500mg and 2mg/500mg (Glimepiride-Metformin Fixed Dose Combination Tablet) in Healthy Subjects [NCT00934817]Phase 136 participants (Actual)Interventional2007-03-31Completed
A Multi-national, Open-labelled, Randomised, Parallel Group, 4 Week run-in and 26 Weeks Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Insulin na [NCT00469092]Phase 4480 participants (Actual)Interventional2007-05-31Completed
Comparison of Efficacy and Safety of Biphasic Insulin Aspart 30 Plus Metformin With Insulin Glargine Plus Glimepiride in Type 2 Diabetes [NCT00619697]Phase 4260 participants (Actual)Interventional2003-12-31Completed
A Multi-center, Open, Randomized, Parallel-group, 2 Arm Study to Compare the Efficacy and Safety of Amaryl®M 1/500mg Twice Daily Versus Amaryl® 4mg Both in Combination With Lantus® Once-daily Regimen in Type 2 Diabetes Mellitus Patients With Inadequate Gl [NCT00913367]Phase 4110 participants (Anticipated)Interventional2009-05-31Completed
A Relative Bioavailability Study of Glimepiride 1 MG Tablets Under Fed Conditions [NCT00776620]32 participants (Actual)Interventional2003-07-31Completed
Insulin Glargine Combined With Sulfonylurea Versus Metformin in Patients With Type 2 Diabetes: A Randomized, Controlled Trial. [NCT00708578]Phase 499 participants (Actual)Interventional2008-05-31Completed
Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT [NCT00722631]70 participants (Actual)Interventional2007-05-31Completed
A 24-Week,Int.,Rand.,Double-blind,Parallel-group,Multi-centre, Plac.-Controlled Phase III Study With a 24-Wk Ext.Per.to Eval.the Efficacy and Safety of Dapagliflozin in Comb.With Glimepiride (a Sulphonylurea) in Subjects With Type2 Diab.Who Have Inadeq. G [NCT00680745]Phase 3597 participants (Actual)Interventional2008-04-30Completed
A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks With a 104 Week Extension Period in Patients With Type 2 Diabetes Mellitus and Insuff [NCT01167881]Phase 31,549 participants (Actual)Interventional2010-08-31Completed
An Open-labelled, Randomised, Parallel Group, 3 Week run-in and 24 Week Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Chinese and Japanese Insul [NCT01123980]Phase 4521 participants (Actual)Interventional2010-05-31Completed
Comparison of Type 2 Diabetes Pharmacotherapy Regimens Using Targeted Learning [NCT05073692]270,000 participants (Anticipated)Observational2021-07-01Recruiting
A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, [NCT00838903]Phase 31,049 participants (Actual)Interventional2009-02-28Completed
A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2608204 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus [NCT01408095]Phase 2240 participants (Anticipated)Interventional2011-09-30Withdrawn(stopped due to Trial terminated no patients were screened or enrolled)
Effects of Pioglitazone in Combination With Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients With Type 2 Diabetes Mellitus [NCT00770952]Phase 391 participants (Actual)Interventional2006-12-31Completed
The Comparative Study of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on the Effect of Improving Glucose Variability and Oxidative Stress in Type 2 Diabetic Patients With Inadequate Glycemic Control on Metformin [NCT00699322]Phase 436 participants (Anticipated)Interventional2008-06-30Recruiting
A Relative Bioavailability Study of Glimepiride 1 MG Tablets Under Fasting Conditions [NCT00776490]32 participants (Actual)Interventional2003-07-31Completed
28-week, Open, Randomized, Multinational, Multicenter Clinical Trial to Compare Efficacy and Safety of Combination Therapy of Glimepiride Plus Metformin Plus HOE901 Insulin Analogue Versus a Two-injection Conventional Therapy With Premixed Insulin NPH 30/ [NCT00783744]Phase 3375 participants (Actual)Interventional2001-12-31Completed
An Open, Randomized, Two-Treatment, Crossover Study to Assess the Dose Proportionality of Glimepiride Between Amaryl M SR 1/500mg and 2/500mg (Glimepiride-Metformin Fixed Dose Combination Tablet) in Healthy Male Subjects [NCT00934323]Phase 133 participants (Actual)Interventional2008-10-31Completed
A Randomised Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 1356 ( 5.0 mg, Administered Orally Once Daily) Compared to Glimepiride Over Two Years in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metfo [NCT00622284]Phase 31,560 participants (Actual)Interventional2008-02-29Completed
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects [NCT00842556]Phase 118 participants (Actual)Interventional2009-03-31Completed
A Randomised, db, Placebo-controlled, Parallel Group Efficacy and Safety Study of BI 1356 (5mg), Administered Orally Once Daily for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic [NCT00740051]Phase 3227 participants (Actual)Interventional2008-08-31Completed
A Double-Blind, Randomized, Comparator-Controlled Study In Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultr [NCT00225277]Phase 3547 participants (Actual)Interventional2003-07-31Completed
Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes [NCT00294723]Phase 3746 participants (Actual)Interventional2006-02-28Terminated(stopped due to The trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power)
Comparison of Two Therapeutic Strategies for Treating Type 2 Diabetic Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs : 6-month Proof of Concept Study. [NCT00360698]Phase 4106 participants (Actual)Interventional2006-07-31Completed
Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study) [NCT00359762]Phase 31,029 participants (Actual)Interventional2006-09-30Completed
A Randomised, Double-blind, Placebo-controlled, Five Parallel Groups Study Investigating the Efficacy and Safety of BI 1356 BS (1 mg, 5 mg and 10 mg Administered Orally Once Daily) Over 12 Weeks as add-on Therapy in Patients With Type 2 Diabetes and Insuf [NCT00309608]Phase 2333 participants (Actual)Interventional2006-04-30Completed
Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia [NCT00608179]32 participants (Actual)Interventional2002-08-31Completed
Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin [NCT02026310]40 participants (Actual)Interventional2014-01-31Completed
Lantus vs Sulfonylurea as add-on Therapy in Type 2 Diabetic Patients Failing Metformin Monotherapy: Comparison of Effects on Beta Cell Function and Metabolic Profile. [NCT00562172]Phase 475 participants (Actual)Interventional2007-09-30Completed
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects [NCT00562250]Phase 111 participants (Actual)Interventional2008-05-31Completed
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepi [NCT01087502]Phase 3241 participants (Actual)Interventional2010-03-31Completed
A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therap [NCT01177384]Phase 3380 participants (Actual)Interventional2011-01-25Completed
An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting [NCT01340768]Phase 3870 participants (Actual)Interventional2010-06-22Completed
A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin [NCT00792935]Phase 2143 participants (Actual)Interventional2009-01-31Completed
A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes [NCT00775684]47 participants (Actual)Interventional2008-10-31Completed
A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study [NCT02694263]Phase 425 participants (Actual)Interventional2016-07-31Completed
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control [NCT01189890]Phase 3480 participants (Actual)Interventional2010-08-16Completed
Efficacy and Safety Comparison of Sitagliptin and Glimepiride in Elderly Japanese Patients With Type 2 Diabetes [NCT01183104]305 participants (Actual)Interventional2010-08-31Completed
SGLT2 Inhibition With Empagliflozin in Patients With Type 2 Diabetes Mellitus: Influences on Left Ventricular Mass, Function, and Cardiac Lipid Content [NCT02728453]Phase 47 participants (Actual)Interventional2016-04-27Terminated(stopped due to Insufficient recruitment.)
Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents [NCT04287387]Phase 4180 participants (Anticipated)Interventional2020-03-02Not yet recruiting
Single-Dose Food In Vivo Bioequivalence Study of Glimepiride Tablets (1 mg; Mylan) to Amaryl® Tablets (1 mg; Aventis) in Healthy Volunteers [NCT00650533]Phase 140 participants (Actual)Interventional2004-11-30Completed
Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function After Early Intensive Diabetes Treatment [NCT02823808]Phase 496 participants (Anticipated)Interventional2017-07-31Recruiting
Risk Reduction in Coronary Heart Disease - a Prospective Randomized Study [NCT00679237]1,600 participants (Actual)Interventional2007-09-30Completed
A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placeb [NCT00839527]Phase 3685 participants (Actual)Interventional2009-02-28Completed
A Phase III, Randomized, Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on a Sulfonylurea in Combination With Metformin [NCT01076075]Phase 3427 participants (Actual)Interventional2010-06-03Completed
A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Co [NCT00968812]Phase 31,452 participants (Actual)Interventional2009-09-30Completed
A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. [NCT01243424]Phase 36,103 participants (Actual)Interventional2010-11-11Completed
The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes [NCT01404676]Phase 434 participants (Actual)Interventional2010-06-30Completed
Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin [NCT01425580]Phase 262 participants (Actual)Interventional2012-01-31Completed
The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes [NCT05386186]Phase 4192 participants (Anticipated)Interventional2022-01-01Recruiting
Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients. Positron Emission Tomography Assessment(PET) [NCT01429818]Phase 416 participants (Actual)Interventional2007-07-31Completed
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride Arm [NCT00620282]Phase 349 participants (Actual)Interventional2008-02-29Completed
Effect of Liraglutide or Glimepiride Added to Metformin on Glycaemic Control in Subjects With Type 2 Diabetes [NCT00614120]Phase 3929 participants (Actual)Interventional2008-01-31Completed
Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia [NCT00770653]Phase 3305 participants (Actual)Interventional2007-04-30Completed
Multi Center, Open Label Study to Evaluate the Influence of Pioglitazone Treatment Over 6 Months on Metabolic Control in Type II Diabetic Patients Previously Treated With Insulin [NCT00576784]Phase 4100 participants (Actual)Interventional2005-04-30Completed
Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects [NCT05468879]34 participants (Actual)Interventional2020-09-21Completed
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus [NCT01699737]Phase 2325 participants (Actual)Interventional2012-09-30Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Monotherapy (VERTIS-ASIA) [NCT02630706]Phase 3506 participants (Actual)Interventional2015-12-16Completed
A Phase 1, Open-label, Randomized, Three-period, Crossover Study to Evaluate Pharmacokinetic Interaction Between Bexagliflozin Tablets and Metformin, Glimepiride, or Sitagliptin in Healthy Subjects [NCT02956044]Phase 154 participants (Actual)Interventional2016-11-30Completed
A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination With Sulfonylurea in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Alone [NCT01242215]Phase 3243 participants (Actual)Interventional2010-09-17Completed
A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Co [NCT01296412]Phase 3653 participants (Actual)Interventional2011-03-11Completed
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes [NCT02946632]Phase 3104 participants (Anticipated)Interventional2016-12-31Not yet recruiting
A Randomized, Unicenter, Parallel Study of the Effect of Dapagliflozin on Central Blood Pressure Reduction Compared to Glimepiride in Adult Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control. [NCT02919059]Phase 4159 participants (Anticipated)Interventional2016-12-13Recruiting
An Open-Label, Randomized, Single Dose, Four-way Crossover, Multi-stage Study to Determine the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations, 500 mg or 1000 mg Extended Release Metformin and 1 mg or 2 mg Extended Release Gl [NCT01725672]Phase 120 participants (Actual)Interventional2012-09-27Terminated(stopped due to Due to changes in EMA guidelines on modified release dosage forms (Feb 2013; EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines.)
Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes [NCT00099944]Phase 3515 participants (Actual)Interventional2004-05-31Completed
A 16-Week Controlled, Double Blind, Double Dummy, Randomized, Two Arm Parallel-Group Study to Compare the Efficacy and Safety of Amaryl M 1/250 mg b.i.d vs. Amaryl M SR 2/500 mg od. in Patients With Type 2 Diabetes Mellitus [NCT00437554]Phase 3188 participants (Anticipated)Interventional2006-08-31Completed
The Effect of Intensive and Short-term Insulin Treatment on Long-term Pancreatic β-cell Function in Newly Diagnosed People With Type 2 Diabetes in Korea [NCT00474838]Phase 4112 participants (Actual)Interventional2007-04-30Completed
[NCT02964572]61 participants (Actual)Interventional2016-11-30Completed
Head-to-head Comparison of Quadruple Combination Therapy With Empagliflozin and Dapagliflozin in Patients With Poorly Controlled Type 2 Diabetes (T2D) Despite Three Existing Oral Antidiabetic Drugs (OAD) [NCT03748810]600 participants (Actual)Observational [Patient Registry]2016-01-01Completed
A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Atherosclerotic Disease as Measured by Carotid Intima-Media Thickn [NCT00225264]Phase 3458 participants (Actual)Interventional2003-10-31Completed
Efficacy and Safety of Inhaled Prandial Insulin Compared to Metformin Plus Glimepiride in Type 2 Diabetes [NCT00469586]Phase 3174 participants (Actual)Interventional2007-04-26Terminated(stopped due to See termination reason in detailed description)
A Randomized, Open-label, Multiple Dosing, Cross-over Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg After Oral Administration in Healthy Male Subjects [NCT02954822]Phase 136 participants (Actual)Interventional2016-11-14Completed
A 4 Week Single Center, Double-dummy, Randomised Double-blind, Balanced Incomplete Latin Square Design Study to Evaluate the Effects of Liraglutide on Appetite in Subjects With Type 2 Diabetes Compared to Glimepiride and Placebo [NCT01511692]Phase 143 participants (Actual)Interventional2005-11-30Completed
Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus [NCT01547104]Phase 440 participants (Anticipated)Interventional2012-04-30Recruiting
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]Phase 310,251 participants (Actual)Interventional1999-09-30Completed
A Multi-center, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy and Safety of Fixed-dose Rosiglitazone/Glimepiride Combination Therapy With Glimepiride Monotherapy for 24 Weeks in Drug Naive Subjects With Type 2 Diabetes [NCT01453049]Phase 386 participants (Actual)Interventional2010-04-30Terminated(stopped due to US FDA/EMA/SFDA decisions to rosiglitazone-containing medicines, ethic)
A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy [NCT00044447]Phase 3170 participants (Actual)Interventional2001-05-31Completed
Effect of Vildagliptin Versus Glimepiride on Copeptin and Fetuin-A in Type 2 Diabetic Patients [NCT06068686]70 participants (Anticipated)Interventional2022-10-01Recruiting
SGLT2-inhibition With Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema (The SUPER-Trial) [NCT02985242]Phase 46 participants (Actual)Interventional2017-06-12Terminated(stopped due to difficulties to recruit planned numbers of patients within reasonable time frame)
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study [NCT05220917]781,430 participants (Anticipated)Observational2021-08-01Active, not recruiting
Comparative Effects of Empagliflozin Versus Glimepiride After 26-weeks of Treatment Add on Metformin on Myocardial Metabolic Rate of Glucose Estimated Through 18FDG-PET in Patients With Type 2 Diabetes [NCT04183868]Phase 426 participants (Actual)Interventional2016-04-30Completed
The Use of Incretin-based Drugs and the Risk of Pancreatic Cancer in Patients With Type 2 Diabetes [NCT02475499]886,172 participants (Actual)Observational2014-03-31Completed
Multi-center, Randomized, Open Label Study of the Durability of Glycemic Control With Nateglinide Versus Glimepiride as Monotherapy in Type 2 Diabetic Patients [NCT00858013]Phase 488 participants (Actual)Interventional2009-04-24Completed
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Glimepiride In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin [NCT01517373]Phase 2304 participants (Actual)Interventional2012-02-29Completed
Safety and Efficacy of Inhaled Pre-prandial Human Insulin Plus Glimepiride Versus Rosiglitazone Plus Glimepiride in Type 2 Diabetes [NCT00343980]Phase 3363 participants (Actual)Interventional2006-10-10Terminated(stopped due to See termination reason in detailed description)
A Phase 1, Single-Blind, Placebo Controlled, Sequential Design Study to Evaluate the Drug Interaction Potential Between Glimepiride and TAK-875 in Subjects With Type 2 Diabetes Mellitus [NCT01496443]Phase 128 participants (Actual)Interventional2012-01-31Completed
Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes [NCT01509001]Phase 420 participants (Actual)Interventional2011-01-31Completed
Dose-response Relationship of Five Dose Levels of NNC90-1170 and Placebo on Glycaemic Control in Type 2 Diabetic Patients Compared to OHA Treatment. A 12-week Multi-centre, Double-blind, Randomised, Parallel Group Trial With an Open Labelled OHA Arm [NCT01509755]Phase 2196 participants (Anticipated)Interventional2000-10-31Completed
Effect on Glycemic Control of Individual Maximum Effective Dose of NNC 90-1170 as Add on Therapy to Metformin Compared to Monotherapy of NNC 90-1170 or Metformin or a Metformin-SU Combination Therapy in Patients With Type 2 Diabetes. A Double-blind, Doubl [NCT01511172]Phase 2145 participants (Actual)Interventional2002-08-31Completed
"An Open-label, Randomized, Four-way Cross-over, Single Dose Study to Compare the Different Effect of DPP-4 Inhibitors and Sulfonylurea on the Beta Cell Function by Using Biphase-Hyperglycemic Clamp" [NCT01660386]Phase 412 participants (Anticipated)Interventional2012-07-31Recruiting
Randomized Double Blind Parallel Design Study Comparing Risk of Nocturnal Hypoglycemia and Critical Arrhythmia With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy [NCT02373865]Phase 44 participants (Actual)Interventional2015-09-30Terminated(stopped due to Premature termination due to insufficient patient recruitement..)
Bioequivalence Study of Two Formulations of Glimepiride Tablet in Healthy Subjects [NCT01677247]24 participants (Actual)Interventional2011-02-28Completed
A Multinational, Open Label, Non Comparative, 24-week Study to Evaluate the Blood Glucose Lowering Efficacy and Safety of a Fixed Dose Combination of Glimepiride and Metformin in Patients With Inadequately Controlled Type 2 Diabetes [NCT01699932]Phase 3167 participants (Actual)Interventional2012-09-30Completed
A Phase 3, Randomized, Double-blind, Placebo-controlled, 26-week Multicenter Study With a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic [NCT01958671]Phase 3461 participants (Actual)Interventional2013-10-09Completed
A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Gemigliptin and Glimepiride in Healthy Male Subjects [NCT01768455]Phase 127 participants (Actual)Interventional2013-02-28Completed
Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS [NCT01812122]Phase 416 participants (Actual)Interventional2013-03-31Completed
Effects of Pioglitazone on Visceral Fat Metabolic Activity [NCT01819402]60 participants (Anticipated)Interventional2012-03-31Recruiting
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study [NCT01794143]Phase 35,047 participants (Actual)Interventional2013-05-31Completed
An Open-label, Randomized, Two-treatment Crossover Bioequivalence Study Comparing Two Batches of the Same Fixed Dose Combinations Amaryl® M IR 2/1000 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy M [NCT02395237]Phase 10 participants (Actual)Interventional2015-05-31Withdrawn
Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) in Healthy Mexican Volunteers [NCT01437800]Phase 124 participants (Actual)Interventional2011-01-31Completed
Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) After a High Fat Diet, in Healthy Mexican Volunteers [NCT01437813]Phase 124 participants (Actual)Interventional2011-01-31Completed
A Multi-center, Open, Randomized, Parallel-group Study to Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy [NCT01444248]Phase 4168 participants (Actual)Interventional2010-08-31Completed
Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data [NCT05162183]3,474 participants (Actual)Observational2019-09-01Completed
Replication of the GRADE Diabetes Trial in Healthcare Claims Data [NCT05099198]6,403 participants (Actual)Observational2018-09-01Completed
A Multicenter, Randomized, Double Blind Study to Compare the Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (Janumet®) Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus [NCT00993187]Phase 4292 participants (Actual)Interventional2010-05-04Completed
A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination With Metformin in Subjects With Type 2 Diabetes [NCT01481116]Phase 32,454 participants (Actual)Interventional2012-01-31Terminated(stopped due to Due to potential concerns about liver safety (See Detailed Description))
[NCT03009513]Phase 126 participants (Actual)Interventional2017-01-31Completed
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes [NCT01455883]Phase 30 participants (Actual)Interventional2013-02-28Withdrawn
A Multicenter, Randomized, Open-label, 2-arm Parallel Group, 20-week Study Comparing the Efficacy and Safety of Fixed-dose Combination of 1 mg Glimepiride and 250 mg Metformin (AMARYL M 1/250 mg) Versus Glimepiride (AMARYL®) in Chinese Type 2 Diabetes Pat [NCT01457911]Phase 3244 participants (Actual)Interventional2011-10-31Completed
A Multicenter, Randomized, Active-controlled, Parallel Group, Open-label, Exploratory Study to Evaluate the Efficacy on Glucose Variability(MAGE, Glucose SD) and Safety of Initial Combination Therapy of Gemigliptin 50mg q.d., Versus Sitagliptin 100mg q.d. [NCT01890629]Phase 469 participants (Actual)Interventional2013-05-31Completed
The Effects of Glimepiride in Patients With Type 2 Diabetes and Chronic Heart Failure [NCT05538819]1,018 participants (Actual)Observational [Patient Registry]2017-06-01Completed
Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With Metformin [NCT02564926]Phase 4125 participants (Actual)Interventional2016-01-05Completed
A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects W [NCT02099110]Phase 31,233 participants (Actual)Interventional2014-04-22Completed
A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 [NCT01593137]Phase 40 participants (Actual)Interventional2012-05-31Withdrawn(stopped due to Lack of patients with the criteria established in the protocol.)
Phase 2 Study: A Double-blind, Randomised, Clinical Cross-over Trial to Investigate the Treatment Potential of Liraglutide Compared to Glimepiride in MODY Patients [NCT01610934]Phase 2/Phase 315 participants (Actual)Interventional2012-08-31Completed
Comparison of the Effect of Fenofibrate Versus Curcumin in Type 2 Diabetic Patients Treated With Glimepiride [NCT04528212]Phase 460 participants (Actual)Interventional2020-11-01Completed
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin [NCT01682759]Phase 3751 participants (Actual)Interventional2012-09-10Completed
Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subje [NCT00318422]Phase 31,041 participants (Actual)Interventional2006-05-31Completed
Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine [NCT00331851]Phase 3584 participants (Actual)Interventional2006-05-31Completed
Glimepiride Versus Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus: A Single Blind Comparison Study [NCT00353691]Phase 3100 participants Interventional2002-10-31Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Placebo as an Add-on to Glimepiride in Subjects With Type 2 Diabetes [NCT01829477]Phase 333 participants (Actual)Interventional2013-04-30Terminated(stopped due to Due to potential concerns about liver safety (See Detailed Description))
Sonias Combination Tablets LD Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone [NCT02098746]294 participants (Actual)Observational2011-06-30Completed
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabe [NCT01999218]Phase 31,326 participants (Actual)Interventional2013-12-16Completed
Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes: a Multicenter, Randomized, Prospective, Open-label, Clinical Trial [NCT02312063]Phase 448 participants (Actual)Interventional2015-02-28Completed
Effects of Rosuvastatin on Markers of Atherosclerosis in Diabetic Patients Treated With Glimepiride/Metformin Combination [NCT03907423]70 participants (Actual)Interventional2019-04-01Completed
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy [NCT01477853]Phase 3166 participants (Actual)Interventional2011-10-24Terminated(stopped due to The study was terminated early by the Sponsor for business reasons.)
The Effect of Food on the Pharmacokinetics of Metformin Given Either as Metformin Hydrochloride SR 1000mg Tablet or as a Fixed Dose Combination of Metformin Hydrochloride SR 1000mg/Glimepiride 2mg Tablet in Healthy Indian Volunteers. [NCT01561976]30 participants (Actual)Interventional2012-01-30Completed
A 16 Week PILOT Study to Determine the Frequency of Sulphonylurea-Associated Hypoglycaemia in Older Moderately Frail Patients With Type 2 Diabetes Mellitus Poorly Controlled on Metformin: an Open Label Study ( DIAFRAIL Study) [NCT02484209]Phase 30 participants (Actual)Interventional2016-02-29Withdrawn(stopped due to Inclusion criteria too strict making it difficult to recruit in primary care)
The Effects of Saxagliptin 5mg, Once Daily for 52 Weeks on 24 Hour Urine Albumin Creatinine Rate(ACR) , in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin or/and Acarbose [NCT02462369]Phase 488 participants (Anticipated)Interventional2015-06-30Enrolling by invitation
Exploring Effective and Safety Therapies Which Protect Islet β Cell on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity [NCT03180281]135 participants (Anticipated)Interventional2017-07-01Not yet recruiting
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Gl [NCT01704261]Phase 3307 participants (Actual)Interventional2012-10-18Completed
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea T [NCT01590771]Phase 3498 participants (Actual)Interventional2012-07-09Completed
A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8) [NCT01769378]Phase 3300 participants (Actual)Interventional2013-01-31Completed
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes [NCT01455922]Phase 30 participants (Actual)Interventional2013-02-28Withdrawn
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus [NCT01494987]Phase 3431 participants (Actual)Interventional2012-01-31Completed
A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Inappropriate Due to Intolerance or Contraindication [NCT01863667]Phase 365 participants (Actual)Interventional2013-07-08Terminated
A Study to Assess the Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus [NCT01614769]Phase 110 participants (Actual)Interventional2012-07-18Completed
A Comparative Study to Assess the Effect of Vildagliptin Versus Glimepiride on Glucose Variability in Type 2 Diabetic Patients Uncontrolled on Metformin Alone [NCT01910441]Phase 495 participants (Actual)Interventional2013-07-31Terminated(stopped due to The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point.)
A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Ty [NCT01709305]Phase 45,570 participants (Actual)Interventional2012-11-08Completed
Effect of INitial Combination Therapy With GEmigliptin and Metformin on Microbiota Change and Glycemic Control in patientS With Type 2 DIabetes aNd ObEsity (INTESTINE Study) [NCT02609815]70 participants (Actual)Interventional2015-11-01Completed
The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases [NCT03693560]Phase 480 participants (Actual)Interventional2018-10-08Completed
A Multinational, Open Label, Randomized, Active-controlled, 3-arm Parallel Group, 24-week Study Comparing the Combination of Glimepiride and Metformin Versus Glimepiride and Metformin Alone in Patients With Type 2 Diabetes [NCT01459809]Phase 3538 participants (Actual)Interventional2012-02-29Completed
Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure [NCT04841096]Phase 3172 participants (Anticipated)Interventional2023-03-21Recruiting
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy [NCT01755156]Phase 3402 participants (Actual)Interventional2013-01-11Completed
Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA') [NCT01703286]Phase 142 participants (Actual)Interventional2012-10-31Completed
Study ATG115317, a Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus [NCT01495013]Phase 3427 participants (Actual)Interventional2011-12-31Completed
An Individualized treatMent aPproach for oldER patIents: A Randomized, Controlled stUdy in Type 2 Diabetes Mellitus (IMPERIUM) [NCT02072096]Phase 4192 participants (Actual)Interventional2014-02-28Terminated(stopped due to The trial was terminated per protocol because of lack of feasibility.)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Inadequate [NCT02036515]Phase 3464 participants (Actual)Interventional2014-03-12Completed
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin [NCT01841697]Phase 3642 participants (Actual)Interventional2013-06-13Completed
Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin (GalvusMet) Versus Glimepiride and Metformin [NCT02007278]Phase 440 participants (Actual)Interventional2014-01-03Completed
Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey on Long-term Use for in Type 2 Diabetes Mellitus [NCT02098733]1,168 participants (Actual)Observational2011-06-30Completed
A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control [NCT01717313]Phase 3329 participants (Actual)Interventional2012-12-05Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Initial Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Subjects With [NCT02226003]Phase 3291 participants (Actual)Interventional2014-09-23Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monothe [NCT02033889]Phase 3621 participants (Actual)Interventional2013-12-13Completed
The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus [NCT01644500]Phase 3737 participants (Actual)Interventional2012-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00000620 (6) [back to overview]First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]Stroke in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00032487 (2) [back to overview]Primary Major Macrovascular Events
NCT00032487 (2) [back to overview]Secondary Endpoint
NCT00131664 (18) [back to overview]Number of Subjects Achieving FPG Target at Month 12
NCT00131664 (18) [back to overview]Mean Change From Baseline in 5 Year UKPDS Risk Scores at Month 12
NCT00131664 (18) [back to overview]Mean Change From Baseline in 5 Year UKPDS Risk Scores at Month 6
NCT00131664 (18) [back to overview]Mean Change From Baseline in A1C at Month 12
NCT00131664 (18) [back to overview]Mean Change From Baseline in A1C at Month 4
NCT00131664 (18) [back to overview]Mean Change From Baseline in Adiponectin at Month 12
NCT00131664 (18) [back to overview]Mean Change From Baseline in Adiponectin at Month 6
NCT00131664 (18) [back to overview]Mean Change From Baseline in C-reactive Protein (CRP) at Month 12
NCT00131664 (18) [back to overview]Mean Change From Baseline in C-reactive Protein (CRP) at Month 6
NCT00131664 (18) [back to overview]Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Month 12
NCT00131664 (18) [back to overview]Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Month 4
NCT00131664 (18) [back to overview]Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6
NCT00131664 (18) [back to overview]Number of Subjects Achieving A1C Target at Month 12
NCT00131664 (18) [back to overview]Number of Subjects Achieving A1C Target at Month 4
NCT00131664 (18) [back to overview]Number of Subjects Achieving A1C Target at Month 6
NCT00131664 (18) [back to overview]Number of Subjects Achieving FPG Target at Month 4
NCT00131664 (18) [back to overview]Number of Subjects Achieving FPG Target at Month 6
NCT00131664 (18) [back to overview]Mean Change From Baseline in A1C at Month 6
NCT00225277 (6) [back to overview]Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events
NCT00225277 (6) [back to overview]Number of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events
NCT00225277 (6) [back to overview]Number of Subjects Experiencing Any of the Composite Endpoint B Cardiovascular Events
NCT00225277 (6) [back to overview]Nominal Change From Baseline in Normalized Total Atheroma Volume
NCT00225277 (6) [back to overview]Nominal Change From Baseline in Percent Atheroma Volume
NCT00225277 (6) [back to overview]Number of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee
NCT00294723 (17) [back to overview]Change in Fasting Plasma Glucose at Week 104
NCT00294723 (17) [back to overview]Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 156
NCT00294723 (17) [back to overview]Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 104
NCT00294723 (17) [back to overview]Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 52
NCT00294723 (17) [back to overview]Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 156
NCT00294723 (17) [back to overview]Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 104
NCT00294723 (17) [back to overview]Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 52
NCT00294723 (17) [back to overview]Change in Fasting Plasma Glucose at Week 52
NCT00294723 (17) [back to overview]Hypoglycaemic Episodes
NCT00294723 (17) [back to overview]Hypoglycaemic Episodes
NCT00294723 (17) [back to overview]Change in Fasting Plasma Glucose at Week 156
NCT00294723 (17) [back to overview]Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52
NCT00294723 (17) [back to overview]Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156
NCT00294723 (17) [back to overview]Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 104
NCT00294723 (17) [back to overview]Change in Body Weight at Week 104
NCT00294723 (17) [back to overview]Change in Body Weight at Week 156
NCT00294723 (17) [back to overview]Change in Body Weight at Week 52
NCT00309608 (3) [back to overview]HbA1c Change From Baseline at Week 12
NCT00309608 (3) [back to overview]Fasting Blood Plasma Glucose Level (FPG) Change From Baseline at Week 12
NCT00309608 (3) [back to overview]Percentage of Patients With HbA1c<=7.0% at Week 12
NCT00318461 (14) [back to overview]Change in Beta-cell Function at Week 26
NCT00318461 (14) [back to overview]Change in Body Weight at Week 104
NCT00318461 (14) [back to overview]Change in Body Weight at Week 26
NCT00318461 (14) [back to overview]Change in Fasting Plasma Glucose (FPG) at Week 104
NCT00318461 (14) [back to overview]Change in Fasting Plasma Glucose (FPG) at Week 26
NCT00318461 (14) [back to overview]Change in Glycosylated A1c (HbA1c) at Week 104
NCT00318461 (14) [back to overview]Change in Glycosylated A1c (HbA1c) at Week 26
NCT00318461 (14) [back to overview]Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104
NCT00318461 (14) [back to overview]Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26
NCT00318461 (14) [back to overview]Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104
NCT00318461 (14) [back to overview]Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26
NCT00318461 (14) [back to overview]Hypoglycaemic Episodes at Week 104
NCT00318461 (14) [back to overview]Hypoglycaemic Episodes at Week 26
NCT00318461 (14) [back to overview]Change in Beta-cell Function at Week 104
NCT00318656 (17) [back to overview]Glycaemia According to CGMS (Diurnal), mg/dL
NCT00318656 (17) [back to overview]Glycaemia According to CGMS (Nocturnal), mg/dL
NCT00318656 (17) [back to overview]Glycaemia According to CGMS (MAGE), mg/dL
NCT00318656 (17) [back to overview]Glycaemia According to CGMS (Postprandial Incremental AUC or Values Above 1 mg/dL), mg/dL
NCT00318656 (17) [back to overview]Glycaemia According to CGMS (Total Area Under the Curve (AUC) for Values Above 1 mg/dL), mg/dL
NCT00318656 (17) [back to overview]HbA1c (Glycosylated Hemoglobin)
NCT00318656 (17) [back to overview]Glycaemia According to CGMS (Basal Incremental AUC or Values Above 1 mg/dL), mg/dL
NCT00318656 (17) [back to overview]Duration of Hypoglycaemia (<60 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment
NCT00318656 (17) [back to overview]Episodes of Severe Hyperglycaemia (>150 mg/dL) at Baseline Compared to After 12 Weeks on Treatment
NCT00318656 (17) [back to overview]Episodes of Hypoglycaemia (<80 mg/dL) at Baseline Compared to After 12 Weeks on Treatment
NCT00318656 (17) [back to overview]Episodes of Hypoglycaemia (<60 mg/dL) at Baseline Compared to After 12 Weeks on Treatment
NCT00318656 (17) [back to overview]Episodes of Hyperglycaemia (>126 mg/dL) at Baseline Compared to After 12 Weeks on Treatment
NCT00318656 (17) [back to overview]Duration of Severe Hyperglycaemia (>150 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment
NCT00318656 (17) [back to overview]Duration of Hypoglycaemia (<80 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment
NCT00318656 (17) [back to overview]Duration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment
NCT00318656 (17) [back to overview]8-Iso Prostaglandin F2α (8-iso PGF2α) Excretion Rate
NCT00318656 (17) [back to overview]Glycaemia According to CGMS (Dawn), mg/dL
NCT00359762 (27) [back to overview]Heart Rate at Year 3
NCT00359762 (27) [back to overview]Fasting Proinsulin/Insulin Ratio at Year 3
NCT00359762 (27) [back to overview]Fasting Plasma Glucose at Year 3
NCT00359762 (27) [back to overview]Disposition Index at Year 3
NCT00359762 (27) [back to overview]Diastolic Blood Pressure at Year 3
NCT00359762 (27) [back to overview]Change in Postprandial (2 Hours) Plasma Glucose From Baseline to Endpoint
NCT00359762 (27) [back to overview]Change in HOMA-B From Baseline to Endpoint
NCT00359762 (27) [back to overview]Change in HbA1c From Baseline to Year 3
NCT00359762 (27) [back to overview]Change in HbA1c From Baseline to Year 2 for Patients Randomized at Entry in Period III
NCT00359762 (27) [back to overview]Change in HbA1c From Baseline to Year 2 for Patients Not Randomized at Entry in Period III
NCT00359762 (27) [back to overview]Change in HbA1c From Baseline to Endpoint
NCT00359762 (27) [back to overview]Change in Fasting Proinsulin/Insulin Ratio From Baseline to Endpoint.
NCT00359762 (27) [back to overview]Change in Fasting Plasma Glucose From Baseline to Endpoint
NCT00359762 (27) [back to overview]Change in Disposition Index From Baseline to Endpoint
NCT00359762 (27) [back to overview]Change in Body Weight From Baseline to Year 3
NCT00359762 (27) [back to overview]Number of Patients With Treatment Failure
NCT00359762 (27) [back to overview]Triglycerides at Year 3
NCT00359762 (27) [back to overview]Total Cholesterol at Year 3
NCT00359762 (27) [back to overview]Time to Treatment Failure
NCT00359762 (27) [back to overview]Systolic Blood Pressure at Year 3
NCT00359762 (27) [back to overview]Ratio of the 30 Minute Increment in Plasma Insulin Concentration and the 30 Minute Increment in Plasma Glucose During the Oral Glucose Tolerance Test (DI30/DG30 Ratio) at Year 3
NCT00359762 (27) [back to overview]Postprandial (2 Hours) Plasma Glucose at Year 3
NCT00359762 (27) [back to overview]Hypoglycemia Rate Per Year in Period III
NCT00359762 (27) [back to overview]Hypoglycemia Rate Per Year
NCT00359762 (27) [back to overview]Homeostasis Model Assessment of Beta-cell Function (HOMA-B) at Year 3
NCT00359762 (27) [back to overview]High-density Lipoprotein (HDL) Cholesterol at Year 3
NCT00359762 (27) [back to overview]Change in DI30/DG30 Ratio From Baseline to Endpoint
NCT00360698 (11) [back to overview]Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
NCT00360698 (11) [back to overview]Rate of Severe Symptomatic Hypoglycemia
NCT00360698 (11) [back to overview]Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
NCT00360698 (11) [back to overview]Glycosylated Haemoglobin (HbA1c) Value
NCT00360698 (11) [back to overview]Daily Mean Plasma Glucose
NCT00360698 (11) [back to overview]Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%
NCT00360698 (11) [back to overview]Daily Dose of Insulin Glulisine
NCT00360698 (11) [back to overview]Daily Dose of Insulin Glargine
NCT00360698 (11) [back to overview]Change in Weight
NCT00360698 (11) [back to overview]Change in Glycosylated Haemoglobin (HbA1c) Value
NCT00360698 (11) [back to overview]Change in Daily Mean Plasma Glucose
NCT00469092 (6) [back to overview]9-point Self-measured Plasma Glucose Profiles
NCT00469092 (6) [back to overview]Number of Hypoglycaemic Episodes
NCT00469092 (6) [back to overview]Number of Subjects Achieving the Treatment Target for Glycosylated Haemoglobin A1c (HbA1c)
NCT00469092 (6) [back to overview]Treatment Satisfaction as Measured by the Diabetes Medication Satisfaction Questionnaire (Diab MedSat)
NCT00469092 (6) [back to overview]Number of Subjects Reporting Treatment Emergent Adverse Events
NCT00469092 (6) [back to overview]Glycosylated Haemoglobin A1c (HbA1c)
NCT00614120 (8) [back to overview]7-point Self-measured Plasma Glucose Profiles
NCT00614120 (8) [back to overview]Change in Self-measured Fasting Plasma Glucose
NCT00614120 (8) [back to overview]Change in Glycosylated Haemoglobin A1c (HbA1c)
NCT00614120 (8) [back to overview]Change in Fasting Lipid Profile, APO-B
NCT00614120 (8) [back to overview]Change in Body Weight
NCT00614120 (8) [back to overview]Change in Beta-cell Function
NCT00614120 (8) [back to overview]Hypoglycaemic Episodes
NCT00614120 (8) [back to overview]Change in Fasting Lipid Profile
NCT00620282 (14) [back to overview]Number of Hypoglycaemic Episodes
NCT00620282 (14) [back to overview]Change in Body Weight
NCT00620282 (14) [back to overview]Haematology and Biochemistry Tests - Number of Subjects With Creatinine Values Outside Reference Range
NCT00620282 (14) [back to overview]Fasting Lipid Profile - Change in Triglycerides (TG)
NCT00620282 (14) [back to overview]Fasting Lipid Profile - Change in Total Cholesterol (TC)
NCT00620282 (14) [back to overview]Fasting Lipid Profile - Change in LDL-C
NCT00620282 (14) [back to overview]Fasting Lipid Profile - Change in HDL-C
NCT00620282 (14) [back to overview]Change in Sodium Nitroprusside (SNP)-Mediated Forearm Blood Flow (FBF)
NCT00620282 (14) [back to overview]Change in Mean Postprandial Glucose (PPG) Based on Self-measured 7-point Plasma Glucose Profiles
NCT00620282 (14) [back to overview]Change in HbA1c (Glycosylated Haemoglobin A1c)
NCT00620282 (14) [back to overview]Change in Fasting Plasma Glucose (FPG)
NCT00620282 (14) [back to overview]Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)
NCT00620282 (14) [back to overview]Biomarkers of Cardiovascular Risk - Change in TNF-alpha
NCT00620282 (14) [back to overview]Haematology and Biochemistry Tests - Number of Subjects With Blood Urea Nitrogen (BUN) Values Outside Reference Range
NCT00622284 (29) [back to overview]Percentage of Patients With HbA1c <7.0% at Week 104
NCT00622284 (29) [back to overview]Percentage of Patients With HbA1c <7.0% at Week 52
NCT00622284 (29) [back to overview]Percentage of Patients With HbA1c Lowering by 0.5% at Week 104
NCT00622284 (29) [back to overview]HbA1c Change at Week 104
NCT00622284 (29) [back to overview]HbA1c Change at Week 12
NCT00622284 (29) [back to overview]HbA1c Change at Week 16
NCT00622284 (29) [back to overview]HbA1c Change at Week 28
NCT00622284 (29) [back to overview]Change in Baseline Lipid Parameter Triglyceride at Week 104
NCT00622284 (29) [back to overview]HbA1c Change at Week 40
NCT00622284 (29) [back to overview]HbA1c Change at Week 52
NCT00622284 (29) [back to overview]HbA1c Change at Week 65
NCT00622284 (29) [back to overview]HbA1c Change at Week 8
NCT00622284 (29) [back to overview]HbA1c Change at Week 4
NCT00622284 (29) [back to overview]Incidence of Hypoglycaemic Events up to 104 Weeks
NCT00622284 (29) [back to overview]HbA1c Change From Baseline at Week 52
NCT00622284 (29) [back to overview]Fasting Plasma Glucose (FPG) Change From Baseline at Week 104
NCT00622284 (29) [back to overview]Incidence of Hypoglycaemic Events up to 52 Weeks
NCT00622284 (29) [back to overview]Percentage of Patients With HbA1c <6.5% at Week 104
NCT00622284 (29) [back to overview]Percentage of Patients With HbA1c <6.5% at Week 52
NCT00622284 (29) [back to overview]Change in Baseline Lipid Parameter Low Density Lipoprotein (LDL) at Week 104
NCT00622284 (29) [back to overview]Change in Baseline Lipid Parameter HDL at Week 104
NCT00622284 (29) [back to overview]Change in Baseline Lipid Parameter Cholesterol at Week 104
NCT00622284 (29) [back to overview]Body Weight Change From Baseline at Week 52
NCT00622284 (29) [back to overview]HbA1c Change at Week 78
NCT00622284 (29) [back to overview]Body Weight Change From Baseline at Week 104
NCT00622284 (29) [back to overview]2 hr Postprandial Glucose (PPG) Change From Baseline at Week 104
NCT00622284 (29) [back to overview]HbA1c Change at Week 91
NCT00622284 (29) [back to overview]HbA1c Change From Baseline at Week 104
NCT00622284 (29) [back to overview]Fasting Plasma Glucose (FPG) Change From Baseline at Week 52
NCT00680745 (6) [back to overview]Adjusted Mean Change in Body Weight for Participants With Baseline Body Mass Index (BMI)≥27 kg/m2
NCT00680745 (6) [back to overview]Adjusted Mean Change in Fasting Plasma Glucose (FPG)
NCT00680745 (6) [back to overview]Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%
NCT00680745 (6) [back to overview]Adjusted Mean Change in HbA1c Levels
NCT00680745 (6) [back to overview]Adjusted Mean Change in 2-h Post-challenge Plasma Glucose Rise
NCT00680745 (6) [back to overview]Adjusted Mean Change in Body Weight
NCT00701090 (6) [back to overview]Change From Baseline in Body Weight at Week 30
NCT00701090 (6) [back to overview]Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30
NCT00701090 (6) [back to overview]Change From Baseline in HbA1c at Week 30
NCT00701090 (6) [back to overview]Percent of Patients With A1C <6.5% at Week 30
NCT00701090 (6) [back to overview]Percent of Patients With A1C <7.0% at Week 30
NCT00701090 (6) [back to overview]Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30
NCT00740051 (8) [back to overview]HbA1c Change From Baseline at Week 18 (Final Analysis)
NCT00740051 (8) [back to overview]HbA1c Change From Baseline at Week 18 (Interim Analysis)
NCT00740051 (8) [back to overview]Percentage of Patients With HbA1c Lowering by 0.5% at Week 18 (Interim Analysis)
NCT00740051 (8) [back to overview]Percentage of Patients With HbA1c<6.5 at Week 18 (Interim Analysis)
NCT00740051 (8) [back to overview]Percentage of Patients With HbA1c<7.0 at Week 18 (Interim Analysis)
NCT00740051 (8) [back to overview]The Change in FPG From Baseline by Visit Over Time
NCT00740051 (8) [back to overview]The Change in HbA1c From Baseline by Visit Over Time
NCT00740051 (8) [back to overview]Fasting Plasma Glucose (FPG) Change From Baseline at Week 18 (Interim Analysis)
NCT00770653 (32) [back to overview]Change From Baseline in Fasting Glucose.
NCT00770653 (32) [back to overview]Change From Baseline in Erythrocyte Deformability (60.00).
NCT00770653 (32) [back to overview]Change From Baseline in High-Density Lipoprotein Cholesterol.
NCT00770653 (32) [back to overview]Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.
NCT00770653 (32) [back to overview]Change From Baseline in Low-Density Lipoprotein Cholesterol.
NCT00770653 (32) [back to overview]Change From Baseline in Low-Density Lipoprotein Subfractions.
NCT00770653 (32) [back to overview]Change From Baseline in Matrix Metallo Proteinase-9.
NCT00770653 (32) [back to overview]Change From Baseline in Nitrotyrosine.
NCT00770653 (32) [back to overview]Change From Baseline in Platelet Function.
NCT00770653 (32) [back to overview]Change From Baseline in Soluble CD40 Ligand.
NCT00770653 (32) [back to overview]Change From Baseline in Soluble Intracellular Adhesion Molecule.
NCT00770653 (32) [back to overview]Change From Baseline in Soluble Vascular Cell Adhesion Molecule.
NCT00770653 (32) [back to overview]Change From Baseline in Systolic Blood Pressure.
NCT00770653 (32) [back to overview]Change From Baseline in Erythrocyte Deformability (6.00).
NCT00770653 (32) [back to overview]Change From Baseline in Thromboxane B2.
NCT00770653 (32) [back to overview]Change From Baseline in Triglycerides.
NCT00770653 (32) [back to overview]Change From Baseline in Von-Willebrand Factor.
NCT00770653 (32) [back to overview]Change From Baseline in Erythrocyte Deformability (0.30%).
NCT00770653 (32) [back to overview]The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.
NCT00770653 (32) [back to overview]Intake of Study Medication Greater Than 80% and Less Than 120%.
NCT00770653 (32) [back to overview]Change From Baseline in Erythrocyte Deformability (1.20).
NCT00770653 (32) [back to overview]Change From Baseline in Adiponectin.
NCT00770653 (32) [back to overview]Change From Baseline in Diastolic Blood Pressure.
NCT00770653 (32) [back to overview]Change From Baseline in E-Selectin.
NCT00770653 (32) [back to overview]Change From Baseline in Erythrocyte Deformability (0.60%)
NCT00770653 (32) [back to overview]Change From Baseline in Erythrocyte Deformability (12.00).
NCT00770653 (32) [back to overview]Change From Baseline in Erythrocyte Deformability (3.00).
NCT00770653 (32) [back to overview]Change From Baseline in Erythrocyte Deformability (30.00).
NCT00770653 (32) [back to overview]Change From Baseline in Fasting Intact Proinsulin.
NCT00770653 (32) [back to overview]Change From Baseline in High Sensitivity C-reactive Protein (Original).
NCT00770653 (32) [back to overview]Change From Baseline in Glycosylated Hemoglobin.
NCT00770653 (32) [back to overview]Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).
NCT00775684 (5) [back to overview]PG 50 (the Plasma Glucose Level at Which Half-maximal Insulin Secretion is Achieved During the Glucose-potentiated Arginine Test) at Baseline and 6 Months
NCT00775684 (5) [back to overview]Insulin Sensitivity at Baseline and 6 Months
NCT00775684 (5) [back to overview]Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (μU/ml)
NCT00775684 (5) [back to overview]Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (pg/mL)
NCT00775684 (5) [back to overview]Change in Acute Insulin Response to Arginine. (AIRarg)
NCT00792935 (2) [back to overview]Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic)
NCT00792935 (2) [back to overview]Change From Baseline to Week 6 in 24-hour Weighted Mean Glucose
NCT00834340 (3) [back to overview]Cmax - Maximum Observed Concentration
NCT00834340 (3) [back to overview]AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00834340 (3) [back to overview]AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration
NCT00835172 (3) [back to overview]AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00835172 (3) [back to overview]AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00835172 (3) [back to overview]Cmax - Maximum Observed Concentration
NCT00838903 (9) [back to overview]Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104
NCT00838903 (9) [back to overview]Change From Baseline in Body Weight at Week 104
NCT00838903 (9) [back to overview]Change From Baseline in Body Weight at Week 156
NCT00838903 (9) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 104
NCT00838903 (9) [back to overview]Change From Baseline in FPG at Week 156
NCT00838903 (9) [back to overview]Change From Baseline in HbA1c at Week 156
NCT00838903 (9) [back to overview]Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 104
NCT00838903 (9) [back to overview]Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 156
NCT00838903 (9) [back to overview]Time to Hyperglycemia Rescue
NCT00839527 (9) [back to overview]Change From Baseline in HbA1c at Week 104 and Week 156
NCT00839527 (9) [back to overview]Change From Baseline in Body Weight at Week 104 and Week 156
NCT00839527 (9) [back to overview]Time to Hyperglycemia Rescue
NCT00839527 (9) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52
NCT00839527 (9) [back to overview]Change From Baseline in Body Weight at Week 52
NCT00839527 (9) [back to overview]Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52
NCT00839527 (9) [back to overview]Change From Baseline in FPG at Week 104 and Week 156
NCT00839527 (9) [back to overview]Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 52
NCT00839527 (9) [back to overview]Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 156
NCT00858013 (5) [back to overview]Fasting Glucose
NCT00858013 (5) [back to overview]The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate
NCT00858013 (5) [back to overview]HOMA-IR
NCT00858013 (5) [back to overview]HbA1c
NCT00858013 (5) [back to overview]C-peptide
NCT00968812 (4) [back to overview]Percent Change in Body Weight From Baseline to Week 52
NCT00968812 (4) [back to overview]Change in HbA1c From Baseline to Week 52
NCT00968812 (4) [back to overview]Change in HbA1c From Baseline to Week 104
NCT00968812 (4) [back to overview]Percentage of Patients Experiencing at Least 1 Hypoglycemic Event From Baseline to Week 52
NCT00974090 (4) [back to overview]Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12
NCT00974090 (4) [back to overview]Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12
NCT00974090 (4) [back to overview]Change From Baseline in HbA1c at Week 12
NCT00974090 (4) [back to overview]Change From Baseline in Fasting Plasma Glucose at Week 12
NCT00993187 (7) [back to overview]Percentage of Participants With HbA1C < 7.0% at Week 30
NCT00993187 (7) [back to overview]Number of Participants Who Experienced at Least One Adverse Event (AE)
NCT00993187 (7) [back to overview]Percentage of Participants With One or More Episodes of Hypoglycemia
NCT00993187 (7) [back to overview]Number of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT00993187 (7) [back to overview]Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30
NCT00993187 (7) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30
NCT00993187 (7) [back to overview]Change From Baseline in Body Weight at Week 30
NCT01006603 (7) [back to overview]Change From Baseline to Week 52 in HbA1c.
NCT01006603 (7) [back to overview]Change From Baseline to Week 52 in Fasting Plasma Glucose (FPG)
NCT01006603 (7) [back to overview]Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia.
NCT01006603 (7) [back to overview]Change From Baseline to Week 52 in Insulin
NCT01006603 (7) [back to overview]Proportion of Patients Having Experienced at Least One Hypoglycaemic Event (Confirmed or Severe) Over the 52-week Double-blind Treatment Period.
NCT01006603 (7) [back to overview]Proportion of Patients Achieving a Therapeutic Glycaemic Response at Week 52 Defined as HbA1c <7.0%
NCT01006603 (7) [back to overview]Change From Baseline to Week 52 in β-cell Function (as Measured by Homeostasis Model Assessment-β [HOMA-β]
NCT01068860 (16) [back to overview]Mean Change in Absolute Glucose Level at 2 Hours, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 2-4 Hours, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Number of Participants Reporting Death, Serious Adverse Events (SAEs) and Adverse Events (AEs) Above 5% Frequency, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in Fasting Glucose Disposition Index(GDI)1 and Index 2, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in Quantitative Insulin Sensitivity Check Index (QUICKI) Score, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in Post-prandial Glucose Area Under the Curve (AUC)0-4 Hours, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in Peak Plasma Insulin, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in Peak Plasma Glucose, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in Peak Plasma C-peptide Level, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-4 Hours, From Baseline to 4 Weeks.
NCT01068860 (16) [back to overview]Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks.
NCT01068860 (16) [back to overview]Mean Change in Insulin Area Under the Curve (AUC) 0-4 Hours, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in Fructosamine, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in Fasting Plasma Insulin, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in Fasting Plasma Glucose, From Baseline to 4 Weeks
NCT01068860 (16) [back to overview]Mean Change in C-peptide Area Under the Curve (AUC), 0-4 Hours, From Baseline to 4 Weeks
NCT01075282 (26) [back to overview]Rate of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]Number of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]Number of Participants With Treatment Emergent Adverse Events at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]Number of Participants With LY2189265 Antibodies at 26, 52, 78 Weeks and 4 Weeks After Last Dose of Study Drug (83 Weeks Maximum)
NCT01075282 (26) [back to overview]Number of Participants With Adjudicated Pancreatitis at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]Number of Participants With Adjudicated Cardiovascular Events at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than or Equal to 6.5% at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]Change From Baseline to 52 and 78 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)
NCT01075282 (26) [back to overview]Change From Baseline to 52 and 78 Weeks in Glucagon Concentration
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52, and 78 Weeks on Blood Pressure
NCT01075282 (26) [back to overview]Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52 and 78 Weeks on Serum Calcitonin
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52 and 78 Weeks on Pancreatic Enzymes
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52 and 78 Weeks in the Low Blood Sugar Survey
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52 and 78 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52 and 78 Weeks for Body Weight
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52 and 78 Weeks for Body Mass Index
NCT01075282 (26) [back to overview]Change From Baseline to 26 Weeks and 78 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Activities of Daily Living
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Self-Perception
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52 and 78 Weeks in the EuroQol 5 Dimension
NCT01075282 (26) [back to overview]Change in Baseline to 26, 52 and 78 Weeks on Pulse Rate
NCT01075282 (26) [back to overview]Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Heart Rate
NCT01076075 (5) [back to overview]Number of Participants Discontinuing Study Drug Due to An Adverse Event
NCT01076075 (5) [back to overview]Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54
NCT01076075 (5) [back to overview]Change From Baseline in Fasting Plasma Glucose at Week 24
NCT01076075 (5) [back to overview]Change From Baseline in 2-hour Post-Meal Glucose at Week 24
NCT01076075 (5) [back to overview]Change From Baseline in Hemoglobin A1C (%) at Week 24
NCT01087502 (8) [back to overview]Percentage of Patients With HbA1c <7.0%
NCT01087502 (8) [back to overview]Percentage of Patients With HbA1c <6.5%
NCT01087502 (8) [back to overview]Percentage of Patients Who Have a HbA1c Lowering by at Least 0.5%
NCT01087502 (8) [back to overview]HbA1c Change From Baseline Over Time
NCT01087502 (8) [back to overview]Plasma Concentration of Linagliptin at Trough
NCT01087502 (8) [back to overview]Fasting Plasma Glucose (FPG) Change From Baseline to Week 12
NCT01087502 (8) [back to overview]HbA1c Change From Baseline to Week 12
NCT01087502 (8) [back to overview]Fasting Plasma Glucose (FPG) Change From Baseline Over Time
NCT01123980 (7) [back to overview]Number of Hypoglycaemic Episodes - All
NCT01123980 (7) [back to overview]Percentage of Subjects Achieving HbA1c Below 7.0%
NCT01123980 (7) [back to overview]Percentage of Subjects Achieving HbA1c Below or Equal to 6.5%
NCT01123980 (7) [back to overview]Number of Hypoglycaemic Episodes - Severe and Minor
NCT01123980 (7) [back to overview]9-point Plasma Glucose Profiles
NCT01123980 (7) [back to overview]Number of Hypoglycaemic Episodes
NCT01123980 (7) [back to overview]Change in Glycosylated Haemoglobin (HbA1c)
NCT01167881 (10) [back to overview]The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment.
NCT01167881 (10) [back to overview]The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.
NCT01167881 (10) [back to overview]The Change From Baseline in HbA1c After 52 Weeks of Treatment.
NCT01167881 (10) [back to overview]The Change in Body Weight From Baseline After 104 Weeks of Treatment.
NCT01167881 (10) [back to overview]The Change in Body Weight From Baseline After 52 Weeks of Treatment.
NCT01167881 (10) [back to overview]The Change in Diastolic Blood Pressure (DBP) From Baseline After 104 Weeks of Treatment.
NCT01167881 (10) [back to overview]The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.
NCT01167881 (10) [back to overview]The Change in Systolic Blood Pressure (SBP) From Baseline After 104 Weeks of Treatment.
NCT01167881 (10) [back to overview]The Change in Systolic Blood Pressure (SBP) From Baseline After 52 Weeks of Treatment.
NCT01167881 (10) [back to overview]The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment.
NCT01177384 (4) [back to overview]Number of Participants Who Experienced at Least One Adverse Event
NCT01177384 (4) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
NCT01177384 (4) [back to overview]Change From Baseline in Hemoglobin A1c (A1C) at Week 24
NCT01177384 (4) [back to overview]Number of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01183104 (6) [back to overview]Number of Participants With Hypoglycaemia
NCT01183104 (6) [back to overview]Change From Baseline in HOMA-β at 52 W
NCT01183104 (6) [back to overview]Change From Baseline in Body Weight at 52 W
NCT01183104 (6) [back to overview]The Number of Participants Achieving HbA1c < 6.9 %
NCT01183104 (6) [back to overview]Change From Baseline in HbA1c at 52 W
NCT01183104 (6) [back to overview]Change From Baseline in Insulin/Proinsulin Ratio at 52 W
NCT01189890 (8) [back to overview]Number of Participants Experiencing An Adverse Event (AE)
NCT01189890 (8) [back to overview]Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30
NCT01189890 (8) [back to overview]LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30
NCT01189890 (8) [back to overview]LS Mean Change From Baseline in Participant Body Weight at Week 30
NCT01189890 (8) [back to overview]Number of Participants Discontinuing Study Treatment Due to An AE
NCT01189890 (8) [back to overview]Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30
NCT01189890 (8) [back to overview]Percentage of Participants With HbA1c <7.0% at Week 30
NCT01189890 (8) [back to overview]Percentage of Participants With HbA1c <6.5% at Week 30
NCT01243424 (20) [back to overview]Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE
NCT01243424 (20) [back to overview]Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE
NCT01243424 (20) [back to overview]CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study
NCT01243424 (20) [back to overview]Change From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks
NCT01243424 (20) [back to overview]Change From Baseline to Final Visit in Creatinine
NCT01243424 (20) [back to overview]Change From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR)
NCT01243424 (20) [back to overview]Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events
NCT01243424 (20) [back to overview]Percentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up
NCT01243424 (20) [back to overview]Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without >2% Weight Gain During Maintenance Phase
NCT01243424 (20) [back to overview]Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without >2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase
NCT01243424 (20) [back to overview]Continuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study
NCT01243424 (20) [back to overview]Change From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR)
NCT01243424 (20) [back to overview]Change From Baseline to Final Visit Fasting Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and High-density Lipoprotein (HDL) Cholesterol
NCT01243424 (20) [back to overview]Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c)
NCT01243424 (20) [back to overview]Percentage of Participants With Transition in Albuminuria Classes
NCT01243424 (20) [back to overview]Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG)
NCT01243424 (20) [back to overview]Change From Baseline to Final Visit in Triglycerides
NCT01243424 (20) [back to overview]Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events
NCT01243424 (20) [back to overview]The First 4-point (4P)- MACE
NCT01243424 (20) [back to overview]The First 3-point Major Adverse Cardiovascular Events (3P-MACE)
NCT01296412 (4) [back to overview]Percentage of Participants Reaching A1C Goal of <7.0%
NCT01296412 (4) [back to overview]Percentage of Participants Reaching A1C Goal of <6.5%
NCT01296412 (4) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG)
NCT01296412 (4) [back to overview]Change From Baseline in Hemoglobin A1c (A1C)
NCT01318083 (9) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 8).
NCT01318083 (9) [back to overview]Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).
NCT01318083 (9) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 12).
NCT01318083 (9) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 2).
NCT01318083 (9) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 4).
NCT01318083 (9) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 12).
NCT01318083 (9) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 2).
NCT01318083 (9) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 4).
NCT01318083 (9) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 8).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 12).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 16).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 24).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 28).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 32).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 36).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 40).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 44).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 48).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 52).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 8).
NCT01318135 (31) [back to overview]Number of Participants With Adverse Events.
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 24).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 20).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 16).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 12).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Final Visit).
NCT01318135 (31) [back to overview]Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 24).
NCT01318135 (31) [back to overview]Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).
NCT01318135 (31) [back to overview]Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).
NCT01318135 (31) [back to overview]Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 52).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 20).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 28).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 32).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 36).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 40).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 44).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 48).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 52).
NCT01318135 (31) [back to overview]Change From Baseline in Fasting Blood Glucose (Week 8).
NCT01318135 (31) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Final Visit).
NCT01340768 (2) [back to overview]Percentage of Participants With at Least One Symptomatic Hypoglycemic Event
NCT01340768 (2) [back to overview]Percentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event
NCT01453049 (33) [back to overview]Change From Baseline in Heart Rate at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Hematocrit (HCT) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in High Sensitivity C-reactive Protein (Hs-CRP) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Homeostasis Model Assessment Beta-cell Function (HOMA-B) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Homeostasis Model Assessment Sensitivity (HOMA-S) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Mean Corpuscular Hemoglobin (MCH) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Mean Corpuscular Volume (MCV) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Red Blood Cell (RBC) Count at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Weight at Week 24/EW
NCT01453049 (33) [back to overview]Number of Participants With a Bone Fracture
NCT01453049 (33) [back to overview]Percent Change From Baseline in High Sensitivity C-reactive Protein (Hs-CRP) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Alanine Transaminase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transpeptidase (GGT), Lactate Dehydrogenase (LDH), Alkaline Phosphatase (ALP), and Creatine Kinase (CK) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Electrocardiogram (ECG) Data at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Fasting Proinsulin and Insulin at Week 24/Early Withdrawal (EW)
NCT01453049 (33) [back to overview]Change From Baseline in Hemoglobin (HE), Mean Corpuscular Hemoglobin Concentration (MCHC), Total Protein (TP), and Albumin at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in the Ratio of TC/HDL-C and LDL-C/HDL-C at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Total Bilirubin (TB), Direct Bilirubin (DB), Creatinine, and Uric Acid (UC) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C), Low Density Lipoprotein-cholesterol (LDL-C), and Triglyceride (TG) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in White Blood Cell (WBC) Count and Platelet Count at Week 24/EW
NCT01453049 (33) [back to overview]Number of HbA1c Responders and Non-responders
NCT01453049 (33) [back to overview]Number of Hypoglycemic Events
NCT01453049 (33) [back to overview]Number of Participants at Various Dose Levels at Week 24/EW
NCT01453049 (33) [back to overview]Number of Participants Who Achieved HbA1c <7%, HbA1c <=6.5%, or Who Achieved a Decrease of >=0.7% From Baseline
NCT01453049 (33) [back to overview]Number of Participants With Hypoglycemic Events
NCT01453049 (33) [back to overview]Number of FPG Responders and Non-responders
NCT01453049 (33) [back to overview]Change From Baseline in Adjusted Diabetes Quality of Life (A-DQOL) Scores at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Electrocardiogram (ECG) Assessment of Heart Rate at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) at Week 24/EW
NCT01453049 (33) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
NCT01453049 (33) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
NCT01477853 (11) [back to overview]Change From Baseline in Hemoglobin A1C (A1C) at Week 16
NCT01477853 (11) [back to overview]Percent Change From Baseline in Triglycerides at Week 16
NCT01477853 (11) [back to overview]Percent Change From Baseline in Total Cholesterol at Week 16
NCT01477853 (11) [back to overview]Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16
NCT01477853 (11) [back to overview]Number of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01477853 (11) [back to overview]Number of Participants Who Experienced at Least One Adverse Event
NCT01477853 (11) [back to overview]Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16
NCT01477853 (11) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16
NCT01477853 (11) [back to overview]Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16
NCT01477853 (11) [back to overview]Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 16
NCT01477853 (11) [back to overview]Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16
NCT01481116 (6) [back to overview]Change From Baseline in HbA1c at Weeks 26 and 52
NCT01481116 (6) [back to overview]Change From Baseline in Body Weight at Weeks 78 and 104
NCT01481116 (6) [back to overview]Percentage of Participants With Hypoglycemia
NCT01481116 (6) [back to overview]Percentage of Participants With HbA1c <7%
NCT01481116 (6) [back to overview]Change From Baseline in HbA1c at Weeks 78 and 104
NCT01481116 (6) [back to overview]Change From Baseline in Fasting Plasma Glucose at Weeks 26, 52, 78 and 104
NCT01494987 (4) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
NCT01494987 (4) [back to overview]Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24
NCT01494987 (4) [back to overview]Change From Baseline in Fasting Serum Glucose at Week 24
NCT01494987 (4) [back to overview]Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24
NCT01517373 (11) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8
NCT01517373 (11) [back to overview]Percentage of Participants With at Least 1 Hypoglycemic Events (HAE) Episode
NCT01517373 (11) [back to overview]Change From Baseline in Body Weight at Week 2, 4, 6, 8, 12 and 14
NCT01517373 (11) [back to overview]Change From Baseline in Fasting Plasma Glucose at Week 2, 4, 6, 8 and 12
NCT01517373 (11) [back to overview]Number of Participants With Abnormal Laboratory Values
NCT01517373 (11) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12
NCT01517373 (11) [back to overview]Number of Participants With Increase From Baseline Electrocardiogram (ECG) Data
NCT01517373 (11) [back to overview]Number of Participants With Increase/Decrease From Baseline Vital Signs Data
NCT01517373 (11) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
NCT01517373 (11) [back to overview]Percentage of Participants Achieving Less Than 6.5 Percent and Less Than 7 Percent Glycosylated Hemoglobin (HbA1c) Levels at Week 12
NCT01517373 (11) [back to overview]Number of Hypoglycemic Events (HAE) Episodes Per Participant
NCT01561976 (8) [back to overview]PK Lag Time (Tlag)
NCT01561976 (8) [back to overview]Maximum Observed Concentration (Cmax)
NCT01561976 (8) [back to overview]Elimination Constant (Kel)
NCT01561976 (8) [back to overview]AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments [AUC (0-t)]
NCT01561976 (8) [back to overview]Area Under Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC (0-infinity)]
NCT01561976 (8) [back to overview]Terminal Phase Half Life (t1/2)
NCT01561976 (8) [back to overview]Time of Occurrence of Cmax (Tmax)
NCT01561976 (8) [back to overview]Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01590771 (11) [back to overview]Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone
NCT01590771 (11) [back to overview]Number of Participants Who Experienced an Adverse Event
NCT01590771 (11) [back to overview]Number of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01590771 (11) [back to overview]Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin
NCT01590771 (11) [back to overview]Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and a Sulfonylurea in Combination With Metformin
NCT01590771 (11) [back to overview]Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin
NCT01590771 (11) [back to overview]Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone
NCT01590771 (11) [back to overview]Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin
NCT01590771 (11) [back to overview]Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin
NCT01590771 (11) [back to overview]Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone
NCT01590771 (11) [back to overview]Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin
NCT01614769 (3) [back to overview]Rate of Recovery From Hypoglycemia to Euglycemia
NCT01614769 (3) [back to overview]Incremental Weighted Average Blood Glucose Concentration Over 3 Hours of Hypoglycemic Recovery
NCT01614769 (3) [back to overview]Recovery Time From Hypoglycemia to Euglycemia
NCT01644500 (21) [back to overview]Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in Electrocardiogram (ECG) Parameters, Fridericia Corrected QT (QTcF) Interval and P-R Wave (PR) Interval at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β) - Cell Function (HOMA2-%B) at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in Pancreatic Enzymes at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in Sitting Blood Pressure at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in Serum Calcitonin at 26 Weeks
NCT01644500 (21) [back to overview]Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in Body Mass Index (BMI) at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in Body Weight at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in HbA1c at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in Heart Rate From ECG at 26 Weeks
NCT01644500 (21) [back to overview]Change From Baseline in Sitting Pulse Rate at 26 Weeks
NCT01644500 (21) [back to overview]Number of Participants With Adjudicated Cardiovascular Events
NCT01644500 (21) [back to overview]European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score Responses at 26 Weeks
NCT01644500 (21) [back to overview]Number of Participants With Adjudicated Pancreatitis
NCT01644500 (21) [back to overview]Number of Participants With Self-Reported Hypoglycemic Episodes
NCT01644500 (21) [back to overview]Rate of Hypoglycemic Episodes
NCT01644500 (21) [back to overview]Percentage of Participants Developing Antibodies to Dulaglutide
NCT01644500 (21) [back to overview]Visual Analog Scale (VAS) Score at 26 Weeks
NCT01678820 (13) [back to overview]Number of Participants Who Experienced at Least One Adverse Event (AE)
NCT01678820 (13) [back to overview]Number of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01678820 (13) [back to overview]Change From Baseline in Hemoglobin A1C (A1C) at Week 16 (Sitagliptin/Simvastatin FDC vs. Sitagliptin)
NCT01678820 (13) [back to overview]Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 16
NCT01678820 (13) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16
NCT01678820 (13) [back to overview]Change From Baseline in A1C at Week 16 (Sitagliptin/Simvastatin FDC vs. Simvastatin)
NCT01678820 (13) [back to overview]Percentage of Participants With A1C Level <7% at Week 16
NCT01678820 (13) [back to overview]Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16
NCT01678820 (13) [back to overview]Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16
NCT01678820 (13) [back to overview]Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 16
NCT01678820 (13) [back to overview]Percent Change From Baseline in Triglycerides (TG) at Week 16
NCT01678820 (13) [back to overview]Percent Change From Baseline in Total Cholesterol (TC) at Week 16
NCT01678820 (13) [back to overview]Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16
NCT01682759 (8) [back to overview]Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54
NCT01682759 (8) [back to overview]Percentage of Participants Achieving a Hemoglobin A1C of <6.5% at Week 54
NCT01682759 (8) [back to overview]Change From Baseline in Hemoglobin A1C at Week 54
NCT01682759 (8) [back to overview]Change From Baseline in Fasting Plasma Glucose at Week 54
NCT01682759 (8) [back to overview]Change From Baseline in Body Weight at Week 54 Excluding Data After Gylcemic Rescue
NCT01682759 (8) [back to overview]Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue
NCT01682759 (8) [back to overview]Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Excluding Data After Glycemic Rescue
NCT01682759 (8) [back to overview]Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue
NCT01703286 (4) [back to overview]Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28
NCT01703286 (4) [back to overview]Number of Patients With Adverse Events
NCT01703286 (4) [back to overview]Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28
NCT01703286 (4) [back to overview]Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28
NCT01704261 (5) [back to overview]Change From Baseline in Hemoglobin A1c (A1C) at Week 24
NCT01704261 (5) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
NCT01704261 (5) [back to overview]Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% at Week 24
NCT01704261 (5) [back to overview]Percentage of Participants Who Experienced at Least One Adverse Event (AE)
NCT01704261 (5) [back to overview]Percentage of Participants Who Discontinued From the Study Due to an AE
NCT01709305 (7) [back to overview]Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)
NCT01709305 (7) [back to overview]Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)
NCT01709305 (7) [back to overview]Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)
NCT01709305 (7) [back to overview]Percentage of Participants With Hypoglycemia Events (Phase 2)
NCT01709305 (7) [back to overview]Percentage of Participants With a GI AE of Diarrhea (Phase 2)
NCT01709305 (7) [back to overview]Percentage of Participants With a GI AE of Vomiting (Phase 2)
NCT01709305 (7) [back to overview]Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)
NCT01717313 (16) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Phase A, FAS Population)
NCT01717313 (16) [back to overview]Change From Baseline in A1C at Week 54 (Phase A + Phase B, FAS Population)
NCT01717313 (16) [back to overview]Change From Baseline in A1C at Week 24 (Phase A, Per-Protocol Population)
NCT01717313 (16) [back to overview]Percentage of Participants Who Experienced at Least One Adverse Event in Phase A (Excluding Data After Glycemic Rescue, Safety Population)
NCT01717313 (16) [back to overview]Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event in Phase A (Excluding Data After Glycemic Rescue, Safety Population)
NCT01717313 (16) [back to overview]Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population)
NCT01717313 (16) [back to overview]Percentage of Participants Who Experienced at Least One Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population)
NCT01717313 (16) [back to overview]Change From Baseline in 2-hour Post Meal Glucose (PMG) at Week 24 (Phase A, FAS Population)
NCT01717313 (16) [back to overview]Change From Baseline in 2-hour PMG at Week 24 (Phase A, Per-Protocol Population)
NCT01717313 (16) [back to overview]Change From Baseline in FPG at Week 24 (Phase A, Per-Protocol Population)
NCT01717313 (16) [back to overview]Change From Baseline in FPG at Week 54 (Phase A + Phase B, FAS Population)
NCT01717313 (16) [back to overview]Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Phase A, FAS Population)
NCT01717313 (16) [back to overview]Percentage of Participants Who Achieve an A1C Goal of <6.5% (48 mmol/Mol) at Week 24 (Phase A, FAS Population)
NCT01717313 (16) [back to overview]Percentage of Participants Who Achieve an A1C Goal of <6.5% at Week 54 (Phase A + Phase B, FAS Population)
NCT01717313 (16) [back to overview]Percentage of Participants Who Achieve an A1C Goal of <7% (53 mmol/Mol) at Week 24 (Phase A, FAS Population)
NCT01717313 (16) [back to overview]Percentage of Participants Who Achieve an A1C Goal of <7% (53 mmol/Mol) at Week 54 (Phase A + Phase B, FAS Population)
NCT01755156 (19) [back to overview]Percentage of Participants Attaining A1C Glycemic Goals of <7% After 104 Weeks of Treatment (Phase A+B)
NCT01755156 (19) [back to overview]Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 104 (Phase A+B)
NCT01755156 (19) [back to overview]Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A+B)
NCT01755156 (19) [back to overview]Percentage of Participants Who Experienced an Adverse Event Which Were Included Under the System Order Class of Investigations (Phase A+B)
NCT01755156 (19) [back to overview]Percentage of Participants Who Experienced at Least One Adverse Event (Phase A+B)
NCT01755156 (19) [back to overview]Change From Baseline in FPG at Week 104 (Phase A+B)
NCT01755156 (19) [back to overview]Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24 (Phase A)
NCT01755156 (19) [back to overview]Change From Baseline in A1C at Week 104 (Phase A+B)
NCT01755156 (19) [back to overview]Change From Baseline in Fasting Insulin at Week 104 (Phase A+B)
NCT01755156 (19) [back to overview]Change From Baseline in Fasting Insulin at Week 24 (Phase A)
NCT01755156 (19) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Phase A)
NCT01755156 (19) [back to overview]Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A)
NCT01755156 (19) [back to overview]Change From Baseline in PMG Total Area Under the Plasma Concentration Time Curve (AUC) at Week 24 (Phase A)
NCT01755156 (19) [back to overview]Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 104 Weeks (Phase A+B)
NCT01755156 (19) [back to overview]Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 24 Weeks (Phase A)
NCT01755156 (19) [back to overview]Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 24 (Phase A)
NCT01755156 (19) [back to overview]Percentage of Participants Attaining A1C Glycemic Goals of <6.5% After 104 Weeks of Treatment (Phase A+B)
NCT01755156 (19) [back to overview]Percentage of Participants Attaining A1C Glycemic Goals of <6.5% After 24 Weeks of Treatment (Phase A)
NCT01755156 (19) [back to overview]Percentage of Participants Attaining A1C Glycemic Goals of <7.0% After 24 Weeks of Treatment (Phase A)
NCT01769378 (16) [back to overview]Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia
NCT01769378 (16) [back to overview]Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia
NCT01769378 (16) [back to overview]Number of Participants With Adjudicated Acute Pancreatitis Events
NCT01769378 (16) [back to overview]Dulaglutide Anti-Drug Antibodies (ADA)
NCT01769378 (16) [back to overview]Change From Baseline in Mean of All 7-Point Self Monitored Plasma Glucose (SMPG) at 24 Weeks
NCT01769378 (16) [back to overview]Percentage of Participants Who Achieve HbA1c <7.0% and ≤6.5% at 24 Weeks
NCT01769378 (16) [back to overview]Number of Participants With Reported and Adjudicated Cardiovascular Events
NCT01769378 (16) [back to overview]Change From Baseline in Body Weight at 24 Weeks
NCT01769378 (16) [back to overview]Change From Baseline in Calcitonin at 24 Weeks
NCT01769378 (16) [back to overview]Change From Baseline in Fasting Serum Glucose (FSG) at 24 Weeks
NCT01769378 (16) [back to overview]Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks
NCT01769378 (16) [back to overview]Change From Baseline in Lipase
NCT01769378 (16) [back to overview]Percentage of Participants With Self-Reported Events of Hypoglycemia
NCT01769378 (16) [back to overview]Rate of HE Adjusted Per 30 Days
NCT01769378 (16) [back to overview]Change From Baseline in Amylase
NCT01769378 (16) [back to overview]Change From Baseline in Body Mass Index (BMI) at 24 Weeks
NCT01841697 (6) [back to overview]Percentage of Participants Achieving an A1C Goal <7.0% After 24 Weeks of Treatment
NCT01841697 (6) [back to overview]Change From Baseline in A1C at Week 24
NCT01841697 (6) [back to overview]Change From Baseline in FPG at Week 24
NCT01841697 (6) [back to overview]Percentage of Participants Achieving an A1C Goal <6.5% After 24 Weeks of Treatment
NCT01841697 (6) [back to overview]Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01841697 (6) [back to overview]Percentage of Participants Who Experienced at Least One Adverse Event
NCT01863667 (2) [back to overview]Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01863667 (2) [back to overview]Percentage of Participants Who Experienced at Least One Adverse Event
NCT01951339 (8) [back to overview]Changes From Baseline in 31P Measurement: Adenosine Diphosphate (ADP) Time Constant
NCT01951339 (8) [back to overview]Changes From Baseline in 31P Measurement: Adenosine Triphosphate (ATP) Peaks
NCT01951339 (8) [back to overview]Changes From Baseline in 31P Measurement: Free Pi Time Constant
NCT01951339 (8) [back to overview]Changes From Baseline in 31P Measurement: pH
NCT01951339 (8) [back to overview]Changes From Baseline in 31P Measurement: Phosphocreatine Time Constant
NCT01951339 (8) [back to overview]Changes From Baseline in Echocardiographic Measures (Stroke Volume)
NCT01951339 (8) [back to overview]Peak Oxygen Consumption (VO2peak).
NCT01951339 (8) [back to overview]Change in Oxygen Uptake Kinetics (VO2 Kinetics)
NCT01958671 (12) [back to overview]Change From Baseline in Body Weight at Week 26
NCT01958671 (12) [back to overview]Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level
NCT01958671 (12) [back to overview]Percentage of Participants With A1C <7% (<53 mmol/Mol) at Week 26
NCT01958671 (12) [back to overview]Percentage of Participants Experiencing An Adverse Event (AE)
NCT01958671 (12) [back to overview]Percentage of Participants Discontinuing Study Treatment Due to an AE
NCT01958671 (12) [back to overview]Change From Baseline in SBP at Week 26
NCT01958671 (12) [back to overview]Change From Baseline in FPG at Week 26
NCT01958671 (12) [back to overview]Change From Baseline in DBP at Week 26
NCT01958671 (12) [back to overview]Change From Baseline In A1C at Week 26
NCT01958671 (12) [back to overview]Change From Baseline in 2-hr PPG at Week 26
NCT01958671 (12) [back to overview]Baseline Sitting Systolic Blood Pressure (SBP)
NCT01958671 (12) [back to overview]Baseline Sitting Diastolic Blood Pressure (DBP)
NCT01999218 (6) [back to overview]Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach
NCT01999218 (6) [back to overview]Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach
NCT01999218 (6) [back to overview]Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach
NCT01999218 (6) [back to overview]Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104
NCT01999218 (6) [back to overview]Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106
NCT01999218 (6) [back to overview]Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach
NCT02007278 (8) [back to overview]Mean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment
NCT02007278 (8) [back to overview]Number of Patients With Incidence of Hypoglycemia
NCT02007278 (8) [back to overview]Percentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12
NCT02007278 (8) [back to overview]Number of Patients With Any Adverse Events, Serious Adverse Events and Death
NCT02007278 (8) [back to overview]Glycemic Variability Measured by Total Standard Deviation (TSD)
NCT02007278 (8) [back to overview]Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE)
NCT02007278 (8) [back to overview]Glycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA)
NCT02007278 (8) [back to overview]Change in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline
NCT02033889 (49) [back to overview]Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52
NCT02033889 (49) [back to overview]Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26
NCT02033889 (49) [back to overview]Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104
NCT02033889 (49) [back to overview]Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)
NCT02033889 (49) [back to overview]Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)
NCT02033889 (49) [back to overview]Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Time to Glycemic Rescue Therapy at Week 26
NCT02033889 (49) [back to overview]Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
NCT02033889 (49) [back to overview]Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)
NCT02036515 (24) [back to overview]Change From Baseline in Sitting Diastolic Blood Pressure at Week 52
NCT02036515 (24) [back to overview]Percentage of Participants Discontinuing Study Treatment Due to an AE
NCT02036515 (24) [back to overview]Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 26
NCT02036515 (24) [back to overview]Percentage of Participants Receiving Glycemic Rescue Medication by Week 52
NCT02036515 (24) [back to overview]Percentage of Participants Receiving Glycemic Rescue Medication by Week 26
NCT02036515 (24) [back to overview]Percentage of Participants Experiencing An Adverse Event (AE)
NCT02036515 (24) [back to overview]Change From Baseline in EQ-5D-3L Score at Week 52
NCT02036515 (24) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
NCT02036515 (24) [back to overview]Change From Baseline in HOMA-%β at Week 52
NCT02036515 (24) [back to overview]Change From Baseline in HOMA-%β at Week 26
NCT02036515 (24) [back to overview]Change From Baseline in Hemoglobin A1C at Week 52
NCT02036515 (24) [back to overview]Change From Baseline in Hemoglobin A1C at Week 26
NCT02036515 (24) [back to overview]Change From Baseline in FPG at Week 52
NCT02036515 (24) [back to overview]Change From Baseline in Sitting Diastolic Blood Pressure at Week 26
NCT02036515 (24) [back to overview]Change From Baseline in EQ-5D-3L Questionnaire Score at Week 26
NCT02036515 (24) [back to overview]Change From Baseline in Body Weight at Week 52
NCT02036515 (24) [back to overview]Change From Baseline in Body Weight at Week 26
NCT02036515 (24) [back to overview]Baseline Homeostasis Model Assessment of β-cell Function (HOMA-%β) Value
NCT02036515 (24) [back to overview]Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 52
NCT02036515 (24) [back to overview]Baseline EQ-5D 3-level Version (EQ-5D-3L) Questionnaire Score
NCT02036515 (24) [back to overview]Time to Initiation of Glycemic Rescue by Week 52
NCT02036515 (24) [back to overview]Time to Initiation of Glycemic Rescue by Week 26
NCT02036515 (24) [back to overview]Change From Baseline in Sitting Systolic Blood Pressure at Week 52
NCT02036515 (24) [back to overview]Change From Baseline in Sitting Systolic Blood Pressure at Week 26
NCT02072096 (6) [back to overview]Change From Baseline of Estimated Glomerular Filtration Rate (eGFR)
NCT02072096 (6) [back to overview]Number of Participants With Total Hypoglycemia and Other Categories of Hypoglycemia
NCT02072096 (6) [back to overview]Change From Baseline in Body Mass Index (BMI)
NCT02072096 (6) [back to overview]Change From Baseline of Urinary Albumin to Creatinine Ratio
NCT02072096 (6) [back to overview]Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia
NCT02072096 (6) [back to overview]Percentage of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy
NCT02098733 (7) [back to overview]Fasting Blood Glucose Level
NCT02098733 (7) [back to overview]Change From Baseline in Fasting Blood Glucose Level
NCT02098733 (7) [back to overview]Change From Baseline in Fasting Insulin Level
NCT02098733 (7) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1c)
NCT02098733 (7) [back to overview]Fasting Insulin Level
NCT02098733 (7) [back to overview]Glycosylated Hemoglobin (HbA1c)
NCT02098733 (7) [back to overview]Number of Participants With Adverse Drug Reactions
NCT02098746 (5) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1c)
NCT02098746 (5) [back to overview]Frequency of Adverse Drug Reactions
NCT02098746 (5) [back to overview]Frequency of Serious Adverse Drug Reactions
NCT02098746 (5) [back to overview]Change From Baseline in Fasting Blood Glucose Level
NCT02098746 (5) [back to overview]Change From Baseline in Fasting Insulin Level
NCT02099110 (8) [back to overview]Change From Baseline in A1C at Week 26: Excluding Rescue Approach
NCT02099110 (8) [back to overview]Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach
NCT02099110 (8) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach
NCT02099110 (8) [back to overview]Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach
NCT02099110 (8) [back to overview]Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach
NCT02099110 (8) [back to overview]Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach
NCT02099110 (8) [back to overview]Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach
NCT02099110 (8) [back to overview]Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach
NCT02226003 (9) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Full Analysis Set Excluding Rescue Approach
NCT02226003 (9) [back to overview]Percentage of Participants Who Discontinued Study Medication Due to an AE - All Participants as Treated Excluding Rescue Approach
NCT02226003 (9) [back to overview]Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants as Treated Excluding Rescue Approach
NCT02226003 (9) [back to overview]Percentage of Participants With HbA1C <7% (<53 mmol/Mol) at Week 26
NCT02226003 (9) [back to overview]Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach
NCT02226003 (9) [back to overview]Change From Baseline in Sitting Systolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach
NCT02226003 (9) [back to overview]Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 26 - Full Analysis Set Excluding Rescue Approach
NCT02226003 (9) [back to overview]Change From Baseline in Body Weight at Week 26 - Full Analysis Set Excluding Rescue Approach
NCT02226003 (9) [back to overview]Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach
NCT02312063 (2) [back to overview]Correlation of Estimated Seafood Intake With HbA1c Reduction
NCT02312063 (2) [back to overview]Correlation of Plasma Levels of EPA and DHA With HbA1c Reduction
NCT02419612 (8) [back to overview]Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 156
NCT02419612 (8) [back to overview]Change From Baseline in Total Body Weight at Week 52
NCT02419612 (8) [back to overview]Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52
NCT02419612 (8) [back to overview]Change From Baseline in Systolic Blood Pressure (SBP) at Week 52
NCT02419612 (8) [back to overview]Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.
NCT02419612 (8) [back to overview]Percentage of Subjects With Treatment Intensification During the 52-week Short-term Treatment Period
NCT02419612 (8) [back to overview]Percentage of Subjects With Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.
NCT02419612 (8) [back to overview]Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 52
NCT02471404 (6) [back to overview]Patients With at Least One Episode of Confirmed Hypoglycaemia
NCT02471404 (6) [back to overview]Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52
NCT02471404 (6) [back to overview]Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52
NCT02471404 (6) [back to overview]Change in Total Body Weight From Baseline at Week 52
NCT02471404 (6) [back to overview]Number of Patients Rescued
NCT02471404 (6) [back to overview]Time to Rescue
NCT02564926 (15) [back to overview]Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Change in Waist Circumference at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan
NCT02564926 (15) [back to overview]Adjusted Mean Change in HbA1c at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan
NCT02564926 (15) [back to overview]Adjusted Mean Change in Lean Body Mass at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) Area at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Change in Adinopectin at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Change in Total Body Weight at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52
NCT02564926 (15) [back to overview]Adjusted Mean Change in Body Mass Index (BMI) at Week 52
NCT02630706 (34) [back to overview]Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)
NCT02630706 (34) [back to overview]Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
NCT02630706 (34) [back to overview]Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
NCT02630706 (34) [back to overview]Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
NCT02630706 (34) [back to overview]Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)
NCT02630706 (34) [back to overview]Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation)
NCT02630706 (34) [back to overview]Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)
NCT02630706 (34) [back to overview]Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation)
NCT02630706 (34) [back to overview]Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26 (China Subpopulation)
NCT02630706 (34) [back to overview]Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)
NCT02630706 (34) [back to overview]Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
NCT02630706 (34) [back to overview]Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) (China Subpopulation)
NCT02630706 (34) [back to overview]Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach)
NCT02630706 (34) [back to overview]Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach) (China Subpopulation)
NCT02630706 (34) [back to overview]Time to Glycemic Rescue Therapy
NCT02630706 (34) [back to overview]Time to Glycemic Rescue Therapy (China Subpopulation)
NCT02630706 (34) [back to overview]Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation)
NCT02630706 (34) [back to overview]Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26.
NCT02630706 (34) [back to overview]Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) (China Subpopulation)
NCT02630706 (34) [back to overview]Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)
NCT02630706 (34) [back to overview]Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) (China Subpopulation)
NCT02630706 (34) [back to overview]Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)
NCT02630706 (34) [back to overview]Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)
NCT02769481 (5) [back to overview]Change From Baseline in Body Weight at Week 60 for Subjects With Baseline BMI ≥ 25 kg/m2
NCT02769481 (5) [back to overview]Change From Baseline in HbA1c at Week 60
NCT02769481 (5) [back to overview]Difference in Proportion of Subjects With ≥ 1 Severe or Documented Symptomatic Hypoglycemia Events Over 96 Weeks
NCT02769481 (5) [back to overview]Superiority of Bexagliflozin Over Glimepiride in HbA1c Reduction at Week 60.
NCT02769481 (5) [back to overview]Change From Baseline in Systolic Blood Pressure (SBP) at Week 60 for Subjects With Baseline SBP ≥ 140 mmHg
NCT02956044 (30) [back to overview]Cmax (Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]Cmax (Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]Cmax (Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]T1/2 (Apparent Terminal Elimination Half-life)
NCT02956044 (30) [back to overview]T1/2 (Apparent Terminal Elimination Half-life)
NCT02956044 (30) [back to overview]T1/2 (Apparent Terminal Elimination Half-life)
NCT02956044 (30) [back to overview]T1/2 (Apparent Terminal Elimination Half-life)
NCT02956044 (30) [back to overview]T1/2 (Apparent Terminal Elimination Half-life)
NCT02956044 (30) [back to overview]T1/2 (Apparent Terminal Elimination Half-life)
NCT02956044 (30) [back to overview]T1/2 (Apparent Terminal Elimination Half-life)
NCT02956044 (30) [back to overview]Tmax (Time of Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
NCT02956044 (30) [back to overview]Tmax (Time of Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]Tmax (Time of Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]Tmax (Time of Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]Tmax (Time of Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]Tmax (Time of Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
NCT02956044 (30) [back to overview]Urinary Glucose Excretion up to 0-72 hr
NCT02956044 (30) [back to overview]Tmax (Time of Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
NCT02956044 (30) [back to overview]Urinary Glucose Excretion up to 0-72 hr
NCT02956044 (30) [back to overview]AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
NCT02956044 (30) [back to overview]AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
NCT02956044 (30) [back to overview]AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
NCT02956044 (30) [back to overview]Cmax (Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
NCT02956044 (30) [back to overview]Cmax (Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]Cmax (Maximum Observed Plasma Concentration)
NCT02956044 (30) [back to overview]Cmax (Maximum Observed Plasma Concentration)
NCT02973477 (4) [back to overview]Change in B-type Natriuretic Peptide With Each Intervention as a Measure of Left Ventricular Function
NCT02973477 (4) [back to overview]Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride.
NCT02973477 (4) [back to overview]Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs)
NCT02973477 (4) [back to overview]Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride.
NCT03332771 (8) [back to overview]Change From Baseline in Hemoglobin A1c at Week 52
NCT03332771 (8) [back to overview]Percentage of Participants With At Least One Documented Symptomatic Hypoglycemic Event
NCT03332771 (8) [back to overview]Percentage of Participants With Hypoglycemic Events
NCT03332771 (8) [back to overview]Change From Baseline in Systolic Blood Pressure (SBP) for All Participants at Week 12
NCT03332771 (8) [back to overview]Change From Baseline in Body Weight at Week 26 and 52
NCT03332771 (8) [back to overview]Change From Baseline in Hemoglobin A1c at Week 26
NCT03332771 (8) [back to overview]Change From Baseline in Systolic Blood Pressure (SBP) for Participants With SBP ≥130 mmHg at Week 12
NCT03332771 (8) [back to overview]Percentage of Participants With Adverse Events (AEs)

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate641
Lipid Trial: Placebo667

[back to top]

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control391
Glycemia Trial: Standard Control327

[back to top]

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control503
Glycemia Trial: Standard Control543

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control208
BP Trial: Standard Control237

[back to top]

Stroke in the Blood Pressure Trial.

Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control36
BP Trial: Standard Control62

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate291
Lipid Trial: Placebo310

[back to top]

Primary Major Macrovascular Events

Myocardial infarction (MI), intervention for coronary artery or Peripheral Vascular Disease (PVD), severe inoperable Coronary Artery Disease (CAD), new or worsening Congestive Heart Failure (CHF), stroke, Cardiovascular (CV) death, or amputation for ischemic gangrene. (NCT00032487)
Timeframe: Post baseline time to the first major macrovascular event up to 82 months

Interventionparticipants (Number)
Arm 1264
Arm 2235

[back to top]

Secondary Endpoint

New or worsening angina, new transient ischemic attack (TIA), new intermittent claudication or critical limb ischemia with Doppler evidence or total mortality. (NCT00032487)
Timeframe: Post baseline time to first event up to 82 months

Interventionparticipants (Number)
Arm 1283
Arm 2312

[back to top]

Number of Subjects Achieving FPG Target at Month 12

FPG responders were described as subjects having achieved FPG less than 7 mmol/L at Month 12 with LOCF from Month 2. (NCT00131664)
Timeframe: Month 12

Interventionparticipants (Number)
Avandia and Amaryl64
Avandamet86
Metformin51

[back to top]

Mean Change From Baseline in 5 Year UKPDS Risk Scores at Month 12

"Change from baseline was calculated as the Month 12 value minus the baseline value, with LOCF from Month 2. The UKPDS (U.K. Prospective Diabetes Study) risk engine calculated was based on 5 years risk using gender, race, age at diagnosis of diabetes, duration of diabetes, smoking status, A1C, systolic blood pressure and total cholesterol to HDL ratio at a specified visit.~The UKPDS cardiovascular disease (CVD) risk engine is used to estimate the risk of having coronary heart disease in type II diabetes according to the UKPDS model. The possible risk scores can range from 0 to 100% and hence lower scores would predict a person is less likely to have an event." (NCT00131664)
Timeframe: Baseline and Month 12

Interventionpercent (Mean)
Avandia and Amaryl-0.72
Avandamet-0.62
Metformin-1.11

[back to top]

Mean Change From Baseline in 5 Year UKPDS Risk Scores at Month 6

"Change from baseline was calculated as the Month 6 value minus the baseline value, with LOCF from Month 2. The UKPDS (United Kingdom Prospective Diabetes Study) risk engine calculated was based on 5 years risk using gender, race, age at diagnosis of diabetes, duration of diabetes, smoking status, A1C, systolic blood pressure and total cholesterol to high-density lipoprotein (HDL) ratio at a specified visit.~The UKPDS cardiovascular disease (CVD) risk engine is used to estimate the risk of having coronary heart disease in type II diabetes according to the UKPDS model. The possible risk scores can range from 0 to 100% and hence lower scores would predict a person is less likely to have an event." (NCT00131664)
Timeframe: Baseline and Month 6

Interventionpercent (Mean)
Avandia and Amaryl-1.09
Avandamet-1.05
Metformin-1.54

[back to top]

Mean Change From Baseline in A1C at Month 12

Change from baseline was calculated as the Month 12 value minus the baseline value, with last on-treatment observation carried forward (LOCF) from Month 2 for withdrawn subjects or missing values. (NCT00131664)
Timeframe: Baseline and Month 12

Interventionpercent (Mean)
Avandia and Amaryl-1.50
Avandamet-1.56
Metformin-1.14

[back to top]

Mean Change From Baseline in A1C at Month 4

Change from baseline was calculated as the Month 4 value minus the baseline value, with last on-treatment observation carried forward (LOCF) from Month 2 for withdrawn subjects or missing values. (NCT00131664)
Timeframe: Baseline and Month 4

Interventionpercent (Mean)
Avandia and Amaryl-1.44
Avandamet-1.28
Metformin-0.94

[back to top]

Mean Change From Baseline in Adiponectin at Month 12

Change from baseline was calculated as the Month 12 value minus the baseline value, with LOCF from Month 6. Adiponectin was only done at baseline, months 6 and 12. The test was optional and performed only by participating sites. (NCT00131664)
Timeframe: Baseline and Month 12

Interventionµg/mL (Mean)
Avandia and Amaryl4.95
Avandamet8.21
Metformin1.453

[back to top]

Mean Change From Baseline in Adiponectin at Month 6

Change from baseline was calculated as the Month 6 value minus the baseline value. LOCF was not used for this analysis. Adiponectin was only done at baseline, months 6 and 12. The test was optional and performed only by participating sites. (NCT00131664)
Timeframe: Baseline and Month 6

Interventionmicrogram per millilitre (µg/mL) (Mean)
Avandia and Amaryl5.73
Avandamet6.37
Metformin0.23

[back to top]

Mean Change From Baseline in C-reactive Protein (CRP) at Month 12

Change from baseline was calculated as the Month 12 value minus the baseline value, with LOCF from Month 6. CRP was only done at baseline, months 6 and 12. The test was optional and performed only by participating sites. (NCT00131664)
Timeframe: Baseline and Month 12

Interventionmg/dL (Mean)
Avandia and Amaryl-0.40
Avandamet-1.52
Metformin-1.52

[back to top]

Mean Change From Baseline in C-reactive Protein (CRP) at Month 6

Change from baseline was calculated as the Month 6 value minus the baseline value. LOCF was not used for this analysis. CRP was only done at baseline, months 6 and 8. The test was optional and performed only by participating sites. (NCT00131664)
Timeframe: Baseline and Month 6

Interventionmilligram per decilitre (mg/dL) (Mean)
Avandia and Amaryl-1.20
Avandamet-1.68
Metformin-1.25

[back to top]

Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Month 12

Change from baseline was calculated as the Month 12 value minus the baseline value, with LOCF from Month 2 for withdrawn subjects or missing values. (NCT00131664)
Timeframe: Baseline and Month 12

Interventionmillimoles per litre (mmol/L) (Mean)
Avandia and Amaryl-2.71
Avandamet-2.76
Metformin-2.12

[back to top]

Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Month 4

Change from baseline was calculated as the Month 4 value minus the baseline value, with last on-treatment observation carried forward (LOCF) from Month 2 for withdrawn subjects or missing values. (NCT00131664)
Timeframe: Baseline and Month 4

Interventionmillimoles per litre (mmol/L) (Mean)
Avandia and Amaryl-2.86
Avandamet-2.33
Metformin-1.75

[back to top]

Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6

Change from baseline was calculated as the Month 6 value minus the baseline value, with last on-treatment observation carried forward (LOCF) from Month 2 for withdrawn subjects or missing values. (NCT00131664)
Timeframe: Baseline and Month 6

Interventionmillimoles per litre (mmol/L) (Mean)
Avandia and Amaryl-2.98
Avandamet-2.55
Metformin-1.86

[back to top]

Number of Subjects Achieving A1C Target at Month 12

A1C responders were described as subjects having achieved A1C less than 7 percent at Month 12 with LOCF from Month 2. (NCT00131664)
Timeframe: Month 12

Interventionparticipants (Number)
Avandia and Amaryl95
Avandamet111
Metformin82

[back to top]

Number of Subjects Achieving A1C Target at Month 4

A1C responders were described as subjects having achieved A1C less than 7 percent at Month 4, with LOCF from Month 2. (NCT00131664)
Timeframe: Month 4

Interventionparticipants (Number)
Avandia and Amaryl83
Avandamet96
Metformin69

[back to top]

Number of Subjects Achieving A1C Target at Month 6

A1C responders were described as subjects having achieved A1C less than 7 percent at Month 6, with LOCF from Month 2. (NCT00131664)
Timeframe: Month 6

Interventionparticipants (Number)
Avandia and Amaryl94
Avandamet98
Metformin69

[back to top]

Number of Subjects Achieving FPG Target at Month 4

FPG responders were described as subjects having achieved FPG less than 7 mmol/L at Month 4 with LOCF from Month 2. (NCT00131664)
Timeframe: Month 4

Interventionparticipants (Number)
Avandia and Amaryl58
Avandamet65
Metformin38

[back to top]

Number of Subjects Achieving FPG Target at Month 6

FPG responders were described as subjects having achieved FPG less than 7 mmol/L at Month 6 with LOCF from Month 2. (NCT00131664)
Timeframe: Month 6

Interventionparticipants (Number)
Avandia and Amaryl61
Avandamet76
Metformin43

[back to top]

Mean Change From Baseline in A1C at Month 6

Change from baseline was calculated as the Month 6 value minus the baseline value, with last on-treatment observation carried forward (LOCF) from Month 2 for withdrawn subjects or missing values. (NCT00131664)
Timeframe: Baseline and Month 6

,,
Interventionpercent (Mean)
BaselineChange from baseline
Avandamet7.96-1.39
Avandia and Amaryl8.14-1.61
Metformin7.90-1.02

[back to top]

Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint C cardiovascular events is being reported instead of time to first occurrence. Endpoint C conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks

Interventionparticipants (Number)
Pioglitazone QD11
Glimepiride QD13

[back to top]

Number of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint A cardiovascular events is being reported instead of time to first occurrence. Endpoint A conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks

InterventionParticipants (Number)
Pioglitazone QD5
Glimepiride QD6

[back to top]

Number of Subjects Experiencing Any of the Composite Endpoint B Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint B cardiovascular events is being reported instead of time to first occurrence. Endpoint B conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks

InterventionParticipants (Number)
Pioglitazone QD40
Glimepiride QD41

[back to top]

Nominal Change From Baseline in Normalized Total Atheroma Volume

The nominal change in normalized total atheroma volume as measured by the average of plaque areas for all slices of anatomically comparable segments of the target coronary artery multiplied by the mean number of matched slices in the population. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)

,
InterventionPercent volume (Least Squares Mean)
BaselineNominal Change from Baseline
Glimepiride QD217.619-1.480
Pioglitazone QD206.579-5.528

[back to top]

Nominal Change From Baseline in Percent Atheroma Volume

The nominal change from baseline in percent atheroma volume for all slices of anatomically comparable segments of the target coronary artery. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)

,
InterventionPercent volume (Least Squares Mean)
BaselineNominal Change from Baseline
Glimepiride QD40.0160.725
Pioglitazone QD40.592-0.161

[back to top]

Number of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee

The incidence of cardiovascular events and composite endpoints occurring within 30 days of last dose as adjudicated by the Clinical Endpoint Committee. Abbreviations: PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; CHF: Congestive Heart Failure. (NCT00225277)
Timeframe: Up to 72 weeks

,
InterventionNumber of Events (Number)
Nonfatal Myocardial InfarctionNonfatal StrokeCoronary Revascularization: PCI/CABG counted onceCoronary Revascularization: PCICoronary Revascularization: CABGCarotid Endarterectomy/StentingHospitalization for Unstable AnginaCHF Hospitalization: new/exacerbated counted onceHospitalization for New CHFHospitalization for Exacerbated CHFNoncardiovascular MortalityCardiovascular MortalityComposite Endpoint AComposite Endpoint BComposite Endpoint C
Glimepiride QD4130282025231164113
Pioglitazone QD2029255144400354011

[back to top]

Change in Fasting Plasma Glucose at Week 104

Change in fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104

Interventionmg/dL (Least Squares Mean)
Lira 1.8-15.82
Lira 1.2-9.36
Glimepiride1.97

[back to top]

Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 156

Change in mean prandial increments (incr.) of plasma glucose from baseline (week 0) to 156 weeks. The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 156

Interventionmg/dL (Least Squares Mean)
Lira 1.8-11.01
Lira 1.2-7.53
Glimepiride-7.97

[back to top]

Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 104

Change in mean prandial increments of plasma glucose from baseline (week 0) to 104 weeks (end of 52-week extension). The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 104

Interventionmg/dL (Least Squares Mean)
Lira 1.8-11.76
Lira 1.2-8.28
Glimepiride-7.95

[back to top]

Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 52

Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 52 weeks (end of double-blind period). The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 52

Interventionmg/dL (Least Squares Mean)
Lira 1.8-37.4
Lira 1.2-30.8
Glimepiride-24.5

[back to top]

Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 156

Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 156 weeks. The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 156

Interventionmg/dL (Least Squares Mean)
Lira 1.8-34.83
Lira 1.2-25.68
Glimepiride-23.84

[back to top]

Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 104

Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of 52-week extension). The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 104

Interventionmg/dL (Least Squares Mean)
Lira 1.8-37.15
Lira 1.2-27.34
Glimepiride-24.85

[back to top]

Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 52

Change in mean prandial increments of plasma glucose from baseline (week 0) to 52 weeks (end of double-blind period). The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 52

Interventionmg/dL (Least Squares Mean)
Lira 1.8-9.6
Lira 1.2-8.4
Glimepiride-5.6

[back to top]

Change in Fasting Plasma Glucose at Week 52

Change in fasting plasma glucose (FPG) from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52

Interventionmg/dL (Least Squares Mean)
Lira 1.8-25.57
Lira 1.2-15.21
Glimepiride-5.29

[back to top]

Hypoglycaemic Episodes

Total number of hypoglycaemic episodes occuring from baseline (week 0) to 104 weeks (end of the 52-week extension). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL. (NCT00294723)
Timeframe: weeks 0-104

,,
Interventionepisodes (Number)
MajorMinorSymptoms only
Glimepiride0533405
Lira 1.2068133
Lira 1.817187

[back to top]

Hypoglycaemic Episodes

Total number of hypoglycaemic episodes occuring from week 104 to end of trial (week 195). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL. (NCT00294723)
Timeframe: weeks 104-195

,,
Interventionepisodes (Number)
MajorMinorSymptoms only
Glimepiride1344
Lira 1.2031
Lira 1.80133

[back to top]

Change in Fasting Plasma Glucose at Week 156

Change in fasting plasma glucose (FPG) from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156

Interventionmg/dL (Least Squares Mean)
Lira 1.8-12.06
Lira 1.2-5.45
Glimepiride4.57

[back to top]

Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52

Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52

Interventionpercentage point of total HbA1c (Least Squares Mean)
Lira 1.8-1.14
Lira 1.2-0.84
Glimepiride-0.51

[back to top]

Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156

Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156

Interventionpercentage point of total HbA1c (Least Squares Mean)
Lira 1.8-0.71
Lira 1.2-0.44
Glimepiride-0.16

[back to top]

Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 104

Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104

Interventionpercentage point of total HbA1c (Least Squares Mean)
Lira 1.8-0.88
Lira 1.2-0.59
Glimepiride-0.28

[back to top]

Change in Body Weight at Week 104

Change in body weight from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104

Interventionkg (Least Squares Mean)
Lira 1.8-2.70
Lira 1.2-1.89
Glimepiride0.95

[back to top]

Change in Body Weight at Week 156

Change in body weight from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156

Interventionkg (Least Squares Mean)
Lira 1.8-2.43
Lira 1.2-1.68
Glimepiride1.05

[back to top]

Change in Body Weight at Week 52

Change in body weight from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52

Interventionkg (Least Squares Mean)
Lira 1.8-2.45
Lira 1.2-2.05
Glimepiride1.12

[back to top]

HbA1c Change From Baseline at Week 12

HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the HbA1c percent baseline value. Means are treatment adjusted for baseline HbA1c. (NCT00309608)
Timeframe: Baseline and week 12

InterventionPercent (Mean)
Placebo0.25
Linagliptin 1 mg-0.15
Linagliptin 5 mg-0.48
Linagliptin 10 mg-0.42
Glimepiride-0.59

[back to top]

Fasting Blood Plasma Glucose Level (FPG) Change From Baseline at Week 12

This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication. (NCT00309608)
Timeframe: Baseline and week 12

Interventionmg/dL (Mean)
Placebo13.63
Linagliptin 1 mg-5.32
Linagliptin 5 mg-21.29
Linagliptin 10 mg-15.87

[back to top]

Percentage of Patients With HbA1c<=7.0% at Week 12

Descriptive calculation of Patients with HbA1c <= 7.0% at Week 12. (NCT00309608)
Timeframe: week 12

InterventionPercentage of Patients (Number)
Placebo1.4
Linagliptin 1 mg15.6
Linagliptin 5 mg14.5
Linagliptin 10 mg21.2
Glimepiride31.3

[back to top]

Change in Beta-cell Function at Week 26

"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 26

Interventionpercentage point (%point) (Least Squares Mean)
Lira 0.6 + Met20.45
Lira 1.2 + Met20.33
Lira 1.8 + Met26.12
Met Mono-1.63
Met + Glim24.68

[back to top]

Change in Body Weight at Week 104

Change in body weight from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104

Interventionkg (Least Squares Mean)
Lira 0.6 + Met-2.07
Lira 1.2 + Met-3.03
Lira 1.8 + Met-2.91
Met Mono-1.80
Met + Glim0.70

[back to top]

Change in Body Weight at Week 26

Change in body weight from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26

Interventionkg (Least Squares Mean)
Lira 0.6 + Met-1.78
Lira 1.2 + Met-2.58
Lira 1.8 + Met-2.79
Met Mono-1.51
Met + Glim0.95

[back to top]

Change in Fasting Plasma Glucose (FPG) at Week 104

Change in Fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-0.80
Lira 1.2 + Met-1.20
Lira 1.8 + Met-1.18
Met Mono0.75
Met + Glim-0.64

[back to top]

Change in Fasting Plasma Glucose (FPG) at Week 26

Change in fasting plasma glucose (FPG) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-1.13
Lira 1.2 + Met-1.63
Lira 1.8 + Met-1.68
Met Mono0.40
Met + Glim-1.31

[back to top]

Change in Glycosylated A1c (HbA1c) at Week 104

Change in glycosylated A1c (HbA1c) baseline (week 0) to 104 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 104

Interventionpercentage of total haemoglobin (Least Squares Mean)
Lira 0.6 + Met-0.36
Lira 1.2 + Met-0.56
Lira 1.8 + Met-0.58
Met Mono0.25
Met + Glim-0.50

[back to top]

Change in Glycosylated A1c (HbA1c) at Week 26

Percentage point change in Glycosylated A1c (HbA1c) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26

InterventionPercentage point of total HbA1c (Least Squares Mean)
Lira 0.6 + Met-0.69
Lira 1.2 + Met-0.97
Lira 1.8 + Met-1.00
Met Mono0.09
Met + Glim-0.98

[back to top]

Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104

Change in mean post prandial plasma glucose from baseline (Week 0) to 104 weeks (end of treatment) The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 104

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-1.59
Lira 1.2 + Met-2.22
Lira 1.8 + Met-2.10
Met Mono-0.43
Met + Glim-1.80

[back to top]

Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26

Change in mean post prandial plasma glucose from baseline (Week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-1.68
Lira 1.2 + Met-2.33
Lira 1.8 + Met-2.57
Met Mono-0.62
Met + Glim-2.46

[back to top]

Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104

"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of treatment). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 104

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-0.27
Lira 1.2 + Met-0.56
Lira 1.8 + Met-0.44
Met Mono-0.20
Met + Glim-0.29

[back to top]

Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26

"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 26

Interventionmmol/l (Least Squares Mean)
Lira 0.6 + Met-0.23
Lira 1.2 + Met-0.40
Lira 1.8 + Met-0.56
Met Mono-0.44
Met + Glim-0.44

[back to top]

Hypoglycaemic Episodes at Week 104

Total number of hypoglycaemic episodes occuring after baseline (week 0) until 104 weeks (end of treatment). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-104

,,,,
Interventionepisodes (Number)
AllMajorMinorSymptoms only
Lira 0.6 + Met5202329
Lira 1.2 + Met5112624
Lira 1.8 + Met4902227
Met + Glim5240284240
Met Mono180612

[back to top]

Hypoglycaemic Episodes at Week 26

Total number of hypoglycaemic episodes occuring after baseline (week 0) until week 26 (end of randomisation). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-26

,,,,
Interventionepisodes (Number)
MajorMinorSymptoms only
Lira 0.6 + Met01517
Lira 1.2 + Met037
Lira 1.8 + Met0922
Met + Glim0136175
Met Mono0610

[back to top]

Change in Beta-cell Function at Week 104

"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 104

Interventionpercentage point (%point) (Least Squares Mean)
Lira 0.6 + Met64.48
Lira 1.2 + Met27.30
Lira 1.8 + Met17.81
Met Mono-7.89
Met + Glim11.25

[back to top]

Glycaemia According to CGMS (Diurnal), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The diurnal glycemia measured by CGM system will be the average of glycemic values recorded between breakfast time and midnight. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)162.1139.1
Glimepiride/Metformin158.7130.13

[back to top]

Glycaemia According to CGMS (Nocturnal), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The nocturnal glycemia measured by CGM system will be defined as the average of glycemic values collected between midnight and breakfast time. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)148.4130.2
Glimepiride/Metformin140.4126.3

[back to top]

Glycaemia According to CGMS (MAGE), mg/dL

Calculation of the Mean amplitude of glycemic excursion (MAGE) was obtained by measuring the arithmetic mean of the major glucose concentration increases or decreases on days 2 and 3 of glycaemic profile and then averaging results on the two days. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)75.144.2
Glimepiride/Metformin61.650.8

[back to top]

Glycaemia According to CGMS (Postprandial Incremental AUC or Values Above 1 mg/dL), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)522.8356.9
Glimepiride/Metformin443.0362.7

[back to top]

Glycaemia According to CGMS (Total Area Under the Curve (AUC) for Values Above 1 mg/dL), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)1428.2891.4
Glimepiride/Metformin1293.1717.7

[back to top]

HbA1c (Glycosylated Hemoglobin)

Uncontrolled HbA1c>8.5%. HbA1c and fasting blood glucose taken at hospital (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionPercentage (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)7.87.4
Glimepiride/Metformin7.77.1

[back to top]

Glycaemia According to CGMS (Basal Incremental AUC or Values Above 1 mg/dL), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)905.6534.5
Glimepiride/Metformin850.1355.0

[back to top]

Duration of Hypoglycaemia (<60 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionHours (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)0.510.14
Glimepiride/Metformin00.08

[back to top]

Episodes of Severe Hyperglycaemia (>150 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionEpisodes (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)4.005.00
Glimepiride/Metformin3.552.95

[back to top]

Episodes of Hypoglycaemia (<80 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionEpisodes (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)0.640.50
Glimepiride/Metformin0.300.80

[back to top]

Episodes of Hypoglycaemia (<60 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionEpisodes (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)0.500.14
Glimepiride/Metformin00.1

[back to top]

Episodes of Hyperglycaemia (>126 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionEpisodes (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)3.915.36
Glimepiride/Metformin4.055.90

[back to top]

Duration of Severe Hyperglycaemia (>150 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionHours (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)11.286.39
Glimepiride/Metformin12.354.23

[back to top]

Duration of Hypoglycaemia (<80 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionHours (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)0.850.64
Glimepiride/Metformin0.240.41

[back to top]

Duration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionHours (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)17.3115.30
Glimepiride/Metformin17.5310.83

[back to top]

8-Iso Prostaglandin F2α (8-iso PGF2α) Excretion Rate

8-Iso Prostaglandin F2α (8-iso PGF2α) excretion rate measured during the 24 hours preceding the CGM system removal. The nocturnal glycemia measured by CGM system will be defined as the average of glycemic values collected between midnight and breakfast time. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionpg/mL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)361.9373.5
Glimepiride/Metformin325.1320.4

[back to top]

Glycaemia According to CGMS (Dawn), mg/dL

"Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The glycemia at dawn measured by CGM system will be defined as the average of glycemic values recorded between 4 AM and breakfast time." (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)145.0130.6
Glimepiride/Metformin138.6124.7

[back to top]

Heart Rate at Year 3

Heart rate at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionbeats per minute (Least Squares Mean)
Exen + Met73.51
Glim + Met74.23

[back to top]

Fasting Proinsulin/Insulin Ratio at Year 3

Fasting proinsulin (measured in pmol/L)/insulin (measured in pmol/L) ratio at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionratio (Least Squares Mean)
Exen + Met0.22
Glim + Met0.23

[back to top]

Fasting Plasma Glucose at Year 3

Fasting plasma glucose at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionmmol/L (Least Squares Mean)
Exen + Met7.27
Glim + Met7.96

[back to top]

Disposition Index at Year 3

Disposition Index at Year 3. Disposition index was calculated as (DI30/DG30 ratio)/(HOMA index for insulin resistance (HOMA-IR)); where HOMA-IR=(fasting insulin (measured in pmol/L) x fasting glucose (measured in mmol/L))/(22.5 x 7.175). (NCT00359762)
Timeframe: Year 3 in Period II

Interventionratio (Least Squares Mean)
Exen + Met12.56
Glim + Met7.89

[back to top]

Diastolic Blood Pressure at Year 3

Diastolic Blood pressure at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

InterventionmmHg (Least Squares Mean)
Exen + Met77.45
Glim + Met79.16

[back to top]

Change in Postprandial (2 Hours) Plasma Glucose From Baseline to Endpoint

Change from baseline in postprandial (2 hours) plasma glucose to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionmmol/L (Least Squares Mean)
Exen + Met-2.72
Glim + Met-0.53

[back to top]

Change in HOMA-B From Baseline to Endpoint

Change in HOMA-B from baseline to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionratio (Least Squares Mean)
Exen + Met5.56
Glim + Met19.92

[back to top]

Change in HbA1c From Baseline to Year 3

Change in HbA1c from baseline to Year 3. (NCT00359762)
Timeframe: Baseline, Year 3 in Period II

Interventionpercentage of total hemoglobin (Least Squares Mean)
Exen + Met-0.30
Glim + Met-0.12

[back to top]

Change in HbA1c From Baseline to Year 2 for Patients Randomized at Entry in Period III

Change in HbA1c from baseline to Year 2. (NCT00359762)
Timeframe: Baseline in Period III, Year 2 in Period III

Interventionpercentage of total hemoglobin (Least Squares Mean)
Exen + Met + Glim - Randomized-0.19
Exen + Met + Pio or Rosi - Randomized-0.47

[back to top]

Change in HbA1c From Baseline to Year 2 for Patients Not Randomized at Entry in Period III

Change in HbA1c from baseline to Year 2. (NCT00359762)
Timeframe: Baseline in Period III, Year 2 in Period III

Interventionpercentage of total hemoglobin (Mean)
Glim + Met + Exen - Not Randomized-0.47

[back to top]

Change in HbA1c From Baseline to Endpoint

Change in HbA1c from baseline to endpoint. Endpoint for HbA1c was defined as the HbA1c measured at the treatment failure for patients reaching primary endpoint and was the last observation in study period II for other patients (either followed until the end of the study period II or discontinuing the study). (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionpercentage of total hemoglobin (Least Squares Mean)
Exen + Met-0.36
Glim + Met-0.21

[back to top]

Change in Fasting Proinsulin/Insulin Ratio From Baseline to Endpoint.

Change in fasting proinsulin (measured in pmol/L)/insulin (measured in pmol/L) ratio from baseline to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionratio (Least Squares Mean)
Exen + Met0.03
Glim + Met0.05

[back to top]

Change in Fasting Plasma Glucose From Baseline to Endpoint

Change in fasting plasma glucose from baseline to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionmmol/L (Least Squares Mean)
Exen + Met-0.87
Glim + Met-0.41

[back to top]

Change in Disposition Index From Baseline to Endpoint

Change in disposition index from baseline to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionratio (Least Squares Mean)
Exen + Met9.15
Glim + Met1.82

[back to top]

Change in Body Weight From Baseline to Year 3

Change in Body weight from baseline to Year 3. (NCT00359762)
Timeframe: Baseline, Year 3 in Period II

Interventionkg (Least Squares Mean)
Exen + Met-3.92
Glim + Met1.47

[back to top]

Number of Patients With Treatment Failure

Treatment failure is defined as one of the following:1. HbA1c exceeding 9% at any visit after the initial 3 months of treatment (i.e., earliest at Month 6), on the maximally tolerated dose of antidiabetic agents. 2. HbA1c exceeding 7% at 2 consecutive visits 3 months apart, after the initial 6 months of treatment (i.e., earliest at Month 9), on the maximally tolerated dose of antidiabetic agents. (NCT00359762)
Timeframe: Baseline to end of Period II (up to 4.5 years)

,
Interventionnumber of patients (Number)
Number of patients with treatment failureNumber of patients censored
Exen + Met203287
Glim + Met262225

[back to top]

Triglycerides at Year 3

Triglycerides at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionmmol/L (Least Squares Mean)
Exen + Met1.69
Glim + Met1.95

[back to top]

Total Cholesterol at Year 3

Total Cholesterol at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionmmol/L (Least Squares Mean)
Exen + Met4.77
Glim + Met4.75

[back to top]

Time to Treatment Failure

Treatment failure is defined as one of the following:1. HbA1c exceeding 9% at any visit after the initial 3 months of treatment (i.e., earliest at Month 6), on the maximally tolerated dose of antidiabetic agents. 2. HbA1c exceeding 7% at 2 consecutive visits 3 months apart, after the initial 6 months of treatment (i.e., earliest at Month 9), on the maximally tolerated dose of antidiabetic agents. (NCT00359762)
Timeframe: Baseline to end of Period II (up to 4.5 years)

Interventionweek (Median)
Exen + Met180.0
Glim + Met142.1

[back to top]

Systolic Blood Pressure at Year 3

Systolic Blood pressure at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

InterventionmmHg (Least Squares Mean)
Exen + Met130.58
Glim + Met135.78

[back to top]

Ratio of the 30 Minute Increment in Plasma Insulin Concentration and the 30 Minute Increment in Plasma Glucose During the Oral Glucose Tolerance Test (DI30/DG30 Ratio) at Year 3

DI30/DG30 at Year 3. DI30/DG30 ratio was calculated as (30 minute post prandial insulin - fasting insulin) (measured in pmol/L)/(30 minute post prandial glucose - fasting glucose) (measured in mmol/L). (NCT00359762)
Timeframe: Year 3 in Period II

Interventionratio (Least Squares Mean)
Exen + Met25.81
Glim + Met26.38

[back to top]

Postprandial (2 Hours) Plasma Glucose at Year 3

Postprandial (2 hours) plasma glucose at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionmmol/L (Least Squares Mean)
Exen + Met12.65
Glim + Met15.45

[back to top]

Hypoglycemia Rate Per Year in Period III

All hypoglycemia episodes were taken into account. Severe hypoglycemia: event requiring assistance of another person to administer carbohydrate, glucagons, or other resuscitative actions; Documented symptomatic hypoglycemia: event with typical symptoms accompanied by a measured plasma glucose concentration <=70 mg/dL; Asymptomatic hypoglycemia: event not accompanied by typical symptoms but with a measured plasma glucose concentration <=70 mg/dL; Probable symptomatic hypoglycemia: event with symptoms not accompanied by a plasma glucose determination. (NCT00359762)
Timeframe: Start of Period III to end of study

Interventionevents per subject-year (Mean)
Exen + Metformin + Glim - Randomized2.78
Exen + Met + Pio or Rosi - Randomized0.60
Glim + Met + Exen - Not Randomized4.62

[back to top]

Hypoglycemia Rate Per Year

All hypoglycemia episodes were taken into account. Severe hypoglycemia: event requiring assistance of another person to administer carbohydrate, glucagons, or other resuscitative actions; Documented symptomatic hypoglycemia: event with typical symptoms accompanied by a measured plasma glucose concentration <=70 mg/dL; Asymptomatic hypoglycemia: event not accompanied by typical symptoms but with a measured plasma glucose concentration <=70 mg/dL; Probable symptomatic hypoglycemia: event with symptoms not accompanied by a plasma glucose determination. (NCT00359762)
Timeframe: Baseline to end of Period II (up to 4.5 years)

Interventionevents per subject-year (Least Squares Mean)
Exen + Met1.52
Glim + Met5.32

[back to top]

Homeostasis Model Assessment of Beta-cell Function (HOMA-B) at Year 3

HOMA-B at Year 3. HOMA-B is an index of beta-cell function and was calculated as: HOMA-B = (20 x fasting insulin (measured in pmol/L))/((fasting glucose (measured in mmol/L) - 3.5) x 7.175). (NCT00359762)
Timeframe: Year 3 in Period II

Interventionratio (Least Squares Mean)
Exen + Met66.86
Glim + Met68.52

[back to top]

High-density Lipoprotein (HDL) Cholesterol at Year 3

HDL Cholesterol at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionmmol/L (Least Squares Mean)
Exen + Met1.31
Glim + Met1.25

[back to top]

Change in DI30/DG30 Ratio From Baseline to Endpoint

Change in DI30/DG30 ratio from baseline to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionratio (Least Squares Mean)
Exen + Met12.10
Glim + Met0.91

[back to top]

Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL

(NCT00360698)
Timeframe: during treatment period (12 weeks)

InterventionNumber of hypoglycemia per patient-year (Mean)
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride1.62
Insulin Glargine+Metformin+Glimepiride3.95

[back to top]

Rate of Severe Symptomatic Hypoglycemia

(NCT00360698)
Timeframe: during treatment period (12 weeks)

InterventionNumber of hypoglycemia per patient-year (Mean)
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride0.00
Insulin Glargine+Metformin+Glimepiride0.20

[back to top]

Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL

(NCT00360698)
Timeframe: during treatment period (12 weeks)

InterventionNumber of hypoglycemia per patient-year (Mean)
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride8.19
Insulin Glargine+Metformin+Glimepiride7.68

[back to top]

Glycosylated Haemoglobin (HbA1c) Value

(NCT00360698)
Timeframe: at the end of treatment (week 24)

Interventionpercent (Mean)
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride7.5
Insulin Glargine+Metformin+Glimepiride7.8

[back to top]

Daily Mean Plasma Glucose

(NCT00360698)
Timeframe: at the end of treatment (week 24)

Interventionmg/dL (Mean)
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride154.7
Insulin Glargine+Metformin+Glimepiride165.8

[back to top]

Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%

Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c <7% (NCT00360698)
Timeframe: at the end of treatment (week 24)

Interventionpercentage of participants (Number)
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride22.4
Insulin Glargine+Metformin+Glimepiride8.8

[back to top]

Daily Dose of Insulin Glulisine

Mean of 3 daily doses reported during the week prior to the final visit (NCT00360698)
Timeframe: at the end of treatment (week 24)

Interventionunits of insulin glulisine per day (Mean)
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride12.8

[back to top]

Daily Dose of Insulin Glargine

Mean of 3 daily doses reported during the week prior to the final visit (NCT00360698)
Timeframe: at the end of treatment (week 24)

Interventionunits of insulin glargine per day (Mean)
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride54.7
Insulin Glargine+Metformin+Glimepiride62.2

[back to top]

Change in Weight

(NCT00360698)
Timeframe: from baseline to the end of treatment (week 24)

Interventionkg (Least Squares Mean)
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride0.46
Insulin Glargine+Metformin+Glimepiride0.22

[back to top]

Change in Glycosylated Haemoglobin (HbA1c) Value

(NCT00360698)
Timeframe: from baseline to the end of treatment (week 24)

Interventionpercent (Least Squares Mean)
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride-0.37
Insulin Glargine+Metformin+Glimepiride-0.11

[back to top]

Change in Daily Mean Plasma Glucose

(NCT00360698)
Timeframe: from baseline to the end of treatment (week 24)

Interventionmg/dL (Least Squares Mean)
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride-15.01
Insulin Glargine+Metformin+Glimepiride-2.07

[back to top]

9-point Self-measured Plasma Glucose Profiles

Glycaemic control measured by 9-point self-measured plasma glucose (SMPG) profiles. The 9 time points for self-measurement during the day were: Before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, before bedtime, at 2-4 AM, and before breakfast the following day. Hypoglycaemia episodes were defined as major or minor. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. (NCT00469092)
Timeframe: After 26 weeks of treatment

,
Interventionmmol/L (Mean)
Before breakfast2 hours after breakfastBefore lunch2 hours after lunchBefore dinner2 hours after dinnerBefore bedtime02:00-04:00 AMBefore breakfast following day
BIAsp 306.739.407.248.907.908.667.776.566.65
Glargine6.569.077.288.987.809.188.546.696.40

[back to top]

Number of Hypoglycaemic Episodes

Total number of hypoglycaemic episodes experienced in each treatment arm. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. Symptoms only if subject was able to treat her/himself and with either no plasma glucose or blood glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L or 56 mg/dL. (NCT00469092)
Timeframe: Weeks 0-26

,
Interventionevents (Number)
MinorSymptom onlyMajorUnclassified
BIAsp 3044326531
Glargine31822430

[back to top]

Number of Subjects Achieving the Treatment Target for Glycosylated Haemoglobin A1c (HbA1c)

The number of subjects achieving the treatment target for glycosylated haemoglobin A1c after 26 weeks treatment. The treatment targets were: HbA1c <= 6.5% of haemoglobin and HbA1c < 7% of haemoglobin. (NCT00469092)
Timeframe: After 26 weeks of treatment

,
Interventionparticipants (Number)
HbA1c <= 6.5% of haemoglobinHbA1c < 7.0% of haemoglobinReduction > 1% point from baselineHbA1c < 7% no nocturnal hypoglycemiaHbA1c < 7%, no daytime hypoglycemiaHbA1c < 7%, no hypoglycemia
BIAsp 3054101134825245
Glargine60106132925045

[back to top]

Treatment Satisfaction as Measured by the Diabetes Medication Satisfaction Questionnaire (Diab MedSat)

Subjects assessed the burden, efficacy, symptoms and overall score in the treatment satisfaction questionnaire, Diab MedSat (Diabetes Medication Satisfaction questionnaire). The scores were transformed to a 0-100 scale with higher scores indicating greater satisfaction. The score of the subscales was computed as the mean of the items in each subscale. (NCT00469092)
Timeframe: After 26 weeks of treatment

,
Interventionscores on a scale (Mean)
Burden ScoreEfficacy ScoreSymptoms ScoreOverall Score
BIAsp 3083.1073.2572.4276.53
Glargine83.0673.4772.8176.64

[back to top]

Number of Subjects Reporting Treatment Emergent Adverse Events

Number of subjects reporting treatment emergent adverse events during the trial (from week 0 to week 26). Adverse events were reported as treatment emergent if they occurred from the date of first insulin trial product administration up to and including the date of last insulin trial product administration. (NCT00469092)
Timeframe: Weeks 0-26

Interventionparticipants (Number)
BIAsp 30117
Glargine115

[back to top]

Glycosylated Haemoglobin A1c (HbA1c)

Glycosylated Haemoglobin A1c measured in blood samples after 26 weeks of treatment. (NCT00469092)
Timeframe: After 26 weeks of treatment

Interventionpercentage of total haemoglobin (Least Squares Mean)
BIAsp 307.08
Glargine7.23

[back to top]

7-point Self-measured Plasma Glucose Profiles

Summary of 7-Point Profiles of Self-Measured Plasma Glucose by Treatment, Week and Time. The 7 time points for self-measurements for all treatment groups were: Before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime, measured over 16 weeks of treatment (at week 0, 8, 12 and 16). (NCT00614120)
Timeframe: week 0, 8, 12 and 16

,,,
Interventionmg/dl (Mean)
Week 0 - Before breakfastWeek 0 - 90 minutes after breakfastWeek 0 - Before lunchWeek 0 - 90 minutes after lunchWeek 0 - Before dinnerWeek 0 - 90 minutes after dinnerWeek 0 - BedtimeWeek 8 - Before breakfastWeek 8 - 90 minutes after breakfastWeek 8 - Before lunchWeek 8 - 90 minutes after lunchWeek 8 - Before dinnerWeek 8 - 90 minutes after dinnerWeek 8 - BedtimeWeek 12 - Before breakfastWeek 12 - 90 minutes after breakfastWeek 12 - Before lunchWeek 12 - 90 minutes after lunchWeek 12 - Before dinnerWeek 12 - 90 minutes after dinnerWeek 12 - BedtimeWeek 16 - Before breakfastWeek 16 - 90 minutes after breakfastWeek 16 - Before lunchWeek 16 - 90 minutes after lunchWeek 16 - Before dinnerWeek 16 - 90 minutes after dinnerWeek 16 - Bedtime
Glim + Met163.8238.5175.8227.6180.2231.6202.7130.1201.2132.6184.3143.3190.2163.6128.5200.8129.3185.3144.2188.5159.9131.0195.1128.8182.2144.9192.6157.7
Lira 0.6 + Met168.2245.9178.5234.2194.8239.6205.7137.0198.5144.8187.2159.1193.7169.1137.8197.5141.8183.7156.4197.2168.2137.3195.6140.5185.8151.5195.0166.4
Lira 1.2 + Met167.5248.0180.5232.3184.8239.6208.1130.4190.1136.5176.9147.8187.1161.6130.2185.7135.6174.7143.4185.7158.9132.9188.7137.0181.4148.4183.3159.8
Lira 1.8 + Met168.8245.4176.9234.4190.9244.0219.3133.7178.5138.0177.9144.2183.3155.8130.2178.6134.1173.7144.5183.5158.9128.6177.6137.8173.2140.9173.2151.6

[back to top]

Change in Self-measured Fasting Plasma Glucose

Change in self-measured fasting plasma glucose from baseline (week 0) to 16 weeks (end of treatment). Self-measurement of plasma glucose was performed using a glucose meter and subjects were instructed to record self-measured plasma glucose values into a diary. (NCT00614120)
Timeframe: week 0, week 16

Interventionmg/dL (Mean)
Lira 0.6 + Met-1.83
Lira 1.2 + Met-1.96
Lira 1.8 + Met-2.28
Glim + Met-2.13

[back to top]

Change in Glycosylated Haemoglobin A1c (HbA1c)

Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 16 weeks (end of treatment). (NCT00614120)
Timeframe: week 0, week 16

Interventionpercentage point of total HbA1c (Mean)
Lira 0.6 + Met-1.0
Lira 1.2 + Met-1.3
Lira 1.8 + Met-1.4
Glim + Met-1.3

[back to top]

Change in Fasting Lipid Profile, APO-B

Change in fasting lipid profiles based on apolipoprotein B (Apo-B) from baseline (week 0) to 16 weeks (end of treatment). (NCT00614120)
Timeframe: week 0, week 16

Interventiong/L (Median)
Lira 0.6 + Met0.02
Lira 1.2 + Met0.00
Lira 1.8 + Met-0.00
Glim + Met0.01

[back to top]

Change in Body Weight

Change in body weight from baseline (week 0) to 16 weeks (end of treatment) (NCT00614120)
Timeframe: week 0, week 16

Interventionkg (Mean)
Lira 0.6 + Met-1.8
Lira 1.2 + Met-2.3
Lira 1.8 + Met-2.4
Glim + Met0.1

[back to top]

Change in Beta-cell Function

"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00614120)
Timeframe: week 0, week 16

Interventionpercentage point (%point) (Mean)
Lira 0.6 + Met15.3
Lira 1.2 + Met17.8
Lira 1.8 + Met21.7
Glim + Met21.8

[back to top]

Hypoglycaemic Episodes

Total number of hypoglycaemic episodes over 16 weeks of treatment occurring from baseline (week 0) to end of treatment (week 16). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00614120)
Timeframe: weeks 0-16

,,,
Interventionepisodes (Number)
MajorMinorSymptoms only
Glim + Met28086
Lira 0.6 + Met0612
Lira 1.2 + Met0011
Lira 1.8 + Met059

[back to top]

Change in Fasting Lipid Profile

"Change in fasting lipid profiles from baseline (week 0) to 16 weeks (end of treatment). Fasting lipid profiles is based on:~Total Cholesterol (TC)~Low-density Lipoprotein-cholesterol (LDL-C)~Very Low-density Lipoprotein-cholesterol (VLDL-C)~High-density Lipoprotein-cholesterol (HDL-C)~Triglyceride (TG)~Free Fatty Acid (FFA)" (NCT00614120)
Timeframe: week 0, week 16

,,,
Interventionmmol/L (Mean)
Change in TC (Absolute), N=221, 216, 216, 228Change in LDL-C (Absolute), N=221, 216, 216, 228Change in VLDL-C (Absolute), N=213, 210, 207, 220Change in HDL-C (Absolute), N=217, 212, 212, 220Change in TG (Absolute), N=220, 212, 213, 226Change in FFA (Absolute), N=218, 214, 216, 227
Glim + Met0.020.040.05-0.01-0.07-0.02
Lira 0.6 + Met0.060.060.03-0.02-0.08-0.03
Lira 1.2 + Met-0.01-0.030.05-0.05-0.06-0.04
Lira 1.8 + Met-0.030.000.01-0.05-0.22-0.10

[back to top]

Number of Hypoglycaemic Episodes

Total number of hypoglycaemic episodes occurring from week 0 to week 12. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself and either plasma glucose was below 56 mg/dL or symptoms were reversed after food intake or glucagon/intravenous glucose administration. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL. (NCT00620282)
Timeframe: weeks 0-12

,,
Interventionepisodes (Number)
MajorMinorSymptoms Only
Glimepiride0104
Lira 1.8013
Placebo000

[back to top]

Change in Body Weight

(NCT00620282)
Timeframe: week 0, week 12

Interventionkg (Least Squares Mean)
Lira 1.8-1.821
Placebo-0.293
Glimepiride1.038

[back to top]

Haematology and Biochemistry Tests - Number of Subjects With Creatinine Values Outside Reference Range

Number of subjects with serum creatinine values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 0.600 mg/dL, upper value 1.100 mg/dL) Male (lower value 0.800 mg/dL, upper value 1.300 mg/dL). (NCT00620282)
Timeframe: week 0, week 12

,,
Interventionparticipants (Number)
Week 0Week 12
Glimepiride52
Lira 1.811
Placebo32

[back to top]

Fasting Lipid Profile - Change in Triglycerides (TG)

Change in TG (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.8-8.163
Placebo28.546
Glimepiride-4.377

[back to top]

Fasting Lipid Profile - Change in Total Cholesterol (TC)

Change in TC (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.82.006
Placebo4.243
Glimepiride0.094

[back to top]

Fasting Lipid Profile - Change in LDL-C

Change in LDL-C (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.81.243
Placebo-2.459
Glimepiride-1.529

[back to top]

Fasting Lipid Profile - Change in HDL-C

Change in HDL-C (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.80.393
Placebo0.562
Glimepiride1.116

[back to top]

Change in Sodium Nitroprusside (SNP)-Mediated Forearm Blood Flow (FBF)

Assessed endothelial function by measuring the change in SNP-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute. (NCT00620282)
Timeframe: week 0, week 12

InterventionmL/100 mL/min (Least Squares Mean)
Lira 1.83.455
Placebo-1.044
Glimepiride2.746

[back to top]

Change in Mean Postprandial Glucose (PPG) Based on Self-measured 7-point Plasma Glucose Profiles

The 7-point profile included plasma glucose measurements at the following time points: before each main meal (breakfast, lunch and dinner), 90 minutes after the start of each main meal (breakfast, lunch and dinner) and at bedtime. (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.8-32.175
Placebo-20.304
Glimepiride-35.99

[back to top]

Change in HbA1c (Glycosylated Haemoglobin A1c)

Percentage point change in HbA1c (NCT00620282)
Timeframe: week 0, week 12

Interventionpercentage of total haemoglobin (Least Squares Mean)
Lira 1.8-0.629
Placebo-0.094
Glimepiride-0.552

[back to top]

Change in Fasting Plasma Glucose (FPG)

Change in FPG (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.8-41.672
Placebo-6.067
Glimepiride-32.019

[back to top]

Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)

Assessed endothelial function by measuring the change in ACh-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute. (NCT00620282)
Timeframe: week 0, week 12

InterventionmL/100 mL/min (Least Squares Mean)
Lira 1.84.244
Placebo-3.187
Glimepiride2.164

[back to top]

Biomarkers of Cardiovascular Risk - Change in TNF-alpha

Change in TNF-alpha (NCT00620282)
Timeframe: week 0, week 12

Interventionpg/mL (Least Squares Mean)
Lira 1.8-0.024
Placebo0.397
Glimepiride-0.0050

[back to top]

Haematology and Biochemistry Tests - Number of Subjects With Blood Urea Nitrogen (BUN) Values Outside Reference Range

Number of subjects with serum BUN values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 6.000 mg/dL, upper value 21.000 mg/dL) Male (lower value 8.000 mg/dL, upper value 25.000 mg/dL). (NCT00620282)
Timeframe: week 0, week 12

,,
Interventionparticipants (Number)
Week 0Week 12
Glimepiride10
Lira 1.811
Placebo02

[back to top]

Percentage of Patients With HbA1c <7.0% at Week 104

The percentage of patients with an HbA1c value below 7.0% at week 104, based upon patients with baseline HbA1c >= 7%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c >= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 104

InterventionPercentage of patients (Number)
Linagliptin21.0
Glimepiride28.3

[back to top]

Percentage of Patients With HbA1c <7.0% at Week 52

The percentage of patients with an HbA1c value below 7.0% at week 52, based upon patients with baseline HbA1c >= 7%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c >= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 52

InterventionPercentage of patients (Number)
Linagliptin29.6
Glimepiride38.9

[back to top]

Percentage of Patients With HbA1c Lowering by 0.5% at Week 104

Occurrence of relative efficacy response, defined as a lowering of 0.5% HbA1c at week 104 (NCT00622284)
Timeframe: Week 104

InterventionPercentage of patients (Number)
Linagliptin26.2
Glimepiride33.5

[back to top]

HbA1c Change at Week 104

The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement available during the first phase of the study. Last observation carried forward (LOCF) was used as imputation rule. (NCT00622284)
Timeframe: Baseline and week 104

InterventionPercent (Mean)
Linagliptin-0.21
Glimepiride-0.41

[back to top]

HbA1c Change at Week 12

(NCT00622284)
Timeframe: Baseline and week 12

InterventionPercent (Mean)
Linagliptin-0.43
Glimepiride-0.75

[back to top]

HbA1c Change at Week 16

(NCT00622284)
Timeframe: Baseline and week 16

InterventionPercent (Mean)
Linagliptin-0.45
Glimepiride-0.78

[back to top]

HbA1c Change at Week 28

(NCT00622284)
Timeframe: Baseline and week 28

InterventionPercent (Mean)
Linagliptin-0.43
Glimepiride-0.74

[back to top]

Change in Baseline Lipid Parameter Triglyceride at Week 104

(NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dL (Mean)
Linagliptin-11
Glimepiride-7

[back to top]

HbA1c Change at Week 40

(NCT00622284)
Timeframe: Baseline and week 40

InterventionPercent (Mean)
Linagliptin-0.42
Glimepiride-0.69

[back to top]

HbA1c Change at Week 52

(NCT00622284)
Timeframe: Baseline and week 52

InterventionPercent (Mean)
Linagliptin-0.41
Glimepiride-0.63

[back to top]

HbA1c Change at Week 65

(NCT00622284)
Timeframe: Baseline and week 65

InterventionPercent (Mean)
Linagliptin-0.32
Glimepiride-0.53

[back to top]

HbA1c Change at Week 8

(NCT00622284)
Timeframe: Baseline and week 8

InterventionPercent (Mean)
Linagliptin-0.37
Glimepiride-0.58

[back to top]

HbA1c Change at Week 4

Difference of base percent value [Week x(%) - baseline (%)] (NCT00622284)
Timeframe: Baseline and week 4

InterventionPercent (Mean)
Linagliptin-0.26
Glimepiride-0.33

[back to top]

Incidence of Hypoglycaemic Events up to 104 Weeks

A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a HBGM of below 55 mg/dl (3.1 mmol/L) (NCT00622284)
Timeframe: Week 104

InterventionPatients (Number)
Linagliptin58
Glimepiride280

[back to top]

HbA1c Change From Baseline at Week 52

This co-primary endpoint, change from baseline, reflects the Week 52 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 52

InterventionPercent (Mean)
Linagliptin-0.36
Glimepiride-0.57

[back to top]

Fasting Plasma Glucose (FPG) Change From Baseline at Week 104

This change from baseline reflects the Week 104 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dL (Mean)
Linagliptin-2.34
Glimepiride-8.72

[back to top]

Incidence of Hypoglycaemic Events up to 52 Weeks

A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a home blood glucose monitoring (HBGM) of below 55 mg/dl (3.1 mmol/L) (NCT00622284)
Timeframe: Week 52

InterventionPatients (Number)
Linagliptin41
Glimepiride249

[back to top]

Percentage of Patients With HbA1c <6.5% at Week 104

The percentage of patients with an HbA1c value below 6.5% at week 104, based upon patients with baseline HbA1c >= 6.5%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c >= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 104

InterventionPercentage of patients (Number)
Linagliptin10.9
Glimepiride14.7

[back to top]

Percentage of Patients With HbA1c <6.5% at Week 52

The percentage of patients with an HbA1c value below 6.5% at week 52, based upon patients with baseline HbA1c >= 6.5%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c >= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 52

InterventionPercentage of patients (Number)
Linagliptin16.9
Glimepiride22.7

[back to top]

Change in Baseline Lipid Parameter Low Density Lipoprotein (LDL) at Week 104

(NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dL (Mean)
Linagliptin1
Glimepiride3

[back to top]

Change in Baseline Lipid Parameter HDL at Week 104

(NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dl (Mean)
Linagliptin1
Glimepiride0

[back to top]

Change in Baseline Lipid Parameter Cholesterol at Week 104

(NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dL (Mean)
Linagliptin0
Glimepiride1

[back to top]

Body Weight Change From Baseline at Week 52

This key secondary endpoint, change from baseline, reflects the Week 52 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications. (NCT00622284)
Timeframe: Baseline and week 52

Interventionkg (Mean)
Linagliptin-1.12
Glimepiride1.38

[back to top]

HbA1c Change at Week 78

(NCT00622284)
Timeframe: Baseline and week 78

InterventionPercent (Mean)
Linagliptin-0.22
Glimepiride-0.43

[back to top]

Body Weight Change From Baseline at Week 104

This key secondary endpoint, change from baseline, reflects the Week 104 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications. (NCT00622284)
Timeframe: Baseline and week 104

Interventionkg (Mean)
Linagliptin-1.39
Glimepiride1.29

[back to top]

2 hr Postprandial Glucose (PPG) Change From Baseline at Week 104

This change from baseline reflects the Week 104 2 hr PPG minus the Baseline 2hr PPG. Means are treatment adjusted for baseline HbA1c, baseline 2hr PPG and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dL (Mean)
Linagliptin-28.47
Glimepiride-18.72

[back to top]

HbA1c Change at Week 91

(NCT00622284)
Timeframe: Baseline and week 91

InterventionPercent (Mean)
Linagliptin-0.21
Glimepiride-0.43

[back to top]

HbA1c Change From Baseline at Week 104

This co-primary endpoint, change from baseline, reflects the Week 104 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 104

InterventionPercent (Mean)
Linagliptin-0.16
Glimepiride-0.36

[back to top]

Fasting Plasma Glucose (FPG) Change From Baseline at Week 52

This change from baseline reflects the Week 52 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and the number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 52

Interventionmg/dL (Mean)
Linagliptin-8.40
Glimepiride-15.24

[back to top]

Adjusted Mean Change in Body Weight for Participants With Baseline Body Mass Index (BMI)≥27 kg/m2

To show that dapagliflozin plus glimepiride results in greater reductions in body weight or less weight gain in participants with baseline BMI ≥27 kg/m2 after 24 weeks of treatment when compared to placebo plus glimepiride. (NCT00680745)
Timeframe: Baseline to Week 24

Interventionkg (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride-1.17
Dapagliflozin 5mg + Glimepiride-1.74
Dapagliflozin 10mg + Glimepiride-2.47
Placebo + Glimepiride-0.80

[back to top]

Adjusted Mean Change in Fasting Plasma Glucose (FPG)

To show that dapagliflozin plus glimepiride leads to greater reductions in FPG after 24 weeks of treatment compared to placebo plus glimepiride. (NCT00680745)
Timeframe: Baseline to Week 24

Interventionmg/dL (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride-16.8
Dapagliflozin 5mg + Glimepiride-21.2
Dapagliflozin 10mg + Glimepiride-28.5
Placebo + Glimepiride-2.0

[back to top]

Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%

To show that dapagliflozin plus glimepiride results in a larger proportion of participants achieving a therapeutic glycemic response, defined as HbA1c < 7% after 24 weeks of treatment, compared to placebo plus glimepiride. (NCT00680745)
Timeframe: At Week 24

InterventionPercentage of participants (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride26.8
Dapagliflozin 5mg + Glimepiride30.3
Dapagliflozin 10mg + Glimepiride31.7
Placebo + Glimepiride13.0

[back to top]

Adjusted Mean Change in HbA1c Levels

To assess the efficacy of dapagliflozin compared to placebo as add-on therapy to glimepiride in improving glycemic control in participants with type 2 diabetes, as determined by the change in HbA1C levels from baseline to the end of the 24-week double-blind treatment period. (NCT00680745)
Timeframe: Baseline to Week 24

InterventionPercent (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride-0.58
Dapagliflozin 5mg + Glimepiride-0.63
Dapagliflozin 10mg + Glimepiride-0.82
Placebo + Glimepiride-0.13

[back to top]

Adjusted Mean Change in 2-h Post-challenge Plasma Glucose Rise

To show that dapagliflozin plus glimepiride results in greater reductions in the 2-h post-challenge plasma glucose rise as a response to an oral glucose tolerance test (OGTT) from baseline to Week 24. (NCT00680745)
Timeframe: Baseline to Week 24

Interventionmg/dL (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride-37.5
Dapagliflozin 5mg + Glimepiride-32.0
Dapagliflozin 10mg + Glimepiride-34.9
Placebo + Glimepiride-6.0

[back to top]

Adjusted Mean Change in Body Weight

To show that dapagliflozin plus glimepiride results in greater reduction in body weight or less weight gain after 24 weeks of treatment when compared to placebo plus glimepiride. (NCT00680745)
Timeframe: Baseline to Week 24

Interventionkg (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride-1.18
Dapagliflozin 5mg + Glimepiride-1.56
Dapagliflozin 10mg + Glimepiride-2.26
Placebo + Glimepiride-0.72

[back to top]

Change From Baseline in Body Weight at Week 30

Change from baseline at Week 30 was defined as Week 30 minus Week 0. (NCT00701090)
Timeframe: Week 0 to Week 30

InterventionKilograms (Least Squares Mean)
Sitagliptin-0.8
Glimepiride1.2

[back to top]

Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30

Change from baseline at Week 30 was defined as Week 30 minus Week 0. (NCT00701090)
Timeframe: Week 0 to Week 30

Interventionmg/dL (Least Squares Mean)
Sitagliptin-14.6
Glimepiride-17.5

[back to top]

Change From Baseline in HbA1c at Week 30

Patient-level HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 30 HbA1c percent minus the Week 0 HbA1c percent. (NCT00701090)
Timeframe: Week 0 to Week 30

InterventionPercent (Least Squares Mean)
Sitagliptin-0.47
Glimepiride-0.54

[back to top]

Percent of Patients With A1C <6.5% at Week 30

(NCT00701090)
Timeframe: Week 30

InterventionPercentage of Participants (Number)
Sitagliptin21.2
Glimepiride27.5

[back to top]

Percent of Patients With A1C <7.0% at Week 30

(NCT00701090)
Timeframe: Week 30

InterventionPercentage of Participants (Number)
Sitagliptin52.4
Glimepiride59.6

[back to top]

Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30

(NCT00701090)
Timeframe: Week 0 to Week 30

InterventionPercentage of Participants (Number)
Sitagliptin7.0
Glimepiride22.0

[back to top]

HbA1c Change From Baseline at Week 18 (Final Analysis)

HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. The primary analysis was re-run at the completion of the study in the final study report. (NCT00740051)
Timeframe: Baseline and week 18

Interventionpercent (Mean)
Placebo0.21
Linagliptin-0.39

[back to top]

HbA1c Change From Baseline at Week 18 (Interim Analysis)

HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. (NCT00740051)
Timeframe: Baseline and week 18

Interventionpercent (Mean)
Placebo0.14
Linagliptin-0.44

[back to top]

Percentage of Patients With HbA1c Lowering by 0.5% at Week 18 (Interim Analysis)

Odds ratios are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. (NCT00740051)
Timeframe: Week 18

Interventionpercent of patients (Number)
Placebo17.8
Linagliptin36.1

[back to top]

Percentage of Patients With HbA1c<6.5 at Week 18 (Interim Analysis)

Odds ratios are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. (NCT00740051)
Timeframe: Week 18

Interventionpercent of patients (Number)
Placebo2.9
Linagliptin8.9

[back to top]

Percentage of Patients With HbA1c<7.0 at Week 18 (Interim Analysis)

Odds ratios are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. (NCT00740051)
Timeframe: Week 18

Interventionpercent of patients (Number)
Placebo11.8
Linagliptin23.5

[back to top]

The Change in FPG From Baseline by Visit Over Time

This change from baseline reflects the FPG (at weeks 6, 12, 18, 22, 26, 30, 34, 40, 46, 52) minus the Week 0 FPG. (NCT00740051)
Timeframe: Baseline and weeks 6,12,18, 22, 26, 30, 34, 40, 46, 52

,
Interventionmg/dL (Mean)
Change from baseline at week 6 (N=63, 134)Change from baseline at week 12 (N=55,92)Change from baseline at week 18 (N=47, 115)Change from baseline at week 22 (N=46, 110)Change from baseline at week 26 (N=50, 108)Change from baseline at week 30 (N=48, 95)Change from baseline at week 34 (N=48, 95)Change from baseline at week 40 (N=47, 92)Change from baseline at week 46 (N=47, 92)Change from baseline at week 52 (N=43, 86)
Linagliptin-8.4-14.3-12.9-14.0-17.0-19.1-15.8-19.0-18.1-14.0
Placebo/Glimepiride9.75.45.0-19.3-22.6-31.4-25.6-19.5-22.8-19.1

[back to top]

The Change in HbA1c From Baseline by Visit Over Time

HbA1c is measured as a percentage. Thus, this change from baseline reflects the HbA1c percent (at weeks 6, 12, 18, 22, 26, 30, 34, 40, 46, 52) minus the Week 0 HbA1c percent. (NCT00740051)
Timeframe: Baseline and weeks 6,12, 18, 22, 26, 30, 34, 40, 46, 52

,
Interventionpercent (Mean)
Change from baseline at week 6 (N=64, 136)Change from baseline at week 12 (N=57, 129)Change from baseline at week 18 (N=47, 118)Change from baseline at week 22 (N=46, 113)Change from baseline at week 26 (N=50, 110)Change from baseline at week 30 (N=49, 98)Change from baseline at week 34 (N=50, 96)Change from baseline at week 40 (N=49, 94)Change from baseline at week 46 (N=45, 92)Change from baseline at week 52 (N=45, 92)
Linagliptin-0.21-0.43-0.38-0.40-0.48-0.49-0.49-0.45-0.42-0.44
Placebo/Glimepiride0.260.260.10-0.32-0.53-0.79-0.75-0.73-0.78-0.72

[back to top]

Fasting Plasma Glucose (FPG) Change From Baseline at Week 18 (Interim Analysis)

This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG, baseline HbA1c, prior OADs and reason for metformin intolerance (Interim Analysis). (NCT00740051)
Timeframe: Baseline and week 18

Interventionmg/dl (Mean)
Placebo7.2
Linagliptin-13.3

[back to top]

Change From Baseline in Fasting Glucose.

The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-21.6
Glimepiride 2 mg and Metformin 850 mg BID-21.1

[back to top]

Change From Baseline in Erythrocyte Deformability (60.00).

The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.7
Glimepiride 2 mg and Metformin 850 mg BID-1.3

[back to top]

Change From Baseline in High-Density Lipoprotein Cholesterol.

The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.3
Glimepiride 2 mg and Metformin 850 mg BID-0.4

[back to top]

Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.

The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID0.1
Glimepiride 2 mg and Metformin 850 mg BID0.3

[back to top]

Change From Baseline in Low-Density Lipoprotein Cholesterol.

The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID9.7
Glimepiride 2 mg and Metformin 850 mg BID11.2

[back to top]

Change From Baseline in Low-Density Lipoprotein Subfractions.

The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID6.2
Glimepiride 2 mg and Metformin 850 mg BID6.1

[back to top]

Change From Baseline in Matrix Metallo Proteinase-9.

The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID31.4
Glimepiride 2 mg and Metformin 850 mg BID51.6

[back to top]

Change From Baseline in Nitrotyrosine.

The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionnmol/L (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-2.7
Glimepiride 2 mg and Metformin 850 mg BID32.5

[back to top]

Change From Baseline in Platelet Function.

The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionsec (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-30.3
Glimepiride 2 mg and Metformin 850 mg BID-1.0

[back to top]

Change From Baseline in Soluble CD40 Ligand.

The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpg/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-40.7
Glimepiride 2 mg and Metformin 850 mg BID102.4

[back to top]

Change From Baseline in Soluble Intracellular Adhesion Molecule.

The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-13.0
Glimepiride 2 mg and Metformin 850 mg BID-3.2

[back to top]

Change From Baseline in Soluble Vascular Cell Adhesion Molecule.

The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID11.6
Glimepiride 2 mg and Metformin 850 mg BID3.3

[back to top]

Change From Baseline in Systolic Blood Pressure.

The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

InterventionmmHg (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-2.5
Glimepiride 2 mg and Metformin 850 mg BID0.5

[back to top]

Change From Baseline in Erythrocyte Deformability (6.00).

The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.1
Glimepiride 2 mg and Metformin 850 mg BID-1.4

[back to top]

Change From Baseline in Thromboxane B2.

The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpg/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-216.4
Glimepiride 2 mg and Metformin 850 mg BID527.8

[back to top]

Change From Baseline in Triglycerides.

The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-40.9
Glimepiride 2 mg and Metformin 850 mg BID-16.7

[back to top]

Change From Baseline in Von-Willebrand Factor.

The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-19.5
Glimepiride 2 mg and Metformin 850 mg BID1.4

[back to top]

Change From Baseline in Erythrocyte Deformability (0.30%).

The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID1.3
Glimepiride 2 mg and Metformin 850 mg BID-0.4

[back to top]

The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.

The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.2
Glimepiride 2 mg and Metformin 850 mg BID-0.3

[back to top]

Intake of Study Medication Greater Than 80% and Less Than 120%.

The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionparticipants (Number)
Pioglitazone 15 mg and Metformin 850 mg BID136
Glimepiride 2 mg and Metformin 850 mg BID137

[back to top]

Change From Baseline in Erythrocyte Deformability (1.20).

The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.2
Glimepiride 2 mg and Metformin 850 mg BID-1.1

[back to top]

Change From Baseline in Adiponectin.

The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionμg/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID6.79
Glimepiride 2 mg and Metformin 850 mg BID0.72

[back to top]

Change From Baseline in Diastolic Blood Pressure.

The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

InterventionmmHg (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-1.3
Glimepiride 2 mg and Metformin 850 mg BID-0.1

[back to top]

Change From Baseline in E-Selectin.

The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-3.7
Glimepiride 2 mg and Metformin 850 mg BID-0.5

[back to top]

Change From Baseline in Erythrocyte Deformability (0.60%)

The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.4
Glimepiride 2 mg and Metformin 850 mg BID-0.5

[back to top]

Change From Baseline in Erythrocyte Deformability (12.00).

The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.7
Glimepiride 2 mg and Metformin 850 mg BID-1.3

[back to top]

Change From Baseline in Erythrocyte Deformability (3.00).

The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.3
Glimepiride 2 mg and Metformin 850 mg BID-.15

[back to top]

Change From Baseline in Erythrocyte Deformability (30.00).

The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.5
Glimepiride 2 mg and Metformin 850 mg BID-1.3

[back to top]

Change From Baseline in Fasting Intact Proinsulin.

The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpmol/L (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-5.18
Glimepiride 2 mg and Metformin 850 mg BID-0.11

[back to top]

Change From Baseline in High Sensitivity C-reactive Protein (Original).

The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/L (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-0.21
Glimepiride 2 mg and Metformin 850 mg BID-0.04

[back to top]

Change From Baseline in Glycosylated Hemoglobin.

The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-0.83
Glimepiride 2 mg and Metformin 850 mg BID-0.95

[back to top]

Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).

The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/L (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-0.87
Glimepiride 2 mg and Metformin 850 mg BID0.00

[back to top]

PG 50 (the Plasma Glucose Level at Which Half-maximal Insulin Secretion is Achieved During the Glucose-potentiated Arginine Test) at Baseline and 6 Months

Between ∼60 and 250 mg/dL, the magnitude of AIRarg is a linear function of the plasma glucose level, so the difference in AIRarg at fasting and 230 mg/dL glucose levels divided by the difference in plasma glucose (ΔAIRarg/ΔPG) gives the glucose-potentiation slope (GPS) (8,24-26). Using the y-intercept (b) from the line created by these two points, the plasma glucose level at which half-maximal insulin secretion is achieved (PG50) is derived from solving the equation 1/2 (AIRmax) = (GPS · PG50) + b, and provides a measure of β-cell sensitivity to glucose The mean difference after 6 months in PG 50 were compared. Listed below are the PG50 values at baseline and 6 months. (NCT00775684)
Timeframe: Baseline and 6 months

,,
Interventionmg/dL (Mean)
PG50 BaselinePG50 6 Months
P50 Exenatide175190
P50 Glimepiride168182
P50 Sitagliptin226209

[back to top]

Insulin Sensitivity at Baseline and 6 Months

Insulin sensitivity (M/I) was determined by dividing the mean glucose infusion rate required during the 230 mg/dL glucose clamp (M) by the mean prestimulus insulin level (I) between 40 and 45 min of the glucose infusion The mean difference after 6 months in insulin sensitivity (M/I) were compared (NCT00775684)
Timeframe: Baseline and 6 months

,,
Intervention((mg/kg) /min) /uU/mL (Mean)
M/I BaselineM/I 6 Months
M/I Exenatide0.30.3
M/I Glimepiride0.30.3
M/I Sitagliptin0.30.3

[back to top]

Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (μU/ml)

The acute insulin response to arginine (AIRarg) performed during the 340mg/dl glucose clamp allows for estimation of the the beta-cell secretory capacity (AIRmax) or functional beta-cell mass. Changes from baseline to 6 months of AIRmax were compared across groups (NCT00775684)
Timeframe: Baseline and 6 months

,,
InterventionμU/ml (Mean)
Acute Insulin Response (AIRmax)BaselineAcute Insulin Response (AIRmax) 6 Months
Exenatide214188.5
Glimepiride133202.5
Sitagliptin149158.3

[back to top]

Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (pg/mL)

AGRmin is performed during the 340mg/dl glucose clamp allows for estimation of the minimum alpha-cell glucagon secretion. Changes from baseline to 6 months of AGRmin were compared across groups. (NCT00775684)
Timeframe: Baseline and 6 months

,,
Interventionpg/mL (Mean)
Acute Glucose Response (AGRmin) BaselineAcute Glucose Response (AGRmin) 6 Months
Exenatide5152
Glimepiride3759
Sitagliptin5559

[back to top]

Change in Acute Insulin Response to Arginine. (AIRarg)

The changes in B-cell insulin secretion, Acute Insulin Response to arginine (AIRarg) after 6 months were compared to baseline AIRarg for each group. Listed below are AIRarg at baseline and 6 months for each group. (NCT00775684)
Timeframe: Baseline and 6 months

,,
InterventionuU/mL (Mean)
Acute Insulin Response (AIRarg) BaselineAcute Insulin Response (AIRarg) 6 Months
AIRarg Exenatide5252
AIRarg Glimepiride4442
AIRarg Sitagliptin3534

[back to top]

Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic)

"Hypoglycemic episodes are defined as either a fingerstick glucose~measurement of ≤70 mg/dL [3.9 mmol/L] with or without symptoms or symptomatic hypoglycemia." (NCT00792935)
Timeframe: Baseline to Week 6

Interventionparticipants (Number)
MK-094132
Glimepiride37

[back to top]

Change From Baseline to Week 6 in 24-hour Weighted Mean Glucose

"Weighted Mean Glucose (WMG) is a measure of the amount of glucose in the blood over a period of 24 hours. The WMG was derived from multiple glucose values collected during both fasting and post-meal periods. The weighted mean was used to avoid over-representation of post-meal glucose values." (NCT00792935)
Timeframe: Baseline and Week 6

Interventionmg/dL (Least Squares Mean)
MK-0941-43.4
Glimepiride-44.2

[back to top]

Cmax - Maximum Observed Concentration

Bioequivalence based on Cmax (NCT00834340)
Timeframe: Blood samples collected over 24 hour period

Interventionng/mL (Mean)
Glimepiride231.700
Amaryl®226.890

[back to top]

AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUCinf (NCT00834340)
Timeframe: Blood samples collected over 24 hour period

Interventionng*h/mL (Mean)
Glimepiride1613.846
Amaryl®1660.082

[back to top]

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration

Bioequivalence based on AUC0-t (NCT00834340)
Timeframe: Blood samples collected over 24 hour period

Interventionng*h/mL (Mean)
Glimepiride1479.961
Amaryl®1469.352

[back to top]

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

Bioequivalence based on AUC0-t (NCT00835172)
Timeframe: Blood samples collected over 24 hour period

Interventionng*h/mL (Mean)
Glimepiride1639.083
Amaryl®1632.301

[back to top]

AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUCinf (NCT00835172)
Timeframe: Blood samples collected over 24 hour period

Interventionng*h/mL (Mean)
Glimepiride1751.420
Amaryl®1824.742

[back to top]

Cmax - Maximum Observed Concentration

Bioequivalence based on Cmax (NCT00835172)
Timeframe: Blood samples collected over 24 hour period

Interventionng/mL (Mean)
Glimepiride267.629
Amaryl®266.706

[back to top]

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The BL HbA1c value is defined as the last non-missing value before the start of treatment. Change from BL was calculated as the value at Week 104 minus the value at BL. Based on analysis of covariance (ANCOVA): change = treatment + BL HbA1c + prior myocardial infarction history + age category + region. Difference of least squares means (albiglutide - placebo, albiglutide - sitagliptin, albiglutide - glimepiride) is from the ANCOVA model. The last observation carried forward (LOCF) method was used to impute missing post-Baseline HbA1c values; the last non-missing post-BL on-treatment measurement was used to impute the missing measurement. HbA1c values obtained after hyperglycemic rescue were treated as missing and were replaced with pre-rescue values. (NCT00838903)
Timeframe: Baseline and Week 104

InterventionPercentage of HbA1c in the blood (Least Squares Mean)
Placebo Plus Metformin0.27
Sitagliptin 100 mg Plus Metformin-0.28
Glimepiride 2 mg Plus Metformin-0.36
Albiglutide 30 mg Plus Metformin-0.63

[back to top]

Change From Baseline in Body Weight at Week 104

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The LOCF method was used to impute missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue were treated as missing and replaced with prerescue values. Based on ANCOVA: change = treatment + Baseline weight + Baseline HbA1c category + prior myocardial infarction history + age category + region. (NCT00838903)
Timeframe: Baseline and Week 104

InterventionKilograms (Least Squares Mean)
Placebo Plus Metformin-1.00
Sitagliptin 100 mg Plus Metformin-0.86
Glimepiride 2 mg Plus Metformin1.17
Albiglutide 30 mg Plus Metformin-1.21

[back to top]

Change From Baseline in Body Weight at Week 156

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. This analysis used observed body weight values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00838903)
Timeframe: Baseline and Week 156

InterventionKilograms (Mean)
Placebo Plus Metformin-3.61
Sitagliptin 100 mg Plus Metformin-2.05
Glimepiride 2 mg Plus Metformin0.98
Albiglutide 30 mg Plus Metformin-2.31

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 104

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. The LOCF method was used to impute missing post-Baseline FPG values. FPG values obtained after hyperglycemia rescue were treated as missing and replaced with pre-rescue values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Based on ANCOVA: change = treatment + Baseline FPG + Baseline HbA1c category + prior myocardial infarction history + age category + region. (NCT00838903)
Timeframe: Baseline and Week 104

InterventionMillimoles per liter (mmol/L) (Least Squares Mean)
Placebo Plus Metformin0.55
Sitagliptin 100 mg Plus Metformin-0.12
Glimepiride 2 mg Plus Metformin-0.41
Albiglutide 30 mg Plus Metformin-0.98

[back to top]

Change From Baseline in FPG at Week 156

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed FPG values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00838903)
Timeframe: Baseline and Week 156

InterventionMillimoles per liter (mmol/L) (Mean)
Placebo Plus Metformin-0.11
Sitagliptin 100 mg Plus Metformin-0.50
Glimepiride 2 mg Plus Metformin-0.71
Albiglutide 30 mg Plus Metformin-1.30

[back to top]

Change From Baseline in HbA1c at Week 156

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed HbA1c values, excluding those obtained after hyperglycemia rescue; no missing data imputation was performed . (NCT00838903)
Timeframe: Baseline and Week 156

InterventionPercentage of HbA1c in the blood (Mean)
Placebo Plus Metformin-0.46
Sitagliptin 100 mg Plus Metformin-0.56
Glimepiride 2 mg Plus Metformin-0.59
Albiglutide 30 mg Plus Metformin-0.88

[back to top]

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 104

The number of participants who achieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 52) were assessed. (NCT00838903)
Timeframe: Week 104

,,,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7.0%HbA1c <7.5%
Albiglutide 30 mg Plus Metformin50113172
Glimepiride 2 mg Plus Metformin4094147
Placebo Plus Metformin71527
Sitagliptin 100 mg Plus Metformin4594132

[back to top]

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 156

The number of participants who achieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 156) were assessed. (NCT00838903)
Timeframe: Week 156

,,,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7.0%HbA1c <7.5%
Albiglutide 30 mg Plus Metformin316990
Glimepiride 2 mg Plus Metformin154469
Placebo Plus Metformin4713
Sitagliptin 100 mg Plus Metformin234469

[back to top]

Time to Hyperglycemia Rescue

Participants who experienced persistent hyperglycemia (high blood glucose) could have qualified for hyperglycemia rescue.The conditions for hyperglycemic rescue were as follows: FPG >=280 milligrams/deciliter (mg/dL) between >=Week 2 and =250 mg/dL between >=Week 4 and =8.5% and a <=0.5% reduction from Baseline between >=Week 12 and =8.5% between >=Week 24 and =8.0% between >= Week 48 and NCT00838903)
Timeframe: From the start of study medication until the end of the treatment (up to Week 156)

InterventionWeeks (Median)
Placebo Plus Metformin67.71
Sitagliptin 100 mg Plus MetforminNA
Glimepiride 2 mg Plus MetforminNA
Albiglutide 30 mg Plus MetforminNA

[back to top]

Change From Baseline in HbA1c at Week 104 and Week 156

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed HbA1c values, excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00839527)
Timeframe: Baseline, Week 104, and Week 156

,,
InterventionPercentage of HbA1c in the blood (Mean)
Week 104, n=12, 130, 104Week 156, n=9, 89, 71
Albiglutide + Metformin + Glimepiride-0.76-0.46
Pioglitazone + Metformin + Glimepiride-1.09-0.97
Placebo + Metformin + Glimepiride-0.32-0.10

[back to top]

Change From Baseline in Body Weight at Week 104 and Week 156

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. This analysis used observed body weight values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00839527)
Timeframe: Baseline, Week 104, and Week 156

,,
InterventionKilograms (Mean)
Week 104, n=12, 130, 104Week 156, n=9, 90, 71
Albiglutide + Metformin + Glimepiride-0.90-1.53
Pioglitazone + Metformin + Glimepiride6.286.52
Placebo + Metformin + Glimepiride-2.16-4.47

[back to top]

Time to Hyperglycemia Rescue

Participants who experienced persistent hyperglycemia (high blood glucose) could have qualified for hyperglycemia rescue. The conditions for hyperglycemia rescue were as follows: FPG >=280 milligrams/deciliter (mg/dL) between >=Week 2 and =250 mg/dL between >=Week 4 and =8.5% and a <=0.5% reduction from Baseline between >=Week 12 and =8.5% between >=Week 24 and =8.0% between >= Week 48 and NCT00839527)
Timeframe: From the start of study medication until the end of the treatment (up to Week 156)

InterventionWeeks (Median)
Placebo + Metformin + Glimepiride49.57
Pioglitazone + Metformin + GlimepirideNA
Albiglutide + Metformin + Glimepiride137.71

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. The LOCF method was used to impute missing post-Baseline FPG values. FPG values obtained after hyperglycemia rescue were treated as missing and replaced with pre-rescue values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Based on ANCOVA: change = treatment + Baseline FPG + Baseline HbA1c category + prior myocardial infarction history + age category + region. (NCT00839527)
Timeframe: Baseline and Week 52

InterventionMillimoles per liter (mmol/L) (Least Squares Mean)
Placebo + Metformin + Glimepiride0.64
Pioglitazone + Metformin + Glimepiride-1.74
Albiglutide + Metformin + Glimepiride-0.69

[back to top]

Change From Baseline in Body Weight at Week 52

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The LOCF method was used to impute missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue were treated as missing and replaced with pre-rescue values. Based on ANCOVA: change = treatment + Baseline weight + Baseline HbA1c category + prior myocardial infarction history + age category + region. (NCT00839527)
Timeframe: Baseline and Week 52

InterventionKilograms (Least Squares Mean)
Placebo + Metformin + Glimepiride-0.40
Pioglitazone + Metformin + Glimepiride4.43
Albiglutide + Metformin + Glimepiride-0.42

[back to top]

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The BL HbA1c value is defined as the last non-missing value before the start of treatment. Change from BL was calculated as the value at Week 52 minus the value at BL. Based on analysis of covariance (ANCOVA): change = treatment + BL HbA1c + prior myocardial infarction history + age category + region. The last observation carried forward (LOCF) method was used to impute missing post-BL HbA1c values; the last non-missing post-BL on-treatment measurement was used to impute the missing measurement. HbA1c values obtained after hyperglycemic rescue were treated as missing and were replaced with pre-rescue values. Nine par. with post-BL values obtained >14 days after the last dose or after hyperglycemic rescue were included in the analysis population but were not analyzed for this endpoint. (NCT00839527)
Timeframe: Baseline and Week 52

InterventionPercentage of HbA1c in the blood (Least Squares Mean)
Placebo + Metformin + Glimepiride0.33
Pioglitazone + Metformin + Glimepiride-0.80
Albiglutide + Metformin + Glimepiride-0.55

[back to top]

Change From Baseline in FPG at Week 104 and Week 156

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed FPG values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00839527)
Timeframe: Baseline, Week 104, and Week 156

,,
InterventionMillimoles per liter (mmol/L) (Mean)
Week 104, n=12, 128, 103Week 156, n=9, 88, 71
Albiglutide + Metformin + Glimepiride-0.99-0.88
Pioglitazone + Metformin + Glimepiride-1.98-1.94
Placebo + Metformin + Glimepiride0.43-0.50

[back to top]

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 52

The number of participants who acheieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 52) was assessed. Values were carried forward for participants who were rescued or discontinued from active treatment before Week 52. (NCT00839527)
Timeframe: Week 52

,,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7.0%HbA1c <7.5%
Albiglutide + Metformin + Glimepiride2779126
Pioglitazone + Metformin + Glimepiride3794150
Placebo + Metformin + Glimepiride41019

[back to top]

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 156

The number of participants who acheieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 156) was assessed. (NCT00839527)
Timeframe: Week 156

,,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7.0%HbA1c <7.5%
Albiglutide + Metformin + Glimepiride162645
Pioglitazone + Metformin + Glimepiride234468
Placebo + Metformin + Glimepiride135

[back to top]

Fasting Glucose

fasting glucose (mg/dL) at 24 months (NCT00858013)
Timeframe: at 24 months

Interventionmg/dL (Mean)
Nateglinide131.2
Glimepiride115.7

[back to top]

The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate

% monotherapy failure, that means % number of participants who withdrew from the study due to high HbA1c (>8.0%) (NCT00858013)
Timeframe: every 3 months following randomization, for 24 months

InterventionParticipants (Count of Participants)
Nateglinide10
Glimepiride7

[back to top]

HOMA-IR

insulin resistance marker HOMA-IR at 24 months (NCT00858013)
Timeframe: at 24 months

Interventionmg/dL x mIU/L (Mean)
Nateglinide2.40
Glimepiride2.31

[back to top]

HbA1c

HbA1c (%) at 24 months (NCT00858013)
Timeframe: at 24 months

Intervention% HbA1c (Mean)
Nateglinide6.9
Glimepiride6.5

[back to top]

C-peptide

c-peptide(uU/mL) at 24 months (NCT00858013)
Timeframe: at 24 months

InterventionuU/mL (Mean)
Nateglinide1.29
Glimepiride1.77

[back to top]

Percent Change in Body Weight From Baseline to Week 52

The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean percent change. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent change (Least Squares Mean)
Canagliflozin 100 mg-4.2
Canagliflozin 300 mg-4.7
Glimepiride1.0

[back to top]

Change in HbA1c From Baseline to Week 52

The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent (Least Squares Mean)
Canagliflozin 100 mg-0.82
Canagliflozin 300 mg-0.93
Glimepiride-0.81

[back to top]

Change in HbA1c From Baseline to Week 104

The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 104 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change. (NCT00968812)
Timeframe: Baseline, Week 104

InterventionPercent (Least Squares Mean)
Canagliflozin 100 mg-0.65
Canagliflozin 300 mg-0.74
Glimepiride-0.55

[back to top]

Percentage of Patients Experiencing at Least 1 Hypoglycemic Event From Baseline to Week 52

The table below shows the percentage of patients who experienced at least 1 documented hypoglycemic event from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in percentages. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercentage of patients (Number)
Canagliflozin 100 mg5.6
Canagliflozin 300 mg4.9
Glimepiride34.2

[back to top]

Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12

The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline 2-hour Postprandial Plasma Glucose as a covariate. (NCT00974090)
Timeframe: at Week 0 and Week 12

Interventionmg / dL (Least Squares Mean)
Placebo / Teneli + SU6.0
Teneli / Teneli + SU-43.1

[back to top]

Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12

The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline AUC0-2h for Postprandial Plasma Glucose as a covariate. (NCT00974090)
Timeframe: 0, 0.5, 1, 2 hours post-dose at Week 0 and Week 12

Interventionmg・hr/dL (Least Squares Mean)
Placebo / Teneli + SU15.514
Teneli / Teneli + SU-65.544

[back to top]

Change From Baseline in HbA1c at Week 12

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate. (NCT00974090)
Timeframe: at Week 0 and Week 12

Interventionpercentage of HbA1c (Least Squares Mean)
Placebo / Teneli + SU0.29
Teneli / Teneli + SU-0.71

[back to top]

Change From Baseline in Fasting Plasma Glucose at Week 12

The change from Baseline in Fasting Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline Fasting Plasma Glucose as a covariate. (NCT00974090)
Timeframe: at Week 0 and Week 12

Interventionmg / dL (Least Squares Mean)
Placebo / Teneli + SU9.8
Teneli / Teneli + SU-17.3

[back to top]

Percentage of Participants With HbA1C < 7.0% at Week 30

HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). (NCT00993187)
Timeframe: Week 30

InterventionPercentage of Participants (Number)
Sitagliptin/Metformin81.2
Glimepiride40.1

[back to top]

Number of Participants Who Experienced at Least One Adverse Event (AE)

An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product. (NCT00993187)
Timeframe: Up to 32 weeks

InterventionParticipants (Number)
Sitagliptin/Metformin88
Glimepiride101

[back to top]

Percentage of Participants With One or More Episodes of Hypoglycemia

Symptomatic episodes assessed as likely to be due to hypoglycemia were reported by investigators as adverse experiences of hypoglycemia. Adverse experiences of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required. (NCT00993187)
Timeframe: Up to Week 30

InterventionPercentage of participants (Number)
Sitagliptin/Metformin5.5
Glimepiride20.1

[back to top]

Number of Participants Who Discontinued Study Drug Due to an Adverse Event

An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product. (NCT00993187)
Timeframe: Up to 30 weeks

InterventionParticipants (Number)
Sitagliptin/Metformin8
Glimepiride8

[back to top]

Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30

HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Change in A1C following 30 weeks of therapy (i.e., A1C at Week 30 minus A1C at baseline). (NCT00993187)
Timeframe: Baseline and Week 30

InterventionPercent of total hemoglobin (Least Squares Mean)
Sitagliptin/Metformin-1.5
Glimepiride-0.7

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30

Blood glucose was measured on a fasting basis (collected after an 8- to 10-hour fast). FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at baseline). (NCT00993187)
Timeframe: Baseline and Week 30

Interventionmg/dL (Least Squares Mean)
Sitagliptin/Metformin-47.0
Glimepiride-23.5

[back to top]

Change From Baseline in Body Weight at Week 30

Change in body weight following 30 weeks of therapy (i.e., body weight at Week 30 minus body weight at baseline) (NCT00993187)
Timeframe: Baseline and Week 30

Interventionkg (Least Squares Mean)
Sitagliptin/Metformin-0.83
Glimepiride0.90

[back to top]

Change From Baseline to Week 52 in HbA1c.

Measured as the difference between the last on-treatment value (defined as obtained before or on the 8th day after the last dosing date), and the last pre-randomisation HbA1c value, as determined by central laboratory. Full analysis set. (NCT01006603)
Timeframe: From week 0 to week 52.

Intervention% of glycosylated hemoglobin (Mean)
Saxagliptin 5 mg-0.44
Glimepiride 1 - 6 mg-0.64

[back to top]

Change From Baseline to Week 52 in Fasting Plasma Glucose (FPG)

Measured as the difference between the last on-treatment value (defined as obtained before or on the first day after the last dosing date)and the last pre-randomisation fasting plasma glucose value, as determined by central laboratory. Full analysis set. (NCT01006603)
Timeframe: From week 0 to week 52

Interventionmmol/L (Mean)
Saxagliptin 5 mg-0.73
Glimepiride 1 - 6 mg-1.29

[back to top]

Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia.

"Defined as obtained on or before the 8th day after the last dosing day, as determined by central laboratory. Safety analysis set.~Confirmed hypoglycaemia defined as: any event defined as either a symptomatic event with blood glucose level <3 mmol/L (<54 mg/dL) and no need for external assistance, or an asymptomatic blood glucose measurement <3 mmol/L (<54 mg/dL).~Major (or severe) hypoglycaemia defined as: symptomatic events requiring external assistance due to severe impairment in consciousness or behaviour, with or without blood glucose level <3 mmol/L (<54 mg/dL), but with prompt recovery after glucose or glucagon administration. These events may be associated with sufficient neuroglycopenia to induce seizure or coma. Plasma glucose measurements may not be available during such an event, but neurological recovery, attributable to the restoration of plasma glucose to normal, was considered sufficient evidence that the event was induced by a low plasma glucose concentration." (NCT01006603)
Timeframe: From week 0 to week 52.

,
Interventionpercentage of participants (Number)
All patientspatients aged <75 years (n=217, n=216)patients aged ≥75 years (n=142, n=143)
Glimepiride 1 - 6 mg38.233.345.5
Saxagliptin 5 mg37.939.235.9

[back to top]

Change From Baseline to Week 52 in Insulin

Measured as the difference between the last on-treatment value (defined as obtained before or on the first day after the last dosing date) and the last pre-randomisation fasting plasma insulin value, as determined by central laboratory. Full analysis set. (NCT01006603)
Timeframe: From week 0 to week 52

InterventionµU/mL (Mean)
Saxagliptin 5 mg-2.0
Glimepiride 1 - 6 mg-0.6

[back to top]

Proportion of Patients Having Experienced at Least One Hypoglycaemic Event (Confirmed or Severe) Over the 52-week Double-blind Treatment Period.

"Hypoglyceamic event defined as, Confirmed hypoglycaemia: any event defined as either a symptomatic event with blood glucose level <3 mmol/L (<54 mg/dL) and no need for external assistance, or an asymptomatic blood glucose measurement <3 mmol/L (<54 mg/dL).~Major (or severe) hypoglycaemia: symptomatic events requiring external assistance due to severe impairment in consciousness or behaviour, with or without blood glucose level <3 mmol/L (<54 mg/dL), but with prompt recovery after glucose or glucagon administration. These events may be associated with sufficient neuroglycopenia to induce seizure or coma. Plasma glucose measurements may not be available during such an event, but neurological recovery, attributable to the restoration of plasma glucose to normal, was considered sufficient evidence that the event was induced by a low plasma glucose concentration. Safety analysis set." (NCT01006603)
Timeframe: From week 0 to week 52.

Interventionpercentage of patients (Number)
Saxagliptin 5 mg1.1
Glimepiride 1 - 6 mg15.3

[back to top]

Proportion of Patients Achieving a Therapeutic Glycaemic Response at Week 52 Defined as HbA1c <7.0%

Proportion of patients with their last on-treatment value (defined as obtained before or on the 8th day after the last dosing date), as determined by central laboratory, below the specified limits. Full analysis set. (NCT01006603)
Timeframe: From week 0 to week 52

Interventionpercentage of responders (Number)
Saxagliptin 5 mg44.7
Glimepiride 1 - 6 mg54.7

[back to top]

Change From Baseline to Week 52 in β-cell Function (as Measured by Homeostasis Model Assessment-β [HOMA-β]

β-cell function as estimated by the homeostasis model assessment (HOMA) model. Value is derived from FPG and fasting insulin; fasting insulin values below 2.074 μU/mL or above 57.595 μU/mL and FPG values below 3 mmol/L or above 25 mmol/L are excluded (as restricted by the calculation method used). Full analysis set. (NCT01006603)
Timeframe: From week 0 to week 52

Interventionpercentage of change from baseline (Mean)
Saxagliptin 5 mg3.83
Glimepiride 1 - 6 mg16.22

[back to top]

Mean Change in Absolute Glucose Level at 2 Hours, From Baseline to 4 Weeks

"Change in glucose level measured after 2 hours of fasting. Blood sample was drawn at 0 minutes and at 240 minutes.~A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population." (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionmmol/L (Least Squares Mean)
Canakinumab 150 mg + Metformin-0.53
Placebo + Metformin0.13
Canakinumab 150 mg + Metformin + Sulfonylurea-0.60
Placebo + Metformin + Sulfonylurea0.18
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia-1.08
Placebo + Met + Sulfonyl + Thiaz-0.56
Canakinumab 150 mg + Insulin-0.56
Placebo + Insulin-0.16
Canakinumab 150 mg in Participants With IGT-0.26
Placebo in Participants With IGT-0.25

[back to top]

Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 2-4 Hours, From Baseline to 4 Weeks

Change in Insulin Secretion Rate stimulated by Liquid mixed-meal challenge Blood samples were taken prior to and after meal for glucose and insulin at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes relative to the start of the meal. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionpmol/min/m^2/mmol/L (Least Squares Mean)
Canakinumab 150 mg + Metformin0.21
Placebo + Metformin-2.15
Canakinumab 150 mg + Metformin + Sulfonylurea-2.98
Placebo + Metformin + Sulfonylurea2.02
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia0.15
Placebo + Met + Sulfonyl + Thiaz1.19
Canakinumab 150 mg + Insulin-0.43
Placebo + Insulin-0.51
Canakinumab 150 mg in Participants With IGT-0.71
Placebo in Participants With IGT-1.00

[back to top]

Number of Participants Reporting Death, Serious Adverse Events (SAEs) and Adverse Events (AEs) Above 5% Frequency, From Baseline to 4 Weeks

An adverse event is any unwanted event, whether related to study drug or not occuring during the study period. A Serious Adverse Event (SAE) is an event resulting in death, requiring or prolonging hospitalization, a congenital anomaly or other important medical event. AEs and SAEs were recorded at each visit. (NCT01068860)
Timeframe: Baseline, 4 weeks

,,,,,,,,,
Interventionparticipants (Number)
Number of Participants with Serious Adverse EventsNumber of Participants with Non-serious AEs > 5%
Canakinumab 150 mg + Insulin06
Canakinumab 150 mg + Metformin00
Canakinumab 150 mg + Metformin + Sulfonylurea06
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia04
Canakinumab 150 mg in Participants With IGT00
Placebo + Insulin03
Placebo + Met + Sulfonyl + Thiaz03
Placebo + Metformin04
Placebo + Metformin + Sulfonylurea03
Placebo in Participants With IGT00

[back to top]

Mean Change in Fasting Glucose Disposition Index(GDI)1 and Index 2, From Baseline to 4 Weeks

GDI 1 is the product of insulin sensitivity index (Si)during the 1st phase of insulin secretion and β-cell function as measured by the acute insulin response (AIR).GDI 2 is the product of (Si)during the 2nd phase of insulin secretion and β-cell function as measured by the acute insulin response (AIR). A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT group. (NCT01068860)
Timeframe: Baseline, 4 weeks

,,,,,,,,,
Interventionnumber (Least Squares Mean)
Index 1Index 2 (n= 32,15, 29,15, 30,13, 25, 15, 20, 26)
Canakinumab 150 mg + Insulin0.25-0.21
Canakinumab 150 mg + Metformin0.060.14
Canakinumab 150 mg + Metformin + Sulfonylurea0.06-0.94
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia0.240.62
Canakinumab 150 mg in Participants With IGT-0.51-0.16
Placebo + Insulin-0.27-0.25
Placebo + Met + Sulfonyl + Thiaz0.330.49
Placebo + Metformin-0.29-0.81
Placebo + Metformin + Sulfonylurea0.370.81
Placebo in Participants With IGT-0.64-0.31

[back to top]

Mean Change in Quantitative Insulin Sensitivity Check Index (QUICKI) Score, From Baseline to 4 Weeks

"The Quantitative Insulin Sensitivity Check Index (QUICKI) score, measures insulin sensitivity which is the inverse of insulin resistance. The score is calculated by the equation: 1 /(log(fasting insulin µU/mL) + log(fasting glucose mg/dL)). In normal subjects the mean score ± SE is 0.366 ± 0.029.~A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population." (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionnumber (Least Squares Mean)
Canakinumab 150 mg + Metformin0.004
Placebo + Metformin-0.000
Canakinumab 150 mg + Metformin + Sulfonylurea0.002
Placebo + Metformin + Sulfonylurea0.009
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia0.018
Placebo + Met + Sulfonyl + Thiaz-0.001
Canakinumab 150 mg + Insulin-0.003
Placebo + Insulin0.005
Canakinumab 150 mg in Participants With IGT-0.001
Placebo in Participants With IGT0.001

[back to top]

Mean Change in Post-prandial Glucose Area Under the Curve (AUC)0-4 Hours, From Baseline to 4 Weeks

Blood samples were drawn after a test meal at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve,(AUC). AUC was calculated as: x=1 AUC ΣAx n Where Ax = AUC for the 240 min.interval, and X = 1 for the 1st interval. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab vs placebo within each T2DM group. The mixed model didn't include the IGT group. (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionmmol*hr/L (Least Squares Mean)
Canakinumab 150 mg + Metformin-0.59
Placebo + Metformin0.46
Canakinumab 150 mg + Metformin + Sulfonylurea-1.37
Placebo + Metformin + Sulfonylurea-1.24
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia-3.58
Placebo + Met + Sulfonyl + Thiaz-2.88
Canakinumab 150 mg + Insulin-1.49
Placebo + Insulin-1.76
Canakinumab 150 mg in Participants With IGT-0.71
Placebo in Participants With IGT-0.10

[back to top]

Mean Change in Peak Plasma Insulin, From Baseline to 4 Weeks

Change in mean peak plasma Insulin level as measured from Baseline to 4 weeks of treatment. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population. (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionpmol/L (Least Squares Mean)
Canakinumab 150 mg + Metformin8.09
Placebo + Metformin44.56
Canakinumab 150 mg + Metformin + Sulfonylurea-55.07
Placebo + Metformin + Sulfonylurea11.33
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia5.13
Placebo + Met + Sulfonyl + Thiaz-5.15
Canakinumab 150 mg + Insulin91.74
Placebo + Insulin36.87
Canakinumab 150 mg in Participants With IGT56.21
Placebo in Participants With IGT-26.43

[back to top]

Mean Change in Peak Plasma Glucose, From Baseline to 4 Weeks

"Change in peak plasma glucose level as measured from Baseline to 4 weeks of treatment.~A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population." (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionmmol/L (Least Squares Mean)
Canakinumab 150 mg + Metformin-0.41
Placebo + Metformin0.21
Canakinumab 150 mg + Metformin + Sulfonylurea-0.43
Placebo + Metformin + Sulfonylurea-0.03
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia-0.82
Placebo + Met + Sulfonyl + Thiaz-0.77
Canakinumab 150 mg + Insulin-0.15
Placebo + Insulin-0.60
Canakinumab 150 mg in Participants With IGT-0.34
Placebo in Participants With IGT-0.04

[back to top]

Mean Change in Peak Plasma C-peptide Level, From Baseline to 4 Weeks

"Change in mean peak plasma C-peptide level measured from Baseline to 4 weeks of treatment.~A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population." (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionnmol/L (Least Squares Mean)
Canakinumab 150 mg + Metformin-0.04
Placebo + Metformin-0.04
Canakinumab 150 mg + Metformin + Sulfonylurea-0.10
Placebo + Metformin + Sulfonylurea0.16
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia-0.21
Placebo + Met + Sulfonyl + Thiaz0.05
Canakinumab 150 mg + Insulin0.07
Placebo + Insulin-0.14
Canakinumab 150 mg in Participants With IGT-0.18
Placebo in Participants With IGT-0.18

[back to top]

Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-4 Hours, From Baseline to 4 Weeks.

Change in Insulin Secretion Rate stimulated by Liquid mixed-meal challenge. Blood samples were taken prior to and after meal for glucose, insulin and C-peptide at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes relative to the start of the meal. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population. (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionpmol/min/m^2/mmol/L (Least Squares Mean)
Canakinumab 150 mg + Metformin0.44
Placebo + Metformin-0.99
Canakinumab 150 mg + Metformin + Sulfonylurea-0.32
Placebo + Metformin + Sulfonylurea1.22
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia-0.63
Placebo + Met + Sulfonyl + Thiaz1.24
Canakinumab 150 mg + Insulin0.53
Placebo + Insulin-0.49
Canakinumab 150 mg in Participants With IGT-1.38
Placebo in Participants With IGT-1.35

[back to top]

Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks.

Change in Insulin Secretion Rate stimulated by Liquid mixed-meal challenge. Blood samples were taken prior to and after meal for glucose and insulin at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes relative to the start of the meal.A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include patients from the IGT population (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionpmol/min/m^2/mmol/L (Least Squares Mean)
Canakinumab 150 mg + Metformin-0.06
Placebo + Metformin-0.23
Canakinumab 150 mg + Metformin + Sulfonylurea0.04
Placebo + Metformin + Sulfonylurea0.45
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia-0.79
Placebo + Met + Sulfonyl + Thiaz1.16
Canakinumab 150 mg + Insulin1.23
Placebo + Insulin-0.49
Canakinumab 150 mg in Participants With IGT-1.50
Placebo in Participants With IGT-1.93

[back to top]

Mean Change in Insulin Area Under the Curve (AUC) 0-4 Hours, From Baseline to 4 Weeks

Blood samples were drawn after a test meal at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve,(AUC). AUC was calculated as: x=1 AUC ΣAx n Where Ax = AUC for the 240 min.interval, and X = 1 for the 1st interval. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab vs placebo within each T2DM group. The mixed model didn't include the IGT group. (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionpmol*hour/L (Least Squares Mean)
Canakinumab 150 mg + Metformin-9.37
Placebo + Metformin1.21
Canakinumab 150 mg + Metformin + Sulfonylurea-73.25
Placebo + Metformin + Sulfonylurea-38.32
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia-36.96
Placebo + Met + Sulfonyl + Thiaz8.46
Canakinumab 150 mg + Insulin163.87
Placebo + Insulin139.24
Canakinumab 150 mg in Participants With IGT44.27
Placebo in Participants With IGT-106.68

[back to top]

Mean Change in Fructosamine, From Baseline to 4 Weeks

"Change in Fructosamine Level taken from plasma, measured at Baseline and after 4 weeks of treatment.~A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population" (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionmmol/L (Least Squares Mean)
Canakinumab 150 mg + Metformin-5.30
Placebo + Metformin-0.75
Canakinumab 150 mg + Metformin + Sulfonylurea-3.45
Placebo + Metformin + Sulfonylurea-7.50
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia-1.81
Placebo + Met + Sulfonyl + Thiaz-3.07
Canakinumab 150 mg + Insulin-3.00
Placebo + Insulin-19.73
Canakinumab 150 mg in Participants With IGT-6.36
Placebo in Participants With IGT1.39

[back to top]

Mean Change in Fasting Plasma Insulin, From Baseline to 4 Weeks

"Change in Fasting Insulin level taken from plasma, measured at Baseline and after 4 weeks of treatment.~A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population" (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionpmol/L (Least Squares Mean)
Canakinumab 150 mg + Metformin-3.58
Placebo + Metformin10.73
Canakinumab 150 mg + Metformin + Sulfonylurea-16.07
Placebo + Metformin + Sulfonylurea-9.40
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia-0.77
Placebo + Met + Sulfonyl + Thiaz2.31
Canakinumab 150 mg + Insulin21.27
Placebo + Insulin25.67
Canakinumab 150 mg in Participants With IGT-.021
Placebo in Participants With IGT-3.43

[back to top]

Mean Change in Fasting Plasma Glucose, From Baseline to 4 Weeks

"Change in Fasting Glucose Level measured from plasma taken at Baseline and after 4 weeks of treatment.~A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population" (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionmmol/L (Least Squares Mean)
Canakinumab 150 mg + Metformin-0.32
Placebo + Metformin0.33
Canakinumab 150 mg + Metformin + Sulfonylurea-0.20
Placebo + Metformin + Sulfonylurea-0.23
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia-0.33
Placebo + Met + Sulfonyl + Thiaz-0.36
Canakinumab 150 mg + Insulin-0.26
Placebo + Insulin-0.80
Canakinumab 150 mg in Participants With IGT-0.06
Placebo in Participants With IGT0.10

[back to top]

Mean Change in C-peptide Area Under the Curve (AUC), 0-4 Hours, From Baseline to 4 Weeks

Blood samples were drawn after a test meal at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve,(AUC). AUC was calculated as: x=1 AUC ΣAx n Where Ax = AUC for the 240 min.interval, and X = 1 for the 1st interval. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab vs placebo within each T2DM group. The mixed model didn't include the IGT group. (NCT01068860)
Timeframe: Baseline, 4 weeks

Interventionnmol*hour/L (Least Squares Mean)
Canakinumab 150 mg + Metformin-0.18
Placebo + Metformin-0.18
Canakinumab 150 mg + Metformin + Sulfonylurea-0.21
Placebo + Metformin + Sulfonylurea0.12
Canakinumab 150 mg Canakinumab 150 mg + Met + Sulfonyl + Thia-0.61
Placebo + Met + Sulfonyl + Thiaz0.02
Canakinumab 150 mg + Insulin0.16
Placebo + Insulin-0.29
Canakinumab 150 mg in Participants With IGT-0.43
Placebo in Participants With IGT-0.40

[back to top]

Rate of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks

,,
Interventionevents per participant per year (Mean)
Severe HE, 26 weeksSevere HE, 52 weeksSevere HE, 78 weeksDocumented symptomatic HE, 26 weeksDocumented symptomatic HE, 52 weeksDocumented symptomatic HE, 78 weeksAsymptomatic HE, 26 weeksAsymptomatic HE, 52 weeksAsymptomatic HE, 78 weeksNocturnal HE, 26 weeksNocturnal HE, 52 weeksNocturnal HE, 78 weeksProbable symptomatic HE, 26 weeksProbable symptomatic HE, 52 weeksProbable symptomatic HE, 78 weeks
Insulin Glargine0.010.010.013.643.343.034.824.413.801.862.071.810.150.080.07
LY2189265 0.75 mg0.000.000.002.521.971.663.582.682.380.960.650.590.140.090.07
LY2189265 1.5 mg0.010.000.012.352.031.673.793.082.561.230.900.770.080.070.05

[back to top]

Number of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks

,,
Interventionevents (Number)
Severe HE, 26 weeksSevere HE, 52 weeksSevere HE, 78 weeksDocumented symptomatic HE, 26 weeksDocumented symptomatic HE, 52 weeksDocumented symptomatic HE, 78 weeksAsymptomatic HE, 26 weeksAsymptomatic HE, 52 weeksAsymptomatic HE, 78 weeksNocturnal HE, 26 weeksNocturnal HE, 52 weeksNocturnal HE, 78 weeksProbable symptomatic HE, 26 weeksProbable symptomatic HE, 52 weeksProbable symptomatic HE, 78 weeks
Insulin Glargine122447789103360910931358240519635202226
LY2189265 0.75 mg000315444515484709911117147184192428
LY2189265 1.5 mg112311515607500757884145185215111720

[back to top]

Number of Participants With Treatment Emergent Adverse Events at 26, 52 and 78 Weeks

A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
26 weeks52 weeks78 weeks
Insulin Glargine137175192
LY2189265 0.75 mg146175188
LY2189265 1.5 mg160189201

[back to top]

Number of Participants With LY2189265 Antibodies at 26, 52, 78 Weeks and 4 Weeks After Last Dose of Study Drug (83 Weeks Maximum)

LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed at baseline, 26, 52, and 78 weeks, and at the safety follow-up visit 30 days after study drug discontinuation (83 weeks). The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA at each time point were summarized. (NCT01075282)
Timeframe: Baseline, 26, 52, 78, and 83 weeks

Interventionparticipants (Number)
26 weeks52 weeks78 weeks83 weeks
LY2189265 1.5 mg and 0.75 mg11310

[back to top]

Number of Participants With Adjudicated Pancreatitis at 26, 52 and 78 Weeks

The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
26 weeks52 weeks78 weeks
Insulin Glargine000
LY2189265 0.75 mg111
LY2189265 1.5 mg122

[back to top]

Number of Participants With Adjudicated Cardiovascular Events at 26, 52 and 78 Weeks

Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
Any CV event, 26 weeksAny fatal CV event, 26 weeksAny non-fatal CV event, 26 weeksAny CV event, 52 weeksAny fatal CV event, 52 weeksAny non-fatal CV event, 52 weeksAny CV event, 78 weekAny fatal CV event, 78 weekAny non-fatal CV event, 78 week
Insulin Glargine303615918
LY2189265 0.75 mg101404616
LY2189265 1.5 mg202303303

[back to top]

Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26, 52 and 78 Weeks

Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26, 52, and 78 weeks. (NCT01075282)
Timeframe: 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
26 weeks52 weeks78 weeks
Insulin Glargine0816
LY2189265 0.75 mg42034
LY2189265 1.5 mg21124

[back to top]

Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than or Equal to 6.5% at 26, 52 and 78 Weeks

Number of participants achieving HbA1c levels less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model. (NCT01075282)
Timeframe: 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
26 weeks (n=263, 266, 258)52 weeks (n=263, 267, 259)78 weeks (n=263, 267, 259)
Insulin Glargine403543
LY2189265 0.75 mg746059
LY2189265 1.5 mg977174

[back to top]

Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% at 26, 52 and 78 Weeks

Number of participants achieving HbA1c levels less than 7.0% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model. (NCT01075282)
Timeframe: 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
26 weeks (n=263, 266, 258)52 weeks (n=263, 267, 259)78 weeks (n=263, 267, 259)
Insulin Glargine848079
LY2189265 0.75 mg1229991
LY2189265 1.5 mg153140129

[back to top]

Change From Baseline to 52 and 78 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)

The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-B and HOMA-2S were set at 100%. Least Squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 52, and 78 weeks

,
Interventionpercentage of HOMA2 (Least Squares Mean)
HOMA2-%B, 52 weeks (n=175, 181)HOMA2-%B, 78 weeks (n=167, 165)HOMA2-%S, 52 weeks (n=175,181)HOMA2-%S, 78 weeks (n=167, 165)
LY2189265 0.75 mg24.6015.66-2.66-3.62
LY2189265 1.5 mg29.9528.54-2.89-2.64

[back to top]

Change From Baseline to 52 and 78 Weeks in Glucagon Concentration

Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 52, and 78 weeks

,,
Interventionpicomoles per liter (pmol/L) (Least Squares Mean)
52 weeks (n=232, 231, 228)78 weeks (n=235, 235, 232)
Insulin Glargine-3.85-3.65
LY2189265 0.75 mg-3.31-3.37
LY2189265 1.5 mg-3.91-3.57

[back to top]

Change From Baseline to 26, 52, and 78 Weeks on Blood Pressure

Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionmilliliter of mercury (mmHG) (Least Squares Mean)
SBP, 26 weeks (n=257, 261, 245)SBP, 52 weeks (n=250, 252, 240)SBP, 78 weeks (n=246, 244, 238)DBP, 26 weeks (n=257, 261, 245)DBP, 52 weeks (n=250, 252, 240)DBP, 78 weeks (n=246, 244, 238)
Insulin Glargine-0.030.510.51-0.29-0.93-1.04
LY2189265 0.75 mg-1.600.09-0.59-0.17-0.19-0.36
LY2189265 1.5 mg-1.280.17-0.70-0.16-0.26-0.44

[back to top]

Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate. (NCT01075282)
Timeframe: Baseline, 52 weeks

Interventionpercentage of glycosylated hemoglobin (Least Squares Mean)
LY2189265 1.5 mg-1.08
LY2189265 0.75 mg-0.76
Insulin Glargine-0.63

[back to top]

Change From Baseline to 26, 52 and 78 Weeks on Serum Calcitonin

(NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionpicogram/milliliter (Mean)
26 weeks (n=266, 267, 258)52 weeks (n=266, 269, 259)78 weeks (n=267, 269, 259)
Insulin Glargine0.1490.1760.151
LY2189265 0.75 mg0.0970.1320.035
LY2189265 1.5 mg0.1630.1280.086

[back to top]

Change From Baseline to 26, 52 and 78 Weeks on Pancreatic Enzymes

Amylase (total and pancreas-derived) and lipase concentrations were measured. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionunits/liter (Median)
Amylase (total), 26 weeksAmylase (total), 52 weeksAmylase (total), 78 weeksAmylase (pancreas-derived), 26 weeksAmylase (pancreas-derived), 52 weeksAmylase (pancreas-derived), 78 weeksLipase, 26 weeksLipase, 52 weeksLipase, 78 weeks
Insulin Glargine2.0003.0001.0001.0001.0000.000-1.000-1.000-2.000
LY2189265 0.75 mg4.0005.0004.0003.0003.0002.0005.0004.0004.000
LY2189265 1.5 mg4.0004.0004.0003.0003.0002.0005.0004.0004.000

[back to top]

Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionmilliseconds (msec) (Least Squares Mean)
QTcF interval, 26 weeks (n=240, 245, 229)QTcF interval, 52 weeks (n=231, 240, 228)QTcF interval, 78 weeks (n=221, 220, 222)PR interval, 26 weeks (n=240, 245, 229)PR interval, 52 weeks (n=230, 240, 227)PR interval, 78 weeks (n=221, 220, 222)
Insulin Glargine1.243.704.441.241.501.21
LY2189265 0.75 mg-0.101.343.442.331.883.27
LY2189265 1.5 mg-1.711.551.662.782.612.62

[back to top]

Change From Baseline to 26, 52 and 78 Weeks in the Low Blood Sugar Survey

The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionunits on a scale (Least Squares Mean)
26 weeks (n=255, 255, 244)52 weeks (n=258, 259, 245)78 weeks (n=258, 259, 245)
Insulin Glargine0.3-1.0-2.0
LY2189265 0.75 mg-2.4-4.1-4.7
LY2189265 1.5 mg-2.8-4.2-4.6

[back to top]

Change From Baseline to 26, 52 and 78 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles

The self-monitored blood glucose (SMBG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3 AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (Daily Mean) were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionmillimoles per liter (mmol/L) (Least Squares Mean)
26 weeks (n=199, 204, 190)52 weeks (n=180, 185, 176)78 weeks (n=172, 164, 168)
Insulin Glargine-1.58-1.44-1.47
LY2189265 0.75 mg-1.46-1.32-1.15
LY2189265 1.5 mg-1.79-1.69-1.55

[back to top]

Change From Baseline to 26, 52 and 78 Weeks for Body Weight

Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionkilogram (kg) (Least Squares Mean)
26 weeks52 weeks78 weeks
Insulin Glargine1.011.441.28
LY2189265 0.75 mg-1.47-1.33-1.54
LY2189265 1.5 mg-1.82-1.87-1.96

[back to top]

Change From Baseline to 26, 52 and 78 Weeks for Body Mass Index

Body mass index (BMI) is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionkilograms per square meter (kg/m^2) (Least Squares Mean)
26 weeks (n=257, 261, 245)52 weeks (n=250, 252, 238)78 weeks (n=246, 244, 238)
Insulin Glargine0.440.620.59
LY2189265 0.75 mg-0.50-0.39-0.39
LY2189265 1.5 mg-0.64-0.64-0.64

[back to top]

Change From Baseline to 26 Weeks and 78 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate. (NCT01075282)
Timeframe: Baseline, 26 weeks, and 78 weeks

,,
Interventionpercent (Least Squares Mean)
26 weeks (n=263, 266, 258)78 weeks (n=263, 267, 259)
Insulin Glargine-0.65-0.59
LY2189265 0.75 mg-0.89-0.62
LY2189265 1.5 mg-1.16-0.90

[back to top]

Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Activities of Daily Living

"The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire [APPADL]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = not at all difficult and 1 = unable to do. The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate." (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionunits on a scale (Least Squares Mean)
26 weeks (n=256, 256, 248)52 weeks (n=260, 261, 249)78 weeks (n=260, 261, 249)
Insulin Glargine-0.3-0.6-0.3
LY2189265 0.75 mg0.10.40.3
LY2189265 1.5 mg0.70.91.0

[back to top]

Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Self-Perception

The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionunits on a scale (Least Squares Mean)
26 weeks (n=258, 258, 251)52 weeks (n=260, 261, 252)78 weeks (n=260, 261, 252)
Insulin Glargine-0.10.10.1
LY2189265 0.75 mg0.20.20.3
LY2189265 1.5 mg0.10.50.5

[back to top]

Change From Baseline to 26, 52 and 78 Weeks in the EuroQol 5 Dimension

The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a 100-mm visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionunits on a scale (Least Squares Mean)
EQ-5D UK, 26 weeks (n=257, 254, 249)EQ-5D UK, 52 weeks (n=259, 260, 253)EQ-5D UK, 78 weeks (n=259, 260, 253)VAS, 26 weeks (n=253, 252, 243)VAS, 52 weeks (n=260, 258, 252)VAS, 78 weeks (n=260, 258, 252)
Insulin Glargine-0.01-0.040.000.81.12.2
LY2189265 0.75 mg0.000.000.003.42.33.2
LY2189265 1.5 mg0.010.010.013.33.23.8

[back to top]

Change in Baseline to 26, 52 and 78 Weeks on Pulse Rate

Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionbeats per minute (bpm) (Least Squares Mean)
26 weeks (n=257, 260, 245)52 weeks (n=250, 252, 240)78 weeks (n=246, 244, 238)
Insulin Glargine-1.21-0.52-0.91
LY2189265 0.75 mg0.740.510.61
LY2189265 1.5 mg1.561.291.31

[back to top]

Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Heart Rate

Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionbeats per minute (bpm) (Least Squares Mean)
26 weeks (n=241, 247, 231)52 weeks (n=232, 242, 231)78 weeks (n=223, 222, 225)
Insulin Glargine-1.24-1.01-0.26
LY2189265 0.75 mg0.900.380.47
LY2189265 1.5 mg2.642.412.49

[back to top]

Number of Participants Discontinuing Study Drug Due to An Adverse Event

(NCT01076075)
Timeframe: Week 0 to Week 54

Interventionparticipants (Number)
Sitagliptin3
Placebo/Pioglitazone9

[back to top]

Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54

(NCT01076075)
Timeframe: Week 0 to Week 54

Interventionparticipants (Number)
Sitagliptin120
Placebo/Pioglitazone122

[back to top]

Change From Baseline in Fasting Plasma Glucose at Week 24

Change from baseline reflects the Week 24 value minus the baseline value. (NCT01076075)
Timeframe: Baseline to Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-13.2
Placebo/Pioglitazone5.3

[back to top]

Change From Baseline in 2-hour Post-Meal Glucose at Week 24

Change from baseline reflects the Week 24 value minus the baseline value. Two-hour post-meal glucose was measured following a standard meal. (NCT01076075)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-36.8
Placebo/Pioglitazone-3.3

[back to top]

Change From Baseline in Hemoglobin A1C (%) at Week 24

Change from baseline reflects the Week 24 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin. (NCT01076075)
Timeframe: Baseline and Week 24

InterventionPercentage of glycosylated hemoglobin (Least Squares Mean)
Sitagliptin-0.84
Placebo/Pioglitazone-0.16

[back to top]

Percentage of Patients With HbA1c <7.0%

The percentage of patients with an HbA1c value below 7% at week 12 and week 52 were calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively, they were considered a failure, so HbA1c above 7%. (NCT01087502)
Timeframe: Baseline, week 12 and week 52

,
Interventionpercentage of patients (Number)
Week 52 (N=110, 104)Week 12 (N=110, 108)
Linagliptin 5 mg22.119.4
Placebo/Glimepiride11.89.1

[back to top]

Percentage of Patients With HbA1c <6.5%

The percentage of patients with an HbA1c value below 6.5% at week 12 and week 52 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively they were considered a failure, so HbA1c above 6.5%. (NCT01087502)
Timeframe: Baseline, week 12 and week 52

,
Interventionpercentage of patients (Number)
Week 52 (N=119, 111)Week 12 (N=120, 115)
Linagliptin 5 mg9.96.1
Placebo/Glimepiride6.75.0

[back to top]

Percentage of Patients Who Have a HbA1c Lowering by at Least 0.5%

The percentage of patients with an HbA1c reduction of ≥0.5% at week 12 and week 52 from baseline was calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively they were considered a failure, so HbA1c reduction less than 0.5%. (NCT01087502)
Timeframe: Baseline, week 12 and week 52

,
Interventionpercentage of patients (Number)
Week 52 (N=120, 113)Week 12 (N= 121, 117)
Linagliptin 5 mg34.549.6
Placebo/Glimepiride23.324.0

[back to top]

HbA1c Change From Baseline Over Time

HbA1c is measured as a percentage. Thus, this change from baseline reflects the HbA1c percent over time minus the baseline HbA1c percent. This outcome measure only provides descriptive statistics without any modelling. (NCT01087502)
Timeframe: Baseline, week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 34, week 40, week 46, week 52

,
InterventionPercent (Mean)
Week 4 (N=120, 113)Week 8 (N=120, 113)Week 12 (N=120, 113)Week 16 (N=120, 113)Week 20 (N=120, 113)Week 24 (N=120, 113)Week 28 (N=120, 113)Week 34 (N=120, 113)Week 40 (N=120, 113)Week 46 (N=120, 113)Week 52 (N=120, 113)
Linagliptin 5 mg-0.29-0.47-0.50-0.47-0.48-0.52-0.50-0.45-0.42-0.40-0.40
Placebo/Glimepiride-0.08-0.09-0.08-0.31-0.48-0.51-0.47-0.37-0.23-0.24-0.25

[back to top]

Plasma Concentration of Linagliptin at Trough

Trough levels of concentration of Linagliptin in plasma. (NCT01087502)
Timeframe: Week 12, 24 and 52

InterventionNmol/L (Geometric Mean)
Week 12 (N=103)Week 24 (N=103)Week 52 (N=105)
Linagliptin 5 mg7.777.625.94

[back to top]

Fasting Plasma Glucose (FPG) Change From Baseline to Week 12

This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction. (NCT01087502)
Timeframe: Baseline and week 12

Interventionmg/dL (Mean)
Placebo/Glimepiride9.53
Linagliptin 5 mg0.24

[back to top]

HbA1c Change From Baseline to Week 12

HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c, renal function impairment and prior use of antidiabetic agents. (NCT01087502)
Timeframe: Baseline and week 12

InterventionPercent (Mean)
Placebo-0.11
Linagliptin 5 mg-0.53

[back to top]

Fasting Plasma Glucose (FPG) Change From Baseline Over Time

This change from baseline reflects the FPG over time minus the baseline FPG. This outcome measure only provides descriptive statistics without any modelling. (NCT01087502)
Timeframe: Baseline, week 4, week 8, week 12, week 20, week 24, week 28, week 34, week 40, week 46, week 52

,
Interventionmg/dL (Mean)
Week 4 (N=119, 112)Week 8 (N=119, 112)Week 12 (N=119, 112)Week 20 (N=119, 112)Week 24 (N=119, 112)Week 28 (N=119, 112)Week 34 (N=119, 112)Week 40 (N=119, 112)Week 46 (N=119, 112)Week 52 (N=119, 112)
Linagliptin 5 mg-10.55-11.25-6.26-5.92-12.78-9.31-2.78-2.69-2.033.09
Placebo/Glimepiride9.808.966.23-9.66-8.83-9.67-9.95-0.75-2.64-3.10

[back to top]

Number of Hypoglycaemic Episodes - All

(NCT01123980)
Timeframe: Weeks 0-24

Interventionepisodes (Number)
BIAsp 30745
Insulin Glargine605

[back to top]

Percentage of Subjects Achieving HbA1c Below 7.0%

The percentage of subjects achieving the treatment target for glycosylated haemoglobin A1c after 24 weeks of treatment (NCT01123980)
Timeframe: Week 24

Interventionpercentage (%) of subjects (Number)
BIAsp 3029.1
Insulin Glargine30.0

[back to top]

Percentage of Subjects Achieving HbA1c Below or Equal to 6.5%

The percentage of subjects achieving the treatment target for glycosylated haemoglobin A1c after 24 weeks of treatment (NCT01123980)
Timeframe: Week 24

Interventionpercentage (%) of subjects (Number)
BIAsp 3014.9
Insulin Glargine14.2

[back to top]

Number of Hypoglycaemic Episodes - Severe and Minor

Hypoglycaemic episodes (hypos) summarised based on American Diabetes Association classification (severe, documented symptomatic, asymptomatic, probable symptomatic, and relative hypoglycaemia) and according to additional definition (minor hypoglycaemia). Severe hypos: requiring another person to actively administer resuscitative actions. Minor hypos: symptoms with plasma glucose below 3.1 mmol/L (56 mg/dl), or any asympomatic plasma glucose below 3.1 mmol/L. (NCT01123980)
Timeframe: Weeks 0-24

,
Interventionepisodes (Number)
SevereMinor
BIAsp 300154
Insulin Glargine1125

[back to top]

9-point Plasma Glucose Profiles

Glycaemic control measured by 9-point plasma glucose (SPMG) profiles. The 9 timepoints for self-measurement during the day were: before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, before bedtime, at 2-4 a.m. and before breakfast the following day. (NCT01123980)
Timeframe: Week 24

,
Interventionmmol/L (Mean)
Before breakfast2 hours after breakfastBefore lunch2 hours after lunchBefore dinner2 hours after dinnerBefore bedtimeAt 2-4 a.m.Before breakfast the following day
BIAsp 306.4610.187.3510.507.679.368.146.586.51
Insulin Glargine6.4910.117.2210.227.0310.889.397.066.35

[back to top]

Number of Hypoglycaemic Episodes

All episodes classified into nocturnal (time of onset between 00:00 (included) and 05:59 (included)). (NCT01123980)
Timeframe: Weeks 0-24

Interventionepisodes (Number)
BIAsp 3097
Insulin Glargine63

[back to top]

Change in Glycosylated Haemoglobin (HbA1c)

(NCT01123980)
Timeframe: Week 0, week 24

Interventionpercentage of glycosylated haemoglobin (Least Squares Mean)
BIAsp 30-0.68
Insulin Glargine-0.56

[back to top]

The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 52 weeks

Interventionparticipants (Number)
Empaglifozin 25 mg12
Glimepiride159

[back to top]

The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.

(NCT01167881)
Timeframe: Baseline and 104 weeks

Interventionpercentage of HbA1c (Mean)
Empaglifozin 25 mg-0.66
Glimepiride-0.55

[back to top]

The Change From Baseline in HbA1c After 52 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 52 weeks

Interventionpercentage of HbA1c (Mean)
Empaglifozin 25 mg-0.73
Glimepiride-0.66

[back to top]

The Change in Body Weight From Baseline After 104 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 104 weeks

Interventionkilograms (Mean)
Empaglifozin 25 mg-3.11
Glimepiride1.33

[back to top]

The Change in Body Weight From Baseline After 52 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 52 weeks

Interventionkilograms (Mean)
Empaglifozin 25 mg-3.21
Glimepiride1.59

[back to top]

The Change in Diastolic Blood Pressure (DBP) From Baseline After 104 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 104 weeks

InterventionmmHg (Mean)
Empaglifozin 25 mg-1.8
Glimepiride0.9

[back to top]

The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 52 weeks

InterventionmmHg (Mean)
Empaglifozin 25 mg-1.9
Glimepiride1.0

[back to top]

The Change in Systolic Blood Pressure (SBP) From Baseline After 104 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 104 weeks

InterventionmmHg (Mean)
Empaglifozin 25 mg-3.1
Glimepiride2.5

[back to top]

The Change in Systolic Blood Pressure (SBP) From Baseline After 52 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 52 weeks

InterventionmmHg (Mean)
Empaglifozin 25 mg-3.6
Glimepiride2.2

[back to top]

The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 104 weeks

Interventionparticipants (Number)
Empaglifozin 25 mg19
Glimepiride189

[back to top]

Number of Participants Who Experienced at Least One Adverse Event

(NCT01177384)
Timeframe: Up to Week 24 + 14 Day Post-Study Follow-up

InterventionParticipants (Number)
Sitagliptin62
Placebo58

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG. Efficacy analyses treated data as missing after the initiation of rescue therapy. (NCT01177384)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-17.9
Placebo-3.5

[back to top]

Change From Baseline in Hemoglobin A1c (A1C) at Week 24

A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. Efficacy analyses treated data as missing after the initiation of rescue therapy. (NCT01177384)
Timeframe: Baseline and Week 24

InterventionPercent (Least Squares Mean)
Sitagliptin-0.76
Placebo-0.14

[back to top]

Number of Participants Who Discontinued Study Drug Due to an Adverse Event

(NCT01177384)
Timeframe: Up to 24 Weeks

InterventionParticipants (Number)
Sitagliptin5
Placebo2

[back to top]

Number of Participants With Hypoglycaemia

(NCT01183104)
Timeframe: From baseline to 52 W

InterventionParticipants (Count of Participants)
Sitagliptin7
Glimepiride23

[back to top]

Change From Baseline in HOMA-β at 52 W

β cell function is measured by the Homeostatic Model Assessment(HOMA-β). HOMA β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) - 3.5] (NCT01183104)
Timeframe: Baseline and 52 W

Interventionpercent (Mean)
Sitagliptin10.2
Glimepiride23.7

[back to top]

Change From Baseline in Body Weight at 52 W

(NCT01183104)
Timeframe: Baseline and 52 W

Interventionkg (Mean)
Sitagliptin-0.367
Glimepiride0.309

[back to top]

The Number of Participants Achieving HbA1c < 6.9 %

(NCT01183104)
Timeframe: 52 W

InterventionParticipants (Count of Participants)
Sitagliptin89
Glimepiride86

[back to top]

Change From Baseline in HbA1c at 52 W

(NCT01183104)
Timeframe: Baseline and 52 W

Interventionpercent (Least Squares Mean)
Sitagliptin-0.66
Glimepiride-0.77

[back to top]

Change From Baseline in Insulin/Proinsulin Ratio at 52 W

(NCT01183104)
Timeframe: Baseline and 52 W

Interventionratio (Mean)
Sitagliptin-0.049
Glimepiride-0.002

[back to top]

Number of Participants Experiencing An Adverse Event (AE)

"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the~study treatment, whether or not considered related to the use of the treatment administered." (NCT01189890)
Timeframe: Up to Week 30

InterventionParticipants (Number)
Sitagliptin118
Glimepiride115

[back to top]

Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30

Participant whole blood samples were collected at baseline and Week 30 to determine the LS mean HbA1c change from baseline. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation. (NCT01189890)
Timeframe: Baseline and Week 30

InterventionPercentage of HbA1c (Least Squares Mean)
Sitagliptin-0.32
Glimepiride-0.51

[back to top]

LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30

Plasma samples were collected from participants after an overnight fast at baseline and Week 30 to determine the mean change from baseline in participant FPG. (NCT01189890)
Timeframe: Baseline and Week 30

Interventionmg/dL (Least Squares Mean)
Sitagliptin-14.5
Glimepiride-21.2

[back to top]

LS Mean Change From Baseline in Participant Body Weight at Week 30

Participants were only permitted to wear a drape gown and undergarments (no street clothes, no shoes or socks) for this evaluation. Body weight was measured after voiding (to the nearest 0.1 kg) and measurements were collected until 2 consecutive measurements did not differ by more than 0.2 kg from each other. Body weight measurements were evaluated using a standardized, calibrated digital scale and was reported in kilograms (kg) at baseline and Week 30. (NCT01189890)
Timeframe: Baseline and Week 30

Interventionkg (Least Squares Mean)
Sitagliptin0.4
Glimepiride1.1

[back to top]

Number of Participants Discontinuing Study Treatment Due to An AE

"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the~study treatment, whether or not considered related to the use of the treatment administered." (NCT01189890)
Timeframe: Up to Week 30

InterventionParticipants (Number)
Sitagliptin3
Glimepiride4

[back to top]

Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30

Symptomatic hypoglycemia was defined as an episode with clinical symptoms attributed to hypoglycemia, without regard to glucose level. Participants were instructed to complete the Hypoglycemia Assessment Log (HAL) for any symptomatic episodes he or she believed represent hypoglycemia. If a fingerstick glucose was obtained before or shortly (i.e., within a few minutes) after treating, the value was recorded in the HAL. In addition, participants were instructed to record in the HAL any fingerstick glucose values ≤70 mg/dL (≤3.9 mmol/L) regardless of the presence of clinical symptoms. (NCT01189890)
Timeframe: Up to Week 30

InterventionParticipants (Number)
Sitagliptin2
Glimepiride11

[back to top]

Percentage of Participants With HbA1c <7.0% at Week 30

Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c <7.0% at Week 30. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation. (NCT01189890)
Timeframe: Week 30

InterventionPercentage of Participants (Number)
Sitagliptin33.5
Glimepiride46.6

[back to top]

Percentage of Participants With HbA1c <6.5% at Week 30

Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c <6.5% at Week 30. Hemoglobin A1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation. (NCT01189890)
Timeframe: Week 30

InterventionPercentage of Participants (Number)
Sitagliptin9.1
Glimepiride20.9

[back to top]

Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE

Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI), non-fatal stroke, and hospitalisation for unstable angina pectoris is presented as secondary CV endpoint. (NCT01243424)
Timeframe: From randomization until individual day of trial completion, up to 432 weeks

InterventionPercentage of participants (%) (Number)
Linagliptin13.2
Glimepiride13.3

[back to top]

Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE

Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI) and non-fatal stroke is presented as secondary CV endpoint. (NCT01243424)
Timeframe: From randomization until individual day of trial completion, up to 432 weeks

InterventionPercentage of participants (%) (Number)
Linagliptin11.8
Glimepiride12.0

[back to top]

CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study

Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint. (NCT01243424)
Timeframe: Baseline

InterventionMillimoles/ Litre (mmol/L) (Mean)
All Participants2.45

[back to top]

Change From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks

The endpoint change from baseline of ISR at fixed glucose concentration at 208 weeks as derived from a 3-hour meal tolerance test is Beta-cell function sub-study endpoint. (NCT01243424)
Timeframe: Baseline and week 208

InterventionPicomol/ minute/meter^2 (pmol/min/m²) (Mean)
Linagliptin11.07
Glimepiride6.95

[back to top]

Change From Baseline to Final Visit in Creatinine

Change from baseline to final visit in creatinine is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

Interventionmg/dL (Least Squares Mean)
Linagliptin0.08
Glimepiride0.09

[back to top]

Change From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR)

Change from baseline to final visit in eGFR is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

InterventionmL/minute/1.73 meter^2 (Least Squares Mean)
Linagliptin-4.0
Glimepiride-5.0

[back to top]

Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events

"Percentage of participants with occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of:~CV death (including fatal stroke and fatal MI)~non-fatal MI~non-fatal stroke~hospitalisation for unstable angina pectoris~TIA~hospitalisation for heart failure~hospitalisation for coronary revascularisation procedures (CABG, PCI)" (NCT01243424)
Timeframe: From start of the treatment until 7 days after the end of treatment, up to 433 weeks

InterventionPercentage of participants (%) (Number)
Linagliptin17.1
Glimepiride17.8

[back to top]

Percentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up

Occurrence of accelerated cognitive decline based on regression based index (RBI) score at end of follow-up (a dichotomous outcome measure; presence or absence of accelerated cognitive decline) is Cognition sub-study endpoint. (NCT01243424)
Timeframe: 433 weeks

InterventionPercentage of participants (%) (Number)
Linagliptin27.8
Glimepiride27.6

[back to top]

Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without >2% Weight Gain During Maintenance Phase

The third key secondary endpoint was a composite endpoint of treatment sustainability, defined as percentage of patients who were on trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, and without >2% weight gain during maintenance phase. (NCT01243424)
Timeframe: From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)

InterventionPercentage of participants (%) (Number)
Linagliptin17.4
Glimepiride14.1

[back to top]

Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without >2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase

The second key secondary endpoint was a composite endpoint of treatment sustainability, defined as the percentage of patients taking trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, without >2% weight gain, and without moderate/severe hypoglycaemic episodes during maintenance phase. (NCT01243424)
Timeframe: From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)

InterventionPercentage of participants (%) (Number)
Linagliptin16.0
Glimepiride10.2

[back to top]

Continuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study

Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint. (NCT01243424)
Timeframe: Baseline

InterventionMilligrams/ deciliter (mg/ dL) (Mean)
All Participants44.2

[back to top]

Change From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR)

Change from baseline to final visit in UACR is presented as secondary diabetes-related endpoint. Least square mean is adjusted geometric mean (gMean) ratio. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

Interventionmg/ gcrea (Geometric Mean)
Linagliptin1.52
Glimepiride1.57

[back to top]

Change From Baseline to Final Visit Fasting Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and High-density Lipoprotein (HDL) Cholesterol

Change from baseline to final visit in total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

,
Interventionmg/dL (Least Squares Mean)
LDL cholesterolHDL cholesterolTotal cholesterol
Glimepiride-6.50.3-0.5
Linagliptin-6.10.7-5.4

[back to top]

Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c)

Change from baseline to final visit in HbA1c is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

InterventionPercentage glycosylated hemoglobin (%) (Least Squares Mean)
Linagliptin0.06
Glimepiride0.15

[back to top]

Percentage of Participants With Transition in Albuminuria Classes

Percentage of patients with transition in albuminuria classes is presented as secondary endpoint. Data for last value on treatment (LVOT) to baseline (base) is presented. (NCT01243424)
Timeframe: Baseline and week 432

,
InterventionPercentage of participants (%) (Number)
Base (<30mg/gcrea) LVOT (<30mg/gcrea)Base(<30mg/gcrea)LVOT(>=30 to<=300mg/gcrea)Base (<30 mg/gcrea) LVOT (>300 mg/gcrea)Base (>=30 to <=300 mg/gcrea) LVOT(<30mg/gcrea)Base(>=30to<=300mg/gcrea)LVOT(>=30to<=300mg/gcrea)Base (>=30 to <=300 mg/gcrea) LVOT(>300 mg/gcrea)Base (>300 mg/gcrea) LVOT (<30 mg/gcrea)Base (>300 mg/gcrea) LVOT(>=30 to<=300mg/gcrea)Base (>300 mg/gcrea) LVOT(>300 mg/gcrea)
Glimepiride57.716.01.45.112.13.70.30.92.7
Linagliptin58.414.11.45.412.73.50.10.83.4

[back to top]

Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG)

Change from baseline to final visit in fasting plasma glucose (FPG) is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

InterventionMilligram/ deciliter (mg/dL) (Least Squares Mean)
Linagliptin12.4
Glimepiride19.7

[back to top]

Change From Baseline to Final Visit in Triglycerides

Change from baseline to final visit in triglycerides is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

Interventionmg/dL (Least Squares Mean)
Linagliptin1.7
Glimepiride5.2

[back to top]

Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events

"Time to first occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of:~CV death (including fatal stroke and fatal MI)~non-fatal MI~non-fatal stroke~hospitalisation for unstable angina pectoris~Transient ischaemic attack (TIA)~hospitalisation for heart failure~hospitalisation for coronary revascularisation procedures (CABG, PCI)" (NCT01243424)
Timeframe: From start of the treatment until 7 days after the end of treatment, up to 433 weeks

InterventionEvents/ 1000 patients-years (Number)
Linagliptin31.1
Glimepiride32.4

[back to top]

The First 4-point (4P)- MACE

The first key secondary endpoint was time to first occurrence of any of the following adjudicated components of the composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal stroke, non-fatal MI (excluding silent MI), or hospitalisation for unstable angina pectoris. (NCT01243424)
Timeframe: From randomization until individual day of trial completion, up to 432 weeks

InterventionEvents/ 1000 patients-years (Number)
Linagliptin23.4
Glimepiride23.7

[back to top]

The First 3-point Major Adverse Cardiovascular Events (3P-MACE)

The first occurrence of any of the following Clinical Event Committee (CEC) confirmed adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), or nonfatal stroke is presented. (NCT01243424)
Timeframe: From randomization until individual day of trial completion, up to 432 weeks

InterventionEvents/ 1000 patients-years (Number)
Linagliptin20.7
Glimepiride21.2

[back to top]

Percentage of Participants Reaching A1C Goal of <7.0%

(NCT01296412)
Timeframe: Week 26

Interventionpercentage of participants (Number)
Sitagliptin +/- Glimepiride62.8
Liraglutide72.3

[back to top]

Percentage of Participants Reaching A1C Goal of <6.5%

(NCT01296412)
Timeframe: Week 26

Interventionpercentage of participants (Number)
Sitagliptin +/- Glimepiride33.8
Liraglutide38.3

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline at Week 26 is defined as Week 26 minus Week 0. (NCT01296412)
Timeframe: Baseline and Week 26

Interventionmg/dL (Least Squares Mean)
Sitagliptin +/- Glimepiride-33.7
Liraglutide-39.6

[back to top]

Change From Baseline in Hemoglobin A1c (A1C)

A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent. (NCT01296412)
Timeframe: Baseline and Week 26

Interventionpercent (Least Squares Mean)
Sitagliptin +/- Glimepiride-1.32
Liraglutide-1.42

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 8).

The change between the value of fasting plasma glucose collected at week 8 and baseline. (NCT01318083)
Timeframe: Baseline and Week 8.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride QD or BID-22.3
Alogliptin 25 mg QD and Glimepiride QD or BID-17.4
Glimepiride 1, 2, 3 or 4 mg QD or BID5.3

[back to top]

Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).

The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01318083)
Timeframe: Baseline and Week 12.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride QD or BID76.6
Alogliptin 25 mg QD and Glimepiride QD or BID80.9
Glimepiride 1, 2, 3 or 4 mg QD or BID100.0

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 12).

The change between the value of fasting plasma glucose collected at week 12 or final visit and baseline. (NCT01318083)
Timeframe: Baseline and Week 12.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride QD or BID-22.3
Alogliptin 25 mg QD and Glimepiride QD or BID-15.9
Glimepiride 1, 2, 3 or 4 mg QD or BID6.0

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 2).

The change between the value of fasting plasma glucose collected at week 2 and baseline. (NCT01318083)
Timeframe: Baseline and Week 2.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride QD or BID-17.5
Alogliptin 25 mg QD and Glimepiride QD or BID-17.4
Glimepiride 1, 2, 3 or 4 mg QD or BID0.2

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 4).

The change between the value of fasting plasma glucose collected at week 4 and baseline. (NCT01318083)
Timeframe: Baseline and Week 4.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride QD or BID-21.2
Alogliptin 25 mg QD and Glimepiride QD or BID-22.9
Glimepiride 1, 2, 3 or 4 mg QD or BID2.0

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 12).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline. (NCT01318083)
Timeframe: Baseline and Week 12.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride QD or BID-0.60
Alogliptin 25 mg QD and Glimepiride QD or BID-0.66
Glimepiride 1, 2, 3 or 4 mg QD or BID0.34

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 2).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline. (NCT01318083)
Timeframe: Baseline and Week 2.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride QD or BID-0.12
Alogliptin 25 mg QD and Glimepiride QD or BID-0.13
Glimepiride 1, 2, 3 or 4 mg QD or BID0.08

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 4).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline. (NCT01318083)
Timeframe: Baseline and Week 4.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride QD or BID-0.32
Alogliptin 25 mg QD and Glimepiride QD or BID-0.36
Glimepiride 1, 2, 3 or 4 mg QD or BID0.09

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 8).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. (NCT01318083)
Timeframe: Baseline and Week 8.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride QD or BID-0.52
Alogliptin 25 mg QD and Glimepiride QD or BID-0.59
Glimepiride 1, 2, 3 or 4 mg QD or BID0.18

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 12).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 12.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.63
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.72
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.61
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.71

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 16).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 16.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.66
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.76
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.69
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.78

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 24).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 24.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.59
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.70
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.68
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.78

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 28).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 28.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.62
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.76
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.70
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.84

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 32).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 32.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.63
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.77
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.67
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.81

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 36).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 36.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.64
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.77
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.67
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.79

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 40).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 40.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.66
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.74
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.63
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.74

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 44).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 44.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.48
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.71
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.47
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.70

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 48).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 48.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.40
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.61
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.36
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.62

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 52).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 52.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.33
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.53
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.29
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.53

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 8).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 8.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.53
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.65
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.53
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.59

[back to top]

Number of Participants With Adverse Events.

Treatment-emergent adverse events (TEAE) are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing. (NCT01318135)
Timeframe: 52 Weeks.

,,,
Interventionparticipants (Number)
Serious Adverse EventOther Adverse Event (≥3% Frequency Threshold)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID16116
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID7108
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID3134
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID5113

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 24).

The change between the value of fasting blood glucose collected at week 24 and baseline. (NCT01318135)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-24.0
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-25.0
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-25.6
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-26.3

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 20).

The change between the value of fasting blood glucose collected at week 20 and baseline. (NCT01318135)
Timeframe: Baseline and Week 20.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-22.4
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-22.3
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-23.4
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-26.1

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 16).

The change between the value of fasting blood glucose collected at week 6 and baseline. (NCT01318135)
Timeframe: Baseline and Week 16.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-22.3
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-17.8
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-21.8
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-26.1

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 12).

The change between the value of fasting blood glucose collected at week 12 and baseline. (NCT01318135)
Timeframe: Baseline and Week 12.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-22.0
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-18.1
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-22.9
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-24.2

[back to top]

Change From Baseline in Fasting Blood Glucose (Final Visit).

The change between the value of fasting blood glucose collected at final visit and baseline. (NCT01318135)
Timeframe: Baseline and Final Visit (up to Week 52).

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-16.0
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-13.0
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-16.4
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-17.7

[back to top]

Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 24).

The change between the value of blood glucose measured by the meal tolerance test collected at week 24 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01318135)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID87.4
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID77.9
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID60.7
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID62.4

[back to top]

Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).

The change between the value of blood glucose measured by the meal tolerance test collected at week 12 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01318135)
Timeframe: Baseline and Week 12.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID80.2
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID80.1
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID61.6
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID64.0

[back to top]

Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).

The change between the value of blood glucose measured by the meal tolerance test collected at final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01318135)
Timeframe: Baseline and Final Visit (up to Week 52).

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID84.8
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID84.9
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID63.5
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID63.7

[back to top]

Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 52).

The change between the value of blood glucose measured by the meal tolerance test collected at week 52 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01318135)
Timeframe: Baseline and Week 52.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID83.8
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID83.2
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID62.5
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID62.7

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 20).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Week 20.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.63
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.70
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.67
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.78

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 28).

The change between the value of fasting blood glucose collected at week 28 and baseline. (NCT01318135)
Timeframe: Baseline and Week 28.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-19.9
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-25.9
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-25.8
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-28.2

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 32).

The change between the value of fasting blood glucose collected at week 32 and baseline. (NCT01318135)
Timeframe: Baseline and Week 32.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-22.4
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-26.1
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-23.2
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-28.2

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 36).

The change between the value of fasting blood glucose collected at week 36 and baseline. (NCT01318135)
Timeframe: Baseline and Week 36.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-25.5
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-26.7
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-23.4
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-26.0

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 40).

The change between the value of fasting blood glucose collected at week 40 and baseline. (NCT01318135)
Timeframe: Baseline and Week 40.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-21.3
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-22.7
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-19.8
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-23.2

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 44).

The change between the value of fasting blood glucose collected at week 44 and baseline. (NCT01318135)
Timeframe: Baseline and Week 44.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-15.4
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-21.9
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-16.3
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-24.0

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 48).

The change between the value of fasting blood glucose collected at week 48 and baseline. (NCT01318135)
Timeframe: Baseline and Week 48.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-13.6
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-16.6
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-14.3
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-23.3

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 52).

The change between the value of fasting blood glucose collected at week 52 and baseline. (NCT01318135)
Timeframe: Baseline and Week 52.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-13.3
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-11.9
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-14.0
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-16.1

[back to top]

Change From Baseline in Fasting Blood Glucose (Week 8).

The change between the value of fasting blood glucose collected at week 8 and baseline. (NCT01318135)
Timeframe: Baseline and Week 8.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-20.7
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-19.6
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-22.0
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-23.4

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Final Visit).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit and glycosylated hemoglobin collected at baseline. (NCT01318135)
Timeframe: Baseline and Final Visit (up to 52).

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID-0.42
Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID-0.58
Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID-0.44
Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID-0.58

[back to top]

Percentage of Participants With at Least One Symptomatic Hypoglycemic Event

Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example, but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change). (NCT01340768)
Timeframe: Up to 30 days (Day 1 through last day of Ramadan)

Interventionpercentage of participants (Number)
Sitagliptin3.8
Sulfonylurea Therapy7.3

[back to top]

Percentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event

Symptomatic hypoglycemic events were based on the participants own self-reported symptoms (for example but not limited to the following: faintness, headache, confusion, anxiety, sweating, tremor, palpitations, nausea, pallor, dizziness, hunger, sudden behavioral change). Asymptomatic hypoglycemic events were based on self-monitored finger-stick blood glucose level. (NCT01340768)
Timeframe: Up to 30 days (Day 1 through last day of Ramadan)

Interventionpercentage of participants (Number)
Sitagliptin4.8
Sulfonylurea Therapy9.6

[back to top]

Change From Baseline in Heart Rate at Week 24/EW

The heart rate of the participants was measured. Change from Baseline in heart rate was calculated as the value at Week 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

Interventionbeats per minute (bpm) (Mean)
Rosiglitazone+Glimepiride FDC1.1
Glimepiride-0.4

[back to top]

Change From Baseline in Hematocrit (HCT) at Week 24/EW

Blood samples of participants were collected for HCT assessment. Change from Baseline in HCT was calculated as the value at Week 24/EW minus the value at Baseline. HCT is measured as the percentage of the volume of whole blood that is made up of red blood cells. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

Interventionpercentage of volume of whole blood (Mean)
Rosiglitazone+Glimepiride FDC-1.21
Glimepiride0.52

[back to top]

Change From Baseline in High Sensitivity C-reactive Protein (Hs-CRP) at Week 24/EW

Blood samples of participants were collected for hs-CRP assessment. CRP is a marker of inflammation. High levels of CRP predict the risk of heart disease and diabetes. Change from Baseline in hs-CRP was calculated as the value at Week 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

Interventionmmol/L (Mean)
Rosiglitazone+Glimepiride FDC-10.71
Glimepiride2.74

[back to top]

Change From Baseline in Homeostasis Model Assessment Beta-cell Function (HOMA-B) at Week 24/EW

Blood samples of participants who had fasted for 12 to 14 hours were collected for fasting glucose (FG) and insulin (FI) assessment. The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance (a condition in which natural hormone insulin becomes less effective in lowering blood sugars) and beta-cell (specialized cells in the pancreas producing insulin) function. HOMA-B is calculated using the following mathematical model to predict glucose and insulin concentrations=(20*FI[mU/ml])/(FG[mmol/l]-3.5). (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

InterventionRatio: 20*FI (num.); FG-3.5 (denom.) (Mean)
Rosiglitazone+Glimepiride FDC1.0494
Glimepiride1.0108

[back to top]

Change From Baseline in Homeostasis Model Assessment Sensitivity (HOMA-S) at Week 24/EW

Blood samples of participants who had fasted for 12-14 hours were collected for fasting glucose (FG) and insulin (FI) assessment. The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance (a condition in which natural hormone insulin becomes less effective in lowering blood sugars) and beta-cell (specialized cells in the pancreas producing insulin) function. HOMA-S is calculated using the following model to predict glucose and insulin concentrations=(FI[milliunits (mU)/milliliter (ml)]*FG [millimoles per liter (mmol/l)])/22.5. numerator, num.; denominator, denom. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

InterventionRatio: FI*FG (num.); 22.5 (denom.) (Mean)
Rosiglitazone+Glimepiride FDC1.7248
Glimepiride-2.9173

[back to top]

Change From Baseline in Mean Corpuscular Hemoglobin (MCH) at Week 24/EW

Blood samples of participants were collected for MCH assessment. Change from Baseline in MCH was calculated as the value at Week 24/EW minus the value at Baseline. MCH is the average amount of hemoblobin inside a RBC expressed in picograms. MCH is calculated by dividing the hemoglobin concentration in grams per deciliter by the RBC count in millions per microliter, then multiplying by 10. MCH is one of the three main RBC indices which are helpful to determine the cause of anemia. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

InterventionPicograms (pg) per cell (Mean)
Rosiglitazone+Glimepiride FDC0.60
Glimepiride0.28

[back to top]

Change From Baseline in Mean Corpuscular Volume (MCV) at Week 24/EW

Blood samples of participants were collected for MCV assessment. Change from Baseline in MCV was calculated as the value at Week 24/EW minus the value at Baseline. MCV is the average size of the red blood cells expressed in femtoliters. MCV is calculated by dividing the hematocrit (as percent) by the RBC count in millions per microliter of blood, then multiplying by 10. MCV is one of the three main RBC indices that are helpful in determining the cause of anemia. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

InterventionFemtoliters (FL) per cell (Mean)
Rosiglitazone+Glimepiride FDC1.82
Glimepiride1.01

[back to top]

Change From Baseline in Red Blood Cell (RBC) Count at Week 24/EW

Blood samples of participants were collected for RBC count assessment. Change from Baseline in RBC count was calculated as the value at Week 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

InterventionPico per liter (10^12/ L) cells (Mean)
Rosiglitazone+Glimepiride FDC-0.213
Glimepiride-0.003

[back to top]

Change From Baseline in Weight at Week 24/EW

The weight of the participants was measured. Change from Baseline in weight was calculated as the value at Week 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

Interventionkilograms (kg) (Mean)
Rosiglitazone+Glimepiride FDC1.55
Glimepiride1.43

[back to top]

Number of Participants With a Bone Fracture

Participants with a break in the continuity (fracture) of the bone were evaluated. (NCT01453049)
Timeframe: Week 24/EW

Interventionparticipants (Number)
Rosiglitazone+Glimepiride FDC0
Glimepiride0

[back to top]

Percent Change From Baseline in High Sensitivity C-reactive Protein (Hs-CRP) at Week 24/EW

Blood samples of participants were collected for hs-CRP assessment. CRP is a marker of inflammation. High levels of CRP predict the risk of heart disease and diabetes. Percent change from Baseline in hs-CRP was calculated as the value at Visit 8 (Wk 24)/ EW minus the value at Baseline divided by value at Wk 24/ EW multiplied by 100. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

Interventionpercent change (Median)
Rosiglitazone+Glimepiride FDC-39.58
Glimepiride0.00

[back to top]

Change From Baseline in Alanine Transaminase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transpeptidase (GGT), Lactate Dehydrogenase (LDH), Alkaline Phosphatase (ALP), and Creatine Kinase (CK) at Week 24/EW

Blood samples of participants were collected for ALT, AST, GGT, LDH, ALP, and CK assessment. Change from Baseline in ALT, AST, GGT, LDH, ALP, and CK was calculated as the value at Week 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

,
InterventionUnits per liter (U/L) (Mean)
ALT; n=39, 42AST; n=38, 38GGT; n=37, 36LDH; n=38, 37ALP; n=38, 38CK; n=35, 41
Glimepiride-4.30-4.2-1.51.6-2.8-1.8
Rosiglitazone+Glimepiride FDC-6.23-3.5-30.02.0-13.320.8

[back to top]

Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW

Blood samples of participants were collected for BUN and electrolyte (sodium, potassium, chloride, calcium, and phosphorus) assessment. The electrolyte balance asseses the condition of the heart and the kidneys, and BUN assesses the condition of the kidneys. Change from Baseline in BUN, sodium, potassium, chloride, calcium, and phosphorus was calculated as the value at Week 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

,
Interventionmmol/L (Mean)
BUN; n=39, 42Sodium; n=39, 41Potassium; n=39, 41Chloride; n=39, 41Calcium; n=38, 35Phosphorus; n=36, 35
Glimepiride0.1460.330.0861.240.0370.028
Rosiglitazone+Glimepiride FDC0.076-0.560.006-1.930.0350.046

[back to top]

Change From Baseline in Electrocardiogram (ECG) Data at Week 24/EW

PR, QT, QTc, RR, QRS, and QRS axis data were measured by ECG. The PR interval (int.) starts at the beginning of the atrial contraction and ends at the beginning of the ventricular contraction. QT (QT int.) and QTc (corrected QT int.) indicate how fast the ventricles are repolarized, becoming ready for a new cycle. The RR int. represents the duration of the ventricular cardiac cycle and is an indicator of ventricular rate. QRS (QRS duration) indicates how fast the ventricles depolarize. The QRS axis is an indicator of the electrical heart axis, which is an average of all heart depolarization. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

,
Interventionmilliseconds (msec) (Mean)
PR intervals; n=38, 43QT intervals; n=38, 43QTc intervals; n=37, 43RR intervals; n=37, 43QRS intervals; n=37, 43QRS axis intervals; n=37, 43
Glimepiride-5.6-9.0-3.1-33.4-1.00.5
Rosiglitazone+Glimepiride FDC1.53.6-0.916.1-0.51.8

[back to top]

Change From Baseline in Fasting Proinsulin and Insulin at Week 24/Early Withdrawal (EW)

Blood samples of participants who had fasted for 12-14 hours were collected for fasting proinsulin (precursor of insulin) and insulin assessment. Preproinsulin is sequentially processed via proinsulin, through intermediate proteolytic cleavage products, to insulin and C-peptide before release from the beta cell granule by exocytosis. Elevated levels of proinsulin are considered indicative of beta cell dysfunction. Insulin is a hormone that regulates carbohydrate and fat metabolism in the body. Change from Baseline was calculated as the value at Week 24/ EW minus the value at Baseline (Week 0). (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

,
InterventionPicomoles per liter (pmol/L) (Mean)
Proinsulin; n=32, 34Insulin; n=15, 19
Glimepiride3.124.9
Rosiglitazone+Glimepiride FDC-2.99.3

[back to top]

Change From Baseline in Hemoglobin (HE), Mean Corpuscular Hemoglobin Concentration (MCHC), Total Protein (TP), and Albumin at Week 24/EW

Blood samples of participants were collected for HE, MCHC, and TP assessment. Change from Baseline in HE, MCHC, and TP was calculated as the value at Week 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

,
InterventionGrams per liter (G/L) (Mean)
HE; n=38, 42MCHC; n=35, 42TP; n=39, 42Albumin; n=39, 42
Glimepiride1.5-0.91.451.44
Rosiglitazone+Glimepiride FDC-3.7-0.2-1.12-0.21

[back to top]

Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW

Blood samples of participants were collected for lymphocyte, monocyte, neutrophil, eosinophil, and basophil assessment. Change from Baseline in lymphocytes, monocytes, neutrophils, eosinophils, and basophils was calculated as the value at Week 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

,
Interventionpercent of WBC count (Mean)
Lymphocytes; n=38, 42Monocytes; n=38, 42Neutrophils; n=38, 42Eosinophils; n=35, 42Basophils; n=35, 42
Glimepiride-2.33-0.332.73-0.120.05
Rosiglitazone+Glimepiride FDC1.530.47-2.840.610.09

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 24/EW

The blood pressure of the participants was measured. Change from Baseline in SBP and DBP was calculated as the value at Weeks 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

,
InterventionMillimeters of mercury (mmHg) (Mean)
SBPDBP
Glimepiride3.12.1
Rosiglitazone+Glimepiride FDC2.02.2

[back to top]

Change From Baseline in the Ratio of TC/HDL-C and LDL-C/HDL-C at Week 24/EW

Blood samples of participants who had fasted for 12 to 14 hours were collected for lipid profile (TC, HDL-C and LDL-C) assessment. The ratio of TC/HDL-C and LDL-C/HDL-C was calculated. Change from Baseline in the ratio of TC/HDL-C and LDL-C/HDL-C was calculated as the value at Week 24/EW minus the value at Baseline. For TC/HDL-C, the numerator is TC, and the denominator is HDL-C. For LDL-C/HDL-C, the numerator is LDL-C, and the denominator is HDL-C. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

,
Interventionratio (Mean)
TC/HDL-C; n=35, 33LDL-C/HDL-C; n=34, 31
Glimepiride-0.1283-0.0782
Rosiglitazone+Glimepiride FDC0.22950.0753

[back to top]

Change From Baseline in Total Bilirubin (TB), Direct Bilirubin (DB), Creatinine, and Uric Acid (UC) at Week 24/EW

Blood samples of participants were collected for TB, DB, creatinine, and UC assessment. Change from Baseline in TB, DB, creatinine, and UC was calculated as the value at Week 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

,
InterventionMicromoles per liter (mcmol/L) (Mean)
TB; n=39, 41DB; n=39, 42Creatitine; n=39, 42UC; n=39, 42
Glimepiride-3.44-0.63-1.144.96
Rosiglitazone+Glimepiride FDC-5.33-1.201.03-13.58

[back to top]

Change From Baseline in Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C), Low Density Lipoprotein-cholesterol (LDL-C), and Triglyceride (TG) at Week 24/EW

Blood samples of participants who had fasted for 12 to 14 hours were collected for lipid profile (TC, HDL-C, LDL-C, TG) assessment. The lipid profile asesses the risk of heart disease. Change from Baseline in TC, HDL-C, LDL-C, and TG was calculated as the value at Week 24)/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

,
Interventionmmol/L (Mean)
TC; n=35, 36HDL-C; n=35, 34LDL-C; n=34, 31TG; n=35, 37
Glimepiride0.1860.0910.0670.056
Rosiglitazone+Glimepiride FDC0.146-0.0030.0020.344

[back to top]

Change From Baseline in White Blood Cell (WBC) Count and Platelet Count at Week 24/EW

Blood samples of participants were collected for WBC count and platelet count assessment. Change from Baseline in WBC count and platelet count was calculated as the value at Week 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

,
InterventionGiga per liter (10^9/L) cells (Mean)
WBC countPlatelet count
Glimepiride0.1483.4
Rosiglitazone+Glimepiride FDC-0.418-5.7

[back to top]

Number of HbA1c Responders and Non-responders

Blood samples of participants were collected for HbA1c assessment. HbA1c responders were defined as participants who had achieved HbA1c <7%, or who achieved a decrease of >= 0.7% from Baseline at Week 24 (LOCF). (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24 (LOCF)

,
Interventionparticipants (Number)
RespondersNon-responders
Glimepiride299
Rosiglitazone+Glimepiride FDC332

[back to top]

Number of Hypoglycemic Events

A hypoglycemic event is a condition that occurs when the blood glucose is below 70 mg/dL or 4 mmol/L. All participants, participants with HbA1c <7%, or who achieved a decrease of >= 0.7% from Baseline at Week 24 (HbA1c responders); and participants who had a >=1.7 mmol/L decrease from Baseline FPG or who achieved a FPG <6.1 mmol/L at Week 24 (FPG responders) were evaluated. (NCT01453049)
Timeframe: Week 24/EW

,
InterventionHypoglycemic events (Number)
HE for all participantsHE for HbA1c respondersHE for FPG responders
Glimepiride11100
Rosiglitazone+Glimepiride FDC13129

[back to top]

Number of Participants at Various Dose Levels at Week 24/EW

The number of participants at the different dose levels at Week 24/EW was recorded. The different dose levels for Rosi + Glim are: Dose level 1, Rosi 4 mg + Glim 1 mg; Dose level 2, Rosi 4 mg + Glim 2 mg; Dose level 3, Rosi 4 mg + Glim 4 mg. The different dose levels for Glim are: Dose level 1, Glim 1 mg; Dose level 2, Glim 2 mg; Dose level 3, Glim 4 mg. (NCT01453049)
Timeframe: Week 24/EW

,
Interventionparticipants (Number)
Dose Level 1Dose Level 2Dose Level 3
Glimepiride71813
Rosiglitazone+Glimepiride FDC16810

[back to top]

Number of Participants Who Achieved HbA1c <7%, HbA1c <=6.5%, or Who Achieved a Decrease of >=0.7% From Baseline

Blood samples of participants were collected for HbA1c assessment. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24 (LOCF)

,
Interventionparticipants (Number)
HbA1c <7%HbA1c <=6.5%HbA1c decrease of >=0.7% from Baseline
Glimepiride13829
Rosiglitazone+Glimepiride FDC13533

[back to top]

Number of Participants With Hypoglycemic Events

Blood samples of participants were collected for the assessment of blood glucose levels. Hypoglycemia is a condition that occurs when the blood glucose is below 70 mg/dL or 4 mmol/L. All participants; participants with HbA1c <7%, or who achieved a decrease of >= 0.7% from Baseline at Week 24 (HbA1c responders); and participants who had a >=1.7 mmol/L decrease from Baseline FPG or who achieved a FPG <6.1 mmol/L at Week 24 (FPG responders) were evaluated. (NCT01453049)
Timeframe: Week 24/EW

,
Interventionparticipants (Number)
All participants with any hypoglycemic events (HE)HbA1c responders with any HEsFPG responders with any HEs
Glimepiride760
Rosiglitazone+Glimepiride FDC875

[back to top]

Number of FPG Responders and Non-responders

Blood samples of participants were collected for FPG assessment. FPG responders are definded as participants who had a >=1.7 mmol/L decrease from Baseline FPG or who achieved a FPG level < 6.1 mmol/L at Week 24 (LOCF). (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24 (LOCF)

,
Interventionparticipants (Number)
RespondersNon-responders
Glimepiride1226
Rosiglitazone+Glimepiride FDC2114

[back to top]

Change From Baseline in Adjusted Diabetes Quality of Life (A-DQOL) Scores at Week 24/EW

In diabetic participants, QOL, anxiety, and depression were measured by the A-DQOL scale . There are 46 core items (10 additional items for adolescents) and 4 major dimensions: treatment satisfaction, treatment impact, worry about long-term complications, and worry about social/vocational issues. Participants respond to all items on a 5-point Likert scale: 1, no impact, no worries, or always satisfied; 5, always affected, always worried, or never satisfied. The total score is a sum of the individual scores of all 46 items (range of 46 to 230); a lower score indicates a better QOL. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

Interventionscores on a scale (Mean)
Rosiglitazone+Glimepiride FDC-7.0
Glimepiride-0.1

[back to top]

Change From Baseline in Electrocardiogram (ECG) Assessment of Heart Rate at Week 24/EW

Electrocardiograms of the participants were taken for the evaluation of heart rate. Change from Baseline in heart rate was calculated as the value at Week 24/EW minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

Interventionbpm (Mean)
Rosiglitazone+Glimepiride FDC-1.5
Glimepiride3.0

[back to top]

Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) at Week 24/EW

EQ-5D is used as a measure of health outcome and includes single-item measures (coded on a 3-point scale [1, no problems; 2, some problems; 3, severe problems]) of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The instrument includes a global rating of current health using a visual analog scale (VAS): 0 (worst imaginable) to 100 (best imaginable). Health states may be converted to a single summary index by applying a formula that attaches values to each of the levels in each dimension. The index scale is -0.111 to 1. A lower index indicates worse health. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24/EW

Interventionscores on a scale (Mean)
Rosiglitazone+Glimepiride FDC0.0584
Glimepiride0.0447

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Blood samples of participants were collected for FPG assessment. The FPG test, also known as the fasting blood sugar test, measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. Change from Baseline in FBG was calculated as the value at Week 24 minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24

InterventionMillimoles per liter (mmol/L) (Mean)
Rosiglitazone+Glimepiride FDC-1.907
Glimepiride-0.877

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

Blood samples of participants were collected for HbA1c assessment. HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The American Diabetes Association has recommended an HbA1c value below 53 millimoles per mole (mmol/mol) (7.0%) for most participants. Change from Baseline in HbA1c was calculated as the value at Week 24 minus the value at Baseline. (NCT01453049)
Timeframe: Baseline (Week 0) and Week 24

InterventionPercent of total hemoglobin (Mean)
Rosiglitazone+Glimepiride FDC-1.75
Glimepiride-1.47

[back to top]

Change From Baseline in Hemoglobin A1C (A1C) at Week 16

A1C is measured as percent. Thus, this change from baseline reflects the Week 16 A1C percent minus the Week 0 A1C percent. (NCT01477853)
Timeframe: Baseline and Week 16

InterventionPercent (Mean)
Sitagliptin/Sitagliptin + Atorvastatin-1.17
Atorvastatin/Atorvastatin + Glimepiride0.04
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin-1.01

[back to top]

Percent Change From Baseline in Triglycerides at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01477853)
Timeframe: Baseline and Week 16

InterventionPercent change (Mean)
Sitagliptin/Sitagliptin + Atorvastatin-9.9
Atorvastatin/Atorvastatin + Glimepiride-28.7
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin-10.5

[back to top]

Percent Change From Baseline in Total Cholesterol at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01477853)
Timeframe: Baseline and Week 16

InterventionPercent change (Mean)
Sitagliptin/Sitagliptin + Atorvastatin-1.7
Atorvastatin/Atorvastatin + Glimepiride-28.3
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin-25.7

[back to top]

Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01477853)
Timeframe: Baseline and Week 16

InterventionPercent change (Mean)
Sitagliptin/Sitagliptin + Atorvastatin-1.0
Atorvastatin/Atorvastatin + Glimepiride-34.4
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin-34.6

[back to top]

Number of Participants Who Discontinued Study Drug Due to an Adverse Event

An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an adverse event. Data presented exclude data following the initiation of glycemic rescue therapy. (NCT01477853)
Timeframe: Up to 54 weeks

InterventionParticipants (Number)
Sitagliptin/Sitagliptin + Atorvastatin1
Atorvastatin/Atorvastatin + Glimepiride2
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin2

[back to top]

Number of Participants Who Experienced at Least One Adverse Event

An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an adverse event. Data presented exclude data following the initiation of glycemic rescue therapy. (NCT01477853)
Timeframe: Up to 56 weeks (including 2-week follow-up)

InterventionParticipants (Number)
Sitagliptin/Sitagliptin + Atorvastatin10
Atorvastatin/Atorvastatin + Glimepiride13
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin13

[back to top]

Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01477853)
Timeframe: Baseline and Week 16

InterventionPercent change (Mean)
Sitagliptin/Sitagliptin + Atorvastatin-4.8
Atorvastatin/Atorvastatin + Glimepiride-32.9
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin-29.0

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16

Change from baseline reflects the Week 16 value minus the Week 0 value. (NCT01477853)
Timeframe: Baseline and Week 16

Interventionmg/dL (Mean)
Sitagliptin/Sitagliptin + Atorvastatin-15.7
Atorvastatin/Atorvastatin + Glimepiride22.7
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin-26.0

[back to top]

Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01477853)
Timeframe: Baseline and Week 16

InterventionPercent change (Mean)
Sitagliptin/Sitagliptin + Atorvastatin-15.5
Atorvastatin/Atorvastatin + Glimepiride-28.6
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin-10.4

[back to top]

Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01477853)
Timeframe: Baseline and Week 16

InterventionPercent change (Mean)
Sitagliptin/Sitagliptin + Atorvastatin4.9
Atorvastatin/Atorvastatin + Glimepiride-35.7
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin-38.7

[back to top]

Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01477853)
Timeframe: Baseline and Week 16

InterventionPercent change (Mean)
Sitagliptin/Sitagliptin + Atorvastatin-0.3
Atorvastatin/Atorvastatin + Glimepiride-5.8
Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin1.5

[back to top]

Change From Baseline in HbA1c at Weeks 26 and 52

The change in the value of HbA1c collected at Weeks 26 and 52 relative to baseline. (NCT01481116)
Timeframe: Baseline and Weeks 26 and 52

,,
Interventionpercentage of glycosylated hemoglobin (Least Squares Mean)
Week 26Week 52
Glimepiride-0.91-0.78
TAK-875 25 mg-0.63-0.65
TAK-875 50 mg-0.81-0.81

[back to top]

Change From Baseline in Body Weight at Weeks 78 and 104

The change between the body weight to be collected at Weeks 78 and 104 relative to baseline. (NCT01481116)
Timeframe: Baseline and Weeks 78 and 104

,,
Interventionkg (Least Squares Mean)
BaselineChange at Week 78
Glimepiride84.321.24
TAK-875 25 mg84.55-0.07
TAK-875 50 mg85.67-0.21

[back to top]

Percentage of Participants With Hypoglycemia

Participants were provided diaries to document any hypoglycemic events that occurred between study visits. Any experience of hypoglycemic signs and symptoms (regardless of the blood glucose value by glucometer) or had a blood glucose value less than or equal to (<=) 70 milligram per deciliter (mg/dL) (3.9 millimole per liter (mmol/L) by glucometer (regardless of symptoms) were to be recorded. (NCT01481116)
Timeframe: Day 1 up to Weeks 78 and 104

,,
Interventionpercentage of participants (Number)
Day 1 up to Week 78Day 1 up to Week 104
Glimepiride30.230.2
TAK-875 25 mg5.45.4
TAK-875 50 mg5.35.3

[back to top]

Percentage of Participants With HbA1c <7%

(NCT01481116)
Timeframe: Weeks 26, 52, 78 and 104

,,
Interventionpercentage of participants (Number)
Week 26Week 52Week 78Week 104
Glimepiride51.847.845.2NA
TAK-875 25 mg38.343.337.733.3
TAK-875 50 mg48.754.554.533.3

[back to top]

Change From Baseline in HbA1c at Weeks 78 and 104

The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) to be collected at Weeks 78 and 104 relative to baseline. (NCT01481116)
Timeframe: Baseline and Weeks 78 and 104

,,
Interventionpercentage of glycosylated hemoglobin (Least Squares Mean)
BaselineChange at Week 78Change at Week 104
Glimepiride8.00-0.80NA
TAK-875 25 mg8.01-0.82-1.03
TAK-875 50 mg7.99-0.980.03

[back to top]

Change From Baseline in Fasting Plasma Glucose at Weeks 26, 52, 78 and 104

The change between the fasting plasma glucose value to be collected at Weeks 26, 52, 78 and 104 relative to baseline. (NCT01481116)
Timeframe: Baseline and Weeks 26, 52, 78 and 104

,,
Interventionmilligram per deciliter (mg/dL) (Least Squares Mean)
BaselineChange at Week 26Change at Week 52Change at Week 78Change at Week 104
Glimepiride164.5-19.5-19.80.0NA
TAK-875 25 mg165.2-17.4-19.3-17.6-24.0
TAK-875 50 mg163.7-23.0-23.7-21.4-32.0

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

The average (mean) change from baseline in HbA1c at Week 24 was analyzed. (NCT01494987)
Timeframe: Baseline; Week 24

,
Interventionpercent of HbA1c in blood (Mean)
HbA1c at Week 24Change from baseline in HbA1c at Week 24
Placebo+Glimepiride8.080.03
Ranolazine+Glimepiride7.58-0.47

[back to top]

Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24

"The average (mean) change from baseline in incremental change of 2-hour postprandial serum glucose at Week 24 was analyzed.~Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at T=120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations, analyzed based on the randomized treatment regardless of actual treatment received." (NCT01494987)
Timeframe: Baseline; Week 24

Interventionmg/dL (Mean)
Placebo+Glimepiride-2
Ranolazine+Glimepiride1

[back to top]

Change From Baseline in Fasting Serum Glucose at Week 24

The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed. (NCT01494987)
Timeframe: Baseline; Week 24

Interventionmg/dL (Mean)
Placebo+Glimepiride8
Ranolazine+Glimepiride2

[back to top]

Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24

The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed. (NCT01494987)
Timeframe: Baseline; Week 24

Interventionmg/dL (Mean)
Placebo+Glimepiride4
Ranolazine+Glimepiride1

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8

HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than 6.5 percent by the study-specific central laboratory used. Change from baseline in percentage of HbA1C was reported. (NCT01517373)
Timeframe: Baseline (Day 1), Week 2, 4, 6, 8

,,,,
Interventionpercentage of hemoglobin (Mean)
Week 4 (n=58, 57, 55, 58, 60)Week 6 (n=57, 55, 55, 58, 55)Week 8 (n=58, 55, 53, 57, 55)
Glimepiride-0.54-0.78-0.89
PF-04937319 10 mg-0.07-0.14-0.17
PF-04937319 100 mg-0.32-0.51-0.59
PF-04937319 50 mg-0.22-0.22-0.38
Placebo-0.08-0.14-0.19

[back to top]

Percentage of Participants With at Least 1 Hypoglycemic Events (HAE) Episode

A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. HAE was defined as 1 of the given definitions: Characteristic symptoms of HAE with no home glucose monitoring performed where clinical picture included prompt resolution with food intake, subcutaneous glucagon, or intravenous glucose; or characteristic symptoms of HAE with home glucose monitoring measurement =< 70 milligram per deciliter (mg/dL) using ACCU-CHEK plasma-referenced home glucometers or =<74 mg/dL using International Federation of Clinical Chemistry (IFCC) referenced ACCU-CHEK or central laboratory glucometers; or any laboratory glucose value, meeting the following criterion with or without accompanying symptoms: =<49 mg/dL using ACCU-CHEK plasma-referenced home glucometers or =<53 mg/dL using IFCC referenced ACCU-CHEK or central laboratory glucometers. (NCT01517373)
Timeframe: Baseline (Day 1) up to Week 14

Interventionpercentage of participants (Number)
Placebo4.9
PF-04937319 10 mg3.3
PF-04937319 50 mg4.9
PF-04937319 100 mg6.6
Glimepiride34.4

[back to top]

Change From Baseline in Body Weight at Week 2, 4, 6, 8, 12 and 14

(NCT01517373)
Timeframe: Baseline (Day 1), Week 2, 4, 6, 8, 12, 14 (follow-up)

,,,,
Interventionkilogram (kg) (Mean)
Baseline (n=59, 57, 58, 61, 60)Change at Week 2 (n=59, 57, 58, 61, 58)Change at Week 4 (n=58, 56, 55, 59, 60)Change at Week 6 (n=57, 54, 55, 59, 56)Change at Week 8 (n=58, 54, 53, 58, 56)Change at Week 12 (n=56, 52, 53, 55, 54)Change at Week 14 (n=55, 51, 53, 55, 53)
Glimepiride90.388-0.0240.3100.4730.4931.2111.234
PF-04937319 10 mg89.518-0.069-0.378-0.604-0.522-0.685-0.472
PF-04937319 100 mg87.530-0.021-0.284-0.290-0.397-0.545-0.573
PF-04937319 50 mg89.860-0.028-0.074-0.228-0.311-0.961-0.978
Placebo89.859-0.402-0.620-0.564-1.082-1.529-1.478

[back to top]

Change From Baseline in Fasting Plasma Glucose at Week 2, 4, 6, 8 and 12

(NCT01517373)
Timeframe: Baseline (Day 1), Week 2, 4, 6, 8, 12

,,,,
Interventionmilligram per deciliter (mg/dL) (Mean)
Baseline (n=60, 59, 60, 61, 61)Change at Week 2 (n=60, 59, 60, 61, 59)Change at Week 4 (n=59, 58, 56, 59, 60)Change at Week 6 (n=58, 56, 56, 59, 57)Change at Week 8 (n=59, 56, 54, 58, 57)Change at Week 12 (n=57, 54, 54, 55, 55)
Glimepiride163.7-19.9-26.2-23.4-26.9-22.5
PF-04937319 10 mg168.7-2.0-8.4-6.9-7.0-6.2
PF-04937319 100 mg160.4-10.5-11.4-10.4-13.0-10.3
PF-04937319 50 mg174.7-7.9-7.7-7.2-13.0-9.9
Placebo161.33.1-0.5-2.60.93.4

[back to top]

Number of Participants With Abnormal Laboratory Values

Hemoglobin,hematocrit,red blood cells(RBC) count:less than [<]0.8*lower limit of normal [LLN],platelets:<0.5*LLN/greater than [>]1.75*upper limit of normal [ULN],white blood cells(WBC):<0.6*LLN or >1.5*ULN,lymphocytes,total neutrophils:<0.8*LLN or >1.2*ULN, basophils,eosinophil,monocytes:>1.2*ULN;aspartate aminotransferase,alanine aminotransferase, alkaline phosphatase:>0.3*ULN,total protein,albumin:<0.8*LLN or >1.2*ULN;total bilirubin,direct bilirubin,indirect bilirubin:>1.5*ULN;triglycerides,cholesterol:>1.3*ULN, HDL:<0.8*LLN, LDL:>1.2*ULN,blood urea nitrogen,creatinine:>1.3*ULN,uric acid:>1.2*ULN;sodium: <0.95*LLN or >1.05*ULN,potassium,chloride,calcium,bicarbonate:<0.9*LLN or >1.1*ULN;creatine kinase:>2.0*ULN;glucose:<0.6*LLN or >1.5*ULN,urine WBC and RBC:>= 20/High Power Field [HPF]),urine epithelial cells (>=1 HPF),urine bacteria >20 high-powered field;qualitative urine glucose,urine blood to Hgb ratio (>=1);urine(protein,nitrite,mucus,leukocyte >=1 in urine dipstick test). (NCT01517373)
Timeframe: Baseline (Day 1) up to Week 14

Interventionparticipants (Number)
Placebo56
PF-04937319 10 mg52
PF-04937319 50 mg56
PF-04937319 100 mg54
Glimepiride51

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12

HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than 6.5 percent by the study-specific central laboratory used. Change from baseline in percentage of HbA1C was reported. (NCT01517373)
Timeframe: Baseline (Day 1), Week 12

,,,,
Interventionpercentage of hemoglobin (Mean)
Baseline (n=59, 57, 55, 60, 60)Change at Week 12 (n=56, 53, 53, 54, 54)
Glimepiride8.12-1.01
PF-04937319 10 mg7.97-0.18
PF-04937319 100 mg7.88-0.64
PF-04937319 50 mg7.91-0.45
Placebo7.90-0.13

[back to top]

Number of Participants With Increase From Baseline Electrocardiogram (ECG) Data

Participants who met the criteria for increase from baseline in ECG data were reported. Criteria for increase from baseline data: PR interval (percent change of greater than or equal to [>=] 25/50% [if baseline value was >200 then percent change of >25% counts; if baseline value was <=200 then percent change of >50% counts]); QRS complex (percent change of >=50%); QT Fridericia's correction (QTcF) interval (change of >= 30 to <60 millisecond [msec], and change of >=60 msec). (NCT01517373)
Timeframe: Baseline (Day 1) up to Week 14

,,,,
Interventionparticipants (Number)
PR interval: Percent change of >=25/50%QRS interval: Percent change of >=50%QTcF interval: Change of >=30 to <60 msecQTcF interval: Change of >=60 msec
Glimepiride0141
PF-04937319 10 mg0152
PF-04937319 100 mg0262
PF-04937319 50 mg1182
Placebo0062

[back to top]

Number of Participants With Increase/Decrease From Baseline Vital Signs Data

Participants who met the criteria for increase or decrease in vital signs data were reported. Criteria for increase or decrease from baseline vital signs data: sitting systolic blood pressure (BP) of >=30 millimeter of mercury (mmHg); sitting diastolic BP of >=20 mmHg and pulse rate was based on investigator's discretion. (NCT01517373)
Timeframe: Baseline (Day 1) up to Week 14

,,,,
Interventionparticipants (Number)
Increase in systolic BP (>=30 mmHg)Increase in diastolic BP (>=20 mmHg)Decrease in systolic BP (>=30 mmHg)Decrease in diastolic BP (>=20 mmHg)
Glimepiride5215
PF-04937319 10 mg1333
PF-04937319 100 mg3456
PF-04937319 50 mg3032
Placebo2154

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events. (NCT01517373)
Timeframe: Baseline (Day 1) up to 14 days after last dose of study treatment (up to 101 days)

,,,,
Interventionparticipants (Number)
AEsSAEs
Glimepiride361
PF-04937319 10 mg281
PF-04937319 100 mg291
PF-04937319 50 mg312
Placebo260

[back to top]

Percentage of Participants Achieving Less Than 6.5 Percent and Less Than 7 Percent Glycosylated Hemoglobin (HbA1c) Levels at Week 12

HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than 6.5 percent by the study-specific central laboratory used and data are presented in categories of less than 6.5 percent and less than 7 percent. (NCT01517373)
Timeframe: Week 12

,,,,
Interventionpercentage of participants (Number)
Less Than 6.5 PercentLess Than 7 Percent
Glimepiride18.245.5
PF-04937319 10 mg1331.5
PF-04937319 100 mg27.352.7
PF-04937319 50 mg18.527.8
Placebo7.026.3

[back to top]

Number of Hypoglycemic Events (HAE) Episodes Per Participant

A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. Median of 1 and 2 events per participant was reported. (NCT01517373)
Timeframe: Baseline (Day 1) up to Week 14

Interventionevents per participant (Median)
Placebo0
PF-04937319 10 mg0
PF-04937319 50 mg0
PF-04937319 100 mg0
Glimepiride0

[back to top]

PK Lag Time (Tlag)

PK blood samples for estimation of Tlag were collected at 0.0 (pre-dose) and 0.5,1,2,2.5,3,3.5,4,4.5,5,6,7,8,10, 12, 16,24 and 30 hours after dosing. Point estimates and corresponding 90% confidence interval was constructed for the ratio of the geometric mean of the test treatment (fed condition) to the geometric mean of the reference treatment (fasting condition). (NCT01561976)
Timeframe: 0.0 (pre-dose) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24 and 30 hours after dosing

InterventionHour (Median)
METLEAD ForteSR-Fasting0.00
METLEAD ForteSR-Fed0.00
METLEAD G2 Forte0.50

[back to top]

Maximum Observed Concentration (Cmax)

Pharmacokinetic (PK) blood samples for estimation of Cmax were collected at 0.0 (pre-dose) and 0.5,1,2,2.5,3,3.5,4,4.5,5,6,7,8,10, 12, 16,24 and 30 hours after dosing. Point estimates and corresponding 90% confidence interval was constructed for the ratio of the geometric mean of the test treatment (fed condition) to the geometric mean of the reference treatment (fasting condition). (NCT01561976)
Timeframe: 0.0 (pre-dose) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24 and 30 hours after dosing

InterventionNanograms per milliliter (ng/mL) (Geometric Mean)
METLEAD ForteSR-Fasting884.297
METLEAD ForteSR-Fed963.384
METLEAD G2 Forte942.653

[back to top]

Elimination Constant (Kel)

PK blood samples for estimation of Kel were collected at 0.0 (pre-dose) and 0.5,1,2,2.5,3,3.5,4,4.5,5,6,7,8,10, 12, 16,24 and 30 hours after dosing. Point estimates and corresponding 90% confidence interval was constructed for the ratio of the geometric mean of the test treatment (fed condition) to the geometric mean of the reference treatment (fasting condition). (NCT01561976)
Timeframe: 0.0 (pre-dose) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24 and 30 hours after dosing

InterventionFraction/hour (Median)
METLEAD ForteSR-Fasting0.162
METLEAD ForteSR-Fed0.167
METLEAD G2 Forte0.165

[back to top]

AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments [AUC (0-t)]

PK blood samples for estimation of AUC (0-t) were collected at 0.0 (pre-dose) and 0.5,1,2,2.5,3,3.5,4,4.5,5,6,7,8,10, 12, 16,24 and 30 hours after dosing. Point estimates and corresponding 90% confidence interval was constructed for the ratio of the geometric mean of the test treatment (fed condition) to the geometric mean of the reference treatment (fasting condition). (NCT01561976)
Timeframe: 0.0 (pre-dose) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24 and 30 hours after dosing

Interventionµ.hr/mL (Geometric Mean)
METLEAD ForteSR-Fasting9894.580
METLEAD ForteSR-Fed11563.589
METLEAD G2 Forte10546.905

[back to top]

Area Under Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC (0-infinity)]

PK blood samples for estimation of AUC (0-infinity) were collected at 0.0 (pre-dose) and 0.5,1,2,2.5,3,3.5,4,4.5,5,6,7,8,10, 12, 16,24 and 30 hours after dosing. Point estimates and corresponding 90% confidence interval was constructed for the ratio of the geometric mean of the test treatment (fed condition) to the geometric mean of the reference treatment (fasting condition). (NCT01561976)
Timeframe: 0.0 (pre-dose) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24 and 30 hours after dosing

InterventionMicrograms hour per milliliter (µ.hr/mL) (Geometric Mean)
METLEAD ForteSR-Fasting10099.285
METLEAD ForteSR-Fed11765.202
METLEAD G2 Forte10751.895

[back to top]

Terminal Phase Half Life (t1/2)

PK blood samples for estimation of t1/2 were collected at 0.0 (pre-dose) and 0.5,1,2,2.5,3,3.5,4,4.5,5,6,7,8,10, 12, 16,24 and 30 hours after dosing. Point estimates and corresponding 90% confidence interval was constructed for the ratio of the geometric mean of the test treatment (fed condition) to the geometric mean of the reference treatment (fasting condition). (NCT01561976)
Timeframe: 0.0 (pre-dose) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24 and 30 hours after dosing

InterventionHour (Median)
METLEAD ForteSR-Fasting4.281
METLEAD ForteSR-Fed4.155
METLEAD G2 Forte4.199

[back to top]

Time of Occurrence of Cmax (Tmax)

PK blood samples for estimation of Tmax were collected at 0.0 (pre-dose) and 0.5,1,2,2.5,3,3.5,4,4.5,5,6,7,8,10, 12, 16,24 and 30 hours after dosing. Point estimates and corresponding 90% confidence interval was constructed for the ratio of the geometric mean of the test treatment (fed condition) to the geometric mean of the reference treatment (fasting condition). (NCT01561976)
Timeframe: 0.0 (pre-dose) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24 and 30 hours after dosing

InterventionHour (Median)
METLEAD ForteSR-Fasting8.00
METLEAD ForteSR-Fed8.00
METLEAD G2 Forte8.00

[back to top]

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect, medically significant or possible drug-induced liver injury. (NCT01561976)
Timeframe: Up to approximately 24 days (during treatment and washout) after initiation of study

,,
InterventionParticipants (Count of Participants)
Any AEsAny SAEs
METLEAD ForteSR-Fasting00
METLEAD ForteSR-Fed10
METLEAD G2 Forte20

[back to top]

Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone

This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0. (NCT01590771)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-26.3
Placebo-9.3

[back to top]

Number of Participants Who Experienced an Adverse Event

An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions. (NCT01590771)
Timeframe: Up to 26 weeks

InterventionParticipants (Number)
Sitagliptin106
Placebo98

[back to top]

Number of Participants Who Discontinued Study Drug Due to an Adverse Event

An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions. (NCT01590771)
Timeframe: Up to 24 weeks

InterventionParticipants (Number)
Sitagliptin3
Placebo7

[back to top]

Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin

This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0. (NCT01590771)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-22.2
Placebo-5.7

[back to top]

Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and a Sulfonylurea in Combination With Metformin

This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0. (NCT01590771)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-33.4
Placebo-6.2

[back to top]

Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin

This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0. (NCT01590771)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-24.4
Placebo-7.7

[back to top]

Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone

A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0. (NCT01590771)
Timeframe: Baseline and Week 24

InterventionPercent of glycosylated hemoglobin (A1C) (Least Squares Mean)
Sitagliptin-0.85
Placebo-0.05

[back to top]

Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin

A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0. (NCT01590771)
Timeframe: Baseline and Week 24

InterventionPercent of glycosylated hemoglobin (A1C) (Least Squares Mean)
Sitagliptin-0.88
Placebo-0.27

[back to top]

Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin

A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0. (NCT01590771)
Timeframe: Baseline and Week 24

InterventionPercent of glycosylated hemoglobin (A1C) (Least Squares Mean)
Sitagliptin-0.86
Placebo-0.45

[back to top]

Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone

This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0. (NCT01590771)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-49.5
Placebo-11.9

[back to top]

Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin

This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0. (NCT01590771)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-40.7
Placebo-7.7

[back to top]

Rate of Recovery From Hypoglycemia to Euglycemia

The rate of recovery is the difference in concentration between blood glucose at euglycemia and at the end of the hypoglycemic clamp, divided by the recovery time. (NCT01614769)
Timeframe: From 1 to 180 minutes post hypoglycemic clamp

Interventionmg/dL/minute (Least Squares Mean)
Placebo0.32
Glimepiride 2 mg0.22
Glimepiride 4 mg0.19

[back to top]

Incremental Weighted Average Blood Glucose Concentration Over 3 Hours of Hypoglycemic Recovery

The incremental weighted average qualitatively assesses overall hypoglycemic recovery by measuring mean glycemia over the 3 hour recovery period. Blood glucose measured at the release of the hypoglycemic clamp, considered the baseline value, was subtracted from blood glucose values measured over the ensuing 3 hours of hypoglycemic recovery. These differences from baseline were averaged to calculate the incremental weighted average blood glucose concentration. (NCT01614769)
Timeframe: From 1 to 180 minutes post hypoglycemic clamp

Interventionmg/dL (Least Squares Mean)
Placebo22.61
Glimepiride 2 mg17.58
Glimepiride 4 mg15.34

[back to top]

Recovery Time From Hypoglycemia to Euglycemia

Immediately after release of the hypoglycemic clamp, which maintained blood glucose close to 50 mg/dL, the time taken until glucose reached euglycemia, defined as 3 consecutive measurements >= 70 mg/dL, is called the recovery time. (NCT01614769)
Timeframe: From 1 to 180 minutes post hypoglycemic clamp

InterventionMinutes (Least Squares Mean)
Placebo74.49
Glimepiride 2 mg88.90
Glimepiride 4 mg109.81

[back to top]

Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks

Change from baseline in mean daily blood glucose (BG) values were measured with a 7-point SMBG profile. Participants recorded their 7-point SMBG profiles on 2 separate, non-consecutive days during the 2-week period immediately before randomization, Week 8, Week 16, and Week 26 (or the Early Discontinuation Visit). The 7-point SMBG profile consisted of pre-prandial BG measures before the morning (fasting), midday, and evening meals; BG measures 2 hours after the start (post-prandial) of the morning, midday, and evening meals; and BG measures at bedtime. Mean at 26 weeks was assessed in all treatment groups. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect. (NCT01644500)
Timeframe: Baseline, 26 Weeks

,,
Interventionmmol/L (Least Squares Mean)
Morning (fasting)Morning (2 hours post-prandial) mealMidday (pre-prandial) mealMidday (2 hours post-prandial) mealEvening (pre-prandial) mealEvening (2 hours post-prandial) mealBedtime
0.75 mg Dulaglutide-1.91-3.75-2.43-3.40-1.77-2.80-2.69
1.5 mg Dulaglutide-2.47-4.56-3.09-4.15-2.36-3.63-3.22
Glimepiride-1.80-3.20-2.37-2.58-1.69-2.35-2.03

[back to top]

Change From Baseline in Electrocardiogram (ECG) Parameters, Fridericia Corrected QT (QTcF) Interval and P-R Wave (PR) Interval at 26 Weeks

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex. (NCT01644500)
Timeframe: Baseline, 26 Weeks

,,
Interventionmilliseconds (msec) (Mean)
QT intervalPR interval
0.75 mg Dulaglutide-2.063.29
1.5 mg Dulaglutide-6.183.73
Glimepiride1.21-0.23

[back to top]

Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks

Change from baseline in HOMA2-%S was assessed by using the HOMA to quantify insulin sensitivity. HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means were calculated using an ANCOVA model with country, baseline, pre-treatment, and treatment as fixed effects. (NCT01644500)
Timeframe: Baseline, up to 26 Weeks

,,
Interventionpercentage of HOMA2-%S (Least Squares Mean)
Insulin-Based HOMA2-%SC-Peptide-Based HOMA2-%S
0.75 mg Dulaglutide-10.33-11.84
1.5 mg Dulaglutide-6.85-6.44
Glimepiride-7.19-5.05

[back to top]

Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β) - Cell Function (HOMA2-%B) at 26 Weeks

Change from baseline in HOMA2-%B was assessed by using the homeostasis model assessment (HOMA) to quantify β-cell function. HOMA2-%B is a computer model that uses FBG, insulin, and C-peptide concentrations to estimate steady state β-cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means were calculated using an analysis of covariance (ANCOVA) model with country, baseline, pre-treatment, and treatment as fixed effects. (NCT01644500)
Timeframe: Baseline, up to 26 Weeks

,,
Interventionpercentage of HOMA2-%B (Least Squares Mean)
Insulin-based HOMA-2%BC-peptide HOMA-2%B
0.75 mg Dulaglutide37.9234.57
1.5 mg Dulaglutide47.4041.02
Glimepiride30.0024.58

[back to top]

Change From Baseline in Pancreatic Enzymes at 26 Weeks

Amylase (total and pancreas-derived) and lipase concentrations were measured. (NCT01644500)
Timeframe: Baseline, 26 Weeks

,,
Interventionunits per liter (u/L) (Mean)
Total amylasePancreas-derived amylaseLipase
0.75 mg Dulaglutide7.044.929.28
1.5 mg Dulaglutide9.296.1910.62
Glimepiride3.792.642.38

[back to top]

Change From Baseline in Sitting Blood Pressure at 26 Weeks

Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline blood pressure as covariate; and participant as a random effect. (NCT01644500)
Timeframe: Baseline, 26 Weeks

,,
Interventionmillimeters of mercury (mmHg) (Least Squares Mean)
SBPDBP
0.75 mg Dulaglutide-1.88-0.11
1.5 mg Dulaglutide-2.07-0.10
Glimepiride-0.660.15

[back to top]

Change From Baseline in Serum Calcitonin at 26 Weeks

(NCT01644500)
Timeframe: Baseline, 26 Weeks

Interventionpicomoles per liter (pmol/L) (Mean)
1.5 mg Dulaglutide-0.01
0.75 mg Dulaglutide-0.02
Glimepiride0.02

[back to top]

Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks

Percentages of participants who achieved HbA1c levels of <7% or ≤6.5% were analyzed using a logistic regression model, controlling for treatment, pre-treatment, baseline HbA1c and country. (NCT01644500)
Timeframe: 26 Weeks

,,
Interventionpercentage of participants (Number)
HbA1c ≤6.5%HbA1c <7.0%
0.75 mg Dulaglutide47.763.6
1.5 mg Dulaglutide59.474.1
Glimepiride41.357.4

[back to top]

Change From Baseline in Body Mass Index (BMI) at 26 Weeks

BMI is an estimate of body fat based on body weight divided by height squared. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect. (NCT01644500)
Timeframe: Baseline, 26 Weeks

Interventionkilograms per meter squared (kg/m^2) (Least Squares Mean)
1.5 mg Dulaglutide-0.55
0.75 mg Dulaglutide-0.29
Glimepiride0.32

[back to top]

Change From Baseline in Body Weight at 26 Weeks

LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect. (NCT01644500)
Timeframe: Baseline, 26 Weeks

Interventionkilogram (kg) (Least Squares Mean)
1.5 mg Dulaglutide-1.46
0.75 mg Dulaglutide-0.77
Glimepiride0.89

[back to top]

Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks

FBG is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. FBG was measured by a central laboratory. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline FBG as covariate; and participant as a random effect. (NCT01644500)
Timeframe: Baseline, 26 Weeks

Interventionmillimoles per liter (mmol/L) (Least Squares Mean)
1.5 mg Dulaglutide-2.71
0.75 mg Dulaglutide-2.26
Glimepiride-1.89

[back to top]

Change From Baseline in HbA1c at 26 Weeks

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline HbA1c as covariate; and participant as a random effect. (NCT01644500)
Timeframe: Baseline, 26 Weeks

Interventionpercentage of HbA1c (Least Squares Mean)
1.5 mg Dulaglutide-1.48
0.75 mg Dulaglutide-1.22
Glimepiride-0.92

[back to top]

Change From Baseline in Heart Rate From ECG at 26 Weeks

(NCT01644500)
Timeframe: Baseline, 26 Weeks

Interventionbpm (Mean)
1.5 mg Dulaglutide3.99
0.75 mg Dulaglutide1.90
Glimepiride0.44

[back to top]

Change From Baseline in Sitting Pulse Rate at 26 Weeks

LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline pulse rate as covariate; and participant as a random effect. (NCT01644500)
Timeframe: Baseline, 26 Weeks

Interventionbeats per minute (bpm) (Least Squares Mean)
1.5 mg Dulaglutide3.07
0.75 mg Dulaglutide1.24
Glimepiride-0.34

[back to top]

Number of Participants With Adjudicated Cardiovascular Events

Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs that were adjudicated included myocardial infarction; hospitalization for unstable angina; hospitalization for heart failure; coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention); and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious AEs regardless of causality, is located in the Reported Adverse Events module. (NCT01644500)
Timeframe: Baseline through 26 Weeks

Interventionnumber of participants (Number)
1.5 mg Dulaglutide0
0.75 mg Dulaglutide1
Glimepiride0

[back to top]

European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score Responses at 26 Weeks

The EQ-5D questionnaire is a widely used, generic questionnaire that assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 5 response categories is summarized for each of the 5 dimensions. (NCT01644500)
Timeframe: Week 26

,,
Interventionparticipants (Number)
Mobility - no problemMobility - some problemMobility - extreme problemMobility - ambiguousMobility - missingSelf-care - no problemSelf-care - some problemSelf-care - extreme problemSelf-care - ambiguousSelf-care - missingUsual activities - no problemsUsual activities - some problemsUsual activities - extreme problemsUsual activities - ambiguousUsual activities - missingPain/Discomfort - no problemsPain/Discomfort - some problemsPain/Discomfort - extreme problemsPain/Discomfort - ambiguousPain/Discomfort - missingAnxiety/Depression - no problemsAnxiety/Depression - some problemsAnxiety/Depression - extreme problemsAnxiety/Depression - ambiguousAnxiety/Depression - missing
0.75 mg Dulaglutide218300322010032192003192280032147003
1.5 mg Dulaglutide2174001221000122100011982300120813001
Glimepiride2246001228200122820012002900121317001

[back to top]

Number of Participants With Adjudicated Pancreatitis

The number of adjudicated (by an independent committee of expert physicians) pancreatic events is summarized at 26 weeks. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module. (NCT01644500)
Timeframe: Baseline through 26 Weeks

Interventionparticipants (Number)
1.5 mg Dulaglutide7
0.75 mg Dulaglutide5
Glimepiride1

[back to top]

Number of Participants With Self-Reported Hypoglycemic Episodes

The overall number of participants with self-reported hypoglycemic episodes is presented. (NCT01644500)
Timeframe: Baseline through 26 Weeks

Interventionparticipants (Number)
1.5 mg Dulaglutide14
0.75 mg Dulaglutide9
Glimepiride38

[back to top]

Rate of Hypoglycemic Episodes

Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented BG concentrations of ≤70 milligrams per deciliter (mg/dL) (≤3.9 mmol/L). A severe hypoglycemic episode was defined as any hypoglycemic event for which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Log mean rates of total hypoglycemia (per 30 days per participant) are presented and were calculated from negative binomial regression model. The model included country/region, prior medication group, treatment, visit, and treatment-by-visit interaction. The logarithm of days between visits was adjusted as an offset to account for possible unequal duration between visits and between participants. (NCT01644500)
Timeframe: Baseline through 26 Weeks

,,
Interventionepisodes/participant/30 days (Mean)
All Hypoglycemic EpisodesSevere Hypoglycemic EpisodesNocturnal Hypoglycemic Episodes
0.75 mg Dulaglutide0.01NA0.00
1.5 mg Dulaglutide0.01NA0.00
Glimepiride0.09NA0.01

[back to top]

Percentage of Participants Developing Antibodies to Dulaglutide

Dulaglutide anti-drug antibodies (ADA) were assessed at baseline and 26 weeks. A participant was considered to have treatment-emergent dulaglutide ADA if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. (NCT01644500)
Timeframe: Baseline through 26 Weeks

Interventionpercentage of participants (Number)
1.5 mg Dulaglutide17
0.75 mg Dulaglutide8
Glimepiride4

[back to top]

Visual Analog Scale (VAS) Score at 26 Weeks

The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life and consists of a 100-milliliter (mm) visual analog scale (VAS) on which the participant rated their perceived health state on that day from 0-mm (worst imaginable health state) to 100-mm (best imaginable health state). (NCT01644500)
Timeframe: Week 26

Interventionunits on a scale (Mean)
1.5 mg Dulaglutide85.72
0.75 mg Dulaglutide86.17
Glimepiride85.96

[back to top]

Number of Participants Who Experienced at Least One Adverse Event (AE)

Excludes data after rescue therapy. Adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. (NCT01678820)
Timeframe: Up to 16 weeks for non-serious AEs, up to 18 weeks for serious AEs

InterventionParticipants (Number)
Sitagliptin/Simvastatin FDC13
Sitagliptin13
Simvastatin17

[back to top]

Number of Participants Who Discontinued Study Drug Due to an Adverse Event

Excludes data after rescue therapy. Adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. (NCT01678820)
Timeframe: Up to 16 weeks

InterventionParticipants (Number)
Sitagliptin/Simvastatin FDC2
Sitagliptin1
Simvastatin2

[back to top]

Change From Baseline in Hemoglobin A1C (A1C) at Week 16 (Sitagliptin/Simvastatin FDC vs. Sitagliptin)

A1C is measured as percent. Thus, this change from baseline reflects the Week 16 A1C percent minus the Week 0 A1C percent. This primary outcome measure only includes results for sitagliptin/simvastatin FDC vs. sitagliptin. Results for simvastatin are presented below under secondary outcome measures. (NCT01678820)
Timeframe: Baseline and Week 16

InterventionPercent (Least Squares Mean)
Sitagliptin/Simvastatin FDC-0.41
Sitagliptin-0.59

[back to top]

Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01678820)
Timeframe: Baseline and Week 16

InterventionPercent change (Least Squares Mean)
Sitagliptin/Simvastatin FDC2.5
Sitagliptin2.0
Simvastatin2.1

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16

Change from baseline reflects the Week 16 value minus the Week 0 value. (NCT01678820)
Timeframe: Baseline and Week 16

Interventionmg/dL (Least Squares Mean)
Sitagliptin/Simvastatin FDC-7.9
Sitagliptin-9.6
Simvastatin21.3

[back to top]

Change From Baseline in A1C at Week 16 (Sitagliptin/Simvastatin FDC vs. Simvastatin)

A1C is measured as percent. Thus, this change from baseline reflects the Week 16 A1C percent minus the Week 0 A1C percent. This primary outcome measure only includes results for sitagliptin/simvastatin FDC vs. simvastatin. Results for sitagliptin are presented above under primary outcome measures. (NCT01678820)
Timeframe: Baseline and Week 16

InterventionPercent (Least Squares Mean)
Sitagliptin/Simvastatin FDC-0.41
Simvastatin0.21

[back to top]

Percentage of Participants With A1C Level <7% at Week 16

Percentage of participants achieving glycemic goal (A1C <7%) after 16 weeks of treatment. Data as observed. (NCT01678820)
Timeframe: Week 16

InterventionPercentage of participants (Number)
Sitagliptin/Simvastatin FDC29.9
Sitagliptin29.6
Simvastatin17.6

[back to top]

Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01678820)
Timeframe: Baseline and Week 16

InterventionPercent change (Least Squares Mean)
Sitagliptin/Simvastatin FDC-17.5
Sitagliptin12.9
Simvastatin-2.2

[back to top]

Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01678820)
Timeframe: Baseline and Week 16

InterventionPercent change (Least Squares Mean)
Sitagliptin/Simvastatin FDC-23.9
Sitagliptin0.6
Simvastatin-24.2

[back to top]

Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01678820)
Timeframe: Baseline and Week 16

InterventionPercent change (Least Squares Mean)
Sitagliptin/Simvastatin FDC-21.6
Sitagliptin4.0
Simvastatin-26.9

[back to top]

Percent Change From Baseline in Triglycerides (TG) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01678820)
Timeframe: Baseline and Week 16

InterventionPercent change (Mean)
Sitagliptin/Simvastatin FDC-20.4
Sitagliptin-4.9
Simvastatin-10.1

[back to top]

Percent Change From Baseline in Total Cholesterol (TC) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01678820)
Timeframe: Baseline and Week 16

InterventionPercent change (Least Squares Mean)
Sitagliptin/Simvastatin FDC-18.4
Sitagliptin-0.4
Simvastatin-18.4

[back to top]

Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16

Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%. (NCT01678820)
Timeframe: Baseline and Week 16

InterventionPercent change (Least Squares Mean)
Sitagliptin/Simvastatin FDC-16.9
Sitagliptin3.3
Simvastatin-19.8

[back to top]

Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54

The percentage of participants who achieved A1C values <7.0% (53 mmol/mol) in the FAS Population at Week 54. (NCT01682759)
Timeframe: Week 54

InterventionPercentage of participants (Number)
Omarigliptin47.7
Glimepiride58.0

[back to top]

Percentage of Participants Achieving a Hemoglobin A1C of <6.5% at Week 54

The percentage of participants who achieved A1C values <6.5% (48 mmol/mol) in the FAS Population at Week 54. (NCT01682759)
Timeframe: Week 54

InterventionPercentage of participants (Number)
Omarigliptin25.1
Glimepiride28.8

[back to top]

Change From Baseline in Hemoglobin A1C at Week 54

Hemoglobin A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Thus, this change from baseline reflects the Week 54 A1C minus the Week 0 A1C. (NCT01682759)
Timeframe: Baseline and Week 54

InterventionA1C (%) (Least Squares Mean)
Omarigliptin-0.30
Glimepiride-0.48

[back to top]

Change From Baseline in Fasting Plasma Glucose at Week 54

Blood glucose was measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 54 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 54 minus FPG at baseline). (NCT01682759)
Timeframe: Baseline and Week 54

Interventionmg/dL (Least Squares Mean)
Omarigliptin-2.7
Glimepiride-8.3

[back to top]

Change From Baseline in Body Weight at Week 54 Excluding Data After Gylcemic Rescue

(NCT01682759)
Timeframe: Baseline and Week 54

Interventionkg (Least Squares Mean)
Omarigliptin-0.4
Glimepiride1.5

[back to top]

Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. (NCT01682759)
Timeframe: Up to Week 57

InterventionPercentage of participants (Number)
Omarigliptin54.7
Glimepiride61.6

[back to top]

Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Excluding Data After Glycemic Rescue

Symptomatic episode of hypoglycemia was an episode with clinical symptoms reported by the investigator as hypoglycemia (concurrent fingerstick glucose not required). (NCT01682759)
Timeframe: Up to Week 54

InterventionPercentage of participants (Number)
Omarigliptin5.3
Glimepiride26.7

[back to top]

Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue

(NCT01682759)
Timeframe: Up to Week 54

InterventionPercentage of participants (Number)
Omarigliptin3.7
Glimepiride2.7

[back to top]

Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28

Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm

Interventionpercentage (Geometric Mean)
Linagliptin 5 mg0.885
Glimepiride 1-4 mg1.002
Placebo1.002

[back to top]

Number of Patients With Adverse Events

Number of patients with any adverse events (NCT01703286)
Timeframe: up to 20 weeks

Interventionparticipants (Number)
Linagliptin 5 mg11
Glimepiride 1-4 mg25
Placebo14
REP - Linagliptin 5 mg4
REP - Glimepiride 1-4 mg7
Rep - Placebo7

[back to top]

Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28

Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm

Interventionpercentage (Mean)
Linagliptin 5 mg1.003
Glimepiride 1-4 mg1.053
Placebo0.981

[back to top]

Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28

Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm

InterventionPercentage (Geometric Mean)
Linagliptin 5 mg1.262
Glimepiride 1-4 mg1.045
Placebo1.009

[back to top]

Change From Baseline in Hemoglobin A1c (A1C) at Week 24

A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Thus, this change from baseline reflects the Week 24 A1C minus the Week 0 A1C. (NCT01704261)
Timeframe: Baseline and Week 24

Intervention%A1C (Least Squares Mean)
Omarigliptin-0.67
Placebo-0.06

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Blood glucose was measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 24 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 24 minus FPG at baseline). (NCT01704261)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Omarigliptin-19.6
Placebo-3.0

[back to top]

Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% at Week 24

The percentage of participants who achieved A1C values <6.5% (48 mmol/mol) or <7.0% (53 mmol/mol) in the FAS population at Week 24. (NCT01704261)
Timeframe: 24 weeks

,
InterventionPercentage of participants (Number)
<7.0%<6.5%
Omarigliptin23.810.1
Placebo4.42.1

[back to top]

Percentage of Participants Who Experienced at Least One Adverse Event (AE)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. (NCT01704261)
Timeframe: Up to Week 27

InterventionPercentage of participants (Number)
Omarigliptin57.5
Placebo47.7

[back to top]

Percentage of Participants Who Discontinued From the Study Due to an AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. (NCT01704261)
Timeframe: Up to Week 24

InterventionPercentage of participants (Number)
Omarigliptin2.6
Placebo2.6

[back to top]

Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)

HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20) and Week 44

InterventionPercent (Least Squares Mean)
Phase 2: Metformin + Sitagliptin + Glimepiride-0.65
Phase 2: Metformin + Sitagliptin + Repaglinide-0.62
Phase 2: Metformin + Sitagliptin + Acarbose-0.46
Phase 2: Metformin + Sitagliptin + Gliclazide-0.69

[back to top]

Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)

Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20), Week 44

Interventionkg (Mean)
Phase 2: Metformin + Sitagliptin + Glimepiride0.4
Phase 2: Metformin + Sitagliptin + Repaglinide0.2
Phase 2: Metformin + Sitagliptin + Acarbose-0.9
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

[back to top]

Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)

"The percentage of participants with a GI AE of nausea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

[back to top]

Percentage of Participants With Hypoglycemia Events (Phase 2)

Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported. (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride8.9
Phase 2: Metformin + Sitagliptin + Repaglinide6.1
Phase 2: Metformin + Sitagliptin + Acarbose0.5
Phase 2: Metformin + Sitagliptin + Gliclazide3.6

[back to top]

Percentage of Participants With a GI AE of Diarrhea (Phase 2)

"The percentage of participants with a GI AE of diarrhea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0.5
Phase 2: Metformin + Sitagliptin + Repaglinide0.4
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.9

[back to top]

Percentage of Participants With a GI AE of Vomiting (Phase 2)

"The percentage of participants with a GI AE of vomiting was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0.2
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.2
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

[back to top]

Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)

"The percentage of participants with a GI AE of abdominal pain was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Phase A, FAS Population)

"Blood glucose was measured on a fasting basis (collected after an 10-hour fast). FPG is expressed as mg/dL. This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.~Because it was discovered that in another omarigliptin study (MK-3102-028, NCT01814748) subjects had taken metformin (prohibited per protocol, and taken without investigator knowledge), after unblinding of Phase A of this study, an analysis of metformin levels was performed on stored Week 18 blood samples. Of the subjects not rescued with metformin prior to Week 18, 10% in the omarigliptin group and 20% in the placebo group had levels showing that they were taking metformin (prohibited per protocol). The use of prohibited metformin disproportionately by the placebo group may have resulted in a smaller than expected treatment effect for efficacy outcome measures (see post-hoc analysis)." (NCT01717313)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Omarigliptin-12.8
Placebo to Omarigliptin-2.5

[back to top]

Change From Baseline in A1C at Week 54 (Phase A + Phase B, FAS Population)

"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Thus, this change from baseline reflects the Week 54 A1C minus the Week 0 A1C.~The results of the study at Week 54 may have been confounded by use of prohibited metformin (see results above for description of the use of prohibited metformin)." (NCT01717313)
Timeframe: Baseline and Week 54

InterventionPercent (Least Squares Mean)
Omarigliptin-0.40
Placebo to Omarigliptin-0.80

[back to top]

Change From Baseline in A1C at Week 24 (Phase A, Per-Protocol Population)

"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Thus, this change from baseline reflects the Week 24 A1C minus the Week 0 A1C.~A post-hoc sensitivity analysis was performed that excluded participants in both treatment groups who were found to have used prohibited metformin (see results above for a description of the use of prohibited metformin)." (NCT01717313)
Timeframe: Baseline and Week 24

InterventionPercent (Least Squares Mean)
Omarigliptin-0.54
Placebo to Omarigliptin-0.00

[back to top]

Percentage of Participants Who Experienced at Least One Adverse Event in Phase A (Excluding Data After Glycemic Rescue, Safety Population)

"An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of preexisting conditions.~This analysis may have been confounded by use of prohibited metformin (see results above for description of the use of prohibited metformin)." (NCT01717313)
Timeframe: Up to 27 weeks

InterventionPercentage of participants (Number)
Omarigliptin41.8
Placebo to Omarigliptin50.0

[back to top]

Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event in Phase A (Excluding Data After Glycemic Rescue, Safety Population)

"An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of preexisting conditions.~This analysis may have been confounded by use of prohibited metformin (see results above for description of the use of prohibited metformin)." (NCT01717313)
Timeframe: Up to 24 weeks

InterventionPercentage of participants (Number)
Omarigliptin2.4
Placebo to Omarigliptin1.8

[back to top]

Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population)

"An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of preexisting conditions.~This analysis may have been confounded by use of prohibited metformin (see results above for description of the use of prohibited metformin)." (NCT01717313)
Timeframe: Up to 57 weeks

InterventionPercentage of participants (Number)
Omarigliptin3.0
Placebo to Omarigliptin2.4

[back to top]

Percentage of Participants Who Experienced at Least One Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population)

"An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of preexisting conditions.~This analysis may have been confounded by use of prohibited metformin (see results above for description of the use of prohibited metformin)." (NCT01717313)
Timeframe: Up to 57 weeks

InterventionPercentage of participants (Number)
Omarigliptin54.5
Placebo to Omarigliptin60.4

[back to top]

Change From Baseline in 2-hour Post Meal Glucose (PMG) at Week 24 (Phase A, FAS Population)

"Blood glucose was measured 2 hours after a meal (2-hour PMG). 2-hour PMG is expressed as mg/dL. This change from baseline in 2-hour PMG reflects the Week 24 2-hour PMG minus the Week 0 2-hour PMG.~Because it was discovered that in another omarigliptin study (MK-3102-028, NCT01814748) subjects had taken metformin (prohibited per protocol, and taken without investigator knowledge), after unblinding of Phase A of this study, an analysis of metformin levels was performed on stored Week 18 blood samples. Of the subjects not rescued with metformin prior to Week 18, 10% in the omarigliptin group and 20% in the placebo group had levels showing that they were taking metformin (prohibited per protocol). The use of prohibited metformin disproportionately by the placebo group may have resulted in a smaller than expected treatment effect for efficacy outcome measures (see post-hoc analysis)." (NCT01717313)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Omarigliptin-25.6
Placebo to Omarigliptin-13.9

[back to top]

Change From Baseline in 2-hour PMG at Week 24 (Phase A, Per-Protocol Population)

"Blood glucose was measured 2 hours after a meal (2-hour PMG). 2-hour PMG is expressed as mg/dL. This change from baseline in 2-hour PMG reflects the Week 24 2-hour PMG minus the Week 0 2-hour PMG.~A post-hoc sensitivity analysis was performed that excluded participants in both treatment groups who were found to have used prohibited metformin (see results above for a description of the use of prohibited metformin)." (NCT01717313)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Omarigliptin-40.1
Placebo to Omarigliptin-19.6

[back to top]

Change From Baseline in FPG at Week 24 (Phase A, Per-Protocol Population)

"Blood glucose was measured on a fasting basis (collected after an 10-hour fast). FPG is expressed as mg/dL. This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.~A post-hoc sensitivity analysis was performed that excluded participants in both treatment groups who were found to have used prohibited metformin (see results above for a description of the use of prohibited metformin)." (NCT01717313)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Omarigliptin-15.5
Placebo to Omarigliptin-2.2

[back to top]

Change From Baseline in FPG at Week 54 (Phase A + Phase B, FAS Population)

"Blood glucose was measured on a fasting basis (collected after an 10-hour fast). FPG is expressed as mg/dL. This change from baseline reflects the FPG level at Week 54 minus the FPG level at Week 0.~The results of the study at Week 54 may have been confounded by use of prohibited metformin (see results above for description of the use of prohibited metformin)." (NCT01717313)
Timeframe: Baseline and Week 54

Interventionmg/dL (Least Squares Mean)
Omarigliptin-8.3
Placebo to Omarigliptin-21.1

[back to top]

Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Phase A, FAS Population)

"A1C (%) is used to report average blood glucose levels over prolonged periods of time.~Because it was discovered that in another omarigliptin study (MK-3102-028, NCT01814748) subjects had taken metformin (prohibited per protocol, and taken without investigator knowledge), after unblinding of Phase A of this study, an analysis of metformin levels was performed on stored Week 18 blood samples. Of the subjects not rescued with metformin prior to Week 18, 10% in the omarigliptin group and 20% in the placebo group had levels showing that they were taking metformin (prohibited per protocol). The use of prohibited metformin disproportionately by the placebo group may have resulted in a smaller than expected treatment effect for efficacy outcome measures (see post-hoc analysis)." (NCT01717313)
Timeframe: Baseline and Week 24

InterventionPercent (Least Squares Mean)
Omarigliptin-0.49
Placebo to Omarigliptin-0.10

[back to top]

Percentage of Participants Who Achieve an A1C Goal of <6.5% (48 mmol/Mol) at Week 24 (Phase A, FAS Population)

"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). The percentage of participants who achieved A1C values <6.5% (48 mmol/mol) in the FAS population at Week 24.~Because it was discovered that in another omarigliptin study (MK-3102-028, NCT01814748) subjects had taken metformin (prohibited per protocol, and taken without investigator knowledge), after unblinding of Phase A of this study, an analysis of metformin levels was performed on stored Week 18 blood samples. Of the subjects not rescued with metformin prior to Week 18, 10% in the omarigliptin group and 20% in the placebo group had levels showing that they were taking metformin (prohibited per protocol). The use of prohibited metformin disproportionately by the placebo group may have resulted in a smaller than expected treatment effect for efficacy outcome measures (see post-hoc analysis)." (NCT01717313)
Timeframe: Week 24

InterventionPercentage of participants (Number)
Omarigliptin16.4
Placebo to Omarigliptin5.0

[back to top]

Percentage of Participants Who Achieve an A1C Goal of <6.5% at Week 54 (Phase A + Phase B, FAS Population)

"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). The percentage of participants who achieved A1C values <6.5% (48 mmol/mol) in the FAS population at Week 54.~The results of the study at Week 54 may have been confounded by use of prohibited metformin (see results above for description of the use of prohibited metformin)." (NCT01717313)
Timeframe: Week 54

InterventionPercentage of participants (Number)
Omarigliptin14.5
Placebo to Omarigliptin20.6

[back to top]

Percentage of Participants Who Achieve an A1C Goal of <7% (53 mmol/Mol) at Week 24 (Phase A, FAS Population)

"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). The percentage of participants who achieved A1C values <7.0% (53 mmol/mol) in the FAS population at Week 24.~Because it was discovered that in another omarigliptin study (MK-3102-028, NCT01814748) subjects had taken metformin (prohibited per protocol, and taken without investigator knowledge), after unblinding of Phase A of this study, an analysis of metformin levels was performed on stored Week 18 blood samples. Of the subjects not rescued with metformin prior to Week 18, 10% in the omarigliptin group and 20% in the placebo group had levels showing that they were taking metformin (prohibited per protocol). The use of prohibited metformin disproportionately by the placebo group may have resulted in a smaller than expected treatment effect for efficacy outcome measures (see post-hoc analysis)." (NCT01717313)
Timeframe: Week 24

InterventionPercentage of participants (Number)
Omarigliptin36.5
Placebo to Omarigliptin16.3

[back to top]

Percentage of Participants Who Achieve an A1C Goal of <7% (53 mmol/Mol) at Week 54 (Phase A + Phase B, FAS Population)

"The percentage of participants who achieved A1C values <7.0% (53 mmol/mol) in the FAS population at Week 54.~The results of the study at Week 54 may have been confounded by use of prohibited metformin (see results above for description of the use of prohibited metformin)." (NCT01717313)
Timeframe: Week 54

InterventionPercentage of participants (Number)
Omarigliptin33.8
Placebo to Omarigliptin43.8

[back to top]

Percentage of Participants Attaining A1C Glycemic Goals of <7% After 104 Weeks of Treatment (Phase A+B)

Percentage of participants attaining A1C glycemic goals of <7.0% (53 mmol/mol) after 104 weeks of treatment estimated using standard multiple imputation techniques. (NCT01755156)
Timeframe: 104 weeks

InterventionPercentage of participants (Least Squares Mean)
Omarigliptin (Phase A) → Omarigliptin (Phase B)32.2
Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)39.0

[back to top]

Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 104 (Phase A+B)

Data presented are a cumulative incidence of participants with glycemic rescue by Week 104. (NCT01755156)
Timeframe: Up to 104 weeks

InterventionPercentage of participants (Number)
Omarigliptin (Phase A) → Omarigliptin (Phase B)17.4
Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)13.9

[back to top]

Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A+B)

An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Presented data exclude data after glycemic rescue. (NCT01755156)
Timeframe: Up to 104 weeks

InterventionPercentage of participants (Number)
Omarigliptin (Phase A) → Omarigliptin (Phase B)2.0
Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)4.5

[back to top]

Percentage of Participants Who Experienced an Adverse Event Which Were Included Under the System Order Class of Investigations (Phase A+B)

The following laboratory parameters were included: blood chemistry, hematology, electrocardiograms, lipids, body weight, and vital signs. (NCT01755156)
Timeframe: Up to 104 weeks

InterventionPercentage of participants (Number)
Omarigliptin (Phase A) → Omarigliptin (Phase B)21.9
Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)17.4

[back to top]

Percentage of Participants Who Experienced at Least One Adverse Event (Phase A+B)

An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Presented data exclude data after glycemic rescue. (NCT01755156)
Timeframe: Up to 107 weeks

InterventionPercentage of participants (Number)
Omarigliptin (Phase A) → Omarigliptin (Phase B)65.7
Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)65.2

[back to top]

Change From Baseline in FPG at Week 104 (Phase A+B)

Change from baseline in FPG at Week 104 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment. (NCT01755156)
Timeframe: Baseline and Week 104

Interventionmg/dL (Least Squares Mean)
Omarigliptin (Phase A) → Omarigliptin (Phase B)-7.8
Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)-18.2

[back to top]

Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24 (Phase A)

Change from baseline in 2-hour PMG at Week 24 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment. (NCT01755156)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Omarigliptin (Phase A)-26.8
Placebo to Omarigliptin (Phase A)-12.2

[back to top]

Change From Baseline in A1C at Week 104 (Phase A+B)

A1C is measured as a percent. Change from baseline in A1C at Week 104 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment. (NCT01755156)
Timeframe: Baseline and Week 104

InterventionPercent (Least Squares Mean)
Omarigliptin (Phase A) → Omarigliptin (Phase B)-0.42
Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)-0.51

[back to top]

Change From Baseline in Fasting Insulin at Week 104 (Phase A+B)

Change from baseline in fasting insulin at Week 104 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment. (NCT01755156)
Timeframe: Baseline and Week 104

InterventionμIU/mL (Least Squares Mean)
Omarigliptin (Phase A) → Omarigliptin (Phase B)1.2
Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)1.8

[back to top]

Change From Baseline in Fasting Insulin at Week 24 (Phase A)

Change from baseline in fasting insulin at Week 24 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment. (NCT01755156)
Timeframe: Baseline and Week 24

Interventionmicro International Unit (μIU)/mL (Least Squares Mean)
Omarigliptin (Phase A)1.8
Placebo to Omarigliptin (Phase A)-1.9

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Phase A)

Change from baseline in FPG at Week 24 was analyzed using cLDA method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment. (NCT01755156)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Omarigliptin (Phase A)-10.7
Placebo to Omarigliptin (Phase A)-1.2

[back to top]

Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A)

A1C is measured as a percent. Change from baseline in A1C at Week 24 was analyzed using a constrained longitudinal data analysis (cLDA) method with a restriction of the same baseline mean across treatment groups. The cLDA model included terms for treatment, time, and the interaction of time by treatment. (NCT01755156)
Timeframe: Baseline and Week 24

InterventionPercent (Least Squares Mean)
Omarigliptin (Phase A)-0.54
Placebo to Omarigliptin (Phase A)0.00

[back to top]

Change From Baseline in PMG Total Area Under the Plasma Concentration Time Curve (AUC) at Week 24 (Phase A)

Change from baseline in PMG total AUC at Week 24 based on a cLDA model including terms for treatment, time, and the interaction of time by treatment. Plasma glucose levels were measured before the meal (0 minutes), and at 60 and 120 minutes after the meal. (NCT01755156)
Timeframe: Baseline and Week 24

Interventionmg*h/dL (Least Squares Mean)
Omarigliptin (Phase A)-46.4
Placebo to Omarigliptin (Phase A)-18.6

[back to top]

Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 104 Weeks (Phase A+B)

Participants who did not meet progressively stricter glycemic criteria in Phase A had rescue initiated with open-label glimepiride. If during Phase B participants on open-label glimepiride or blinded glimepiride/glimepiride matching placebo needed rescue after maximum up-titration, then insulin glargine was initiated and the dose of open-label glimepiride or blinded glimepiride/glimepiride-matching placebo was discontinued. (NCT01755156)
Timeframe: Up to 104 weeks

InterventionPercentage of participants (Number)
Omarigliptin (Phase A) → Omarigliptin (Phase B)20.2
Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)16.2

[back to top]

Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 24 Weeks (Phase A)

Participants who did not meet progressively stricter glycemic criteria in Phase A had rescue initiated with open-label glimepiride. (NCT01755156)
Timeframe: Up to 24 weeks

InterventionPercentage of participants (Number)
Omarigliptin (Phase A)8.5
Placebo to Omarigliptin (Phase A)9.7

[back to top]

Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 24 (Phase A)

Data presented are a cumulative incidence of participants with glycemic rescue by Week 24. (NCT01755156)
Timeframe: Up to 24 weeks

InterventionPercentage of participants (Number)
Omarigliptin (Phase A)8.0
Placebo to Omarigliptin (Phase A)9.0

[back to top]

Percentage of Participants Attaining A1C Glycemic Goals of <6.5% After 104 Weeks of Treatment (Phase A+B)

Percentage of participants attaining A1C glycemic goals of <6.5% (48 mmol/mol) after 104 weeks of treatment estimated using standard multiple imputation techniques. (NCT01755156)
Timeframe: 104 weeks

InterventionPercentage of participants (Least Squares Mean)
Omarigliptin (Phase A) → Omarigliptin (Phase B)13.7
Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B)17.9

[back to top]

Percentage of Participants Attaining A1C Glycemic Goals of <6.5% After 24 Weeks of Treatment (Phase A)

Percentage of participants attaining A1C glycemic goals of <6.5% (48 mmol/mol) after 24 weeks of treatment estimated using standard multiple imputation techniques. (NCT01755156)
Timeframe: 24 weeks

InterventionPercentage of participants (Number)
Omarigliptin (Phase A)10.6
Placebo to Omarigliptin (Phase A)6.4

[back to top]

Percentage of Participants Attaining A1C Glycemic Goals of <7.0% After 24 Weeks of Treatment (Phase A)

Percentage of participants attaining A1C glycemic goals of <7.0% (53 mmol/mol) after 24 weeks of treatment estimated using standard multiple imputation techniques. (NCT01755156)
Timeframe: 24 weeks

InterventionPercentage of participants (Number)
Omarigliptin (Phase A)38.0
Placebo to Omarigliptin (Phase A)18.8

[back to top]

Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia

An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. (NCT01769378)
Timeframe: Baseline through 24 Weeks

Interventionweeks (Mean)
Dulaglutide22.59
Placebo22.47

[back to top]

Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia

Additional Intervention: any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. (NCT01769378)
Timeframe: Baseline through 24 Weeks

Interventionpercentage of participants (Number)
Dulaglutide2.1
Placebo11.7

[back to top]

Number of Participants With Adjudicated Acute Pancreatitis Events

The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 24 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01769378)
Timeframe: Baseline through 24 Weeks, 30-day Follow Up

Interventionparticipants (Number)
Dulaglutide0
Placebo0

[back to top]

Dulaglutide Anti-Drug Antibodies (ADA)

Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant is considered to have TE dulaglutide ADA if the participant has at least one titer that is treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. (NCT01769378)
Timeframe: Baseline up to 4 Weeks Post-Last Dose of Study Drug

Interventionparticipants (Number)
Dulaglutide2

[back to top]

Change From Baseline in Mean of All 7-Point Self Monitored Plasma Glucose (SMPG) at 24 Weeks

LS Means of the SMPG change from baseline to primary endpoint at week 24 was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline SMPG value as covariate, via a MMRM analysis using REML. (NCT01769378)
Timeframe: Baseline, 24 Weeks

Interventionmg/dL (Least Squares Mean)
Dulaglutide-37.22
Placebo-8.27

[back to top]

Percentage of Participants Who Achieve HbA1c <7.0% and ≤6.5% at 24 Weeks

The percentage of participants who achieved the target HbA1c values at endpoint will be analyzed with a repeated logistic regression model (the generalized estimation equation [GEE] model). The model includes country, treatment, visit and treatment interaction and baseline HbA1c as a continuous covariate. (NCT01769378)
Timeframe: 24 Weeks

,
Interventionpercentage of participants (Number)
Percent Achieved <7.0 HbA1c LevelPercent Achieved ≤6.5 HbA1c Level
Dulaglutide55.340.0
Placebo18.99.4

[back to top]

Number of Participants With Reported and Adjudicated Cardiovascular Events

Information on cardiovascular (CV) risk factors was collected at baseline. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 24 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module. (NCT01769378)
Timeframe: Baseline through 24 Weeks, 30-day Follow Up

,
Interventionparticipants (Number)
Any reported CV eventsAny adjudicated nonfatal CV eventsAny confirmed adjudicated CV deaths
Dulaglutide220
Placebo000

[back to top]

Change From Baseline in Body Weight at 24 Weeks

LS Means of the body weight change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline body weight as covariate, via a MMRM analysis using REML. (NCT01769378)
Timeframe: Baseline, 24 Weeks

Interventionkilograms (kg) (Least Squares Mean)
Dulaglutide-0.91
Placebo-0.24

[back to top]

Change From Baseline in Calcitonin at 24 Weeks

(NCT01769378)
Timeframe: Baseline, 24 Weeks

Interventionpicogram per milliliter (pg/ml) (Median)
Dulaglutide0.00
Placebo0.00

[back to top]

Change From Baseline in Fasting Serum Glucose (FSG) at 24 Weeks

LS Means of the FSG from baseline to primary endpoint was adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline FSG as covariate, via Analysis of Covariance Model (ANCOVA) with Last Observation Carried Forward (LOCF). (NCT01769378)
Timeframe: Baseline, 24 Weeks

Interventionmilligrams per deciliter (mg/dL) (Least Squares Mean)
Dulaglutide-30.60
Placebo2.93

[back to top]

Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks

Least Squares Means (LS Means) of the HbA1c change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline HbA1c as covariate, via a Mixed-effects model for repeated measures (MMRM) analysis using restricted maximum likelihood (REML). (NCT01769378)
Timeframe: Baseline, 24 Weeks

Interventionpercent change of HbA1c (Least Squares Mean)
Dulaglutide-1.38
Placebo-0.11

[back to top]

Change From Baseline in Lipase

A summary of changes in lipase evaluation from baseline to endpoint. (NCT01769378)
Timeframe: Baseline, 24 Weeks

InterventionUnits/Liter (Median)
Dulaglutide8.0
Placebo4.5

[back to top]

Percentage of Participants With Self-Reported Events of Hypoglycemia

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). Percentage is calculated as the number of participants reporting HE each visit/ the total number of participants reporting HE during the entire study treatment period. (NCT01769378)
Timeframe: Baseline through 24 Weeks

,
Interventionpercentage of participants (Number)
SymptomaticAsymptomaticProbableSevereNocturnal
Dulaglutide11.313.42.506.7
Placebo1.71.70.001.7

[back to top]

Rate of HE Adjusted Per 30 Days

The hypoglycemia rate per 30 days during defined period is calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period*30 days. (NCT01769378)
Timeframe: Baseline through 24 weeks

,
Interventionnumber of events/participants/30 days (Mean)
Total HEDocumented symptomatic HEAsymptomatic HESevere HENocturnal HEProbable symptomatic HE
Dulaglutide0.190.070.1100.020.01
Placebo0.010.000.0000.000

[back to top]

Change From Baseline in Amylase

A summary of changes in amylase evaluation from baseline to endpoint. (NCT01769378)
Timeframe: Baseline, 24 Weeks

InterventionUnits/Liter (Median)
Dulaglutide8.0
Placebo2.0

[back to top]

Change From Baseline in Body Mass Index (BMI) at 24 Weeks

LS Means of the BMI change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline BMI as covariate, via a MMRM analysis using REML. (NCT01769378)
Timeframe: Baseline, 24 Weeks

Interventionkilograms per/square meter kg/m^2 (Least Squares Mean)
Dulaglutide-0.32
Placebo-0.10

[back to top]

Percentage of Participants Achieving an A1C Goal <7.0% After 24 Weeks of Treatment

Participant whole blood samples were collected at Week 24 to determine the number of participants achieving A1C <7.0% at Week 24. (NCT01841697)
Timeframe: Week 24

InterventionPercentage of participants (Number)
Omarigliptin 25 mg Once Weekly50.9
Sitagliptin 100 mg Once Daily49.1

[back to top]

Change From Baseline in A1C at Week 24

A1C is a measure of the percentage of glycated hemoglobin in the blood. Participant whole blood samples were collected at baseline and Week 24 to determine the least squares mean A1C change from baseline. (NCT01841697)
Timeframe: Baseline and Week 24

InterventionPercent (Least Squares Mean)
Omarigliptin 25 mg Once Weekly-0.47
Sitagliptin 100 mg Once Daily-0.43

[back to top]

Change From Baseline in FPG at Week 24

Participant whole blood samples were collected after an overnight fast at baseline and Week 24 to determine the least squares mean change from baseline in participant FPG. (NCT01841697)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Omarigliptin 25 mg Once Weekly-13.7
Sitagliptin 100 mg Once Daily-9.5

[back to top]

Percentage of Participants Achieving an A1C Goal <6.5% After 24 Weeks of Treatment

Participant whole blood samples were collected at Week 24 to determine the percentage of participants achieving A1C <6.5% at Week 24. (NCT01841697)
Timeframe: Week 24

InterventionPercentage of participants (Number)
Omarigliptin 25 mg Once Weekly27.0
Sitagliptin 100 mg Once Daily22.8

[back to top]

Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event

An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after initiation of glycemic rescue therapy. (NCT01841697)
Timeframe: Up to 24 weeks

InterventionPercentage of participants (Number)
Omarigliptin 25 mg Once Weekly0.9
Sitagliptin 100 mg Once Daily2.2

[back to top]

Percentage of Participants Who Experienced at Least One Adverse Event

An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after initiation of glycemic rescue therapy. (NCT01841697)
Timeframe: Up to 27 weeks (including 3-week follow-up)

InterventionPercentage of participants (Number)
Omarigliptin 25 mg Once Weekly36.3
Sitagliptin 100 mg Once Daily40.6

[back to top]

Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event

An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions. (NCT01863667)
Timeframe: Up to 54 weeks

InterventionPercentage of participants (Number)
Omarigliptin3
Glimepiride0

[back to top]

Percentage of Participants Who Experienced at Least One Adverse Event

An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions. (NCT01863667)
Timeframe: Up to 57 weeks (including 3 weeks following the last dose of study drug)

InterventionPercentage of participants (Number)
Omarigliptin9.1
Glimepiride15.6

[back to top]

Changes From Baseline in 31P Measurement: Adenosine Diphosphate (ADP) Time Constant

Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
Interventionseconds (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo24.521.2
Sitagliptin Plus Placebo28.019.4

[back to top]

Changes From Baseline in 31P Measurement: Adenosine Triphosphate (ATP) Peaks

Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
InterventionmM (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo7.938.02
Sitagliptin Plus Placebo8.1912.66

[back to top]

Changes From Baseline in 31P Measurement: Free Pi Time Constant

Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment. Data are represented as the change in Pi through the scan. (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
Interventionseconds (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo28.5426.15
Sitagliptin Plus Placebo29.7327.94

[back to top]

Changes From Baseline in 31P Measurement: pH

Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
InterventionpH (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo6.886.89
Sitagliptin Plus Placebo6.886.85

[back to top]

Changes From Baseline in 31P Measurement: Phosphocreatine Time Constant

Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
Interventionseconds (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo30.929.6
Sitagliptin Plus Placebo34.126.6

[back to top]

Changes From Baseline in Echocardiographic Measures (Stroke Volume)

Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
InterventionmL/beat (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo72.777.8
Sitagliptin Plus Placebo58.264.6

[back to top]

Peak Oxygen Consumption (VO2peak).

Subjects' peak oxygen consumption will be tested on a stationary bike before and after 3 months of study medication. (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
Interventionml/min (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo19531881
Sitagliptin Plus Placebo18931849

[back to top]

Change in Oxygen Uptake Kinetics (VO2 Kinetics)

Oxygen uptake kinetics will be tested on a stationary bike before and after 3 months of study medication. VO2 kinetics is reported as the time constant associated with the change in oxygen update from rest to steady state. (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
Interventionseconds (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo54.254.6
Sitagliptin Plus Placebo56.267.5

[back to top]

Change From Baseline in Body Weight at Week 26

The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy. (NCT01958671)
Timeframe: Baseline and Week 26

InterventionKilograms (Least Squares Mean)
Ertugliflozin 5 mg-3.18
Ertugliflozin 15 mg-3.58
Placebo-1.42

[back to top]

Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level

Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the Mixed Meal Tolerance Test (MMTT). Change from baseline in 2-hr PPG level at Week 26 data are presented in the following outcome measure. (NCT01958671)
Timeframe: Baseline

Interventionmg/dL (Mean)
Ertugliflozin 5 mg260.32
Ertugliflozin 15 mg262.91
Placebo256.21

[back to top]

Percentage of Participants With A1C <7% (<53 mmol/Mol) at Week 26

A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy. (NCT01958671)
Timeframe: Week 26

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg28.2
Ertugliflozin 15 mg35.8
Placebo13.1

[back to top]

Percentage of Participants Experiencing An Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy. (NCT01958671)
Timeframe: Up to 54 weeks (including 2 weeks following last dose)

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg/Ertugliflozin 5 mg64.1
Ertugliflozin 15 mg/Ertugliflozin 15 mg62.5
Placebo/Metformin66.7

[back to top]

Percentage of Participants Discontinuing Study Treatment Due to an AE

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy. (NCT01958671)
Timeframe: Up to 52 weeks

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg/Ertugliflozin 5 mg4.5
Ertugliflozin 15 mg/Ertugliflozin 15 mg3.9
Placebo/Metformin6.5

[back to top]

Change From Baseline in SBP at Week 26

The change from baseline is the Week 26 SBP minus the Week 0 SBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy. (NCT01958671)
Timeframe: Baseline and Week 26

InterventionmmHg (Least Squares Mean)
Ertugliflozin 5 mg-5.54
Ertugliflozin 15 mg-3.93
Placebo-2.22

[back to top]

Change From Baseline in FPG at Week 26

The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of glycemic rescue therapy. (NCT01958671)
Timeframe: Baseline and Week 26

Interventionmg/dL (Least Squares Mean)
Ertugliflozin 5 mg-33.96
Ertugliflozin 15 mg-43.44
Placebo0.57

[back to top]

Change From Baseline in DBP at Week 26

The change from baseline is the Week 26 DBP minus the Week 0 DBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy. (NCT01958671)
Timeframe: Baseline and Week 26

InterventionmmHg (Least Squares Mean)
Ertugliflozin 5 mg-2.52
Ertugliflozin 15 mg-1.10
Placebo-0.72

[back to top]

Change From Baseline In A1C at Week 26

A1C is measured as percent. The change from baseline is the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy. (NCT01958671)
Timeframe: Baseline and Week 26

InterventionPercent (Least Squares Mean)
Ertugliflozin 5 mg-0.79
Ertugliflozin 15 mg-0.96
Placebo0.20

[back to top]

Change From Baseline in 2-hr PPG at Week 26

The change from baseline is the Week 26 2-hr PPG minus the Week 0 2-hr PPG. Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the MMTT. Data presented exclude data following the initiation of rescue therapy. (NCT01958671)
Timeframe: Baseline and Week 26

Interventionmg/dL (Least Squares Mean)
Ertugliflozin 5 mg-64.15
Ertugliflozin 15 mg-62.45
Placebo4.88

[back to top]

Baseline Sitting Systolic Blood Pressure (SBP)

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in SBP at Week 26 data are presented in the following outcome measure. (NCT01958671)
Timeframe: Baseline

InterventionmmHg (Mean)
Ertugliflozin 5 mg130.49
Ertugliflozin 15 mg129.67
Placebo129.80

[back to top]

Baseline Sitting Diastolic Blood Pressure (DBP)

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in DBP at Week 26 data are presented in the following outcome measure. (NCT01958671)
Timeframe: Baseline

InterventionmmHg (Mean)
Ertugliflozin 5 mg78.46
Ertugliflozin 15 mg78.53
Placebo78.13

[back to top]

Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach

This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. (NCT01999218)
Timeframe: Baseline and Week 52

InterventionKilograms (Least Squares Mean)
Ertugliflozin 5 mg-2.96
Ertugliflozin 15 mg-3.38
Glimepiride0.91

[back to top]

Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. The primary study objective was the MK-8835 15 mg vs. glimepiride comparison; the MK-8835 5mg vs glimerpiride comparison was a secondary study objective. (NCT01999218)
Timeframe: Baseline and Week 52

InterventionPercent (Least Squares Mean)
Ertugliflozin 5 mg-0.56
Ertugliflozin 15 mg-0.64
Glimepiride-0.74

[back to top]

Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach

This change from baseline reflects the Week 52 SBP minus the Week 0 SBP. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. (NCT01999218)
Timeframe: Baseline and Week 52

InterventionmmHg (Least Squares Mean)
Ertugliflozin 5 mg-2.25
Ertugliflozin 15 mg-3.81
Glimepiride0.95

[back to top]

Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01999218)
Timeframe: Up to Week 104

InterventionPercentage of Participants (Number)
Ertugliflozin 5 mg6.5
Ertugliflozin 15 mg8.0
Glimepiride5.1

[back to top]

Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01999218)
Timeframe: Up to Week 106

InterventionPercentage of Participants (Number)
Ertugliflozin 5 mg70.1
Ertugliflozin 15 mg71.3
Glimepiride69.7

[back to top]

Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach

Symptomatic hypoglycemia was an event with clinical symptoms reported by the investigator as hypoglycemia (biochemical documentation not required). Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. (NCT01999218)
Timeframe: Up to Week 52

InterventionPercentage of Participants (Number)
Ertugliflozin 5 mg3.1
Ertugliflozin 15 mg5.2
Glimepiride19.2

[back to top]

Mean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment

MAGE , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula Σ λ / χ if λ> ν (where λ = changes in blood glucose from peak to nadir, χ = number of valid observations, ν = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement. In this endpoint, mean MAGE value is reported for hypo glycemic patients. (NCT02007278)
Timeframe: 12 weeks

Interventionmg/dL (Mean)
Vildagliptin and Metformin5.23
Glimepiride and Metformin5.53

[back to top]

Number of Patients With Incidence of Hypoglycemia

Hypoglycemia defined as Glycemia < 70 mg/dl (NCT02007278)
Timeframe: 12 weeks

InterventionPatients (Number)
Vildagliptin and Metformin1
Glimepiride and Metformin4

[back to top]

Percentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12

(NCT02007278)
Timeframe: Screening visit , 12 weeks of treatment

Interventionpercentage of patients (Number)
Vildagliptin and Metformin100.0
Glimepiride and Metformin100.0

[back to top]

Number of Patients With Any Adverse Events, Serious Adverse Events and Death

(NCT02007278)
Timeframe: 12 weeks

,
InterventionPatients (Number)
Any adverse events (serious and non-serious)Serious Adverse EventsDeath
Glimepiride and Metformin1310
Vildagliptin and Metformin900

[back to top]

Glycemic Variability Measured by Total Standard Deviation (TSD)

"Total standard deviation (TSD) or standard deviation of all values of a given measurement period, which has the advantage of being able to include all measured values on a given time period (even several days) through a common and simple statistical concept.~TSD is calculated conventionally with the formula σ = √Σ (Xi - ῦ) 2 / N (where Xi represents each of the values, ῦ represents the population mean and N is the number of observations) from the data of continuous monitoring of tissue glucose obtained during the measurement." (NCT02007278)
Timeframe: Week 12

Interventionmg/dL (Mean)
Vildagliptin and Metformin1.36
Glimepiride and Metformin1.40

[back to top]

Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE)

Mean Amplitude of Glycemic Excursions (MAGE) , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula Σ λ / χ if λ> ν (where λ = changes in blood glucose from peak to nadir, χ = number of valid observations, ν = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement. (NCT02007278)
Timeframe: Week 12

Interventionmg/dL (Mean)
Vildagliptin and Metformin6.68
Glimepiride and Metformin6.23

[back to top]

Glycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA)

"Continuous Overlapping Net Glycemic Action (CONGA) which assesses intra-day glycemic variability by calculating the difference between values at different intervals, adjusted according to requirements with the advantage of being highly reproducible.~CONGA is calculated in the conventional way with the formula √tқΣt = t1 (Dt -Ď2) / қ - 1, Ď = tқ Σ Dt t = t1 / қ, Dt = Gt-Gt-m (where қ = Observations with an observation n x 60 minutes, G = glucose measure) from the data of continuous monitoring of tissue glucose obtained during the measurement period." (NCT02007278)
Timeframe: Week 12

Interventionmg/dL (Mean)
Vildagliptin and Metformin2.92
Glimepiride and Metformin3.01

[back to top]

Change in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline

(NCT02007278)
Timeframe: baseline, 12 weeks of treatment

InterventionPercentage of glycosylated haemoglobin (Mean)
Vildagliptin and Metformin1.92
Glimepiride and Metformin2.28

[back to top]

Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 104

InterventionPercentage of Participants (Number)
Placebo/Glimepiride19.1
Ertugliflozin 5 mg24.6
Ertugliflozin 15 mg33.7

[back to top]

Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 52

InterventionPercentage of Participants (Number)
Placebo/Glimepiride11.0
Ertugliflozin 5 mg10.6
Ertugliflozin 15 mg14.6

[back to top]

Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 26

InterventionPercentage of Participants (Number)
Placebo/Glimepiride2.9
Ertugliflozin 5 mg8.7
Ertugliflozin 15 mg12.2

[back to top]

Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 104

InterventionPercentage of Participants (Number)
Placebo/Glimepiride7.2
Ertugliflozin 5 mg10.6
Ertugliflozin 15 mg12.2

[back to top]

Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 52

InterventionPercentage of Participants (Number)
Placebo/Glimepiride17.2
Ertugliflozin 5 mg4.3
Ertugliflozin 15 mg1.5

[back to top]

Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 26

InterventionPercentage of Participants (Number)
Placebo/Glimepiride17.7
Ertugliflozin 5 mg2.9
Ertugliflozin 15 mg1.5

[back to top]

Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104

Per protocol participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 104

InterventionPercentage of participants (Number)
Placebo/Glimepiride24.4
Ertugliflozin 5 mg11.1
Ertugliflozin 15 mg10.7

[back to top]

Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 106

InterventionPercentage of Participants (Number)
Placebo/Glimepiride77.5
Ertugliflozin 5 mg70.5
Ertugliflozin 15 mg75.6

[back to top]

Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 104

InterventionPercentage of Participants (Number)
Placebo/Glimepiride2.4
Ertugliflozin 5 mg3.4
Ertugliflozin 15 mg3.9

[back to top]

Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)

PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent Change (Mean)
Placebo/Glimepiride8.11
Ertugliflozin 5 mg11.09
Ertugliflozin 15 mg2.48

[back to top]

Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)

PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Mean)
Placebo/Glimepiride10.12
Ertugliflozin 5 mg8.16
Ertugliflozin 15 mg5.46

[back to top]

Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)

P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Mean)
Placebo/Glimepiride0.5
Ertugliflozin 5 mg0.8
Ertugliflozin 15 mg0.5

[back to top]

Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)

PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Mean)
Placebo/Glimepiride-0.98
Ertugliflozin 5 mg0.28
Ertugliflozin 15 mg0.14

[back to top]

Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)

P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent Change (Mean)
Placebo/Glimepiride24.50
Ertugliflozin 5 mg8.41
Ertugliflozin 15 mg19.79

[back to top]

Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)

P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Mean)
Placebo/Glimepiride19.38
Ertugliflozin 5 mg10.11
Ertugliflozin 15 mg24.21

[back to top]

Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)

CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent change (Mean)
Placebo/Glimepiride15.54
Ertugliflozin 5 mg34.36
Ertugliflozin 15 mg41.57

[back to top]

Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)

CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Mean)
Placebo/Glimepiride19.29
Ertugliflozin 5 mg26.94
Ertugliflozin 15 mg32.53

[back to top]

Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)

CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Mean)
Placebo/Glimepiride10.8
Ertugliflozin 5 mg51.9
Ertugliflozin 15 mg80.2

[back to top]

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.82
Ertugliflozin 5 mg-1.04
Ertugliflozin 15 mg-1.32

[back to top]

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.10
Ertugliflozin 5 mg-0.28
Ertugliflozin 15 mg0.07

[back to top]

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.69
Ertugliflozin 5 mg-0.49
Ertugliflozin 15 mg-0.44

[back to top]

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.44
Ertugliflozin 5 mg-0.59
Ertugliflozin 15 mg-0.39

[back to top]

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.63
Ertugliflozin 5 mg-0.55
Ertugliflozin 15 mg-0.36

[back to top]

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercentage change (Least Squares Mean)
Placebo/Glimepiride0.22
Ertugliflozin 5 mg-0.01
Ertugliflozin 15 mg0.12

[back to top]

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.40
Ertugliflozin 5 mg-0.10
Ertugliflozin 15 mg0.30

[back to top]

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride0.06
Ertugliflozin 5 mg-0.15
Ertugliflozin 15 mg-0.13

[back to top]

Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-1.18
Ertugliflozin 5 mg-1.72
Ertugliflozin 15 mg-2.02

[back to top]

Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride0.09
Ertugliflozin 5 mg-0.19
Ertugliflozin 15 mg-0.13

[back to top]

Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-1.23
Ertugliflozin 5 mg-1.11
Ertugliflozin 15 mg-0.96

[back to top]

Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)

This change from baseline reflects the Week 52 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionmmHg (Mean)
Placebo/Glimepiride0.65
Ertugliflozin 5 mg-2.63
Ertugliflozin 15 mg-4.28

[back to top]

Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionmmHg (Least Squares Mean)
Placebo/Glimepiride-0.70
Ertugliflozin 5 mg-4.38
Ertugliflozin 15 mg-5.20

[back to top]

Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)

This change from baseline reflects the Week 104 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionmmHg (Mean)
Placebo/Glimepiride0.05
Ertugliflozin 5 mg-3.61
Ertugliflozin 15 mg-3.13

[back to top]

Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)

This change from baseline reflects the Week 52 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionmmHg (Mean)
Placebo/Glimepiride0.38
Ertugliflozin 5 mg-1.40
Ertugliflozin 15 mg-1.19

[back to top]

Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionmmHg (Least Squares Mean)
Placebo/Glimepiride0.23
Ertugliflozin 5 mg-1.59
Ertugliflozin 15 mg-2.19

[back to top]

Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)

This change from baseline reflects the Week 104 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionmmHg (Mean)
Placebo/Glimepiride-0.46
Ertugliflozin 5 mg-2.36
Ertugliflozin 15 mg-1.52

[back to top]

Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

Interventionmg/dL (Mean)
Placebo/Glimepiride-12.0
Ertugliflozin 5 mg-22.4
Ertugliflozin 15 mg-35.2

[back to top]

Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

Interventionmg/dL (Least Squares Mean)
Placebo/Glimepiride-0.85
Ertugliflozin 5 mg-27.54
Ertugliflozin 15 mg-39.10

[back to top]

Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 104 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 104 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

Interventionmg/dL (Mean)
Placebo/Glimepiride-10.9
Ertugliflozin 5 mg-18.2
Ertugliflozin 15 mg-28.2

[back to top]

Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionKilograms (Mean)
Placebo/Glimepiride0.07
Ertugliflozin 5 mg-3.23
Ertugliflozin 15 mg-3.35

[back to top]

Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionKilograms (Least Squares Mean)
Placebo/Glimepiride-1.33
Ertugliflozin 5 mg-3.01
Ertugliflozin 15 mg-2.93

[back to top]

Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 104 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionKilograms (Mean)
Placebo/Glimepiride-0.18
Ertugliflozin 5 mg-3.77
Ertugliflozin 15 mg-3.63

[back to top]

Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 52 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent A1C (Mean)
Placebo/Glimepiride-0.68
Ertugliflozin 5 mg-0.72
Ertugliflozin 15 mg-0.96

[back to top]

Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent A1C (Least Squares Mean)
Placebo/Glimepiride-0.03
Ertugliflozin 5 mg-0.73
Ertugliflozin 15 mg-0.91

[back to top]

Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 104 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent A1C (Mean)
Placebo/Glimepiride-0.58
Ertugliflozin 5 mg-0.60
Ertugliflozin 15 mg-0.89

[back to top]

Time to Glycemic Rescue Therapy at Week 26

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Week 26

InterventionDays (Median)
Placebo/Glimepiride105
Ertugliflozin 5 mg112
Ertugliflozin 15 mg139

[back to top]

Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.58
Ertugliflozin 5 mg-0.40
Ertugliflozin 15 mg-0.64

[back to top]

Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 52

InterventionPercentage of Participants (Number)
Placebo/Glimepiride30.6
Ertugliflozin 5 mg34.8
Ertugliflozin 15 mg36.6

[back to top]

Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 26

InterventionPercentage of Participants (Number)
Placebo/Glimepiride15.8
Ertugliflozin 5 mg35.3
Ertugliflozin 15 mg40.0

[back to top]

Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)

Pharmacokinetic samples were collected at approximately 24 hours following the prior day's dose and before administration of the current day's dose. The lower limit of quantitation (LLOQ) was 0.500 mg/mL. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Pre-dose and/or 60 minutes post-dose on Weeks 6, 12, 18, and 30

,,
Interventionng/mL (Mean)
Week 6:Pre-doseWeek 12:Pre-doseWeek 12:60 mins post-doseWeek 18:Pre-doseWeek 18:60 mins post-doseWeek 30:Pre-dose
Ertugliflozin 15 mg38.3829.23228.1324.46214.9630.55
Ertugliflozin 5 mg14.8912.3474.849.9174.3912.66
Placebo/GlimepirideNANANA0.010.010.15

[back to top]

Change From Baseline in Sitting Diastolic Blood Pressure at Week 52

The change from baseline is the Week 52 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 52

,,
InterventionmmHg (Least Squares Mean)
BaselineChange from baseline
Ertugliflozin 15 mg78.44-1.38
Ertugliflozin 5 mg78.44-1.52
Placebo78.44-0.53

[back to top]

Percentage of Participants Discontinuing Study Treatment Due to an AE

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Up to Week 52

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg4.5
Ertugliflozin 15 mg3.9
Placebo3.9

[back to top]

Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 26

A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Week 26

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg32.1
Ertugliflozin 15 mg39.9
Placebo17.0

[back to top]

Percentage of Participants Receiving Glycemic Rescue Medication by Week 52

Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). (NCT02036515)
Timeframe: Week 52

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg12.8
Ertugliflozin 15 mg13.7
Placebo41.8

[back to top]

Percentage of Participants Receiving Glycemic Rescue Medication by Week 26

Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). (NCT02036515)
Timeframe: Week 26

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg1.3
Ertugliflozin 15 mg2.0
Placebo16.3

[back to top]

Percentage of Participants Experiencing An Adverse Event (AE)

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Up to Week 54

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg57.7
Ertugliflozin 15 mg60.1
Placebo63.4

[back to top]

Change From Baseline in EQ-5D-3L Score at Week 52

"The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with 3 corresponding to no problems and 15 corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy." (NCT02036515)
Timeframe: Baseline and Week 52

InterventionScore on a scale (Least Squares Mean)
Ertugliflozin 5 mg0.03
Ertugliflozin 15 mg-0.00
Placebo0.02

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26

The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 26

Interventionmg/dL (Least Squares Mean)
Ertugliflozin 5 mg-26.91
Ertugliflozin 15 mg-33.04
Placebo-1.76

[back to top]

Change From Baseline in HOMA-%β at Week 52

HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) - 3.5]. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 52

InterventionPercentage (Least Squares Mean)
Ertugliflozin 5 mg10.85
Ertugliflozin 15 mg10.93
Placebo-1.93

[back to top]

Change From Baseline in HOMA-%β at Week 26

HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) - 3.5]. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 26

InterventionPercentage (Least Squares Mean)
Ertugliflozin 5 mg13.28
Ertugliflozin 15 mg12.43
Placebo0.52

[back to top]

Change From Baseline in Hemoglobin A1C at Week 52

A1C is measured as percent. Thus this change from baseline reflects the Week 52 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 52

InterventionPercent (Least Squares Mean)
Ertugliflozin 5 mg-0.75
Ertugliflozin 15 mg-0.81
Placebo0.02

[back to top]

Change From Baseline in Hemoglobin A1C at Week 26

A1C is measured as percent. Thus this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 26

InterventionPercent (Least Squares Mean)
Ertugliflozin 5 mg-0.78
Ertugliflozin 15 mg-0.86
Placebo-0.09

[back to top]

Change From Baseline in FPG at Week 52

The change from baseline is the Week 52 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 52

Interventionmg/dL (Least Squares Mean)
Ertugliflozin 5 mg-25.57
Ertugliflozin 15 mg-26.38
Placebo3.19

[back to top]

Change From Baseline in Sitting Diastolic Blood Pressure at Week 26

The change from baseline is the Week 26 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 26

,,
InterventionmmHg (Least Squares Mean)
BaselineChange from baseline
Ertugliflozin 15 mg78.42-1.81
Ertugliflozin 5 mg78.42-1.68
Placebo78.42-0.43

[back to top]

Change From Baseline in EQ-5D-3L Questionnaire Score at Week 26

"The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with 3 corresponding to no problems and 15 corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy." (NCT02036515)
Timeframe: Baseline and Week 26

InterventionScore on a scale (Least Squares Mean)
Ertugliflozin 5 mg0.00
Ertugliflozin 15 mg0.02
Placebo0.01

[back to top]

Change From Baseline in Body Weight at Week 52

The change from baseline is the Week 52 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 52

Interventionkg (Least Squares Mean)
Ertugliflozin 5 mg-3.46
Ertugliflozin 15 mg-2.83
Placebo-0.95

[back to top]

Change From Baseline in Body Weight at Week 26

The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 26

Interventionkg (Least Squares Mean)
Ertugliflozin 5 mg-3.35
Ertugliflozin 15 mg-3.04
Placebo-1.32

[back to top]

Baseline Homeostasis Model Assessment of β-cell Function (HOMA-%β) Value

HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) - 3.5] (NCT02036515)
Timeframe: Baseline

InterventionPercentage (Mean)
Ertugliflozin 5 mg47.99
Ertugliflozin 15 mg48.54
Placebo48.04

[back to top]

Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 52

A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Week 52

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg33.3
Ertugliflozin 15 mg32.7
Placebo13.7

[back to top]

Baseline EQ-5D 3-level Version (EQ-5D-3L) Questionnaire Score

"The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 1-15 with 3 corresponding to no problems and 15 corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ visual analogue score (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best)." (NCT02036515)
Timeframe: Baseline

InterventionScore on a scale (Mean)
Ertugliflozin 5 mg0.88
Ertugliflozin 15 mg0.89
Placebo0.90

[back to top]

Time to Initiation of Glycemic Rescue by Week 52

Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days. (NCT02036515)
Timeframe: Up to week 52

,,
InterventionDays (Number)
Minimum time to initiation of glycemic rescueMaximum time to initiation of glycemic rescue
Ertugliflozin 15 mg43299
Ertugliflozin 5 mg135295
Placebo26327

[back to top]

Time to Initiation of Glycemic Rescue by Week 26

Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days. Below data include data from 1 participant in the Placebo arm who continued Phase A treatment for an additional 30 days. (NCT02036515)
Timeframe: Up to Week 26 (plus 30 days for 1 placebo participant)

,,
InterventionDays (Number)
Minimum time to initiation of glycemic rescueMaximum time to initiation of glycemic rescue
Ertugliflozin 15 mg43147
Ertugliflozin 5 mg135141
Placebo26212

[back to top]

Change From Baseline in Sitting Systolic Blood Pressure at Week 52

The change from baseline is the Week 52 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 52

,,
InterventionmmHg (Least Squares Mean)
BaselineChange from baseline
Ertugliflozin 15 mg130.92-4.09
Ertugliflozin 5 mg130.92-4.16
Placebo130.920.83

[back to top]

Change From Baseline in Sitting Systolic Blood Pressure at Week 26

The change from baseline is the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy. (NCT02036515)
Timeframe: Baseline and Week 26

,,
InterventionmmHg (Least Squares Mean)
BaselineChange from baseline
Ertugliflozin 15 mg130.87-4.82
Ertugliflozin 5 mg130.87-3.81
Placebo130.87-0.88

[back to top]

Change From Baseline of Estimated Glomerular Filtration Rate (eGFR)

The eGFR is used in addition to the Urinary Albumin to Creatinine Ratio to measure the incidence and progression of diabetic kidney disease. (NCT02072096)
Timeframe: Baseline, Week 72

Interventionmilliliter per minute/1.73 square meter (Mean)
Strategy A (Glucose-Dependent)-5.00
Strategy B (Reference)-5.88

[back to top]

Number of Participants With Total Hypoglycemia and Other Categories of Hypoglycemia

(NCT02072096)
Timeframe: Baseline to last participant visit (up to 72 weeks)

,
InterventionParticipants (Number)
Total HypoglycemiaSevere HypoglycemiaClinically Significant HypoglycemiaSymptomatic HypoglycemiaAsymptomatic HypoglycemiaProbable Symptomatic HypoglycemiaUnspecified HypoglycemiaRelative HypoglycemiaNocturnal Hypoglycemia
Strategy A (Glucose-Dependent)1000580214
Strategy B (Reference)5001343077610

[back to top]

Change From Baseline in Body Mass Index (BMI)

(NCT02072096)
Timeframe: Baseline, Week 72

Interventionkilogram per square meter (kg/m^2) (Mean)
Strategy A (Glucose-Dependent)-0.47
Strategy B (Reference)0.20

[back to top]

Change From Baseline of Urinary Albumin to Creatinine Ratio

The Urinary Albumin to Creatinine Ratio is used in addition to Estimated Glomerular Filtration Rate (eGFR) to measure the incidence and progression of diabetic kidney disease. (NCT02072096)
Timeframe: Baseline, Week 72

Interventionmilligram per millimole (mg/mmol) (Mean)
Strategy A (Glucose-Dependent)1.85
Strategy B (Reference)1.85

[back to top]

Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia

Failed to reach and maintain HbA1c target, without clinically significant hypoglycemia, is defined as having 2 consecutive HbA1c > upper limit of HbA1c target over 12 weeks starting from Week 24 for participants with HbA1c data beyond Week 24, or Week 24 HbA1c > upper limit of HbA1c target for participants without HbA1c data beyond Week 24. Clinically significant hypoglycemia is defined as any severe hypoglycemia or repeated hypoglycemia interrupting participants activities or sleep and associated with blood glucose ≤3.9 millimole per liter (mmol/L), or repeated asymptomatic hypoglycemia associated with blood glucose <3.0 mmol/L. Success is defined as lacking of failure. (NCT02072096)
Timeframe: Baseline to last participant visit (up to 72 weeks)

Interventionpercentage of participants (Number)
Strategy A (Glucose-Dependent)64.5
Strategy B (Reference)54.9

[back to top]

Percentage of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy

(NCT02072096)
Timeframe: Baseline to last participant visit (up to 72 weeks)

Interventionpercentage of participants (Number)
Strategy A (Glucose-Dependent)21
Strategy B (Reference)13

[back to top]

Fasting Blood Glucose Level

Tabulated fasting blood glucose level from baseline at each test time point. (NCT02098733)
Timeframe: Baseline, Months 3, 6, 9, 12 and at Final Assessment

Interventionmg/dL (Mean)
At the start of treatment (n=369)Month 3 (n=331)Month 6 (n=287)Month 9 (n=273)Month 12 (n=462)Final Assessment (n=369)
Pioglitazone/Glimepiride147.2130.2131.7129.2126.8130.9

[back to top]

Change From Baseline in Fasting Blood Glucose Level

Tabulated the changes from baseline in fasting blood glucose level at each test time point (test value at each test time point after baseline - test value at baseline). A negative change from Baseline indicates improvement. (NCT02098733)
Timeframe: Baseline, Months 3, 6, 9, 12 and at Final Assessment

Interventionmg/dL (Mean)
Month 3 (n=331)Month 6 (n=287)Month 9 (n=273)Month 12 (n=462)Final Assessment (n=369)
Pioglitazone/Glimepiride-16.7-14.3-15.7-12.5-16.4

[back to top]

Change From Baseline in Fasting Insulin Level

Tabulated the changes from baseline at each test time point (test value at each test time point after baseline - test value at baseline). A negative change from Baseline indicates improvement. (NCT02098733)
Timeframe: Baseline, Months 3, 6, 9, 12 and at Final Assessment

InterventionμU/dL (Mean)
Month 3 (n=39)Month 6 (n=32)Month 9 (n=30)Month 12 (n=18)Final Assessment (n=46)
Pioglitazone/Glimepiride-0.240.02-0.600.58-0.01

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1c)

Tabulated the changes from baseline in glycosylated hemoglobin (HbA1c) values at each test time point (test value at each test time point after baseline - test value at baseline). A negative change from Baseline indicates improvement. (NCT02098733)
Timeframe: Baseline, and Months 3, 6, 9, 12 and at Final Assessment

Interventionpercentage of glycosylated haemoglobin (Mean)
Month 3 (n=1016)Month 6 (n=893)Month 9 (n=831)Month 12 (n=462)Final Assessment (n=1,054)
Pioglitazone/Glimepiride-0.45-0.55-0.56-0.57-0.57

[back to top]

Fasting Insulin Level

Tabulated fasting insulin level at each test time point. (NCT02098733)
Timeframe: Baseline, Months 3, 6, 9, 12 and at Final Assessment

InterventionμU/dL (Mean)
At the start of treatment (n=46)Month 3 (n=39)Month 6 (n=32)Month 9 (n=30)Month 12 (n=18)Final Assessment (n=46)
Pioglitazone/Glimepiride5.785.385.485.406.575.77

[back to top]

Glycosylated Hemoglobin (HbA1c)

Tabulated glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each test time point or final visit relative to baseline. (NCT02098733)
Timeframe: Baseline, and Months 3, 6, 9, 12 and at Final Assessment

Interventionpercentage of glycosylated haemoglobin (Mean)
At the start of treatment (n=1054)Month 3 (n=1016)Month 6 (n=893)Month 9 (n=831)Month 12 (n=462)Final Assessment (n=1054)
Pioglitazone/Glimepiride7.707.257.147.087.127.13

[back to top]

Number of Participants With Adverse Drug Reactions

Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions. (NCT02098733)
Timeframe: For 12 months

Interventionparticipants (Number)
HypoglycaemiaDizzinessDysgeusiaHeadacheHypoaesthesiaCardiac failureCardiac failure congestivePleural effusionEructationNauseaCholelithiasisDrug eruptionPruritusSwelling faceUrticariaFace oedemaFeeling abnormalHungerOedemaOedema peripheralSudden deathBlood creatine phosphokinase increasedAlanine aminotransferase increasedBlood triglycerides increasedBlood glucose decreasedWeight increased
Pioglitazone/Glimepiride134111211111121111274111118

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1c)

Tabulation of HbA1c values and the changes from Baseline at each test time point (test value at each test time point after Baseline - test value at Baseline). A negative change from Baseline indicates improvement. (NCT02098746)
Timeframe: Baseline, Months 3, 6, 9, 12 and at Final assessment

Interventionpercent (Mean)
Month 3 (n=234)Month 6 (n=190)Month 9 (n=177)Month 12 (n=84)Final Assessment (n=247)
Pioglitazone/Glimepiride-0.83-0.84-0.83-0.62-0.92

[back to top]

Frequency of Adverse Drug Reactions

Frequency of adverse drug reactions is defined as the number of participants with adverse drug reactions. Frequency, seriousness, and time to onset of adverse drug reactions were tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions. (NCT02098746)
Timeframe: 12 months

Interventionparticipants (Number)
AnaemiaHypoglycaemiaGeneralised oedemaOedemaWeight increased
Pioglitazone/Glimepiride17116

[back to top]

Frequency of Serious Adverse Drug Reactions

Frequency of serious adverse drug reactions is defined at the number of participants with serious adverse drug reactions. Frequency of serious adverse drug reactions were tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions. (NCT02098746)
Timeframe: 12 months

Interventionparticipants (Number)
Pioglitazone/Glimepiride0

[back to top]

Change From Baseline in Fasting Blood Glucose Level

Tabulation of fasting blood glucose level and the changes from Baseline at each test time point (test value at each test time point after Baseline - test value at Baseline). A negative change from Baseline indicates improvement. (NCT02098746)
Timeframe: Baseline, Months 3, 6, 9, 12 and at Final assessment

Interventionmg/dL (Mean)
Month 3 (n=76)Month 6 (n=59)Month 9 (n=53)Month 12 (n=28)Final Assessment (n=83)
Pioglitazone/Glimepiride-15.9-23.2-12.7-17.0-17.7

[back to top]

Change From Baseline in Fasting Insulin Level

Tabulation of fasting insulin level and the changes from Baseline at each test time point (test value at each test time point after Baseline - test value at Baseline). A negative change from Baseline indicates improvement. A positive change from Baseline indicates a worsening. (NCT02098746)
Timeframe: Baseline, Months 3, 6, 9, 12 and at Final assessment

InterventionμU/dL (Mean)
Month 3 (n=33)Month 6 (n=25)Month 9 (n=17)Month 12 (n=15)Final Assessment (n=39)
Pioglitazone/Glimepiride1.66-0.251.32-0.290.98

[back to top]

Change From Baseline in A1C at Week 26: Excluding Rescue Approach

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: Baseline and Week 26

InterventionPercentage (Least Squares Mean)
Ertugliflozin 5 mg-1.02
Ertugliflozin 15 mg-1.08
Sitagliptin 100 mg-1.05
Ertugliflozin 5 mg + Sitagliptin 100 mg-1.49
Ertugliflozin 15 mg + Sitagliptin 100 mg-1.52

[back to top]

Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach

This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: Baseline and Week 26

InterventionKilograms (Least Squares Mean)
Ertugliflozin 5 mg-2.69
Ertugliflozin 15 mg-3.74
Sitagliptin 100 mg-0.67
Ertugliflozin 5 mg + Sitagliptin 100 mg-2.52
Ertugliflozin 15 mg + Sitagliptin 100 mg-2.94

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach

Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: Baseline and Week 26

Interventionmg/dL (Least Squares Mean)
Ertugliflozin 5 mg-35.73
Ertugliflozin 15 mg-36.91
Sitagliptin 100 mg-25.56
Ertugliflozin 5 mg + Sitagliptin 100 mg-43.96
Ertugliflozin 15 mg + Sitagliptin 100 mg-48.70

[back to top]

Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach

This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: Baseline and Week 26

Interventionmm Hg (Least Squares Mean)
Ertugliflozin 5 mg-3.89
Ertugliflozin 15 mg-3.69
Sitagliptin 100 mg-0.66
Ertugliflozin 5 mg + Sitagliptin 100 mg-3.42
Ertugliflozin 15 mg + Sitagliptin 100 mg-3.67

[back to top]

Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach

A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: Week 26

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg26.4
Ertugliflozin 15 mg31.9
Sitagliptin 100 mg32.8
Ertugliflozin 5 mg + Sitagliptin 100 mg52.3
Ertugliflozin 15 mg + Sitagliptin 100 mg49.2

[back to top]

Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy. (NCT02099110)
Timeframe: Up to 52 weeks

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg3.2
Ertugliflozin 15 mg3.2
Sitagliptin 100 mg2.8
Ertugliflozin 5 mg + Sitagliptin 100 mg3.3
Ertugliflozin 15 mg + Sitagliptin 100 mg3.7

[back to top]

Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy. (NCT02099110)
Timeframe: Up to 54 weeks

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg62.0
Ertugliflozin 15 mg57.7
Sitagliptin 100 mg57.5
Ertugliflozin 5 mg + Sitagliptin 100 mg58.8
Ertugliflozin 15 mg + Sitagliptin 100 mg55.7

[back to top]

Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach

Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L * L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based [including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC] and model-based [beta cell function and insulin secretion rate at 9 mM glucose] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10^-9 min^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy. (NCT02099110)
Timeframe: 30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26

InterventionSBCSGI (10^-9min^-1) (Least Squares Mean)
Ertugliflozin 5 mg8.62
Ertugliflozin 15 mg9.71
Sitagliptin 100 mg21.11
Ertugliflozin 5 mg + Sitagliptin 100 mg16.24
Ertugliflozin 15 mg + Sitagliptin 100 mg11.51

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Full Analysis Set Excluding Rescue Approach

Blood glucose was measured after a ≥10 hour fast. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at baseline). Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride. (NCT02226003)
Timeframe: Baseline and Week 26

Interventionmilligrams/deciliter (Least Squares Mean)
Ertugliflozin 5 mg + Sitagliptin 100 mg-48.25
Ertugliflozin 15 mg + Sitagliptin 100 mg-55.36
Placebo-9.30

[back to top]

Percentage of Participants Who Discontinued Study Medication Due to an AE - All Participants as Treated Excluding Rescue Approach

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride. (NCT02226003)
Timeframe: Up to Week 26

InterventionPercentage of Participants (Number)
Ertugliflozin 5 mg + Sitagliptin 100 mg2.0
Ertugliflozin 15 mg + Sitagliptin 100 mg2.1
Placebo2.1

[back to top]

Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants as Treated Excluding Rescue Approach

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride. (NCT02226003)
Timeframe: Up to Week 28

InterventionPercentage of Participants (Number)
Ertugliflozin 5 mg + Sitagliptin 100 mg44.9
Ertugliflozin 15 mg + Sitagliptin 100 mg44.8
Placebo42.3

[back to top]

Percentage of Participants With HbA1C <7% (<53 mmol/Mol) at Week 26

HbA1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). HbA1c represents the percentage of glycated hemoglobin. (NCT02226003)
Timeframe: Week 26

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg + Sitagliptin 100 mg35.7
Ertugliflozin 15 mg + Sitagliptin 100 mg31.3
Placebo8.3

[back to top]

Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach

HbA1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). HbA1C represents the percentage of glycated hemoglobin. A negative number indicates a reduction in HbA1C level. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride. (NCT02226003)
Timeframe: Baseline and Week 26

InterventionPercentage (Least Squares Mean)
Ertugliflozin 5 mg + Sitagliptin 100 mg-1.60
Ertugliflozin 15 mg + Sitagliptin 100 mg-1.68
Placebo-0.44

[back to top]

Change From Baseline in Sitting Systolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach

Blood pressure measurements were taken after at least 5 minutes of rest. Three measurements were taken approximately 2 minutes apart with the triplicate set recorded. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride. (NCT02226003)
Timeframe: Baseline and Week 26

Interventionmillimeters of mercury (Least Squares Mean)
Ertugliflozin 5 mg + Sitagliptin 100 mg-2.04
Ertugliflozin 15 mg + Sitagliptin 100 mg-3.98
Placebo2.41

[back to top]

Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 26 - Full Analysis Set Excluding Rescue Approach

Change from baseline at Week 26 is defined as 2-hour PMG at Week 26 minus 2-hour PMG at Week 0. Two-hour post-meal glucose was measured following a standard meal. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride. (NCT02226003)
Timeframe: Baseline and Week 26

Interventionmilligrams/deciliter (Least Squares Mean)
Ertugliflozin 5 mg + Sitagliptin 100 mg-82.80
Ertugliflozin 15 mg + Sitagliptin 100 mg-90.03
Placebo-20.38

[back to top]

Change From Baseline in Body Weight at Week 26 - Full Analysis Set Excluding Rescue Approach

Body weight was measured using a standardized, digital scale at each of the pre-defined nominal time points. Weight was taken in duplicate throughout the trial at approximately the same time of day, after voiding (i.e., forced void) and while wearing only a gown and underwear. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride. (NCT02226003)
Timeframe: Baseline and Week 26

InterventionKilograms (Least Squares Mean)
Ertugliflozin 5 mg + Sitagliptin 100 mg-2.94
Ertugliflozin 15 mg + Sitagliptin 100 mg-3.04
Placebo-0.94

[back to top]

Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach

Blood pressure measurements were taken after at least 5 minutes of rest. Three measurements were taken approximately 2 minutes apart with the triplicate set recorded. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride. (NCT02226003)
Timeframe: Baseline and Week 26

Interventionmillimeters of mercury (Least Squares Mean)
Ertugliflozin 5 mg + Sitagliptin 100 mg-0.44
Ertugliflozin 15 mg + Sitagliptin 100 mg-0.97
Placebo1.21

[back to top]

Correlation of Estimated Seafood Intake With HbA1c Reduction

Pearson's correlation coefficient of HbA1c reduction with estimated seafood intake (NCT02312063)
Timeframe: 0-16 weeks

Interventionpearson's correlation coefficient (Number)
Sitagliptin-0.042
Glimepiride0.215

[back to top]

Correlation of Plasma Levels of EPA and DHA With HbA1c Reduction

Pearson's correlation coefficient of HbA1c reduction with plasma levels of EPA and DHA at baseline (NCT02312063)
Timeframe: 0-16 weeks

,
Interventionpearson's correlation coefficient (Number)
r (EPA and delta HbA1c)r (DHA and delta HbA1c)
Glimepiride0.0670.093
Sitagliptin-0.414-0.319

[back to top]

Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 156

Therapeutic glycemic response was defined as HbA1c <7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 156 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c. (NCT02419612)
Timeframe: At Week 156

InterventionPercentage of Subjects (Number)
Dapagliflozin 10mg and Saxagliptin 5mg21.4
Titrated Glimepiride11.7

[back to top]

Change From Baseline in Total Body Weight at Week 52

To examine whether the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment. (NCT02419612)
Timeframe: Baseline and Week 52

Interventionkilogram (kg) (Least Squares Mean)
Dapagliflozin 10mg and Saxagliptin 5mg-3.11
Titrated Glimepiride0.95

[back to top]

Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52

To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment. (NCT02419612)
Timeframe: Baseline and Week 52

Intervention% HbA1c (Least Squares Mean)
Dapagliflozin 10mg and Saxagliptin 5mg-1.35
Titrated Glimepiride-0.98

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) at Week 52

To examine whether the change from baseline in SBP with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment. (NCT02419612)
Timeframe: Baseline and Week 52

InterventionmmHg (Least Squares Mean)
Dapagliflozin 10mg and Saxagliptin 5mg-2.6
Titrated Glimepiride1.0

[back to top]

Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.

Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. Time to treatment intensification curves were generated using Kaplan-Meier estimates and compared using a Cox proportional hazards model. (NCT02419612)
Timeframe: Up to Week 156

InterventionWeeks (Median)
Dapagliflozin 10mg and Saxagliptin 5mgNA
Titrated Glimepiride92.3

[back to top]

Percentage of Subjects With Treatment Intensification During the 52-week Short-term Treatment Period

Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after the 52-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 52 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 52-week short -term treatment period. (NCT02419612)
Timeframe: Up to Week 52

InterventionPercentage of Subjects (Number)
Dapagliflozin 10mg and Saxagliptin 5mg1.3
Titrated Glimepiride8.8

[back to top]

Percentage of Subjects With Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.

Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 156-week treatment period. (NCT02419612)
Timeframe: Up to Week 156

InterventionPercentage of Subjects (Number)
Dapagliflozin 10mg and Saxagliptin 5mg37.0
Titrated Glimepiride55.6

[back to top]

Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 52

Therapeutic glycemic response was defined as HbA1c <7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 52 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c. (NCT02419612)
Timeframe: At Week 52

InterventionPercentage of subjects (Number)
Dapagliflozin 10mg and Saxagliptin 5mg44.3
Titrated Glimepiride34.3

[back to top]

Patients With at Least One Episode of Confirmed Hypoglycaemia

Percentage of patients reporting at least 1 episode of hypoglycaemia (symptomatic + blood glucose <=50 mg/dL) during the double-blind treatment period (NCT02471404)
Timeframe: Up to Week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

InterventionPercentage of participants (Number)
Dapaglifozin 10mg0
Saxagliptin 5mg and Dapagliflozin 10mg0.32
Glimepiride 1mg/2mg/4mg4.21

[back to top]

Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52

Change in HbA1c from baseline (week 0) to week 52. (NCT02471404)
Timeframe: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

InterventionHbA1c % (Least Squares Mean)
Dapaglifozin 10mg-0.82
Saxagliptin 5mg and Dapagliflozin 10mg-1.2
Glimepiride 1mg/2mg/4mg-0.99

[back to top]

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52

Change in FPG from baseline (week 0) to week 52 (NCT02471404)
Timeframe: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

InterventionFPG (mmol/L) (Least Squares Mean)
Dapaglifozin 10mg-1.62
Saxagliptin 5mg and Dapagliflozin 10mg-2.08
Glimepiride 1mg/2mg/4mg-1.49

[back to top]

Change in Total Body Weight From Baseline at Week 52

Change in body weight from baseline (week 0) to week 52 (NCT02471404)
Timeframe: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

InterventionWeight (kg) (Least Squares Mean)
Dapaglifozin 10mg-3.54
Saxagliptin 5mg and Dapagliflozin 10mg-3.15
Glimepiride 1mg/2mg/4mg1.76

[back to top]

Number of Patients Rescued

Number (%) of patients rescued. (NCT02471404)
Timeframe: Over the 52 week treatment period

InterventionPercentage of participants (Number)
Dapaglifozin 10mg18.6
Saxagliptin 5mg and Dapagliflozin 10mg8.3
Glimepiride 1mg/2mg/4mg21.4

[back to top]

Time to Rescue

The time to rescue (from first dose date after randomisation to start of rescue medication or discontinuation due to lack of glycaemic control) during the 52 week double blind treatment period (NCT02471404)
Timeframe: Over the 52 week treatment period

InterventionWeeks (Median)
Dapaglifozin 10mgNA
Saxagliptin 5mg and Dapagliflozin 10mgNA
Glimepiride 1mg/2mg/4mgNA

[back to top]

Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52

Adjusted Mean Change in Visceral Adipose Tissue (VAT) area at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

Interventioncm^2 (Least Squares Mean)
Dapagliflozin-16.06
Glimepiride1.48

[back to top]

Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52

Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

Interventionratio (Least Squares Mean)
Dapagliflozin-0.05
Glimepiride-0.02

[back to top]

Adjusted Mean Change in Waist Circumference at Week 52

Adjusted Mean Change in Waist Circumference at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

Interventioncm (Least Squares Mean)
Dapagliflozin-2.37
Glimepiride-0.16

[back to top]

Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan

Adjusted mean percent changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment (NCT02564926)
Timeframe: From baseline to Week 52

Interventionpercent change (Least Squares Mean)
Dapagliflozin-1.21
Glimepiride0.73

[back to top]

Adjusted Mean Change in HbA1c at Week 52

Adjusted Mean Change in HbA1c at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

Interventionpercentages (Least Squares Mean)
Dapagliflozin-1.00
Glimepiride-0.54

[back to top]

Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52

Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

Interventionmg/L (Least Squares Mean)
Dapagliflozin-0.51
Glimepiride-0.39

[back to top]

Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan

Adjusted mean changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment (NCT02564926)
Timeframe: From baseline to Week 52

Interventiongrams (Least Squares Mean)
Dapagliflozin-1485.69
Glimepiride1096.34

[back to top]

Adjusted Mean Change in Lean Body Mass at Week 52

Adjusted Mean Change in Lean Body Mass at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

InterventionKg (Least Squares Mean)
Dapagliflozin-1.1
Glimepiride0.2

[back to top]

Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) Area at Week 52

Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) area at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

Interventioncm^2 (Least Squares Mean)
Dapagliflozin-5.41
Glimepiride12.98

[back to top]

Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52

Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

InterventionmmHg (Least Squares Mean)
Dapagliflozin-2.18
Glimepiride4.63

[back to top]

Adjusted Mean Change in Adinopectin at Week 52

Adjusted Mean Change in Adinopectin at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

Interventionng/mL (Least Squares Mean)
Dapagliflozin1746.66
Glimepiride1088.95

[back to top]

Adjusted Mean Change in Total Body Weight at Week 52

Adjusted Mean Change in Total Body Weight at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

Interventionkg (Least Squares Mean)
Dapagliflozin-2.4
Glimepiride1.3

[back to top]

Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52

Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

Interventionmg/dL (Least Squares Mean)
Dapagliflozin-30.94
Glimepiride-12.70

[back to top]

Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52

Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

InterventionmmHg (Least Squares Mean)
Dapagliflozin-0.25
Glimepiride2.36

[back to top]

Adjusted Mean Change in Body Mass Index (BMI) at Week 52

Adjusted Mean Change in Body Mass Index (BMI) at Week 52 (NCT02564926)
Timeframe: From baseline to Week 52

Interventionkg/m^2 (Least Squares Mean)
Dapagliflozin-0.91
Glimepiride0.46

[back to top]

Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)

This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Baseline and Week 26

InterventionmmHg (Least Squares Mean)
Ertugliflozin 5 mg-2.82
Ertugliflozin 15 mg-2.77
Placebo-1.82

[back to top]

Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Baseline and Week 26

InterventionmmHg (Least Squares Mean)
Ertugliflozin 5 mg-5.09
Ertugliflozin 15 mg-3.87
Placebo0.22

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 12: 60 min. Post-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg91.49
Ertugliflozin 15 mg277.60

[back to top]

Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)

This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Baseline and Week 26

InterventionmmHg (Least Squares Mean)
Ertugliflozin 5 mg-5.64
Ertugliflozin 15 mg-4.19
Placebo-1.56

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 12: Pre-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg8.18
Ertugliflozin 15 mg27.11

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 18: 60 min. Post-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg91.40
Ertugliflozin 15 mg274.23

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 18: Pre-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg6.59
Ertugliflozin 15 mg17.54

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 26: Pre-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg7.34
Ertugliflozin 15 mg26.66

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 6: Pre-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg9.17
Ertugliflozin 15 mg24.59

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 12: 60 min. Post-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg97.36
Ertugliflozin 15 mg294.49

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 12: Pre-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg7.40
Ertugliflozin 15 mg23.84

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 18: 60 min. Post-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg94.82
Ertugliflozin 15 mg285.28

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 18: Pre-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg6.30
Ertugliflozin 15 mg17.07

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 26: Pre-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg7.26
Ertugliflozin 15 mg24.91

[back to top]

Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL. (NCT02630706)
Timeframe: Week 6: Pre-Dose

Interventionng/mL (Mean)
Ertugliflozin 5 mg7.88
Ertugliflozin 15 mg22.29

[back to top]

Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT02630706)
Timeframe: Up to 26 weeks

InterventionPercentage of Participants (Number)
Ertugliflozin 5 mg1.2
Ertugliflozin 15 mg0.6
Placebo1.8

[back to top]

Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT02630706)
Timeframe: Up to 26 weeks

InterventionPercentage of Participants (Number)
Ertugliflozin 5 mg0.7
Ertugliflozin 15 mg0.7
Placebo2.2

[back to top]

Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT02630706)
Timeframe: Up to 28 weeks

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg56.5
Ertugliflozin 15 mg53.3
Placebo59.3

[back to top]

Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT02630706)
Timeframe: Up to 28 weeks

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg54.4
Ertugliflozin 15 mg50.4
Placebo59.3

[back to top]

Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26 (China Subpopulation)

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. (NCT02630706)
Timeframe: Week 26

InterventionPercentage of Participants (Number)
Ertugliflozin 5 mg0.0
Ertugliflozin 15 mg0.7
Placebo9.6

[back to top]

Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Baseline and Week 26

InterventionKilograms (Least Squares Mean)
Ertugliflozin 5 mg-2.95
Ertugliflozin 15 mg-3.18
Placebo-1.17

[back to top]

Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Week 26

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg14.7
Ertugliflozin 15 mg15.4
Placebo2.4

[back to top]

Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) (China Subpopulation)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Week 26

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg14.7
Ertugliflozin 15 mg17.0
Placebo3.0

[back to top]

Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Week 26

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg38.2
Ertugliflozin 15 mg40.8
Placebo16.2

[back to top]

Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach) (China Subpopulation)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Week 26

InterventionPercentage of participants (Number)
Ertugliflozin 5 mg35.3
Ertugliflozin 15 mg42.2
Placebo18.5

[back to top]

Time to Glycemic Rescue Therapy

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. (NCT02630706)
Timeframe: Up to 183 days

InterventionDays (Median)
Ertugliflozin 5 mgNA
Ertugliflozin 15 mgNA
PlaceboNA

[back to top]

Time to Glycemic Rescue Therapy (China Subpopulation)

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. (NCT02630706)
Timeframe: Up to 149 days

InterventionDays (Median)
Ertugliflozin 15 mgNA
PlaceboNA

[back to top]

Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Baseline and Week 26

InterventionPercentage A1C (Least Squares Mean)
Ertugliflozin 5 mg-1.01
Ertugliflozin 15 mg-0.92
Placebo-0.24

[back to top]

Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26.

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. (NCT02630706)
Timeframe: Week 26

InterventionPercentage of Participants (Number)
Ertugliflozin 5 mg1.2
Ertugliflozin 15 mg0.6
Placebo9.6

[back to top]

Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) (China Subpopulation)

The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Baseline and Week 26

InterventionKilograms (Least Squares Mean)
Ertugliflozin 5 mg-3.11
Ertugliflozin 15 mg-3.38
Placebo-1.33

[back to top]

Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Baseline and Week 26

Interventionmg/dL (Least Squares Mean)
Ertugliflozin 5 mg-37.09
Ertugliflozin 15 mg-34.47
Placebo-6.69

[back to top]

Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) (China Subpopulation)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Baseline and Week 26

Interventionmg/dL (Least Squares Mean)
Ertugliflozin 5 mg-39.01
Ertugliflozin 15 mg-36.67
Placebo-10.46

[back to top]

Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Baseline and Week 26

InterventionmmHg (Least Squares Mean)
Ertugliflozin 5 mg-2.38
Ertugliflozin 15 mg-2.36
Placebo-0.96

[back to top]

Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02630706)
Timeframe: Baseline and Week 26

InterventionPercentage A1C (Least Squares Mean)
Ertugliflozin 5 mg-1.00
Ertugliflozin 15 mg-0.89
Placebo-0.20

[back to top]

Change From Baseline in Body Weight at Week 60 for Subjects With Baseline BMI ≥ 25 kg/m2

Least squares (LS) mean treatment difference between the bexagliflozin group and placebo group in the change of body weight in subjects with baseline BMI ≥ 25 kg/m2 at week 60 is analyzed using ANCOVA. (NCT02769481)
Timeframe: Baseline and 60 weeks

Interventionkg (Least Squares Mean)
Bexagliflozin-3.71
Glimepiride0.59

[back to top]

Change From Baseline in HbA1c at Week 60

The primary objective is to demonstrate that bexagliflozin is non-inferior to glimepiride by evaluating the treatment effect on HbA1c reduction at week 60 in subjects whose T2DM is inadequately controlled by metformin. The least square mean (LSM) change from baseline to Week 60 was analyzed using a mixed model repeated measures (MMRM) analysis of covariance model (ANCOVA). (NCT02769481)
Timeframe: Baseline and Week 60

Interventionpercentage of glycated hemoglin (Least Squares Mean)
Bexagliflozin-0.70
Glimepiride-0.66

[back to top]

Difference in Proportion of Subjects With ≥ 1 Severe or Documented Symptomatic Hypoglycemia Events Over 96 Weeks

The difference in proportion of subjects with ≥ 1 severe or documented symptomatic hypoglycemia events in the bexagliflozin group compared with glimepiride group over 96 weeks is analyzed using a logistic regression model. The full model included region, baseline HbA1c value, background treatment status (metformin or metformin + OHA), eGFR at baseline ≥ 90 or < 90 mL min 1 per 1.73 m2), treatment as a fixed effect covariate. (NCT02769481)
Timeframe: During the 96 week treatment period

InterventionProportion of participants (Number)
Bexagliflozin0.02
Glimepiride0.15

[back to top]

Superiority of Bexagliflozin Over Glimepiride in HbA1c Reduction at Week 60.

Superiority of bexagliflozin over glimepiride in HbA1c reduction from baseline to week 60 will be declared if the upper bound of 95% CI is less than 0. (NCT02769481)
Timeframe: Baseline to Week 60

Interventionpercentage of glycated hemoglobin (Least Squares Mean)
Bexagliflozin-0.70
Glimepiride-0.66

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) at Week 60 for Subjects With Baseline SBP ≥ 140 mmHg

Least squares (LS) mean treatment difference between the bexagliflozin group and placebo group in the change of SBP in subjects with baseline SBP ≥ 140 mmHg at week 60 is analyzed using ANCOVA. (NCT02769481)
Timeframe: Baseline and 60 weeks

Interventionmm Hg (Least Squares Mean)
Bexagliflozin-13.48
Glimepiride-6.95

[back to top]

Cmax (Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionng/mL (Geometric Mean)
Bexagliflozin PK parametersGlimepiride PK parameters
Group 2: Bexagliflozin + Glimepiride143.767.1

[back to top]

Cmax (Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionng/mL (Geometric Mean)
Bexagliflozin PK parametersMetformin PK parameters
Group 1: Bexagliflozin + Metformin135.51965.2

[back to top]

Cmax (Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionng/mL (Geometric Mean)
Bexagliflozin PK parametersSitagliptin PK parameters
Group 3: Bexagliflozin + Sitagliptin148.3351.2

[back to top]

T1/2 (Apparent Terminal Elimination Half-life)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

,,
Interventionhours (Geometric Mean)
Bexagliflozin PK parameters
Group 1: Bexagliflozin Alone10.3
Group 2: Bexagliflozin Alone8.0
Group 3: Bexagliflozin Alone12.6

[back to top]

T1/2 (Apparent Terminal Elimination Half-life)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Geometric Mean)
Glimepiride PK parameters
Group 2: Glimepiride Alone7.8

[back to top]

T1/2 (Apparent Terminal Elimination Half-life)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Geometric Mean)
Metformin PK parameters
Group 1: Metformin Alone9.0

[back to top]

T1/2 (Apparent Terminal Elimination Half-life)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Geometric Mean)
Sitagliptin PK parameters
Group 3: Sitagliptin Alone14.3

[back to top]

T1/2 (Apparent Terminal Elimination Half-life)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Geometric Mean)
Bexagliflozin PK parametersGlimepiride PK parameters
Group 2: Bexagliflozin + Glimepiride7.86.6

[back to top]

T1/2 (Apparent Terminal Elimination Half-life)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Geometric Mean)
Bexagliflozin PK parametersMetformin PK parameters
Group 1: Bexagliflozin + Metformin7.810.2

[back to top]

T1/2 (Apparent Terminal Elimination Half-life)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Geometric Mean)
Bexagliflozin PK parametersSitagliptin PK parameters
Group 3: Bexagliflozin + Sitagliptin13.314.8

[back to top]

Tmax (Time of Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

,,
Interventionhours (Median)
Bexagliflozin PK parameters
Group 1: Bexagliflozin Alone4.0
Group 2: Bexagliflozin Alone8.0
Group 3: Bexagliflozin Alone3.0

[back to top]

AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject. (NCT02956044)
Timeframe: Up to 72 hours

Interventionh*ng/mL (Geometric Mean)
Glimepiride PK parameters
Group 2: Glimepiride Alone496.1

[back to top]

Tmax (Time of Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Median)
Sitagliptin PK parameters
Group 3: Sitagliptin Alone2.5

[back to top]

Tmax (Time of Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Median)
Bexagliflozin PK parametersGlimepiride PK parameters
Group 2: Bexagliflozin + Glimepiride6.07.0

[back to top]

Tmax (Time of Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Median)
Bexagliflozin PK parametersMetformin PK parameters
Group 1: Bexagliflozin + Metformin3.02.0

[back to top]

Tmax (Time of Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Median)
Bexagliflozin PK parametersSitagliptin PK parameters
Group 3: Bexagliflozin + Sitagliptin4.02.5

[back to top]

Tmax (Time of Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Median)
Metformin PK parametersGlimepiride PK parameters
Group 2: Glimepiride Alone05.5

[back to top]

AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject. (NCT02956044)
Timeframe: Up to 72 hours

,,
Interventionh*ng/mL (Geometric Mean)
Bexagliflozin PK parameters
Group 1: Bexagliflozin Alone1154.4
Group 2: Bexagliflozin Alone1204.9
Group 3: Bexagliflozin Alone1011.8

[back to top]

Urinary Glucose Excretion up to 0-72 hr

Pre-dose urine samples were collected from -12 to 0 h for baseline measurement. Subjects was instructed to empty their bladder prior to dosing. Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections. Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h. (NCT02956044)
Timeframe: up to 0-72 hr

,,
Interventiong (Mean)
0 - 12 hours12 - 24 hours24 - 36 hours36 - 48 hours48 - 60 hours60 - 72 hours
Group 3: Bexagliflozin + Sitagliptin23.9422.8524.1510.1711.502.70
Group 3: Bexagliflozin Alone29.0124.3822.319.8311.322.67
Group 3: Sitagliptin Alone0.030.040.170.030.050.02

[back to top]

Tmax (Time of Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionhours (Median)
Metformin PK parameters
Group 1: Metformin Alone2.5

[back to top]

AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject. (NCT02956044)
Timeframe: Up to 72 hours

Interventionh*ng/mL (Geometric Mean)
Metformin PK parameters
Group 1: Metformin Alone13351.9

[back to top]

Urinary Glucose Excretion up to 0-72 hr

Pre-dose urine samples were collected from -12 to 0 h for baseline measurement. Subjects was instructed to empty their bladder prior to dosing. Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections. Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h. (NCT02956044)
Timeframe: up to 0-72 hr

,,,,,
Interventiong (Mean)
0 - 12 hours12 - 24 hours24 - 36 hours36 - 48 hours
Group 1: Bexagliflozin + Metformin26.2622.5719.505.53
Group 1: Bexagliflozin Alone31.5717.3223.948.91
Group 1: Metformin Alone0.020.040.040.02
Group 2: Bexagliflozin + Glimepiride31.0222.5928.469.34
Group 2: Bexagliflozin Alone36.9926.8529.7911.03
Group 2: Glimepiride Alone1.260.040.200.03

[back to top]

AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject. (NCT02956044)
Timeframe: Up to 72 hours

Interventionh*ng/mL (Geometric Mean)
Bexagliflozin PK parametersGlimepiride PK parameters
Group 2: Bexagliflozin + Glimepiride1162.2633.0

[back to top]

AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject. (NCT02956044)
Timeframe: Up to 72 hours

Interventionh*ng/mL (Geometric Mean)
Bexagliflozin PK parametersMetformin PK parameters
Group 1: Bexagliflozin + Metformin1008.613784.6

[back to top]

AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject. (NCT02956044)
Timeframe: Up to 72 hours

Interventionh*ng/mL (Geometric Mean)
Sitagliptin PK parameters
Group 3: Sitagliptin Alone3579.6

[back to top]

Cmax (Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

,,
Interventionng/mL (Geometric Mean)
Bexagliflozin PK parameters
Group 1: Bexagliflozin Alone124.6
Group 2: Bexagliflozin Alone158.6
Group 3: Bexagliflozin Alone117.1

[back to top]

AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject. (NCT02956044)
Timeframe: Up to 72 hours

Interventionh*ng/mL (Geometric Mean)
Bexagliflozin PK parametersSitagliptin PK parameters
Group 3: Bexagliflozin + Sitagliptin1158.13692.8

[back to top]

Cmax (Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionng/mL (Geometric Mean)
Glimepiride PK parameters
Group 2: Glimepiride Alone59.9

[back to top]

Cmax (Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionng/mL (Geometric Mean)
Metformin PK parameters
Group 1: Metformin Alone2067.6

[back to top]

Cmax (Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations. (NCT02956044)
Timeframe: Up to 72 hours

Interventionng/mL (Geometric Mean)
Sitagliptin PK parameters
Group 3: Sitagliptin Alone356.6

[back to top]

Change in B-type Natriuretic Peptide With Each Intervention as a Measure of Left Ventricular Function

Changes in B-type Natriuretic Peptide (BNP) with each intervention as a measure of left ventricular function. (NCT02973477)
Timeframe: 12 weeks for each intervention

,
Interventionpg/ml (Mean)
BNP before treatmentBNP after treatment
All Participants Who Received Dapagliflozin12.7214.76
All Participants Who Received Glimepiride16.9315.49

[back to top]

Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride.

Heart Rate Variability, as shown by the difference of the LF:HF ratio from baseline to 12 weeks per arm (two 12-week periods with a 2-week washout period. The frequency domain measures [ low-frequency (LF) power (0.04-0.15 Hz), high-frequency (HF) power (0.15-0.4 Hz), and LF:HF ratio] are obtained by spectral analysis of R-R interval from continuous electrocardiogram recordings to evaluate for sympathetic/parasympathetic (autonomic nervous function) balance. (NCT02973477)
Timeframe: from first baseline to end of 12 weeks' treatment and from second baseline (following 2 weeks of washout) to end of 12 weeks' treatment

,
InterventionLF:HF ratio (Mean)
value at 12 weeks minus value at 1st baselinevalue at 26 weeks minus value at 2nd baseline
First Dapagliflozin Then Glimepiride-0.180.26
First Glimepiride Then Dapagliflozin-0.340.26

[back to top]

Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs)

Changes in CARTs as defined by: i) expiration/inspiration (E/I) ratio, ii) Valsalva ratio and iii) 30:15 ratio. Cardiovascular autonomic reflex tests assess the cardiovascular autonomic function using provocative physiological maneuvers under paced breathing [R-R response to breathing (E:I ratio), to Valsalva maneuver (Valsalva ratio) and to postural changes (30:15 ratio)] at baseline and at the end of each study drug period using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.). (NCT02973477)
Timeframe: 12 weeks on each intervention

,
Interventionratio (Mean)
E/I ratio before treatmentEI ratio after treatmentValsalva ratio before treatmentValsalva ratio after treatment30:15 ratio before treatment30:15 ratio after treatment
All Participants Who Received Dapagliflozin1.131.141.501.601.171.14
All Participants Who Received Glimiperide1.141.141.441.581.141.14

[back to top]

Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride.

"Changes in measures of HRV as defined by: Time domain measures of HRV (continuous variables): (i) standard deviation of the normal RR interval (SDNN) (msec) and (ii) root mean square of the differences of successive RR intervals (rmsSD) (msec).~Time domain (SDNN and rmsSD) measures of the normal R-R intervals are derived from HRV studies using a physiologic monitor (Nightingale PPM2; Zoe Medical Inc.) under paced breathing, reflecting parasympathetic activity.~Time domain measures of the normal R-R intervals, basically reflecting parasympathetic activity, include: the difference between the longest and shortestR-R interval, standard deviation of 5-min average of normal R-R intervals (SDANN), root-mean square of the difference of successive R-R intervals (rMSSD)." (NCT02973477)
Timeframe: 12 weeks on each intervention

,
Interventionmsec (Mean)
SDNN before treatmentSDNN after treatmentrmsSD before treatmentrmsSD after treatment
Participants Who Received Dapagliflozin Intervention40.7237.7426.9124.30
Participants Who Received Glimepiride Intervention39.7536.4625.1424.63

[back to top]

Change From Baseline in Hemoglobin A1c at Week 52

An analysis of covariance (ANCOVA) model was used for the analysis. (NCT03332771)
Timeframe: Baseline, Week 52

Interventionpercentage of HbA1c (Least Squares Mean)
Placebo-0.40
Sotagliflozin 400 mg-0.65
Sotagliflozin 200 mg-0.49
Glimepiride-0.61

[back to top]

Percentage of Participants With At Least One Documented Symptomatic Hypoglycemic Event

Documented symptomatic hypoglycemia includes the typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L). (NCT03332771)
Timeframe: Up to Week 52

Interventionpercentage of participants (Number)
Placebo0.63
Sotagliflozin 400 mg1.26
Sotagliflozin 200 mg3.75
Glimepiride16.67

[back to top]

Percentage of Participants With Hypoglycemic Events

Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia [typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)]; Severe [an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions] or documented symptomatic hypoglycemia [typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL]. (NCT03332771)
Timeframe: Up to Week 52

,,,
Interventionpercentage of participants (Number)
Any hypoglycemiaDocumented symptomatic hypoglycemiaSevere or documented symptomatic hypoglycemia
Glimepiride25.916.716.7
Placebo2.50.60.6
Sotagliflozin 200 mg6.33.83.8
Sotagliflozin 400 mg4.11.31.3

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) for All Participants at Week 12

An ANCOVA model was used for the analysis. (NCT03332771)
Timeframe: Baseline, Week 12

InterventionmmHg (Least Squares Mean)
Placebo-2.64
Sotagliflozin 400 mg-4.70
Sotagliflozin 200 mg-4.77
Glimepiride-0.68

[back to top]

Change From Baseline in Body Weight at Week 26 and 52

An ANCOVA model was used for the analysis. (NCT03332771)
Timeframe: Baseline, Week 26, Week 52

,,,
Interventionkilogram (kg) (Least Squares Mean)
Change at Week 26Change at Week 52
Glimepiride0.700.94
Placebo-1.26-0.47
Sotagliflozin 200 mg-2.24-1.74
Sotagliflozin 400 mg-2.75-2.64

[back to top]

Change From Baseline in Hemoglobin A1c at Week 26

An ANCOVA model was used for the analysis. (NCT03332771)
Timeframe: Baseline, Week 26

Interventionpercentage of HbA1c (Least Squares Mean)
Placebo-0.41
Sotagliflozin 400 mg-0.77
Sotagliflozin 200 mg-0.61
Glimepiride-1.02

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) for Participants With SBP ≥130 mmHg at Week 12

An ANCOVA model was used for the analysis. (NCT03332771)
Timeframe: Baseline, Week 12

InterventionmmHg (Least Squares Mean)
Placebo-5.34
Sotagliflozin 400 mg-8.03
Sotagliflozin 200 mg-9.12
Glimepiride-3.86

[back to top]

Percentage of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. (NCT03332771)
Timeframe: Up to Week 52

Interventionpercentage of participants (Number)
Placebo57.2
Sotagliflozin 400 mg59.9
Sotagliflozin 200 mg56.6
Glimepiride49.2

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ethylene dichloride
ethylene dichloride: RN given refers to 1,2-isomer; structure given in first source. 1,2-dichloroethane : A member of the class of chloroethanes substituted by two chloro groups at positions 1 and 2.		2.4620chloroethaneshepatotoxic agent;
mutagen;
non-polar solvent
ethylene glycol
Ethylene Glycol: A colorless, odorless, viscous dihydroxy alcohol. It has a sweet taste, but is poisonous if ingested. Ethylene glycol is the most important glycol commercially available and is manufactured on a large scale in the United States. It is used as an antifreeze and coolant, in hydraulic fluids, and in the manufacture of low-freezing dynamites and resins.. ethanediol : Any diol that is ethane or substituted ethane carrying two hydroxy groups.. ethylene glycol : A 1,2-glycol compound produced via reaction of ethylene oxide with water.		2.4620ethanediol;
glycol		metabolite;
mouse metabolite;
solvent;
toxin
adenine
[no description available]		2.52206-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
quinacrine
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.		2.4620acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
betaine
glycine betaine : The amino acid betaine derived from glycine.		4.2950amino-acid betaine;
glycine derivative		fundamental metabolite
carbamates
[no description available]		11.62297amino-acid anion
carnitine
[no description available]		2.4620amino-acid betainehuman metabolite;
mouse metabolite
coumarin
2H-chromen-2-one: coumarin derivative		2.0710coumarinsfluorescent dye;
human metabolite;
plant metabolite
4-aminophenol
4-aminophenol: RN given refers to parent cpd. 4-aminophenol : An amino phenol (one of the three possible isomers) which has the single amino substituent located para to the phenolic -OH group.		2.0510aminophenolallergen;
metabolite
bupropion
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.		4.4260aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
guaiacol
Guaiacol: An agent thought to have disinfectant properties and used as an expectorant. (From Martindale, The Extra Pharmacopoeia, 30th ed, p747). methylcatechol : Any member of the class of catechols carrying one or more methyl substituents.. guaiacol : A monomethoxybenzene that consists of phenol with a methoxy substituent at the ortho position.		2.0710guaiacolsdisinfectant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
expectorant;
plant metabolite
n(g),n(g')-dimethyl-l-arginine
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine		3.4711alpha-amino acid
aminocaproic acid
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.		4.2550amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		4.08312-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
ethanolamine
[no description available]		2.0610ethanolamines;
primary alcohol;
primary amine		Escherichia coli metabolite;
human metabolite;
mouse metabolite
hexachlorocyclohexane
Lindane: An organochlorine insecticide made up of greater than 99% gamma-Hexachlorocyclohexane. It has been used as a pediculicide and scabicide, and shown to cause cancer.. beta-hexachlorocyclohexane : The beta-isomer of hexachlorocyclohexane.		2.4620chlorocyclohexane
glycine
[no description available]		4.3411alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
histamine
[no description available]		2.0710aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
thioctic acid
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.		2.7620dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector
methanol
Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.		2.4420alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
inositol
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.		7.75115cyclitol;
hexol
melatonin
[no description available]		2.7630acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
acetanilide
acetanilide: a phenylacetamide; use ACETANILIDES for the plural group meaning of the singular term. N-phenylacetamide : A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen is substituted by a phenyl group.		2.0710acetamides;
anilide		analgesic
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		3.8330pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
niacin
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.		4.2850pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
4-nitrophenol
4-nitrophenol: RN given refers to parent cpd. mononitrophenol : A nitrophenol that is phenol carrying a single nitro substituent at unspecified position.. 4-nitrophenol : A member of the class of 4-nitrophenols that is phenol in which the hydrogen that is para to the hydroxy group has been replaced by a nitro group.		2.03104-nitrophenolshuman xenobiotic metabolite;
mouse metabolite
palmitic acid
Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.		3.1450long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite
pyrazinamide
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.		4.4360monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
pyridoxine
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).		4.0940hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyruvic acid
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.		2.01102-oxo monocarboxylic acidcofactor;
fundamental metabolite
thiamine
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.		3.8630primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		3.9821pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.2510isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1-(3-chlorophenyl)piperazine
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.		2.4620monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.		7.610methylpyridines;
phenylpyridine;
tetrahydropyridine		neurotoxin
hoe 33342
BXI-72: structure in first source		2.0410bibenzimidazole;
N-methylpiperazine		fluorochrome
2,4-dinitrophenol
2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed). dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents.. 2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions.		2.4620dinitrophenolallergen;
antiseptic drug;
bacterial xenobiotic metabolite;
geroprotector;
oxidative phosphorylation inhibitor
3-methylcholanthrene
Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.		2.0510ortho- and peri-fused polycyclic arenearyl hydrocarbon receptor agonist;
carcinogenic agent
enprofylline
enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.		2.7430oxopurineanti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug
phenytoin
[no description available]		4.7690imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
5-hydroxydecanoate
5-hydroxydecanoic acid: Potassium Channel Blocker; RN refers to parent cpd		2.0410medium-chain fatty acid
oxyquinoline
Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.		2.0710monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
tacrine
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.		3.6690acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
acebutolol
Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.		4.2550aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		4.94110acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
acetarsol
[no description available]		2.0710acetamides;
anilide
acetazolamide
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)		4.5570monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohexamide
Acetohexamide: A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide.. acetohexamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is replaced by a p-acetylphenylsulfonyl group, while a hydrogen attached to the other nitrogen is replaced by a cyclohexyl group.		3.8730acetophenones;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
acetohydroxamic acid
acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.		3.5620acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
ethacridine
Ethacridine: A topically applied anti-infective agent.		2.0710acridines
4-(acetylamino)benzeneacetic acid
[no description available]		2.0710acetamides;
anilide
adiphenine
adiphenine: was heading 1963-94; use DIPHENYLACETIC ACIDS to search ADIPHENINE 1966-94		2.0710diarylmethane
aklomide
aklomide: structure		2.0710carbonyl compound;
organohalogen compound
alaproclate
alaproclate: specific 5-hydroxytryptamine uptake inhibitors; RN given refers to (DL)-isomer		3.5920alpha-amino acid ester
albendazole
[no description available]		4.2650aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
albuterol
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).		4.87100phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
alendronate
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.		4.08401,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alfuzosin
alfuzosin: structure given in first source		3.5820monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
alosetron
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.		3.8530imidazoles;
pyridoindole		antiemetic;
gastrointestinal drug;
serotonergic antagonist
alprazolam
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.		4.2550organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
alprenolol
Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.		3.3160secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
altretamine
Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.		4.0840triamino-1,3,5-triazine
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		4.6680adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
ambenonium
ambenonium : A symmetrical oxalamide-based bis-quaternary ammonium ion having ethyl and 2-chlorobenzyl groups attached to the nitrogens.		3.2310quaternary ammonium ionEC 3.1.1.8 (cholinesterase) inhibitor
diatrizoic acid
Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.		3.8730acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
amifostine anhydrous
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.		3.8530diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
aminoglutethimide
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.		3.1550dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
p-aminohippuric acid
p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.		3.8630N-acylglycineDaphnia magna metabolite
theophylline
[no description available]		5.01120dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		5.171401-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
dan 2163
[no description available]		2.7530aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
amitriptyline
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.		4.6580carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
amlexanox
amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.		2.4520monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
amlodipine
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.		4.5470dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
amodiaquine
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.		2.0710aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
amoxapine
Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.		4.4160dibenzooxazepineadrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor
amprolium
Amprolium: A veterinary coccidiostat that interferes with THIAMINE metabolism.. amprolium : An organic chloride salt having 1-[(4-amino-2-propylpyrimidin-5-yl)methyl]-2-methylpyridin-1-ium as the counterion. Used for prevention of coccidiosis in poultry and cattle.. amprolium(1+) : A pyridinium ion that is the cationic portion of amprolium, a veterinary drug which is used for prevention of coccidiosis in poultry and cattle.		2.0710pyridinium ioncoccidiostat
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		2.4620acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole
[no description available]		4.0740nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
antazoline
Antazoline: An antagonist of histamine H1 receptors.. antazoline : A member of the class of imidazolines that is 2-aminomethyl-2-imidazoline in which the exocyclic amino hydrogens are replaced by benzyl and phenyl groups. Antazoline is only found in individuals that have taken the drug.		2.0710aromatic amine;
imidazolines;
tertiary amino compound		cholinergic antagonist;
H1-receptor antagonist;
xenobiotic
anthralin
Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.		2.0810anthracenesantipsoriatic
antipyrine
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.		3.5680pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
[no description available]		2.0710aporphine alkaloid
apraclonidine
apraclonidine: relieves postoperative intraocular pressure following trabeculoplasty; RN given refers to parent cpd. apraclonidine : An imidazoline that is 2-amino 4,5-dihydro-1H-imidazoline in which one of the exocyclic amino hydrogens has been replaced by a 4-amino-2,6-dichlorophenyl group.		2.0210dichlorobenzene;
guanidines;
imidazolines		alpha-adrenergic agonist;
antiglaucoma drug;
beta-adrenergic agonist;
diagnostic agent;
ophthalmology drug
arecoline
Arecoline: An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.. arecoline : A tetrahydropyridine that is 1,2,5,6-tetrahydropyridine with a methyl group at position 1, and a methoxycarbonyl group at position 3. An alkaloid found in the areca nut, it acts as an agonist of muscarinic acetylcholine.		2.0710enoate ester;
methyl ester;
pyridine alkaloid;
tetrahydropyridine		metabolite;
muscarinic agonist
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		4.95110benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
astemizole
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.		3.4370benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
atenolol
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.		4.6680ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
azathioprine
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.		4.7790aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
azelaic acid
nonanedioic acid : An alpha,omega-dicarboxylic acid that is heptane substituted at positions 1 and 7 by carboxy groups.		2.0210alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		antibacterial agent;
antineoplastic agent;
dermatologic drug;
plant metabolite
azelastine
azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.		2.7330monochlorobenzenes;
phthalazines;
tertiary amino compound		anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
azobenzene
azobenzene: photosensor molecule known to undergo reversible isomerization from trans to cis on illumination with photons of appropriate wavelength; RN given refers to cpd without isomeric designation; structure. (E)-azobenzene : The (E)-isomer of azobenzene.. (Z)-azobenzene : The (Z)-isomer of azobenzene.. azobenzene : A molecule whose structure comprises two phenyl rings linked by a N=N double bond; the parent compound of the azobenzene class of compounds.		2.1110azobenzenes
baclofen
[no description available]		3.8530amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
bendazac
bendazac : A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.		3.5920indazoles;
monocarboxylic acid		non-steroidal anti-inflammatory drug;
radical scavenger
bendroflumethiazide
Bendroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810). bendroflumethiazide : A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.		3.620benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
benserazide
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.. benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.		2.0710carbohydrazide;
catechols;
primary alcohol;
primary amino compound		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
benzbromarone
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.		9.891001-benzofurans;
aromatic ketone		uricosuric drug
benzocaine
Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.		2.4820benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
benzothiazide
benzothiazide: structure. benzthiazide : 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema.		2.0710benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
bepridil
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.. bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.		2.4420pyrrolidines;
tertiary amine		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
berberine
[no description available]		3.3510alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker
betaxolol
[no description available]		4.460propanolamineantihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bethanechol
Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.. bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.		3.8730carbamate ester;
quaternary ammonium ion		muscarinic agonist
bevantolol
bevantolol: structure given in first source. bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.		2.4520propanolamineanti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
calcium channel blocker
bicalutamide
bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.		4.6780(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
bay h 4502
bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections.. 1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1.		2.0810biphenyls;
imidazoles
biperiden
Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.		4.2750piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic
bisacodyl
Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)		3.8830diarylmethane
bisoprolol
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.		4.460secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bithionol
Bithionol: Halogenated anti-infective agent that is used against trematode and cestode infestations.. bithionol : An aryl sulfide that is diphenyl sulfide in which each phenyl group is substituted at position 2 by hydroxy and at positions 3 and 5 by chlorine. A fungicide and anthelmintic, it was used in various topical drug products for the treatment of liver flukes, but withdrawn after being shown to be a potent photosensitizer with the potential to cause serious skin disorders.		2.4620aryl sulfide;
bridged diphenyl antifungal drug;
bridged diphenyl fungicide;
dichlorobenzene;
organochlorine pesticide;
polyphenol		antifungal agrochemical;
antiplatyhelmintic drug
bretylium
bretylium: RN given refers to parent cpd. bretylium : A quaternary ammonium cation having 2-bromobenzyl, ethyl and two methyl groups attached to the nitrogen. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.		2.0710quaternary ammonium ionadrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent
brimonidine
[no description available]		2.0210imidazoles;
quinoxaline derivative;
secondary amine		adrenergic agonist;
alpha-adrenergic agonist;
antihypertensive agent
bromazepam
Bromazepam: One of the BENZODIAZEPINES that is used in the treatment of ANXIETY DISORDERS.		2.7430organic molecular entity
bromhexine
Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).		2.0710organobromine compound;
substituted aniline;
tertiary amino compound		mucolytic
bromopride
bromopride: RN given refers to parent cpd; structure		2.7530benzamides
seratrodast
[no description available]		2.0710organic molecular entity
bronopol
[no description available]		2.0810nitro compound
brotizolam
brotizolam: structure		2.0410organic molecular entity
buflomedil
buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure		2.7430aromatic ketone
buformin
Buformin: An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.. buformin : A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect.		2.4110biguanidesantineoplastic agent;
antiviral agent;
geroprotector;
hypoglycemic agent;
radiosensitizing agent
bumetanide
[no description available]		4.94110amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bunazosin
bunazosin: structure		2.0410quinazolines
bupivacaine
Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.		3.1550aromatic amide;
piperidinecarboxamide;
tertiary amino compound
buspirone
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.		4.6780azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
busulfan
[no description available]		5.1130methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
secbutabarbital
secbutabarbital: Butabarbital (a synonym for Secbutabarbital) should be distinguished from Butobarbital		3.2310barbiturates
butacaine
butacaine: was MH 1965-92; BUTAPROBENZ & BUTOCAIN were see BUTACAINE 1978-92; use 4-AMINOBENZOIC ACID to search BUTACAINE 1966-92		2.0710benzoate ester
butamben
butamben: structure. butamben : An amino acid ester resulting from the formal condensation of the carboxy group of 4-aminobenzoic acid with the hydroxy group of butan-1-ol. Its local anaesthetic properties have been used for surface anaesthesia of the skin and mucous membranes, and for relief of pain and itching associated with some anorectal disorders.		2.0710amino acid ester;
benzoate ester;
primary amino compound;
substituted aniline		local anaesthetic
butenafine
butenafine: studied on experimental dermatophytosis. butenafine : Trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections.		2.0210naphthalenes;
tertiary amine		antifungal drug;
EC 1.14.13.132 (squalene monooxygenase) inhibitor
caffeine
[no description available]		4.95110purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		4.95110aromatic ether;
nitrile;
polyether;
tertiary amino compound
metrizoate
Metrizoic Acid: A diagnostic radiopaque that usually occurs as the sodium salt.		2.4520monocarboxylic acidradioopaque medium
candesartan
candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.		4.0840benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
carbamylcholine
[no description available]		2.0710
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		4.86100dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
carbinoxamine
carbinoxamine: Note: tradenames that start with Histex refer to more than one drug. carbinoxamine : An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.		3.8730monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
carisoprodol
Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202). carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.		3.2310carbamate estermuscle relaxant
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		3.1550N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
carprofen
carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.		2.0810carbazoles;
organochlorine compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent
carteolol
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.		2.4420quinolone;
secondary alcohol		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
carvedilol
[no description available]		4.5470carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
celecoxib
[no description available]		4.0840organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
cetirizine
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.		3.5620ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
chlorambucil
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.		4.5470aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
chlorcyclizine
chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness		3.2310diarylmethane
chlordiazepoxide
Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.		4.4160benzodiazepine
chlormezanone
Chlormezanone: A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.. chlormezanone : A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.		3.85301,3-thiazine;
lactam;
monochlorobenzenes;
sulfone		antipsychotic agent;
anxiolytic drug;
muscle relaxant
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		4.7790aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chlorothiazide
Chlorothiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812). thiazide : Heterocyclic compound with sulfur and nitrogen in the ring.. chlorothiazide : 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.		3.2310benzothiadiazineantihypertensive agent;
diuretic
chloroxylenol
chloroxylenol: topical antiseptic; RN given refers to parent cpd; structure. 4-chloro-3,5-dimethylphenol : A member of the class of phenols that is 3,5-xylenol which is substituted at position 4 by chlorine. It is bactericidal against most Gram-positive bacteria but less effective against Staphylococci and Gram-negative bacteria, and often inactive against Pseudomonas species. It is ineffective against bacterial spores.		2.0710monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide
chlorpheniramine
Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.		4.5570monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		5.17140organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
chlorpropamide
Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.		6.69161monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
chlorthalidone
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.		4.2650isoindoles;
monochlorobenzenes;
sulfonamide
chlorzoxazone
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.		4.42601,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
cifenline
[no description available]		2.9740diarylmethane
ciclopirox
[no description available]		2.9640cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone		antibacterial agent;
antiseborrheic
ciglitazone
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.		2.9840aromatic ether;
thiazolidinone		antineoplastic agent;
insulin-sensitizing drug
cilostazol
[no description available]		3.6120lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		5.03120aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
aricine
[no description available]		2.0710cinchona alkaloid
cinoxacin
Cinoxacin: Synthetic antimicrobial related to OXOLINIC ACID and NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.. cinoxacin : A member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections.		2.0210cinnolines;
oxacycle;
oxo carboxylic acid		antibacterial drug;
antiinfective agent
ciprofibrate
[no description available]		2.9840cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		4.95110aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
cisapride
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed). cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.		2.7330benzamides
citalopram
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.		4.55702-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
clioquinol
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.		2.0810monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
clobazam
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.. clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.		2.08101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator
clofazimine
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.		2.9740monochlorobenzenes;
phenazines		dye;
leprostatic drug;
non-steroidal anti-inflammatory drug
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		4.6780aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clomiphene
[no description available]		4.140tertiary amineestrogen antagonist;
estrogen receptor modulator
clomipramine
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.		4.7790dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
clonazepam
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.		4.25501,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		4.5470clonidine;
imidazoline
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide
[no description available]		2.4720sulfonamide
chlorazepate
clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.		3.84301,4-benzodiazepinoneanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug
clotrimazole
[no description available]		4.6880conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
cloxyquin
cloxyquin: has antitubercular activity; structure in first source		2.0710organochlorine compound;
quinolines
cromolyn
cromoglycic acid : A dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer.		2.7530chromones;
dicarboxylic acid		anti-asthmatic drug;
calcium channel blocker
cyclandelate
Cyclandelate: A direct-acting SMOOTH MUSCLE relaxant used to dilate BLOOD VESSELS.. cyclandelate : The ester obtained by formal condensation of mandelic acid and 3,3,5-tricyclohexanol. It is a direct-acting smooth muscle relaxant used to dilate blood vessels.		2.0710carboxylic ester;
secondary alcohol		vasodilator agent
cyclobenzaprine
cyclobenzaprine: RN given refers to parent cpd; Lisseril is synonymous for HCl; structure. cyclobenzaprine : 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.		3.8530carbotricyclic compoundantidepressant;
muscle relaxant;
tranquilizing drug
cyclofenil
Cyclofenil: A gonadal stimulant and inducer of ovulation. It is used in the treatment of infertility and amenorrhea, but is thought to be less effective than CLOMIPHENE.		3.5920organic molecular entity
cyproheptadine
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.		3.2310piperidines;
tertiary amine		anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist
dapsone
[no description available]		4.86100substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
debrisoquin
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.		2.0710carboxamidine;
isoquinolines		adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		3.8930acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
desipramine
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.		5.03120dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
nordazepam
Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.		2.04101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative
amphetamine
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.		3.5820primary amine
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		4.65801,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazoxide
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.		12.46143benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
dibenzothiophene
dibenzothiophene : A mancude organic heterotricyclic parent that consists of a thiophene ring flanked by two benzene rings ortho-fused across the 2,3- and 4,5-positions.		2.0710dibenzothiophenes;
mancude organic heterotricyclic parent		keratolytic drug
dibucaine
Dibucaine: A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006). cinchocaine : A monocarboxylic acid amide that is the 2-(diethylamino)ethyl amide of 2-butoxyquinoline-4-carboxylic acid. One of the most potent and toxic of the long-acting local anesthetics, its parenteral use was restricted to spinal anesthesia. It is now generally only used (usually as the hydrochloride) in creams and ointments and in suppositories for temporary relief of pain and itching associated with skin and anorectal conditions.		2.0710aromatic ether;
monocarboxylic acid amide;
tertiary amino compound		topical anaesthetic
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		5.17140amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
dichlorphenamide
Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.		3.620dichlorobenzene;
sulfonamide		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug
dicyclomine
Dicyclomine: A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.. dicyclomine : The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.		3.620carboxylic ester;
tertiary amine		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
diethylcarbamazine
Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.		2.4620N-carbamoylpiperazine;
N-methylpiperazine
pentetic acid
Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.		3.2310pentacarboxylic acidcopper chelator
diflunisal
Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.		4.460monohydroxybenzoic acid;
organofluorine compound		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
dilacor xr
5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate : A lactam that is 2,3-dihydro-1,5-benzothiazepin-4(5H)-one in which positions 2 and 3 are substituted by 4-methoxyphenyl and acetoxy, respectively, while the hydrogen attached to the nitrogen is substituted by a 2-(dimethylamino)ethyl group.		2.0710acetate ester;
aromatic ether;
benzothiazepine;
lactam;
tertiary amino compound
dimercaprol
Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.		3.8630dithiol;
primary alcohol		chelator
dimethadione
Dimethadione: An anticonvulsant that is the active metabolite of TRIMETHADIONE.		2.0710oxazolidinone
diphenhydramine
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.		4.5570ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
diphenylpyraline
diphenylpyraline: RN given refers to parent cpd; structure. allergen : A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.. diphenylpyraline : A member of the class of piperidines that is the benzhydryl ether derivative of 1-methyl-4-hydroxypiperidine. A sedating antihistamine, it is used as the hydrochloride for the symptomatic relief of allergic conditions including rhinitis and hay fever, and in pruritic skin disorders. It is also used as the teoclate salt (piprinhydrinate) as an ingredient in compound preparations for the symptomatic relief of coughs and the common cold.		2.0710piperidines;
tertiary amine		cholinergic antagonist;
H1-receptor antagonist
dipivefrin
dipivefrin: used in treatment of both primary & open angle glaucoma; RN given refers to (+-)-isomer. dipivefrin : The dipivalate ester of (+-)-epinephrine (racepinephrine). A pro-drug of epinephrine, the hydrochloride is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension.		2.0210ethanolamines;
pivalate ester		adrenergic agonist;
antiglaucoma drug;
ophthalmology drug;
prodrug;
sympathomimetic agent
dipyridamole
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.		5.7961piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
disopyramide
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.		4.5470monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
disulfiram
[no description available]		4.4160organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		5.02120branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
domperidone
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.		3.3160benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
donepezil
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.		4.2750aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
doxapram
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.		3.8630morpholines;
pyrrolidin-2-ones		central nervous system stimulant
doxazosin
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.		4.0640aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
doxepin
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.		4.4160dibenzooxepine;
tertiary amino compound		antidepressant
doxylamine
Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.		3.620pyridines;
tertiary amine		anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative
droperidol
Droperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593). droperidol : An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon.		3.8530aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
dyclonine
[no description available]		2.0710aromatic ketone;
piperidines		topical anaesthetic
dyphylline
Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.		4.0840oxopurine;
propane-1,2-diols		bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent
e 4031
E 4031: class III anti-arrhythmia agent; structure given in UD		1.9910sulfonamide
ebastine
[no description available]		2.0810organic molecular entity
ebselen
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.		2.0710benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
econazole
Econazole: An imidazole derivative that is commonly used as a topical antifungal agent.. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.. 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group.		2.7530dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes
edrophonium
Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.. edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.		3.2310phenols;
quaternary ammonium ion		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
enflurane
Enflurane: An extremely stable inhalation anesthetic that allows rapid adjustments of anesthesia depth with little change in pulse or respiratory rate.. enflurane : An ether in which the oxygen atom is connected to 2-chloro-1,1,2-trifluoroethyl and difluoromethyl groups.		2.0210ether;
organochlorine compound;
organofluorine compound		anaesthetic
enoxacin
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.		2.73301,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		2.0410
estazolam
Estazolam: A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than DIAZEPAM or NITRAZEPAM.. estazolam : A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia.		3.5620triazoles;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA modulator
ethacrynic acid
Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.		4.2850aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
ether
Ether: A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes.. ether : An organooxygen compound with formula ROR, where R is not hydrogen.. diethyl ether : An ether in which the oxygen atom is linked to two ethyl groups.		2.0210ether;
volatile organic compound		inhalation anaesthetic;
non-polar solvent;
refrigerant
profenamine
profenamine: was heading 1972-94 (see under PHENOTHIAZINES 1972-90); use PHENOTHIAZINES to search ETHOPROPAZINE 1972-94. profenamine : A member of the class of phenothiazines that is phenothiazine in which the hydrogen attached to the nitrogen is substituted by a 2-(diethylamino)propyl group. An antimuscarinic, it is used as the hydrochloride for the symptomatic treatment of Parkinson's disease.		2.0710phenothiazines;
tertiary amino compound		adrenergic antagonist;
antidyskinesia agent;
antiparkinson drug;
histamine antagonist;
muscarinic antagonist
ethosuximide
Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.		4.2750dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
ethotoin
ethotoin: was heading 1966-94 (see under HYDANTOINS 1966-90); use HYDANTOINS to search ETHOTOIN 1966-94. ethotoin : An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.		3.620imidazolidine-2,4-dioneanticonvulsant
etidronate
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.		4.08401,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
etilefrine
Etilefrine: A phenylephrine-related beta-1 adrenergic and alpha adrenergic agonist used as a cardiotonic and antihypotensive agent.		2.7430phenols
etodolac
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.		4.0840monocarboxylic acid;
organic heterotricyclic compound		antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
brl 42810
[no description available]		4.07402-aminopurines;
acetate ester		antiviral drug;
prodrug
famotidine
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.		2.07101,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
carbonyl cyanide p-trifluoromethoxyphenylhydrazone
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.		2.4620aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore
felbamate
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.		4.4160carbamate esteranticonvulsant;
neuroprotective agent
4-biphenylylacetic acid
biphenyl-4-ylacetic acid : A monocarboxylic acid in which one of the alpha-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis.		2.0810biphenyls;
monocarboxylic acid		non-steroidal anti-inflammatory drug
felodipine
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.		4.6580dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
fendiline
Fendiline: Coronary vasodilator; inhibits calcium function in muscle cells in excitation-contraction coupling; proposed as antiarrhythmic and antianginal agents.		2.0410diarylmethane
fenfluramine
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.. fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.		2.0210(trifluoromethyl)benzenes;
secondary amino compound		appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
fenofibrate
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE		5.04120aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
fenoldopam
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.		3.620benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
fenoprofen
Fenoprofen: A propionic acid derivative that is used as a non-steroidal anti-inflammatory agent.. fenoprofen : A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.		4.1140monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
berotek
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.		2.4620resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
fenspiride
fenspiride: was heading 1975-94 (see under SPIRO COMPOUNDS 1975-90); use SPIRO COMPOUNDS to search FENSPIRIDE 1975-94; bronchodilator agent used in asthma		2.4520azaspiro compound
fentanyl
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.		2.7330anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
fexofenadine
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.		4.2550piperidines;
tertiary amine		anti-allergic agent;
H1-receptor antagonist
fipexide
fipexide: regulates dopaminergic systems at macromolecular level		4.2850benzodioxoles
flavoxate
Flavoxate: A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.. flavoxate : A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.		3.5920carboxylic ester;
flavones;
piperidines;
tertiary amino compound		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
flecainide
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).		4.460aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug
fleroxacin
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.		2.9740difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines		antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		11.24101conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flucytosine
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.		4.7690aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
flufenamic acid
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16). flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.		2.4620aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluphenazine
[no description available]		4.2550N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
flumazenil
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.		4.95110ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
flunitrazepam
Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.		2.04101,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes		anxiolytic drug;
GABAA receptor agonist;
sedative
fluorescite
fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.		4.2650benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye		fluorescent dye;
radioopaque medium
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		5.46110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
fluoxetine
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.		9.87100(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
fluphenazine depot
fluphenazine decanoate : The prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia.		2.0210decanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines		dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug
fluphenazine enanthate
[no description available]		2.0210phenothiazines
flurazepam
Flurazepam: A benzodiazepine derivative used mainly as a hypnotic.. flurazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.		3.23101,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
flurbiprofen
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.		4.7790fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluspirilene
Fluspirilene: A long-acting injectable antipsychotic agent used for chronic schizophrenia.		2.4620diarylmethane
flutamide
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.		4.96110(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
fomepizole
Fomepizole: A pyrazole and competitive inhibitor of ALCOHOL DEHYDROGENASE that is used for the treatment of poisoning by ETHYLENE GLYCOL or METHANOL.. fomepizole : A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.		3.2310pyrazolesantidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		4.5470carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
furosemide
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.		5.24150chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
gabapentin
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.		4.7690gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
gemfibrozil
[no description available]		11.6691aromatic etherantilipemic drug
glafenine
Glafenine: An anthranilic acid derivative with analgesic properties used for the relief of all types of pain.. glafenine : A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.		4.2750aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound		inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gliclazide
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.		12.565513N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger
glipizide
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.		8.44401aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines		EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue
glutethimide
Glutethimide: A hypnotic and sedative. Its use has been largely superseded by other drugs.		2.4620piperidines
glyburide
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.		16.2614120monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester
[no description available]		3.2310benzenes
granisetron
[no description available]		4.460aromatic amide;
indazoles
guaifenesin
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.		3.620methoxybenzenes
guanethidine
Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.		4.1140azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
guanfacine
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.		4.5470acetamides
guanidine
Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.		3.2310carboxamidine;
guanidines;
one-carbon compound
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		5.03120aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
halothane
[no description available]		2.0210haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound		inhalation anaesthetic
hexachlorophene
Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.		2.4620bridged diphenyl fungicide;
polyphenol;
trichlorobenzene		acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug
hexobarbital
Hexobarbital: A barbiturate that is effective as a hypnotic and sedative.. hexobarbital : A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.		2.4520barbiturates
hexoprenaline
Hexoprenaline: Stimulant of adrenergic beta 2 receptors. It is used as a bronchodilator, antiasthmatic agent, and tocolytic agent.		2.0710
hexamethylene bisacetamide
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208		2.0710acetamides
hycanthone
Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.		2.7530thioxanthenesmutagen;
schistosomicide drug
hydralazine
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.		4.0840azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
hydrochlorothiazide
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.		4.5470benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
hydroflumethiazide
Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.		4.2750benzothiadiazine;
thiazide		antihypertensive agent;
diuretic
hydroxychloroquine
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.		6.0742aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
hydroxyurea
[no description available]		4.86100one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
hydroxyzine
Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.		4.2750hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
hypericin
[no description available]		2.0410
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		5.02120monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
phenelzine
Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.		4.2550primary amine
lidocaine
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.		4.6780benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
ifosfamide
[no description available]		4.86100ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.		4.7790dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.		4.7690bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide
Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.		4.2650indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		5.68140aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
iodixanol
iodixanol: dimeric contrast media; structure given in first source. iodixanol : A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography.		2.0210organoiodine compoundradioopaque medium
iodoquinol
Iodoquinol: One of the halogenated 8-quinolinols widely used as an intestinal antiseptic, especially as an antiamebic agent. It is also used topically in other infections and may cause CNS and eye damage. It is known by very many similar trade names world-wide.. iodoquinol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by iodine. It is considered the drug of choice for treating asymptomatic or moderate forms of amoebiasis.		2.0710monohydroxyquinoline;
organoiodine compound		antiamoebic agent;
antibacterial agent;
antiprotozoal drug;
antiseptic drug
iohexol
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.		2.7330benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
iopromide
iopromide: structure given in first source. iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.		2.7330dicarboxylic acid diamide;
organoiodine compound		environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic
iothalamic acid
Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.		2.0410organic molecular entity
ioversol
[no description available]		3.5620amidobenzoic acid
iproniazid
[no description available]		4.6880carbohydrazide;
pyridines
avapro
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.		4.6880azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
1-methyl-3-isobutylxanthine
1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES. 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.		1.98103-isobutyl-1-methylxanthine
isocarboxazid
Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)		4.0840benzenes
isoetharine
Isoetharine: Adrenergic beta-2 agonist used as bronchodilator for emphysema, bronchitis and asthma.		2.0710catecholamine
isoflurane
Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.		2.0210organofluorine compoundinhalation anaesthetic
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		10.03120carbohydrazideantitubercular agent;
drug allergen
isoproterenol
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.		4.4260catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
isoxsuprine
Isoxsuprine: A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.		3.620alkylbenzene
isradipine
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.		4.460benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
itraconazole
[no description available]		4.7690piperazines
ketamine
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.		4.2750cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketanserin
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.		3.1550aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		4.86100dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		4.7690benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
ketorolac
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.		4.5470amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate		analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
ketotifen
Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.		4.3741cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound		anti-asthmatic drug;
H1-receptor antagonist
labetalol
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.		4.95110benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound
lamotrigine
[no description available]		4.08401,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
lansoprazole
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.		4.7690benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
leflunomide
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.		4.5670(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
letrozole
[no description available]		4.5470nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lofepramine
Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.		2.0810aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound		antidepressant
lomefloxacin
lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.		3.5620fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antimicrobial agent;
antitubercular agent;
photosensitizing agent
lomustine
[no description available]		3.6120N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
loperamide
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.		3.8730monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
loratadine
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.		4.0740benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
lorazepam
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.		4.0840benzodiazepine
losartan
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position		5.1130biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
loxapine
Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.		3.5620dibenzooxazepineantipsychotic agent;
dopaminergic antagonist
ly 171883
LY 171883: structure in first source; leukotriene receptor antagonist. tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity.		2.0710acetophenones;
aromatic ether;
phenols;
tetrazoles		anti-asthmatic drug;
leukotriene antagonist
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		2.7430chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
maprotiline
Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.		4.86100anthracenes
mebendazole
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.		4.7690aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
mecamylamine
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.		3.2310primary aliphatic amine
mechlorethamine
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.		3.2310nitrogen mustard;
organochlorine compound		alkylating agent
meclizine
Meclizine: A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.		3.5920diarylmethane
meclofenamic acid
Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.		3.8530aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
meclofenamate sodium anhydrous
[no description available]		2.4620organic sodium salt
mefenamic acid
Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.		4.4260aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
mefloquine hydrochloride
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.		2.0210organofluorine compound;
piperidines;
quinolines;
secondary alcohol
memantine
[no description available]		4.0940adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
vitamin k 3
Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.		2.46201,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
mepenzolate
mepenzolic acid: anticholinergic, antispasmodic agent; RN given refers to parent cpd; structure		3.2310diarylmethane
meperidine
Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.		3.8530ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
mephenesin
Mephenesin: A centrally acting muscle relaxant with a short duration of action.. 1-(2-methylphenyl)glycerol : A glycerol ether in which a single 2-methylphenyl group is attached at position 1 of glycerol via an ether linkage.		2.0710aromatic ether;
glycerol ether
mephenytoin
Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.		3.620imidazolidine-2,4-dioneanticonvulsant
mepivacaine
Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.		3.5820piperidinecarboxamidedrug allergen;
local anaesthetic
meprobamate
Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)		4.0840organic molecular entity
benzoic acid [2-methyl-2-(propylamino)propyl] ester
[no description available]		2.0710benzoate ester
mesalamine
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.		4.2550amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug
mesoridazine
Mesoridazine: A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE.. mesoridazine : A phenothiazine substituted at position 2 (para to the S atom) by a methylsulfinyl group, and on the nitrogen by a 2-(1-methylpiperidin-2-yl)ethyl group.		3.2310phenothiazines;
sulfoxide;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic
metaproterenol
Metaproterenol: A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.. orciprenaline : A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.. 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol : A member of the class of resorcinols bearing an additional 1-hydroxy-2-(isopropanylamino)ethyl substituent at position 5 of resorcinol itself.		4.1140aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		21.92273159guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
methadone
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.		4.0840benzenes;
diarylmethane;
ketone;
tertiary amino compound
methapyrilene
Methapyrilene: Histamine H1 antagonist with sedative action used as a hypnotic and in allergies.. methapyrilene : A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.		2.9740ethylenediamine derivativeanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
methazolamide
Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.		3.2310sulfonamide;
thiadiazoles
methocarbamol
Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.		3.620aromatic ether;
carbamate ester;
secondary alcohol
methoxsalen
Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.		3.2310aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
methyclothiazide
Methyclothiazide: A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)		3.2310benzothiadiazine
nocodazole
[no description available]		2.4620aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
methylphenidate
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.		4.2650beta-amino acid ester;
methyl ester;
piperidines
metoclopramide
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.		4.6580benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
metolazone
Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.		4.4160organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor
metoprolol
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.		4.95110aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		4.7690C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
metyrapone
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.		3.8730aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.		4.5570aromatic ether;
primary amino compound		anti-arrhythmia drug
mianserin
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.		2.9840dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
miconazole
Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.		2.7530dichlorobenzene;
ether;
imidazoles
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		4.7690imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
midodrine
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.. midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.		3.5620amino acid amide;
aromatic ether;
secondary alcohol		alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent
milrinone
[no description available]		4.2550bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
minoxidil
Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.		4.4160dialkylarylamine;
tertiary amino compound
mirtazapine
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.		4.4160benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist
mitotane
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.		3.620diarylmethane
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		4.2450dihydroxyanthraquinoneanalgesic;
antineoplastic agent
moclobemide
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.		3.1550benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
modafinil
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.. modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.. 2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.		3.2310monocarboxylic acid amide;
sulfoxide
moxisylyte
Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)		3.5920monoterpenoid
acecainide
Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.		3.1650acetamides;
benzamides		anti-arrhythmia drug
ethylmaleimide
Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.		210maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
nabumetone
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.		3.5620methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
nadolol
[no description available]		4.140tetralins
nafronyl
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.		2.0710naphthalenes
naftopidil
[no description available]		2.0710piperazines
nalidixic acid
[no description available]		4.09401,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
naphazoline
Naphazoline: An adrenergic vasoconstrictor agent used as a decongestant.		2.0710naphthalenes
naratriptan
naratriptan: structure given in first source		4.2550heteroarylpiperidine;
sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
nefazodone
nefazodone: may be useful as an opiate adjunct		5.11130aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
nefopam
Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.		2.7530benzoxazocine;
tertiary amino compound
neostigmine
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.		2.7630quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		5.03120cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nialamide
Nialamide: An MAO inhibitor that is used as an antidepressive agent.		3.5920organonitrogen compound;
organooxygen compound
nicardipine
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.		4.86100benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		5.36170C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
niflumic acid
Niflumic Acid: An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.		2.1710aromatic carboxylic acid;
pyridines
nilutamide
[no description available]		3.5620(trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone		androgen antagonist;
antineoplastic agent
nilvadipine
[no description available]		2.4120dihydropyridine;
isopropyl ester;
methyl ester;
nitrile
nimesulide
nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.		4.5770aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
nimodipine
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.		4.941102-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nisoldipine
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.		4.85100C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nitrazepam
Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).		3.3601,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
nitrendipine
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.		3.1550C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
nitroglycerin
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.		3.2310nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
nitromide
nitromide: antibacterial agent for prevention & treatment of Salmonella pullorum infections in chickens & turkeys & for fowl typhoid & paratyphoid; used in feed; structure		2.0710
nizatidine
[no description available]		4.65801,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist
nomifensine
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.		4.7790isoquinolinesdopamine uptake inhibitor
masoprocol
nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)		2.0210catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		3.8530fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
nortriptyline
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.		4.7790organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one
[no description available]		2.0710isoquinolines
nylidrin
Nylidrin: A beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor.		2.0710alkylbenzene
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		11.14913-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		4.7690aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
ondansetron
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.		4.4160carbazoles
orphenadrine
Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.. orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.		3.620ether;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
oxaprozin
Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.		4.26501,3-oxazoles;
monocarboxylic acid		analgesic;
non-steroidal anti-inflammatory drug
oxazepam
Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.		4.25501,4-benzodiazepinone;
organochlorine compound		anxiolytic drug;
environmental contaminant;
xenobiotic
oxethazaine
[no description available]		2.0710amino acid amide
oxibendazole
oxibendazole: structure		2.7530benzimidazoles;
carbamate ester
oxiracetam
oxiracetam: structure in first source		2.4520organonitrogen compound;
organooxygen compound
oxprenolol
Oxprenolol: A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.		2.0710aromatic ether
benoxinate
benoxinate: RN given refers to parent cpd; structure. oxybuprocaine : A benzoate ester in which 4-amino-3-butoxybenzoic acid and 2-(diethylamino)ethanol have combined to form the ester bond; an ester-based local anaesthetic (ester "caine") used especially in ophthalmology and otolaryngology.		2.0710amino acid ester;
benzoate ester;
substituted aniline;
tertiary amino compound		drug allergen;
local anaesthetic;
topical anaesthetic
oxybutynin
oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.		4.5670acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic
aminosalicylic acid
Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.		4.2850aminobenzoic acid;
phenols		antitubercular agent
pamidronate
[no description available]		4.2550phosphonoacetic acid
pantoprazole
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.		4.2550aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic
papaverine
Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.		4.5570benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
4-dichlorobenzene
dichlorobenzene : Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.. 1,4-dichlorobenzene : A dichlorobenzene carrying chloro groups at positions 1 and 4.		2.4620dichlorobenzeneinsecticide
pargyline
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.		2.7530aromatic amine
pemoline
Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.		4.41601,3-oxazolescentral nervous system stimulant
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		4.4160aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
pentobarbital
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		3.5820barbituratesGABAA receptor agonist
pentoxifylline
[no description available]		4.2550oxopurine
perhexiline
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.		4.4360piperidinescardiovascular drug
perphenazine
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.		4.5470N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
phenacemide
phenacemide: anti-epileptic drug; structure		2.0710acetamides
phenacetin
Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione		3.4470acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		4.6680barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
phenoxybenzamine
Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.		4.1140aromatic amine
phentermine
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.		3.5920primary amineadrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent
4-phenylbutyric acid
4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.		3.2310monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
phenylbutazone
Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.		2.4620pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
moxonidine
moxonidine: structure given in first source		2.7430organohalogen compound;
pyrimidines
1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate
[no description available]		2.0710pyrroloindole
pimobendan
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source		2.0410benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
pinacidil
Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)		2.9740pyridines
pindolol
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.		4.7690indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
pioglitazone
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.		17.9311066aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
piperazine
[no description available]		7.1110azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent		anthelminthic drug
piracetam
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.		2.4820organonitrogen compound;
organooxygen compound
pirbuterol
pirbuterol: structure		2.0210pyridines
pirenzepine
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.		2.0710pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
piretanide
piretanide: potent inhibitor of chloride transport; structure		2.7430aromatic ether
piribedil
Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.		2.0810N-arylpiperazine
polythiazide
[no description available]		3.2310benzothiadiazine
ag 1879
3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor		3.2710aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine		beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
practolol
Practolol: A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS.. practolol : N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythmias.		2.7530acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
beta-adrenergic antagonist
duodote
duodote: consists of atropine and pralidoxime chloride; for treating those exposed to organophosphorus-containing nerve agents		3.620pyridinium ionantidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator
pramoxine
pramoxine: RN given refers to parent cpd; structure. pramocaine : A member of the class of morpholines that is morpholine substituted at the nitrogen atom by a 3-(4-butoxyphenoxy)propyl group.		2.0410aromatic ether;
morpholines		local anaesthetic
ono 1078
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist		2.0810chromones
pyranoprofen
pyranoprofen: RN given refers to unlabled parent cpd; structure given in first source		2.0810pyridochromene
prazepam
Prazepam: A benzodiazepine that is used in the treatment of ANXIETY DISORDERS.		2.0210benzodiazepine
praziquantel
azinox: Russian drug		4.4160isoquinolines
prazosin
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.		4.94110aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine
Prilocaine: A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.. prilocaine : An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic.		2.0410amino acid amide;
monocarboxylic acid amide		anticonvulsant;
local anaesthetic
primaquine
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.		4.5670aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
primidone
Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.		4.6680pyrimidoneanticonvulsant;
environmental contaminant;
xenobiotic
proadifen
Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.		2.0710diarylmethane
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		4.95110benzoic acids;
sulfonamide		uricosuric drug
probucol
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.		2.7530dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
procainamide
Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.		4.6580benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
procaine
Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).. procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.		2.0710benzoate ester;
substituted aniline;
tertiary amino compound		central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug
procarbazine
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.		3.5620benzamides;
hydrazines		antineoplastic agent
prochlorperazine
Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.		4.4260N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
procyclidine
Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.		4.4160pyrrolidines;
tertiary alcohol		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist
promazine
Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.		2.4620phenothiazines;
tertiary amine		antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
promethazine
Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.		4.2650phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
propafenone
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.		4.5470aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
propantheline
Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.		3.2310xanthenes
propofol
Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.		4.2550phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		5.17140naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
protriptyline
Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.		3.8630carbotricyclic compoundantidepressant
pyridostigmine
[no description available]		4.0840pyridinium ion
pyrilamine
Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.		2.0710aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
pyrimethamine
Maloprim: contains above 2 cpds		4.2650aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
sch 16134
quazepam: structure given in first source		3.5620benzodiazepine
quetiapine
[no description available]		3.2310dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
rabeprazole
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.		4.0840benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
raloxifene
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.		4.08401-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
ranitidine
[no description available]		3.6690aralkylamine
riluzole
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.		4.4160benzothiazoles
rimantadine
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.		3.5620alkylamine
risperidone
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.		5.021201,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
ritanserin
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.. ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.		2.0410organofluorine compound;
piperidines;
thiazolopyrimidine		antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
rizatriptan
rizatriptan: structure given in first source; RN given refers to benzoate		4.0740tryptaminesanti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
rofecoxib
[no description available]		2.9740butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
ropinirole
[no description available]		3.5720indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
roxarsone
Roxarsone: An arsenic derivative which has anticoccidial action and promotes growth in animals.. roxarsone : An organoarsonic acid where the organyl group is 4-hydroxy-3-nitrophenyl.		2.07102-nitrophenols;
organoarsonic acid		agrochemical;
animal growth promotant;
antibacterial drug;
coccidiostat
saccharin
Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.		2.03101,2-benzisothiazole;
N-sulfonylcarboxamide		environmental contaminant;
sweetening agent;
xenobiotic
salicylamide
salamide: a major impurity of hydrochlorothiazide; structure in first source		2.0710phenols;
salicylamides		antirheumatic drug;
non-narcotic analgesic
salmeterol xinafoate
salmeterol : A racemate consisting of equal parts of (R)- and (S)-salmeterol. It is a potent and selective beta2-adrenoceptor agonist (EC50 = 5.3 nM). Unlike other beta2 agonists, it binds to the exo-site domain of beta2 receptors, producing a slow onset of action and prolonged activation.. 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol : A phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine.		2.0210ether;
phenols;
primary alcohol;
secondary alcohol;
secondary amino compound
salicylsalicylic acid
salicylsalicylic acid: structure. salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.		3.620benzoate ester;
benzoic acids;
phenols;
salicylates		antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
secobarbital
Secobarbital: A barbiturate that is used as a sedative. Secobarbital is reported to have no anti-anxiety activity.. secobarbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by prop-2-en-1-yl and pentan-2-yl groups.		3.2310barbituratesanaesthesia adjuvant;
GABA modulator;
sedative
sevoflurane
Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.. sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.		2.0210ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor
sibutramine
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride		3.6820organochlorine compound;
tertiary amino compound		anti-obesity agent;
serotonin uptake inhibitor
sulfadiazine
Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.		4.6680pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
risedronic acid
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.		4.0840pyridines
sotalol
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.		4.6580ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
spiperone
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.		2.0710aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
imatinib
[no description available]		4.5570aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		3.8730dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
succinylcholine
Succinylcholine: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.. succinylcholine : A quaternary ammonium ion that is the bis-choline ester of succinic acid.		3.5920quaternary ammonium ion;
succinate ester		drug allergen;
muscle relaxant;
neuromuscular agent
succinylsulfathiazole
succinylsulfathiazole: intestinal antimicrobial agent; structure		2.07101,3-thiazoles
sulconazole
sulconazole: RN given refers to cpd with unspecified isomeric designation; structure given in first source. sulconazole : A racemate comprising equimolar amounts of (R)- and (S)-sulconazole. An antifungal agent with activity against Candida species, it is used (generally as the nitrate salt) for the topical treatment of fungal skin infections.. 1-{2-[(4-chlorobenzyl)sulfanyl]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole : A member of the class of imidazoles that is 1-ethyl-1H-imidazole in which one of the hydrogens of the methyl group is replaced by a (4-chlorobenzyl)sulfanediyl group while a second is replaced by a 2,4-dichlorophenyl group.		2.0210dichlorobenzene;
imidazoles;
monochlorobenzenes;
organic sulfide
sulfabenzamide
sulfabenzamide : A sulfonamide containing a benzamido substituent on nitrogen. An antibacterial/antimicrobial, it is often used in conjunction with sulfathiazole and sulfacetamide as a topical, intravaginal antibacterial preparation.		2.4620benzenes;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antimicrobial drug
sulfacetamide
Sulfacetamide: An anti-bacterial agent that is used topically to treat skin infections and orally for urinary tract infections.. sulfacetamide : A sulfonamide that is sulfanilamide acylated on the sulfonamide nitrogen.		2.0710N-sulfonylcarboxamide;
substituted aniline		antibacterial drug;
antiinfective agent;
antimicrobial agent;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfadimethoxine
Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent.. sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position.		2.0710aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic
sulfamerazine
[no description available]		2.0710pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen
sulfamethazine
Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position.		2.0710pyrimidines;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic
sulfamethizole
Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.		4.0940sulfonamide antibiotic;
sulfonamide;
thiadiazoles		antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.		3.5780isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfanilamide
[no description available]		2.4620substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfanitran
[no description available]		2.4620sulfonamide
sulfasalazine
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.		4.6680
sulfathiazole
Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.		3.59201,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sulfinpyrazone
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.		3.4470pyrazolidines;
sulfoxide		uricosuric drug
sulfisoxazole
Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.		3.3160isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
sulfobromophthalein
Sulfobromophthalein: A phenolphthalein that is used as a diagnostic aid in hepatic function determination.		2.05102-benzofurans;
organobromine compound;
organosulfonic acid;
phenols		dye
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol
[no description available]		3.5920alkylbenzene
sulpiride
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.		2.7530benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
sumatriptan
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.		4.7690sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
suprofen
Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.		2.9540aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
suramin
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.		2.7430naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		8.4470N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tazarotene
tazarotene: a topical acetylenic retinoid; a topical kerytolytic. tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.		2.4520acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane		keratolytic drug;
prodrug;
teratogenic agent
telenzepine
telenzepine: structure given in first source		2.7430benzodiazepine
temazepam
Temazepam: A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent.		3.5620benzodiazepine
temozolomide
[no description available]		4.0840imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
terazosin
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia		4.6680furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
terbutaline
Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.		4.4160phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
terfenadine
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.		3.4370diarylmethane
tetracaine
Tetracaine: A potent local anesthetic of the ester type used for surface and spinal anesthesia.. tetracaine : A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia.		2.0710benzoate ester;
tertiary amino compound		local anaesthetic
tetrahydroxy-1,4-quinone
tetrahydroxy-1,4-quinone: structure. tetrahydroxy-1,4-benzoquinone : A hydroxybenzoquinone in which all four protons of the benzoquinone structure are substituted by hydroxy groups. A systemic keratolytic, it is normally supplied as its hydrate (CHEBI:137471).		2.0710hydroxybenzoquinonekeratolytic drug
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		3.8630phthalimides;
piperidones
thiabendazole
Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate		3.6201,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
2,4-thiazolidinedione
thiazolidine-2,4-dione: structure in first source. 1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.		6.1631thiazolidenedione
2-thiosalicylic acid
2-thiosalicylic acid: a degradation product of thimerosal; RN given refers to parent cpd. thiosalicylic acid : A sulfanylbenzoic acid that is the 2-sulfanyl derivative of benzoic acid.		2.0710sulfanylbenzoic acidantipyretic;
non-narcotic analgesic
thioridazine
Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.		4.0740phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
thiotepa
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).		4.5470aziridines
tiapride
[no description available]		2.0810benzamides
ticlopidine
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.		4.5570monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
tilorone
Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.		2.4720aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound		anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist
tinidazole
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.		4.4160imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
tioconazole
tioconazole : A racemate comprising equimolar amounts of (R)- and (S)-tioconazole.. 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that comprises 2-(2,4-dichlorophenyl)ethylimidazole carrying an additional (2-chloro-3-thienyl)methoxy substituent at position 2.		2.0210dichlorobenzene;
ether;
imidazoles;
thiophenes
tiopronin
Tiopronin: Sulfhydryl acylated derivative of GLYCINE.		3.5620N-acyl-amino acid
tizanidine
tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.		4.5470benzothiadiazole;
imidazoles		alpha-adrenergic agonist;
muscle relaxant
nikethamide
Nikethamide: A central nervous system stimulant. It was formerly used in the treatment of barbiturate overdose but is now considered to be of no value for such purposes and may be dangerous. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1229)		2.0810pyridinecarboxamide
tolazamide
Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.		4.350N-sulfonylureahypoglycemic agent;
potassium channel blocker
tolazoline
Tolazoline: A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn.. tolazoline : A member of the class of imidazoles that is 4,5-dihydro-1H-imidazole substituted by a benzyl group.		2.0710imidazolesalpha-adrenergic antagonist;
antihypertensive agent;
vasodilator agent
tolbutamide
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.		5.93180N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
tolmetin
Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.		3.8630aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
tolnaftate
[no description available]		2.4820monothiocarbamic esterantifungal drug
ultram
2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.		4.5370aromatic ether;
tertiary alcohol;
tertiary amino compound
tranexamic acid
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.		3.8630amino acid
trapidil
Trapidil: A coronary vasodilator agent.		2.0710triazolopyrimidines
trazodone
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.		4.87100monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
triamterene
Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.		4.4160pteridinesdiuretic;
sodium channel blocker
triazolam
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.		4.460triazolobenzodiazepinesedative
trientine
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.. TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.. 2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.		2.0210polyazaalkane;
tetramine		copper chelator
trifluoperazine
[no description available]		4.5570N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
trifluperidol
Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)		2.0710aromatic ketone
triflupromazine
Triflupromazine: A phenothiazine used as an antipsychotic agent and as an antiemetic.. triflupromazine : A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position.		2.0710organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
trihexyphenidyl
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.		3.2310amine
trimebutine
Trimebutine: Proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.		2.0710trihydroxybenzoic acid
trimeprazine
Trimeprazine: A phenothiazine derivative that is used as an antipruritic.		2.0710phenothiazines
trimethadione
Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.		4.0740oxazolidinoneanticonvulsant;
geroprotector
trimethobenzamide
trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd. trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.		3.2310benzamides;
tertiary amino compound		antiemetic
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		4.95110aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
trimetrexate
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.		4.0640
trimipramine
Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.		4.0740dibenzoazepine;
tertiary amino compound		antidepressant;
environmental contaminant;
xenobiotic
trioxsalen
Trioxsalen: Pigmenting photosensitizing agent obtained from several plants, mainly Psoralea corylifolia. It is administered either topically or orally in conjunction with ultraviolet light in the treatment of vitiligo.. lactone : Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.. antipsoriatic : A drug used to treat psoriasis.. trioxsalen : 7H-Furo[3,2-g]chromen-7-one in which positions 2, 5, and 9 are substituted by methyl groups. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered orally in conjunction with UV-A for phototherapy treatment of vitiligo. After photoactivation it creates interstrand cross-links in DNA, inhibiting DNA synthesis and cell division, and can lead to cell injury; recovery from the cell injury may be followed by increased melanisation of the epidermis.		2.0710psoralensdermatologic drug;
photosensitizing agent
troglitazone
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.		5.46110chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
tropicamide
Tropicamide: One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic.		2.0710acetamides
thenoyltrifluoroacetone
Thenoyltrifluoroacetone: Chelating agent and inhibitor of cellular respiration.		2.0810
tulobuterol
[no description available]		2.0710organochlorine compound
tyramine
[no description available]		3.2310monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		3.5720aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
undecylenic acid
undecylenic acid: a fatty acid with a terminal double bond. 10-undecenoic acid : An undecenoic acid having its double bond in the 10-position. It is derived from castor oil and is used for the treatment of skin problems.. undecenoic acid : A C11, straight-chain fatty acid carrying a C=C double bond at any position.		2.0810undecenoic acidantifungal drug;
plant metabolite
urapidil
[no description available]		3.1650piperazines
urethane
[no description available]		2.0710carbamate esterfungal metabolite;
mutagen
venlafaxine
venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.		4.7690cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
vigabatrin
[no description available]		3.6120gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
viloxazine
Viloxazine: A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.		2.0410aromatic ether
pirinixic acid
pirinixic acid: structure		2.7630aryl sulfide;
organochlorine compound;
pyrimidines
xylazine
Xylazine: An adrenergic alpha-2 agonist used as a sedative, analgesic and centrally acting muscle relaxant in VETERINARY MEDICINE.. xylazine : A methyl benzene that is 1,3-dimethylbenzene which is substituted by a 5,6-dihydro-4H-1,3-thiazin-2-ylnitrilo group at position 2. It is an alpha2 adrenergic receptor agonist and frequently used in veterinary medicine as an emetic and sedative with analgesic and muscle relaxant properties.		2.07101,3-thiazine;
methylbenzene;
secondary amino compound		alpha-adrenergic agonist;
analgesic;
emetic;
muscle relaxant;
sedative
xylometazoline
xylometazoline: RN given refers to parent cpd; structure		2.0710alkylbenzene
ici 204,219
zafirlukast: a leukotriene D4 receptor antagonist		4.6780carbamate ester;
indoles;
N-sulfonylcarboxamide		anti-asthmatic agent;
leukotriene antagonist
zaleplon
zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.		4.4160nitrile;
pyrazolopyrimidine		anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative
zolpidem
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.		10.2790imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
zomepirac
zomepirac: RN given refers to parent cpd; structure		2.7330aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles		cardiovascular drug;
non-steroidal anti-inflammatory drug
zonisamide
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.		3.87301,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
zopiclone
zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.		2.9740monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
cortisone acetate
Cortisone Acetate: The acetate ester of cortisone that is used mainly for replacement therapy in adrenocortical insufficiency and in the treatment of many allergic and inflammatory disorders.		3.2310corticosteroid hormone
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		3.5920mitomycinalkylating agent;
antineoplastic agent
oxyphenonium
Oxyphenonium: A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of ATROPINE. It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect.		2.4620acylcholine
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		5.5412011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
estriol
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.		2.071016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
reserpine
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.		4.2750alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
cephaloridine
Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.		2.7430beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
phentolamine
Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.		4.2950imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
sorbitol
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).		5.4841glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent
alloxan
Alloxan: Acidic compound formed by oxidation of URIC ACID. It is isolated as an efflorescent crystalline hydrate.. alloxan : A member of the class of pyrimidones, the structure of which is that of perhydropyrimidine substituted at C-2, -4, -5 and -6 by oxo groups.		2.2510pyrimidonehyperglycemic agent;
metabolite
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		2.7330nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
piperonyl butoxide
[no description available]		2.0710benzodioxolespesticide synergist
isoproterenol hydrochloride
[no description available]		2.4620catechols
thyroxine
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.		3.23102-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
dextroamphetamine
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.		3.23101-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
spironolactone
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.		4.53703-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
penicillamine
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.		4.0840non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
cysteine
[no description available]		3.2310cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
prednisone
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.		4.759011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		4.094017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
oxandrolone
Oxandrolone: A synthetic hormone with anabolic and androgenic properties.		3.592017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid		anabolic agent;
androgen
promazine hydrochloride
[no description available]		2.4620hydrochloride
2-acetylaminofluorene
2-Acetylaminofluorene: A hepatic carcinogen whose mechanism of activation involves N-hydroxylation to the aryl hydroxamic acid followed by enzymatic sulfonation to sulfoxyfluorenylacetamide. It is used to study the carcinogenicity and mutagenicity of aromatic amines.		2.05102-acetamidofluorenesantimitotic;
carcinogenic agent;
epitope;
mutagen
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		4.4160penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
idoxuridine
[no description available]		2.4620organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
metaraminol
Metaraminol: A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.. metaraminol : A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension.		2.0710phenylethanolaminesalpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent
pilocarpine
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.		4.2550pilocarpineantiglaucoma drug
pentylenetetrazole
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.		2.0710organic heterobicyclic compound;
organonitrogen heterocyclic compound
triiodothyronine
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.		4.27502-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
isonicotinic acid
isonicotinic acid : A pyridinemonocarboxylic acid in which the carboxy group is at position 4 of the pyridine ring.		2.0510pyridinemonocarboxylic acidalgal metabolite;
human metabolite
biguanides
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.. biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.		3.1310guanidines
carbon tetrachloride
Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.		2.9840chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		4.6680C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		3.2310amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		2.0710aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
vincristine
[no description available]		4.0640acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
physostigmine
Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.		4.2650carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
sucrose
Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.		2.110glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
ethinyl estradiol
Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.		3.447017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
testosterone propionate
Testosterone Propionate: An ester of TESTOSTERONE with a propionate substitution at the 17-beta position.. androgen : A sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.		2.0210steroid ester
tubocurarine
Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.		2.4720bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		4.2750aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
methyltestosterone
Methyltestosterone: A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL).. methyltestosterone : A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.		3.231017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone		anabolic agent;
androgen;
antineoplastic agent
promethazine hydrochloride
[no description available]		2.4620hydrochlorideanti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
geroprotector;
H1-receptor antagonist;
local anaesthetic;
sedative
tetrabenazine
9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.		3.2310benzoquinolizine;
cyclic ketone;
tertiary amino compound
cephalothin
Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.		2.0410azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes		antibacterial drug;
antimicrobial agent
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		4.4360kanamycinsbacterial metabolite
ethopabate
Ethopabate: An inhibitor of folate metabolism. It is used as a coccidiostat in poultry.		2.0710amidobenzoic acid
galactose
galactopyranose : The pyranose form of galactose.		2.1710D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
levodopa
Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease		3.1550amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		3.2310ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		2.4120amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
cysteamine
Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.		3.620amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
acetylcholine chloride
acetylcholine chloride : The chloride salt of acetylcholine, and a parasympatomimetic drug.		3.8630quaternary ammonium salt
phlorhizin
[no description available]		3.5720aryl beta-D-glucoside;
dihydrochalcones;
monosaccharide derivative		antioxidant;
plant metabolite
mepazine
mepazine: major descriptor (66-85); on-line search PHENOTHIAZINES (66-85); Index Medicus search MEPAZINE (66-85); RN given refers to parent cpd. pacatal : A phenothiazine derivative in which 10H-phenothiazine has an N-methylpiperidin-4-ylmethyl substituent at the N-10 position.		3.5920phenothiazines
acepromazine
Acepromazine: A phenothiazine that is used in the treatment of PSYCHOSES.. acepromazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by an acetyl group at position 2 and a 3-(dimethylamino)propyl group at position 10.		2.0710aromatic ketone;
methyl ketone;
phenothiazines;
tertiary amino compound		phenothiazine antipsychotic drug
methoxamine hydrochloride
[no description available]		2.4620dimethoxybenzene
methoxamine
Methoxamine: An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.. methoxamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group and the phenyl ring is 2- and 5-substituted with methoxy groups. It is an antihypotensive agent (pressor), an agonist acting directly at alpha-adrenoceptors with selectivity for the alpha-1 adrenoceptor subtype similar to phenylephrine .		2.0710amphetaminesalpha-adrenergic agonist;
antihypotensive agent
methicillin
Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.		2.4520penicillin allergen;
penicillin		antibacterial drug
cloxacillin
Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.		4.0840penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial agent;
antibacterial drug
bretylium tosylate
Bretylium Tosylate: An agent that blocks the release of adrenergic transmitters and may have other actions. It was formerly used as an antihypertensive agent, but is now proposed as an anti-arrhythmic.. bretylium tosylate : The tosylate salt of bretylium. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.		2.0210organosulfonate salt;
quaternary ammonium salt		adrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent
zoxazolamine
Zoxazolamine: A uricosuric and muscle relaxant. Zoxazolamine acts centrally as a muscle relaxant, but the mechanism of its action is not understood.		2.0710benzoxazole
berlition
berlition: antioxidant preparation containing alpha-lipoic acid, used in the neuroprotective therapy of chronic brain ischemia for correction of free-radical processes. (R)-lipoic acid : The (R)-enantiomer of lipoic acid. A vitamin-like, C8 thia fatty acid with anti-oxidant properties.. lipoic acid : A heterocyclic thia fatty acid comprising pentanoic acid with a 1,2-dithiolan-3-yl group at the 5-position.		2.0710dithiolanes;
heterocyclic fatty acid;
lipoic acid;
thia fatty acid		cofactor;
nutraceutical;
prosthetic group
calcium acetate
calcium acetate: a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer. calcium acetate : The calcium salt of acetic acid. It is used, commonly as a hydrate, to treat hyperphosphataemia (excess phosphate in the blood) in patients with kidney disease: the calcium ion combines with dietary phosphate to form (insoluble) calcium phosphate, which is excreted in the faeces.		3.2310calcium saltchelator
dimethylnitrosamine
Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.		2.4620nitrosaminegeroprotector;
mutagen
lactose
Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.		2.7530lactose
primaquine phosphate
[no description available]		2.4620
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		3.5220aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		9.88173amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
desoxycorticosterone
Desoxycorticosterone: A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE		2.071020-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		4.87100alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
gallamine triethiodide
Gallamine Triethiodide: A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of TUBOCURARINE, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)		2.4620
mebanazine
mebanazine: RN given refers to parent cpd without isomeric designation; structure		3.5920benzenes
uracil mustard
Uracil Mustard: Nitrogen mustard derivative of URACIL. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.		2.4620aminouracil;
nitrogen mustard
oxacillin
Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.		3.8530penicillinantibacterial agent;
antibacterial drug
chloroform
Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.		2.4620chloromethanes;
one-carbon compound		carcinogenic agent;
central nervous system drug;
inhalation anaesthetic;
non-polar solvent;
refrigerant
triamcinolone diacetate
triamcinolone diacetate: lysyl oxidase antagonist; Polcortolon may also refers to triamcinolone		2.0810corticosteroid hormone
dimethylformamide
Dimethylformamide: A formamide in which the amino hydrogens are replaced by methyl groups.. N,N-dimethylformamide : A member of the class of formamides that is formamide in which the amino hydrogens are replaced by methyl groups.		2.0510formamides;
volatile organic compound		geroprotector;
hepatotoxic agent;
polar aprotic solvent
norethindrone
Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.		3.155017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
cycloserine
Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).		3.6204-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
benziodarone
benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)		3.8930aromatic ketone
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		4.0840beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
mannitol
[no description available]		3.5920mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
cytarabine
[no description available]		4.7850beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
trifluridine
Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.		2.4420nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
medroxyprogesterone acetate
[no description available]		2.964020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
sulfobromophthalein sodium
bromosulfophthalein sodium : An organic sodium salt that is the disodium salt of bromosulfophthalein.. bromosulfophthalein : An organosulfonic acid that consists of phthalide bearing four bromo substituents at positions 4, 5, 6 and 7 as well as two 4-hydroxy-3-sulfophenyl groups both located at position 1.		2.0410organic sodium saltdye
mestranol
[no description available]		2.733017beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen
tryptophan
Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.		2.0410erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		5.8561arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
acetonitrile
acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.		2.0410aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
perflutren
Definity: a fluorocarbon-filled ultrasonic contrast agent; Definity is tradename. octafluoropropane : A fluorocarbon that is propane in which all of the hydrogens have been replaced by fluorines.		3.2310fluoroalkane;
fluorocarbon
triamcinolone acetonide
Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.		2.462011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
fluoxymesterone
Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.		3.231011beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid		anabolic agent;
antineoplastic agent
mepenzolate bromide
[no description available]		2.0710diarylmethane
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		2.9640benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
methsuximide
methsuximide: anticonvulsant effective in petit mal & psychomotor epilepsy; has a number of unpleasant & toxic side effects; minor descriptor (75-86); on-line & INDEX MEDICUS search SUCCINIMIDES (75-86); RN given refers to parent cpd without isomeric designation		3.2310organic molecular entity
tromethamine
Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)		3.8630primary amino compound;
triol		buffer
trichloroethylene
Trichloroethylene: A highly volatile inhalation anesthetic used mainly in short surgical procedures where light anesthesia with good analgesia is required. It is also used as an industrial solvent. Prolonged exposure to high concentrations of the vapor can lead to cardiotoxicity and neurological impairment.. triol : A chemical compound containing three hydroxy groups.		2.4620chloroethenesinhalation anaesthetic;
mouse metabolite
dichloroacetic acid
[no description available]		2.0410monocarboxylic acid;
organochlorine compound		astringent;
marine metabolite
pantothenic acid
Pantothenic Acid: A butyryl-beta-alanine that can also be viewed as pantoic acid complexed with BETA ALANINE. It is incorporated into COENZYME A and protects cells against peroxidative damage by increasing the level of GLUTATHIONE.. pantothenic acid : A member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine.. vitamin B5 : Any member of a group of vitamers that belong to the chemical structural class called pantothenic acids that exhibit biological activity against vitamin B5 deficiency. Deficiency of vitamin B5 is rare due to its widespread distribution in whole grain cereals, legumes and meat. Symptoms associated with vitamin B5 deficiency are difficult to asses since they are subtle and resemble those of other B vitamin deficiencies. The vitamers include (R)-pantothenic acid and its ionized and salt forms.. (R)-pantothenate : A pantothenate that is the conjugate base of (R)-pantothenic acid, obtained by deprotonation of the carboxy group.. (R)-pantothenic acid : A pantothenic acid having R-configuration.		2.0710pantothenic acid;
vitamin B5		antidote to curare poisoning;
geroprotector;
human blood serum metabolite
sulfachlorpyridazine
Sulfachlorpyridazine: A sulfonamide antimicrobial used for urinary tract infections and in veterinary medicine.. sulfachloropyridazine : A sulfonamide antimicrobial used for urinary tract infections and in veterinary medicine.		2.0710organochlorine compound;
pyridazines;
sulfonamide		antibacterial drug;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
taurocholic acid
Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.		2.0410amino sulfonic acid;
bile acid taurine conjugate		human metabolite
cyclizine
Cyclizine: A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935). cyclizine : An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group.		2.4620N-alkylpiperazineantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		4.76906-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
rotenone
Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.		2.9740organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
diquat
Diquat: A contact herbicide used also to produce desiccation and defoliation. (From Merck Index, 11th ed). diquat : The organic cation formed formally by addition of an ethylene bridge between the nitrogen atoms of 2,2'-bipyridine. Most often available as the dibromide.		2.0510organic cationdefoliant;
herbicide
brompheniramine
Brompheniramine: Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.. brompheniramine : Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		3.9130organobromine compound;
pyridines		anti-allergic agent;
H1-receptor antagonist
phensuximide
phensuximide: major descriptor (73-84); on-line search SUCCINIMIDES (73-84); Index Medicus search PHENSUXIMIDE (73-84); RN given refers to cpd without isomeric designation		2.0710pyrrolidines
dimethisoquin
[no description available]		2.0710isoquinolines
penicillin v
Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.		5.6251penicillin allergen;
penicillin
isosorbide dinitrate
Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.		4.0840glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
hexachlorobutadiene
hexachlorobutadiene: a potent nephrotoxicant in rats; structure		2.0510organochlorine compound
n-vinyl-2-pyrrolidinone
N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source		2.7830pyrrolidin-2-ones
pseudoephedrine
Pseudoephedrine: A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.. pseudoephedrine : A member of the class of the class of phenylethanolamines that is (1S)-2-(methylamino)-1-phenylethan-1-ol in which the pro-S hydrogen at position 2 is replaced by a methyl group.		3.2310phenylethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
diethylpropion
Diethylpropion: A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290). diethylpropion : An aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity.		3.2310aromatic ketone;
tertiary amine		appetite depressant
phenothiazine
10H-phenothiazine : The 10H-tautomer of phenothiazine.		2.4620phenothiazineferroptosis inhibitor;
plant metabolite;
radical scavenger
synephrine
[no description available]		2.0710ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite
2-bromophenol
bromophenol : A halophenol that is any phenol containing one or more covalently bonded bromine atoms.		2.4620bromophenolmarine metabolite
3-dinitrobenzene
dinitrobenzene : Any member of the class of nitrobenzenes that consists of a benzene ring substituted by two nitro groups. A closed class.. 1,3-dinitrobenzene : A dinitrobenzene that is benzene disubstituted at positions 1 and 3 with nitro groups.		2.0510dinitrobenzeneneurotoxin
pyridostigmine bromide
Pyridostigmine Bromide: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.		2.7530pyridinium salt
4,4'-diaminodiphenylmethane
4,4'-diaminodiphenylmethane: RN given refers to parent cpd; structure. 4,4'-diaminodiphenylmethane : An aromatic amine that is diphenylmethane substituted at the 4-position of each benzene ring by an amino group.		2.4620aromatic amineallergen;
carcinogenic agent
phenylisothiocyanate
phenylisothiocyanate: structure. phenyl isothiocyanate : An isothiocyanate having a phenyl group attached to the nitrogen; used for amino acid sequencing in the Edman degradation.		2.4620isothiocyanateallergen;
reagent
benzonatate
benzonatate: structure in Merck Index, 9th ed, #1107. benzonatate : The ester obtained by formal condensation of 4-butylaminobenzoic acid with nonaethylene glycol monomethyl ether. Structurally related to procaine and benzocaine, it has an anaesthetic effect on the stretch sensors in the lungs, and is used as a non-narcotic cough suppressant.		3.8730benzoate ester;
secondary amino compound;
substituted aniline		anaesthetic;
antitussive
4-bromophenol
4-bromophenol : A bromophenol containing only hydroxy and bromo substituents that are para to one another.		2.4620bromophenolhuman urinary metabolite;
human xenobiotic metabolite;
marine metabolite;
mouse metabolite;
persistent organic pollutant;
rat metabolite
dimethyl succinate
dimethyl succinate: potent insulin secretagogue		2.3920fatty acid methyl ester
2-bromoethylamine
[no description available]		2.4620
allylamine
Allylamine: Possesses an unusual and selective cytotoxicity for VASCULAR SMOOTH MUSCLE cells in dogs and rats. Useful for experiments dealing with arterial injury, myocardial fibrosis or cardiac decompensation.		3.4811alkylamine
allyl alcohol
allyl alcohol: structure. allylic alcohol : An alcohol where the hydroxy group is attached to a saturated carbon atom adjacent to a double bond (R groups may be H, organyl, etc.).. allyl alcohol : A propenol in which the C=C bond connects C-2 and C-3. It is has been found in garlic (Allium sativum). Formerly used as a herbicide for the control of various grass and weed seeds.		2.4620primary allylic alcohol;
propenol		antibacterial agent;
fungicide;
herbicide;
insecticide;
plant metabolite
bromobenzene
[no description available]		2.4620bromoarene;
bromobenzenes;
volatile organic compound		hepatotoxic agent;
mouse metabolite;
non-polar solvent
cyclohexanol
Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.		1.9710cyclohexanols;
secondary alcohol		solvent
n-pentanoic acid
n-pentanoic acid: RN given refers to unlabeled parent cpd. valeric acid : A straight-chain saturated fatty acid containing five carbon atoms.		2.0510short-chain fatty acid;
straight-chain saturated fatty acid		plant metabolite
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.4920pyrrole;
secondary amine
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		9.2874mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
ergotamine
Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.		2.0410peptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent
estradiol dipropionate
estradiol dipropionate: RN given refers to (17beta)-isomer; RN for cpd without isomeric designation not in Chemline 7/83		2.0210steroid ester
methylergonovine
Methylergonovine: A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)		3.2310ergoline alkaloid
imipramine hydrochloride
[no description available]		2.4620hydrochlorideantidepressant
neostigmine bromide
neostigmine bromide : The bromide salt of neostigmine.		2.4520bromide salt
phenformin
Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.		2.9840biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
mephobarbital
Mephobarbital: A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL.. mephobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups.		2.4620barbituratesanticonvulsant
edrophonium chloride
edrophonium chloride : The chloride salt of edrophonium. A reversible inhibitor of cholinesterase with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes), it is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.		2.4620chloride salt;
quaternary ammonium salt		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
framycetin
Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.		2.4620aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
di-n-pentyl phthalate
dipentyl phthalate : A phthalate ester that is the dipentyl ester of benzene-1,2-dicarboxylic acid.		2.4620diester;
phthalate ester		plasticiser
cinchophen
cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94		4.4360quinolines
chloroprocaine
chloroprocaine: RN given refers to parent cpd; structure. chloroprocaine : Procaine in which one of the hydrogens ortho- to the carboxylic acid group is substituted by chlorine. It is used as its monohydrochloride salt as a local anaesthetic, particularly for oral surgery. It has the advantage over lidocaine of constricting blood vessels, so reducing bleeding.		2.0710benzoate ester;
monochlorobenzenes		central nervous system depressant;
local anaesthetic;
peripheral nervous system drug
phenazopyridine hydrochloride
phenazopyridine hydrochloride : A hydrochloride obtained by combining phenazopyridine with one equivalent of hydrochloric acid. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.		2.7730hydrochloridecarcinogenic agent;
local anaesthetic;
non-narcotic analgesic
tetrracaine hydrochloride
leocaine: a crystal beta-modification of the beta-dimethylaminoethyl ether of n-butylaminobenzoic acid hydrochloride		2.4620benzoate ester
ethyl acetate
ethyl acetate : The acetate ester formed between acetic acid and ethanol.		2.4420acetate ester;
ethyl ester;
volatile organic compound		EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor;
metabolite;
polar aprotic solvent;
Saccharomyces cerevisiae metabolite
yohimbine
Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.		2.0710methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
3-o-methylglucose
3-O-Methylglucose: A non-metabolizable glucose analogue that is not phosphorylated by hexokinase. 3-O-Methylglucose is used as a marker to assess glucose transport by evaluating its uptake within various cells and organ systems. (J Neurochem 1993;60(4):1498-504). 3-O-methyl-D-glucose : A D-aldohexose that is D-glucose in which the hydrogen of the hydroxy group at position 3 has been substituted by a methyl group. It is a non-metabolisable glucose analogue that is not phosphorylated by hexokinase and is used as a marker to assess glucose transport by evaluating its uptake within various cells and organ systems.		2.3920D-aldohexose derivative
diphenhydramine hydrochloride
Antitussive Agents: Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.. diphenhydramine hydrochloride : The hydrochloride salt of diphenhydramine.		2.4620hydrochloride;
organoammonium salt		anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative
nafcillin
Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.		4.0640penicillin allergen;
penicillin		antibacterial drug
ditiocarb
Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.		2.0710dithiocarbamic acidschelator;
copper chelator
methohexital
Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.		3.8430acetylenic compound;
barbiturates		drug allergen;
intravenous anaesthetic
fluocortolone
Fluocortolone: A glucocorticoid with anti-inflammatory activity used topically for various skin disorders.		2.031021-hydroxy steroid
tripelennamine hydrochloride
[no description available]		2.4620
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		10.28127azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
adamantane
Adamantane: A tricyclo bridged hydrocarbon.		14.233228adamantanes;
polycyclic alkane
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		4.34111,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazoles
[no description available]		5.19311,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		13.492618diazine;
pyrazines		Daphnia magna metabolite
ethynodiol diacetate
Ethynodiol Diacetate: A synthetic progestational hormone used alone or in combination with estrogens as an oral contraceptive (CONTRACEPTIVES, ORAL).		2.7630steroid ester;
terminal acetylenic compound		contraceptive drug;
estrogen receptor modulator;
synthetic oral contraceptive
propantheline bromide
[no description available]		2.0710xanthenes
ephedrine
Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.		3.2310phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
hydrazine
diamine : Any polyamine that contains two amino groups.		2.4620azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
pirinitramide
Pirinitramide: A diphenylpropylamine with intense narcotic analgesic activity of long duration. It is a derivative of MEPERIDINE with similar activity and usage.		2.4520nitrile
edrophonium bromide
[no description available]		2.4620
estradiol 17 beta-cypionate
[no description available]		2.0210steroid ester
monocrotaline
Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.		2.4620pyrrolizidine alkaloid
testosterone enanthate
[no description available]		2.4620heptanoate ester;
sterol ester		androgen
aminophylline
Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.. aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio.		3.6120mixturebronchodilator agent;
cardiotonic drug
azacitidine
Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.		4.0840N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
pseudoephedrine hydrochloride
pseudoephedrine hydrochloride : A hydrochloride that is the monohydrochloride salt of pseudoephedrine.		2.4620hydrochlorideplant metabolite
galantamine
Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.		5.9371benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
nandrolone decanoate
Nandrolone Decanoate: Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS.		3.2310steroid ester
methysergide
Methysergide: An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.. methysergide : A synthetic ergot alkaloid, structurally related to the oxytocic agent methylergonovine and to the potent hallucinogen LSD and used prophylactically to reduce the frequency and intensity of severe vascular headaches.		2.1310ergoline alkaloid
procarbazine hydrochloride
procarbazine hydrochloride : A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.		2.7630hydrochlorideantineoplastic agent
betamethasone
Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)		3.437011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
fluorometholone
Fluorometholone: A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluorometholone : A member of the class of glucocorticoids that is Delta(1)-progesterone substituted at positions 11beta and 17 by hydroxy groups, at position 6alpha by a methyl group and at position 9 by a fluoro group. Used for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.		2.071011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
cyproterone acetate
[no description available]		2.462020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester		androgen antagonist;
geroprotector;
progestin
lithocholic acid
Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.. lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.. lithocholate : A bile acid anion that is the conjugate base of lithocholic acid.		2.4620bile acid;
C24-steroid;
monohydroxy-5beta-cholanic acid		geroprotector;
human metabolite;
mouse metabolite
nandrolone
Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.. nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.		2.041017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid		human metabolite
dicyandiamido
dicyandiamido: RN given refers to parent cpd; structure. cyanoguanidine : A guanidine in which one of the amino hydrogens of guanidine itself is substituted by a cyano group. It is used in the manufacture of fertilizers, pharmaceuticals, explosives, oil well drilling muds, and dyestuffs.		2.1310guanidines;
nitrile		curing agent;
explosive;
fertilizer;
flame retardant;
nitrification inhibitor
fluorobenzenes
Fluorobenzenes: Derivatives of BENZENE that contain FLUORINE.. monofluorobenzene : The simplest member of the class of monofluorobenzenes that is benzene carrying a single fluoro substituent.. fluorobenzenes : Any fluoroarene that is a benzene or a substituted benzene carrying at least one fluoro group.		2.0810monofluorobenzenesNMR chemical shift reference compound
homocystine
[no description available]		3.4111amino acid zwitterion;
homocystines		human metabolite
dextropropoxyphene
Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.		3.58201-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoatemu-opioid receptor agonist;
opioid analgesic
ketobemidone
ketobemidone: structure		2.0410piperidines
chenodeoxycholic acid
Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.		4.4160bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
emetine
Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.		2.4720isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
dihydralazine
Dihydralazine: 1,4-Dihydrazinophthalazine. An antihypertensive agent with actions and uses similar to those of HYDRALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p354)		2.0710phthalazines
4-hydroxybutyric acid
4-hydroxybutyric acid: was an entry term to Sodium Oxybate (74-98). 4-hydroxybutyric acid : A 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group.		3.23104-hydroxy monocarboxylic acid;
hydroxybutyric acid		general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative
thiazolidines
Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.		7.554thiazolidine
dihydroergotamine
Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.		3.5920ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.0210furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
medroxyprogesterone
[no description available]		3.582017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
dimenhydrinate
gravinol: has antioxidant and ant-inflammatory activities; structure in first source		3.8830diarylmethane
4-(benzoylamino)-2-hydroxybenzoic acid
4-(benzoylamino)-2-hydroxybenzoic acid: Bepask is calcium salt		2.0710benzamides
chlormethiazole
Chlormethiazole: A sedative and anticonvulsant often used in the treatment of alcohol withdrawal. Chlormethiazole has also been proposed as a neuroprotective agent. The mechanism of its therapeutic activity is not entirely clear, but it does potentiate GAMMA-AMINOBUTYRIC ACID receptors response and it may also affect glycine receptors.		2.4520thiazoles
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		3.5820amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
levocarnitine
(R)-carnitine : The (R)-enantiomer of carnitine.		3.8530carnitineantilipemic drug;
nootropic agent;
nutraceutical;
Saccharomyces cerevisiae metabolite;
water-soluble vitamin (role)
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		3.8221dialdehydebiomarker
sulfanilylurea
sulfanilylurea: antimicrobial agent; structure		3.5920benzenes;
sulfonamide
amitriptyline hydrochloride
[no description available]		2.4620organic tricyclic compound
1-naphthylisothiocyanate
1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.		2.9840isothiocyanateinsecticide
lithium carbonate
Lithium Carbonate: A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.		2.0410carbonate salt;
lithium salt		antimanic drug
4-chloromercuribenzenesulfonate
4-Chloromercuribenzenesulfonate: A cytotoxic sulfhydryl reagent that inhibits several subcellular metabolic systems and is used as a tool in cellular physiology.		2.0510arenesulfonic acid;
arylmercury compound
lactulose
[no description available]		3.5920glycosylfructosegastrointestinal drug;
laxative
isoxsuprine hydrochloride
[no description available]		2.4620alkylbenzene
betaine hydrochloride
[no description available]		2.4620
megestrol acetate
[no description available]		2.743020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
pamabrom
[no description available]		3.2310
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		4.460acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
3-hydroxyacetanilide
metacetamol : A derivative of phenol which has an acetamido substituent located meta to the phenolic -OH group. It is a non-toxic regioisomer of paracetamol with analgesic properties, but has never been marketed as a drug.		2.4620acetamides;
phenols		non-narcotic analgesic
methoxyacetic acid
methoxyacetic acid: RN given refers to parent cpd. methoxyacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a methoxy group.		2.4620ether;
monocarboxylic acid		antineoplastic agent;
apoptosis inducer;
human xenobiotic metabolite;
mutagen
trimetozine
[no description available]		2.0710morpholines
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		4.94110cyclic ketone;
erythromycin
dehydroepiandrosterone sulfate
Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone.		2.041017-oxo steroid;
steroid sulfate		EC 2.7.1.33 (pantothenate kinase) inhibitor;
human metabolite;
mouse metabolite
isosorbide
Isosorbide: 1,4:3,6-Dianhydro D-glucitol. Chemically inert osmotic diuretic used mainly to treat hydrocephalus; also used in glaucoma.		2.0610organic molecular entity
docosanol
Tadenan: from powdered bark of Pygaeum africanum (Rosaceae), see also heading for docosanol (a priciple ingredient of extract). docosan-1-ol : A long-chain primary fatty alcohol that is docosane substituted by a hydroxy group at position 1. It is a non-prescription medicine approved by the FDA to shorten healing time of cold sores.. docosanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of twenty-two carbon atoms.		2.0710docosanol;
long-chain primary fatty alcohol		antiviral drug;
plant metabolite
2-piperidone
2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.		5.1733delta-lactam;
piperidones		EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
hydroxychloroquine sulfate
[no description available]		2.0810
levonorgestrel
Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.		4.255017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
lormetazepam
lormetazepam: RN given refers to cpd with specified locant for methyl group; structure given in first source. lormetazepam : A 1,4-benzodiazepinone compound having a methyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-chlorophenyl group at the 5-position and a chloro substituent at the 7-position.		2.74301,4-benzodiazepinone;
organochlorine compound		sedative
vinblastine
[no description available]		2.9640
diphenoxylate
Diphenoxylate: A MEPERIDINE congener used as an antidiarrheal, usually in combination with ATROPINE. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity.. diphenoxylate : A piperidinecarboxylate ester that is the ethyl ester of difenoxin.		3.2310ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine		antidiarrhoeal drug
cyproheptadine hydrochloride (anhydrous)
cyproheptadine hydrochloride (anhydrous) : The hydrochloride salt of cyproheptadine. Note that the drug named cyproheptadine hydrochloride generally refers to cyproheptadine hydrochloride sesquihydrate.		2.4620hydrochloride
estradiol valerate
[no description available]		2.4320steroid ester
ethambutol hydrochloride
ethambutol dihydrochloride : The dihydrchloride salt of ethambutol. A bacteriostatic antimycobacterial drug, it is effective against Mycobacterium tuberculosis and some other mycobacteria. It is used in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol dihydrochloride is used alone.		2.0810hydrochlorideantitubercular agent
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		4.5470ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
tetramethylpyrazine
tetramethylpyrazine: found in Ligusticum chuanxiong. tetramethylpyrazine : A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum wallichii).		2.0710alkaloid;
pyrazines		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
antimycin a
[no description available]		2.4720benzamides;
formamides;
macrodiolide;
phenols		antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		4.6780glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
glycyrrhizic acid
glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.		2.0410enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin		EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
d-alpha tocopherol
Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.		3.2310alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
pregnenolone carbonitrile
Pregnenolone Carbonitrile: A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage.		2.4720aliphatic nitrile
flurandrenolone
Flurandrenolone: A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)		2.071021-hydroxy steroid
ibufenac
ibufenac: used in the treatment of rheumatism; also possesses antipyretic properties; minor descriptor (75-84); on-line & Index Medicus search PHENYLACETATES (75-84); RN given refers to parent cpd. ibufenac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.		4.0840monocarboxylic acidEC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
metylperon
metylperon: RN given refers to parent cpd		2.4620aromatic ketone
metaxalone
[no description available]		3.2310aromatic ether
spectinomycin
Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.		3.5820cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
2,3,7,8-tetrachlorodibenzodioxine
Tetrachlorodibenzodioxin: A mixture of isomers.		2.0510polychlorinated dibenzodioxine
paraquat
Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.		7.7830organic cationgeroprotector;
herbicide
dronabinol
Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.		4.0640benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
amiloride
Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.		3.8630aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
pimozide
Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.		4.460benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
benperidol
Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)		2.0410aromatic ketone
flumethasone
Flumethasone: An anti-inflammatory glucocorticoid used in veterinary practice.		2.071011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
betamethasone valerate
Betamethasone Valerate: The 17-valerate derivative of BETAMETHASONE. It has substantial topical anti-inflammatory activity and relatively low systemic anti-inflammatory activity.. betamethasone valerate : A steroid ester that is betamethasone in which the hydroxy group at the 17alpha position has been converted to the corresponding pentanoate ester.		2.021011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
primary alpha-hydroxy ketone;
steroid ester		anti-inflammatory drug
phenethyl isothiocyanate
phenethyl isothiocyanate: a dietary liver aldehyde dehydrogenase inhibitor; promotes urinary bladder carcinoma. phenethyl isothiocyanate : An isothiocyanate having a phenethyl group attached to the nitrogen. It is a naturally occurring compound found in some cruciferous vegetables (e.g. watercress) and is known to possess anticancer properties.		2.0410isothiocyanateantineoplastic agent;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
metabolite
methylprednisolone hemisuccinate
Methylprednisolone Hemisuccinate: A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies.		2.0210corticosteroid hormone;
hemisuccinate
dexbrompheniramine
dexbrompheniramine : The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		3.2310brompheniramineanti-allergic agent;
H1-receptor antagonist
sulfadoxine
Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.		2.0710pyrimidines;
sulfonamide		antibacterial drug;
antimalarial
chlordesmethyldiazepam
[no description available]		2.0410benzodiazepine
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		4.86100dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine
doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.		2.7430organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
dicloxacillin
Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.		4.5570dichlorobenzene;
penicillin		antibacterial drug
cyclacillin
Cyclacillin: A cyclohexylamido analog of PENICILLANIC ACID.		2.0210penicillinantibacterial drug
megestrol
Megestrol: A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.. megestrol : A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17.		3.231017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
tranylcypromine
Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.		2.44202-phenylcyclopropan-1-amine
streptomycin
[no description available]		4.4260antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
clonidine hydrochloride
[no description available]		2.4620dichlorobenzene
cladribine
[no description available]		4.5470organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
beclomethasone
[no description available]		2.753011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug
fructosamine
Fructosamine: An amino sugar formed when glucose non-enzymatically reacts with the N-terminal amino group of proteins. The fructose moiety is derived from glucose by the classical Amadori rearrangement.		3.8321
ethylene dimethanesulfonate
ethylene dimethanesulfonate: antispermatogenic agent; structure		2.4620
carbenicillin
Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.. carbenicillin : A penicillin antibiotic having a 6beta-2-carboxy-2-phenylacetamido side-chain.		3.8530penicillin allergen;
penicillin		antibacterial drug
estradiol enanthate
[no description available]		2.0210steroid ester
metocurine
metocurine: from Chinese herb Cyclea hainanensis Mrr		2.4720isoquinolines
floxacillin
Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.		3.1450penicillin allergen;
penicillin		antibacterial drug
clomacran
clomacran: RN given refers to parent cpd; structure		3.5920acridines
mexiletine hydrochloride
mexiletine hydrochloride : A hydrochloride composed of equimolar amounts of mexiletine and hydrogen chloride.		2.4620hydrochlorideanti-arrhythmia drug
beclomethasone dipropionate
beclomethasone dipropionate : A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.		2.743011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
enone;
glucocorticoid;
propanoate ester;
steroid ester		anti-arrhythmia drug;
anti-asthmatic drug;
anti-inflammatory drug;
prodrug
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		2.4620beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
betamethasone-17,21-dipropionate
[no description available]		2.021011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
propanoate ester;
steroid ester		antipsoriatic
methenamine hippurate
methenamine hippurate: both parts of molecule contribute to its antibacterial action		3.2310N-acylglycine
terbutylazine
terbutylazine : A diamino-1,3,5-triazine that is N-tert-butyl-N'-methyl-1,3,5-triazine-2,4-diamine substituted by a chloro group at position 6.		2.3110chloro-1,3,5-triazine;
diamino-1,3,5-triazine		environmental contaminant;
herbicide;
xenobiotic
levomethadone
levomethadone : A 6-(dimethylamino)-4,4-diphenylheptan-3-one that has (R)-configuration. It is the active enantiomer of methadone and its hydrochloride salt is used to treat adults who are addicted to drugs such as heroin and morphine.		2.03106-(dimethylamino)-4,4-diphenylheptan-3-oneantitussive;
mu-opioid receptor agonist;
NMDA receptor antagonist;
opioid analgesic
olsalazine
olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.		4.0640azobenzenes;
dicarboxylic acid		non-steroidal anti-inflammatory drug;
prodrug
terodiline
[no description available]		2.7430diarylmethane
1-(4-carboxyphenyl)-3,3-dimethyltriazene
1-(4-carboxyphenyl)-3,3-dimethyltriazene: RN given refers to parent cpd		2.0410
phenylethylmalonamide
Phenylethylmalonamide: A metabolite of primidone.		2.0310amine
metoclopramide hydrochloride
metoclopramide hydrochloride : A hydrate that is the monohydrate form of metoclopramide monohydrochloride.		2.4620
etidronate disodium
etidronate disodium : An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions.		2.0810organic sodium saltantineoplastic agent;
bone density conservation agent;
chelator
silver
Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.		2.2110copper group element atom;
elemental silver		Escherichia coli metabolite
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		3.5680pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
metocurine iodide
[no description available]		2.4520aromatic ether
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.4720delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
potassium persulfate
[no description available]		2.0210
sodium thiosulfate
sodium thiosulfate: do not confuse synonym sodium hyposulfite with sodium hyposulfite, synonym for di-Na salt of dithionous acid. sodium thiosulfate : An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio.		3.2310inorganic sodium saltantidote to cyanide poisoning;
antifungal drug;
nephroprotective agent
carbendazim
carbendazim: carcinogen when combined with sodium nitrite; principle metabolite of thiophanate methyl & benomyl; structure. carbendazim : A member of the class of benzimidazoles that is 2-aminobenzimidazole in which the primary amino group is substituted by a methoxycarbonyl group. A fungicide, carbendazim controls Ascomycetes, Fungi Imperfecti, and Basidiomycetes on a wide variety of crops, including bananas, cereals, cotton, fruits, grapes, mushrooms, ornamentals, peanuts, sugarbeet, soybeans, tobacco, and vegetables.		2.4620benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		antifungal agrochemical;
antinematodal drug;
metabolite;
microtubule-destabilising agent
mafenide acetate
[no description available]		2.0810carboxylic acid
ethionine
L-ethionine : An S-ethylhomocysteine that has S-configuration at the chiral centre.		2.4620S-ethylhomocysteineantimetabolite;
carcinogenic agent
(1S,2R)-tranylcypromine
(1S,2R)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1S,2R)-enantiomer of tranylcypromine.		2.07102-phenylcyclopropan-1-amine
apazone
Apazone: An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.. apazone : A member of the class of benzotriazines that is 1,2-dihydro-1,2,4-benzotriazine bearing a dimethylamino substitutent at position 3 and a methyl substituent at position 7 and in which the nitrogens at positions 1 and 2 are both acylated by a carboxy group of propylmalonic acid.		2.0410benzotriazinesnon-steroidal anti-inflammatory drug;
uricosuric drug
diacerein
diacerein: chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase;		2.0810anthraquinone
metopimazine
metopimazine: RN given refers to parent cpd; structure		2.0310phenothiazines
parbendazole
parbendazole: anthelmintic used against a variety of gastrointestinal parasites; minor descriptor (75-86); on-line & INDEX MEDICUS search BENZIMIDAZOLES; RN given refers to parent cpd		2.0710benzimidazoles;
carbamate ester
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		4.2550selegiline;
terminal acetylenic compound		geroprotector
selegiline hydrochloride, (r)-isomer
[no description available]		2.4720hydrochloride;
terminal acetylenic compound		antiparkinson drug;
dopaminergic agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor
levamisole
Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.		2.44206-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
clemastine
Clemastine: A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.. clemastine : 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.		3.8930monochlorobenzenes;
N-alkylpyrrolidine		anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
thiamphenicol
[no description available]		2.0810monocarboxylic acid amide;
sulfone		antimicrobial agent;
immunosuppressive agent
pancuronium bromide
pancuronium bromide : A bromide salt consisting of two bromide ions and one pancuronium dication.		2.0810bromide saltcholinergic antagonist;
muscle relaxant;
nicotinic antagonist
cephalexin
Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.		4.460beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
cromolyn sodium
Cromolyn Sodium: A chromone complex that acts by inhibiting the release of chemical mediators from sensitized MAST CELLS. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.. disodium cromoglycate : An organic sodium salt that is the disodium salt of cromoglycic acid.		2.0610organic sodium saltanti-asthmatic drug;
drug allergen
isosorbide-5-mononitrate
isosorbide-5-mononitrate: for prevention of angina pectoris; structure given in first source; a Russian drug		2.9540glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
ornidazole
Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.		2.0810C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol		antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope
danazol
Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.		4.779017beta-hydroxy steroid;
terminal acetylenic compound		anti-estrogen;
estrogen antagonist;
geroprotector
metergoline
Metergoline: A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy.. metergoline : An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7.		2.4620carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
fenclozic acid
fenclozic acid: an analgesic & antipyretic with anti-inflammatory properties; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZOLES (75-86); RN given refers to parent cpd		3.8730
laxagetten 4,4'-diacetoxydiphenylpyridylemethane
[no description available]		3.5920
1-deoxynojirimycin
1-deoxy-nojirimycin: structure in first source. duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.		6.57532-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid		anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		3.5620aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
capobenic acid
[no description available]		2.0710benzamides
cephapirin
Cephapirin: Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.. cephapirin : A cephalosporin with acetoxymethyl and 2(pyridin-4-ylsulfanyl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. It is used (as its sodium salt) as an antibiotic, being effective against gram-negative and gram-positive organisms.		2.4320cephalosporinantibacterial drug
diftalone
[no description available]		2.0710
fludarabine phosphate
fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.		3.6120nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate		antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
disopyramide phosphate
[no description available]		2.4620organoammonium phosphate
alclofenac
alclofenac: was heading 1975-94 (was see under PHENYLACETATES 1975-90); use PHENYLACETATES to search ALCLOFENAC 1975-94; an anti-inflammatory agent used in the treatment of rheumatoid arthritis; acts also as an analgesic and an antipyretic. alclofenac : An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash.		3.5920aromatic ether;
monocarboxylic acid;
monochlorobenzenes		drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
carbimazole
Carbimazole: An imidazole antithyroid agent. Carbimazole is metabolized to METHIMAZOLE, which is responsible for the antithyroid activity.. carbimazole : A member of the class of imidazoles that is methimazole in which the nitrogen bearing a hydrogen is converted into its ethoxycarbonyl derivative. A prodrug for methimazol, carbimazole is used for the treatment of hyperthyroidism.		2.07101,3-dihydroimidazole-2-thiones;
carbamate ester		antithyroid drug;
prodrug
bromocriptine
Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.		3.8430indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
ergocristine
ergocristine: an ergot alkaloid; one of the three components of ergotoxine; has alpha blocking action, stimulates smooth muscles & antagonizes serotonin; used as oxytocic & in peripheral disorders; minor descriptor (77-86); on-line & INDEX MEDICUS search EROLINES (77-86); RN given refers to ((5'alpha)-isomer). ergocristine : Ergotaman bearing benzyl, hydroxy, and isopropyl groups at the 5', 12' and 2' positions, respectively, and oxo groups at positions 3', 6', and 18. It is a natural ergot alkaloid.		2.0410ergot alkaloid
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.4420benzenes;
phenyl acetates
oxyphenisatin
[no description available]		3.5920indoles
fludrocortisone
Fludrocortisone: A synthetic mineralocorticoid with anti-inflammatory activity.		3.231011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid		adrenergic agent;
anti-inflammatory drug
ursodeoxycholic acid
Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.		4.2550bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
pregnanolone
Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.		2.04103-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid		human metabolite;
intravenous anaesthetic;
sedative
butylated hydroxytoluene
2,6-di-tert-butyl-4-methylphenol : A member of the class of phenols that is 4-methylphenol substituted by tert-butyl groups at positions 2 and 6.		2.4620phenolsantioxidant;
ferroptosis inhibitor;
food additive;
geroprotector
metipranolol
Metipranolol: A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.. metipranolol : 3-(Propan-2-ylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by a 4-acetoxy-2,3,5-trimethylphenoxy group. A non-cardioselective beta-blocker, it is used to lower intra-ocular pressure in the management of open-angle glaucoma.		2.0210acetate ester;
aromatic ether;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		2.0810C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
halazepam
halazepam: structure		2.4120organic molecular entity
du-21220
Ritodrine: An adrenergic beta-2 agonist used to control PREMATURE LABOR.. 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol : A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group.		2.7230benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound
rose bengal b disodium salt
[no description available]		2.0710
clobetasol propionate
Clobetasol Propionate: This is the form in trademark preparations.. clobetasol propionate : The 17-O-propionate ester of clobetasol. A potent corticosteroid, it is used to treat various skin disorders, including exzema and psoriasis.		2.11011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid		anti-inflammatory drug
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		2.0710glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
dexchlorpheniramine
dexchlorpheniramine: RN given refers to parent cpd(S)-isomer		3.2310chlorphenamine
ribostamycin
Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.. ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).		2.0410amino cyclitol glycoside;
aminoglycoside antibiotic		antibacterial drug;
antimicrobial agent;
metabolite
clometacin
clometacin: structure		3.5920N-acylindole
cefazolin
Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.		4.460beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		4.95110penicillin allergen;
penicillin		antibacterial drug
timolol
(S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.		4.7690timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
indoramin
Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.		2.9840tryptamines
oxcarbazepine
Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.		3.6120cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen
carbidopa
carbidopa (anhydrous) : 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.		4.1140catechols;
hydrazines;
monocarboxylic acid		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
toloxatone
toloxatone: oxazolidinone derivative; psychotropic drug; structure. toloxatone : A racemate consisting of equimolar amounts of (R)- and (S)-toloxatone. It is a reversible monoamine oxidase A inhibitor and antidepressant.. 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one : A member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3.		2.4520oxazolidinone;
primary alcohol;
toluenes
moricizine hydrochloride
moricizine hydrochloride : A hydrochloride salt obtained from equimola amounts of moricizine and hydrogen chloride.		2.4620hydrochlorideanti-arrhythmia drug
moricizine
Moricizine: An antiarrhythmia agent used primarily for ventricular rhythm disturbances.. moricizine : A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.		3.5620carbamate ester;
morpholines;
phenothiazines		anti-arrhythmia drug
amineptin
amineptin: used in treatment of neuroses with psychoasthenic, anxio-phobic & depressive manifestations; synonym S 1694 refers to HCl; structure. amineptine : A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.		3.8930amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound		antidepressant;
dopamine uptake inhibitor
bitolterol
bitolterol: RN given refers to parent cpd; structure. bitolterol : The di-4-toluate ester of (+-)-N-tert-butylnoradrenaline (colterol). A pro-drug for colterol, a beta2-adrenergic receptor agonist, bitolterol is used as its methanesulfonate salt for relief of bronchospasm in conditions such as asthma, chronic bronchitis and emphysema.		2.0210carboxylic ester;
diester;
ethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
prodrug
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		4.95110azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
feprazone
Feprazone: A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)		2.0810organic molecular entity
pirprofen
pirprofen: anti-inflammatory agent used in therapy of rheumatoid arthritis; prostaglandin synthetase inhibitor; more potent than indomethacin; structure		4.0840pyrroline
sisomicin
Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).		2.4520amino cyclitol glycoside;
aminoglycoside antibiotic;
beta-L-arabinoside;
monosaccharide derivative
serentil
mesoridazine besylate : The benzenesulfonate salt of mesoridazine prepared using equimolar amounts of mesoridazine and benzenesulfonic acid.		2.4620organosulfonate saltdopaminergic antagonist;
first generation antipsychotic
amdinocillin
Amdinocillin: An amidinopenicillanic acid derivative with broad spectrum antibacterial action.. mecillinam : A penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria.		2.0410penicillinantibacterial drug;
antiinfective agent
tobramycin
Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.		3.360amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		4.87100taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		4.7690beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
propafenone hydrochloride
propafenone hydrochloride : A hydrochloride that is the monohydrochloride salt of propafenone. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used in the management of supraventricular and ventricular arrhythmias.		2.4620hydrochlorideanti-arrhythmia drug
dobutamine
Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.		4.4360catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
ticarcillin
Ticarcillin: An antibiotic derived from penicillin similar to CARBENICILLIN in action.. ticarcillin : A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.		2.4520penicillin allergen;
penicillin		antibacterial drug
trimazosin
trimazosin: RN given refers to parent cpd; structure		2.0410N-arylpiperazine
penbutolol
Penbutolol: A nonselective beta-blocker used as an antihypertensive and an antianginal agent.		4.0840ethanolamines
ribavirin
Rebetron: Rebetron is tradename		5.461101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adinazolam
adinazolam: structure in first source. adinazolam : A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position.		2.7430triazolobenzodiazepineanticonvulsant;
antidepressant;
anxiolytic drug;
sedative
amikacin
Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.		4.0840alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
tolamolol
[no description available]		2.0410
carbidopa
[no description available]		2.7530catechols;
hydrate;
hydrazines;
monocarboxylic acid		antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
cephradine
Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.		4.4160beta-lactam antibiotic allergen;
cephalosporin		antibacterial drug
ticrynafen
Ticrynafen: A novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.. tienilic acid : An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.		4.2850aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes		antihypertensive agent;
hepatotoxic agent;
loop diuretic
guanadrel
guanadrel: RN given refers to parent cpd; structure. guanadrel : A spiroketal resulting from the formal condensation of the keto group of cyclohexanone with the hydroxy groups of 1-(2,3-dihydroxypropyl)guanidine. A postganglionic adrenergic blocking agent formerly used (generally as the sulfate salt) for the management of hypertension, it has been largely superseded by other drugs less likely to cause orthostatic hypotension (dizzy spells on standing up or stretching).		2.0210guanidines;
spiroketal		adrenergic antagonist;
antihypertensive agent
methyldopa
Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.		4.7690L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
tocainide
Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.		2.9540monocarboxylic acid amideanti-arrhythmia drug;
local anaesthetic;
sodium channel blocker
sulbenicillin
Sulbenicillin: Semisynthetic penicillin-type antibiotic.. sulbenicillin : A penicillin antibiotic having a 6beta-[phenyl(sulfo)acetamido] side-chain.		2.4520penicillin
bezafibrate
[no description available]		2.7530aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
sq-11725
Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.		3.360
diltiazem
Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.		4.76905-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
levobunolol
Levobunolol: The L-Isomer of bunolol.. levobunolol : A cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma.		2.0210aromatic ether;
cyclic ketone;
propanolamine		antiglaucoma drug;
beta-adrenergic antagonist
1-methyl-4-phenylpyridinium
1-Methyl-4-phenylpyridinium: An active neurotoxic metabolite of 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE. The compound reduces dopamine levels, inhibits the biosynthesis of catecholamines, depletes cardiac norepinephrine and inactivates tyrosine hydroxylase. These and other toxic effects lead to cessation of oxidative phosphorylation, ATP depletion, and cell death. The compound, which is related to PARAQUAT, has also been used as an herbicide.. N-methyl-4-phenylpyridinium : A pyridinium ion that is N-methylpyridinium having a phenyl substituent at the 4-position.		2.0410pyridinium ionapoptosis inducer;
herbicide;
human xenobiotic metabolite;
neurotoxin
nonachlazine
Nonachlazine: Coronary vasodilator with a novel mechanism of action; proposed as antianginal agent.		2.0510
vecuronium bromide
Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.		2.7330organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent;
nicotinic antagonist
vecuronium
vecuronium : A 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidino- and 16beta-N-methylpiperidinium substituents.		3.2310acetate ester;
androstane;
quaternary ammonium ion		drug allergen;
muscle relaxant;
neuromuscular agent;
nicotinic antagonist
dexibuprofen
dexibuprofen: structure in first source		2.0310ibuprofennon-narcotic analgesic;
non-steroidal anti-inflammatory drug
benoxaprofen
benoxaprofen: RN given refers to parent cpd; structure. benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.		4.43601,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes		antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
permethrin
hemoglobin Atlanta-Coventry: Leu replaced by Pro at beta75 and Leu deleted at beta141		2.7330cyclopropanecarboxylate ester;
cyclopropanes		agrochemical;
ectoparasiticide;
pyrethroid ester acaricide;
pyrethroid ester insecticide;
scabicide
exifone
[no description available]		3.5920benzophenones
mefloquine
(-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.		3.2310[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial
flecainide acetate
flecainide acetate : An acetate salt obtained by combining flecainide with one molar equivalent of acetic acid. An antiarrhythmic agent used to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).		2.4620acetate saltanti-arrhythmia drug
meptazinol
Meptazinol: A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.		2.4520azepanes
nicardipine hydrochloride
[no description available]		2.4620dihydropyridinegeroprotector
meglitinide
meglitinide: structure given in first source & in Negwer, 5th ed, #6436		5.0650
nitazoxanide
nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug		3.6120benzamides;
carboxylic ester
sufentanil
Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.		4.2550anilide;
ether;
piperidines;
thiophenes		anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
acarbose
[no description available]		4.4430tetrasaccharide derivativeEC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent
torsemide
Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.		4.5370aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic
medroxalol
medroxalol: RN given refers to parent cpd without isomeric designation		2.0410salicylamides
epirubicin
Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.		4.2650aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefmetazole
Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.		2.4320cephalosporinantibacterial drug
desflurane
Desflurane: A fluorinated ether that is used as a volatile anesthetic for maintenance of general anesthesia.		2.0210organofluorine compoundinhalation anaesthetic
indacrinone
indacrinone: polyvalent saluretic; RN given refers to parent cpd without isomeric designation; structure		2.4620
lorcainide
[no description available]		3.1550acetamides
idarubicin
Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.		4.2450anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
ceforanide
ceforanide: RN given refers to (6R-(trans))-isomer. ceforanide : A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.		2.0410cephalosporinantibacterial drug
cefonicid
Cefonicid: A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.. cefonicid : A cephalosporin bearing {[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and (R)-2-hydroxy-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		2.0210cephalosporinantibacterial drug
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		4.2550penicillin allergen;
penicillin		antibacterial drug
paroxetine
Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.		4.6680aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		4.95110alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
pirogliride
pirogliride: RN given refers to parent cpd; structure		1.9710
cefoperazone
Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.		3.8430cephalosporinantibacterial drug
staurosporine
[no description available]		2.4720indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
foscarnet sodium
trisodium phosphonoformate : The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		2.0810one-carbon compound;
organic sodium salt		antiviral drug
lodoxamide
[no description available]		2.0210organonitrogen compound;
organooxygen compound
indalpine
indalpine: selective 5-hydroxytryptamine uptake inhibitor; RN given refers to parent cpd		2.0710indoles
atracurium
Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.. atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.		4.0740diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
atracurium besylate
atracurium besylate : The bisbenzenesulfonate salt of atracurium.		2.0810organosulfonate salt;
quaternary ammonium salt		muscle relaxant;
nicotinic antagonist
butoconazole nitrate
butoconazole nitrate : An organic nitrate salt obtained by reaction of equimolar amounts of butaconazole and nitric acid. An antifungal agent, it is used in gynaecology for treatment of vulvovaginal infections caused by Candida species, particularly Candida albicans.		2.4620aryl sulfide;
conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
organic nitrate salt
butoconazole
butoconazole: RN given refers to parent cpd; structure. butoconazole : A member of the class of imidazoles that is 1H-imidazole in which the hydrogen attached to the nitrogen is substituted by a 4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl group. An antifungal agent, it is used as its nitrate salt in gynaecology for treatment of vulvovaginal infections caused by Candida species, particularly Candida albicans.		2.0210aryl sulfide;
conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes
moxalactam
Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.. moxalactam : A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents.		2.4520cephalosporin;
oxacephem		antibacterial drug
lidamidine
lidamidine: synonym WHR-1142A refers to HCl; structure		2.0710ureas
nicorandil
Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.. nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris.		2.7330nitrate ester;
pyridinecarboxamide		potassium channel opener;
vasodilator agent
endralazine
BQ 22-708: RN given refers to parent cpd		2.4420benzamides
naftifine
naftifine: allylamine der; RN given refers to unlabeled parent cpd. naftifine : A tertiary amine in which the nitrogen is substituted by methyl, alpha-naphthylmethyl, and (1E)-cinnamyl groups. It is used (usually as its hydrochloride salt) for the treatment of fungal skin infections.		2.0210allylamine antifungal drug;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
sterol biosynthesis inhibitor
pergolide
Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.		3.5620diamine;
methyl sulfide;
organic heterotetracyclic compound		antiparkinson drug;
dopamine agonist
pergolide mesylate
pergolide mesylate : A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.		2.0810methanesulfonate saltantiparkinson drug;
dopamine agonist;
geroprotector
cefadroxil anhydrous
Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		4.7690cephalosporinantibacterial drug
encainide
Encainide: One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.. encainide : 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.		2.9540benzamides;
piperidines		anti-arrhythmia drug;
sodium channel blocker
talniflumate
talniflumate: an anti-inflammatory molecule for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma		2.4820benzofurans
fenoldopam mesylate
[no description available]		2.0810benzazepine
nedocromil
Nedocromil: A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with ASTHMA, including EOSINOPHILS; NEUTROPHILS; MACROPHAGES; MAST CELLS; MONOCYTES; AND PLATELETS.		2.4420dicarboxylic acid;
organic heterotricyclic compound		anti-allergic agent;
anti-asthmatic drug;
non-steroidal anti-inflammatory drug
fialuridine
[no description available]		4.0840
cefaclor anhydrous
Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		4.0740cephalosporinantibacterial drug;
drug allergen
pefloxacin
Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.		3.1550fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor
mitoxantrone hydrochloride
[no description available]		2.4620hydrochlorideantineoplastic agent
pirazolac
[no description available]		2.0310
alfentanil
Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.		4.460monocarboxylic acid amide;
piperidines		central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug
miglustat
miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.		3.2310piperidines;
tertiary amino compound		anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
haloperidol decanoate
[no description available]		3.2310organic molecular entity
dazoxiben
dazoxiben: RN given refers to parent cpd		2.0710
cefotetan
Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.		4.5470
recainam
recainam: structure given in first source		2.7430
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		4.86100delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
flupirtine
flupirtine: RN given refers to parent cpd without isomeric designation		3.1550aminopyridine
tolrestat
tolrestat: RN & structure given in first source		4.0940naphthalenesEC 1.1.1.21 (aldehyde reductase) inhibitor
enoximone
Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.		2.9640aromatic ketone
stepronin
[no description available]		2.0810N-acyl-amino acid
levocabastine
levocabastine: for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis		2.0210piperidines
simvastatin
Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.		5.25150delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
idazoxan
Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.		2.9740benzodioxine;
imidazolines		alpha-adrenergic antagonist
remoxipride
Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.		3.3160dimethoxybenzene
balsalazide
balsalazide: a mesalamine 5-aminosalicylate prodrug; 99% of ingested drug remains intact through the stomach and is delivered to and activated in the colon; used for inflammatory bowel disease, ulcerative colitis and radiation-induced proctosigmoiditis but avoided in patients with known hypersensitivity reaction to salicylates or mesalamine; structure in first source. balsalazide : A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond.		3.2310
pravastatin
Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.		4.76903-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
cabergoline
Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.		3.8530N-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist
bambuterol
bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.		2.7430carbamate ester;
phenylethanolamines		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
prodrug;
sympathomimetic agent;
tocolytic agent
atomoxetine hydrochloride
Atomoxetine Hydrochloride: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.. atomoxetine hydrochloride : The hydrochloride salt of atomoxetine.		2.0810hydrochlorideadrenergic uptake inhibitor;
antidepressant
atomoxetine
atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.		4.6580aromatic ether;
secondary amino compound;
toluenes		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic
quinapril
Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.		4.4160dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
alpidem
[no description available]		4.4360imidazoles
eproxindine
eproxindine: structure given in first source		2.0310
mifepristone
Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.		3.87303-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
dopexamine
dopexamine: RN given refers to parent cpd; structure given in first source		2.0710catecholamine
trospectomycin
trospectomycin: active against Neisseria gonorrhoeae; RN refers to 2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9beta,9alpha,9aalpha,10abeta)-(9CI)-isomer		2.0410dioxanes
(S)-nomifensine
(S)-nomifensine : The S enantiomer of nomifensine.		2.0310nomifensine
lonapalene
RS 43179: used in treatment of psoriasis		2.0710naphthalenes;
organochlorine compound
fosphenytoin
fosphenytoin: structure given in first & second source		3.5620imidazolidine-2,4-dione
salmeterol xinafoate
Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.		2.0810naphthoic acid
ranolazine
Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.		10.0221aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol
ipsapirone
[no description available]		2.0710N-arylpiperazine
fura-2
Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.		1.9810
finasteride
Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.		4.66803-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
imiquimod
Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.		2.0810imidazoquinolineantineoplastic agent;
interferon inducer
sematilide
sematilide: RN refers to HCl; structure given in first source		2.9740
esmolol
methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group.. esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure.		4.2650aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound
temafloxacin
temafloxacin: structure given in first source. temafloxacin : A racemate comprising equimolar amounts of (R)- and (S)-temafloxacin. Both enantiomers both exhibit similar pharmacological profiles. Temafloxacin was briefly used (either as the free base or as the hydrochloride salt) as an antibacterial drug but was withdrawn worldwide in 1992 following reports of serious side effects, including severe hypoglycaemia, haemolytic anaemia, liver and kidney dysfunction, anaphylaxis, and death.. 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid : A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, and 7 by 2,4-difluorophenyl, fluorine, and 3-methylpiperazin-1-yl groups, respectively.		2.4620amino acid;
monocarboxylic acid;
N-arylpiperazine;
organofluorine compound;
quinolone antibiotic;
quinolone;
secondary amino compound;
tertiary amino compound
(2S)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid
[no description available]		2.0310phenylalanine derivative
clinafloxacin
clinafloxacin: structure given in first source; RN given is for monoHCl		3.1550quinolines
sertindole
sertindole : A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group.		2.0810heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole		alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist
adapalene
Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.. adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.		2.4520adamantanes;
monocarboxylic acid;
naphthoic acid		dermatologic drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
non-steroidal anti-inflammatory drug
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		4.25506-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
loxiglumide
loxiglumide: cholecystokinin receptor antagonist; RN refers to (+-)-isomer; structure in first source		2.4520organic molecular entity
aromasil
[no description available]		3.612017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
sparfloxacin
[no description available]		3.360fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
zileuton
[no description available]		4.55701-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
remacemide
remacemide: structure given in first source		2.0710stilbenoid
clopidogrel
Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.		3.6320methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
cidofovir anhydrous
Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.		4.4160phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
tiagabine
Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.		4.2550beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor
mibefradil
Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.		2.9740tetralinsT-type calcium channel blocker
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		4.2450pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
bromfenac
bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.		4.7790aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gemcitabine hydrochloride
[no description available]		2.0810hydrochloride;
organofluorine compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		4.0640organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
ibutilide
ibutilide: RN & structure in first source; RN refers to the fumarate salt		4.0640benzenes;
organic amino compound
aripiprazole
Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.		3.8730aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
remifentanil
Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.		4.0640alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
atorvastatin calcium anhydrous
[no description available]		2.0810organic calcium salt
atorvastatin
[no description available]		5.8161aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
lamivudine
[no description available]		4.95110monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
duloxetine hydrochloride
Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.		2.0810duloxetine hydrochlorideantidepressant
duloxetine
[no description available]		3.2310duloxetine
irinotecan
[no description available]		4.2450carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
valsartan
Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.		4.7690biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
ibandronic acid
Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.		3.5820
ziprasidone
ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.		4.25501,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
zanamivir
Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.		2.7430guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan
zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.		4.4160oxazolidinone;
tryptamines		anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
adefovir dipivoxil
bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.		2.08106-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
emtricitabine
Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.		3.8630monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
tasosartan
tasosartan: angiotensin II antagonist; structure given in first source		4.2850biphenyls
saquinavir monomethanesulfonate
[no description available]		2.4620organic molecular entity
tiludronic acid
tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source		3.2310organochlorine compound
tirofiban
Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.		3.8530L-tyrosine derivative;
piperidines;
sulfonamide		anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist
capecitabine
Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.		3.2310carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		4.2550adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
octyl gallate
[no description available]		3.3510gallate esterfood antioxidant;
hypoglycemic agent;
plant metabolite
allyl formate
[no description available]		2.4620
pipothiazine
pipothiazine: was heading 1975-94 (see under PHENOTHIAZINE TRANQUILIZERS 1975-90); use PHENOTHIAZINES to search PIPOTHIAZINE 1975-94; a member of the family of phenothiazine tranquilizers		2.0310
paroxetine hydrochloride
paroxetine hydrochloride : The hydrochloride salt of paroxetine. It is an antidepressant drug.		2.4820hydrochlorideantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
desferrioxamine b mesylate
desferrioxamine B mesylate : A methanesulfonate salt obtained by reaction of desferrioxamine B with one molar equivalent of methanesulfonic acid. It is an iron-chelating medicine used to remove excess iron from the body. It binds to iron in the blood, which is then passed out in the urine.		2.4620methanesulfonate saltantidote;
ferroptosis inhibitor;
iron chelator
bupropion hydrochloride
[no description available]		2.7630aromatic ketone
cisatracurium
cisatracurium: RN refers to (1R-(1alpha,2alpha(1'R*,2'R*)))-isomer. cisatracurium : A diester that is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium, a quaternary ammonium ion consisting of pentane-1,5-diol with both hydroxy functions bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. The active species in the skeletal muscle relaxant cisatracurium besylate.		2.0410diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
diltiazem hydrochloride
Carex: fluoride (1.8%) containing varnish; no further information available 8/91. diltiazem hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of diltiazem and hydrogen chloride. A calcium-channel blocker and vasodilator, it is used in the management of angina pectoris and hypertension.		2.0510hydrochlorideantihypertensive agent;
calcium channel blocker;
vasodilator agent
trazodone hydrochloride
Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.		2.7630hydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
fosinoprilat
fosinoprilat: active phosphinic acid metabolite of prodrug fosenopril, which is activated by esterases in vivo; structure given in first source; binds zinc with phosphinic acid group. fosinoprilat : A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure.		2.0410L-proline derivative;
phosphinic acids		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trovafloxacin
trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.		4.6780
verapamil hydrochloride
verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.		2.7530
cefprozil
[no description available]		3.8430cephalosporin;
semisynthetic derivative		antibacterial drug
doxazosin mesylate
Cardura: Trade name in United States.		2.0810methanesulfonate saltgeroprotector
ciprofloxacin hydrochloride anhydrous
[no description available]		2.4620hydrochlorideantibacterial drug;
antiinfective agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
methylprednisolone aceponate
methylprednisolone aceponate: RN given for (6alpha,11beta)-isomer		2.0210corticosteroid hormone
dexamethasone 17-valerate
dexamethasone 17-valerate: RN given refers to (11beta,16alpha)-isomer; structure		2.021021-hydroxy steroid
dexamethasone dipropionate
[no description available]		2.0210corticosteroid hormone
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		3.6120acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nelfinavir
Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.		4.140aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
amantadine hydrochloride
[no description available]		2.4620hydrochlorideantiviral agent;
dopamine agonist;
NMDA receptor antagonist
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		14.563624D-glucopyranoseepitope;
mouse metabolite
mevastatin
mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.		2.08102-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
bupivacaine hydrochloride
bupivacaine hydrochloride (anhydrous) : A racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride : A hydrochloride obtained by combining 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide with one molar equivalent of hydrochloric acid.		2.0810hydrochloride;
racemate		adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic
fenofibric acid
fenofibric acid: RN given refers to parent cpd without isomeric designation; structure. fenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.		3.2310aromatic ketone;
chlorobenzophenone;
monocarboxylic acid		drug metabolite;
marine xenobiotic metabolite
n-methylnicotinamide
N-methylnicotinamide: structure. N-methylnicotinamide : A pyridinecarboxamide that is nicotinamide in which one of the amide hydrogens is substituted by a methyl group.		2.0410pyridinecarboxamidemetabolite
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		2.0510organic bromide saltcolorimetric reagent;
dye
baicalin
[no description available]		2.0410dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative		antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug
plerixafor
plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.		3.6120azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
amprenavir
[no description available]		4.140carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
oseltamivir
Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.		4.0940acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
dobutamine hydrochloride
dobutamine hydrochloride : The hydrochloride salt of dobutamine. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used to increase the contractility of the heart in the management of acute heart failure.		2.4620hydrochloridebeta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
ticlopidine hydrochloride
[no description available]		2.0810hydrochloride
epirubicin hydrochloride
[no description available]		2.0810
glutathione disulfide
Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.		2.0410glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite
fenclofenac
fenclofenac: RN given refers to parent cpd		2.0710aromatic ether
iopamidol
Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.		2.9640benzenedicarboxamide;
organoiodine compound;
pentol		environmental contaminant;
radioopaque medium;
xenobiotic
proxicromil
proxicromil: RN given refers to parent cpd; structure		2.0710
sulconazole, mononitrate, (+-)-isomer
[no description available]		2.4620conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt
histamine phosphate
histamine phosphate : A phosphate salt that is the diphosphate salt of histamine.		3.2310phosphate salthistamine agonist
imipramine n-oxide
imipramine N-oxide: RN given refers to parent cpd; structure		2.0410dibenzooxazepine
tilbroquinol
[no description available]		3.5920organohalogen compound;
quinolines
bendamustine
[no description available]		3.2310benzimidazoles
droxicam
droxicam: structure given in first source. droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.		3.5920organic heterotricyclic compound;
pyridines		cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug
ebrotidine
ebrotidine: an H2-receptor antagonist and gastric mucosa protector		3.5920sulfonamide
torbafylline
torbafylline: structure given in first source		2.0710
dexloxiglumide
dexloxiglumide: a CCK receptor antagonist; structure given in first source		2.7430glutamic acid derivative
intoplicine
intoplicine: structure in first source		2.0410pyridoindole
pazufloxacin
[no description available]		2.0810quinolines
rilmakalim
rilmakalim: potassium channel opener; rimalkalim may be a typo		710
repaglinide
[no description available]		12.17377piperidines
telmisartan
Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.		4.7790benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
dexfenfluramine
Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.		2.7230fenfluramineappetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
ethinyl estradiol-17-sulfate
ethinyl estradiol-17-sulfate: RN given refers to the (17alpha)-isomer		2.0410
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		13.4926181,2,3-triazole
trimethobenzamide monohydrochloride
[no description available]		2.4620
amiloride hydrochloride
amiloride hydrochloride dihydrate : A hydrate that is the dihydrate of amiloride hydrochloride.		2.4620hydratediuretic;
sodium channel blocker
miconazole nitrate
miconazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-miconazole nitrate. An antifungal used for the treatment of athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.		2.0810
ethinylestradiol-3-sulfate
ethinylestradiol-3-sulfate: binds to albumin at 2 sites		2.041017beta-hydroxy steroid;
steroid sulfate		antineoplastic agent;
estrogen
econazole nitrate
econazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-econazole nitrate. Used to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.		2.4620
fluorodeoxyglucose f18
Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)		8.78962-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
sertraline
Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.		4.5470dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
lomefloxacin hydrochloride
lomefloxacin hydrochloride : The hydrochloride salt of lomefloxacin. It is administered by mouth to treat bacterial infections including bronchitis and urinary tract infections. It is also used topically as eye drops for the treatment of bacterial conjunctivitis, and as ear drops for the treatment of otitis externa and otitis media.		2.4620hydrochlorideantimicrobial agent;
antitubercular agent;
photosensitizing agent
sanguinarine chloride
[no description available]		2.0410
cefcanel
cefcanel: RN given refers to (6R-(6 alpha,7 beta(R*)))-isomer; structure		2.4520
zoledronic acid
Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.		4.26501,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
epristeride
epristeride: structure given in first source		2.7430steroid acid
talinolol
[no description available]		2.7430ureas
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.0810organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
brinzolamide
brinzolamide: an antiglaucoma agent		2.0810sulfonamide;
thienothiazine		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
midaglizole
midaglizole: orally effective hypoglycemic agent structurally unrelated to known hypoglycemics; RN given for parent cpd		1.9710
flunoxaprofen
flunoxaprofen: structure given in first source. flunoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group (the S-enantiomer). Although it was shown to be effective in treatment of rheumatoid arthritis and osteoarthritis, the clinical use of flunoxaprofen was discontinued due to possible hepatotoxic side-effects.		2.46201,3-benzoxazoles;
monocarboxylic acid;
organofluorine compound		antirheumatic drug;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
tianeptine
tianeptine: structure given in first source. tianeptine : A racemate comprising of equimolar amounts of (R)- and (S)-tianeptine. It is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs).. 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid : A member of the class of dibenzothiazepines that is 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide substituted by a (6-carboxyhexyl)amino group at position 11.. (S)-tianeptine : The S-enantiomer of tianeptine.		2.4620dibenzothiazepine;
monocarboxylic acid;
organochlorine compound
drospirenone
drospirenone: a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source		2.46203-oxo-Delta(4) steroid;
steroid lactone		aldosterone antagonist;
contraceptive drug;
progestin
artemether
Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.0810artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
fenflumizole
fenflumizole: structure in first source		2.0310
denaverine
denaverine: RN given refers to parent cpd; structure		2.0410diarylmethane
acamprosate
Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.. acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.		3.2310acetamides;
organosulfonic acid		environmental contaminant;
neurotransmitter agent;
xenobiotic
isaxonine
isaxonine: promotes nerve growth		3.5920aminopyrimidine
enrofloxacin
Enrofloxacin: A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.. enrofloxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets.		2.0710cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		antibacterial agent;
antimicrobial agent;
antineoplastic agent
cromakalim
Cromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352)		2.4220
diprafenone
diprafenone: structure given in first source		2.4520aromatic compound
erythromycin propionate
erythromycin propionate: form in which erythromycin estolate is principally absorbed		2.0210erythromycin derivative
nebivolol
2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] : A member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group.		3.5820chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound
uk 68798
[no description available]		4.4260aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
ljc 10627
biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.		2.4520carbapenems;
organic sulfide;
pyrazolotriazole		antibacterial drug
hp 873
iloperidone: an atypical, negative symptom antipsychotic agent. iloperidone : A member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia.		3.61201,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
dexrazoxane
Dexrazoxane: The (+)-enantiomorph of razoxane.		4.0640razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
loxapine succinate
[no description available]		2.0810succinate saltgeroprotector
loperamide hydrochloride
loperamide hydrochloride : A hydrochloride obtained by combining loperamide with one equivalent of hydrochloric acid. Used for treatment of diarrhoea resulting from gastroenteritis or inflammatory bowel disease.		2.4620hydrochlorideanticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
fenoxypropazine
[no description available]		3.5920aromatic ether
antebate
betamethasone butyrate propionate: a topical corticosteroid		2.0210corticosteroid hormone
voriconazole
Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.		3.8730conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
betamipron
[no description available]		2.7530organonitrogen compound;
organooxygen compound
mepindolol
mepindolol: 2-methyl deriv of pindolol; RN given refers to parent cpd; structure		2.0710indoles
fpl 52791
FPL 52791: also has anti-allergic properties; related to sodium cromoglycate; structure		2.0710
bufuralol
bufuralol: RN given refers to cpd without isomeric designation; structure		2.9740benzofurans
uroxatral
[no description available]		2.0810hydrochloride
aceclofenac
[no description available]		3.6120amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
nitrefazole
[no description available]		3.5920imidazoles
epanolol
epanolol: structure given in first source		2.0710acetamides
panipenem
panipenem: synthetic cpd; structure given in first source		2.0410organic molecular entity
perindoprilat
perindoprilat : A dipeptide obtained by formal condensation of one of the carboxy groups of N-[(1S)-1-carboxyethyl]-L-norvaline with the amino group of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid. The major active metabolite of perindopril.		2.0410dicarboxylic acid;
dipeptide;
L-alanine derivative;
organic heterobicyclic compound		antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
thiocolchicoside
[no description available]		2.0810glycoside
prednisolone phosphate
prednisolone phosphate: RN given refers to (11 beta)-isomer. prednisolone phosphate : A synthetic glucocorticoid resulting from the formal condensation of the 21-hydroxy group of prednisolone with one of the hydroxy groups of phosphoric acid. It is a prodrug for prednisolone that is activated in vivo by phosphatases.		2.031011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
glucocorticoid;
steroid phosphate;
tertiary alpha-hydroxy ketone		anti-inflammatory agent;
antineoplastic agent;
glucocorticoid receptor agonist;
prodrug
(S)-flurbiprofen
[no description available]		2.0310flurbiprofen
7-hydroxystaurosporine
[no description available]		2.0410
methotrimeprazine
Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.		2.7530phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
chelerythrine chloride
[no description available]		2.0410
9-aminocamptothecin
[no description available]		2.0410pyranoindolizinoquinoline
sch 34343
Sch 34343: structure given in first source; RN given refers to (5R-(5alpha,6alpha))-isomer		2.4520
grepafloxacin
grepafloxacin: structure in first source		2.4620fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
squalamine
squalamine: from dogfish shark Squalus acanthias; structure given in first source		2.0410bile acid
doripenem
Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.		3.6120carbapenems
2-naphthylisothiocyanate
[no description available]		2.4620
atovaquone
Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.		4.460hydroxy-1,2-naphthoquinone
rivastigmine
[no description available]		3.8530carbamate ester;
tertiary amino compound		cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent
frovatriptan
[no description available]		4.0840carbazoles
eletriptan
eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.		3.8530indoles;
N-alkylpyrrolidine;
sulfone		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
rosiglitazone
[no description available]		15.596232aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
tamiflu
[no description available]		2.0810phosphate salt
bexarotene
[no description available]		3.6120benzoic acids;
naphthalenes;
retinoid		antineoplastic agent
s20098
[no description available]		2.0810acetamides
flunisolide
flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones		2.733011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
primary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug;
immunosuppressive agent
4-nitrophenylglucuronide
4-nitrophenyl beta-D-glucuronide : A beta-D-glucosiduronic acid having a 4-nitrophenyl substituent at the anomeric position.		2.0410beta-D-glucosiduronic acid;
C-nitro compound		chromogenic compound
chloroquine diphosphate
[no description available]		2.4620
orphenadrine citrate
orphenadrine citrate : A citrate salt which comprises equimolar amounts of orphenadrine and citric acid.		2.4620citrate saltH1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
acetaminophen glucuronide
acetaminophen glucuronide: acetaminophen metabolite in rats. acetaminophen O-beta-D-glucosiduronic acid : A beta-D-glucosiduronic acid that is the O-glucuronide of paracetamol (acetaminophen).		2.0410beta-D-glucosiduronic aciddrug metabolite
ketorolac tromethamine
Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.		2.7630organoammonium saltanalgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		4.6580macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		3.55803-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
n-(3,5-dichlorophenyl)succinimide
N-(3,5-dichlorophenyl)succinimide: nephrotoxic; post-treatment enhanced induction of renal cell tumors in rats by dimethylnitrosamine, pre-treatment inhibited induction of tumors, & alone caused interstitial nephritis but no tumors		2.4620pyrrolidines
fibrinogen
Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.		4.3822iditolfungal metabolite
moexipril
[no description available]		3.8430peptide
phentolamine mesylate
[no description available]		2.4620
oxybutynin hydrochloride
[no description available]		2.4620hydrochloride
homocysteine
Homocysteine: A thiol-containing amino acid formed by a demethylation of METHIONINE.. homocysteine : A sulfur-containing amino acid consisting of a glycine core with a 2-mercaptoethyl side-chain.. L-homocysteine : A homocysteine that has L configuration.		5.0333amino acid zwitterion;
homocysteine;
serine family amino acid		fundamental metabolite;
mouse metabolite
1-cyano-2-hydroxy-3-butene
[no description available]		2.0510secondary alcohol
gliquidone
gliquidone: structure; RN given refers to parent cpd		3.1750isoquinolines
cordium
bepridil hydrochloride monohydrate : The hydrochloride monohydrate of bepridril.		2.4620hydrate;
hydrochloride
lekoptin
(S)-verapamil : A 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile that has S configuration.		2.03102-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
tarenflurbil
tarenflurbil: R-enantiomer of flurbiprofen but not a COX inhibitor; modulates NF-kB, gamma-secretase, amyloid beta-protein;		2.0310flurbiprofen
mci 9038
[no description available]		3.5820peptide
lopinavir
[no description available]		2.7530amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
levcromakalim
[no description available]		2.07101-benzopyran
moxifloxacin hydrochloride
moxifloxacin hydrochloride : A hydrochloride comprising equimolar amounts of moxifloxacin and hydrogen chloride.		2.0810hydrochlorideantibacterial drug
hexylcaine hydrochloride
[no description available]		2.0710
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		3.612017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
mizoribine
[no description available]		2.0810imidazolesanticoronaviral agent
eudragit rl
[no description available]		2.1710
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.7530beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
sr141716
[no description available]		2.7530amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
bosentan anhydrous
Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.		5.12130primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist
diacetyldichlorofluorescein
diacetyldichlorofluorescein: stable storage form of dichlorofluorescein		2.0410
fluo-3
Fluo-3: fluorescent Ca(2+) indicator; permits continuous monitoring of Ca without interference with use of UV-sensitive caged compounds		2.0410xanthene dyefluorochrome
fpl 55712
FPL 55712: inhibitor of SRS-A and LTC4 and LTD4 receptors		2.0710aromatic ketone
sivelestat
sivelestat: inhibitor of neutrophil elastase; structure given in first source		2.0710N-acylglycine;
pivalate ester
racecadotril
racecadotril: parenterally active enkephalinase inhibitor		2.0810N-acyl-amino acid
perindopril
Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline		3.2310alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
asulacrine
asulacrine: derivative of amsacrine; structure given in first source		2.0410acridines
hydroxycotinine
hydroxycotinine: metabolite of nicotine; RN given refers to (S)-isomer; structure. trans-3-hydroxycotinine : An N-alkylpyrrolidine that is cotinine substituted at position C-3 by a hydroxy group (the 3R,5S-diastereomer).		2.0410N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid
quinaprilat
quinaprilat: metabolite of quinapril. quinaprilat : A dicarboxylic acid resulting from the hydrolysis of the ethyl ester group of quinapril to give the corresponding dicarboxylic acid. The active angiotensin-converting enzyme inhibitor (ACE inhibitor) of the prodrug quinapril.		2.7430dicarboxylic acid;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent
2-hydroxyimipramine
2-hydroxyimipramine: RN given refers to parent cpd		2.4520dibenzoazepine
ecteinascidin 743
[no description available]		2.0410acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		1.9810
tadalafil
[no description available]		3.6120benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
ibuprofen, (r)-isomer
[no description available]		2.0310ibuprofen
thromboxanes
thromboxane : A class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.		3.4511
paliperidone
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one : A member of the class of pyridopyrimidines that is 9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.. paliperidone : A racemate comprising equimolar amounts of (R)- and (S)-paliperidone. Paliperidone is the primary active metabolite of the older antipsychotic risperidone and is used for treatment of schizophrenia.		3.23101,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol
nitisinone
[no description available]		3.2310(trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione		EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
plavix
[no description available]		2.0810azaheterocycle sulfate salt;
organoammonium sulfate salt		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
clofarabine
[no description available]		3.6120adenosines;
organofluorine compound		antimetabolite;
antineoplastic agent
elacridar
Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source		2.0410
pramipexole
Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.		3.8630benzothiazoles;
diamine		antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger
valdecoxib
[no description available]		3.6120isoxazoles;
sulfonamide		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
293b cpd
6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethylchromane: RN given for (trans-(+-))-isomer		1.99101-benzopyran
mitiglinide
mitiglinide: a rapid and short-acting hypoglycemic agent; acts on sulfonylurea receptor closing KATP channels; considered one of the glinides-an imprecise grouping; structure given in first source		7.16103benzenes;
monocarboxylic acid
fpl-52694
FPL-52694: mast cell stabilizer; RN given refers to parent cpd; FPL-52694 is mono-Na salt; structure given in first source		2.0710
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		2.0410methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
almotriptan
almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.		4.0740indoles;
sulfonamide;
tertiary amine		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
mk 0663
[no description available]		2.7530bipyridines;
organochlorine compound;
sulfone		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
gefitinib
[no description available]		4.6680aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
n,n-dimethylarginine
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine. N(omega),N(omega)-dimethyl-L-arginine : A L-arginine derivative having two methyl groups both attached to the primary amino moiety of the guanidino group.		3.4711dimethylarginine;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor
ramatroban
[no description available]		2.0710organic molecular entity
desloratadine
desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.		3.6120benzocycloheptapyridineanti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist
desvenlafaxine
O-desmethylvenlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine.		3.2310cyclohexanols;
phenols;
tertiary amino compound		antidepressant;
drug metabolite;
marine xenobiotic metabolite
methotrexate
[no description available]		5.17140dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
xaliproden
xaliproden : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine which is substituted on the nitrogen by a 2-(2-naphthyl)ethyl group and at position 4 by a m-trifluoromethylphenyl group.		2.0710(trifluoromethyl)benzenes;
naphthalenes;
tertiary amino compound;
tetrahydropyridine		serotonergic agonist
tamsulosin
[no description available]		4.42605-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent
rufinamide
rufinamide: for treatment of Lennox-Gastaut syndrome; structure in first source		3.2310aromatic amide;
heteroarene
n-isobutyrylcysteine
N-isobutyrylcysteine: RN given refers to L-isomer		2.0710
sulbactam
[no description available]		2.7530penicillanic acids
olmesartan medoxomil
Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.		10.2831biphenyls
dexpanthenol
dexpanthenol: The alcohol of pantothenic acid		3.620amino alcohol;
monocarboxylic acid amide		cholinergic drug;
provitamin
fosamprenavir
fosamprenavir: a prodrug of the protease inhibitor amprenavir. fosamprenavir : A sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir.		3.2310sulfonamideprodrug
quilostigmine
quilostigmine: RN given for (3aS,cis)-isomer; structure in first source		2.0710pyrroloindole
abiraterone
[no description available]		2.08103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
5-carboxyfluorescein diacetate
[no description available]		2.0410
imiloxan
[no description available]		2.0710benzodioxine
febuxostat
Febuxostat: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.. febuxostat : A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.		3.9301,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile		EC 1.17.3.2 (xanthine oxidase) inhibitor
dilevalol
(R,R)-labetalol : A 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide that has 1R,2R-configuration.		2.45202-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
aspartame
[no description available]		2.0710carboxylic acid;
dipeptide zwitterion;
dipeptide;
methyl ester		apoptosis inhibitor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
environmental contaminant;
micronutrient;
nutraceutical;
sweetening agent;
xenobiotic
tempol
[no description available]		2.0710aminoxyls;
hydroxypiperidine		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
catalyst;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
radical scavenger
escitalopram
Escitalopram: S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.. escitalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram.		3.57201-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrileantidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
lexapro
Lexapro: Trade name of escitalopram, the active S-enantiomer of the racemic citalopram.		2.0810
10-propargyl-10-deazaaminopterin
10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.		3.2310N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel
[no description available]		2.9640hydrate;
secondary alpha-hydroxy ketone		antineoplastic agent
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		3.6120secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
irofulven
irofulven: structure in first source		2.0410cyclohexenones
atazanavir
atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).		3.2310carbohydrazideantiviral drug;
HIV protease inhibitor
ym 872
YM 872: structure in first source		2.0410
nsc-141549
[no description available]		2.4620
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		11.321119-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
ezetimibe
Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).		3.6120azetidines;
beta-lactam;
organofluorine compound		anticholesteremic drug;
antilipemic drug;
antimetabolite
ertapenem
Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.		3.5820carbapenemcarboxylic acid;
pyrrolidinecarboxamide		antibacterial drug
dx 8951
[no description available]		2.0410pyranoindolizinoquinoline
cox 189
lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.		4.0940amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
cilomilast
[no description available]		2.7430methoxybenzenes
conivaptan
conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).		3.8630benzazepineaquaretic;
vasopressin receptor antagonist
tezosentan
tezosentan: structure in first source		2.0410
vatalanib
[no description available]		2.0710monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
sabarubicin
sabarubicin: structure given in first source		2.0410
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		4.4160aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
pralnacasan
pralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source		3.5920
clevidipine
clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source		3.8630dihydropyridine
solifenacin
[no description available]		4.0840isoquinolines
dexmethylphenidate
dexmethylphenidate : A methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate.		3.2310methyl phenyl(piperidin-2-yl)acetateadrenergic agent
hyoscyamine
Hyoscyamine: The 3(S)-endo isomer of atropine.. (S)-atropine : An atropine with a 2S-configuration.		2.0710tropane alkaloid
xamoterol
Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.		2.9740morpholines
disopyramide, (s)-isomer
[no description available]		2.4420
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		4.95110methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
cinacalcet
cinacalcet : A secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group.		3.2310(trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound		calcimimetic;
P450 inhibitor
lactitol
lactitol : A glycosyl alditol consisting of beta-D-galactopyranose and D-glucitol joined by a 1->4 glycosidic bond. It is used as a laxative, as an excipient, and as replacement bulk sweetener in some low-calorie foods.		2.0710glycosyl alditolcathartic;
excipient;
laxative
lubiprostone
[no description available]		3.2310
isradipine, (s)-isomer
[no description available]		2.0310
olmesartan
olmesartan: an active metabolite of CS 866		2.4520biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent
telbivudine
[no description available]		3.6120pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
fpl 52757
FPL 52757: FPL 52758 is Na salt of FPL 52757; structure in first source; RN given refers to parent cpd		2.0710
abanoquil
[no description available]		2.0410
paromomycin
Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.		3.8730amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
anidulafungin
Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.		3.5820antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative
17 alpha-hydroxyprogesterone caproate
17 alpha-Hydroxyprogesterone Caproate: Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS.		3.2310corticosteroid hormone
varenicline
Varenicline: A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.. varenicline : An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.		3.2310
biotin
vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.		2.4620biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
fiduxosin
fiduxosin: fiduxosin (ABT-980) is the (3aR,9bR)-isomer; structure in first source		3.5920
fpl 59257
FPL 59257: abolishes cough response & partly inhibits bronchoconstriction produced by leukotrienes C & D		2.0710
atropine
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.		4.87100
ropivacaine
Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.		2.7330piperidinecarboxamide;
ropivacaine		local anaesthetic
erlotinib
[no description available]		3.8630aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
zeneca zd 6169
Zeneca ZD 6169: an ATP-sensitive potassium channel opener; structure given in first source		2.0710
ketoprofen
[no description available]		2.0310
melagatran
[no description available]		2.7430azetidines;
carboxamidine;
dicarboxylic acid monoamide;
non-proteinogenic alpha-amino acid;
secondary amino compound		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
serine protease inhibitor
sibenadet
sibenadet: structure in first source		2.0710
aflatoxin b1
Aflatoxin B1: A potent hepatotoxic and hepatocarcinogenic mycotoxin produced by the Aspergillus flavus group of fungi. It is also mutagenic, teratogenic, and causes immunosuppression in animals. It is found as a contaminant in peanuts, cottonseed meal, corn, and other grains. The mycotoxin requires epoxidation to aflatoxin B1 2,3-oxide for activation. Microsomal monooxygenases biotransform the toxin to the less toxic metabolites aflatoxin M1 and Q1.. aflatoxin B1 : An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.		2.4620aflatoxin;
aromatic ether;
aromatic ketone		carcinogenic agent;
human metabolite
etravirine
[no description available]		3.2310aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
latrepirdine
latrepirdine: structure		2.0710methylpyridines;
pyridoindole		geroprotector
glucovance
Glucovance: Glyburide/metformin (Glucovance) for type 2 diabetes		2.1110
troleandomycin
Troleandomycin: A macrolide antibiotic that is similar to ERYTHROMYCIN.. troleandomycin : A semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug.		2.4620acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative		EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic
muraglitazar
muraglitazar: has glucose- and lipid-lowering activities; structure in first source; molecule composed of benzyloxazole-phenoxy-oxybenzylglycine-phenoxyl having structural analogy to PHENOXYBENZAMINE		9.34111,3-oxazoles
dronedarone
Dronedarone: A non-iodinated derivative of amiodarone that is used for the treatment of ARRHYTHMIA.. dronedarone : A member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias.		3.23101-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
environmental contaminant;
xenobiotic
tesaglitazar
tesaglitazar: structure in first source		2.7430
ramelteon
ramelteon: melatonin MT1/MT2 receptor agonist		3.8830indanes
lapatinib
[no description available]		4.5670furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
darunavir
Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.		3.2310carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
deferasirox
Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.		3.8830benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator
bms204352
BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source		2.7530
ilaprazole
ilaprazole: structure in first source		7.1510benzimidazoles;
sulfoxide
fosfluconazole
fosfluconazole: prodrug of fluconazole		2.0410conazole antifungal drug;
triazole antifungal drug;
triazoles		prodrug
tbc-11251
sitaxsentan: endothelin A receptor antagonist; structure in first source		3.6120benzodioxoles
tolvaptan
[no description available]		3.6120benzazepine;
benzenedicarboxamide		aquaretic;
vasopressin receptor antagonist
sorafenib
[no description available]		4.140(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
lenalidomide
[no description available]		3.6120aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
regadenoson
[no description available]		3.2310purine nucleoside
lacosamide
Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.		3.6120N-acyl-amino acid
cp 101,606
traxoprodil mesylate: a selective NMDA antagonist; structure given in first source		2.4520
cholic acid
Cholic Acid: A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.. cholic acid : A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12.		2.041012alpha-hydroxy steroid;
3alpha-hydroxy steroid;
7alpha-hydroxy steroid;
bile acid;
C24-steroid;
trihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
estradiol 3-benzoate
17beta-estradiol 3-benzoate : A benzoate ester resulting from the formal condensation of benzoic acid with the phenolic hydroxy group of 17beta-estradiol.		2.021017beta-hydroxy steroid;
benzoate ester		estrogen receptor agonist;
xenoestrogen
cortisone
[no description available]		2.071011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
fludrocortisone acetate
fludrocortisone acetate : An acetate ester resulting from the formal condensation of the primary hydroxy group of fludrocortisone with acetic acid. A synthetic corticosteroid, it has glucocorticoid actions about 10 times as potent as hydrocortisone, while its mineralocorticoid actions are over 100 times as potent. It is used in partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenal hyperplasia.		2.462011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
fluorinated steroid;
mineralocorticoid;
tertiary alpha-hydroxy ketone
vincaleukoblastine
[no description available]		3.8730acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite
vincristine sulfate
[no description available]		2.7630organic sulfate saltantineoplastic agent;
geroprotector
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		7.6364
benzarone
benzarone: antihemorrhagic agent; structure		3.89301-benzofurans
nsc-89199
estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine.		2.4520carbamate ester;
organochlorine compound;
steroid phosphate
estramustine
Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.		3.562017beta-hydroxy steroid;
carbamate ester;
organochlorine compound		alkylating agent;
antineoplastic agent;
radiation protective agent
phenethicillin
phenethicillin: minor descriptor (85); major descriptor (63-84); on-line search PENICILLIN, PHENOXYMETHYL/AA (66-85); Index Medicus search PHENETHICILLIN (63-84); RN given refers to (2S-(2alpha,5alpha,6beta))-isomer. phenethicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-phenoxypropanamido group.		2.4620penicillin allergen;
penicillin
noscapine
Noscapine: A naturally occurring opium alkaloid that is a centrally acting antitussive agent.. (-)-noscapine : A benzylisoquinoline alkaloid that is 1,2,3,4-tetrahydroisoquinoline which is substituted by a 4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl group at position 1, a methylenedioxy group at positions 6-7 and a methoxy group at position 8. Obtained from plants of the Papaveraceae family, it lacks significant painkilling properties and is primarily used for its antitussive (cough-suppressing) effects.		2.0410aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound		antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite
acivicin
[no description available]		2.7430isoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite
wortmannin
[no description available]		2.7330acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
trimethoprim, sulfamethoxazole drug combination
Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.		2.3110
bortezomib
[no description available]		3.8730amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		4.951101,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
glycogen
glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.		9.0240
glucosamine
D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.		3.8230D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
naringenin
(S)-naringenin : The (S)-enantiomer of naringenin.		2.0410(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		3.2310heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		2.071011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
salicin
[no description available]		2.0710aromatic primary alcohol;
aryl beta-D-glucoside;
benzyl alcohols		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
puromycin
[no description available]		2.4620puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
taxifolin
(+)-taxifolin : A taxifolin that has (2R,3R)-configuration.		2.0410taxifolinmetabolite
pentostatin
Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.		3.8530coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
taurolithocholic acid
Taurolithocholic Acid: A bile salt formed in the liver from lithocholic acid conjugation with taurine, usually as the sodium salt. It solubilizes fats for absorption and is itself absorbed. It is a cholagogue and choleretic.. taurolithocholic acid : The bile acid taurine conjugate of lithocholic acid.		2.4520bile acid taurine conjugate;
monocarboxylic acid amide		human metabolite
(+)-limonene
(4R)-limonene : An optically active form of limonene having (4R)-configuration.		2.4620limoneneplant metabolite
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		5.02120cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		4.2550alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
griseofulvin
Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.		4.42601-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound		antibacterial agent;
Penicillium metabolite
cefoxitin
Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.		4.2550beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
digitoxin
Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.		3.1650cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
moxalactam disodium
[no description available]		2.4620
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		4.95110L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
pancuronium
Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.. pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.		3.5820acetate ester;
steroid ester		cholinergic antagonist;
muscle relaxant;
nicotinic antagonist
rocuronium
Rocuronium: An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM.. rocuronium : A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.		2.04103alpha-hydroxy steroid;
acetate ester;
androstane;
morpholines;
quaternary ammonium ion;
tertiary amino compound		drug allergen;
muscle relaxant;
neuromuscular agent
abacavir
abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.		4.66802,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
netilmicin
Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.		2.7330
perindopril erbumine
[no description available]		2.0810addition compoundantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
miglitol
[no description available]		7.5893piperidines
mometasone furoate
Mometasone Furoate: A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders.		2.462011beta-hydroxy steroid;
2-furoate ester;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
organochlorine compound;
steroid ester		anti-allergic agent;
anti-inflammatory drug
metyrosine
alpha-methyl-L-tyrosine : An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.		3.8530L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
rocuronium bromide
rocuronium bromide : The organic bromide salt of a 5alpha androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.		2.4520organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent
nortriptyline hydrochloride
[no description available]		2.4620organic tricyclic compoundgeroprotector
erythromycin estolate
Erythromycin Estolate: A macrolide antibiotic, produced by Streptomyces erythreus. It is the lauryl sulfate salt of the propionic ester of erythromycin. This erythromycin salt acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.		2.9840aminoglycoside sulfate salt;
erythromycin derivative		enzyme inhibitor
kanamycin sulfate
[no description available]		2.4620aminoglycoside sulfate saltantibacterial drug;
geroprotector
paromomycin sulfate
paromomycin sulfate : An aminoglycoside sulfate salt resulting from the treatment of paromomycin with sulfuric acid. A broad-spectrum antibiotic, it is used for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.		2.4620
terconazole
terconazole: structure & RN for (cis)-isomer from first source. terconazole : A racemate consisting of equimolar amounts of (2R,4S)- and (2S,4R)-terconazole. It has broad-spectrum antifungal activitiy and is used for the treatment of vaginal yeast infections (Candida).. (2R,4S)-terconazole : A 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine in which positions 2 and 4 of the 1,3-dioxolane moiety have R and S configuration, respectively.		2.02101-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine
bacampicillin
bacampicillin: ester prodrug that is hydrolyzed to ampicillin after its absorption from the gastrointestinal tract; RN given refers to parent cpd; structure. bacampicillin : A penicillanic acid ester that is the 1-ethoxycarbonyloxyethyl ester of ampicillin. It is a semi-synthetic, microbiologically inactive prodrug of ampicillin.		2.0210penicillanic acid esterprodrug
linezolid
[no description available]		4.5470acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
(S)-bicalutamide
(S)-bicalutamide : A N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide that is the (S)-enantiomer of bicalutamide.		2.0710N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
stevioside
stevioside: Kaurene glucoside from leaves of Stevia rebaudiana; 300 times as sweet as sugar. stevioside : A diterpene glycoside that is rubusoside in which the hydroxy group at position 2 of the allylic beta-D-glucoside has been converted to the corresponding beta-D-glucoside. It is a natural herbal sweetener that is 250-300 times sweeter than sucrose (though with a bitter aftertaste), extracted from the Stevia rebaudiana plant native to South America.. diterpene glycoside : A terpene glycoside in which the terpene moiety is a diterpenoid.		2.2510beta-D-glucoside;
bridged compound;
diterpene glycoside;
ent-kaurane diterpenoid;
tetracyclic diterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
hypoglycemic agent;
plant metabolite;
sweetening agent
lignans
Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		2.2510
devazepide
Devazepide: A derivative of benzodiazepine that acts on the cholecystokinin A (CCKA) receptor to antagonize CCK-8's (SINCALIDE) physiological and behavioral effects, such as pancreatic stimulation and inhibition of feeding.. devazepide : An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders.		2.07101,4-benzodiazepinone;
indolecarboxamide		antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
chloramphenicol palmitate
chloramphenicol palmitate: RN given refers to ((R-(R*,R*))-isomer)		2.7430hexadecanoate ester
clindamycin phosphate
[no description available]		3.2310
calcium pantothenate
[no description available]		2.4620polymer
pemirolast potassium salt
[no description available]		2.0810
eplerenone
Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.		3.61203-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester		aldosterone antagonist;
antihypertensive agent
tolterodine
[no description available]		4.0840tertiary amineantispasmodic drug;
muscarinic antagonist;
muscle relaxant
doxorubicin hydrochloride
[no description available]		2.4620anthracycline
halcinonide
Halcinonide: A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.		2.0710organic molecular entitySMO receptor agonist
metrizamide
Metrizamide: A solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.		2.0710amino sugar
erythromycin ethylsuccinate
Erythromycin Ethylsuccinate: A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin ethylsuccinate : A erythromycin derivative that is erythromycin A in which the hydroxy group at position 3R is substituted by a (4-ethoxy-4-oxobutanoyl)oxy group. It is used for the treatment of a wide variety of bacterial infections.		2.0210cyclic ketone;
erythromycin derivative;
ethyl ester;
succinate ester
amcinonide
amcinonide: structure		2.021011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
corticosteroid;
fluorinated steroid;
spiroketal		anti-inflammatory drug
betamethasone acetate
[no description available]		2.021011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
fluorinated steroid;
steroid ester;
tertiary alpha-hydroxy ketone
ao 128
AO 128: alpha-glucosidase inhibitor; structure given in first source		7.64105organic molecular entity
loteprednol etabonate
Loteprednol Etabonate: An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.		2.081011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
etabonate ester;
organochlorine compound;
steroid acid ester;
steroid ester		anti-inflammatory drug
darifenacin
darifenacin : 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.		3.58201-benzofurans;
monocarboxylic acid amide;
pyrrolidines		antispasmodic drug;
muscarinic antagonist
fluticasone propionate
fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.		2.462011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester		adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.7230cyclodextrin
acarbose
[no description available]		4.2450amino cyclitol;
glycoside
maleic acid
maleic acid: RN given refers to parent cpd(Z)-isomer which is maleic acid; all RR's given refer to (Z)-isomer; (E)-isomer is fumaric acid. maleic acid : A butenedioic acid in which the double bond has cis- (Z)-configuration.		2.4620butenedioic acidalgal metabolite;
mouse metabolite;
plant metabolite
tretinoin
Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.		4.4160retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
arachidonic acid
icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.		1.9810icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		2.0410resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
retinol
Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).		3.2310retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
cyanoginosin lr
cyanoginosin LR: cyclic heptapeptide from cyanobacterium Microcystis aeruginosa. microcystin-LR : A microcystin consisting of D-alanyl, L-leucyl, (3S)-3-methyl-D-beta-aspartyl,L-arginyl, 2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl, D-gamma-glutamyl, and 2,3-didehydro-N-methylalanyl residues joined into a 25-membered macrocycle. Produced by the cyanobacterium Microcystis aeruginosa, it is the most studied of the microcystins.		2.4620microcystinbacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
environmental contaminant;
xenobiotic
oleic acid
Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.		2.4110octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		4.6780macrolide lactambacterial metabolite;
immunosuppressive agent
cerivastatin
cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source. cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.		3.1550dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic)
rosuvastatin
rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).		4.0840dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide		anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic
cocaine
Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.		2.4520benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
mycophenolic acid
Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.		3.84302-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
mupirocin
Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.		2.4520alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
clindamycin
Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.		4.0840
fosfomycin
Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.		4.2550epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		4.6680macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
drf 2725
ragaglitazar: a phenoxazine analogue of phenyl propanoic acid; Ragaglitazar is a coligand of PPARalpha and PPARgamma		2.4620
diethylstilbestrol
Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.		2.0410olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
bms 214662
7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.		2.0410benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
octreotide
[no description available]		3.2310
eptifibatide
[no description available]		3.5820homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor
gs 4071
GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.		2.7430acetate ester;
amino acid;
cyclohexenecarboxylic acid;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
marine xenobiotic metabolite
decitabine
[no description available]		4.08402'-deoxyribonucleoside
sm 8668
Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive		2.4520
teniposide
[no description available]		4.2550aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
troxacitabine
troxacitabine: shows good anti-HIV activity without cytotoxicity		2.0410carbohydrate derivative;
nucleobase-containing molecular entity
valrubicin
[no description available]		2.0810anthracycline;
trifluoroacetamide
ketoconazole
(2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.		2.1310cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
cefamandole
Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.. cefamandole : A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups.		2.9540cephalosporin;
semisynthetic derivative		antibacterial drug
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		4.0740actinomycinmutagen
tiazofurin
tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).		2.04101,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide		antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
azaserine
Azaserine: Antibiotic substance produced by various Streptomyces species. It is an inhibitor of enzymatic activities that involve glutamine and is used as an antineoplastic and immunosuppressive agent.. azaserine : A carboxylic ester resulting from the formal condensation of the carboxy group of diazoacetic acid with the alcoholic hydroxy group of L-serine. An antibiotic produced by a Streptomyces species.		2.4620carboxylic ester;
diazo compound;
L-serine derivative;
non-proteinogenic L-alpha-amino acid		antifungal agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
glutamine antagonist;
immunosuppressive agent;
metabolite
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		4.5470L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
sitafloxacin
[no description available]		2.7430fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
tenofovir
tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.		4.0840nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
posaconazole
[no description available]		3.6120aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug
dibekacin
Dibekacin: Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.. dibekacin : A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.		2.0410kanamycinsantibacterial agent;
protein synthesis inhibitor
rubitecan
rubitecan: RN refers to (+-)-isomer; anti-HIV agent; DNA Topoisomerases, Type I inhibitor. rubitecan : A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.		2.0810C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
micafungin
Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.		3.5820antibiotic antifungal drug;
echinocandin		antiinfective agent
riboflavin
vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).		3.2310flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
sodium bicarbonate
Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.		3.5920one-carbon compound;
organic sodium salt		antacid;
food anticaking agent
arsenic trioxide
Tetraarsenic Oxide: A form of As2O3 that exists as As4O6 in the solid state. It dissociates to As2O3 upon heating to the vapor phase above 800 degrees Celsius.		3.8630arsenic oxideantineoplastic agent;
insecticide
tolfenamic acid
tolfenamic acid: structure. tolfenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 3-chloro-2-methylphenyl group. Tolfenamic acid is used specifically for relieving the pain of migraine. It also shows anticancer activity.		2.0310aminobenzoic acid;
organochlorine compound;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
idarubicin hydrochloride
[no description available]		2.4620anthracycline
sch 22219
alclometasone dipropionate : A prednisolone compound having an alpha-chloro substituent at the 7-position, an alpha-methyl substituent at the 16-position and O-propanoyl groups at the 17- and 21-positions.		2.021011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
glucocorticoid;
propanoate ester;
steroid ester		anti-inflammatory drug
sr 90107
fondaparinux sodium : An organic sodium salt, being the decasodium salt of fondaparinux.		3.2310
carbenoxolone sodium
Carbenoxolone: An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity.		2.4620triterpenoid
meglumine iodipamide
[no description available]		3.2310organoammonium saltradioopaque medium
piperine
piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.		7.0710benzodioxoles;
N-acylpiperidine;
piperidine alkaloid;
tertiary carboxamide		food component;
human blood serum metabolite;
NF-kappaB inhibitor;
plant metabolite
thyrotropin-releasing hormone
PR 546: no other info available 9/89. protirelin : A tripeptide composed of L-pyroglutamyl, L-histidyl and L-prolinamide residues joined in sequence.		3.2310peptide hormone;
tripeptide		human metabolite
chloroquine diphosphate
[no description available]		2.0310chloroquine
dextromethadone
D-methadone: an NMDA receptor antagonist analgesic that lacks opioid activity. dextromethadone : A 6-(dimethylamino)-4,4-diphenylheptan-3-one that has (S)-configuration. It is the less active enantiomer of methadone and has very little activity on opioid receptors and mainly responsible for the inhibition of hERG K+ channels and thus for cardiac toxicity. The drug is currently under clinical development for the treatment of major depressive disorder.		2.03106-(dimethylamino)-4,4-diphenylheptan-3-oneNMDA receptor antagonist;
opioid analgesic
arginine vasopressin
Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.		3.6120vasopressincardiovascular drug;
hematologic agent;
mitogen
s 1033
[no description available]		3.2310(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
mezlocillin
Mezlocillin: Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.. mezlocillin : A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.		2.7330penicillin allergen;
penicillin		antibacterial drug
trilostane
trilostane: inhibits conversion of pregnenolone to progesterone; adrenal blocking agent used in treatment of Cushing's syndrome. trilostane : An epoxy steroid that is 3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile in which the oxygen of the epoxy group is joined to the 4alpha and 5 alpha positions.		2.081017beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile		abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
cholinophyllin
[no description available]		2.0210
tropisetron
Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.		2.0410indolyl carboxylic acid
leuprolide acetate
leuprolide acetate : An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.		2.0810acetate saltantineoplastic agent;
gonadotropin releasing hormone agonist
leuprolide
Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.		2.0410oligopeptideanti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist
fludarabine
[no description available]		2.4320purine nucleoside
propylthiouracil
Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.		4.6580pyrimidinethioneantidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist
ipratropium bromide anhydrous
[no description available]		2.0210
chlorprothixene
Chlorprothixene: A thioxanthine with effects similar to the phenothiazine antipsychotics.. (Z)-chlorprothixene : A chlorprothixene in which the double bond adopts a (Z)-configuration.		2.4620chlorprothixene
etomidate
Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.		4.0740ethyl ester;
imidazoles		intravenous anaesthetic;
sedative
mercaptopurine
Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.		4.7790aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
methylthiouracil
Methylthiouracil: A thiourea antithyroid agent that inhibits the synthesis of thyroid hormone. It is used in the treatment of hyperthyroidism.		2.0710pyrimidone
dexketoprofen
dexketoprofen : A monocarboxylic acid that is (S)-hydratropic acid substituted at position 3 on the phenyl ring by a benzoyl group. A cyclooxygenase inhibitor, it is used to relieve short-term pain, such as muscular pain, dental pain and dysmenorrhoea.		2.0310benzophenones;
monocarboxylic acid		cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
crotamiton
[no description available]		2.0710
levosulpiride
(S)-(-)-sulpiride : An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).		2.0810sulpirideantidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
ondansetron, (s)-isomer
[no description available]		2.0310
pyrantel
Pyrantel: A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920). pyrantel : A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4'-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO 'Model List of Essential Medicines'.		3.23101,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes		antinematodal drug
cotinine
Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.		2.4520N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid		antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite
flunarizine
Flunarizine: Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.		2.0710diarylmethane
thiothixene
[no description available]		4.2550N-methylpiperazineanticoronaviral agent
eszopiclone
Eszopiclone: A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.. eszopiclone : The (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use.		3.8630zopiclonecentral nervous system depressant;
sedative
benztropine
Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.. benzatropine : Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.		4.2750diarylmethane
methimazole
Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.		4.66801,3-dihydroimidazole-2-thionesantithyroid drug
cinnarizine
Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.		2.7530diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
sulindac
Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.		4.87100monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		2.7530capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
enclomiphene
Enclomiphene: The trans or (E)-isomer of clomiphene.		2.0210
terbinafine
[no description available]		3.8530acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
epalrestat
epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.		2.0810monocarboxylic acid;
thiazolidines		EC 1.1.1.21 (aldehyde reductase) inhibitor
drotaverin
drotaverin: Hungarian drug; RN given refers to parent cpd; structure		3.1550isoquinolines
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		4.42602-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
(1R,2S)-tranylcypromine hydrochloride
(1R,2S)-tranylcypromine hydrochloride : A hydrochloride obtained by combining (1R,2S)-tranylcypromine with one equivalent of hydrochloric acid.		2.4620hydrochloride
thioacetamide
Thioacetamide: A crystalline compound used as a laboratory reagent in place of HYDROGEN SULFIDE. It is a potent hepatocarcinogen.. thioacetamide : A thiocarboxamide consiting of acetamide having the oxygen replaced by sulfur.		2.4620thiocarboxamidehepatotoxic agent
succimer
Succimer: A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.. succimer : A sulfur-containing carboxylic acid that is succinic acid bearing two mercapto substituents at positions 2 and 3. A lead chelator used as an antedote to lead poisoning.		3.5620dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid		chelator
digoxin
Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.		4.95110cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
streptozocin
[no description available]		4.2550
tamoxifen
[no description available]		5.03120stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
ethionamide
Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.		3.8530pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
cancidas
[no description available]		3.5820
fusidic acid
Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.		2.753011alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester		EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor
scopolamine
[no description available]		2.07103-hydroxy carboxylic acid
lincomycin
Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.		3.5820carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
valinomycin
Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.		2.4720cyclodepsipeptide;
macrocycle		antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore
thiopental
Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		2.4520barbituratesanticonvulsant;
drug allergen;
environmental contaminant;
intravenous anaesthetic;
sedative;
xenobiotic
estrone sulfate
estrone sulfate: sulfoconjugated estrone; RN given refers to parent cpd		2.041017-oxo steroid;
steroid sulfate		human metabolite;
mouse metabolite
ranitidine
Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.		4.140C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
aplaviroc
aplaviroc: a spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1; structure in first source		3.5920
hmr 3647
[no description available]		4.7790
latoconazole
latoconazole: RN refers to cpd without isomeric designation; latoconazole is (E)-isomer; structure given in first source		2.0810conazole antifungal drug;
imidazole antifungal drug
maraviroc
[no description available]		3.8830tropane alkaloid
toremifene citrate
[no description available]		2.0810stilbenoidanticoronaviral agent
toremifene
Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.		3.5920aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
nelarabine
nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).		3.8730beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside		antineoplastic agent;
DNA synthesis inhibitor;
prodrug
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine
[no description available]		2.7430aromatic ether
dermatan sulfate
Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed). alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S : An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside.. dermatan sulfate : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated beta1->4-linked L-iduronyl-(alpha1->3)-N-acetyl-D-galactosamine units.		3.2310amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate
dezocine
dezocine: potent analgesic; RN given refers to ((5R-(5alpha,11alpha,13S*)))-isomer (dezocin); structure. dezocine : (7S,8S)-7-Amino-8-methyl-5,6,7,8-tetrahydronaphthalen-2-ol in which the hydrogen at position 8 and one of the hydrogens at position 6 are substituted by each end of a tetramethylene bridge. A synthetic opioid analgesic, it has mixed opiod agonist and antagonist properties. Although it is used for pain management, it can produce opioid withdrawal syndrome in patients already dependent on other opioids, and its clinical application is limited by side effects such as dizziness.		2.0210phenols;
primary amino compound		opioid analgesic
dapiprazole
[no description available]		2.0210N-alkylpiperazine;
N-arylpiperazine;
pyridines		alpha-adrenergic antagonist;
antipsychotic agent;
miotic;
ophthalmology drug
nizatidine
Nizatidine: A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.. nizatidine : A member of the class of 1,3-thiazoles having a dimethylaminomethyl substituent at position 2 and an alkylthiomethyl moiety at position 4.		2.1310
dolasetron
[no description available]		3.5820indolyl carboxylic acid
or 1259
[no description available]		2.0410hydrazone;
nitrile;
pyridazinone		anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent
almokalant
almokalant: structure given in first source		2.0710
gestodene
Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer		2.4620steroidestrogen
orlistat
Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.		9.2750beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine
[no description available]		4.86100cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
isepamicin
[no description available]		2.0410
ifetroban
ifetroban: thromboxane receptor antagonist; structure given in first source; a 7-oxabicyclo(2.2.1)heptane derivative		2.0410benzenes;
monocarboxylic acid
lamifiban
lamifiban: a nonpeptide glycoprotein IIb/IIIa antagonist; prevents platelet loss during experimental cardiopulmonary bypass		2.0410N-acylglycine
fospropofol
[no description available]		3.2310alkylbenzene
vx-745
[no description available]		2.0710aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine		anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
azilect
[no description available]		2.0810
rasagiline
[no description available]		3.2310indanes;
secondary amine;
terminal acetylenic compound		EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent
deracoxib
SC 046: structure in first source. deracoxib : A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3, and 5 by 4-sulfamoylphenyl, difluoromethyl and 3-fluoro-4-methoxyphenyl groups, respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs.		2.0710organofluorine compound;
pyrazoles;
sulfonamide		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		3.88301,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
2-aminohippuric acid
[no description available]		2.0710N-acylglycine
tocainide, (s)-isomer
[no description available]		2.0310
telavancin
telavancin: an anti-infective agent; structure in first source. telavancin : A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria.		2.0410glycopeptideantibacterial drug;
antimicrobial agent
ginsenosides
ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.		2.3110
alatrofloxacin
alatrofloxacin: prodrug of trovafloxacin		2.0610
rs-130830
RS-130830: orally-active broad-spectrum matrix metalloproteinase inhibitor		2.0710
sodium dodecyl sulfate
Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.		2.0710organic sodium saltdetergent;
protein denaturant
clopidogrel carboxylic acid
clopidogrel carboxylic acid: InChIKey: DCASRSISIKYPDD-UHFFFAOYSA-N. clopidogrel carboxylic acid : A thienopyridine that is 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-ylacetic acid substituted by a 2-chlorophenyl group at position 2. It is a metabolite of the drug clopidogrel.		2.1310monocarboxylic acid;
monochlorobenzenes;
tertiary amino compound;
thienopyridine		drug metabolite;
marine xenobiotic metabolite
sitagliptin
sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.		5.1780triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
osteoprotegerin
Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.		2.2510long-chain fatty acid
flosequinan
[no description available]		2.0210quinolines
tolcapone
Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.		4.871002-nitrophenols;
benzophenones;
catechols		antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
quercetin
[no description available]		2.97407-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
bilirubin
[no description available]		2.0610biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.0710prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
dinoprost
Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.		5.3222monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
biochanin a
[no description available]		2.04104'-methoxyisoflavones;
7-hydroxyisoflavones		antineoplastic agent;
EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
apigenin
Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.		2.0410trihydroxyflavoneantineoplastic agent;
metabolite
linoleic acid
Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.		3.3510octadecadienoic acid;
omega-6 fatty acid		algal metabolite;
Daphnia galeata metabolite;
plant metabolite
calcitriol
dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes		4.0740D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
vitamin k semiquinone radical
vitamin K semiquinone radical: found in active preparations of vitamin K-dependent carboxylase. vitamin K : Any member of a group of fat-soluble 2-methyl-1,4-napthoquinones that exhibit biological activity against vitamin K deficiency. Vitamin K is required for the synthesis of prothrombin and certain other blood coagulation factors.		2.0710
beta carotene
beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.		2.0710carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
retinol palmitate
retinol palmitate: RN given refers to parent cpd; structure. retinyl palmitate : A palmitate ester of retinol with undefined geometry about the C=C bonds.. all-trans-retinyl palmitate : An all-trans-retinyl ester obtained by formal condensation of the carboxy group of palmitic (hexadecanoic acid) with the hydroxy group of all-trans-retinol. It is used in cosmetic products to treat various skin disorders such as acne, skin aging, wrinkles, dark spots, and also protect against psoriasis.		2.4620all-trans-retinyl ester;
retinyl palmitate		antioxidant;
Escherichia coli metabolite;
human xenobiotic metabolite
hymecromone
Hymecromone: A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID.		2.0710hydroxycoumarinantineoplastic agent;
hyaluronic acid synthesis inhibitor
alprostadil
[no description available]		2.4520prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
vitamin d 2
Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.		4.2750hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide
genistein
[no description available]		2.04107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		4.2550antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
clavulanic acid
Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.		2.9640oxapenamantibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort
Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.		4.658011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
oxymetholone
Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed). oxymetholone : A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.		3.8830
eprosartan
eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.		4.6680dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
montelukast
montelukast: a leukotriene D4 receptor antagonist		4.7790aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
mivacurium
Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent.		3.5820isoquinolines
timolol maleate
(S)-timolol maleate : The maleic acid salt of the active (S)-enantiomer of timolol, comprising equimolar amounts of (S)-timolol and maleic acid.		2.4620maleate saltanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
brompheniramine maleate
brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		2.7630maleate saltanti-allergic agent
chlorpheniramine maleate
[no description available]		2.4620organic molecular entity
clemastine fumarate
clemastine fumarate : The fumaric acid salt of clemastine. An antihistamine with antimuscarinic and moderate sedative properties, it is used for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.		2.4620fumarate saltanti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
dexchlorpheniramine maleate
[no description available]		2.0810organic molecular entity
olopatadine
[no description available]		2.0210
methylergonovine maleate
[no description available]		2.4620ergoline alkaloidgeroprotector
hemabate
carboprost tromethamine : The tromethamine salt of carboprost. It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.		3.2310
mycophenolate mofetil
mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.		3.6120carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
bw b1090u
[no description available]		2.0210isoquinolines
entacapone
entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.		4.55702-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol
[no description available]		4.0840hydroxy seco-steroid;
seco-cholestane		antiparathyroid drug
chrysin
chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.		2.04107-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
morin
morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.		2.04107-hydroxyflavonol;
pentahydroxyflavone		angiogenesis modulating agent;
anti-inflammatory agent;
antibacterial agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
hepatoprotective agent;
metabolite;
neuroprotective agent
caffeic acid phenethyl ester
phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.		3.3510alkyl caffeate esteranti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent
ellagic acid
[no description available]		2.0510catechols;
cyclic ketone;
lactone;
organic heterotetracyclic compound;
polyphenol		antioxidant;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor;
EC 2.4.1.1 (glycogen phosphorylase) inhibitor;
EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor;
EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor;
EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
food additive;
fungal metabolite;
geroprotector;
plant metabolite;
skin lightening agent
flupenthixol
cis-flupenthixol : A flupenthixol in which the double bond adopts a cis-configuration.		2.4520flupenthixoldopaminergic antagonist
sdz psc 833
valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215		2.0410homodetic cyclic peptide
estradiol-17 beta-glucuronide
17beta-estradiol 17-glucosiduronic acid : A steroid glucosiduronic acid that consists of 17beta-estradiol having a beta-glucuronyl residue attached at position 17 via a glycosidic linkage.		2.46203-hydroxy steroid;
steroid glucosiduronic acid
l 660,711
[no description available]		2.7530quinolines
pheniramine maleate
Naphcon A: tradename; contains above compounds; ophthalmic solution		2.0710organic molecular entity
travoprost
Travoprost: A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.. travoprost : The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.		2.0810(trifluoromethyl)benzenes;
isopropyl ester;
prostaglandins Falpha		antiglaucoma drug;
antihypertensive agent;
ophthalmology drug;
prodrug;
prostaglandin receptor agonist
tranilast
tranilast: antiallergic drug; potent inhibitor of homologous passive cutaneous anaphylaxis. tranilast : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group.		2.4620amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide		anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent
7432 s
Ceftibuten: A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections.. ceftibuten : A third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections.		3.5620cephalosporin;
dicarboxylic acid		antibacterial drug
8-epi-prostaglandin f2alpha
8-epi-prostaglandin F2alpha: a potent preglomerular vasoconstrictor acting principally through thromboxane A2 receptor activation. 8-epi-prostaglandin F2alpha : An isoprostane that is prostaglandin F2alpha having inverted stereochemistry at the 8-position.		5.3222F2-isoprostanebiomarker;
bronchoconstrictor agent;
vasoconstrictor agent
imipenem
[no description available]		2.0810carbapenems
etretinate
retinoid : Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.		2.4520enoate ester;
ethyl ester;
retinoid		keratolytic drug
isotretinoin
Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.		4.5570retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
misoprostol
Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.. misoprostol : A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.		2.0210
ketotifen fumarate
ketotifen fumarate : An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug.		2.0810organoammonium saltanti-asthmatic drug;
H1-receptor antagonist
epoprostenol
[no description available]		3.5620prostaglandins Imouse metabolite
indocyanine green
[no description available]		3.85301,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
dinoprost tromethamine
[no description available]		2.0810organic molecular entity
triprolidine
Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.		3.620N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
pitavastatin
pitavastatin : A dihydroxy monocarboxylic acid that is (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoic acid in which the two hydroxy groups are located at positions 3 and 5 (the 3R,5S-stereoisomer). Used as its calcium salt for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.		8.6420cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic)		antioxidant
rosuvastatin calcium
S 4522: structure in first source		2.0810N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine;
organic calcium salt		anti-inflammatory agent;
cardioprotective agent;
CETP inhibitor
terbinafine hydrochloride
terbinafine hydrochloride : A hydrochloride obtained by reaction of terbinafine with one molar equivalent of hydrogen chloride.		2.0810allylamine antifungal drug;
hydrochloride		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor
cis-flupenthixol dihydrochloride
cis-flupenthixol dihydrochloride : The dihydrochloride salt of cis-flupenthixol.		2.0510hydrochloridegeroprotector
ethamolin
monoethanolamine oleate: used for treatment of pyogenic granuloma		3.2310long-chain fatty acid
betamethasone benzoate
[no description available]		2.021021-hydroxy steroid
alatrofloxacin mesylate
[no description available]		3.2310
homatropine
[no description available]		2.0710tropane alkaloid
codeine
[no description available]		4.0740morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		5.11130homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
phenoxybenzamine hydrochloride
[no description available]		2.4620organic molecular entity
natamycin
[no description available]		2.0810antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic		antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug
acitretin
Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.		4.2750acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid		keratolytic drug
dorzolamide
dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.		2.0210sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
estropipate
estropipate: used therapeutically in menopausal patients		3.2310piperazinium salt;
steroid sulfate
hydromorphone
Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.		4.0640morphinane alkaloid;
organic heteropentacyclic compound		mu-opioid receptor agonist;
opioid analgesic
levetiracetam
Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.		3.8830pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
ly 163892
loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.		4.0740carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
nabilone
nabilone: cannabinol deriv; RN given refers to cpd without isomeric designation; structure		3.2310
nalmefene
nalmefene: RN given refers to 5-alpha isomer		3.360morphinane alkaloid
naloxone
Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		4.5470morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
oxycodone
Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.		3.8530organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
oxymorphone
Oxymorphone: An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)		3.2310morphinane alkaloid
vitamin k 1
Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.		3.2310phylloquinones;
vitamin K		cofactor;
human metabolite;
plant metabolite
proscillaridin
Proscillaridin: A cardiotonic glycoside isolated from Scilla maritima var. alba (Squill).		2.0310organic molecular entity
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		3.8630antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
topiramate
Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.		4.4160cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
trospium chloride
trospium chloride : An organic chloride salt of trospium. It is an antispasmodic drug used for the treatment of overactive bladder.		3.2310
alvocidib
alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.		2.0410dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
calcipotriene
[no description available]		2.0210cyclopropanes;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
triol		antipsoriatic;
drug allergen
morphine
Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.		4.2550morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
demycarosylturimycin h
[no description available]		2.0810
ar c67085mx
PSB-0413: a selective antagonist radioligand for platelet P2Y12 receptors		2.0710
acipimox
acipimox: lipolysis inhibitor		2.0810pyrazinecarboxylic acid
atosiban
[no description available]		2.0810oligopeptide
benzphetamine
Benzphetamine: A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222). benzphetamine : Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity.		3.5920amphetamines;
tertiary amine		adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent
bimatoprost
Bimatoprost: A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.		2.0810monocarboxylic acid amideantiglaucoma drug;
antihypertensive agent
cicaprost
cicaprost: RN given refers to (3aS-(2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha))-isomer		2.0410monoterpenoid
clobetasol
Clobetasol: A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression.. clobetasol : A 3-oxo-Delta(1),Delta(4)-steroid that is 16beta-methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11beta and 17alpha positions, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17alpha-propionate ester to treat various skin disorders, including exzema and psoriasis.		2.021011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug;
SMO receptor agonist
deamino arginine vasopressin
Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.		3.2310heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
desoximetasone
Desoximetasone: A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.. desoximetasone : Dexamethasone in which the hydroxy group at the 17alpha position is substituted by hydrogen. A synthetic corticosteroid with glucocorticoid activity, it is used as an anti-inflammatory and anti-pruritic in the treatment of various skin disorders, including skin allergies and psoriasis.		2.071011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
dexmedetomidine
[no description available]		3.5820medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
fluticasone
Fluticasone: A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.. fluticasone : A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis.		2.432011beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
goserelin
Goserelin: A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.		3.2310organic molecular entity
halobetasol
halobetasol: used in ointment to treat psoriasis; Ulobetasol cream contains 0.05% 6-fluoroclobetasol 17-propionate		2.0210corticosteroid hormone
iloprost
Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.		2.0410carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
latanoprost
Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.. latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.		2.4520isopropyl ester;
prostaglandins Falpha;
triol		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug
nalbuphine
Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.		4.2450organic heteropentacyclic compoundmu-opioid receptor antagonist;
opioid analgesic
nateglinide
Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.		15.47243phenylalanine derivative
cgp 77675
CGP 77675: belongs to class of substituted 5,7-diphenyl-pyrrolo(2,3-d)pyrimidines; structure in first source		3.2710
rimexolone
[no description available]		2.021020-oxo steroid
sb 223412
SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source		2.0710
seglitide
seglitide: more potent than somatostatin for inhibition of insulin, glucagon & growth hormone release; used experimentally in treatment of Alzheimer's disease; somatostatin receptor antagonist		2.0410
vinorelbine
[no description available]		4.0640acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid		antineoplastic agent;
photosensitizing agent
silodosin
silodosin: an alpha(1a)-adrenoceptor-selective antagonist; structure given in first source		3.2310indolecarboxamide
MeJA
[no description available]		3.3510Jasmonate derivatives
tazettine
tazettine: from Amaryllidaceae		3.3510indole alkaloid fundamental parent;
indole alkaloid
furazolidone
[no description available]		2.4620
fluvoxamine
Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.		10.6251(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
su 11248
[no description available]		3.8730monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
romidepsin
depsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating.		2.0410cyclodepsipeptide;
heterocyclic antibiotic;
organic disulfide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.		4.7690dihydroxy monocarboxylic acid;
indoles;
organofluorine compound
molsidomine
[no description available]		2.0810ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
oxiconazole
oxiconazole: RN given refers to parent cpd(Z)-isomer; structure given in first source. oxiconazole : An oxime O-ether that is the 2,4-dichlorobenzyl ether of the oxime obtained by formal condensation of hydroxylamine with the carbonyl group of acetopnenone in which the phenyl group is substituted by chlorines at positions 2 and 4, and in which one of the hydrogens of the methyl group is replaced by a 1H-imidazol-1-yl group. An antifungal agent, it is used (generally as the nitrate salt) in creams and powders for the topical treatment of fungal skin infections.		2.0210conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
oxime O-ether		antiinfective agent
octylmethoxycinnamate
[no description available]		2.4620cinnamate ester
levorphanol
Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.		3.2310morphinane alkaloid
bismuth
Bismuth: A metallic element that has the atomic symbol Bi, and atomic number 83. Its principal isotope is Bismuth 209.		2.0310metal atom;
pnictogen
naltrexone
Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.		4.6580cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
morphine-6-glucuronide
morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer		2.0410morphinane alkaloid
dextromethorphan
Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.		3.58206-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
butorphanol
Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.		4.4160morphinane alkaloidantitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
cefodizime
cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer. cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.		2.04101,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
EC 1.14.18.1 (tyrosinase) inhibitor
methylnaltrexone
methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer		2.0410phenanthrenes
cefixime
[no description available]		4.6680cephalosporinantibacterial drug;
drug allergen
lisinopril
Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.		4.7690dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril
benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.		4.0740benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
ramipril
Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.		4.2650azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug
verteporfin
(2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid : The 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid.		3.2310
indinavir sulfate
Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.		4.86100dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
zimeldine
Zimeldine: One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)		4.1140styrenes
enalapril maleate
enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.		2.0810maleate saltantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
enalapril
Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).		4.0640dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
vinblastine sulfate
[no description available]		2.4620
trientine hydrochloride
[no description available]		3.8630
n-methylscopolamine bromide
scopolamine methobromide : A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide.		3.2310
bleomycin
[no description available]		3.2310bleomycinantineoplastic agent;
metabolite
dextromethorphan hydrobromide
dextromethorphan hydrobromide : The hydrobromide and monohydrate of the antitussive drug dextromethorphan.		2.4620hydrate;
hydrobromide
indinavir sulfate
[no description available]		2.0510azaheterocycle sulfate salt
enalaprilat anhydrous
Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.		4.4260dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
sulindac sulfone
sulindac sulfone: inhibits K-ras-dependent cyclooxygenase-2; sulfated analog of indomethacin;; CP248 is an antineoplastic agent that fosters microtubule depolymerization; structure in first source. sulindac sulfone : A sulfone metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. It inhibits the development and induces regression of premalignant adenomatous polyps. Lipoxygenase and Cox-2 inhibitor.		2.0410monocarboxylic acid;
organofluorine compound;
sulfone		apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
ximelagatran
ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.		3.8730amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor
cefuroxime
[no description available]		4.25503-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether		drug allergen
ceftriaxone
[no description available]		4.25501,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime
Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		4.2550cephalosporin;
oxime O-ether		antibacterial drug
hr 810
cefpirome: structure in first source. cefpirome : A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.		2.0410cephalosporin;
cyclopentapyridine
pafuramidine
pafuramidine: a prodrug of furamidine		3.5920
ceftazidime
[no description available]		4.460cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril
trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.		4.0740dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
pregabalin
Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.		3.6120gamma-amino acidanticonvulsant;
calcium channel blocker
tiotropium
tiotropium : A quaternary ammonium ion obtained by methylation of the tertiary amino group of (1alpha,2beta,4beta,5alpha,7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane. Used (in the form of the bromide hydrate) for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.		2.0710
cefetamet
cefetamet: active against Neisseria gonorrhoeae; structure given in first source. cefetamet : A cephalosporin compound having methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a cephalosporin antibiotic active against Neisseria gonorrhoeae.		2.7430cephalosporin
alvimopan anhydrous
alvimopan: mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain		3.6120peptide
aliskiren
aliskiren: orally active nonpeptidic renin inhibitor. aliskiren : A monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position.		3.2310monocarboxylic acid amide;
monomethoxybenzene		antihypertensive agent
guanabenz
Guanabenz: An alpha-2 selective adrenergic agonist used as an antihypertensive agent.		2.4420dichlorobenzene
famotidine
[no description available]		4.76901,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
fenoterol
fenoterol hydrobromide : The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.		2.4620hydrobromidebeta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
cefotaxime
Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.		4.06401,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
aztreonam
[no description available]		4.5470beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
nw 1029
Ralfinamide: Sodium Channel Blocker; structure in first source		2.0710
(R)-citalopram
(R)-citalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has R-configuration at the chiral centre. It is the inactive enantiomer of citalopram.		2.03101-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
cci 15641
[no description available]		2.4520cephalosporin
rifamycin sv
rifamycin SV: RN given refers to parent cpd; structure in Merck Index, 9th ed, #8009. rifamycin SV : A member of the class of rifamycins that exhibits antibiotic and antitubercular properties.		2.110acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterotetracyclic compound;
polyphenol;
rifamycins		antimicrobial agent;
antitubercular agent;
bacterial metabolite
ginkgolide b
[no description available]		2.4520
cefpodoxime
[no description available]		3.5620carboxylic acid;
cephalosporin		antibacterial drug
palonosetron
Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.		3.5820azabicycloalkane;
delta-lactam;
organic heterotricyclic compound		antiemetic;
serotonergic antagonist
tenofovir disoproxil fumarate
tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.		2.0810fumarate saltantiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
cefatrizine
Cefatrizine: Orally active semisynthetic cephalosporin antibiotic with broad-spectrum activity.. cefatrizine : A cephalosporin compound having (1H-1,2,3-triazol-4-ylsulfanyl)methyl and [(2R)-2-amino-2-(4-hydroxyphenyl)]acetamido side-groups. An antibacterial drug first prepared in the 1970s, it has more recently been found to be an inhibitor of eukaryotic elongation factor-2 kinase (eEF2K), which is known to regulate apoptosis, autophagy and ER stress in many types of human cancers.		2.7430amino acid amide;
carboxylic acid;
cephalosporin;
phenols;
semisynthetic derivative;
triazoles		antibacterial drug;
EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
enclomiphene citrate
[no description available]		2.0510
diphenoxylate hydrochloride
diphenoxylate hydrochloride : The hydrochloride salt of diphenoxylate.		2.4620hydrochlorideantidiarrhoeal drug
eniporide
eniporide: inhibits NHE-1 isoform; structure in first source		2.0410
dexbrompheniramine maleate
dexbrompheniramine maleate : The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		2.0810brompheniramine maleateanti-allergic agent;
H1-receptor antagonist
cilastatin
[no description available]		2.4520carboxamide;
L-cysteine derivative;
non-proteinogenic L-alpha-amino acid;
organic sulfide		EC 3.4.13.19 (membrane dipeptidase) inhibitor;
environmental contaminant;
protease inhibitor;
xenobiotic
rifaximin
[no description available]		3.6120acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative		antimicrobial agent;
gastrointestinal drug;
orphan drug
ergonovine maleate
ergometrine maleate : A maleate salt resulting form the reaction of equimolar amounts of maleic acid and ergometrine. It is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced.		2.4620maleate saltdiagnostic agent;
oxytocic
ici d1542
ICI D1542: redirects arachidonic acid metabolism; an inhibitor of thromboxane A2 synthetase and of thromboxane receptors		2.0710
everolimus
[no description available]		3.6120cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
ixabepilone
[no description available]		3.58201,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
gavestinel
[no description available]		2.0710
dirithromycin
[no description available]		2.0210macrolide antibioticprodrug
azlocillin
Azlocillin: A semisynthetic ampicillin-derived acylureido penicillin.. azlocillin : A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.		2.4520penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial drug
verlukast
verlukast: LTD4 receptor antagonist		2.0410
cefpodoxime proxetil
cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.		2.4520carboxylic acid;
carboxylic ester;
cephalosporin		antibacterial drug;
prodrug
ceftizoxime
[no description available]		4.0640cephalosporinantibacterial drug
linogliride
linogliride: structure given in first source		1.9710
a 419259
[no description available]		3.2710
1-methyl-d-lysergic acid butanolamide
[no description available]		4.0840ergot alkaloid;
monocarboxylic acid amide		serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent
carumonam
carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer. carumonam : An N-sulfonated monobactam antibiotic.		2.0410monobactamantibacterial drug
fluphenazine
[no description available]		2.0810
dantrolene sodium
dantrolene sodium (anhydrous) : The anhydrous sodium salt of dantrolene.		2.4620
nitrofurantoin
Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.		5.03120imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
sq-23377
Ionomycin: A divalent calcium ionophore that is widely used as a tool to investigate the role of intracellular calcium in cellular processes.. ionomycin : A very long-chain fatty acid that is docosa-10,16-dienoic acid which is substituted by methyl groups at positions 4, 6, 8, 12, 14, 18 and 20, by hydroxy groups at positions 11, 19 and 21, and by a (2',5-dimethyloctahydro-2,2'-bifuran-5-yl)ethanol group at position 21. An ionophore produced by Streptomyces conglobatus, it is used in research to raise the intracellular level of Ca(2+) and as a research tool to understand Ca(2+) transport across biological membranes.		1.9810cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid		calcium ionophore;
metabolite
eritoran
eritoran : A lipid A derivative used for the treatment of severe sepsis.		2.0410lipid As
dantrolene
[no description available]		4.2550
roxithromycin
(E)-roxithromycin : A major geometrical isomer of roxithromycin.		2.0810roxithromycinenvironmental contaminant;
xenobiotic
cefdinir
[no description available]		3.6120cephalosporin;
ketoxime		antibacterial drug
etonogestrel
[no description available]		3.231017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin
bisoprolol, fumarate (1:1) salt
[no description available]		2.0810
artesunate
artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether		2.4620artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
tipredane
[no description available]		2.07103-hydroxy steroidandrogen
etoposide phosphate
[no description available]		2.0810furonaphthodioxole
dexniguldipine
niguldipine: structure given in first source; clinical modulator of multidrug resistance		2.0410diarylmethane
ciclesonide
ciclesonide: nasal spray approved for seasonal and perennial allergic rhinitis		2.0810organic molecular entity
napsagatran
napsagatran: structure given in first source		2.0410
temsirolimus
[no description available]		3.8730macrolide lactam
dutasteride
Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.		3.8630(trifluoromethyl)benzenes;
aza-steroid;
delta-lactam		antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
tekturna
[no description available]		2.0810fumarate saltantihypertensive agent
lu 208075
ambrisentan: an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertension		4.1240diarylmethane
bms188797
[no description available]		2.0410
bibx 1382bs
BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001		3.5920substituted aniline
vildagliptin
[no description available]		14.263022amino acid amide
fesoterodine
fesoterodine: a muscarinic antagonist for treatment of overactive bladder		3.2310diarylmethane
rebaudioside a
rebaudioside A: glucoside isolated from the leaves of the paraguayan shrub, Stevia rebaudiana; has taste properties superior to stevioside; structure in first source. rebaudioside A : A rebaudioside that is rubusoside in which the hydroxy groups at positions 3 and 4 of the beta-D-glucopyranosyloxy group at the 13alpha position have both been converted to the corresponding beta-D-glucopyranoside.		2.2510beta-D-glucoside;
rebaudioside;
tetracyclic diterpenoid		sweetening agent
bentiromide
bentiromide: chymotrypsin labile peptide used diagnostically as an index of exocrine pancreas function. bentiromide : The dipeptide obtained by condensation of N-benzoyl-L-tyrosine with 4-aminobenzoic acid. Used as a noninvasive screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy, it is given by mouth: the amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas.		2.0710dipeptidediagnostic agent;
indicator;
reagent
phosphocreatine
Phosphocreatine: An endogenous substance found mainly in skeletal muscle of vertebrates. It has been tried in the treatment of cardiac disorders and has been added to cardioplegic solutions. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1996). phosphagen : Any of a group of guanidine or amidine phosphates that function as storage depots for high-energy phosphate in muscle with the purpose of regenerating ATP from ADP during muscular contraction.. N-phosphocreatine : A phosphoamino acid consisting of creatine having a phospho group attached at the primary nitrogen of the guanidino group.		4.3511phosphagen;
phosphoamino acid		human metabolite;
mouse metabolite
chlorhexidine
Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.		2.0610biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
sgd 301-76
[no description available]		2.0810conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt		antiinfective agent
fluvoxamine maleate
[no description available]		2.0810(trifluoromethyl)benzenes
thioacetazone
Thioacetazone: A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217). thiosemicarbazone : A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-thioacylated nitrogen of thiosemicarbazide or its substituted derivatives.		2.0810
s 1743
Esomeprazole: The S-isomer of omeprazole.. esomeprazole : A 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole that has S configuration at the sulfur atom. An inhibitor of gastric acid secretion, it is used (generally as its sodium or magnesium salt) for the treatment of gastro-oesophageal reflux disease, dyspepsia, peptic ulcer disease, and Zollinger-Ellison syndrome.		2.0610magnesium saltanti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
azimilide
azimilide: structure given in first source; RN given refers to dihydrochloride		2.0410imidazolidine-2,4-dione
gemifloxacin
Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.		3.86301,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor
dexlansoprazole
Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.		3.6120benzimidazoles;
sulfoxide
gemifloxacin mesylate
gemifloxacin mesylate : The mesylate salt of gemifloxacin.		2.0810methanesulfonate saltantimicrobial agent;
topoisomerase IV inhibitor
fosinopril
[no description available]		3.5620
armodafinil
armodafinil : A 2-[(diphenylmethyl)sulfinyl]acetamide that has R configuration at the sulfur atom. Like its racemate, modafinil, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. Peak concentration in the blood later occurs later following administration than with modafinil, so it is thought that armodafinil may be more effective than modafinil in treating people with excessive daytime sleepiness.		3.23102-[(diphenylmethyl)sulfinyl]acetamidecentral nervous system stimulant;
eugeroic
utibapril
utibapril: structure given in first source; prodrug for FPL 63547 diacid		2.0710
tomopenem
[no description available]		2.4520
norfenfluramine
Dexnorfenfluramine: D-isomer of Norfenfluramine		2.0310amphetamines
sergliflozin etabonate
sergliflozin: a hypoglycemic agent that inhibits SGLT2 sodium-glucose transporter; structure in first source		3.1410glycoside
ezetimibe, simvastatin drug combination
Ezetimibe, Simvastatin Drug Combination: A pharmaceutical preparation of ezetimibe and simvastatin that is used in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS.		2.0810
sincalide
Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.		3.2310oligopeptide
tapentadol
Tapentadol: An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES.		3.2310alkylbenzene
etomoxir
[no description available]		2.110aromatic ether
zd 9379
ZD 9379: structure given in first source		2.0710
ly 450139
[no description available]		2.0710peptide
ursodoxicoltaurine
tauroursodeoxycholate : An organosulfonate oxoanion that is the conjugate base of tauroursodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. tauroursodeoxycholic acid : A bile acid taurine conjugate derived from ursoodeoxycholic acid.		2.0510bile acid taurine conjugateanti-inflammatory agent;
apoptosis inhibitor;
bone density conservation agent;
cardioprotective agent;
human metabolite;
neuroprotective agent
bb-83698
BB-83698: peptide deformylase inhibitor		2.0410
pentagastrin
Pentagastrin: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid.		3.2310organic molecular entity
cangrelor
cangrelor: platelet P(2T) receptor antagonist. cangrelor : A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.		2.0710adenosine 5'-phosphate;
aryl sulfide;
nucleoside triphosphate analogue;
organochlorine compound;
organofluorine compound;
secondary amino compound		P2Y12 receptor antagonist;
platelet aggregation inhibitor
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.0610aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
sch 527123
[no description available]		2.0710
cefditoren
cefditoren: structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer. cefditoren : A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.		3.2310carboxylic acid;
cephalosporin		antibacterial drug
remogliflozin etabonate
remogliflozin etabonate: orally administered hypoglycemic agent; structure in first source		3.1410glycoside
cp 724714
2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide: CP-724714 is the ((2E)-isomer, 1:1.5 succinate); structure in first source		2.1102-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamideantineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
hepatotoxic agent
rivaroxaban
Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.		2.0810aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
zotarolimus
zotarolimus: synthetic analog of rapamycin; structure in first source		2.0410lactam;
macrolide
molindone hydrochloride
[no description available]		2.4620indoles
dapagliflozin
[no description available]		11.461610aromatic ether;
C-glycosyl compound;
monochlorobenzenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor
gentamicin sulfate
[no description available]		2.9640
bn 52020
[no description available]		2.4520
hki 272
[no description available]		2.0810nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
ginsenoside rg3
ginsenoside Rg3: from Red ginseng; inhibits lung metastasis of tumor cells; structure given in first source. (20S)-ginsenoside Rg3 : A ginsenoside found in Panax ginseng and Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranosyl-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.		7.3110ginsenoside;
glycoside;
tetracyclic triterpenoid		angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite
tofacitinib
tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.		2.0810N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
linaprazan
linaprazan: structure in first source		2.0710
gymnemagenin
gymnemagenin: isolated from Gymnema sylvestre		2.1310
linagliptin
Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.. linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes.		12.662617aminopiperidine;
quinazolines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
pazopanib
pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.		4.1140aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
lecozotan
lecozotan: structure in first source		2.0710
prasugrel hydrochloride
Prasugrel Hydrochloride: A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.. prasugrel hydrochloride : A racemate comprising equal amounts of (R)- and (S)-prasugrel hydrochloride. Used to prevent blood clots in people with acute coronary syndrome who are undergoing a procedure after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.		3.2310
ar c155858
AR C155858: an MCT1 inhibitor; structure in first source		2.0710
ko 143
[no description available]		2.0410beta-carbolines;
tert-butyl ester
macelignan
macelignan: an NSAID with antioxidant, free radical scavenging, and neuroprotective activities; structure in first source		2.2510lignan
ipragliflozin
[no description available]		9.3711glycoside
amg 009
AMG 009: an anti-inflammatory agent; structure in first source		2.0810
cefotaxime sodium
[no description available]		2.0810organic sodium salt
baci-im
[no description available]		4.0840homodetic cyclic peptide;
polypeptide;
zwitterion		antibacterial agent;
antimicrobial agent
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
[no description available]		2.0710methoxybenzenes;
substituted aniline
1-allyl-3-methylimidazolium
1-allyl-3-methylimidazolium: structure in first source		2.2110
bms 477118
[no description available]		3.2310adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
nystatin a1
Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.		4.0740nystatins
alogliptin
alogliptin: structure in first source. alogliptin : A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes.		8.9821nitrile;
piperidines;
primary amino compound;
pyrimidines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
cytidine diphosphate choline
[no description available]		2.4620nucleotide-(amino alcohol)s;
phosphocholines		human metabolite;
mouse metabolite;
neuroprotective agent;
psychotropic drug;
Saccharomyces cerevisiae metabolite
sitagliptin phosphate
Sitagliptin Phosphate: A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES.		16.596348
milnacipran
[no description available]		3.5720acetamides
vindesine
[no description available]		2.0410
losartan potassium
Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.		2.0810
empagliflozin
[no description available]		11.55169aromatic ether;
C-glycosyl compound;
monochlorobenzenes;
tetrahydrofuryl ether		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor
lc15-0444
LC15-0444: Dipeptidyl Peptidase IV Inhibitors; orally active small molecule for the treatment of type II diabetes		5.744organonitrogen compound;
organooxygen compound
calcimycin
Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.		1.9810benzoxazole
scopolamine hydrobromide
[no description available]		4.0840
dactolisib
dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.		2.0810imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
rabeprazole sodium
[no description available]		2.0810organic sodium salt
amodiaquine hydrochloride
[no description available]		2.0410
clindamycin hydrochloride
[no description available]		2.4620S-glycosyl compound
bisaramil
[no description available]		2.0410
bivalirudin
bivalirudin: designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition. bivalirudin : A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.		3.6120polypeptideanticoagulant;
EC 3.4.21.5 (thrombin) inhibitor
somatostatin
[no description available]		2.0810heterodetic cyclic peptide;
peptide hormone
teicoplanin
teicoplanin A2-1 : A teicoplanin A2 that has (4Z)-dec-4-enoyl as the variable N-acyl group.		2.4520
enfuvirtide
Enfuvirtide: A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.. enfuvirtide : A synthetic 36-amino acid peptide consisting of N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutaminyl, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryptophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes.		3.2310
ganirelix
[no description available]		3.2310polypeptide
glucagon
Glucagon: A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511). glucagon : A 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence.		7.89127peptide hormone
teriparatide
[no description available]		3.2310polypeptide
salmon calcitonin
[no description available]		3.2310heterodetic cyclic peptide;
peptide hormone;
polypeptide		bone density conservation agent;
metabolite
ly-146032
[no description available]		4.0840heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
dalbavancin
[no description available]		2.0410carbohydrate acid derivative;
glycopeptide;
monosaccharide derivative;
semisynthetic derivative		antibacterial drug;
antimicrobial agent
liraglutide
[no description available]		18.777739lipopeptide;
polypeptide		glucagon-like peptide-1 receptor agonist;
neuroprotective agent
glucagon-like peptide 1
Glucagon-Like Peptide 1: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.		22.175743
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide: FE-200486 is the acetate salt		3.2310polypeptide
incretins
Incretins: Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially.		12.46159
c-peptide
C-Peptide: The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.		11.423730
exenatide
[no description available]		4.0920
warfarin sodium
warfarin sodium : A racemate comprising equal amounts of (R)- and (S)-warfarin sodium. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.		2.0810
cellulose
DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.		7.1310glycoside
quinine sulfate
[no description available]		2.4620hydrate
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		2.21101,2-diacyl-sn-glycero-3-phosphocholine
buparlisib
NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source		3.3510aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
azd 7545
AZD 7545: an anilide tertiary carbinol; a pyruvate dehydrogenase kinase 2 inhibitor. AZD7545 : A sulfone that is benzene substituted by [4-(dimethylcarbamoyl)phenyl]sulfonyl, chloro and [(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino groups at positions 1, 3 and 4, respectively. It is a potent and non-ATP-competitive inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2) with IC50 of 6.4 nM and exhibits glucose-lowering activity. Also inhibits PDHK1 at higher levels (IC50 = 36.8 nM).		2.0710benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide		EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent
pravastatin sodium
pravastatin sodium : An organic sodium salt that is the sodium salt of pravastatin. A reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), it is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.		2.0810organic sodium salt;
statin (semi-synthetic)		anticholesteremic drug
alendronate sodium
[no description available]		2.0810
sl 80.0750
[no description available]		2.0810
cefotiam hydrochloride
[no description available]		2.4620
chitosan
[no description available]		7.7830
mesna
Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.		3.8530organosulfonic acid
potassium aminobenzoate
[no description available]		2.4620
ampicillin sodium
[no description available]		2.0510organic sodium salt
clavulanate potassium
potassium clavulanate : A potassium salt having clavulanate as the counterion. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes and has only weak anitbiotic activity when administered alone. However it can be used in combination with amoxicillin trihydrate (under the trade name Augmentin) for treatment of a variety of bacterial infections, where it prevents antibiotic inactivation by microbial lactamases.		2.4820potassium saltantibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefamandole nafate
[no description available]		2.0210organic sodium saltantibacterial drug;
prodrug
cytomel
liothyronine sodium : The sodium salt of liothyronine. Thought to be more active than levothyroxine and with a rapid (few hours) onset and short duration of action, liothyronine sodium is used in the treatment of hypothyroidism, particularly in cases of hypothyroid coma.		2.0710organic sodium salt
sodium lactate
Sodium Lactate: The sodium salt of racemic or inactive lactic acid. It is a hygroscopic agent used intravenously as a systemic and urinary alkalizer.. sodium lactate : An organic sodium salt having lactate as the counterion.		3.2310lactate salt;
organic sodium salt		food acidity regulator;
food preservative
piperacillin sodium
[no description available]		2.0810organic sodium salt
sodium iothalamate
[no description available]		3.2310
methicillin sodium
[no description available]		2.4620organic sodium salt
nafcillin sodium
[no description available]		2.4620organic sodium salt
oxacillin sodium
[no description available]		2.0810organic sodium salt
penicillin g sodium
[no description available]		2.4620organic sodium salt
cefamandole nafate
cefamandole sodium : An organic sodium salt that is the sodium salt of cefamandole.		2.4620organic sodium saltantibacterial drug
cephapirin sodium
cephapirin sodium : The sodium salt of cephapirin. A first-generation cephalosporin antibiotic, it is effective against gram-negative and gram-positive organisms. Being more resistant to beta-lactamases than penicillins, it is effective agains most staphylococci, though not methicillin-resistant staphylococci.		2.4620cephalosporin;
organic sodium salt		antibacterial drug
sodium cephalothin
[no description available]		2.4620organic sodium salt
cefazolin sodium
cefazolin sodium : A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.		2.0810organic sodium salt
dicloxacillin sodium
[no description available]		2.4620hydrate
azlocillin sodium
[no description available]		2.7630organic sodium salt
canagliflozin
canagliflozin hydrate : A hydrate that is the hemihydrate form of canagliflozin. Used for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2.		12.282113C-glycosyl compound;
organofluorine compound;
thiophenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor
insulin, isophane
Insulin, Isophane: An intermediate-acting INSULIN preparation with onset time of 2 hours and duration of 24 hours. It is produced by crystallizing ZINC-insulin-PROTAMINES at neutral pH 7. Thus it is called neutral protamine Hagedorn for inventor Hans Christian Hagedorn.		8.98106
tak-875
[no description available]		10.8842biphenyls
cetrorelix
cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.		3.5820oligopeptideantineoplastic agent;
GnRH antagonist
a 967079
A 967079: a TRPA1 channel antagonist; structure in first source		2.0710
piperidines
Piperidines: A family of hexahydropyridines.		11.88338
pht 427
4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide: an antineoplastic agent; structure in first source		2.0710
anagliptin
anagliptin: anagliptin hydrochloride salt is the active compound		3.5111amino acid amide
pf 04971729
ertugliflozin: structure in first source		6.8632diarylmethane
exenatide
Exenatide: A synthetic form of exendin-4, a 39-amino acid peptide isolated from the venom of the Gila monster lizard (Heloderma suspectum). Exenatide increases CYCLIC AMP levels in pancreatic acinar cells and acts as a GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist and incretin mimetic, enhancing insulin secretion in response to increased glucose levels; it also suppresses inappropriate glucagon secretion and slows gastric emptying. It is used an anti-diabetic and anti-obesity agent.		12.48248
pf-04937319
N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide: a glucokinase activator; structure in first source		5.8522
dinaciclib
[no description available]		3.3510pyrazolopyrimidine
methylcellulose
Methylcellulose: Methylester of cellulose. Methylcellulose is used as an emulsifying and suspending agent in cosmetics, pharmaceutics and the chemical industry. It is used therapeutically as a bulk laxative.		2.4620
natriuretic peptide, brain
Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.		3.9911polypeptide
gsk2656157
[no description available]		2.2110biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor
7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1h-indol-5-yl)-7h-pyrrolo(2,3-d)pyrimidin-4-amine
7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine: inhibits protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK); structure in first source		2.2110
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		3.8630ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
raltegravir
[no description available]		3.23101,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide		antiviral drug;
HIV-1 integrase inhibitor
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		2.4620carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		5.1130
chlortetracycline
Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.		2.4420
oxytetracycline, anhydrous
Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.		4.2550
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		4.5470
methacycline
Methacycline: A broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.. methacycline : A tetracycline that is the 6-methylene analogue of oxytetracycline, obtained by formal dehydration at position 6.		2.0310
dicumarol
Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.		2.0710hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
piroxicam
[no description available]		4.6680benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
roquinimex
roquinimex: structure in first source		2.7530aromatic amide
acenocoumarol
Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233). acenocoumarol : A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group.		2.4620C-nitro compound;
hydroxycoumarin;
methyl ketone		anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
meclocycline
[no description available]		2.0210
mobic
Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.		4.41601,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
mobiflex
tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.		3.1550heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
isoxicam
isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.		3.3160benzothiazine;
isoxazoles;
monocarboxylic acid amide		antirheumatic drug;
non-steroidal anti-inflammatory drug
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		10.17140benzenes;
hydroxycoumarin;
methyl ketone
demeclocycline
Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.. demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.		3.5820
tipranavir
tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.		4.140sulfonamideantiviral drug;
HIV protease inhibitor
chlortetracycline hydrochloride
Alexomycin: a thiopeptide; a cyclic peptide antibiotic produced by Streptomyces arginensis isolated from the soil		2.4620
rolitetracycline
Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.		2.0410
sudoxicam
sudoxicam: proposed ant-inflammatory agent; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZINES (75-86)		2.0510
methacycline monohydrochloride
[no description available]		2.4620
minocycline hydrochloride
[no description available]		2.7630
demeclocycline hydrochloride
demeclocycline hydrochloride : The hydrochloride salt of demeclocycline. A tetracycline antibiotic, it is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.		2.4620
tigecycline
[no description available]		4.0840
(S)-warfarin
(S)-warfarin : A 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one that has (S)-configuration (the racemate is warfarin, an anticoagulant drug and rodenticide).		2.46204-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one
lornoxicam
lornoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.		2.0810heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
2-oxo-clopidogrel
2-oxo-clopidogrel: metabolite of clopidogrel		2.1310
caseins
Caseins: A mixture of related phosphoproteins occurring in milk and cheese. The group is characterized as one of the most nutritive milk proteins, containing all of the common amino acids and rich in the essential ones.		2.2110
fertinex
[no description available]		3.2310
nitrophenols
Nitrophenols: PHENOLS carrying nitro group substituents.		2.0310
insulin glargine
Insulin Glargine: A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.		14.214529
oxyntomodulin
Glucagon-Like Peptides: Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.		7.455
cyclosporine
Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).		2.0610
entecavir
entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.		3.61202-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		4.861002-aminopurines;
oxopurine		antimetabolite;
antiviral drug
levoleucovorin
Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.		3.17105-formyltetrahydrofolic acidantineoplastic agent;
metabolite
deoxyguanosine
[no description available]		3.4411purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
guanosine triphosphate
Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.		210guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
folic acid
folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.		6.0781folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		7.53151cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		5.1130benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		4.6780dacarbazine
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		4.86100purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
ganciclovir
[no description available]		4.77902-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
valtrex
[no description available]		2.0810organic molecular entity
valacyclovir
Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.		3.8430L-valyl esterantiviral drug
sildenafil
sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.		4.5470piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
olanzapine
Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.		4.0840benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
penciclovir
penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.		2.95402-aminopurines;
propane-1,3-diols		antiviral drug
raltitrexed
[no description available]		2.0810N-acyl-amino acid
vardenafil
vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.		4.2550imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
allopurinol
Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.		4.95110nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
citrovorum factor
[no description available]		4.0940tetrahydrofolic acid
leucovorin
5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.		4.4160formyltetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
rifapentine
rifapentine: cyclopentyl derivative of rifampicin		3.6120N-alkylpiperazine;
N-iminopiperazine;
rifamycins		antitubercular agent;
leprostatic drug
bl 4162a
anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source. anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.		3.2310imidazoquinazolineanticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor
tegaserod
tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source		4.0840carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist
pemetrexed
pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).		3.2310N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
tirapazamine
Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.		2.0410aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
sildenafil citrate
Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.		3.0240citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
valganciclovir
Valganciclovir: A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor.. valganciclovir : The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.		3.2310L-valyl ester;
purines		antiviral drug;
prodrug
aprepitant
Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.		4.0840(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
fosaprepitant
fosaprepitant: a pro-drug form of aprepitant. fosaprepitant : A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid.		3.2310(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles		antiemetic;
neurokinin-1 receptor antagonist;
prodrug
tegaserod maleate
[no description available]		2.0810maleate saltserotonergic agonist
ceftobiprole
ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).		2.0410cephalosporin;
thiadiazoles		antimicrobial agent
rifabutin
[no description available]		4.86100
8-hydroxy-2'-deoxyguanosine
8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.		3.4411guanosinesbiomarker
amg531
[no description available]		2.0610
carbadox
Carbadox: An antibacterial agent that has been used in veterinary practice for treating swine dysentery and enteritis and for promoting growth. However, its use has been prohibited in the UK following reports of carcinogenicity and mutagenicity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p125)		2.0710quinoxaline derivative
levomefolate calcium
levomefolate calcium: an ingredient in Contraceptives, Oral, Combined. levomefolate calcium : An organic calcium salt of (6S)-5-methyltetrahydrofolic acid.		3.2310organic calcium saltantidepressant
fenobam
fenobam: in USAN fenobam refers to monohydrate		2.0710ureas
phosphorus radioisotopes
Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.		1.9810
leptin
Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.		5.732
ConditionIndicatedRelationship StrengthStudiesTrials
Adverse Drug Event
[description not available]		03.5580
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		03.5580
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		013.04193
Diabetes Mellitus, Adult-Onset
[description not available]		028.861,080511
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		028.861,080511
Acute Liver Injury, Drug-Induced
[description not available]		06.3131
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		06.3131
Innate Inflammatory Response
[description not available]		010.962111
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		015.962111
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Benign Neoplasms
[description not available]		03.7430
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.7430
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		015.66241
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		015.66241
Alloxan Diabetes
[description not available]		06.04410
Cancer of Prostate
[description not available]		03.0910
HIV Coinfection
[description not available]		03.0910
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		03.0910
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		03.0910
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		04.84110
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Asymmetric Diabetic Proximal Motor Neuropathy
[description not available]		011.541817
Diabetic Neuropathies
Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)		016.541817
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		018.1810890
Autoimmune Disease
[description not available]		03.8321
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.		03.8321
Fasting Hypoglycemia
HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.		019.213285
Hypoglycemia
A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.		019.213285
Fatty Liver, Nonalcoholic
[description not available]		05.8232
Cirrhosis
[description not available]		04.7211
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		04.7211
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		010.8232
Degenerative Diseases, Central Nervous System
[description not available]		02.4110
Tauopathies
Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.		02.4110
Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.		02.4110
Cardiac Failure
[description not available]		08.24128
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		013.24128
Complications of Diabetes Mellitus
[description not available]		07.9263
Dyslipidemia
[description not available]		011.3542
Blood Pressure, High
[description not available]		08.43163
Albuminuria
The presence of albumin in the urine, an indicator of KIDNEY DISEASES.		06.6854
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		015.434529
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		08.43163
Dyslipidemias
Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.		06.3542
Chronic Illness
[description not available]		04.3841
Compensatory Hyperinsulinemia
A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.		04.1131
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		04.3841
Hyperinsulinism
A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.		04.1131
Proteinuria
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.		02.610
Apoplexy
[description not available]		04.6380
Cardiovascular Stroke
[description not available]		05.02140
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		05.02140
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)		04.6380
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		018.594135
Weight Gain
Increase in BODY WEIGHT over existing weight.		012.491916
Idiopathic Parkinson Disease
[description not available]		02.7620
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		02.7620
Disease Exacerbation
[description not available]		07.673
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		05.4851
Insulin Sensitivity
[description not available]		015.556138
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		015.556138
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		05.1231
Overweight
A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.		06.133
Peripheral Arterial Diseases
[description not available]		03.1710
Peripheral Arterial Disease
Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.		03.1710
Cardiac Arrest, Sudden
[description not available]		02.6120
Ventricular Fibrillation
A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.		02.2510
Death, Sudden, Cardiac
Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)		02.6120
Drug-Induced Stevens Johnson Syndrome
[description not available]		02.3110
Stevens-Johnson Syndrome
Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.		02.3110
Atherogenesis
[description not available]		09.35157
Arteriosclerosis, Coronary
[description not available]		08.6686
Blood Clot
[description not available]		04.5511
Coronary Artery Disease
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.		013.6686
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		04.5511
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		09.35157
Diabetic Glomerulosclerosis
[description not available]		05.8883
Diabetic Nephropathies
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.		05.8883
Weight Reduction
[description not available]		019.352918
Weight Loss
Decrease in existing BODY WEIGHT.		014.352918
Diabetic Retinopathy
Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.		02.3110
Fournier Disease
[description not available]		02.3110
Abscess
Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.		02.3110
Keratitis, Acanthamoeba
[description not available]		02.3110
Acanthamoeba Keratitis
Infection of the cornea by an ameboid protozoan which may cause corneal ulceration leading to blindness.		02.3110
Hyperphagia
Ingestion of a greater than optimal quantity of food.		02.1510
Hepatocellular Carcinoma
[description not available]		0921
Cancer of Liver
[description not available]		0421
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		0421
Liver Neoplasms
Tumors or cancer of the LIVER.		0421
Cognitive Decline
[description not available]		04.4811
Cognitive Dysfunction
Diminished or impaired mental and/or intellectual function.		04.4811
Ventricular Dysfunction
A condition in which HEART VENTRICLES exhibit impaired function.		02.1710
Arrhythmia
[description not available]		02.7130
Diabetic Angiopathies
VASCULAR DISEASES that are associated with DIABETES MELLITUS.		014.133325
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		02.7130
Symptom Cluster
[description not available]		02.1710
Syndrome
A characteristic symptom complex.		07.1710
Sex Disorders
[description not available]		02.1710
Sexual Dysfunction, Physiological
Physiological disturbances in normal sexual performance in either the male or the female.		02.1710
Bone Fractures
[description not available]		05.7721
Fractures, Bone
Breaks in bones.		05.7721
Urinary Tract Infections
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.		04.4811
Kaposi Disease
[description not available]		03.1210
Xeroderma Pigmentosum
A rare, pigmentary, and atrophic autosomal recessive disease. It is manifested as an extreme photosensitivity to ULTRAVIOLET RAYS as the result of a deficiency in the enzyme that permits excisional repair of ultraviolet-damaged DNA.		03.1210
Autosomal Dominant Juvenile Parkinson Disease
[description not available]		02.2110
Age-Related Memory Disorders
[description not available]		02.2110
Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.		02.2110
Parkinsonian Disorders
A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.		02.2110
Impaired Glucose Tolerance
[description not available]		010.21128
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.7330
Glucose Intolerance
A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.		010.21128
Genital Tract Infections
[description not available]		04.5111
Fungal Diseases
[description not available]		04.5111
Mycoses
Diseases caused by FUNGI.		04.5111
Vulvovaginitis
Inflammation of the VULVA and the VAGINA, characterized by discharge, burning, and PRURITUS.		04.5111
Glycosuria
The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).		02.4220
Latent Tuberculosis
The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.		02.0810
Cognition Disorders
Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.		04.9540
Coronary Heart Disease
[description not available]		03.8221
Coronary Disease
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.		03.8221
Amentia
[description not available]		02.0810
Dementia
An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.		07.0810
Elevated Cholesterol
[description not available]		02.4620
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		02.4620
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		06.86132
Hyperlipemia
[description not available]		05.4353
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		05.4353
Bone Loss, Osteoclastic
[description not available]		02.110
Chronic Pancreatitis
[description not available]		019.242890
Acute Edematous Pancreatitis
[description not available]		019.242910
Acute Disease
Disease having a short and relatively severe course.		019.252940
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		024.242910
Pancreatitis, Chronic
INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.		019.242890
Antidiuretic Hormone, Inappropriate Secretion
[description not available]		02.1110
Inappropriate ADH Syndrome
A condition of HYPONATREMIA and renal salt loss attributed to overexpansion of BODY FLUIDS resulting from sustained release of ANTIDIURETIC HORMONES which stimulates renal resorption of water. It is characterized by normal KIDNEY function, high urine OSMOLALITY, low serum osmolality, and neurological dysfunction. Etiologies include ADH-producing neoplasms, injuries or diseases involving the HYPOTHALAMUS, the PITUITARY GLAND, and the LUNG. This syndrome can also be drug-induced.		02.1110
Chronic Kidney Failure
[description not available]		02.1110
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		02.1110
Liver Steatosis
[description not available]		03.511
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.		03.511
Cholera Infantum
[description not available]		07.5444
Cancer of the Urinary Tract
[description not available]		03.0310
Licheniform Eruptions
[description not available]		02.4520
Dermatitis Medicamentosa
[description not available]		02.4520
Acute Confusional Senile Dementia
[description not available]		02.5320
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.5320
Cardiac Rupture, Traumatic
[description not available]		03.0310
Heart Disease, Ischemic
[description not available]		04.1860
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		04.1860
Drug Overdose
Accidental or deliberate use of a medication or street drug in excess of normal dosage.		03.8740
Hypergonadotropic Hypogonadism
[description not available]		02.1310
Hypogonadism
Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).		07.1310
Indigestion
[description not available]		04.4511
Infection
[description not available]		04.4511
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		04.4511
Dyspepsia
Impaired digestion, especially after eating.		04.4511
Infections
Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.		04.4511
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		05.7321
Cardiometabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.		07.75107
Metabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.		07.75107
Cardiac Remodeling, Ventricular
[description not available]		04.7521
Recrudescence
[description not available]		02.0410
Palmoplantaris Pustulosis
[description not available]		02.0410
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		02.0410
Asthma, Bronchial
[description not available]		02.0410
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		07.0410
Injury, Ischemia-Reperfusion
[description not available]		02.4620
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		02.4620
Left Ventricular Dysfunction
[description not available]		04.7521
Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.		04.7521
Cat Diseases
Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.		02.0510
Autoimmune Diabetes
[description not available]		04.3270
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		04.3270
Cardiomyopathies, Primary
[description not available]		02.0510
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		02.0510
Genetic Predisposition
[description not available]		02.0510
Factitious Disorders
Disorders characterized by physical or psychological symptoms that are not real, genuine, or natural.		02.0510
Calcification, Pathologic
[description not available]		03.4411
Arterial Diseases, Carotid
[description not available]		07.1273
Calcinosis
Pathologic deposition of calcium salts in tissues.		03.4411
Carotid Artery Diseases
Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.		07.1273
Cancer of the Thyroid
[description not available]		02.9710
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.		02.9710
Central Nervous System Lupus
[description not available]		02.9810
Pneumatosis Cystoides Intestinalis
A condition characterized by the presence of multiple gas-filled cysts in the intestinal wall, the submucosa and/or subserosa of the INTESTINE. The majority of the cysts are found in the JEJUNUM and the ILEUM.		02.9810
Active Hyperemia
[description not available]		02.0610
Hyperemia
The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).		02.0610
Poisoning
Used with drugs, chemicals, and industrial materials for human or animal poisoning, acute or chronic, whether the poisoning is accidental, occupational, suicidal, by medication error, or by environmental exposure.		02.0610
Aortic Diseases
Pathological processes involving any part of the AORTA.		05.0631
Brachial Paresis
[description not available]		02.9910
Anterior Choroidal Artery Infarction
[description not available]		02.0710
Eosinophilia, Tropical
[description not available]		02.0710
Gastroduodenal Ulcer
[description not available]		02.0710
Cerebral Infarction
The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).		02.0710
Eosinophilia
Abnormal increase of EOSINOPHILS in the blood, tissues or organs.		02.0710
Peptic Ulcer
Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		02.0710
Atheroma
[description not available]		04.3711
Acute Coronary Syndrome
An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.		04.3711
Malnourishment
[description not available]		02.9910
Adenocarcinoma, Basal Cell
[description not available]		02.9910
Coma, Hyperglycemic Hyperosmolar Nonketotic
[description not available]		02.9910
Cancer of Pancreas
[description not available]		04.340
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.9910
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		04.340
Malnutrition
An imbalanced nutritional status resulting from insufficient intake of nutrients to meet normal physiological requirement.		02.9910
Injury, Myocardial Reperfusion
[description not available]		02.9340
Diabetic Cardiomyopathies
Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.		02.0810
Precordial Catch
[description not available]		02.0110
Chest Pain
Pressure, burning, or numbness in the chest.		02.0110
Arteriosclerosis
Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.		03.8121
Bile Duct Obstruction, Intrahepatic
[description not available]		02.0210
Cholestasis, Intrahepatic
Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).		02.0210
Congenital Myotonic Dystrophy
[description not available]		02.0210
Myotonic Dystrophy
Neuromuscular disorder characterized by PROGRESSIVE MUSCULAR ATROPHY; MYOTONIA, and various multisystem atrophies. Mild INTELLECTUAL DISABILITY may also occur. Abnormal TRINUCLEOTIDE REPEAT EXPANSION in the 3' UNTRANSLATED REGIONS of DMPK PROTEIN gene is associated with Myotonic Dystrophy 1. DNA REPEAT EXPANSION of zinc finger protein-9 gene intron is associated with Myotonic Dystrophy 2.		02.0210
Complications, Pregnancy
[description not available]		02.0210
Bile Duct Obstruction
[description not available]		02.4220
Cholestasis
Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).		02.4220
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.0210
Multiple System Atrophy Syndrome
[description not available]		02.0210
Age-Related Osteoporosis
[description not available]		02.0210
Angiitis, Central Nervous System
[description not available]		02.0210
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		02.0210
Multiple System Atrophy
A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)		02.0210
Acidosis, Diabetic
[description not available]		02.9410
Diabetic Ketoacidosis
A life-threatening complication of diabetes mellitus, primarily of TYPE 1 DIABETES MELLITUS with severe INSULIN deficiency and extreme HYPERGLYCEMIA. It is characterized by KETOSIS; DEHYDRATION; and depressed consciousness leading to COMA.		02.9410
Muscle Relaxation
That phase of a muscle twitch during which a muscle returns to a resting position.		02.0310
Prediabetes
[description not available]		02.0310
Prediabetic State
The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).		02.0310
Angiitis
[description not available]		02.0310
Vasculitis
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.		07.0310
Neovascularization, Optic Disc
[description not available]		02.0310
Ischemia
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.		03.8121
Retinal Neovascularization
Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.		02.0310
Anasarca
[description not available]		02.0410
Chylopericardium
[description not available]		02.0410
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0410
Pericardial Effusion
Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.		02.0410
Pleural Effusion
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.		02.0410
Cataract, Membranous
[description not available]		01.9810
Cataract
Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)		01.9810
Adenoma, beta-Cell
[description not available]		02.3920
Insulinoma
A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.		02.3920
Liver Dysfunction
[description not available]		02.910
Liver Diseases
Pathological processes of the LIVER.		02.910
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		01.9910
Anesthesia
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.		0210
Purpura, Thrombopenic
[description not available]		0210
Purpura, Thrombocytopenic
Any form of purpura in which the PLATELET COUNT is decreased. Many forms are thought to be caused by immunological mechanisms.		0210
Lactic Acidosis
[description not available]		02.9210
Coma
A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.		02.9210
Acidosis, Lactic
Acidosis caused by accumulation of lactic acid more rapidly than it can be metabolized. It may occur spontaneously or in association with diseases such as DIABETES MELLITUS; LEUKEMIA; or LIVER FAILURE.		02.9210
Diabetes Mellitus, Gestational
[description not available]		0210
Diabetes, Gestational
Diabetes mellitus induced by PREGNANCY but resolved at the end of pregnancy. It does not include previously diagnosed diabetics who become pregnant (PREGNANCY IN DIABETICS). Gestational diabetes usually develops in late pregnancy when insulin antagonistic hormones peaks leading to INSULIN RESISTANCE; GLUCOSE INTOLERANCE; and HYPERGLYCEMIA.		0210
Alcohol Abuse
[description not available]		0210
Aura
[description not available]		0210
Alcoholism
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)		0210
Epilepsy
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)		0210
Hibernation, Myocardial
[description not available]		0210